<SEC-DOCUMENT>0001628280-23-016646.txt : 20230509
<SEC-HEADER>0001628280-23-016646.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509090039
ACCESSION NUMBER:		0001628280-23-016646
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Esperion Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001434868
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35986
		FILM NUMBER:		23900199

	BUSINESS ADDRESS:	
		STREET 1:		3891 RANCHERO DRIVE, SUITE 150
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		734-887-3903

	MAIL ADDRESS:	
		STREET 1:		3891 RANCHERO DRIVE, SUITE 150
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HDL THERAPEUTICS INC
		DATE OF NAME CHANGE:	20080513
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>espr-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:7abd0a45-1af4-4bbb-ab52-3d00de73fc2d,g:05387136-6cd8-4464-bd5b-5fa183ea52d1,d:9237fb157928404b96a8fc7ef6f6efba--><html xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:espr="http://www.esperion.com/20230331" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>espr-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80L2ZyYWc6YTJkM2NiNDFkN2Q5NGIxODk4NDRmZDg1NmQ0ODg1NmYvdGFibGU6OTEwYWI4ZjRkYzM0NGMxNjhlYTRiMjI5Yjk1OTdhNTMvdGFibGVyYW5nZTo5MTBhYjhmNGRjMzQ0YzE2OGVhNGIyMjliOTU5N2E1M18zLTEtMS0xLTY1Mjcz_0ebe5e1f-be55-433b-aaf8-b4adcdcbd788">0001434868</ix:nonNumeric><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80L2ZyYWc6YTJkM2NiNDFkN2Q5NGIxODk4NDRmZDg1NmQ0ODg1NmYvdGFibGU6OTEwYWI4ZjRkYzM0NGMxNjhlYTRiMjI5Yjk1OTdhNTMvdGFibGVyYW5nZTo5MTBhYjhmNGRjMzQ0YzE2OGVhNGIyMjliOTU5N2E1M180LTEtMS0xLTY1Mjcz_5bf5d28c-ecd9-43df-bb9f-3f5f314ca4e4">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80L2ZyYWc6YTJkM2NiNDFkN2Q5NGIxODk4NDRmZDg1NmQ0ODg1NmYvdGFibGU6OTEwYWI4ZjRkYzM0NGMxNjhlYTRiMjI5Yjk1OTdhNTMvdGFibGVyYW5nZTo5MTBhYjhmNGRjMzQ0YzE2OGVhNGIyMjliOTU5N2E1M181LTEtMS0xLTY1Mjcz_5a1c58cd-a76f-480b-a1c9-5ad35e7a6feb">2023</ix:nonNumeric><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80L2ZyYWc6YTJkM2NiNDFkN2Q5NGIxODk4NDRmZDg1NmQ0ODg1NmYvdGFibGU6OTEwYWI4ZjRkYzM0NGMxNjhlYTRiMjI5Yjk1OTdhNTMvdGFibGVyYW5nZTo5MTBhYjhmNGRjMzQ0YzE2OGVhNGIyMjliOTU5N2E1M182LTEtMS0xLTY1Mjcz_472b67fe-4533-48c9-9803-6ad6ed3d9b64">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80L2ZyYWc6YTJkM2NiNDFkN2Q5NGIxODk4NDRmZDg1NmQ0ODg1NmYvdGFibGU6OTEwYWI4ZjRkYzM0NGMxNjhlYTRiMjI5Yjk1OTdhNTMvdGFibGVyYW5nZTo5MTBhYjhmNGRjMzQ0YzE2OGVhNGIyMjliOTU5N2E1M183LTEtMS0xLTY1Mjcz_b1f04915-157c-4c36-93d5-449e0db3c442">false</ix:nonNumeric><ix:nonNumeric contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" name="espr:ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81NS9mcmFnOjgyODBlZTExMDViODQ2NjE5NGZiOTE0M2U5MDA3ODY3L3RhYmxlOjY2NTA4NmU4MDdlNDQ5Y2Y5MDczNTEwOTk4NzhhNWQzL3RhYmxlcmFuZ2U6NjY1MDg2ZTgwN2U0NDljZjkwNzM1MTA5OTg3OGE1ZDNfMTMtMS0xLTEtNjUyNzM_c52b541e-4ad8-4737-a2af-34559298fcba">6</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="4" name="espr:PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81NS9mcmFnOjgyODBlZTExMDViODQ2NjE5NGZiOTE0M2U5MDA3ODY3L3RhYmxlOjY2NTA4NmU4MDdlNDQ5Y2Y5MDczNTEwOTk4NzhhNWQzL3RhYmxlcmFuZ2U6NjY1MDg2ZTgwN2U0NDljZjkwNzM1MTA5OTg3OGE1ZDNfMTQtMS0xLTEtNjUyNzM_6c41105f-5a64-477b-926c-7c356e5663ec">33.33</ix:nonFraction><ix:nonNumeric contextRef="i20ddb90b5807415aa23e0e6e68488a19_D20211022-20211022" name="espr:DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODIwOA_adc66ab1-dedb-4d22-80ef-7e400f74515e">P5D</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="espr-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i138e5960375b40e09f319237f97dcd65_I20230501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="id6505e18f8b44bb1be4b3c88b659408a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i914746ebf548485ab38582d5985e0ada_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie2b77b80c5d249d29e61285804d99500_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f18e48d6294e8b944c473a6e0492ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db3ef3bcd8641beb4f52ba5d002ddb4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i465260a8cedb484e9ea4a4a8159d8ed6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6e2ffdc00584f51b68b18c17fd34cd7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96cd74dcb04940069b98e07d316c536b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13fe6538e08e4e9e95c7d4ea4d868263_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00efd75341744eafa3659cc293e6f016_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i735d7eb128bb425881b2106dba0bc826_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ed0b5ab60804e7ba2963330f6311982_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied4203a5755144439c1cc7549b1adda6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3682159d79c4bc58c63d3f05153448b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65b2edc7703246bb9244d72048a96b56_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85ece9e3706a4128875ddb42c594ca79_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ac34f1300344bff8cbb530bbc966b3a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c5aee48198c4721a9a6396775fbc9df_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5d8ac1d3b1f4bfd9174292f26013954_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c4384b7bf6a4a13a1b8e29a389fa42c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5617bf716d28411ebabd53cd816b47f0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99f951895edd442e82a9307c2fd15632_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9df09bf3eb9f4d92a8093c27cf22cb5a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b8c5a52c3b749aaa0e91a6da46ae301_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i530db00620494f0d8c03838ac8b04a07_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d56f0010704f36816774ad7c5f40f4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d5484c9784f4fd1aa72d1ad735a068e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb28160fa7384975be907af6cd2a9f51_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69cd4c90044a41f7861387a767ee94d2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia012cc762a894ec387428edb3a5b3bac_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a9f1879a9d4499392ef45ea2e774ecb_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib55dcb7213154d228df81b8e761f46b0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f4442b575984c518a0936302e598e13_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97c9874b2c3a4d5a806023ad434054ce_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i834d7e9dd8044b26a5dda1d39659e958_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia033e96d244b4ac48293f47e9660b8be_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f6734ada96468a9b81e77531464725_D20190801-20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="patient"><xbrli:measure>espr:patient</xbrli:measure></xbrli:unit><xbrli:context id="idabb0477bfa648dab7fecedc64128780_I20230319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d316e7178014207990f50547c020dad_D20230319-20230319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-19</xbrli:startDate><xbrli:endDate>2023-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97a34cf836d84f4fadef4d721fab3698_I20230319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:CommonStockAndAccompanyingWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice6f0592c1f54f6b9a640b944432f3be_I20230319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:PreFundedWarrantAndAccompanyingWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-22</xbrli:startDate><xbrli:endDate>2023-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ce060f7a8354b51af7f71258119d414_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2905ddfb2a734b91a7b4f966c0bb65da_I20230323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90c4fbf04c494d99bd37f6e4eb559905_I20230322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5664faaee9574db4a202135e028596c8_D20230319-20230319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-19</xbrli:startDate><xbrli:endDate>2023-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82aa535e66f84394b33629688b89827e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>espr:customer</xbrli:measure></xbrli:unit><xbrli:context id="i13c84429beb04adb81c5c0e8a4fa22d3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="revenue_source"><xbrli:measure>espr:revenue_source</xbrli:measure></xbrli:unit><xbrli:context id="ib0dc2923eba0447ab555feccec765db2_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5784cd2d48204ab3a25a3176ccbe3451_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e347119af144cd8d92b13e2b6c5387_D20190102-20190102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-02</xbrli:startDate><xbrli:endDate>2019-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i437ec51f9da947e4957d1c78257d41ca_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RoyaltyRevenueAndProductSalesBulkTabletsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5c8e4669ee430eb7fd9eb3d5682fcc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RoyaltyRevenueAndProductSalesBulkTabletsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia37f88e1d6334cd4988043aa29cb8d9d_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbe99073da5e4665be166412628cfbc6_I20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i774e2569416f4db59556c5fcd4cc0597_I20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9838052375c4929b5e4b845fe66da84_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i556e6b8f854a4c16bc7335cde1d58ab3_D20200417-20200417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic913c0c79880452395a8e14c510b4c70_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa13681c34ae4d84ab904e7d74d950a1_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic924dfffa02f4560877a7d949f08cede_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58cea3ac6b01461cab29af950aeb53a8_D20210426-20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if38679db574c48ac84aa03b68471cdff_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie63bcb21a66346609cd8f6ef61fbffb7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d6b22f936e84b6e9cadcd7659d06dc6_D20230304-20230304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-04</xbrli:startDate><xbrli:endDate>2023-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica364f56b4754e2fb33645747ebebdba_I20230304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:CardiovascularRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ff170b7510847eeb8c913c0268553d5_I20230304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:CardiovascularRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eb81084a86e42b49fbea9ece7638ea5_D20230304-20230304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:CardiovascularRiskOutcomeGreaterThanTwentyPercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-04</xbrli:startDate><xbrli:endDate>2023-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e14be02d3004562870df907dec00d77_I20230304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:RelativeRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6dc542279e7e464ca12100e49501610e_D20230304-20230304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-04</xbrli:startDate><xbrli:endDate>2023-03-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2442189a4e04c14866e4ca5dbe37ae7_D20230327-20230327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-27</xbrli:startDate><xbrli:endDate>2023-03-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77154455e27741eea8b7382d7bae0ad0_I20230327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:CardiovascularRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6cf6eadd1ee45ffbf7b12713791e2c9_D20230504-20230504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-04</xbrli:startDate><xbrli:endDate>2023-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddba95e9a591432fb6bb68b9d99fc675_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4446c0fdb9a84cc7ae17ac1fc0e8e0a0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaee3d89d3ffc4d01a13615bb5476bcf1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2b452feddd34bfab04830af609fee01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70000ff4cfcc4e379e6941a6be6de6ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bf5212861014a2a90c4514e738c57eb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7636ce535be94232b11a93a9e2d54623_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96447b072e33476da43830de87cc58b4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0a643f6059d440590c4f9ef231a9a6a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4a1c26e2f864ba39b7dc746fa87291e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c9a60f0eede463fa23b607d23c6f990_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cadd97215ba4500883c87f85dc8fa2d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1ca33a8008147d78bca5e8eed93423d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fe88940f17f4e6792cd87aaa54541dd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7471d3b7a6ba4353b8cbc8d3e9345bfe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9834c756a92466abb333281240e95ae_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if15b9c81ed564487bd38021a6515575e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a3337053c7d484984eb254e5738a3a5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20434c7136b44164a04d244e3105f708_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f55c80accfb4964b37eccb272c3ab19_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b4f98b104bb49ccbbb686e748c86c53_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dc441d33315499aaa534c51197956c9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie25bd0065058415581124c3cefc0bc4b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2df84ce791dd48a0a34c0e850ff9e8ea_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief6c1f5d0ae340d8af91af461c6b1b1a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie13c0a874a8e4068b43b96843795daac_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1185e14b22bb4ad8b91ff702b16b3dbe_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f66dcce3270487dac3d302e1c309b3f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i293919219d734293958f10064d773142_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i37331eb822c14332aecf98c4a60c9a83_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ae5ff6d06c466e9f4d59d506da6f7e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18c2947b9df14b23b8cc09df417e317f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b0c9a8dfde64edbbed9fa7ad3f7e105_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id23e5091216b49dfac7f65fdd88e2a1f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd852d52cb6c4999a5a4f084a7dabb24_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75e3b605ec754126b40578f924de207a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88342aa86a3b4d5eada1ac9c12a8b565_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3543312988354b0d860025f4d82f6d5a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a04e27d9c67411db002887f7c2f4e82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4189fded356d43ba84b628246a86e8bd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b58988234e7462d88cabcc48176e5cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5dc67741b7147d48b9de0788cbe4d92_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia22b6d1eb1714222833742d1f5e85b9a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-26</xbrli:startDate><xbrli:endDate>2019-06-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if514492bc1304c3e88a7d73b880162d6_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c7a52f49de44809d9de735fcdb4259_D20210426-20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-26</xbrli:startDate><xbrli:endDate>2021-04-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6754f51923214db89d9e97a310f8cc9f_D20210516-20210516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RIPAAmendmentToTheSecurityAgreementAndWaiverMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-16</xbrli:startDate><xbrli:endDate>2021-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05a73c2f8f9840268e786ffef237f263_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RIPAAmendmentToTheSecurityAgreementAndWaiverMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia380cab0f6c44c18a991dc9247a9f988_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62091633ce8842d79fd91f8dcc5437c7_D20221123-20221123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-23</xbrli:startDate><xbrli:endDate>2022-11-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i593d725af50a4b0091e208f4866fe4d9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8971caf868ca48d4bb6027c5bcbc4c0d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60257fb8aa8e4bae83973ec6daf04c7f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7b64718731d44238127edb9d9fdb04b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60e0844b890e44459d45cfea66deae41_D20210516-20210516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-16</xbrli:startDate><xbrli:endDate>2021-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia26aa17e92c241019a3310efe812d480_D20210516-20210516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-16</xbrli:startDate><xbrli:endDate>2021-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9977b26c9b394f16bbdfa5a9ea8bc078_I20210516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4567f7a9b074360b5b429789676c1b0_D20210516-20210516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-16</xbrli:startDate><xbrli:endDate>2021-05-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2677ac65322b4743a3ca63339e6ecf73_I20210516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i282b2fae645341849445d9da9274fa5e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5ce29780ee048d2a07167f083638b4e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9672d71ca80348519f56b4e7a065e01c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3be96d871a141f89c4e0d00a0a0b2ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9d604cc8ce549efb8eacca20225427d_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i558c1c82e52841cd910a7702549badd5_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77878605a83847e6b08dc2b1e23c3d3c_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">espr:PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e9376bd36d849ffb4316ffe1b5485a7_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i443e0a08bb4a4888a6d5462309e5dc2b_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>espr:day</xbrli:measure></xbrli:unit><xbrli:context id="id505115d3ec947189265eca782d4648d_D20201101-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5eeddb8167c498c8696923171b62eb4_I20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20ddb90b5807415aa23e0e6e68488a19_D20211022-20211022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-22</xbrli:startDate><xbrli:endDate>2021-10-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef44d4d210a42b4b9aa0ab56e93f3ea_I20211022"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80cfd1f853144d49b1d183168049513c_D20211103-20211103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-03</xbrli:startDate><xbrli:endDate>2021-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50721021131b4d71b50fa66d28915b11_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e1a076c7ee4e17907f790ab9bf3c54_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i921ae98ba14c414092902fd6b4401923_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1696b3ebb44147b9a3cbeaecc46fbd18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icae7497a06dd4ecf932d2ce48689f651_D20201116-20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-16</xbrli:startDate><xbrli:endDate>2020-11-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa0efd686a824365a3cc55c8e2d823d9_I20201116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:CappedCallMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99ff79bbd6b34af19e4c4f5ffd0dd8bd_I20220531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">espr:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8d1aec6f0a243debcdc270c1c4783d6_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88cb7b840c98434489e5ae6882bf0bde_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ed983231e1c4e1e9acf5a3984e776a1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ddb347cbc7e4b08b9ec62540ce50d3e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66bec0e27b1b48d1bcd58ded58c2e003_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b0445354f6f4558904c97d5373f8c53_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60d797f24c2c4a04b4ff42bb670e3cc1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b9c918318b245b38e4e0d3ba2428dba_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i162d9a4406ca467199ca052182157c66_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i012dbf6545a3491b9f6f9fab381db389_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e9dfbd0c5a54147bd3f860e7e9511c2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83fd6d470bf4439baf8eaf859c790c76_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8632a444e79c46f1a18e5bc0a4625f88_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if882eb7b96d54916b14a19ce79b2ec18_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e0291a026d743f2b05b3fe91e58229b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11f403f253414aff975722250ebed665_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f7bbae10a6e443e8fc0880b3115a1d0_D20220415-20220415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">espr:AtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-15</xbrli:startDate><xbrli:endDate>2022-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5746fa6ad7264580a9b24d5d4c46caa2_D20230221-20230223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">espr:AtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-21</xbrli:startDate><xbrli:endDate>2023-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3456d874c623457a8adcfaacbaeb0697_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">espr:AtTheMarketProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib488c87ccc86426b94cb6b54cc339eab_I20211202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WainwrightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65f77ad90bd045109470849cecbc6ea3_D20211202-20211202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WainwrightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-02</xbrli:startDate><xbrli:endDate>2021-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i326e6c7729314df9be278a89e941857f_I20230319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:TheWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife8d4c895c31407d94cb9c6ff1903a1a_D20230319-20230319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-19</xbrli:startDate><xbrli:endDate>2023-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d4d2015f62f45aaa2e5addfd39b96f2_I20230319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46d8059776cc44b2bb584005f975602b_D20230319-20230319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-19</xbrli:startDate><xbrli:endDate>2023-03-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7e3ecf1db13427a96c7342395cd96b9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WainwrightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3cca07e819f46e68cad7cce1b9900cb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WainwrightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia89bfe8a898240809b23c12addd330c2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc92509623704e8fa809dc4a3cd974f3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4d3e30f8f084676b1159f8204cf214e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39d14dea4b5f4437b4a560e299ef1164_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5ade988872643258980d4d742f28c71_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedd2a0c27a144f8f80418aaca97d59de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dc5d334d016420f99299c9b501f60ff_I20230424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-04-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id729569cba9c49bfb3259c1d0b23594b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b19c75cff2843b98e3df4b11681f893_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic416a391bdff493fbefe5822e04c52ed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i364cd2415d994d3e85d93df2f35e189e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0616f511266b4f73a0978adcfd5aaa0a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f5e3f1ac3ab4878bb7bbbf20e6fe992_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bb62ba99eea46949781dcab102b26a1_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b532ab4d724df2b12bf304d0f7d08a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2e830b24c974bfb99c9f7bd46ee28b5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03a5a3f73f214702aafb0c19d871baab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief954accff7948b38b762497cb61309d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied19a86173ab476f92091aa5b22ef096_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if98ef8167c62483b9317f69d35a8b12b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c01babe5a404671aaf5f037534a61fc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001434868</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i9237fb157928404b96a8fc7ef6f6efba_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:35.818%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE1_361a3510-0fda-4c82-8dd1-5ccdcebf40b6">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:481.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6ZjI2Y2Q5ZTc0YTVjNDcyZjg0MTVlNmE5OGI1M2NmYzQvdGFibGVyYW5nZTpmMjZjZDllNzRhNWM0NzJmODQxNWU2YTk4YjUzY2ZjNF8wLTAtMS0xLTY1Mjcz_13309141-b3cf-4618-84b2-bb04eea618d7">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8xMjg_b5f7fce3-7b98-4782-9889-95e199a44aa8">March 31, 2023</ix:nonNumeric> </span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:481.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NDM5Zjc4MGU5ZDNjNDRiNGI0ZDA2ZjBkNzc5Y2U0MTMvdGFibGVyYW5nZTo0MzlmNzgwZTlkM2M0NGI0YjRkMDZmMGQ3NzljZTQxM18wLTAtMS0xLTY1Mjcz_30f8f722-3692-40e6-9d22-610f8b07a601">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTA4_be948e41-bfa5-422c-801a-f4faf56fc1d0">001-35986</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTA5_abfb0e84-3ef3-48b4-bf0e-31f67498f7a0">Esperion Therapeutics, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NTdiZGE4YmJmMDFkNGU2YThlNzM1Y2JkNzExM2FjYzgvdGFibGVyYW5nZTo1N2JkYThiYmYwMWQ0ZTZhOGU3MzVjYmQ3MTEzYWNjOF8wLTAtMS0xLTY1Mjcz_6d944ac5-0544-4558-91b8-5419ba993487">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NTdiZGE4YmJmMDFkNGU2YThlNzM1Y2JkNzExM2FjYzgvdGFibGVyYW5nZTo1N2JkYThiYmYwMWQ0ZTZhOGU3MzVjYmQ3MTEzYWNjOF8wLTItMS0xLTY1Mjcz_be163861-597f-4246-98e4-8976b14d1c56">26-1870780</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE2_33f796a4-1455-4229-a59f-39e6e6263abd">3891 Ranchero Drive, Suite&#160;150</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTEw_1d6b304c-9be0-4c02-9962-70a65c1b4a3b">Ann Arbor</ix:nonNumeric>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTEx_b65523a0-bf78-4432-99a6-b6695ccacbab">MI</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTEy_b413bf9a-daf8-4f1e-bd4f-06afaa7e0ec9">48108</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of principal executive office) (Zip Code)</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE3_a5b4ad83-0d7b-4588-a715-1321bde07acb">734</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTEz_8121ccdc-3160-47b6-93f3-30805eee4c6d">887-3903</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NDZiMTJmMWI0OWY0NGMyYjhjYjMwOGRhNDUzOTFiODgvdGFibGVyYW5nZTo0NmIxMmYxYjQ5ZjQ0YzJiOGNiMzA4ZGE0NTM5MWI4OF8xLTAtMS0xLTY1Mjcz_ef234387-4628-4ab4-b316-cf4193be13c8">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NDZiMTJmMWI0OWY0NGMyYjhjYjMwOGRhNDUzOTFiODgvdGFibGVyYW5nZTo0NmIxMmYxYjQ5ZjQ0YzJiOGNiMzA4ZGE0NTM5MWI4OF8xLTItMS0xLTY1Mjcz_8215f14f-7650-4bbd-8242-4fdfff6fe51f">ESPR</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NDZiMTJmMWI0OWY0NGMyYjhjYjMwOGRhNDUzOTFiODgvdGFibGVyYW5nZTo0NmIxMmYxYjQ5ZjQ0YzJiOGNiMzA4ZGE0NTM5MWI4OF8xLTQtMS0xLTY1MjczL3RleHRyZWdpb246NjhjY2I3NTAzYWQ5NDIyYWEwMmNhZjRmZjQ3M2QyNWJfNQ_3fe00bc9-feb6-42fc-8555-38f50cc301af">NASDAQ</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock Market LLC</span></div></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE4_4b6f4be4-1e77-451c-af94-12a7487dd87f">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE5_993fa042-0d96-4f88-8693-8c967196d397">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:27.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.922%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">o</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6YTI3ZjIzYjViYWUyNDMyZjgwZGY1NzA2NzVkNzA1MWMvdGFibGVyYW5nZTphMjdmMjNiNWJhZTI0MzJmODBkZjU3MDY3NWQ3MDUxY18yLTAtMS0xLTY3Mjkw_3886e0e1-e895-403c-a7c7-e6aec2ad25cf">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6YTI3ZjIzYjViYWUyNDMyZjgwZGY1NzA2NzVkNzA1MWMvdGFibGVyYW5nZTphMjdmMjNiNWJhZTI0MzJmODBkZjU3MDY3NWQ3MDUxY18yLTQtMS0xLTY1Mjcz_515c28ed-0142-4926-a866-f060ce9ee244">x</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6YTI3ZjIzYjViYWUyNDMyZjgwZGY1NzA2NzVkNzA1MWMvdGFibGVyYW5nZTphMjdmMjNiNWJhZTI0MzJmODBkZjU3MDY3NWQ3MDUxY180LTQtMS0xLTY1Mjcz_d0d49c81-e4ee-4866-b7a7-f09c6b0cc7b3">o</ix:nonNumeric></span></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">o</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE0_5771652b-3c6c-4417-aaad-e38e66a44a8d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">x</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of May&#160;1, 2023, there were <ix:nonFraction unitRef="shares" contextRef="i138e5960375b40e09f319237f97dcd65_I20230501" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMDE3_2d3b0792-6dba-4f7d-933e-09b10de1c190">94,712,657</ix:nonFraction> shares of the registrant&#8217;s Common Stock, $0.001 par value per share, outstanding.</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"></span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Therapeutics,&#160;Inc.</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:89.090%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_10">PART&#160;I &#8212; FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_13">Item 1. Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_16">Condensed Balance Sheets at </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_16">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_16"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_16">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_16">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_16">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_16"> and December&#160;31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_16">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_19">Condensed Statements of Operations and Comprehensive Loss for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_19">month periods ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_19">M</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_19">arch</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_19"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_19">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_19">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_19">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_19"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_19">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_22">Condensed Statements of Stockholders&#8217; Deficit for the three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_22">month periods ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_22">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_22"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_22">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_22">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_22">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_22"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_22">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_22">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_25">Condensed Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_25">three </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_25">month periods ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_25">March</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_25"> 3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_25">1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_25">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_25">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_25"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_25">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_25">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_28">Notes to Condensed Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_28">7</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_79">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_79">26</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_97">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_97">35</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_100">Item 4. Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_100">35</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_103">PART&#160;II &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_106">Item 1. Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_106">37</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_109">Item 1A. Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_109">37</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_112">Item 6. Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_112">40</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_115">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_115">42</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div><span><br/></span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_13"></div><div><span><br/></span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Esperion Therapeutics, Inc.</span><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNC0xLTEtMS02NTI3Mw_52522d78-3b24-4553-8f64-9a8ea841c1a6">144,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNC0zLTEtMS02NTI3Mw_24bb49fb-aacf-468d-a95e-0824262abcff">124,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNS0xLTEtMS02NTI3Mw_923d7430-f6a5-4fe3-a931-fddde4e508c9">17,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNS0zLTEtMS02NTI3Mw_7805a0ea-7a60-43e3-9b9c-122ec078d07a">42,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNi0xLTEtMS02NTI3Mw_9795a55e-2945-483f-a88a-6517b1cb38b9">36,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNi0zLTEtMS02NTI3Mw_f93c924b-00b4-49ac-be88-0ddbac09beb7">33,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="espr:PrepaidClinicalDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNy0xLTEtMS02NTI3Mw_25e5dd21-d0df-47aa-886c-4a2bab7595ca">6,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="espr:PrepaidClinicalDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNy0zLTEtMS02NTI3Mw_0cb1aca2-7f3d-41d4-8078-3675e8ca282d">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfOC0xLTEtMS02NTI3Mw_142796da-eac7-4040-8690-fed3d8c5e111">39,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfOC0zLTEtMS02NTI3Mw_8bdb9510-ea87-4879-a239-9e32f6272fc7">35,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other prepaid and current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfOS0xLTEtMS02NTI3Mw_05a81f49-1473-4ffd-a004-586c926629f9">5,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfOS0zLTEtMS02NTI3Mw_bce990a7-746e-4280-bb88-b3a6094d3a2b">9,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTAtMS0xLTEtNjUyNzM_09f7d1ec-3d12-4ead-87fd-df79c1ad6d3a">250,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTAtMy0xLTEtNjUyNzM_5e0adbd3-ac16-4f99-8933-9093152ddcbf">246,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTMtMS0xLTEtNjUyNzM_95b9f8ff-584f-46ed-b980-9dd7d7bf8130">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTMtMy0xLTEtNjUyNzM_a15dbfda-96ea-4812-85f6-5c7c1be5dbd1">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use operating lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTQtMS0xLTEtNjUyNzM_a73cfef9-2886-4cb2-93e2-1b5d390ee449">1,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTQtMy0xLTEtNjUyNzM_79d5e61e-7bfb-412b-a640-e49374ceb452">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTUtMS0xLTEtNjUyNzM_45a5eca7-6d14-4e11-88b7-4cced0824938">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTUtMy0xLTEtNjUyNzM_71b7641a-9bc9-4adf-b94a-36d8ab4d6ff2">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTYtMS0xLTEtNjUyNzM_6733acbd-294d-4384-822a-4d99b31586c6">251,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTYtMy0xLTEtNjUyNzM_c32daa8f-fe7a-4deb-a5a5-98fb7cfe71bf">247,939</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjAtMS0xLTEtNjUyNzM_d69a4ef5-87e2-49d3-b43d-8685973b8746">17,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjAtMy0xLTEtNjUyNzM_497a2ab0-a80d-4829-ae11-8eb8bf08e079">23,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="espr:AccruedClinicalDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjEtMS0xLTEtNjUyNzM_f9602472-346d-45b4-ba2b-6d06e0c21dd7">4,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="espr:AccruedClinicalDevelopmentCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjEtMy0xLTEtNjUyNzM_7c182a81-5401-4bfd-936b-093b61d2af82">5,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjItMS0xLTEtNjUyNzM_ce83254d-bae6-49c9-a316-55f505034112">34,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjItMy0xLTEtNjUyNzM_31364864-5c74-490f-aa89-d964d22e983c">35,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="espr:RevenueInterestLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjMtMS0xLTEtNjUyNzM_dd3f4c68-4708-4815-a7c0-d6940c703bb6">26,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="espr:RevenueInterestLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjMtMy0xLTEtNjUyNzM_fa3a5c1e-d6ef-4a12-8078-d15d116f30d3">24,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue from collaborations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjQtMS0xLTEtNjUyNzM_4590251d-9398-43be-a227-73355061d201">12,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjQtMy0xLTEtNjUyNzM_243e30cf-6ddd-4c9c-90f0-39a8aa04475e">3,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjUtMS0xLTEtNjUyNzM_6e59b46f-f0be-4c66-9e12-5af958b70d6f">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjUtMy0xLTEtNjUyNzM_e7af4f41-cb5d-4d4a-9c32-5575c14c913f">384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjYtMS0xLTEtNjUyNzM_67db23cd-ef98-4d1c-aa80-28082a520509">95,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjYtMy0xLTEtNjUyNzM_e8d930a3-a6c9-4348-81d2-a2da0aa7b2b3">92,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible notes, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjgtMS0xLTEtNjUyNzM_ab4ad564-9b24-474a-85fa-d129d23c618c">260,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:ConvertibleLongTermNotesPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjgtMy0xLTEtNjUyNzM_efcf1d51-4eee-47d2-a24b-1111ab581600">259,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue interest liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="espr:RevenueInterestLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjktMS0xLTEtNjUyNzM_ca3635e3-66fb-4efe-9853-d48c84ae296d">224,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="espr:RevenueInterestLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjktMy0xLTEtNjUyNzM_08e3ab21-0089-4b1d-88b1-f872393b4b0e">218,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzAtMS0xLTEtNjUyNzM_d923fa57-e760-4071-bbb3-75170a2c62da">782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzAtMy0xLTEtNjUyNzM_88450900-6157-4365-b647-cb422db3392b">665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzMtMS0xLTEtNjUyNzM_8b80cfb2-d0af-47d6-a80a-f1572b892d5a">581,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzMtMy0xLTEtNjUyNzM_7d3f822b-c97f-4fd2-8c07-485c1a729321">571,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 5)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzQtMS0xLTEtNjUyNzM_091b5e43-7085-446b-a999-a41a20edd312"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzQtMy0xLTEtNjUyNzM_e3bd58b9-ae1b-40fe-857e-e366682cca46"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF8yMQ_3f62342f-c57f-4a6a-93bf-893833381ceb"><ix:nonFraction unitRef="usdPerShare" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF8yMQ_5d7d3d28-c313-4674-b2c1-75f3bef44276">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF8zNQ_79d087fc-1e3f-4d6c-8aac-97ed6883a580"><ix:nonFraction unitRef="shares" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF8zNQ_c9af3fcd-23ae-4fd8-b853-6554d716dd0a">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF82MA_18f86288-8829-4fd2-a4c1-690b735bde01"><ix:nonFraction unitRef="shares" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF82MA_67d7290a-2cf6-43c7-adab-5c78c25c9984"><ix:nonFraction unitRef="shares" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF82MA_8d075764-a81e-413c-b9f9-7f4ce56bbed0"><ix:nonFraction unitRef="shares" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF82MA_9c07af7c-b233-4f6b-a64b-4a612131652a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of March&#160;31, 2023 and December 31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMS0xLTEtNjUyNzM_5d460864-2f2a-4adc-bc39-7530303bea9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMy0xLTEtNjUyNzM_00cf12c9-fc4c-4985-b418-dc839fddfbc4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18xOA_af0cf932-03fb-40c1-a7ab-674f3164b803"><ix:nonFraction unitRef="usdPerShare" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18xOA_e6a71bdc-cbad-4266-8116-17dcc363915e">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18zMg_50a3b7e2-6c81-436e-a462-5b29b3da155d"><ix:nonFraction unitRef="shares" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18zMg_5416d906-be40-415c-b14c-a6fb1ce937ee">240,000,000</ix:nonFraction></ix:nonFraction> shares authorized as of March&#160;31, 2023 and as of December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18xMTI_afa6f588-b8ae-4c09-b12e-0328503d3464">89,237,167</ix:nonFraction> shares issued at March&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18xMzk_04d10912-c38a-489c-ba90-0b4a03be4162">76,564,396</ix:nonFraction> shares issued at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMS0xLTEtNjUyNzM_413ea19f-c00f-4624-8683-4fb7d4f7faf6">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMy0xLTEtNjUyNzM_16444ca2-a78b-4e5b-91bc-348b02691ee8">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzgtMS0xLTEtNjUyNzM_eecca7ec-e8af-41e7-85cd-65ebd19c5893">1,127,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzgtMy0xLTEtNjUyNzM_6929adf6-16e8-4750-ba5f-05847ac95ec1">1,071,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost; <ix:nonFraction unitRef="shares" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzktMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjpjOWQ0YTdiZjUyMTg0NjZmYTk5N2E0NDY5NDEwN2FiY18yOQ_6f19d6f5-ebc1-470d-9d2f-b8d9e60a1809"><ix:nonFraction unitRef="shares" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzktMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjpjOWQ0YTdiZjUyMTg0NjZmYTk5N2E0NDY5NDEwN2FiY18yOQ_d1c84a78-11bb-493d-b42d-8201eeeea1a3">1,994,198</ix:nonFraction></ix:nonFraction> shares at March&#160;31, 2023 and December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzktMS0xLTEtNjUyNzM_ee899319-a238-43f0-9afe-2528d04928f2">54,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzktMy0xLTEtNjUyNzM_4f797686-b747-4763-9e02-a3b36d344aa6">54,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDAtMS0xLTEtNjUyNzM_c2640e39-9d91-4559-8b4e-2f3dbc3153a4">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDAtMy0xLTEtNjUyNzM_6b9521c8-9f1e-43c3-a28c-51e80f0973c7">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDEtMS0xLTEtNjUyNzM_0c6c6137-0f86-45e3-a926-121931e4d9a4">1,401,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDEtMy0xLTEtNjUyNzM_85bc791c-d747-46dd-ad0b-a8da21b5dc92">1,340,036</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDItMS0xLTEtNjUyNzM_2a0e4500-5646-4e43-a7e9-4e841dd38ca1">329,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDItMy0xLTEtNjUyNzM_2e234d92-cb54-4f77-9388-6cb762aea7ab">323,778</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; deficit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDMtMS0xLTEtNjUyNzM_873a1ba1-ad42-44f3-8df2-689f96d5a521">251,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDMtMy0xLTEtNjUyNzM_ef9c033e-8e50-4eb0-8e1c-2da5cc42b557">247,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Therapeutics,&#160;Inc.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.391%"><tr><td style="width:1.0%"></td><td style="width:62.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.230%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.796%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.230%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.798%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2b77b80c5d249d29e61285804d99500_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMy0xLTEtMS02NTI3Mw_d57d7a08-caa6-4d16-9959-3ee08814da42">17,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27f18e48d6294e8b944c473a6e0492ed_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMy0zLTEtMS02NTI3Mw_fcd356c1-d9a7-4049-98f8-73d5be05a264">13,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db3ef3bcd8641beb4f52ba5d002ddb4_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfNC0xLTEtMS02NTI3Mw_9f7f6a10-f209-4208-a839-d869b144ca51">7,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i465260a8cedb484e9ea4a4a8159d8ed6_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfNC0zLTEtMS02NTI3Mw_2f70bbcf-bdc9-4f7c-84e4-dfbd838ea23f">5,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfNS0xLTEtMS02NTI3Mw_4cd8c1a6-59ed-4c2a-bbb4-cab6452b0ba2">24,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfNS0zLTEtMS02NTI3Mw_e2aa44ad-3c83-4cb0-8c03-f3b5f335bdd6">18,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfOC0xLTEtMS02NTI3Mw_4c67bc35-42a8-4812-9888-f2b312c64391">11,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:OtherCostAndExpenseOperating" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfOC0zLTEtMS02NTI3Mw_b340ec30-a136-4f80-81be-2d4e558929fb">7,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfOS0xLTEtMS02NTI3Mw_b55db6d5-fe01-4f03-82b2-1e9f6f334c68">31,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfOS0zLTEtMS02NTI3Mw_2cef134b-06ac-4f02-97cf-ec4187ab9daf">24,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTAtMS0xLTEtNjUyNzM_c5187e73-f3b0-4d6f-a4d1-91bd64ca7cf9">29,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTAtMy0xLTEtNjUyNzM_1387df6d-5de7-470d-9e64-e55632095f2d">30,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTEtMS0xLTEtNjUyNzM_b8ea61b5-7b47-4a64-8b7d-4a1a73ab244b">72,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTEtMy0xLTEtNjUyNzM_05941154-ecfb-4578-b9ec-ec509c4f77f1">61,825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTMtMS0xLTEtNjUyNzM_8980281c-4503-4c75-bf13-2be6cbc88195">48,605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTMtMy0xLTEtNjUyNzM_5aba8171-fac3-496f-af60-f597a90ee48f">42,989</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTUtMS0xLTEtNjUyNzM_f21c0262-aa55-4176-8c4c-f56f4178d737">14,387</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTUtMy0xLTEtNjUyNzM_23199a2e-6c50-4daa-be98-74b045e90407">14,062</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTYtMS0xLTEtNjUyNzM_69c1c29e-2f70-4b49-9214-83e2a2835429">1,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTYtMy0xLTEtNjUyNzM_5ee7a395-ea3b-49c9-bbdc-862e69798cf2">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTctMS0xLTEtNjUyNzM_af5e3b3a-0986-4c08-b2ae-275a150d8f0b">61,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTctMy0xLTEtNjUyNzM_f792266a-a04b-44ed-a31a-89e585b4d0ca">56,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTktMS0xLTEtNjUyNzM_1bcaa1d2-164f-4e0b-a8fb-4d7f76ab6b6f"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTktMS0xLTEtNjUyNzM_56f21b0e-290b-401a-bdc0-6b0444cfbb37">0.79</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTktMy0xLTEtNjUyNzM_3407284c-51b2-4afd-81c0-4a1b24c7178c"><ix:nonFraction unitRef="usdPerShare" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTktMy0xLTEtNjUyNzM_d1f22d5f-5dee-4403-98fb-88ddc24c19cb">0.93</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjEtMS0xLTEtNjUyNzM_6a7937b2-d169-4e16-bc39-c5a75539163d"><ix:nonFraction unitRef="shares" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjEtMS0xLTEtNjUyNzM_bb9f3946-17af-4651-bf69-579b31662fb0">78,440,266</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjEtMy0xLTEtNjUyNzM_2603a1b5-5bed-4024-8f8a-9d3149078ed9"><ix:nonFraction unitRef="shares" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjEtMy0xLTEtNjUyNzM_bce0d1f4-7253-4aba-95c3-1289fa72148e">60,954,755</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gain (loss) on investments</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjQtMS0xLTEtNjUyNzM_7cd2db96-3d57-40e5-aea9-a66428bee017">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjQtMy0xLTEtNjUyNzM_3d9f0e76-9382-4d89-a840-fdd3eec68ddc">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjUtMS0xLTEtNjUyNzM_7ebd266d-643b-4361-b05e-92b7eed6c7b7">61,718</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjUtMy0xLTEtNjUyNzM_fccc367b-263c-4e29-afd5-6bae00dc2673">56,963</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Therapeutics, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Stockholders&#8217; Deficit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders' Deficit</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6e2ffdc00584f51b68b18c17fd34cd7_I20211231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi0xLTEtMS02NTU1MA_cf7e9974-8596-4b5f-b389-b28c131ce5eb">60,879,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6e2ffdc00584f51b68b18c17fd34cd7_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi0zLTEtMS02NTU1MA_72c29db2-0207-4717-9986-9ec0e4578a20">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96cd74dcb04940069b98e07d316c536b_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi01LTEtMS02NTU1MA_5a5904f7-5b4d-4187-ad76-962d90c26593">964,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13fe6538e08e4e9e95c7d4ea4d868263_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi03LTEtMS02NTU1MA_901f2638-5df8-4db2-a994-38abcee8a378">1,106,377</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00efd75341744eafa3659cc293e6f016_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi05LTEtMS02NTU1MA_21a5a64c-1dd8-4667-94a6-91c82a02617a">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i735d7eb128bb425881b2106dba0bc826_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi0xMS0xLTEtNjU1NTA_389af8e5-6f68-4930-857e-35084e6489da">54,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ed0b5ab60804e7ba2963330f6311982_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi0xMy0xLTEtNjU1NTA_ebf913f0-29fc-40cc-bf08-e2499e99cbfd">196,944</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied4203a5755144439c1cc7549b1adda6_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNC0xLTEtMS02NTU1MA_1de0be03-f2b3-45d7-844b-5b04a848694a">55,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of ESPP Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied4203a5755144439c1cc7549b1adda6_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNS0xLTEtMS02NTU1MA_1ad84145-f06d-4031-aa5b-ecd012d075e4">123,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3682159d79c4bc58c63d3f05153448b_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNS01LTEtMS02NTU1MA_3c8f2fc0-321e-4bd4-8c9f-b8ec25373522">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNS0xMy0xLTEtNjU1NTA_92800397-0724-4ded-bba2-c2210e1251d1">431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3682159d79c4bc58c63d3f05153448b_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNi01LTEtMS02NTU1MA_2a59a9fe-78d6-48ff-bc70-9c1363a5f78d">4,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNi0xMy0xLTEtNjU1NTA_8f79762c-d95c-4d86-833f-6d6d045b643d">4,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i65b2edc7703246bb9244d72048a96b56_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNy05LTEtMS02NTU1MA_1742ca2a-628e-4a37-b2aa-256f333cc07c">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNy0xMy0xLTEtNjU1NTA_39b6d6d6-0d7a-4815-80cb-cc0ed158a034">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i85ece9e3706a4128875ddb42c594ca79_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOC03LTEtMS02NTU1MA_ce927e8c-8993-43a2-909b-8358ee756035">56,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOC0xMy0xLTEtNjU1NTA_3a5b63ea-aac0-4d7c-9e8e-9bdbac8b46bb">56,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7ac34f1300344bff8cbb530bbc966b3a_I20220331" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS0xLTEtMS02NTU1MA_53a3bdb1-7793-426f-8409-b589dfbc5063">61,058,567</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ac34f1300344bff8cbb530bbc966b3a_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS0zLTEtMS02NTU1MA_093795b5-d637-4f21-9b03-5e8e8219cf5c">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c5aee48198c4721a9a6396775fbc9df_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS01LTEtMS02NTU1MA_eaa35de2-1db2-4229-b073-d7c51bf05fcf">969,268</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5d8ac1d3b1f4bfd9174292f26013954_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS03LTEtMS02NTU1MA_a428fbb1-f127-4c4c-a462-51e8fcb09566">1,163,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c4384b7bf6a4a13a1b8e29a389fa42c_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS05LTEtMS02NTU1MA_19a0397a-f41a-433d-b48f-bb426327e8e4">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5617bf716d28411ebabd53cd816b47f0_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS0xMS0xLTEtNjU1NTA_842cea10-fb49-4fd2-b110-312e3d094a5b">54,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99f951895edd442e82a9307c2fd15632_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS0xMy0xLTEtNjU1NTA_d95acbb7-2817-40eb-9c4b-a7207a1895a8">249,040</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders' Deficit</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9df09bf3eb9f4d92a8093c27cf22cb5a_I20221231" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi0xLTEtMS02NTI3Mw_fac6b1cd-7e05-481a-85bf-71186f1717dc">74,570,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9df09bf3eb9f4d92a8093c27cf22cb5a_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi0zLTEtMS02NTI3Mw_cd22c516-70b5-46c0-8569-d936b7cfa9a3">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b8c5a52c3b749aaa0e91a6da46ae301_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi01LTEtMS02NTI3Mw_c68393e8-8326-4379-b1a1-a3122b82a4a0">1,071,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i530db00620494f0d8c03838ac8b04a07_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi03LTEtMS02NTI3Mw_5a045525-72d3-4c6c-8c52-2ae18f7a6c14">1,340,036</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d56f0010704f36816774ad7c5f40f4_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi05LTEtMS02NTI3Mw_05abd944-8aa1-4139-b666-5b1adddc06e5">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d5484c9784f4fd1aa72d1ad735a068e_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi0xMS0xLTEtNjUyNzM_b37e1022-84cb-4dda-9ec9-58001043463c">54,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi0xMy0xLTEtNjUyNzM_ebb93337-d882-4015-bacf-a4e42507aa0f">323,778</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of restricted stock units and performance-based restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb28160fa7384975be907af6cd2a9f51_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNC0xLTEtMS02NTI3Mw_566b5d9f-ac2f-44e1-bfc0-5873bf8be724">372,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vesting of ESPP Shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb28160fa7384975be907af6cd2a9f51_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNS0xLTEtMS02NTI3Mw_ae38b61d-7423-4e1b-921f-cb38ed9ff8be">95,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69cd4c90044a41f7861387a767ee94d2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNS01LTEtMS02NTI3Mw_59252173-6dc3-41cb-8294-fa410b84400f">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNS0xMy0xLTEtNjUyNzM_80d9f809-92a5-4814-a799-9ddb7880b100">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69cd4c90044a41f7861387a767ee94d2_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNi01LTEtMS02NTI3Mw_60a4c754-3aed-4b3e-8ea2-5f1403dabee7">2,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNi0xMy0xLTEtNjUyNzM_523857f7-b2a7-41c7-9285-445668138af5">2,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock, warrants, and pre-funded warrants, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb28160fa7384975be907af6cd2a9f51_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy0xLTEtMS02NTYyNw_2a22c084-52c8-4fbd-af04-b13027464d16">12,205,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb28160fa7384975be907af6cd2a9f51_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy0zLTEtMS02NTYyNw_7cd18f38-2de8-4242-94a2-de55e3d86f40">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69cd4c90044a41f7861387a767ee94d2_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy01LTEtMS02NTYyNw_19caeccb-6c62-4075-af6e-891a0f3ab564">52,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy0xMy0xLTEtNjU2Mjc_2c1bc93c-9409-4fa5-8303-b050a4b27eee">52,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive gain</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia012cc762a894ec387428edb3a5b3bac_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy05LTEtMS02NTI3Mw_d4331e22-2698-43b4-94c8-2b08a055ec05">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy0xMy0xLTEtNjUyNzM_56b041b6-becb-48fc-b6ce-d9f90c7755d4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8a9f1879a9d4499392ef45ea2e774ecb_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfOC03LTEtMS02NTI3Mw_3d6b0459-d7b8-416d-b575-0680f93157ea">61,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfOC0xMy0xLTEtNjUyNzM_976face0-67e4-4a8f-a6e3-21379e653be9">61,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib55dcb7213154d228df81b8e761f46b0_I20230331" decimals="0" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtMS0xLTEtNjUyNzM_b885a4ed-42dc-4164-9067-a34a96f60bc3">87,242,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55dcb7213154d228df81b8e761f46b0_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtMy0xLTEtNjUyNzM_97f3ddf1-21e1-4c18-944b-66cf483fb287">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f4442b575984c518a0936302e598e13_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtNS0xLTEtNjUyNzM_6891a0fb-f875-46d1-b93c-bea8e1b692cc">1,127,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97c9874b2c3a4d5a806023ad434054ce_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtNy0xLTEtNjUyNzM_9df20987-6658-4091-bf2f-0d9245c6f877">1,401,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i834d7e9dd8044b26a5dda1d39659e958_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtOS0xLTEtNjUyNzM_f7023d2c-ffc1-4625-b60c-ff832dabcbbc">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia033e96d244b4ac48293f47e9660b8be_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtMTEtMS0xLTY1Mjcz_90b74cf7-3d83-4849-86f8-8eff6397b6a1">54,998</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtMTMtMS0xLTY1Mjcz_82b3a20c-4d78-49b2-8eef-384892b86745">329,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.497%"><tr><td style="width:1.0%"></td><td style="width:69.982%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.957%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMy01LTEtMS02NTI3Mw_54e8a7af-bff6-49a8-be33-010d6d11a19c">61,719</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMy03LTEtMS02NTI3Mw_4154aed7-2a85-483a-a3c3-dacd46532655">56,731</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNS01LTEtMS02NTI3Mw_540f753a-e7e1-4662-b06c-a1c278dcbf42">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNS03LTEtMS02NTI3Mw_1a3dcc6d-b3b2-467d-a31e-293ea85b0f95">153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums and discounts on investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNi01LTEtMS02NTI3Mw_0eb80208-db06-4703-b2e4-45d10135bcc8">339</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNi03LTEtMS02NTI3Mw_b9fad5f5-c640-4e2e-b5d5-5077d7655c75">173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNy01LTEtMS02NTI3Mw_d36e65a1-2ca4-4319-8c49-9978da77fe8c">417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNy03LTEtMS02NTI3Mw_d95ccafa-14a1-4267-94d6-b3f4925051ef">398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense related to the revenue interest liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="espr:NonCashInterestExpenseRelatedToRevenueInterestLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfOS01LTEtMS02NTI3Mw_882e26b5-47bd-42fb-a99d-281d29f8d255">11,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="espr:NonCashInterestExpenseRelatedToRevenueInterestLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfOS03LTEtMS02NTI3Mw_3e1bb964-03b6-4bbc-ae55-67357fa87991">11,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTEtNS0xLTEtNjUyNzM_dcc3913c-3b56-4340-ab66-2ebbecde3f2d">2,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTEtNy0xLTEtNjUyNzM_2e466d47-d2bf-4ce8-941c-344438411a45">4,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTMtNS0xLTEtNjUyNzM_d382c13e-113c-4e06-98b9-f8918044c14b">2,686</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTMtNy0xLTEtNjUyNzM_a579eda7-5235-438f-b026-fb9df720014d">2,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaids and other assets</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTQtNS0xLTEtNjUyNzM_4a2969cc-f31d-4d91-b48d-3e07affa43bf">1,608</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTQtNy0xLTEtNjUyNzM_21019f19-018b-4349-8ac9-1023d03fa06b">764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTUtNS0xLTEtNjUyNzM_3ca06894-de09-41f6-b952-adf91f2e500c">8,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTUtNy0xLTEtNjUyNzM_50c94aa3-2684-456a-8272-2ab694f28886">2,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTYtNS0xLTEtNjUyNzM_9f016829-c35d-419c-bd0b-85801ae7eca6">4,151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTYtNy0xLTEtNjUyNzM_3a159d23-0fe5-4bc1-a18f-b00e7c9f2aac">1,260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTgtNS0xLTEtNjUyNzM_5e1f1110-90fb-4897-a9e2-33b49b46276a">5,975</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTgtNy0xLTEtNjUyNzM_d167256c-3390-4b59-9687-288d3ce60180">9,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTktNS0xLTEtNjUyNzM_868a5cc1-b8e3-48fb-a63f-b078b2870d6e">1,249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTktNy0xLTEtNjUyNzM_f253c63b-3a30-4e64-88ef-1e46c2f823ef">3,049</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjAtNS0xLTEtNjUyNzM_27a21692-0d5a-450b-a38f-8ff790f74950">54,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjAtNy0xLTEtNjUyNzM_df36df70-c3e3-45e0-923f-a07bebf47533">38,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjMtNS0xLTEtNjUyNzM_9e3ed085-a3ba-417d-9281-f604d8565178">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjMtNy0xLTEtNjUyNzM_1e6b7bc1-0fd0-45df-b526-4c98dc8825fe">18,102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales/maturities of investments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjQtNS0xLTEtNjUyNzM_8bbc9d68-66e4-4c3d-a7da-ede947d1ffa8">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjQtNy0xLTEtNjUyNzM_ff349685-9295-436d-ae7d-621fcbf3b8e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjYtNS0xLTEtNjUyNzM_3ed06409-a1ea-4d50-949b-24195c25404c">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjYtNy0xLTEtNjUyNzM_0f8c539b-a241-4d48-807a-32d34d3f74e8">18,102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on revenue interest liability</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="espr:PaymentsFromRevenueInterestPurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzMtNS0xLTEtNjUyNzM_880d1946-7f48-4b98-bef6-97d331872312">3,106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="espr:PaymentsFromRevenueInterestPurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzMtNy0xLTEtNjUyNzM_5a879c61-a021-4789-9825-8e9a169fd2ce">1,217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, warrants, and pre-funded warrants, net of issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNS0xLTEtNjczMTE_af37741c-bbcc-4006-9bd7-27d8277756dc"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNS0xLTEtNjczMTE_f59f957b-9608-4bc1-9c73-86683bed32a9">52,598</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNy0xLTEtNjczMTI_daa2fba1-2da9-4232-9080-c08ce979d039"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNy0xLTEtNjczMTI_e031100f-fbd3-424f-ba23-a9b8bff8187d">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of issuance costs</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNS0xLTEtNjUyNzM_59b36f2f-54b4-4ab6-9adc-01710c48c009">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNy0xLTEtNjUyNzM_80b4168f-22fd-43f6-87f8-314fa753cc6e">219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzUtNS0xLTEtNjUyNzM_19f22ee2-52c4-4eb7-a31b-3bccf10098cd">49,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzUtNy0xLTEtNjUyNzM_dc869c5c-dbec-4972-af7c-fcc93b5b5170">1,436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzctNS0xLTEtNjUyNzM_b303859a-1be7-4d24-b5c0-fcf2bf7968bc">20,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzctNy0xLTEtNjUyNzM_17f89a1a-5c85-4cf4-93eb-66729cd6d333">58,528</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzgtNS0xLTEtNjUyNzM_96fa62e4-641d-46db-88bc-641dcb5f8955">124,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0b5ab60804e7ba2963330f6311982_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzgtNy0xLTEtNjUyNzM_fdbecfa4-5e7c-40bd-b8b0-b86b15d653de">258,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzktNS0xLTEtNjUyNzM_01e28c48-dc1c-48b5-92b8-d3896c576c3c">144,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f951895edd442e82a9307c2fd15632_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzktNy0xLTEtNjUyNzM_9b6a4fcc-9e86-4103-ad58-b267a0a76c55">200,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock issuance, warrant, and pre-funded warrant issuance costs not yet paid</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="espr:CommonStockIssuanceCostsIncurredNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNDEtNS0xLTEtNjUyNzM_ff5f95f3-71b0-467c-8d78-d3fd71459542">170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="espr:CommonStockIssuanceCostsIncurredNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNDEtNy0xLTEtNjUyNzM_54f7cbe7-5b24-4fbf-8f15-ba4cf133a873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non cash right of use asset</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="-3" name="espr:NonCashRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNDQtNS0xLTEtNjUyNzM_b5e42548-f3ac-459d-a3c6-ef800495f1ab">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="-3" name="espr:NonCashRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNDQtNy0xLTEtNjUyNzM_57044358-c59b-45a4-9899-b18a746f1dac">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Esperion Therapeutics,&#160;Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_31"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTMxMA_f1775f2f-a12a-4a83-9071-6f7038c5a97b" continuedAt="i022ae27e7d124f4b871562157db603c4" escape="true">The Company and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="i022ae27e7d124f4b871562157db603c4" continuedAt="i15cce3965bdc4bb3834def091fc0d573"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Esperion Therapeutics, Inc. ("the Company&#8221;) is a pharmaceutical company singularly focused on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol ("LDL-C"). Through commercial execution and completion of the CLEAR Outcomes trial as well as advancing the Company's pre-clinical pipeline, the Company continues to evolve into a differentiated, global cardiometabolic biotech. The Esperion team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. The Company's first two products were approved by the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Swiss Agency for Therapeutic Products ("Swissmedic") in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease ("ASCVD") or heterozygous familial hypercholesterolemia ("HeFH").</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recently completed a global cardiovascular outcomes trial, or CVOT,&#8201;&#8212;&#8201;known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">holesterol </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">owering via B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mpedoic Acid, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CL-inhibiting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">egimen (CLEAR) Outcomes. The trial was designed to evaluate whether treatment with bempedoic acid reduced the risk of cardiovascular events in patients who are statin averse and who have CVD or are at high risk for CVD. The Company initiated the CLEAR Outcomes CVOT in December 2016 and fully enrolled the study with over <ix:nonFraction unitRef="patient" contextRef="i55f6734ada96468a9b81e77531464725_D20190801-20190831" decimals="-3" name="espr:NumberOfStudyPatients" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzM2_fd8a6b34-2b4f-4ca1-8151-b0bb6806bdf0">14,000</ix:nonFraction> patients in August 2019. The primary endpoint of the study was the effect of bempedoic acid on four types of major adverse cardiovascular events, or MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization; also referred to as &#8220;four-component MACE&#8221;). CLEAR Outcomes was an event-driven trial and concluded once the predetermined number of MACE endpoints occurred. On December 7, 2022, the Company announced that the study had met its primary endpoint.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 4, 2023, the Company announced the full results from the CLEAR Outcomes trial. The study showed that bempedoic acid demonstrated significant</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">cardiovascular risk reductions and significantly reduced the risk of heart attack and coronary revascularization as compared to placebo. These results were seen in a broad population of primary and secondary prevention patients who are unable to maximize or tolerate a statin. The proportions of patients experiencing adverse events and serious adverse events were similar between the active and placebo treatment groups. Bempedoic acid (contained in NEXLETOL&#174; and NEXLIZET&#174; (bempedoic acid and ezetimibe) tablets) now becomes the first LDL-C lowering therapy since statins proven to lower hard ischemic events, not only in those with ASCVD but also in the large number of primary prevention patients for whom limited therapies exist. The Company believes that it remains on track to submit regulatory filings to the FDA and EMA in the first half of 2023 with expected inclusion in the U.S. and EMA labels in the first half of 2024. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 19, 2023, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers named therein (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the &#8220;Offering&#8221;), <ix:nonFraction unitRef="shares" contextRef="idabb0477bfa648dab7fecedc64128780_I20230319" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzQ0_ea7df3e3-3ea0-40cc-ac4b-ac09e9909258">12,205,000</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="idabb0477bfa648dab7fecedc64128780_I20230319" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzU2_1bd40b02-bea2-4a7d-a2c2-9e777ce26b62">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), pre-funded warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i2d316e7178014207990f50547c020dad_D20230319-20230319" decimals="0" name="espr:CommonStockPurchasableUnderPrefundedWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzY0_67c6e16d-71e7-4572-acd9-649f9cd99bba">20,965,747</ix:nonFraction> shares of Common Stock (the &#8220;Pre-Funded Warrants&#8221;) in lieu of shares of Common Stock, and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i2d316e7178014207990f50547c020dad_D20230319-20230319" decimals="0" name="espr:CommonStockPurchasableUnderWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzc2_34e7f861-424a-49ba-ac33-22202858b6b5">33,170,747</ix:nonFraction> shares of Common Stock (the &#8220;Warrants&#8221;). The combined purchase price of each share of Common Stock and accompanying Warrant is $<ix:nonFraction unitRef="usdPerShare" contextRef="i97a34cf836d84f4fadef4d721fab3698_I20230319" decimals="3" name="espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzg4_fb4a8cbb-39bf-4bbb-9fa8-9fe549e2707d">1.675</ix:nonFraction> per share. The purchase price of each Pre-Funded Warrant and the accompanying Warrant is $<ix:nonFraction unitRef="usdPerShare" contextRef="ice6f0592c1f54f6b9a640b944432f3be_I20230319" decimals="3" name="espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzk2_49d2b3a2-a363-4cf0-9260-4a050ddc1f89">1.674</ix:nonFraction> (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $<ix:nonFraction unitRef="usdPerShare" contextRef="idabb0477bfa648dab7fecedc64128780_I20230319" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxNDA0_86387ad6-e39a-4c26-b588-880bcb6598f3">0.001</ix:nonFraction>). The Purchase Agreement contains customary representations, warranties, covenants and indemnification rights and obligations of the Company and the Purchasers. The Offering closed on March 22, 2023. In connection with the Offering, the Company amended, pursuant to Warrant Amendment Agreements (the &#8220;Warrant Amendment Agreements&#8221;), certain existing warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322" decimals="0" name="espr:CommonStockPurchasableUnderWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODM0NjE5_16c0d97f-632f-44d1-80e7-237923dca99d">9,024,212</ix:nonFraction> shares of the Company's common stock that were previously issued in December 2021 at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7ce060f7a8354b51af7f71258119d414_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODM0NjM3_57584d4e-941d-4627-bc49-9a9e9e42162b">9.00</ix:nonFraction> per share and had an expiration date of December 7, 2023, effective upon the closing of the Offering, such that the amended warrants have a reduced exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2905ddfb2a734b91a7b4f966c0bb65da_I20230323" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODM0NjMw_69da0eb8-6b18-4cc2-a4fa-2832d4c513b1">1.55</ix:nonFraction> per share and expire three and one half years following the closing of the Offering, for additional consideration of $<ix:nonFraction unitRef="usdPerShare" contextRef="i90c4fbf04c494d99bd37f6e4eb559905_I20230322" decimals="3" name="espr:ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODM0NjQ0_adc194ab-b7d7-4c72-8dd1-c6fe49b05d53">0.125</ix:nonFraction> per amended warrant. The Company received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfMjE5OTAyMzI3MzM2Nw_bf49bfbf-249c-4b0c-9e77-0193569ce032">55.5</ix:nonFraction>&#160;million from the Offering, before deducting placement agent fees and related offering expenses. The net proceeds to the Company from the Offering, after deducting the placement agent fees and expenses and the Company&#8217;s estimated offering expenses, are approximately $<ix:nonFraction unitRef="usd" contextRef="i5664faaee9574db4a202135e028596c8_D20230319-20230319" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfMjE5OTAyMzI3MzYyOQ_81836684-c76b-4491-b188-3e7ce82ba3cb">51.3</ix:nonFraction>&#160;million. In addition, the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="i5664faaee9574db4a202135e028596c8_D20230319-20230319" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfMjE5OTAyMzI3MzY4Mg_2595d9ab-0dfb-408c-b25f-ee8ea08c232c">1.2</ix:nonFraction>&#160;million as the gross consideration in connection with the Warrant Amendment Agreements. The net proceeds of the Warrant Amendment Agreements after deducting placement fees were approximately $<ix:nonFraction unitRef="usd" contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMzNTM4_eb4bbd2b-1b7c-4655-80c0-a2985ee26a4e">1.1</ix:nonFraction>&#160;million. Refer to Note 13 "Stockholders' Deficit" for further information.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's primary activities since incorporation have been conducting research and development activities, including nonclinical, preclinical and clinical testing, gaining commercial approval of its products, developing a commercial sales team, performing business and financial planning, recruiting personnel, and raising capital. The Company received approval by the FDA in February 2020 to commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablet in the U.S., and accordingly commenced principal operations on March 30, 2020 with the commercialization of NEXLETOL. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="i15cce3965bdc4bb3834def091fc0d573"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is subject to risks and uncertainties which include the need to successfully commercialize its products, research, develop, and clinically test therapeutic products; obtain regulatory approvals for its products (or additional or expanded indications for approved products); manage its management, commercial and scientific staff; and finance its operations with an ultimate goal of achieving profitable operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained annual operating losses since inception and expects such losses to continue over the foreseeable future. While management believes current cash resources and future cash received from the Company's net product sales and collaboration agreements with Daiichi Sankyo Europe GmbH ("DSE"), Otsuka Pharmaceutical Co., Ltd ("Otsuka"), and Daiichi Sankyo Co. Ltd ("DS"), entered into on January 2, 2019, April 17, 2020 and April 26, 2021, respectively, will fund operations for the foreseeable future, management may continue to fund operations and advance the development of the Company's products and product candidates through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, and permitted private and public equity offerings or through other sources. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funds are not available, the Company may not be able to continue the development of its current products or future product candidates, or to commercialize its current or future product candidates, if approved.</span></div><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTMxMQ_fb3a7551-abf2-427a-8cfc-004d5694ca63" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2022, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</span></div></ix:nonNumeric></ix:continuation><div id="i9237fb157928404b96a8fc7ef6f6efba_34"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwNzc_3fdb15e7-a17d-4cd9-be36-4fe5543d7438" continuedAt="i3a524e8597e54abf94e4aa492468cfc2" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i3a524e8597e54abf94e4aa492468cfc2" continuedAt="if1f3d116929d4b8c8fdd29257cd012ad"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwNzg_5f3fa0ba-28ab-48cb-8dda-303df9b4e53d" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwNzQ_cbcb6858-5ad9-41c0-9a58-dc2e3393968a" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in bank deposits, money market accounts, and short-term investments. The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents are reported at fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwODE_40f3daec-831f-494a-a707-640e1e033cb8" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are considered to be available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are reported in accumulated other comprehensive income (loss). The cost of investments classified as available-for-sale are adjusted for the amortization of premiums and accretion of discounts to maturity and recorded in other income, net. Realized gains and losses, if any, are determined using the specific identification method and recorded in other income, net. Investments with original maturities beyond 90 days at the date of purchase and which mature at, or less than twelve months from, the balance sheet date are classified as current. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwODI_e5e6c463-5a08-4bb0-9e05-dde9235a6c99" continuedAt="i19c321e6dd044c8b8e9d0c9a80b1f142" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of March&#160;31, 2023, <ix:nonFraction unitRef="customer" contextRef="i82aa535e66f84394b33629688b89827e_D20230101-20230331" decimals="INF" name="espr:ConcentrationRiskNumberOfMajorCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMjMzNA_2ebedcc9-5837-4527-8743-da6bf48c0d4c">eleven</ix:nonFraction> customers accounted for all of the </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="if1f3d116929d4b8c8fdd29257cd012ad" continuedAt="i086589f88f2f4496b2da1232e4ad29e7"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i19c321e6dd044c8b8e9d0c9a80b1f142">Company's net trade receivables and as of December 31, 2022, <ix:nonFraction unitRef="customer" contextRef="i13c84429beb04adb81c5c0e8a4fa22d3_D20220101-20221231" decimals="INF" name="espr:ConcentrationRiskNumberOfMajorCustomers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMjQzMw_078f37da-bf2d-49a8-9397-3a1477f952d2">eleven</ix:nonFraction> customers accounted for all the Company's net trade receivables.</ix:continuation></span></div><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwNzk_e338e422-a665-4a4e-869a-cc0a926c46c1" continuedAt="ib66125a92e3044bd9c2b97db2b85eab0" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through <ix:nonFraction unitRef="revenue_source" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="INF" name="espr:NumberOfSourcesOfRevenue" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMzY1Mw_774b5c04-c3f3-4afe-a751-20c9387e47c6">two</ix:nonFraction> primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones as consideration when it is probable that a future reversal is unlikely to occur. For sales-based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (&#8220;API&#8221;) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="i086589f88f2f4496b2da1232e4ad29e7" continuedAt="i3211df20b515449ebb57b3b7da4f038a"><ix:continuation id="ib66125a92e3044bd9c2b97db2b85eab0" continuedAt="i7a7438820675419dbaef65df45399a97"><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt">Product Sales, Net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $<ix:nonFraction unitRef="usd" contextRef="ie2b77b80c5d249d29e61285804d99500_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfODI0NQ_44d9aed9-6886-44be-8d45-ee6d425be94e">17.0</ix:nonFraction> million for the three months ended March&#160;31, 2023, and $<ix:nonFraction unitRef="usd" contextRef="i27f18e48d6294e8b944c473a6e0492ed_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfODI4OA_33fe4396-099c-4da2-b65d-39fa16a6795a">13.4</ix:nonFraction> million for the three months ended March&#160;31, 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers&#8217; distribution facilities, or free on board (&#8220;FOB&#8221;) destination, the terms of which are designated in the contract.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company&#8217;s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as &#8220;Other accrued liabilities&#8221; in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forms of Variable Consideration</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-pay assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company generally offers a right of return based on the product&#8217;s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company&#8217;s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="i3211df20b515449ebb57b3b7da4f038a"><div style="margin-bottom:12pt;text-indent:36pt"><ix:continuation id="i7a7438820675419dbaef65df45399a97"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company&#8217;s expectations regarding future payment patterns.</span></ix:continuation></div><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwODA_85e9130c-ebfa-4e65-b295-3bb89865af00" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwNzY_bf846fd7-b1b8-47a0-8d33-7d980d0d47aa" escape="true"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Implemented Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div></ix:nonNumeric></ix:continuation><div id="i9237fb157928404b96a8fc7ef6f6efba_37"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfOTIxNQ_848328e8-e7c5-496d-88e7-a673ba9903e6" continuedAt="i9faf687457cc478db3a99a5899f2236e" escape="true">Collaborations with Third Parties</ix:nonNumeric></span></div><ix:continuation id="i9faf687457cc478db3a99a5899f2236e" continuedAt="i6258edfe45a14683889b5b8b3927b9e3"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DSE Agreement Terms</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2019, the Company entered into a license and collaboration agreement with DSE, which was furthered amended on June 18, 2020. Pursuant to the amended agreement, the Company granted DSE exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablet in the European Economic Area, Turkey, and Switzerland (&#8220;DSE Territory&#8221;). DSE will be responsible for commercialization in the DSE Territory. DSE's designated affiliate in Turkey will be solely responsible, at its sole cost and expense, for all regulatory matters relating to such products in Turkey, including obtaining regulatory approval for such products in Turkey. The Company remains responsible for clinical development, regulatory and manufacturing activities for the licensed products globally, including in the DSE Territory outside of Turkey.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the Company received upfront cash of $<ix:nonFraction unitRef="usd" contextRef="ib0dc2923eba0447ab555feccec765db2_D20190102-20190102" decimals="-5" name="espr:UpFrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfOTg1_6eb30394-a8e9-4c45-96f7-fcd69d3754b2">150.0</ix:nonFraction> million in 2019 and a $<ix:nonFraction unitRef="usd" contextRef="ib0dc2923eba0447ab555feccec765db2_D20190102-20190102" decimals="-5" name="espr:CashPaymentToBeReceivedUponFirstCommercialSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMTAwMg_227ee460-354c-4476-919b-f1ee1cdb7b7e">150.0</ix:nonFraction> million cash milestone payment in 2020 following the completion of the NUSTENDI&#174; Marketing Authorisation Applications ("MAA"). The Company is responsible for supplying DSE with certain manufacturing supply of the API or bulk tablets. The Company is also eligible to receive an additional regulatory milestone payment of either $<ix:nonFraction unitRef="usd" contextRef="i5784cd2d48204ab3a25a3176ccbe3451_D20190102-20190102" decimals="-5" name="espr:AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNTQ5NzU1ODI1Mzcz_5ffbd79e-c1ae-431d-a266-82fc50cf9d01">200</ix:nonFraction>&#160;million or $<ix:nonFraction unitRef="usd" contextRef="ia4e347119af144cd8d92b13e2b6c5387_D20190102-20190102" decimals="-5" name="espr:AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNTQ5NzU1ODI1Mzg3_401237fa-c763-459f-b5d2-156a858c956b">300</ix:nonFraction>&#160;million upon the grant of the marketing authorisation in the European Union for the CV risk reduction label, depending on the range of relative risk reduction in the CLEAR Outcomes study. Refer to Note 5 "Commitments and Contingencies" for further information. In addition, the Company is eligible to receive additional sales milestone payments related to total net sales achievements for DSE in the DSE Territory. Finally, the Company receives tiered fifteen percent (<ix:nonFraction unitRef="number" contextRef="i5784cd2d48204ab3a25a3176ccbe3451_D20190102-20190102" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMTcxNg_08713d95-b7af-41d1-ac74-22baf0e45c2e">15</ix:nonFraction>%) to twenty-five percent (<ix:nonFraction unitRef="number" contextRef="ia4e347119af144cd8d92b13e2b6c5387_D20190102-20190102" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMTc0NA_24276632-230b-4490-8258-5d4377e4e4c3">25</ix:nonFraction>%) royalties on net DSE Territory sales.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement calls for both parties to participate in a Joint Collaboration Committee (the &#8220;DSE JCC&#8221;). The DSE JCC is comprised of executive management from each company and the Company will lead in all aspects related to development and DSE will lead in all aspects related to commercialization in the DSE Territory.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March&#160;31, 2023 and 2022, the Company recognized collaboration revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="i437ec51f9da947e4957d1c78257d41ca_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMjIxNg_20b58648-4ce5-4cb7-a2fe-d43db22277de">7.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icc5c8e4669ee430eb7fd9eb3d5682fcc_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMjMzMg_75edbf9a-7a00-4e63-ad7f-2dbb51765f63">5.3</ix:nonFraction> million related to royalty revenue from DSE from the sales of NILEMDO&#174; and NUSTENDI as well as the sales of bulk tablets to DSE pursuant to the supply agreement that was executed with DSE. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All remaining future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to sales-based milestones will be recognized when the subsequent sales occur.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="i6258edfe45a14683889b5b8b3927b9e3" continuedAt="i6ca987c32e33481a922cc1a1e493f96e"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Otsuka Agreement Terms</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, the Company entered into a license and collaboration agreement (the "Otsuka Agreement") with Otsuka. Pursuant to the Otsuka Agreement, the Company granted Otsuka exclusive development and commercialization rights to NEXLETOL and NEXLIZET in Japan. Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan. In addition, Otsuka will fund all clinical development costs associated with the program in Japan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the consideration consists of a $<ix:nonFraction unitRef="usd" contextRef="ia37f88e1d6334cd4988043aa29cb8d9d_D20200417-20200417" decimals="-5" name="espr:UpFrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMzUzNQ_911a7780-97d5-45da-b952-35e69658be44">60.0</ix:nonFraction> million upfront cash payment and the Company will be eligible to receive additional payments of up to $<ix:nonFraction unitRef="usd" contextRef="icbe99073da5e4665be166412628cfbc6_I20200417" decimals="-5" name="espr:AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMzYzMg_5116dd89-41df-457e-972c-e7a040d38d7d">450.0</ix:nonFraction> million if certain regulatory and commercial milestones are achieved by Otsuka. The potential future milestone payments include up to $<ix:nonFraction unitRef="usd" contextRef="i774e2569416f4db59556c5fcd4cc0597_I20200417" decimals="-5" name="espr:FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMzc2MQ_dd9d5a34-29d4-49ff-a2cd-012a8dca33b3">20.0</ix:nonFraction> million upon first JNDA submissions in the Otsuka Territory, up to $<ix:nonFraction unitRef="usd" contextRef="i774e2569416f4db59556c5fcd4cc0597_I20200417" decimals="-5" name="espr:FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMzgyMw_8e3cbb4b-d3bd-4d92-a7aa-56bea8b0daa0">70.0</ix:nonFraction> million upon the first NHI Price Listing for NEXLETOL in the Otsuka Territory, and up to $<ix:nonFraction unitRef="usd" contextRef="i774e2569416f4db59556c5fcd4cc0597_I20200417" decimals="-5" name="espr:FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMzkwNw_2ed8aefd-b1a3-44ae-ba06-a795252725a9">50.0</ix:nonFraction> million upon the achievement of the primary major adverse cardiovascular events (&#8220;MACE&#8221;) in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments up to $<ix:nonFraction unitRef="usd" contextRef="i774e2569416f4db59556c5fcd4cc0597_I20200417" decimals="-5" name="espr:FuturePaymentMilestoneSalesMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNDIzOA_b8fd49da-1e00-4068-ad84-436a3963b741">310.0</ix:nonFraction> million related to total net sales achievements for Otsuka in Japan. Finally, the Company will receive tiered fifteen percent (<ix:nonFraction unitRef="number" contextRef="ia9838052375c4929b5e4b845fe66da84_D20200417-20200417" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNDM2MA_6cf2c764-59f6-4ec7-85ec-f367ca2d482b">15</ix:nonFraction>%) to thirty percent (<ix:nonFraction unitRef="number" contextRef="i556e6b8f854a4c16bc7335cde1d58ab3_D20200417-20200417" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNDM4Mw_58c0cb47-f9ce-4877-b22e-f5a5bc6b8c4e">30</ix:nonFraction>%) royalties on net sales in Japan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company did not have any collaboration revenue from the Otsuka Agreement during the three months ended March 31, 2023 and 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not yet recognized any revenue for milestone payments as the related regulatory and commercial milestones have not yet been achieved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Agreement Terms</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Co. Ltd (the "DS Agreement"). Pursuant to the DS Agreement, the Company granted DS exclusive rights to develop and commercialize bempedoic acid and the bempedoic acid / ezetimibe combination tablet in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. Except for certain development activities in South Korea and Taiwan, DS will be responsible for development and commercialization in these territories. In addition, DS will fund all development costs associated with the program in the DS Territory. Pursuant to the agreement, the consideration consists of a $<ix:nonFraction unitRef="usd" contextRef="ic913c0c79880452395a8e14c510b4c70_D20210401-20210430" decimals="-5" name="espr:FutureUpFrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNjQxOA_c79caa04-0a4c-4d97-99b6-13e8a5c29a04">30.0</ix:nonFraction>&#160;million upfront cash payment that is non-refundable, non-reimbursable and non-creditable. The Company also will be eligible to receive additional one-time payments of up to $<ix:nonFraction unitRef="usd" contextRef="ic913c0c79880452395a8e14c510b4c70_D20210401-20210430" decimals="-5" name="espr:CashPaymentToBeReceivedUponCertainCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNjU4Ng_5e656119-ece7-45a4-9ba2-3c4a88376568">175.0</ix:nonFraction>&#160;million if certain commercial milestones are achieved by DS. Also, the Company will receive tiered royalties of five percent (<ix:nonFraction unitRef="number" contextRef="ifa13681c34ae4d84ab904e7d74d950a1_D20210401-20210430" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNjcwNw_9b4e0ab3-f726-490f-89d6-cbe16cc6e824">5</ix:nonFraction>%) to twenty percent (<ix:nonFraction unitRef="number" contextRef="ic924dfffa02f4560877a7d949f08cede_D20210401-20210430" decimals="2" name="espr:PercentageOfRoyaltiesToBeReceivedOnNetSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNjczMA_d8373c94-d9a2-4cab-bcf1-f4957277313e">20</ix:nonFraction>%) of net sales in the DS Territory.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i58cea3ac6b01461cab29af950aeb53a8_D20210426-20210426" decimals="-5" name="espr:FutureUpFrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNjk1Mw_bfc470e6-f073-4448-9e04-48ffb1e69fc9">30.0</ix:nonFraction>&#160;million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company&#8217;s intellectual property and 2) the obligation to provide ongoing development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company&#8217;s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company&#8217;s obligation to provide ongoing development activities. For the three months ended March 31, 2023 and 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="if38679db574c48ac84aa03b68471cdff_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNTQ5NzU1ODI0OTIy_d4c68b78-be62-44cc-be18-8e6fd7cf216a">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie63bcb21a66346609cd8f6ef61fbffb7_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNTQ5NzU1ODI0OTM2_2673b800-4dad-4fd9-bd85-74ee2abd6e86">0.2</ix:nonFraction>&#160;million, respectively of collaboration revenue related to the ongoing regulatory and development activities. The remaining $<ix:nonFraction unitRef="usd" contextRef="if38679db574c48ac84aa03b68471cdff_D20230101-20230331" decimals="-5" name="espr:DeferredUpFrontPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfODQ3Mg_b760bd00-3a4f-4a47-976f-b3229bed9c7e">0.5</ix:nonFraction>&#160;million of the upfront payment was deferred as of March 31, 2023 due to an on-going performance obligation related to the developmental activities in South Korea and Taiwan. This deferred revenue will be recognized ratably over the period leading up to the completion of these developmental activities.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6ca987c32e33481a922cc1a1e493f96e">All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.</ix:continuation></span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_40"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RleHRyZWdpb246MzExYjE5YmM0MWU2NDg1YTkwMzBjMTI2ZmEzZWZiOTBfODU_3d232829-6787-43f6-8500-ba6995ffb7f5" continuedAt="i6be751d2d2ea4b4ab6de6f5ee5e685de" escape="true">Inventories, net</ix:nonNumeric></span></div><ix:continuation id="i6be751d2d2ea4b4ab6de6f5ee5e685de"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RleHRyZWdpb246MzExYjE5YmM0MWU2NDg1YTkwMzBjMTI2ZmEzZWZiOTBfODY_251fed92-c40d-4530-bed3-a4ace2c3bff3" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMS0xLTEtMS02NTI3Mw_d1880c28-012e-4a15-bc56-544c4b4d5c27">35,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMS0zLTEtMS02NTI3Mw_4aa381c0-54d6-4bdd-ad56-3443a67dd24f">26,558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMi0xLTEtMS02NTI3Mw_5f4725b8-de6d-48c6-8a3c-c13d1503a4d8">1,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMi0zLTEtMS02NTI3Mw_ac6191cd-a2c4-4d07-b56c-c6f18403898a">6,548</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMy0xLTEtMS02NTI3Mw_8e7bcc35-566a-4e26-b159-abf19133b2aa">2,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMy0zLTEtMS02NTI3Mw_acc45ffe-1402-46dc-b42e-ac4addecafa3">2,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfNS0xLTEtMS02NTI3Mw_bfa2d20c-d961-467d-9729-25445e3bedf7">39,352</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfNS0zLTEtMS02NTI3Mw_d086244f-65b9-4046-9f92-7148960558b9">35,201</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div id="i9237fb157928404b96a8fc7ef6f6efba_43"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMjA3MQ_91b5ba98-3437-45f1-9dac-76ab5a795de0" continuedAt="i42435fe4073847de80062d361d301323" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i42435fe4073847de80062d361d301323" continuedAt="i4e0deff50aa044a8929255249f2e70a6"><div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 4, 2023, the Company announced the full results from its Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial. Based on the terms of the contract with DSE, the Company is eligible for partner milestone payments upon inclusion of cardiovascular risk reduction data in the EU label, for which payment is tied to the magnitude of the risk percentage reduction included in the label (among other requirements) and ranges from $<ix:nonFraction unitRef="usd" contextRef="i7d6b22f936e84b6e9cadcd7659d06dc6_D20230304-20230304" decimals="-6" name="espr:PotentialProceedsFromPartnerMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMTQ2MDA_4ee328af-44f2-412e-a92d-4a2aa0ab6458">200</ix:nonFraction>&#160;million for the inclusion of cardiovascular risk reduction in the EU label that correlates with a relative risk reduction rate that, based on the CLEAR Outcomes data, is equal or greater than <ix:nonFraction unitRef="number" contextRef="ica364f56b4754e2fb33645747ebebdba_I20230304" decimals="2" name="espr:PercentageOfRiskReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMTQ2MDQ_72852af6-2a39-40d1-95fe-3a96927e24c8">15</ix:nonFraction>% but less than <ix:nonFraction unitRef="number" contextRef="i0ff170b7510847eeb8c913c0268553d5_I20230304" decimals="2" name="espr:PercentageOfRiskReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMTQ2MDg_8fdcb75d-5b1c-4bf4-89ba-dbc42683e4d1">20</ix:nonFraction>%, to $<ix:nonFraction unitRef="usd" contextRef="i5eb81084a86e42b49fbea9ece7638ea5_D20230304-20230304" decimals="-6" name="espr:PotentialProceedsFromPartnerMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMTQ2MzY_a67a00a6-ab1f-48e3-a2c8-348b36d987ab">300</ix:nonFraction>&#160;million if such risk reduction in the EU label that correlates with a relative risk reduction rate is equal or greater than <ix:nonFraction unitRef="number" contextRef="i9e14be02d3004562870df907dec00d77_I20230304" decimals="2" name="espr:PercentageOfRiskReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMTQ2MzI_7d7dd1f8-62ad-4531-aec7-8068d2da762e">20</ix:nonFraction>%. Based on the CLEAR Outcomes data, the Company believes it would be entitled to receive $<ix:nonFraction unitRef="usd" contextRef="i6dc542279e7e464ca12100e49501610e_D20230304-20230304" decimals="-6" name="espr:PotentialProceedsFromPartnerMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfNTQ5NzU1ODI0MjUy_3f3de592-f842-4f5f-bef2-a9c4b685c4b0">300</ix:nonFraction>&#160;million in partner milestone payments upon inclusion of cardiovascular risk reduction data in the EU label. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has had communications with DSE regarding potential milestone payments in which DSE has conveyed that it disagrees with the Company&#8217;s assessment that the CLEAR Outcomes data would support the Company&#8217;s right to receive any milestone payments upon inclusion of certain required cardiovascular risk reduction data in the EU label. Even if the Company is successful in enforcing its rights, there could be a delay in the Company&#8217;s receipt of the milestone payments as a result of any dispute relating to such payments. Any failure to receive or any delay in receipt of the milestone payments may significantly impact the Company&#8217;s future capital needs, ability to recognize revenue for the milestone upon inclusion of cardiovascular risk reduction data in the EU label, and ability to fund operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2023, the Company filed a complaint in the United States District Court for the Southern District of New York seeking declaratory judgment against DSE regarding the Company&#8217;s right to receive a $<ix:nonFraction unitRef="usd" contextRef="ia2442189a4e04c14866e4ca5dbe37ae7_D20230327-20230327" decimals="-6" name="espr:PotentialProceedsFromPartnerMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfNTQ5NzU1ODI0MzA4_b8e05b57-c588-4a99-8250-dc7b0d77dce0">300</ix:nonFraction>&#160;million milestone payment upon inclusion of cardiovascular risk reduction in the EU label that correlates with a relative risk reduction rate of at least <ix:nonFraction unitRef="number" contextRef="i77154455e27741eea8b7382d7bae0ad0_I20230327" decimals="2" name="espr:PercentageOfRiskReduction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfNTQ5NzU1ODI0Mzc1_cd9482e2-6b14-4e6f-987e-27b0abf4b348">20</ix:nonFraction>%, based on the CLEAR Outcomes trial demonstrating significant cardiovascular risk reductions.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i4e0deff50aa044a8929255249f2e70a6">On May 4, 2023, the Company filed an amended complaint against DSE in the Southern District of New York. The complaint seeks a judicial declaration, on an expedited basis, that DSE is contractually required to make a $<ix:nonFraction unitRef="usd" contextRef="ic6cf6eadd1ee45ffbf7b12713791e2c9_D20230504-20230504" decimals="-6" name="espr:PotentialProceedsFromPartnerMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfNTQ5NzU1ODI4NTI3_7c47462c-5e2d-44b6-8306-3ed6bc7ebe49">300</ix:nonFraction>&#160;million milestone payment to the Company upon applicable regulatory approval.</ix:continuation> </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfMTI3MA_d610d324-f91b-47f1-aab4-8cb22ca087d9" continuedAt="ia7cc3c3f6d48400099b01abf7462178f" escape="true">Investments</ix:nonNumeric></span></div><ix:continuation id="ia7cc3c3f6d48400099b01abf7462178f"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfMTI3MQ_fff61389-4ec5-480e-b960-fbb2985427df" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s cash equivalents and short-term investments (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddba95e9a591432fb6bb68b9d99fc675_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfMy0xLTEtMS02NTI3Mw_adbfe1db-0456-4683-bab8-ea5649e1166b">113,566</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddba95e9a591432fb6bb68b9d99fc675_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfMy0zLTEtMS02NTI3Mw_437f34fc-2dd9-46a9-8c66-1d894405a04c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddba95e9a591432fb6bb68b9d99fc675_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfMy01LTEtMS02NTI3Mw_41d14eca-7c7f-42da-951e-a662672e7abe">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddba95e9a591432fb6bb68b9d99fc675_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfMy03LTEtMS02NTI3Mw_88ceac55-35b9-4b8d-a2f5-0430da543a5d">113,566</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4446c0fdb9a84cc7ae17ac1fc0e8e0a0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNC0xLTEtMS02NTI3Mw_c60a691c-db34-4538-afeb-fdb3d96f8efa">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4446c0fdb9a84cc7ae17ac1fc0e8e0a0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNC0zLTEtMS02NTI3Mw_a432ad73-b654-411a-babe-bc22968e3cef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4446c0fdb9a84cc7ae17ac1fc0e8e0a0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNC01LTEtMS02NTI3Mw_c8d0bb74-1b0b-4286-a7ff-ce54f29b680f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4446c0fdb9a84cc7ae17ac1fc0e8e0a0_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNC03LTEtMS02NTI3Mw_8bb8e02b-4c27-4542-8ad1-bac1b08ce529">401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee3d89d3ffc4d01a13615bb5476bcf1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNi0xLTEtMS02NTI3Mw_e56ced06-6c53-4668-b255-fb73e9cfbc51">17,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee3d89d3ffc4d01a13615bb5476bcf1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNi0zLTEtMS02NTI3Mw_062bdb81-059f-4c09-819b-a6b25b90a91e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaee3d89d3ffc4d01a13615bb5476bcf1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNi01LTEtMS02NTI3Mw_27137017-203d-41c9-a0e9-3355021c1304">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaee3d89d3ffc4d01a13615bb5476bcf1_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNi03LTEtMS02NTI3Mw_bdeeb898-3c64-40be-abb3-9f6e2d1b07c4">17,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNy0xLTEtMS02NTI3Mw_986038b9-f576-48fb-b88b-d741bd659d61">131,395</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNy0zLTEtMS02NTI3Mw_f6255796-0702-4863-88f6-f36efe6d3917">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNy01LTEtMS02NTI3Mw_70c78e6d-2d3a-4a5b-9e36-14cba2bc65e3">1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNy03LTEtMS02NTI3Mw_3a3bd02c-e342-4df6-8b33-628eb2b4b668">131,394</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b452feddd34bfab04830af609fee01_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMy0xLTEtMS02NTI3Mw_7743d6c6-b4b8-4036-aab5-3ffbf0b77ced">105,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b452feddd34bfab04830af609fee01_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMy0zLTEtMS02NTI3Mw_4481ac3f-d902-4624-bbe1-9a4d458363ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b452feddd34bfab04830af609fee01_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMy01LTEtMS02NTI3Mw_0a6aa179-d257-4fc8-83d3-d9caa6158fe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2b452feddd34bfab04830af609fee01_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMy03LTEtMS02NTI3Mw_a337f1b8-2364-4471-95be-fa82b2f2b686">105,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70000ff4cfcc4e379e6941a6be6de6ab_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNC0xLTEtMS02NTI3Mw_2c084fc7-a838-41cd-8a2f-60acd1d80a00">4,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70000ff4cfcc4e379e6941a6be6de6ab_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNC0zLTEtMS02NTI3Mw_c6bed803-e472-43ae-ad6d-4db3f7430e93">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70000ff4cfcc4e379e6941a6be6de6ab_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNC01LTEtMS02NTI3Mw_5a91984d-6b31-4fb5-80d7-5a96b9f346a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70000ff4cfcc4e379e6941a6be6de6ab_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNC03LTEtMS02NTI3Mw_4ddf0283-22fc-4812-9341-dd8a0c36a466">4,995</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf5212861014a2a90c4514e738c57eb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNi0xLTEtMS02NTI3Mw_cffce752-fa2c-414a-934f-4b64cd9d0e10">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf5212861014a2a90c4514e738c57eb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNi0zLTEtMS02NTI3Mw_d36b711f-e442-48f2-8044-5800e82e39a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf5212861014a2a90c4514e738c57eb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNi01LTEtMS02NTI3Mw_f9cc6d4f-0e9e-46b6-8540-d90f2ba22ce9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf5212861014a2a90c4514e738c57eb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNi03LTEtMS02NTI3Mw_8edd5757-f102-4e42-8175-72edb726da70">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7636ce535be94232b11a93a9e2d54623_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfOS0xLTEtMS02NTI3Mw_6a69c52d-ae2a-4dc4-a9c7-7decbd57be62">42,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7636ce535be94232b11a93a9e2d54623_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfOS0zLTEtMS02NTI3Mw_f45faadb-3d7e-4690-a4db-67f802206c9b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7636ce535be94232b11a93a9e2d54623_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfOS01LTEtMS02NTI3Mw_5296bc18-610e-4591-8fca-c7c2488c248f">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7636ce535be94232b11a93a9e2d54623_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfOS03LTEtMS02NTI3Mw_58a0705f-9b1d-4347-bc45-f16fda0960bd">42,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMTEtMS0xLTEtNjUyNzM_e4a60cf0-57aa-4a77-8528-1b7bfac7d4c1">152,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMTEtMy0xLTEtNjUyNzM_b1b9eb58-196f-42c3-9450-c61d6e5514a5">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMTEtNS0xLTEtNjUyNzM_9d90bf95-577c-4f36-8d7c-84b4a9a8270b">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMTEtNy0xLTEtNjUyNzM_64009b7f-eb6a-4331-a85f-61617c6058ec">152,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and March&#160;31, 2022, other income, net in the statements of operations includes interest income on investments of $<ix:nonFraction unitRef="usd" contextRef="i96447b072e33476da43830de87cc58b4_D20230101-20230331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfMjcx_29d96f0a-035a-4ca6-94bf-2157e0baf32a">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib0a643f6059d440590c4f9ef231a9a6a_D20220101-20220331" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfNDQz_4f750b97-28ed-42be-a2b7-4fd599c9ac10">0.3</ix:nonFraction> million. During the three months ended March&#160;31, 2023, other income, net in the statements of operations includes accretion of premiums and discounts on investments of $<ix:nonFraction unitRef="usd" contextRef="i96447b072e33476da43830de87cc58b4_D20230101-20230331" decimals="-5" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfNjQx_9d99007c-bb0f-4c42-9b54-57ab7d67c2e4">0.3</ix:nonFraction>&#160;million. During the three months ended March 31, 2022, other income, net in the statements of operations includes amortization of premiums and discounts on investments of $<ix:nonFraction unitRef="usd" contextRef="ib0a643f6059d440590c4f9ef231a9a6a_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfNTQ5NzU1ODE1NTU3_428ef2b5-d30c-4438-8d13-9edc94a23fae">0.2</ix:nonFraction>&#160;million.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="ic4a1c26e2f864ba39b7dc746fa87291e_D20220101-20220331" decimals="INF" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfODAw_193dfc97-d6df-4c1f-b5a2-166a35d297dc"><ix:nonFraction unitRef="usd" contextRef="i9c9a60f0eede463fa23b607d23c6f990_D20230101-20230331" decimals="INF" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfODAw_4c5b9ac8-447e-47c5-8b8f-410c46c7f8b0">no</ix:nonFraction></ix:nonFraction> unrealized gains or losses on investments reclassified from accumulated other comprehensive income (loss) to other income in the statements of operations during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March&#160;31, 2023 and 2022, there were <ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfMTA0Mg_1753be44-5194-4d0f-a4c4-81108498f6b6"><ix:nonFraction unitRef="usd" contextRef="i99f951895edd442e82a9307c2fd15632_I20220331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfMTA0Mg_7c0b5a01-647a-407c-a686-679b4b3b6234">no</ix:nonFraction></ix:nonFraction> allowances for credit losses and all unrealized gains (losses) for available-for-sale securities were recognized in accumulated other comprehensive income (loss). As of March&#160;31, 2023, the Company had <ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-5" name="us-gaap:AccruedInvestmentIncomeReceivable" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfNTQ5NzU1ODE1NTg5_42585964-254c-4182-a273-b84f1c2e9cd8">no</ix:nonFraction> accrued interest receivables.</span></div></ix:continuation><div id="i9237fb157928404b96a8fc7ef6f6efba_49"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RleHRyZWdpb246YzJhMTVhNzMwODI4NDMwMjg3ZGE3YjFiYzMzNWFiYTlfNjUw_d3c498ce-d74a-489d-89bf-bbfbecdfb53f" continuedAt="i78b71a32640543b4b289945b3ba447ce" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i78b71a32640543b4b289945b3ba447ce" continuedAt="ica10432d485947069956584c97e42b40"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; Fair value measurements are defined on a three level hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:12.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.565%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.159%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1 inputs:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices for identical assets or liabilities in active markets;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2 inputs:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level&#160;1 prices, such as quoted market prices for similar assets or liabilities or other inputs that are observable or can be corroborated by market data; and</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3 inputs:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that are supported by little or no market activity and require the reporting entity to develop assumptions that market participants would use when pricing the asset or liability.</span></td></tr></table></div></ix:continuation><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="ica10432d485947069956584c97e42b40"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RleHRyZWdpb246YzJhMTVhNzMwODI4NDMwMjg3ZGE3YjFiYzMzNWFiYTlfNjUx_6adda092-c99e-438a-acdd-ff39d5a694dd" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets that have been measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cadd97215ba4500883c87f85dc8fa2d_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNC0yLTEtMS02NTI3Mw_ab2c2a8c-0030-4c2d-bdfa-e682d77ab4c0">113,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ca33a8008147d78bca5e8eed93423d_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNC00LTEtMS02NTI3Mw_cb57af8f-a2c4-4c7e-a378-f9750162f5aa">113,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fe88940f17f4e6792cd87aaa54541dd_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNC02LTEtMS02NTI3Mw_727120a8-810d-4259-8618-63381a4a6dd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7471d3b7a6ba4353b8cbc8d3e9345bfe_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNC04LTEtMS02NTI3Mw_3eb17271-8cc2-434a-a0da-48604005fba5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9834c756a92466abb333281240e95ae_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNS0yLTEtMS02NTI3Mw_a6ed63f2-b52e-45e2-b777-bdd8ec675de3">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if15b9c81ed564487bd38021a6515575e_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNS00LTEtMS02NTI3Mw_dea7a04f-8c80-48dc-a16a-3bbc3da2628e">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a3337053c7d484984eb254e5738a3a5_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNS02LTEtMS02NTI3Mw_1c82b5b1-0ea7-4aaa-b94e-1e88bc4466f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20434c7136b44164a04d244e3105f708_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNS04LTEtMS02NTI3Mw_c430f937-d437-41d4-817b-e7a97147544b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f55c80accfb4964b37eccb272c3ab19_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNy0yLTEtMS02NTI3Mw_f9bd0d0a-de72-44e4-98fd-665cedf37087">17,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b4f98b104bb49ccbbb686e748c86c53_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNy00LTEtMS02NTI3Mw_9cb02a99-b962-489e-a249-670f5d2676be">17,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dc441d33315499aaa534c51197956c9_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNy02LTEtMS02NTI3Mw_dbb64de3-5209-4ddb-a186-2b78521ebe6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie25bd0065058415581124c3cefc0bc4b_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNy04LTEtMS02NTI3Mw_746005d0-7e99-45d9-9581-300ecdfcb59b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df84ce791dd48a0a34c0e850ff9e8ea_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfOC0yLTEtMS02NTI3Mw_4ffdb399-7e65-469c-b601-8e7f78b9d300">131,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief6c1f5d0ae340d8af91af461c6b1b1a_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfOC00LTEtMS02NTI3Mw_aac7cb45-6b32-4fb4-b3e1-cec4f0f282f6">131,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie13c0a874a8e4068b43b96843795daac_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfOC02LTEtMS02NTI3Mw_d23f6541-a903-44a6-a055-639ae9953b22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1185e14b22bb4ad8b91ff702b16b3dbe_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfOC04LTEtMS02NTI3Mw_552cb455-17bd-4b43-8f03-dc2425cdf5cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f66dcce3270487dac3d302e1c309b3f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTEtMi0xLTEtNjUyNzM_33dcb484-d3c7-4901-bc3b-3521c7038de7">105,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i293919219d734293958f10064d773142_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTEtNC0xLTEtNjUyNzM_f259cd9e-75f1-448f-b669-a6176685f7db">105,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37331eb822c14332aecf98c4a60c9a83_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTEtNi0xLTEtNjUyNzM_e2be2da3-0181-43c8-95c5-4c677e5a8c7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ae5ff6d06c466e9f4d59d506da6f7e_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTEtOC0xLTEtNjUyNzM_5c2ff03e-5188-48a8-bf32-b35e0418fe78">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18c2947b9df14b23b8cc09df417e317f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTItMi0xLTEtNjUyNzM_90b74bd5-6477-4d6b-b89a-45bf99978529">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b0c9a8dfde64edbbed9fa7ad3f7e105_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTItNC0xLTEtNjUyNzM_4e2176a3-01ac-4b30-adad-72c9e451268c">401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id23e5091216b49dfac7f65fdd88e2a1f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTItNi0xLTEtNjUyNzM_71a204a9-9e22-408b-b67d-2389cf0a65c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd852d52cb6c4999a5a4f084a7dabb24_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTItOC0xLTEtNjUyNzM_c30dc51a-e999-4beb-bed3-0baed770d7a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75e3b605ec754126b40578f924de207a_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTUtMi0xLTEtNjUyNzM_04e859bf-f118-4ef3-9c21-b08495e4c4fd">47,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88342aa86a3b4d5eada1ac9c12a8b565_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTUtNC0xLTEtNjUyNzM_b626cc12-cd76-4acd-9062-40a5444a7af7">47,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3543312988354b0d860025f4d82f6d5a_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTUtNi0xLTEtNjUyNzM_ed3de3ee-db95-4da9-8b0c-152accd0fa3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a04e27d9c67411db002887f7c2f4e82_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTUtOC0xLTEtNjUyNzM_c2ffc57d-ba01-44f0-bbbd-7ae047fbb39b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4189fded356d43ba84b628246a86e8bd_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTctMi0xLTEtNjUyNzM_9419aa3b-d06f-42c4-8888-e83161ab5975">152,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b58988234e7462d88cabcc48176e5cd_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTctNC0xLTEtNjUyNzM_7170eee9-1f0e-4b5d-a7bc-9be3893b51e1">152,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5dc67741b7147d48b9de0788cbe4d92_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTctNi0xLTEtNjUyNzM_63c26dae-1c87-411f-ba29-e4b0a2f12a2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22b6d1eb1714222833742d1f5e85b9a_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTctOC0xLTEtNjUyNzM_d336cc21-8747-4f10-a2f6-e5a4d76446c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="0" name="espr:FairValueMeasurementAssetTransfersBetweenLevels" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RleHRyZWdpb246YzJhMTVhNzMwODI4NDMwMjg3ZGE3YjFiYzMzNWFiYTlfNTc1_82cc3393-792b-492d-b127-a5697ed63806"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="0" name="espr:FairValueMeasurementAssetTransfersBetweenLevels" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RleHRyZWdpb246YzJhMTVhNzMwODI4NDMwMjg3ZGE3YjFiYzMzNWFiYTlfNTc1_b025e3fc-c591-4cb0-bb32-7ca55db47ea9">no</ix:nonFraction></ix:nonFraction> transfers between Levels 1, 2 or 3 during the three months ended March&#160;31, 2023 and 2022.</span></div></ix:continuation><div id="i9237fb157928404b96a8fc7ef6f6efba_52"></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTI5Njk_9d192f35-0fec-46a9-b381-250412ede512" continuedAt="i262783c955e84889ae3e5987fc08a9b6" escape="true">Liability Related to the Revenue Interest Purchase Agreement</ix:nonNumeric></span></div><ix:continuation id="i262783c955e84889ae3e5987fc08a9b6" continuedAt="ie136d15c6ef44432a7ef44aa9783b19e"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2019, the Company entered into a Revenue Interest Purchase Agreement ("RIPA") with Oberland, as agent for purchasers party thereto (the &#8220;Purchasers&#8221;), and the Purchasers named therein, to obtain financing in respect to the commercialization and further development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet and other working capital needs. Pursuant to the RIPA, the Company received $<ix:nonFraction unitRef="usd" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="-5" name="espr:GrossProceedsFromRevenueInterestPurchaseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNDk0_52731a75-13cd-4796-b3f1-4c89bc2458a5">125.0</ix:nonFraction> million at closing, less certain issuance costs. The Company was entitled to receive up to approximately $<ix:nonFraction unitRef="usd" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="-5" name="espr:AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTk0_f1bd4be9-3bc5-4502-b07b-782f4806c792">75.0</ix:nonFraction> million in subsequent installments subject to the terms and conditions set forth in the RIPA: (i) $<ix:nonFraction unitRef="usd" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="-5" name="espr:AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNjg3_6a134fdc-87f0-4350-99b9-bc884cce87b2">25.0</ix:nonFraction> million upon certain regulatory approval of its product candidates and (ii) $<ix:nonFraction unitRef="usd" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="-5" name="espr:AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNzU4_b22fb0c5-a473-4952-8860-d24f2283c560">50.0</ix:nonFraction> million, at the Company&#8217;s option, upon reaching $<ix:nonFraction unitRef="usd" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="-5" name="espr:MilestoneAmountForWorldwideSalesToReceiveThirdPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfODAx_8596ac15-8ed2-4844-921a-837261ce7467">100.0</ix:nonFraction> million trailing worldwide six-month net sales any time prior to December 31, 2021 (the &#8220;Third Payment&#8221;). In March 2020, the Company received $<ix:nonFraction unitRef="usd" contextRef="if514492bc1304c3e88a7d73b880162d6_D20200301-20200331" decimals="-5" name="espr:ProceedsFromRevenueInterestPurchaseAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfOTM4_8657788e-bbda-4db1-82e5-0de37a8c78de">25.0</ix:nonFraction> million from Oberland upon receiving regulatory approval of NEXLETOL.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As consideration for such payments, the Purchasers will have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from the Company based upon net sales of the Company&#8217;s certain products, once approved, which will be tiered payments initially ranging from <ix:nonFraction unitRef="number" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="3" name="espr:RevenueInterestRateTierTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1ODIxOQ_b00d970f-095d-4681-b637-bb4a2c99a5af">2.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="3" name="espr:RevenueInterestRateInitialRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1ODIyNg_b2db2de4-ecfc-4bff-a201-bd67451c1403">7.5</ix:nonFraction>% of the Company&#8217;s net sales in the covered territory (the &#8220;Covered Territory&#8221;); provided that if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive <ix:nonFraction unitRef="number" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="INF" name="espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1ODQwOQ_da90a6cf-b56d-4eab-9c39-3e46af76c14e">100</ix:nonFraction>% of their invested capital by December 31, 2024, the revenue interest rate will be decreased to a single rate of <ix:nonFraction unitRef="number" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="3" name="espr:RevenueInterestRateTierThree" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1ODUyNQ_42d4b03d-e2e4-4027-9311-7ef04e9250ed">0.4</ix:nonFraction>% of the Company&#8217;s net sales in the Covered Territory beginning on January 1, 2025. If the Third Payment is drawn down by the Company, the applicable royalty rates will increase by one-third. The Covered Territory is the United States, but is subject to expand to include the world-wide net sales if the Company&#8217;s annual U.S. net sales are less than $<ix:nonFraction unitRef="usd" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="INF" name="espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1ODg3Nw_20073147-df38-4625-b6da-84755d1b725b">350.0</ix:nonFraction>&#160;million for the year ended December 31, 2021. The U.S. net sales milestone thresholds are not to be taken as financial guidance. The Purchasers&#8217; rights to receive the Revenue Interests shall terminate on the date on which the Purchasers have received Revenue Interests payments of <ix:nonFraction unitRef="number" contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626" decimals="INF" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1OTE1NA_778cf08f-fac2-4cb3-8fd4-0588ed2d47d9">195</ix:nonFraction>% of the then aggregate purchase price (the &#8220;Cumulative Purchaser Payments&#8221;) paid to the Company, unless the RIPA is terminated earlier.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RIPA, the Company has an option (the &#8220;Call Option&#8221;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#8220;Put Option&#8221;) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the RIPA contains various representations and warranties, information rights, non-financial covenants, indemnification obligations and other provisions that are customary for a transaction of this nature.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="ie136d15c6ef44432a7ef44aa9783b19e" continuedAt="i43608ce1c54c446b9b451be275cc996e"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RIPA Amendments</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 26, 2021, the Company entered into Amendment No. 2 (the &#8220;RIPA Amendment 2&#8221;) to the RIPA with Oberland, as agent for the purchaser parties thereto. Pursuant to the RIPA Amendment 2, Oberland waived the original trailing <ix:nonNumeric contextRef="i39c7a52f49de44809d9de735fcdb4259_D20210426-20210426" name="espr:TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwMjEx_6f147f11-a7b1-4fc7-bfa3-66c71917ed88">six-month</ix:nonNumeric> world-wide net sales condition to the third installment payment under the RIPA and released the final $<ix:nonFraction unitRef="usd" contextRef="i39c7a52f49de44809d9de735fcdb4259_D20210426-20210426" decimals="-6" name="espr:ProceedsFromRevenueInterestPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2ODAzMw_428f741f-416a-41c4-a4e0-bae8947b6fdb">50</ix:nonFraction>&#160;million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA such that the purchasers will have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from the Company based on net sales of the Company&#8217;s certain products, once approved, which will be tiered payments ranging from <ix:nonFraction unitRef="number" contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426" decimals="INF" name="espr:RevenueInterestRateTierTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2ODQwNw_f066780d-1613-4c36-92af-b2b60fd0598f">3.33</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426" decimals="INF" name="espr:RevenueInterestRateInitialRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2ODQxNA_3ff8139a-2999-4dc0-b8b7-875991b638db">10</ix:nonFraction>% (the &#8220;Third Payment Applicable Percentage&#8221;) of the Company&#8217;s net sales in the covered territory (the &#8220;Covered Territory&#8221;); provided that (a) prior to December 31, 2024, with respect to each country defined in the Daiichi Territory, if the percentage of net sales that Company receives from Daiichi (the &#8220;Receivables Percentage&#8221;) is less than the Third Payment Applicable Percentage, then the Revenue Interest for such country payable to the purchasers will be equal to the Receivables Percentages, (b) if annual net sales equal or exceed $<ix:nonFraction unitRef="usd" contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426" decimals="-6" name="espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2ODk1Ng_8314aaa9-e2a8-4288-b648-f4904d36051a">350</ix:nonFraction>&#160;million and if the Purchasers receive <ix:nonFraction unitRef="number" contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426" decimals="INF" name="espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2ODk5MA_4998758c-1915-47d0-976a-b829ba8e4078">100</ix:nonFraction>% of their invested capital (Cumulative Purchaser Payments") by December 31, 2024, the revenue interest rate will be decreased to a single rate of <ix:nonFraction unitRef="number" contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426" decimals="INF" name="espr:RevenueInterestRateTierTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2OTEzOQ_72220e37-4b3b-480f-bef4-f87f739dfae9">3.33</ix:nonFraction>% of the Company&#8217;s net sales in the Covered Territory for all subsequent calendar quarters and (c) if the Purchasers receive Revenue Interest payments less than <ix:nonFraction unitRef="number" contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426" decimals="INF" name="espr:PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2OTMwMg_b1341f26-684e-4786-bbcc-f4db6da42e0d">100</ix:nonFraction>% of Cumulative Purchaser Payments by December 31, 2024, the Third Payment Applicable Percentage will be increased to a single rate of the Company&#8217;s net sales that would have provided <ix:nonFraction unitRef="number" contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426" decimals="INF" name="espr:PercentageOfCumulativePurchaserPaymentsGuarantee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2OTQ4OA_51cd714a-012f-4b8e-8dad-96741606f79d">100</ix:nonFraction>% of Cumulative Purchaser Payments had such rate applied from the initial funding by the Purchasers. The Covered Territory was originally the United States, but has been expanded to worldwide for all calendar years beginning on or after January 1, 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RIPA Amendment 2, the Company has an option (the &#8220;Call Option&#8221;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#8220;Put Option&#8221;) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option or the Call Option are exercised, the required repurchase price will be <ix:nonFraction unitRef="number" contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426" decimals="INF" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MDI5MQ_9a3bbf5c-c06a-4cee-97c4-5e07ae578cb5">200</ix:nonFraction>% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and <ix:nonFraction unitRef="number" contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426" decimals="INF" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MDUxNA_9ada2d03-0704-4ff2-b593-1ccd4b2875f0">225</ix:nonFraction>% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2021, the Company entered into an Amendment to the Security Agreement and Waiver ("Amendment and Waiver") with the same parties to the Security Agreement, by and among the Company, Eiger Partners II LP (the "Purchaser") and Eiger III SA LLC (the "Purchaser Agent"), dated as of June 26, 2019 (the "Security Agreement"). Pursuant to the Amendment and Waiver, if (i) the net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States (as reported in the Company&#8217;s financial statements as &#8220;product sales, net&#8221; in accordance with GAAP and excluding, for the avoidance of doubt, upfront or milestone payments and other collaboration revenue) (the &#8220;Specified Net Revenue&#8221;) for the calendar quarter ended September 30, 2021 does not exceed $<ix:nonFraction unitRef="usd" contextRef="i6754f51923214db89d9e97a310f8cc9f_D20210516-20210516" decimals="-5" name="espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MTg4NQ_a9e21669-7ae0-4c1f-99df-7cd990b58625">15.0</ix:nonFraction>&#160;million, or (ii) the Specified Net Revenue for any calendar quarter ending after September 30, 2021 does not exceed $<ix:nonFraction unitRef="usd" contextRef="i6754f51923214db89d9e97a310f8cc9f_D20210516-20210516" decimals="-5" name="espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MTk5Nw_9b2e358d-e1fc-462f-ba99-ddff5605b4b1">15.0</ix:nonFraction>&#160;million, then the Company shall deposit $<ix:nonFraction unitRef="usd" contextRef="i6754f51923214db89d9e97a310f8cc9f_D20210516-20210516" decimals="-5" name="espr:BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MjAzMw_311d9eff-b886-4551-add3-a37c3f08a120">50.0</ix:nonFraction>&#160;million in a deposit account that is subject to a block account control agreement in favor of the Purchase Agent, no later than the earlier of (x) the date the Specified Net Revenue for such calendar quarter has been determined and (y) 45 days after the last day of such calendar quarter. Since the Specified Net Revenue for the calendar quarter ended September 30, 2021 did not exceed $<ix:nonFraction unitRef="usd" contextRef="i6754f51923214db89d9e97a310f8cc9f_D20210516-20210516" decimals="-5" name="espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MjQxNQ_0e278763-4602-4f9f-aea5-6d079286de40">15.0</ix:nonFraction>&#160;million, the Company deposited $<ix:nonFraction unitRef="usd" contextRef="i05a73c2f8f9840268e786ffef237f263_I20210930" decimals="-5" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MjQ0Mg_68e87eec-2c11-49dd-b431-19368857927a">50.0</ix:nonFraction>&#160;million in a deposit account that is subject to a block account control agreement, which is classified as restricted cash on the balance sheets. The Purchaser Agent shall have sole dominion and control over all funds deposited in the deposited account and such funds may be withdrawn therefrom only with the consent of the Purchaser Agent. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall have the right to apply amounts held in the deposit account in payment of certain secured obligations in the manner provided for in the Security Agreement. The Amendment and Wavier does not substitute, replace or release the Pledgors from any other obligations under the RIPA or Security Agreement.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 23, 2022, the Company entered into Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement (the &#8220;RIPA Amendment 3&#8221;), by and among the Company, the Purchasers and the Purchaser Agent, which amends (i) the Revenue Interest Purchase Agreement, by and among the Company, the Purchasers, and the Purchaser Agent, dated effective as of June 26, 2019 (as amended by Amendment No. 1 to Revenue Interest Purchase Agreement dated as of November 9, 2020 and Amendment No. 2 to Revenue Interest Purchase Agreement dated as of April 26, 2021, and as may be further amended, restated, supplemented or modified from time to time, the &#8220;RIPA&#8221;) and (ii) the Security Agreement, by the Company in favor of the Purchaser Agent, dated as of June 28, 2019 (as amended by the Amendment to Security Agreement and Waiver by and among the Company, the Purchaser and the Purchaser Agent, effective as of May 16, 2021, and as may be further amended, restated, supplemented or modified from time to time, the &#8220;Security Agreement&#8221;). Pursuant to the RIPA Amendment 3, among other things, (a) the Company agreed to make a one-time partial call payment with regards to the Revenue Interests (as defined in the RIPA) in an amount equal to $<ix:nonFraction unitRef="usd" contextRef="ia380cab0f6c44c18a991dc9247a9f988_D20220101-20221231" decimals="-5" name="espr:OneTimePartialCall" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NDQ0Mw_402fde08-88cb-4e42-afdb-9bdf4be6687e">50</ix:nonFraction>&#160;million from the restricted cash account (the &#8220;Partial Call&#8221;), (b) the amount of the Cumulative Purchaser Payments (as defined in the RIPA) was reduced to </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="i43608ce1c54c446b9b451be275cc996e"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i62091633ce8842d79fd91f8dcc5437c7_D20221123-20221123" decimals="0" name="espr:RevenueInterestsPaymentOnWhichAgreementTerminates" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NDU5NA_d855ac26-a1e5-42c3-8083-5918cbe6d445">177,777,778</ix:nonFraction>, and (c) the Purchasers and Purchaser Agent waived certain claimed defaults, breaches and Put Option Events under the RIPA and other related documents that may have occurred as a result of the Company&#8217;s opening of a new bank account.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 470&#8209;50, &#8220;Debt&#8212;Modifications and Extinguishments,&#8221; the RIPA Amendment 3 was accounted for as a debt modification. The amendment resulted in a less than $<ix:nonFraction unitRef="usd" contextRef="i593d725af50a4b0091e208f4866fe4d9_D20220101-20221231" decimals="-5" sign="-" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NTAyMg_e68e77f9-c149-4a0f-833a-9f64e832f219">0.1</ix:nonFraction>&#160;million loss on modification of debt, consisting of third-party fees associated with the transaction, which is included in selling, general, and administrative expenses in the statements of operations for the year ended December 31, 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the arrangement, as of March 31, 2023, the Company has recorded a liability, referred to as the &#8220;Revenue interest liability&#8221; on the balance sheet, of $<ix:nonFraction unitRef="usd" contextRef="i8971caf868ca48d4bb6027c5bcbc4c0d_I20230331" decimals="-5" name="espr:RevenueInterestLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwNDIy_fd120f6f-2ab2-48b9-9d08-c1a302712ce3">251.8</ix:nonFraction>&#160;million, net of $<ix:nonFraction unitRef="usd" contextRef="i60257fb8aa8e4bae83973ec6daf04c7f_D20230101-20230331" decimals="-5" name="espr:UnamortizedTransactionCostsOnRevenueInterestAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwNDM4_5fd762a8-9756-475e-8b9b-473c963d64ec">0.3</ix:nonFraction>&#160;million of capitalized issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. The total redemption amount is equal to <ix:nonFraction unitRef="number" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="2" name="espr:RevenueInterestPaymentsRedemptionPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NTYxMQ_c555b3b5-cd8c-4c68-a3ab-31b1f124a8ed">225</ix:nonFraction>% of the Cumulative Purchaser Payments, or $<ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-6" name="espr:RevenueInterestPaymentsRedemptionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NTY1Ng_1667d489-e8db-4316-8ee3-603d576b406c">400</ix:nonFraction>&#160;million. At March 31, 2023, the remaining redemption amount is $<ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-5" name="espr:RevenueInterestPaymentsRemainingRedemptionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUxMTE0_8b0116df-3f61-46ac-9d9f-06f492082a00">385.0</ix:nonFraction>&#160;million. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The Company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant increase or decrease in future net sales will materially impact the revenue interest liability, interest expense and the time period for repayment. The Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i60257fb8aa8e4bae83973ec6daf04c7f_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwMzky_16fe846d-a9b4-4ff3-95c5-2eb447eee61e">11.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if7b64718731d44238127edb9d9fdb04b_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwMjEz_ae156b41-89b9-499a-8c8c-a14e728e1108">11.0</ix:nonFraction>&#160;million in interest expense related to this arrangement for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repayment of the RIPA to Oberland does not have a fixed repayment schedule, rather it will be completely repaid and extinguished when the Company has repaid <ix:nonFraction unitRef="number" contextRef="i60e0844b890e44459d45cfea66deae41_D20210516-20210516" decimals="3" name="espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NjY3Mw_e1381108-9727-4679-8a1c-9c012c9cf6a1">225</ix:nonFraction>% of the Cumulative Purchaser Payments. Since there is not a fixed repayment schedule, the Company does not project its future repayments by year. Each period, the Company estimates the future expected sales of its products in the covered territory and determines the effective annual imputed interest rate, which updates and changes the timing of the Company&#8217;s payments. Under the terms of the agreement, every $<ix:nonFraction unitRef="usd" contextRef="ia26aa17e92c241019a3310efe812d480_D20210516-20210516" decimals="-6" name="espr:HypotheticalSalesGeneratedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzA4Nw_b1815e18-ea0a-4676-ab96-d119b143787e">100</ix:nonFraction>&#160;million of net sales generated, less than or equal to $<ix:nonFraction unitRef="usd" contextRef="ia26aa17e92c241019a3310efe812d480_D20210516-20210516" decimals="INF" name="espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzEzNw_578c0a91-733f-406f-ac88-0c65bce06c2e">250</ix:nonFraction>&#160;million in an annual aggregate year, would result in a repayment obligation of approximately $<ix:nonFraction unitRef="usd" contextRef="i9977b26c9b394f16bbdfa5a9ea8bc078_I20210516" decimals="-5" name="espr:HypotheticalRepaymentObligationBasedOnSalesGenerated" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzIyNg_0deaea78-73c3-45be-921a-112ba4fe5877">10.0</ix:nonFraction>&#160;million or <ix:nonFraction unitRef="number" contextRef="ia26aa17e92c241019a3310efe812d480_D20210516-20210516" decimals="3" name="espr:RevenueInterestRateInitialRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzIzMw_940ca7f4-acb0-477b-81d8-85e4128c02f4">10.0</ix:nonFraction>% at the stated repayment rate in the first year. Annual net sales for a calendar year exceeding $<ix:nonFraction unitRef="usd" contextRef="if4567f7a9b074360b5b429789676c1b0_D20210516-20210516" decimals="-6" name="espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzMzMg_4c32d15f-d511-4015-85dd-2dd84e6a68f9">250</ix:nonFraction>&#160;million would result in a repayment obligation of approximately $<ix:nonFraction unitRef="usd" contextRef="i2677ac65322b4743a3ca63339e6ecf73_I20210516" decimals="-5" name="espr:HypotheticalRepaymentObligationBasedOnSalesGenerated" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzM5Mg_6aff7574-77a3-4eec-a59e-0cb0923e3bfa">3.3</ix:nonFraction>&#160;million or <ix:nonFraction unitRef="number" contextRef="if4567f7a9b074360b5b429789676c1b0_D20210516-20210516" decimals="3" name="espr:RevenueInterestRateTierTwo" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzM5OQ_481cc653-6ee2-4aa0-b0ef-817ad43e3650">3.3</ix:nonFraction>% for every $<ix:nonFraction unitRef="usd" contextRef="if4567f7a9b074360b5b429789676c1b0_D20210516-20210516" decimals="-6" name="espr:HypotheticalSalesGeneratedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzQxMw_5db5e05a-ab48-4fc4-bd68-3145386f5b80">100</ix:nonFraction>&#160;million of sales above the threshold. As the U.S. net sales were less than $<ix:nonFraction unitRef="usd" contextRef="i282b2fae645341849445d9da9274fa5e_D20210101-20211231" decimals="INF" name="espr:NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzQ4NA_6706dbf3-06df-4cff-a5df-706a34e57846">350</ix:nonFraction>&#160;million for the year ended December 31, 2021, the Covered Territory was expanded to include worldwide sales beginning in 2022. The Company&#8217;s repayments of the RIPA are directly tied to the growth of its net sales, and as the Company&#8217;s net sales grow, the Company expects the related repayments of the RIPA to grow as well. The Company currently expects to repay $<ix:nonFraction unitRef="usd" contextRef="ic5ce29780ee048d2a07167f083638b4e_I20230331" decimals="-5" name="espr:RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwMzcw_5bca9d5e-2c83-423d-a599-a7e3239eb9a7">26.9</ix:nonFraction>&#160;million in the next twelve months.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual imputed interest rate is <ix:nonFraction unitRef="number" contextRef="i9672d71ca80348519f56b4e7a065e01c_D20230101-20230331" decimals="3" name="espr:RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwMzg1_5b2ac53b-be56-4797-8dab-54707eb372d5">18.2</ix:nonFraction>% as of March&#160;31, 2023. Payments made to Oberland as a result of the Company&#8217;s net sales will reduce the revenue interest liability.</span></div><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="espr:ScheduleOfRevenueInterestLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTI5NzA_5cea289f-60ab-4df4-a4b9-5758db9de752" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue interest liability activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3be96d871a141f89c4e0d00a0a0b2ed_I20221231" decimals="-3" name="espr:RevenueInterestLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RhYmxlOjA2YzUxMzBkYjI3NzRjYmM5YjQ0MGI1ZGZlOWE5MmZmL3RhYmxlcmFuZ2U6MDZjNTEzMGRiMjc3NGNiYzliNDQwYjVkZmU5YTkyZmZfMS0xLTEtMS02NTI3Mw_a5f9d2a4-9be5-44f5-840a-0acbba195022">243,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60257fb8aa8e4bae83973ec6daf04c7f_D20230101-20230331" decimals="-3" name="espr:RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RhYmxlOjA2YzUxMzBkYjI3NzRjYmM5YjQ0MGI1ZGZlOWE5MmZmL3RhYmxlcmFuZ2U6MDZjNTEzMGRiMjc3NGNiYzliNDQwYjVkZmU5YTkyZmZfMi0xLTEtMS02NTI3Mw_668707b0-96e9-42fc-9d12-40399214320b">11,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interests payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i60257fb8aa8e4bae83973ec6daf04c7f_D20230101-20230331" decimals="-3" name="espr:PaymentsFromRevenueInterestPurchaseAgreement" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RhYmxlOjA2YzUxMzBkYjI3NzRjYmM5YjQ0MGI1ZGZlOWE5MmZmL3RhYmxlcmFuZ2U6MDZjNTEzMGRiMjc3NGNiYzliNDQwYjVkZmU5YTkyZmZfMy0xLTEtMS02NTI3Mw_7a11b378-7439-4974-898f-51b69e9c7eaf">3,106</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8971caf868ca48d4bb6027c5bcbc4c0d_I20230331" decimals="-3" name="espr:RevenueInterestLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RhYmxlOjA2YzUxMzBkYjI3NzRjYmM5YjQ0MGI1ZGZlOWE5MmZmL3RhYmxlcmFuZ2U6MDZjNTEzMGRiMjc3NGNiYzliNDQwYjVkZmU5YTkyZmZfNC0xLTEtMS02NTI3Mw_ff3ff8e5-004d-42cb-a9f4-0f263970c7f2">251,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_58"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTI4MDM_2c42ce79-832c-45af-b739-22c648b229ab" continuedAt="i5407943ac13f40c3b552f45a47ef2605" escape="true">Convertible Notes</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5407943ac13f40c3b552f45a47ef2605" continuedAt="i4410e9af36d44abab4ce069276f44ae4">In November 2020, the Company issued $<ix:nonFraction unitRef="usd" contextRef="ie9d604cc8ce549efb8eacca20225427d_I20201130" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNjM_b9b5e13e-41ba-4017-9d9c-07c5201d8827">280.0</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="ie9d604cc8ce549efb8eacca20225427d_I20201130" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfOTY_4d71092f-43a0-4fa8-afdb-c8183f50f1bf">4.0</ix:nonFraction>% senior subordinated convertible notes due November 2025. The net proceeds the Company received from the offering was approximately $<ix:nonFraction unitRef="usd" contextRef="i558c1c82e52841cd910a7702549badd5_D20201101-20201130" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjMw_457d8bf7-14a2-4aab-a478-789e5555bb0a">271.1</ix:nonFraction>&#160;million, after deducting the initial purchasers&#8217; discounts and commissions and offering expenses payable by the Company (the "Convertible Notes") of $<ix:nonFraction unitRef="usd" contextRef="i77878605a83847e6b08dc2b1e23c3d3c_I20201130" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNTQ5NzU1ODI4OTg2_f3a57149-1009-4e5f-a561-0ab903b2c075">8.9</ix:nonFraction>&#160;million. The Company used approximately $<ix:nonFraction unitRef="usd" contextRef="i3e9376bd36d849ffb4316ffe1b5485a7_D20201101-20201130" decimals="-5" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDAz_32ad7fdd-a4d6-4b35-9550-c90f46d8d6d1">46.0</ix:nonFraction>&#160;million of the net proceeds from the offering of the notes to pay the cost of the Capped Call (as defined below) and $<ix:nonFraction unitRef="usd" contextRef="i3e9376bd36d849ffb4316ffe1b5485a7_D20201101-20201130" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNTE1_aa5381a4-ec72-4230-a9ae-dd793c64b0d4">55.0</ix:nonFraction>&#160;million of the net proceeds from the offering of the initial notes to finance the Prepaid Forward (as defined below). The Convertible Notes are the Company's senior unsecured obligations and mature on November 15, 2025 (the &#8220;Maturity Date&#8221;), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Convertible Notes are convertible into shares of the </ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="i4410e9af36d44abab4ce069276f44ae4" continuedAt="ib53e5c60a9ad48dea4963d502c2a73c5"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s common stock, can be repurchased for cash, or a combination thereof, at the Company&#8217;s election, at an initial conversion rate of <ix:nonFraction unitRef="number" contextRef="i558c1c82e52841cd910a7702549badd5_D20201101-20201130" decimals="4" name="us-gaap:DebtInstrumentConvertibleConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTA2MQ_5ff40c68-0c48-45eb-b50a-db40dfae8505">30.2151</ix:nonFraction> shares of common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="ie9d604cc8ce549efb8eacca20225427d_I20201130" decimals="3" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTIwOQ_02357c09-7c23-45af-8538-b9e647ecc42c">33.096</ix:nonFraction> per share of common stock, subject to adjustment. The Company will pay interest on the Convertible Notes semi-annually in arrears on May 15 and November 15 of each year.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes are general unsecured obligations of the Company that are subordinated in right of payment to indebtedness, obligations and other liabilities under the Company&#8217;s RIPA, the revenue interests issued pursuant to such agreement, and any refinancing of the foregoing.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding August 15, 2025 in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ended on March 31, 2021 (and only during such calendar quarter), if the last reported sale price per share of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i443e0a08bb4a4888a6d5462309e5dc2b_I20201130" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjA3OA_9b1360f8-26fc-4d2e-82e9-4dff86074bd6">0.001</ix:nonFraction> per share (&#8220;common stock&#8221;), is greater than or equal to <ix:nonFraction unitRef="number" contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjEzNw_148ebe1a-236f-44cf-9f86-02501ed5a4f5">130</ix:nonFraction>% of the conversion price for each of at least <ix:nonFraction unitRef="day" contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjE4NQ_577b47da-dde1-48d3-a30d-ed1bbc9a2964">20</ix:nonFraction> trading days, whether or not consecutive, during the <ix:nonFraction unitRef="day" contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjI0MQ_b04bd503-fb3d-4f46-a265-dfe219a4b792">30</ix:nonFraction> consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the <ix:nonFraction unitRef="day" contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130" decimals="INF" name="espr:NumberOfBusinessDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjM3OA_8cadf069-6da8-45d3-9fed-6b1862aef218">five</ix:nonFraction> business days after any <ix:nonFraction unitRef="day" contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130" decimals="INF" name="espr:NumberOfConsecutiveTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjQwNQ_783f8994-62e7-488a-bddc-e64ba07298d3">five</ix:nonFraction> consecutive trading day period (such <ix:nonFraction unitRef="day" contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130" decimals="INF" name="espr:NumberOfConsecutiveTradingDays" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjQ0NQ_ea697fb4-9e40-469a-a1a3-6d557bb8754f">five</ix:nonFraction> consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than <ix:nonFraction unitRef="number" contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130" decimals="INF" name="espr:DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjYzMQ_ebd10924-5712-43bf-98b9-d98cddc264fa">98</ix:nonFraction>% of the product of the last reported sale price per share of the Company&#8217;s common stock and the conversion rate for the notes on each such trading day; (3) if the Company calls such notes for redemption, any such notes that have been called for redemption may be converted at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, but only with respect to the notes called for redemption; and (4) upon the occurrence of specified corporate events, as provided in the Indenture. On or after August 15, 2025, to the close of business on the second scheduled trading day immediately before the maturity date, holders may convert all or any portion of their notes at the applicable conversion rate at any time at the option of the holder regardless of the foregoing conditions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, following certain corporate events or following issuance of a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a corporate event or to convert its notes called (or deemed called) for redemption during the related redemption period, as the case may be.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes will be redeemable, in whole or in part, at the Company&#8217;s option at any time, and from time to time, on or after November 20, 2023 and before the 41st scheduled trading day immediately before the maturity date, at a cash redemption price equal to <ix:nonFraction unitRef="number" contextRef="id505115d3ec947189265eca782d4648d_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDEyMA_19998f13-9d35-42a5-b797-2844a11353a9">100</ix:nonFraction>% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company&#8217;s common stock has been at least <ix:nonFraction unitRef="number" contextRef="id505115d3ec947189265eca782d4648d_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDMxNw_193c9aa0-af84-49aa-b143-4e0775deb2fd">130</ix:nonFraction>% of the conversion price then in effect for at least <ix:nonFraction unitRef="day" contextRef="id505115d3ec947189265eca782d4648d_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDM3Mg_7d0584d6-6f84-47e6-aae9-62a02d413c51">20</ix:nonFraction> trading days (whether or not consecutive), including the trading day immediately preceding the date the Company sends the related redemption notice, during any <ix:nonFraction unitRef="day" contextRef="id505115d3ec947189265eca782d4648d_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDUzNQ_5d877a6d-b68a-42ca-b4b7-5093c7e3563f">30</ix:nonFraction> consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company sends such redemption notice. No sinking fund is provided for the notes. If the Company redeems less than all the outstanding notes, at least $<ix:nonFraction unitRef="usd" contextRef="ic5eeddb8167c498c8696923171b62eb4_I20201130" decimals="INF" name="espr:DebtInstrumentCovenantRequiredAmountOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDgwNQ_f7f61dd4-d5ba-43c6-babb-e32869b28178">125.0</ix:nonFraction>&#160;million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a &#8220;fundamental change&#8221; (as defined in the Indenture), holders may require the Company to repurchase their notes for cash all or any portion of their notes at a fundamental change repurchase price equal to <ix:nonFraction unitRef="number" contextRef="i558c1c82e52841cd910a7702549badd5_D20201101-20201130" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNTE2Nw_cafc0254-07fd-410f-8850-6ad5bcdeebe8">100</ix:nonFraction>% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the fundamental change repurchase date. The Indenture includes customary terms and covenants, including certain events of default.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2021, the Company entered into a privately negotiated exchange agreement (the &#8220;Exchange Agreement&#8221;) with two co-managed holders (the &#8220;Holders&#8221;) of its Convertible Notes. Under the terms of the Exchange Agreement the Holders agreed to exchange (the &#8220;Exchange&#8221;) with the Company $<ix:nonFraction unitRef="usd" contextRef="i20ddb90b5807415aa23e0e6e68488a19_D20211022-20211022" decimals="-5" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNzc2Ng_8eaebe94-bdc1-434e-b5e5-72b4f4712a31">15.0</ix:nonFraction>&#160;million aggregate principal amount of the Convertible Notes held in the aggregate by them (and accrued interest thereon) for shares of the Company&#8217;s common stock. Pursuant to the Exchange Agreement, the number of shares of common stock to be issued by the Company to the Holders upon consummation of the Exchange was determined based upon the volume-weighted-average-price per share of common stock, subject to a floor of $<ix:nonFraction unitRef="usdPerShare" contextRef="idef44d4d210a42b4b9aa0ab56e93f3ea_I20211022" decimals="2" name="espr:DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODE4Mw_740aa1e5-0a12-46df-a36b-36b2eacff88b">5.62</ix:nonFraction> per share, during the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODIwOA_adc66ab1-dedb-4d22-80ef-7e400f74515e">five</span> trading-day averaging period, commencing on the trading day immediately following the date of the Exchange Agreement. The Exchange closed on November 3, 2021, with <ix:nonFraction unitRef="shares" contextRef="i80cfd1f853144d49b1d183168049513c_D20211103-20211103" decimals="0" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODM3NQ_de78063e-9627-4a8a-b130-4a5efc633435">1,094,848</ix:nonFraction> shares of the Company's common stock being exchanged.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of March 31, 2023, the principal amount of convertible notes was $<ix:nonFraction unitRef="usd" contextRef="i50721021131b4d71b50fa66d28915b11_I20230331" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODUwNA_4cf73999-637a-4fb1-b830-d71aa68aa7cd">265.0</ix:nonFraction>&#160;million, and the unamortized debt discount and issuance costs were $<ix:nonFraction unitRef="usd" contextRef="i50721021131b4d71b50fa66d28915b11_I20230331" decimals="-3" name="us-gaap:DeferredFinanceCostsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODU2Ng_6b59ee2e-e599-4553-a00f-8480ab477b79">4.7</ix:nonFraction>&#160;million, for a net carrying amount of $<ix:nonFraction unitRef="usd" contextRef="i50721021131b4d71b50fa66d28915b11_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODU5OQ_33855ff6-b7b7-4f8c-9037-1d0468f727d8">260.3</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="ib53e5c60a9ad48dea4963d502c2a73c5"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company recorded $<ix:nonFraction unitRef="usd" contextRef="i85e1a076c7ee4e17907f790ab9bf3c54_D20230101-20230331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODYyNQ_6ab6f4aa-08c4-473a-869b-02c3d4ef175e">3.1</ix:nonFraction>&#160;million of interest expense during the three months ended March 31, 2023, and $<ix:nonFraction unitRef="usd" contextRef="i921ae98ba14c414092902fd6b4401923_D20220101-20220331" decimals="-5" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODczMg_85ec962b-f41f-498f-9379-717d7c3223a8">3.0</ix:nonFraction>&#160;million of interest expense during the three months ended March 31, 2022, relating to the cash interest on the convertible notes due semi-annually and amortization of the debt issuance costs. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of March 31, 2023, no Convertible Notes were convertible pursuant to their terms. The estimated fair value of the Convertible Notes was $<ix:nonFraction unitRef="usd" contextRef="i50721021131b4d71b50fa66d28915b11_I20230331" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfOTA5OA_ec79fe0f-8e81-4a21-8c46-f53ffcb05b88">123.2</ix:nonFraction>&#160;million as of March 31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="i1696b3ebb44147b9a3cbeaecc46fbd18_I20221231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfOTEzMA_aaed2cd0-9ca8-4e43-94f5-3a533fec2aa3">145.9</ix:nonFraction>&#160;million as of December 31, 2022. The estimated fair value of the Convertible Notes was determined through consideration of quoted market prices. As of March 31, 2023, the if-converted value of the Convertible Notes did not exceed the principal value of those notes.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capped Call Transactions</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the Convertible Notes, the Company entered into privately-negotiated capped call transactions with one of the initial purchasers of the convertible notes or its affiliate and certain other financial institutions. The Company used approximately $<ix:nonFraction unitRef="usd" contextRef="icae7497a06dd4ecf932d2ce48689f651_D20201116-20201116" decimals="-5" name="us-gaap:PaymentsForDerivativeInstrumentFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfOTcwMA_124c2fea-7fa0-491e-bbe3-b7c5bf1f0fdd">46.0</ix:nonFraction>&#160;million of the net proceeds from the offering of the Convertible Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce potential dilution to the Company&#8217;s common stock upon any conversion of the Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, in the event that the market value per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions at the time of exercise, is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the Convertible Notes, and is subject to certain adjustments), with such reduction and/or offset subject to a cap initially equal to approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="iaa0efd686a824365a3cc55c8e2d823d9_I20201116" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTA1NDY_47a9d057-ce57-4fb2-853d-1cedfecf787c">55.16</ix:nonFraction> (which represents a premium of approximately <ix:nonFraction unitRef="number" contextRef="iaa0efd686a824365a3cc55c8e2d823d9_I20201116" decimals="INF" name="espr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTA1OTQ_b5b9f14c-ece0-423d-a587-b639616aaf11">100</ix:nonFraction>% over the last reported sale price of the Company&#8217;s common stock on November 11, 2020), subject to certain adjustments. The capped call transactions are separate transactions, entered into by the Company and are not part of the terms of the Convertible Notes.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that the transactions meet certain accounting criteria, the convertible note capped call transactions are recorded in stockholders&#8217; equity, and they are not accounted for as derivatives and are not remeasured each reporting period. As of March&#160;31, 2023 and December 31, 2022, the Company had not purchased any shares under the convertible note capped call transactions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Forward</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the Convertible Notes, the Company entered into a prepaid forward stock repurchase transaction (&#8220;Prepaid Forward&#8221;) with a financial institution (&#8220;Forward Counterparty&#8221;). Pursuant to the Prepaid Forward, the Company used approximately $<ix:nonFraction unitRef="usd" contextRef="icae7497a06dd4ecf932d2ce48689f651_D20201116-20201116" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTE1MDU_8b5b485e-5241-4c68-8c4e-c461f0caa1a3">55.0</ix:nonFraction>&#160;million of the net proceeds from the offering of the Convertible Notes to fund the Prepaid Forward. The aggregate number of shares of the Company&#8217;s common stock underlying the Prepaid Forward was approximately <ix:nonFraction unitRef="shares" contextRef="icae7497a06dd4ecf932d2ce48689f651_D20201116-20201116" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTE3MTA_0f0e884c-a990-4f60-99ff-b9eefbb06fce">1,994,198</ix:nonFraction>. The expiration date for the Prepaid Forward is November 15, 2025, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders&#8217; votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. As of March 31, 2023, <ix:nonFraction unitRef="shares" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="0" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTI0OTM_002bbfbb-445c-40fe-a28a-272d96415990">165,540</ix:nonFraction> shares had been delivered to the Company. The Company&#8217;s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.</span></div></ix:continuation><div id="i9237fb157928404b96a8fc7ef6f6efba_61"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RleHRyZWdpb246NzlkZmNlOTFlOGIxNGFmN2FjNzYwMTY5MDc5MWY0NjhfMTAy_32dbd942-c2c6-48c4-82d0-94095243314c" continuedAt="i7904861b037347d8959525f177340eba" escape="true">Other Accrued Liabilities</ix:nonNumeric></span></div><ix:continuation id="i7904861b037347d8959525f177340eba"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RleHRyZWdpb246NzlkZmNlOTFlOGIxNGFmN2FjNzYwMTY5MDc5MWY0NjhfMTAz_cfd5f110-f768-4d30-aeb2-b6a2bf1d948e" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMS0xLTEtMS02NTI3Mw_3956c980-664f-4c78-84c5-40a54ca70a45">5,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMS0zLTEtMS02NTI3Mw_f0a8d401-43c9-4251-8053-3cabd7d34b71">9,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued variable consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="espr:AccruedVariableConsiderationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMi0xLTEtMS02NTI3Mw_bd61a656-e174-4b31-af96-e0e38fc5a7d5">21,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="espr:AccruedVariableConsiderationCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMi0zLTEtMS02NTI3Mw_d1aeecdb-b349-4e5a-8226-e47414538059">21,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMy0xLTEtMS02NTI3Mw_c34a53a3-8aa3-4dbd-8904-00559770372d">3,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMy0zLTEtMS02NTI3Mw_0fc11cd2-8d25-4cf6-be55-834d2d6c27bf">2,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest on convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNC0xLTEtMS02NTI3Mw_b809f174-5f72-47b6-b194-e00183bddd77">3,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:InterestPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNC0zLTEtMS02NTI3Mw_63f03c8e-c790-4915-a670-3147388aa031">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNS0xLTEtMS02NTI3Mw_a6b88814-041b-4de1-bda9-634515e297df">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNS0zLTEtMS02NTI3Mw_8e20ec96-ae34-4038-a551-34f4b242f89d">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNi0xLTEtMS02NTI3Mw_188f2a55-afbf-41b4-90c5-3acaff886e21">34,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNi0zLTEtMS02NTI3Mw_35a4eedd-3580-4380-a374-47988d832514">35,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNzA3Mw_17ac589e-7830-4e63-aa4c-58cfa4ebd22c" continuedAt="i9cba6d6e9dba48ea8475d254e78afc06" escape="true">Stock Compensation</ix:nonNumeric></span></div><ix:continuation id="i9cba6d6e9dba48ea8475d254e78afc06" continuedAt="ic4190ad8cfe84eb7903ac8f9df973001"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Stock Option and Incentive Plan</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company's stockholders approved the 2022 Stock Option and Incentive Plan (the "2022 Plan"). The number of shares of common stock available for awards under the 2022 Plan was set to <ix:nonFraction unitRef="shares" contextRef="i99ff79bbd6b34af19e4c4f5ffd0dd8bd_I20220531" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjYz_5badeebf-7041-4f95-a199-ef5f96fe426b">4,400,000</ix:nonFraction>, with any shares underlying awards that are forfeited, canceled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance or shares, or otherwise terminated (other than by exercise) under the 2022 Plan may be added back to the shares of common stock available for issuance under the 2022 Plan. The 2022 Plan provides for the award of stock options (both incentive and non-qualified options), stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. Following the approval of the 2022 Plan, no further awards will be issued under the Company&#8217;s 2013 Stock Option and Incentive Plan (the &#8220;2013 Plan&#8221;). </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the board of directors approved the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP") which was approved by the Company's shareholders on May 28, 2020. The ESPP allows eligible employees to authorize payroll deductions of up to <ix:nonFraction unitRef="number" contextRef="ic8d1aec6f0a243debcdc270c1c4783d6_D20200401-20200430" decimals="INF" name="espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMTM3Ng_d73951d5-3210-4bbd-ad91-ef4a5631b4b3">10</ix:nonFraction>% of their base salary or wages up to $<ix:nonFraction unitRef="usd" contextRef="ic8d1aec6f0a243debcdc270c1c4783d6_D20200401-20200430" decimals="INF" name="espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMTQxNQ_d32e1f52-5ab9-4577-bdee-f97b9105b15b">25,000</ix:nonFraction> annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to <ix:nonFraction unitRef="number" contextRef="ic8d1aec6f0a243debcdc270c1c4783d6_D20200401-20200430" decimals="INF" name="espr:EmployeeStockPurchasePlanPercentageDiscountOnShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMTY0Nw_3f41667b-117f-43f1-a301-965888fc0268">15</ix:nonFraction>% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Offering periods under the ESPP will generally be in <ix:nonNumeric contextRef="ic8d1aec6f0a243debcdc270c1c4783d6_D20200401-20200430" name="espr:EmployeeStockPurchasePlanDurationOfOfferingPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMTkwMA_1fef0693-2d2a-43d9-8ae6-f0527548c00d">six months</ix:nonNumeric> increments, commencing on September 1 and March 1 of each calendar year with the administrator having the right to establish different offering periods. In the three months ended March&#160;31, 2023 and 2022, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i88cb7b840c98434489e5ae6882bf0bde_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjEwNw_8c4f7f8f-3d79-43db-81f5-67148f9f3c40">0.1</ix:nonFraction>&#160;million and approximately $<ix:nonFraction unitRef="usd" contextRef="i2ed983231e1c4e1e9acf5a3984e776a1_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfODA5MQ_3b8fcc6e-b015-4398-87c1-cdeeb4f57ee1">0.1</ix:nonFraction>&#160;million of stock compensation expense related to the ESPP. As of March&#160;31, 2023, there have been <ix:nonFraction unitRef="shares" contextRef="i88cb7b840c98434489e5ae6882bf0bde_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjM3NQ_810e0b07-3e39-4f67-bf17-ae8d53fba015">435,076</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="i3ddb347cbc7e4b08b9ec62540ce50d3e_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjM5Ng_d1c58980-e8b8-47fe-994e-9fc4e5783b45">389,924</ix:nonFraction> shares reserved for future issuance under the ESPP.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNzA2Nw_38def785-d1ee-4a9e-b65f-30700034bc94" continuedAt="i5ac436cad0674eda9391c3fe83b8b3f5" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s options to purchase common stock for the three months ended March&#160;31, 2023:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMi0xLTEtMS02NTI3Mw_5444e75a-dc1d-47cd-a154-cddf5ea89373">3,842,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMi0zLTEtMS02NTI3Mw_a84263ab-2686-4024-836b-fb519ea8ab97">27.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia380cab0f6c44c18a991dc9247a9f988_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMi01LTEtMS02NTI3Mw_0dfaf409-4672-468b-8ead-a027770eae0e">4.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMi03LTEtMS02NTI3Mw_4f9032ab-3ad9-4375-92d6-023cd2224983">1,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMy0xLTEtMS02NTI3Mw_f52e8b6b-bec4-4077-8c86-502b3c14ba7c">1,154,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMy0zLTEtMS02NTI3Mw_c606c6a7-4272-4f20-b9e5-4cc6c48fe442">4.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited&#160;or&#160;expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNC0xLTEtMS02NTI3Mw_55663a50-a160-44d4-a14d-03d74ca54798">622,585</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNC0zLTEtMS02NTI3Mw_ffec8130-6ee6-45ee-bcad-722126bc5e9d">38.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNS0xLTEtMS02NTI3Mw_599a4a1b-58d8-4150-8de3-1d1a4f541901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNS0zLTEtMS02NTI3Mw_4d15425e-a2bf-41e3-ada9-012e7bc95939">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNi0xLTEtMS02NTI3Mw_5b732024-4b8c-49b9-ad23-c9f686c7187a">4,374,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNi0zLTEtMS02NTI3Mw_edc4a605-accc-4366-96d0-99257623c5a1">19.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNi01LTEtMS02NTI3Mw_6cfcf63f-48de-4f11-9afd-c6b1a5a30398">6.18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNi03LTEtMS02NTI3Mw_66c0ff5e-9edf-41ef-a6f8-bcdf150d3831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNy0xLTEtMS02NTI3Mw_882e6364-b4f5-4298-95b6-2435625f1a85">4,374,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNy0zLTEtMS02NTI3Mw_7bd24d30-bec3-479a-bc58-fcd58da96bad">19.98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNy01LTEtMS02NTI3Mw_5d13e4f2-c2fc-4794-9cb9-64b9f43c3cf7">6.18</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNy03LTEtMS02NTI3Mw_9b1b6b8d-c838-43f8-9a14-3eb40bdc2aa9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfOC0xLTEtMS02NTI3Mw_d481604a-74cc-43c4-b305-37212e69e70b">2,194,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfOC0zLTEtMS02NTI3Mw_8475ca9d-a2f6-487a-8dea-9eb416366e6e">33.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfOC01LTEtMS02NTI3Mw_e5d85a1f-a185-404f-8a31-2897273129a1">2.99</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfOC03LTEtMS02NTI3Mw_b05c471b-fc58-4e1f-b0ca-a6cba21cceaf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to stock options was $<ix:nonFraction unitRef="usd" contextRef="i66bec0e27b1b48d1bcd58ded58c2e003_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjY0Mg_7b817c8a-b243-4594-bd16-ed7c2696b7c1">1.0</ix:nonFraction> million for the three months ended March&#160;31, 2023, including $<ix:nonFraction unitRef="usd" contextRef="i66bec0e27b1b48d1bcd58ded58c2e003_D20230101-20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjcxMg_ff8295e5-c05e-4508-b9fa-205e558d5781">0.1</ix:nonFraction> million that was capitalized into inventory, and $<ix:nonFraction unitRef="usd" contextRef="i7b0445354f6f4558904c97d5373f8c53_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjc2NA_e6b91619-9fb5-49b3-adee-89ae6dda583e">1.5</ix:nonFraction> million for the three months ended March&#160;31, 2022, including $<ix:nonFraction unitRef="usd" contextRef="i7b0445354f6f4558904c97d5373f8c53_D20220101-20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjgyMQ_2d1d2767-62a0-405c-9550-6ca4fe6a09cf">0.1</ix:nonFraction> million that was capitalized into inventory. As of March&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="i60d797f24c2c4a04b4ff42bb670e3cc1_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjg5Nw_ef305607-34b3-48e5-b49c-f3e6595ed529">9.0</ix:nonFraction> million of unrecognized stock-based compensation expense related to unvested options, which will be recognized over a weighted-average period of <ix:nonNumeric contextRef="i66bec0e27b1b48d1bcd58ded58c2e003_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjE5OTAyMzI2MzMyMg_66ef6ccd-d4d8-4779-90e6-7ed9b3676432">2.9</ix:nonNumeric> years. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="ic4190ad8cfe84eb7903ac8f9df973001" continuedAt="i8ae2760f9808415898e8a6de7bfa3fb5"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Stock Options ("PBSOs")</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company granted PBSOs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company granted PBSOs from the 2022 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met. </span></div><div><span><br/></span></div><ix:continuation id="i5ac436cad0674eda9391c3fe83b8b3f5"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s PBSOs for the three months ended March&#160;31, 2023:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b9c918318b245b38e4e0d3ba2428dba_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMi0xLTEtMS02NTI3Mw_83fc31ec-85aa-4a85-ac5a-3d4a2babb8c4">499,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9b9c918318b245b38e4e0d3ba2428dba_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMi0zLTEtMS02NTI3Mw_9de0c2aa-5fc0-48ea-8a44-e8f7080833df">6.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i162d9a4406ca467199ca052182157c66_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMi01LTEtMS02NTI3Mw_aa79983e-6589-4b9b-8392-b46d9f0ec516">9.32</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b9c918318b245b38e4e0d3ba2428dba_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMi03LTEtMS02NTI3Mw_65813544-dc6a-4cc1-bfdd-750391e0c0d7">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMy0xLTEtMS02NTI3Mw_94ab67d4-4256-4e1f-88b6-f625f1d9cee7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMy0zLTEtMS02NTI3Mw_eeab7d5a-fcec-4a3c-a86d-45972e436cdf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited&#160;or&#160;expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNC0xLTEtMS02NTI3Mw_25dce33f-b178-4f43-84d7-135a5f0e372f">65,250</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNC0zLTEtMS02NTI3Mw_a0d4ea45-07ce-481c-b317-60040c55d274">6.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNS0xLTEtMS02NTI3Mw_a0c1aef5-09be-4a6d-a758-3ad8f0887d66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNS0zLTEtMS02NTI3Mw_f1082615-6470-49e8-a693-04433754fcc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNi0xLTEtMS02NTI3Mw_4ca856ac-1af3-4e9f-bae2-fa6a15811912">433,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNi0zLTEtMS02NTI3Mw_1c86494c-2142-4b3a-b7dc-769f1f88ed22">6.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNi01LTEtMS02NTI3Mw_7b6f16eb-0c6c-417f-9c44-34b9850efb56">8.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNi03LTEtMS02NTI3Mw_2c30d8be-e35f-44b9-aac0-f951459c06a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNy0xLTEtMS02NTI3Mw_b0d99bde-4429-44a9-87f3-91b37b444c6c">433,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNy0zLTEtMS02NTI3Mw_338d8f87-15ef-49b2-82d3-353eebc495cd">6.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNy01LTEtMS02NTI3Mw_f5cae3b5-bfa2-4a21-951a-04a66d5210ce">8.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNy03LTEtMS02NTI3Mw_51238878-d930-45c5-a230-3e93382aa520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfOC0xLTEtMS02NTI3Mw_364c091b-4a6e-438b-bbce-a955ab29b4c1">48,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfOC0zLTEtMS02NTI3Mw_7b0ca256-aec1-4998-91e0-bad405ef8ebc">8.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfOC01LTEtMS02NTI3Mw_28e2adac-e6f4-47b5-aa42-fb14f5768036">6.62</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfOC03LTEtMS02NTI3Mw_77874825-a86e-4acc-a775-73392828c701">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to PBSOs was $<ix:nonFraction unitRef="usd" contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNDU5MA_35f21d3e-7970-435a-a1bc-d0e7d7e9dbc4">0.2</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2023 and $<ix:nonFraction unitRef="usd" contextRef="i012dbf6545a3491b9f6f9fab381db389_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTQ5NzU1ODIxNjA0_d18de68e-f395-4885-a6bd-4be3106d2a82">0.1</ix:nonFraction>&#160;million for the three months ended March 31, 2022. As of March 31, 2023, there was approximately $<ix:nonFraction unitRef="usd" contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNDY5Mg_39798614-f80e-4d74-9988-e74a5feede8a">1.0</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to unvested PBSOs, which will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNDg0NA_32a554fe-aa8d-435a-8d64-f9415c47d0fa">1.2</ix:nonNumeric> years. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units (or RSUs)</span></div><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNzA3Mg_052ca2ff-68f9-4a0d-be24-ee966a80580d" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s RSUs for the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.004%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Fair Value Per <br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e9dfbd0c5a54147bd3f860e7e9511c2_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMS0xLTEtMS02NTI3Mw_2b04828e-3952-4afd-9f78-9535a8b5df82">1,768,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5e9dfbd0c5a54147bd3f860e7e9511c2_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMS0zLTEtMS02NTI3Mw_0f347300-747d-4c27-be11-18b6efd122ed">8.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMi0xLTEtMS02NTI3Mw_28734999-a052-46c0-a1eb-e32c5cfc3dff">1,622,485</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMi0zLTEtMS02NTI3Mw_b08be4ed-c5be-4bd4-9bea-14decd883ed4">4.13</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMy0xLTEtMS02NTI3Mw_da36cab2-ffbf-4b79-8e55-781d7600fcff">101,881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMy0zLTEtMS02NTI3Mw_a4ff2ef8-e864-4a7f-9f2a-0378d4599887">9.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfNC0xLTEtMS02NTI3Mw_74df753c-ea63-47ea-b8a1-551d57cf42ef">171,392</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfNC0zLTEtMS02NTI3Mw_388c4938-a337-4335-a96b-e1b08f51944a">9.23</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83fd6d470bf4439baf8eaf859c790c76_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfNS0xLTEtMS02NTI3Mw_fd5e7d76-b78f-4de8-887c-6e34dd82bb3b">3,117,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i83fd6d470bf4439baf8eaf859c790c76_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfNS0zLTEtMS02NTI3Mw_b7f9b9b4-d1ac-426a-bd18-33de132a2c4f">6.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to RSUs was approximately $<ix:nonFraction unitRef="usd" contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTAzNA_5d2c3880-f2fb-4144-bc49-9854f57ba42f">1.5</ix:nonFraction> million for the three months ended March&#160;31, 2023, including $<ix:nonFraction unitRef="usd" contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTA5Ng_449a5b0f-f84c-4cf5-82b8-0314c561b4a0">0.1</ix:nonFraction>&#160;million that was capitalized into inventory, and approximately $<ix:nonFraction unitRef="usd" contextRef="i8632a444e79c46f1a18e5bc0a4625f88_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTE2MQ_90d95be2-d131-43d9-bb75-e5f5a5e8a186">1.9</ix:nonFraction> million for the three months ended March 31, 2022, including $<ix:nonFraction unitRef="usd" contextRef="i8632a444e79c46f1a18e5bc0a4625f88_D20220101-20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTI2Nw_968644aa-be2d-4d3d-821d-1c624ce277a2">0.1</ix:nonFraction> million that was capitalized into inventory. As of March&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="i83fd6d470bf4439baf8eaf859c790c76_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTM1MA_2d8dc05a-10a8-40b2-abdb-98309940b172">18.6</ix:nonFraction> million of unrecognized stock-based compensation expense related to unvested RSUs, which will be recognized over a weighted-average period of <ix:nonNumeric contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTQ4Nw_5dc8825c-ce24-4fec-806d-5a046541eafb">3.0</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="i8ae2760f9808415898e8a6de7bfa3fb5"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based Restricted Stock Units ("PBRSUs")</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company granted PBRSUs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined milestones based on the Company's U.S. net product sales or clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBRSUs based on the expected performance period to achieve the performance milestone. The fair value of the PBRSUs is based on the quoted market price of the Company's common stock on the date of grant. The Company expects the performance criteria to be met. </span></div><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNzA3MA_658a09ed-0bc2-4fbd-87d3-46dae7bd1428" escape="true"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company's PBRSUs for the three months ended March 31, 2023:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:67.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PBRSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average fair value per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if882eb7b96d54916b14a19ce79b2ec18_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMS0xLTEtMS02NTI3Mw_a69694a0-51be-489c-ad62-2ab90938a2e6">461,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if882eb7b96d54916b14a19ce79b2ec18_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMS0yLTEtMS02NTI3Mw_c56ca1d3-590a-4ba3-9604-41f843d1628a">9.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMi0xLTEtMS02NTI3Mw_d81c3cc7-f651-41fd-bbab-d9a2cd27dd35">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMi0yLTEtMS02NTI3Mw_a515bf8a-8062-48b4-9f08-644bf014871d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMy0xLTEtMS02NTI3Mw_341eb8d6-16d7-4538-ac44-7d764eb01141">69,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMy0yLTEtMS02NTI3Mw_c56de891-5b8c-478f-bc7f-ae2a2138f1e1">12.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfNC0xLTEtMS02NzA5OA_7ed5a45c-950d-407e-bb45-bd1c1fbcb269">200,725</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfNC0yLTEtMS02NzEwOQ_50fe9bf5-97c8-40cd-a1b6-6764a66cf71f">8.94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e0291a026d743f2b05b3fe91e58229b_I20230331" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfNC0xLTEtMS02NTI3Mw_7a7a24d0-eb4b-4da8-95c9-78c9cca49df2">191,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e0291a026d743f2b05b3fe91e58229b_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfNC0yLTEtMS02NTI3Mw_db46dc49-67cc-4216-9f69-eea8b7f0116f">8.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to the PBRSUs was $<ix:nonFraction unitRef="usd" contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNjU5NA_529fff40-9a77-4b9e-af03-3844e0e9aedf">0.1</ix:nonFraction>&#160;million for the three months ended March 31, 2023, including less than $<ix:nonFraction unitRef="usd" contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNjY5NA_6d2640a5-068b-442d-92e3-7fe7d9cbdc50">0.1</ix:nonFraction>&#160;million that was capitalized into inventory, and $<ix:nonFraction unitRef="usd" contextRef="i11f403f253414aff975722250ebed665_D20220101-20220331" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNjgwMg_2a2489b3-5236-409a-955a-8c4e578d5acc">0.8</ix:nonFraction>&#160;million for the three months ended March 31, 2022, including $<ix:nonFraction unitRef="usd" contextRef="i11f403f253414aff975722250ebed665_D20220101-20220331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTQ5NzU1ODIxNjE4_cb9b7366-5891-4d28-88ba-97f63e52203b">0.1</ix:nonFraction>&#160;million that was capitalized into inventory. As of March 31, 2023, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i7e0291a026d743f2b05b3fe91e58229b_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNjkxMQ_ee5f48ef-f665-480c-8564-cbb1f0e08247">0.8</ix:nonFraction>&#160;million of unrecognized stock-based compensation expense related to unvested PBRSUs, which will be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNzA2NA_b77ea84b-21ca-4e44-b52d-efdae8bde12f">1.2</ix:nonNumeric> years.</span></div></ix:continuation><div id="i9237fb157928404b96a8fc7ef6f6efba_67"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82Ny9mcmFnOjBmZjA4OGUwMzdlYzRkZGRhNzI2NjI4ODg3YTg4Mzk5L3RleHRyZWdpb246MGZmMDg4ZTAzN2VjNGRkZGE3MjY2Mjg4ODdhODgzOTlfNDQx_86696f93-4317-49be-bf2f-ddd44d8b8c76" continuedAt="i3535c0e91ced41ed9517d9e3b2cb6735" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3535c0e91ced41ed9517d9e3b2cb6735">There was <ix:nonFraction unitRef="usd" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82Ny9mcmFnOjBmZjA4OGUwMzdlYzRkZGRhNzI2NjI4ODg3YTg4Mzk5L3RleHRyZWdpb246MGZmMDg4ZTAzN2VjNGRkZGE3MjY2Mjg4ODdhODgzOTlfMzI_44fd0903-1b92-4f97-9f0d-0f6a047b77af"><ix:nonFraction unitRef="usd" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82Ny9mcmFnOjBmZjA4OGUwMzdlYzRkZGRhNzI2NjI4ODg3YTg4Mzk5L3RleHRyZWdpb246MGZmMDg4ZTAzN2VjNGRkZGE3MjY2Mjg4ODdhODgzOTlfMzI_7ab08ab6-0854-4226-a467-f2046b79b2e9">no</ix:nonFraction></ix:nonFraction> provision for income taxes for the three months ended March&#160;31, 2023 and 2022, because the Company has incurred annual operating losses since inception. At March&#160;31, 2023, the Company continues to conclude that it is not more likely than not that the Company will realize the benefit of its deferred tax assets due to its history of losses. Accordingly, a full valuation allowance has been applied against the net deferred tax assets.</ix:continuation></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMzM5Ng_cfabf5db-6a96-45e0-9acf-e2a4e8fde18c" continuedAt="i61936e95595d440d8708182d2687723f" escape="true">Stockholders' Deficit</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i61936e95595d440d8708182d2687723f" continuedAt="i66acf1b77e6b4d89987e5ea59a2c4001"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 15, 2022, the Company filed a new registration statement on Form S-3 to replace its prior automatically effective registration statement on Form S-3ASR filed on August 3, 2021, which registers the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="i6f7bbae10a6e443e8fc0880b3115a1d0_D20220415-20220415" decimals="-6" name="espr:SaleOfStockAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ0NjMwMA_3741ee92-77e8-4e71-8aa0-7a7e9c852a31">239</ix:nonFraction>&#160;million of common stock from time to time in &#8220;at-the-market&#8221; offerings (the &#8220;New ATM Program&#8221;). On February 21, 2023, the Company terminated the open market sales agreement with Jefferies LLC and entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald &amp; Co., as sales agent, to provide for the issuance and sale by the Company of up to $<ix:nonFraction unitRef="usd" contextRef="i5746fa6ad7264580a9b24d5d4c46caa2_D20230221-20230223" decimals="-6" name="espr:SaleOfStockAuthorizedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ0NjY0OA_153942b7-0938-4ddc-9138-a6d444e336e7">70</ix:nonFraction>&#160;million of common stock from time to time in &#8220;at-the-market&#8221; offerings (the "2023 ATM Program"), pursuant to its existing Form S-3 and the prospectus supplement filed on February 21, 2023. The Company may continue to use the 2023 ATM Program to address potential short-term or long-term funding requirements that may arise. Such program will continue to be subject to the volatility of the price of the Company's common stock and general market conditions. During the year ended December 31, 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="i3456d874c623457a8adcfaacbaeb0697_D20220101-20221231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ0NzE2Nw_d7b60087-044f-49ca-863b-64c435badf7c">13,043,797</ix:nonFraction> shares of common stock resulting in net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i3456d874c623457a8adcfaacbaeb0697_D20220101-20221231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ0NzIzNw_fa2ac0b8-9537-4377-a388-58f65b715dc4">90.8</ix:nonFraction>&#160;million after deducting $<ix:nonFraction unitRef="usd" contextRef="i3456d874c623457a8adcfaacbaeb0697_D20220101-20221231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ0NzI1Nw_24823bdd-bee8-464c-9a1e-7827a87841e2">3.1</ix:nonFraction>&#160;million of underwriting discounts and commissions and other expenses, pursuant to the New ATM Program. No shares have been issued under the 2023 ATM Program as of the date of this quarterly report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an underwriting agreement with H.C. Wainwright &amp; Co., LLC ("Wainwright") on December 2, 2021, the Company issued warrants to purchase <ix:nonFraction unitRef="shares" contextRef="ib488c87ccc86426b94cb6b54cc339eab_I20211202" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ1MjE4MA_d2e5c8ad-60d1-49c0-a70d-6e3ce68f14f7">36,964,286</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib488c87ccc86426b94cb6b54cc339eab_I20211202" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ1MjIzMQ_72474769-8311-4e87-83e4-036709407814">9.00</ix:nonFraction>. The warrants will terminate on December 7, 2023. The warrants were recorded at fair value of $<ix:nonFraction unitRef="usd" contextRef="i65f77ad90bd045109470849cecbc6ea3_D20211202-20211202" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ1MjMyOQ_6495481d-52d0-4aa2-a9e9-a315855dfe50">61.9</ix:nonFraction>&#160;million to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the proceeds between the common shares issued with the Offering and the warrants. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registered Direct Offering and Warrant Amendment</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2023, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers named therein (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the &#8220;Offering&#8221;), <ix:nonFraction unitRef="shares" contextRef="idabb0477bfa648dab7fecedc64128780_I20230319" decimals="0" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzEz_3cb54cfc-181b-4813-903e-81d672584e13">12,205,000</ix:nonFraction> shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="idabb0477bfa648dab7fecedc64128780_I20230319" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzI1_a9477061-9038-4399-bc71-1f9175731cd9">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), pre-funded warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i2d316e7178014207990f50547c020dad_D20230319-20230319" decimals="0" name="espr:CommonStockPurchasableUnderPrefundedWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzMz_72bbb5ef-7578-4862-9936-b26007324dfd">20,965,747</ix:nonFraction> shares of Common Stock (the &#8220;Pre-Funded Warrants&#8221;) in lieu of shares of Common Stock, and warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i2d316e7178014207990f50547c020dad_D20230319-20230319" decimals="0" name="espr:CommonStockPurchasableUnderWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzQ1_ea1d6322-c65b-42e8-a9c1-5769e2438bf8">33,170,747</ix:nonFraction> shares of Common Stock (the &#8220;Warrants&#8221;). The combined purchase price of each share of Common Stock and accompanying Warrant is $<ix:nonFraction unitRef="usdPerShare" contextRef="i97a34cf836d84f4fadef4d721fab3698_I20230319" decimals="3" name="espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzU3_566067bc-aee8-4cef-a41c-64c589a7a430">1.675</ix:nonFraction> per share. The Warrants expire on September 22, 2026 and have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i326e6c7729314df9be278a89e941857f_I20230319" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM4Mjk4_dc8f9381-81a4-4a1a-ad1e-6ad76e95ff18">1.55</ix:nonFraction>. The purchase price of each Pre-Funded Warrant is $<ix:nonFraction unitRef="usdPerShare" contextRef="ice6f0592c1f54f6b9a640b944432f3be_I20230319" decimals="3" name="espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzY1_44bd7fe5-1fac-44da-bb0d-1be6702e5d26">1.674</ix:nonFraction> (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $<ix:nonFraction unitRef="usdPerShare" contextRef="idabb0477bfa648dab7fecedc64128780_I20230319" decimals="3" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzcz_c31ac576-bea8-4679-998b-7bed0852346f">0.001</ix:nonFraction>). The Purchase Agreement contains customary representations, warranties, covenants and indemnification rights and obligations of the Company and the Purchasers. The Offering closed on March 22, 2023. The warrants and pre-funded warrants were recorded at fair value of $<ix:nonFraction unitRef="usd" contextRef="ife8d4c895c31407d94cb9c6ff1903a1a_D20230319-20230319" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM2ODE4_836889b3-2713-4074-9fcb-214a4c8cea5b">22.8</ix:nonFraction>&#160;million to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the proceeds between the common shares issued with the Offering and the warrants and pre-funded warrants. The Company estimated the fair value of the warrants using a Black-Scholes option-pricing model, which is based, in part, upon subjective assumptions including but not limited to stock price volatility, the expected life of the warrant, the risk-free interest rate and the fair value of the common stock underlying the warrant. The Company estimates the volatility based on its historical volatility that is in line with the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury daily rate for a maturity similar to the expected remaining life of the warrants. The expected remaining life of the warrants is assumed to be equivalent to its remaining contractual term. The Company estimated the fair value of the pre-funded warrants based on the market price of the Company's common stock at issuance. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering, the Company amended, pursuant to Warrant Amendment Agreements (the &#8220;Warrant Amendment Agreements&#8221;), certain existing warrants to purchase up to an aggregate of <ix:nonFraction unitRef="shares" contextRef="i9d4d2015f62f45aaa2e5addfd39b96f2_I20230319" decimals="0" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzgx_b498e4cb-17a8-477c-86ea-e0abee4f5760">9,024,212</ix:nonFraction> shares of the Company's common stock that were previously issued in December 2021 at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7ce060f7a8354b51af7f71258119d414_I20211231" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzky_e35d5ce4-c236-4208-857f-e2e52ebc027f">9.00</ix:nonFraction> per share and had an expiration date of December 7, 2023, effective upon the closing of the Offering, such that the amended warrants have a reduced exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i90c4fbf04c494d99bd37f6e4eb559905_I20230322" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzk5_33689106-0d01-4c4f-953e-c8b5bc6faa7d">1.55</ix:nonFraction> per share and expire three and one half years following the closing of the Offering, or September 22, 2026, for additional consideration of $<ix:nonFraction unitRef="usdPerShare" contextRef="i90c4fbf04c494d99bd37f6e4eb559905_I20230322" decimals="3" name="espr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzNDA2_e26b1fae-eaf8-436b-9bc7-d9f214fb8052">0.125</ix:nonFraction> per amended warrant. Based on the change in the fair value of the amended warrants, the Company recorded issuance costs to additional paid-in capital of $<ix:nonFraction unitRef="usd" contextRef="i46d8059776cc44b2bb584005f975602b_D20230319-20230319" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM2ODMz_c119b868-9832-4fff-b042-4c85eae5c8d0">2.9</ix:nonFraction>&#160;million.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzNDE0_bf49bfbf-249c-4b0c-9e77-0193569ce032">55.5</ix:nonFraction>&#160;million from the Offering, before deducting placement agent fees and related offering expenses. The net proceeds to the Company from the Offering, after deducting the placement agent fees and expenses and the Company&#8217;s estimated offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i5664faaee9574db4a202135e028596c8_D20230319-20230319" decimals="-5" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM4MzA1_b551750c-3922-4251-99cd-46b525a87646">4.2</ix:nonFraction>&#160;million, were approximately $<ix:nonFraction unitRef="usd" contextRef="i5664faaee9574db4a202135e028596c8_D20230319-20230319" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzNDI5_81836684-c76b-4491-b188-3e7ce82ba3cb">51.3</ix:nonFraction>&#160;million. In addition, the Company received approximately $<ix:nonFraction unitRef="usd" contextRef="i5664faaee9574db4a202135e028596c8_D20230319-20230319" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzNDQ0_2595d9ab-0dfb-408c-b25f-ee8ea08c232c">1.2</ix:nonFraction>&#160;million as the gross consideration in connection with the Warrant </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><ix:continuation id="i66acf1b77e6b4d89987e5ea59a2c4001"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amendment Agreements. The net proceeds of the Warrant Amendment Agreements after deducting placement fees of $<ix:nonFraction unitRef="usd" contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM4MzE5_97b6afe4-3e0e-4f9f-8b3b-6dda712f776e">0.1</ix:nonFraction>&#160;million were approximately $<ix:nonFraction unitRef="usd" contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM2ODQ3_32285709-8645-42ed-914d-1af35bf642cd">1.1</ix:nonFraction>&#160;million.</span></div><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="espr:SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM4MzMy_3448f718-a738-4c14-aee8-6c24d31708c0" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the warrants and pre-funded warrants outstanding for the Company as of March 31, 2023 and December 31, 2022:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"></td><td style="width:53.261%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.385%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.389%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding from 2021 agreement, expiring December 7, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if7e3ecf1db13427a96c7342395cd96b9_I20230331" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMS0xLTEtMS03Mjc4NA_da7b6f6b-4a1a-437f-b3e3-d491dcb9245e">27,940,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3cca07e819f46e68cad7cce1b9900cb_I20221231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMS0zLTEtMS03Mjc4Ng_94bd83a5-3d54-4116-bebe-918bf61b14aa">36,964,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if7e3ecf1db13427a96c7342395cd96b9_I20230331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMS01LTEtMS03Mjc4OA_5adad30b-4a26-4f0a-85a5-c66e5baa32bd">9.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding from Warrant Amendment Agreements, expiring September 22, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia89bfe8a898240809b23c12addd330c2_I20230331" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMi0xLTEtMS03Mjc4NA_2d042afc-c261-4088-859c-9c95a146fce6">9,024,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc92509623704e8fa809dc4a3cd974f3_I20221231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMi0zLTEtMS03Mjc4Ng_85a4e132-65bc-460d-8384-a877289e6730">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia89bfe8a898240809b23c12addd330c2_I20230331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMi01LTEtMS03Mjc4OA_402f20fd-8a70-4b92-b9d6-a8baff126c5b">1.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding from Purchase Agreement, expiring September 22, 2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if4d3e30f8f084676b1159f8204cf214e_I20230331" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMy0xLTEtMS03Mjc4NA_5635616d-6dbe-4e0b-97d8-088bd5d2f6fe">33,170,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39d14dea4b5f4437b4a560e299ef1164_I20221231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMy0zLTEtMS03Mjc4Ng_3730f220-f9ef-448e-aa04-938d93b30530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if4d3e30f8f084676b1159f8204cf214e_I20230331" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMy01LTEtMS03Mjc4OA_26883406-fe4e-4876-bddc-d2272527c1e0">1.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded warrants outstanding, no expiration date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie5ade988872643258980d4d742f28c71_I20230331" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfNC0xLTEtMS03Mjc4NA_8e25a3fb-6168-4300-af1b-54346e511f6e">20,965,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iedd2a0c27a144f8f80418aaca97d59de_I20221231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfNC0zLTEtMS03Mjc4Ng_100a7639-d1e7-4d5c-8ac8-a776496bc353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie5ade988872643258980d4d742f28c71_I20230331" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfNC01LTEtMS03Mjc4OA_0e5f1f6f-2590-4197-a53a-05155387c87b">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total warrants and pre-funded warrants outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfNS0xLTEtMS03Mjc4NA_6c96334b-ce02-4bbf-8a73-f92e3273b4fd">91,100,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="0" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfNS0zLTEtMS03Mjc4Ng_9ab1d426-8e79-4545-868d-2bb1f3d8f6c7">36,964,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2023, on April 24, 2023, <ix:nonFraction unitRef="shares" contextRef="i3dc5d334d016420f99299c9b501f60ff_I20230424" decimals="0" name="espr:ClassOfWarrantOrRightExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM4MzM0_8627f4c5-052e-4fcc-84ec-88fd84a5984e">5,865,747</ix:nonFraction> shares of pre-funded warrants were exercised.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_73"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RleHRyZWdpb246NTc1MGY1ZWUxN2FlNDFhNjg5ZmQwNDU5ZDFkMmUzZmNfMTA1MA_a6c1a906-c619-4d54-b741-014341625d99" continuedAt="i26d5125f4b8f4414841aa84603474221" escape="true">Net Loss Per Common Share</ix:nonNumeric></span></div><ix:continuation id="i26d5125f4b8f4414841aa84603474221"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Pre-Funded Warrants are included in the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period, including shares that potentially could be dilutive if they were exercised or vested during the period, determined using the treasury-stock method. For purposes of this calculation, warrants for common stock, stock options, PBSOs, unvested RSUs and PBRSUs, shares issuable under the ESPP and shares issuable upon conversion of the convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RleHRyZWdpb246NTc1MGY1ZWUxN2FlNDFhNjg5ZmQwNDU5ZDFkMmUzZmNfMTA1Mg_509e6d30-b8d3-41c5-9272-585cf50e6041" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"><tr><td style="width:1.0%"></td><td style="width:57.421%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.615%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id729569cba9c49bfb3259c1d0b23594b_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfMi0yLTEtMS02NTI3Mw_caa56884-ad1d-44bd-b114-67ae6e2e4569">4,374,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4b19c75cff2843b98e3df4b11681f893_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfMi00LTEtMS02NTI3Mw_3f996c62-8cfa-499c-af88-cb0d233a54d1">4,101,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under PBSOs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic416a391bdff493fbefe5822e04c52ed_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfMy0yLTEtMS02NTI3Mw_59f29234-a89d-425a-ba98-837578f7b7a2">433,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i364cd2415d994d3e85d93df2f35e189e_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfMy00LTEtMS02NTI3Mw_23b77c3b-bb13-44b9-9e9c-81fce718842c">122,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0616f511266b4f73a0978adcfd5aaa0a_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNC0yLTEtMS02NTI3Mw_f8ad737c-7378-4324-953d-17f24b9abf77">3,117,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f5e3f1ac3ab4878bb7bbbf20e6fe992_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNC00LTEtMS02NTI3Mw_84a91a3c-c020-4745-97e5-c2f4b984dc27">1,978,717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested PBRSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bb62ba99eea46949781dcab102b26a1_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNS0yLTEtMS02NTI3Mw_b61b156f-3d4e-43c0-9bff-5e1eb0cb8cea">191,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i92b532ab4d724df2b12bf304d0f7d08a_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNS00LTEtMS02NTI3Mw_4af78722-3d0a-4b87-bebd-66e732d76562">602,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable related to the ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2e830b24c974bfb99c9f7bd46ee28b5_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNi0yLTEtMS02NTI3Mw_18294965-149b-43ad-8821-a9279ee2201e">33,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03a5a3f73f214702aafb0c19d871baab_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNi00LTEtMS02NTI3Mw_d19f627f-a7a3-43a9-82f2-3d51a6e1b5e0">40,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief954accff7948b38b762497cb61309d_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNy0yLTEtMS02NTI3Mw_e3a8997b-ae52-4d3e-9400-552d973e3b80">8,007,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied19a86173ab476f92091aa5b22ef096_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNy00LTEtMS02NTI3Mw_fc5fce5a-f048-4d8d-b805-e7db0a656990">8,007,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if98ef8167c62483b9317f69d35a8b12b_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfOC0yLTEtMS02NTI3Mw_50ab71be-a29b-4957-b7dd-386824584b8f">70,135,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c01babe5a404671aaf5f037534a61fc_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfOC00LTEtMS02NTI3Mw_9d0ad376-e6b7-482b-b78f-83e991de7789">36,964,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfOS0yLTEtMS02NTI3Mw_745d4aef-388d-48b1-a5ee-1b1f7027e032">86,292,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfOS00LTEtMS02NTI3Mw_54d642b2-1db7-484a-a878-fdd659ea3dca">51,816,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RleHRyZWdpb246OTdhODZmODAzOTczNGIzMjgwZDJiYmJkYjdhOTM4YTlfMzI2_b4d2d389-c9d7-4e46-b0cf-42787f45ff86" continuedAt="i66638f7500ec44a8830b79e353440cde" escape="true">Statements of Cash Flows and Restricted Cash</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i66638f7500ec44a8830b79e353440cde" continuedAt="i9da9127beef343778ad35deac9b0ecaf"><ix:nonNumeric contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331" name="espr:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RleHRyZWdpb246OTdhODZmODAzOTczNGIzMjgwZDJiYmJkYjdhOTM4YTlfMzI3_ad856a4e-b939-4a9a-b52b-a15c49dad61e" continuedAt="i7417132b8b324cfa91113e62548bbefa" escape="true">The following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on March 31, 2023 and 2022 and December 31, 2022 and 2021 (in thousands): </ix:nonNumeric></ix:continuation></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="text-indent:18pt"><ix:continuation id="i9da9127beef343778ad35deac9b0ecaf"><ix:continuation id="i7417132b8b324cfa91113e62548bbefa"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:42.258%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.492%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMS0xLTEtMS02NTI3Mw_c0bf36cd-4c5a-4453-a1d0-28e890ecb966">144,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f951895edd442e82a9307c2fd15632_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMS0zLTEtMS02NTI3Mw_a70e9117-1aba-4e33-a78c-f434ba9bd904">150,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMS01LTEtMS02NTI3Mw_8a0238a0-5489-433f-8b6c-b789ba761664">124,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0b5ab60804e7ba2963330f6311982_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMS03LTEtMS02NTI3Mw_2c9954ce-df45-460f-a991-915ee77bafc0">208,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMi0xLTEtMS02NTI3Mw_810dbf38-9e91-4b77-80c0-6ea1116c1047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f951895edd442e82a9307c2fd15632_I20220331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMi0zLTEtMS02NTI3Mw_9e3b0127-22b1-4806-92d4-0ec0e5c235da">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMi01LTEtMS02NTI3Mw_40df5de1-282f-4fd3-9a4b-92753954c654">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0b5ab60804e7ba2963330f6311982_I20211231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMi03LTEtMS02NTI3Mw_844b433b-c462-42ef-8e61-e00764e882d8">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMy0xLTEtMS02NTI3Mw_33c3fee0-1fa3-4f6f-8621-d20f5ae7e852">144,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99f951895edd442e82a9307c2fd15632_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMy0zLTEtMS02NTI3Mw_0ecc2552-8029-4cc7-8545-052c665f31fa">200,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i914746ebf548485ab38582d5985e0ada_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMy01LTEtMS02NTI3Mw_135acddc-988e-4f9a-b9b3-4ac3e3c38ef0">124,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0b5ab60804e7ba2963330f6311982_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMy03LTEtMS02NTI3Mw_9ca01dbf-6d08-4d4c-b797-175777710040">258,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed financial statements and related notes appearing elsewhere in this Quarterly Report on Form&#160;10-Q and our annual report on Form&#160;10-K for the fiscal year ended December&#160;31, 2022 and other filings that we make with the Securities and Exchange Commission.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act). These forward-looking statements are based on our management&#8217;s belief and assumptions and on information currently available to management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events, including our clinical development and commercialization plans, or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, including in relation to the clinical development, commercialization plans, approval of expanded indications for bempedoic acid and the bempedoic acid / ezetimibe combination tablet and expectations regarding future transactions to further improve our balance sheet to be materially different from any future results, performance or achievements, including in relation to the clinical development, commercialization plans, or approval of expanded indications for bempedoic acid and the bempedoic acid / ezetimibe combination tablet, clinical activities and commercial development plans, expressed or implied by these forward-looking statements.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward-looking statements are often identified by the use of words such as, but not limited to, &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or the negative of these terms or other similar terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and that could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those referred to or discussed in or incorporated by reference into the section titled &#8220;Risk Factors&#8221; included in Item 1A of Part&#160;II of this Quarterly Report on Form&#160;10-Q. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The forward-looking statements in this report represent our views as of the date of this quarterly report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We use the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or the "Company&#8221; in this report to refer to Esperion Therapeutics, Inc.</span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_82"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Overview</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a pharmaceutical company singularly focused on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol, or LDL-C. Through commercial execution and completion of our CLEAR Outcomes trial as well as advancing our pre-clinical pipeline, we continue to evolve into a differentiated, global cardiometabolic biotech. Our team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. Our first two products were approved by the U.S. Food and Drug Administration, or FDA, European Medicines Agency, or EMA and Swiss Agency for Therapeutic Products, or Swissmedic, in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease, or ASCVD, or heterozygous familial hypercholesterolemia, or HeFH. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We recently completed a global cardiovascular outcomes trial, or CVOT,&#8201;&#8212;&#8201;known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">holesterol </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">owering via B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mpedoic Acid, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CL-inhibiting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">egimen (CLEAR) Outcomes. The trial was designed to evaluate whether treatment with bempedoic acid reduced the risk of cardiovascular events in patients who are statin averse and who have CVD or are at high risk for CVD. We initiated the CLEAR Outcomes CVOT in December 2016 and fully enrolled the study with over 14,000 patients in August 2019. The primary endpoint of the study was the effect of bempedoic acid on four types of major adverse cardiovascular events, or MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization; also referred to as &#8220;four-component MACE&#8221;). CLEAR Outcomes was an event-driven trial and concluded </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">once the predetermined number of MACE endpoints occurred. On December 7, 2022, we announced that the study had met its primary endpoint.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 4, 2023, we announced the full results from the CLEAR Outcomes trial. The study showed that bempedoic acid demonstrated significant cardiovascular risk reductions and significantly reduced the risk of heart attack and coronary revascularization as compared to placebo. These results were seen in a broad population of primary and secondary prevention patients who are unable to maximize or tolerate a statin. The proportions of patients experiencing adverse events and serious adverse events were similar between the active and placebo treatment groups. Bempedoic acid (contained in NEXLETOL&#174; and NEXLIZET&#174; (bempedoic acid and ezetimibe) tablets) now becomes the first LDL-C lowering therapy since statins proven to lower hard ischemic events, not only in those with ASCVD but also in the large number of primary prevention patients for whom limited therapies exist. We believe that we remain on track to submit regulatory filings to the FDA and EMA in the first half of 2023 with expected inclusion in the U.S. and EMA labels in the first half of 2024.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Based on the terms of the contract with Daiichi Sankyo Europe GmbH, or DSE, we are eligible for partner milestone payments upon inclusion of cardiovascular risk reduction data in the EU label, for which payment is tied to the magnitude of the cardiovascular risk percentage reduction included in the label (among other requirements) and ranges from $200&#160;million to $300&#160;million. Based on the CLEAR Outcomes data, we believe we would be entitled to receive $300&#160;million in partner milestone payments upon inclusion of cardiovascular risk reduction data in the EU label. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DSE has conveyed that it disagrees with our assessment that the CLEAR Outcomes data would support the our right to receive any milestone payments upon inclusion of certain required cardiovascular risk reduction data in the EU label. On March 27, 2023, we filed a complaint in the United States District Court for the Southern District of New York seeking declaratory judgment against DSE regarding the Company&#8217;s right to receive a $300&#160;million milestone payment upon inclusion of cardiovascular risk reduction in the EU label. On May 4, 2023, we filed an amended complaint against DSE in the Southern District of New York. The complaint seeks a judicial declaration, on an expedited basis, that DSE is contractually required to make a $300&#160;million milestone payment to Esperion upon applicable regulatory approval. Refer to Note 5 "Commitments and Contingencies" in our condensed financial statements included in this Form 10-Q for the quarter ended March 31, 2023 for further information.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Even if we are successful in enforcing our rights, there could be a delay in our receipt of the milestone payments as a result of any dispute relating to such payments. Any failure to receive or any delay in receipt of the milestone payments may significantly impact our future capital needs, ability to recognize revenue for the milestone upon inclusion of cardiovascular risk reduction data in the EU label, and ability to fund operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 19, 2023, we entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers named therein (the &#8220;Purchasers&#8221;), pursuant to which we agreed to issue and sell, in a registered direct offering (the &#8220;Offering&#8221;), 12,205,000 shares of our common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), pre-funded warrants to purchase up to an aggregate of 20,965,747 shares of Common Stock (the &#8220;Pre-Funded Warrants&#8221;) in lieu of shares of Common Stock, and warrants to purchase up to 33,170,747 shares of Common Stock (the &#8220;Warrants&#8221;). The combined purchase price of each share of Common Stock and accompanying Warrant is $1.675 per share. The purchase price of each Pre-Funded Warrant and the accompanying Warrant is $1.674 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $0.001). The Purchase Agreement contains customary representations, warranties, covenants and indemnification rights and obligations of the Company and the Purchasers. The Offering closed on March 22, 2023. In connection with the Offering, we amended, pursuant to Warrant Amendment Agreements (the &#8220;Warrant Amendment Agreements&#8221;), certain existing warrants to purchase up to an aggregate of 9,024,212 shares of our common stock that were previously issued in December 2021 at an exercise price of $9.00 per share and had an expiration date of December 7, 2023, effective upon the closing of the Offering, such that the amended warrants have a reduced exercise price of $1.55 per share and expire three and one half years following the closing of the Offering, for additional consideration of $0.125 per amended warrant. We received gross proceeds of approximately $55.5&#160;million from the Offering, before deducting placement agent fees and related offering expenses. The net proceeds from the Offering, after deducting the placement agent fees and expenses and the Company&#8217;s estimated offering expenses, are approximately $51.3&#160;million. In addition, we received approximately $1.2&#160;million as the gross consideration in connection with the Warrant Amendment Agreements. The net proceeds of the Warrant Amendment Agreements after deducting placement fees were approximately $1.1&#160;million. Refer to Note 13 "Stockholders' Deficit" in our condensed financial statements included in this Form 10-Q for the quarter ended March 31, 2023 for further information.</span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were incorporated in Delaware in January 2008 and commenced our operations in April 2008. Since our inception, we have focused substantially all of our efforts and financial resources on developing and commercializing bempedoic acid and the bempedoic acid / ezetimibe combination tablet. In February 2020, the FDA approved NEXLETOL and NEXLIZET. NEXLETOL was commercially available in the U.S. on March 30, 2020 and NEXLIZET was commercially available in the U.S. on June 4, 2020. We have funded our operations to date primarily through proceeds from sales of preferred stock, convertible promissory notes, warrants and pre-funded warrants, public offerings of common stock, the incurrence of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indebtedness, through collaborations with third parties and revenue interest purchase agreements, and we have incurred losses in each year since our inception.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have never been profitable and our net losses were $61.7 million for the three months ended March&#160;31, 2023, and $56.7 million for the three months ended March&#160;31, 2022.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Substantially all of our net losses resulted from costs incurred in connection with research and development programs and selling, general and administrative costs associated with our operations. W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e expect to incur significant expenses and operating losses for the foreseeable future in connection with our ongoing activities, including, among others:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">commercializing NEXLETOL and NEXLIZET in the U.S; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">pursuing other research and development activities.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we may need additional financing to support our continuing operations and further the development and commercialization of our products. We may seek to fund our operations and further development activities through collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, permitted public or private equity offerings or through other sources. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a material adverse effect on our financial condition and our ability to pursue our business strategy or continue operations. We will need to generate significant revenues to achieve profitability, and we may never do so. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Overview</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEXLETOL is a first-in-class ATP Citrate Lyase, or ACL, inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Completed Phase 3 studies conducted in more than 3,000 patients, with over 2,000 patients treated with NEXLETOL, demonstrated an average 18 percent placebo corrected LDL-C lowering when used in patients on moderate or high-intensity statins. NEXLETOL was approved by the FDA in February 2020 as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. Phase 3 data demonstrated NEXLIZET lowered LDL-C by a mean of 38 percent compared to placebo when added on to maximally tolerated statins. NEXLIZET was approved by the FDA in February 2020 as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NILEMDO&#174; is a first-in-class ACL inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDL receptors. NILEMDO was approved by the European Commission, or EC, in March 2020 for use in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet in combination with a statin or statin with other lipid-lowering therapies in adult patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or alone or in combination with other lipid-lowering therapies as an adjunct to diet in adult patients who are statin-intolerant, or for whom a statin is contraindicated.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NUSTENDI&#174; contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine. NUSTENDI was approved by the EC in March 2020 for use in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet in combination with a statin in adult patients unable to reach LDL-C goals with the maximum tolerated dose of a statin in addition to ezetimibe, alone in patients who are either statin-intolerant or for whom a statin is contraindicated, and are unable to reach LDL-C goals with ezetimibe alone, or as an adjunct to diet in adult patients already being treated with the combination of bempedoic acid and ezetimibe as separate tablets with or without statin.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we incurred $21.7 million in expenses related to our CLEAR Outcomes CVOT and other ongoing clinical studies.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, we incurred $16.0 million in expenses related to our CLEAR Outcomes CVOT and other ongoing clinical studies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales, net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net is related to our sales of NEXLETOL and NEXLIZET. NEXLETOL was commercially available in the U.S. on March 30, 2020 and NEXLIZET was commercially available in the U.S. on June 4, 2020.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is related to our collaboration agreements with DSE, Otsuka Pharmaceutical Co., Ltd., or Otsuka, and Daiichi Sankyo Co. Ltd, or DS. Collaboration revenue in the three months ended March&#160;31, 2023 and March 31, 2022 was primarily related to sales of bulk tablets under supply agreements and royalty revenue received from collaboration partners. Under contracted supply agreements with ex-U.S. collaborators, we may manufacture and supply quantities of active pharmaceutical ingredient, or API, or bulk tablets reasonably required by ex-U.S. collaboration partners for the development or sale of licensed products in their respective territory. We recognize revenue when the collaboration partner has obtained control of the API or bulk tablets. We also receive royalties from the commercialization of such products, and record our share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborators. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of goods sold</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our net product sales of NEXLETOL and NEXLIZET and the cost of goods sold from our supply agreements with collaboration partners. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development expenses consist primarily of costs incurred in connection with the development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet, which include:</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">expenses incurred under agreements with consultants, contract research organizations, or CROs, and investigative sites that conduct our preclinical and clinical studies;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the cost of acquiring, developing and manufacturing clinical study materials and commercial product manufacturing supply prior to product approval, including the procurement of ezetimibe in our continued development of our bempedoic acid / ezetimibe combination tablet;</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">employee-related expenses, including salaries, benefits, stock-based compensation and travel expenses;</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">allocated expenses for rent and maintenance of facilities, insurance and other supplies; and</span></div><div style="margin-bottom:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">costs related to compliance with regulatory requirements.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. To date, substantially all of our research and development work has been related to bempedoic acid and the bempedoic acid / ezetimibe combination tablet. Costs for certain development activities, such as clinical studies, are recognized based on an evaluation of the progress to completion of specific tasks using data such as patient enrollment, clinical site activations or information provided to us by our vendors. Our direct research and development expenses consist principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical studies. We do not allocate acquiring and manufacturing clinical study materials, salaries, stock-based compensation, employee benefits or other indirect costs related to our research and development function to specific programs.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to incur research and development expenses in the foreseeable future as they relate to closing-out activities for the CLEAR Outcomes CVOT and any other development programs or additional indications we choose to pursue. We expect research and development expenses to decrease in the second half of 2023 after reporting the full results of the CLEAR Outcomes CVOT and submitting regulatory filings to the FDA and EMA in the first half of 2023. We cannot determine with certainty the duration and completion costs associated with the ongoing or future clinical studies of bempedoic acid and the bempedoic acid / ezetimibe combination tablet. The duration, costs and timing associated with the development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet will depend on a variety of factors, including uncertainties associated with the results of our clinical studies and our ability to obtain regulatory approval outside the U.S. and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe. For example, if a regulatory authority were to require us to conduct clinical studies beyond those that we currently anticipate that will be required for the completion of clinical development or post-commercialization clinical studies of bempedoic acid or the bempedoic acid / ezetimibe combination tablet, we could be required to expend significant additional financial resources and time on the completion of clinical development or post-commercialization clinical studies of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses primarily consist of salaries and related costs for personnel, including stock-based compensation, associated with our sales, executive, accounting and finance, commercial, operational and other administrative functions. Other general and administrative expenses include selling expenses, facility-related costs, communication expenses and professional fees for legal, patent prosecution, protection and review, consulting and accounting services.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We expect our selling, general and administrative expenses will increase at the end of 2023 now that we reported full results from the CLEAR Outcomes CVOT in connection with potential additional global regulatory submissions for new product indications, expanded commercialization initiatives for NEXLETOL and NEXLIZET and increases in our associated headcount.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense is related to our Revenue Interest Purchase Agreement, or RIPA, with Eiger III SA LLC, or Oberland, an affiliate of Oberland Capital and our convertible notes issued in November 2020. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net, primarily relates to interest income and the accretion or amortization of premiums and discounts earned on our cash, cash equivalents and investment securities and in the three months ended March 31,  2022, also included other income related to the sale of lease vehicles associated with the reduction in force.</span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_88"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. We evaluate our estimates and judgments on an ongoing basis. We base our estimates on historical experience, known trends and events, contractual milestones and other various factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2023 and 2022</span></div><div style="text-indent:36pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.832%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited,&#160;in&#160;thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,354&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,816&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating Expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,381&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,319&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,062&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(480)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,605)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,989)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,616)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,387)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,062)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(325)</span></td><td style="background-color:#cceeff;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,273&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61,719)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,731)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product sales, net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales, net for the three months ended March&#160;31, 2023 was $17.0 million compared to $13.4 million for the three months ended March&#160;31, 2022, an increase of approximately $3.6 million. The increase is primarily due to prescription growth of NEXLETOL and NEXLIZET during the first quarter of 2023 compared to the first quarter of 2022. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue recognized from our collaboration agreements for the three months ended March&#160;31, 2023 was $7.3 million compared to $5.5&#160;million for the three months ended March&#160;31, 2022, an increase of $1.8 million. The increase is primarily due to increased tablet sales to our international partners under the supply agreements and sales growth within the partner territories.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of goods sold</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold for the three months ended March&#160;31, 2023 was $11.7 million compared to $7.1&#160;million for the three months ended March&#160;31, 2022, an increase of approximately $4.6&#160;million. The increase is primarily related to increased product sales to our collaboration partners from our supply agreements and increased net product sales of NEXLETOL and NEXLIZET. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and development expenses</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the three months ended March&#160;31, 2023, were $31.4 million, compared to $24.3 million for the three months ended March&#160;31, 2022, an increase of $7.1 million. The increase in research and development expenses was primarily attributable to costs associated with the announcement and presentation of our CLEAR Outcomes study results, associated close-out activities, and regulatory submission preparation.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, general and administrative expenses</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses for the three months ended March&#160;31, 2023, were $29.9 million, compared to $30.4 million for the three months ended March&#160;31, 2022, a decrease of $0.5&#160;million. The decrease in selling, general and administrative expenses was primarily attributable to decreases in promotional costs in the first quarter of 2023, as well as decreases in stock compensation costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest expense</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended March&#160;31, 2023, was $14.4&#160;million, compared to $14.1 million for the three months ended March&#160;31, 2022, an increase of $0.3 million. The increase in interest expense was primarily due to additional interest expense attributable to our RIPA with Oberland.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income, net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net for the three months ended March&#160;31, 2023, was $1.3&#160;million, compared to $0.3 million for the three months ended March&#160;31, 2022, an increase of $1.0&#160;million. The increase in other income, net was primarily due to higher interest income on our investments due to higher interest rates. </span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_94"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we began to generate revenue from the sales of our products in 2020, we have funded our operations to date primarily through proceeds from sales of preferred stock, convertible promissory notes and warrants, public offerings of common stock, warrants and pre-funded warrants, the incurrence of indebtedness, milestone payments from collaboration agreements and our revenue interest purchase agreement. Pursuant to the license and collaboration agreements with Daiichi Sankyo and Otsuka, we are eligible for substantial additional sales and regulatory milestone payments and royalties. Pursuant to the license and collaboration agreements entered into April 2021 with Daiichi Sankyo, we are eligible for substantial additional sales milestone payments and royalties. On February 21, 2023, we terminated the open market sales agreement with Jefferies LLC and entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald &amp; Co., as sales agent, to provide for the issuance and sale by the Company of up to $70 million of common stock from time to time in &#8220;at-the-market&#8221; offerings, or the 2023 ATM Program, pursuant to our existing Form S-3 and the prospectus supplement filed on February 21, 2023. We may continue to use the 2023 ATM program or issue stock through other capital markets to address potential funding requirements. On March 19, 2023, we entered into a Securities Purchase Agreement, pursuant to which we agreed to issue and sell, in a registered direct offering, shares of common stock, pre-funded warrants, and warrants to purchase common stock. In connection with the Securities Purchase Agreement, we amended certain existing warrants to purchase up to an aggregate of 9,024,212 shares of the Company's common stock that were previously issued in December 2021 at an exercise price of $9.00 per share and had an expiration date of December 7, 2023, effective upon the closing of the offering, such that the amended warrants have a reduced exercise price of $1.55 per share and expire three and one half years following the closing of the Offering, for additional consideration of $0.125 per amended warrant. We received net proceeds of approximately $51.3 million related to the offering and approximately $1.1 million in connection with the amended warrants. We anticipate that we will incur losses for the foreseeable future as we continue to incur substantial expenses related to the ongoing commercialization of NEXLETOL and NEXLIZET and expenses associated with our research and development activities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We anticipate that our current cash, cash equivalents, investments, expected future net product sales of NEXLETOL and NEXLIZET, and expected future revenue under our collaboration agreements is sufficient to fund continuing operations for the foreseeable future. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our primary sources of liquidity were our cash and cash equivalents and available-for-sale investments which totaled $162.3 million. We invest our cash equivalents and investments in highly liquid, interest-bearing investment-grade securities and government securities to preserve principal.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the primary sources and uses of cash for the periods presented below:</span></div><div style="margin-bottom:12pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:67.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.251%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,356)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,102)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,436)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,136&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58,528)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred and expect to continue to incur, significant costs related to the commercialization of NEXLETOL and NEXLIZET and related to ongoing research and development, regulatory and other clinical study costs associated with the development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities totaled $54.4 million for the three months ended March&#160;31, 2023, compared to $39.0 million for the three months ended March 31, 2022. Net cash used for the three months ended March 31, 2023 and 2022 consisted primarily of net product sales of NEXLETOL and NEXLIZET fully offset by cash used to fund the commercialization activities of NEXLETOL and NEXLIZET and the research and development costs related to bempedoic acid and the bempedoic acid / ezetimibe combination tablet, adjusted for non-cash expenses such as stock-based compensation expense, interest expense related to our RIPA with Oberland, depreciation and amortization and changes in working capital. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities of $25.0&#160;million for the three months ended March&#160;31, 2023 consisted of proceeds from the sales of highly liquid, interest bearing investment grade and government securities. Net cash used in investing activities of 18.1 million for the three months ended March 31, 2022 consisted of purchases of highly liquid, interest bearing investment grade and government securities. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds invested in available-for-sale investments at March 31, 2023 will become available for our use over the next twelve months.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities of $49.5 million for the three months ended March&#160;31, 2023 related primarily to proceeds from our registered direct offering, partially offset by payments on our revenue interest liability. Net cash used in financing activities of $1.4 million for the three months ended March&#160;31, 2022 related primarily to payments on our revenue interest liability.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 15, 2022, we filed a new registration statement on Form S-3, which registers the offering, issuance and sale of up to $239 million of common stock from time to time in &#8220;at-the-market&#8221; offerings, or the New ATM Program. During the year ended December 31, 2022, we issued 13,043,797 shares of common stock, resulting in net proceeds of approximately $90.8 million after deducting $3.1 million of underwriting discounts and commissions and other expenses, pursuant to the New ATM Program. On February 21, 2023, we terminated the open market sales agreement with Jefferies LLC and entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald &amp; Co., as sales agent, to provide for the issuance and sale by the Company of up to $70 million of common stock from time to time in &#8220;at-the-market&#8221; offerings, or the 2023 ATM Program, pursuant to our existing Form S-3 and the prospectus supplement filed on February 21, 2023. We may continue to use the 2023 ATM Program to address potential short-term or long-term funding requirements that may arise. Such program will continue to be subject to the volatility of the price of our common stock and general market conditions.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> In December 2021, we entered into an underwriting agreement where we sold 32,142,858 shares of common stock and accompanying warrants to purchase up to an aggregate of 32,142,858 shares of our common stock. We also granted the underwriters a 30-day option to purchase up to 4,821,428 additional shares of common stock and/or accompanying warrants to purchase an aggregate of up to 4,821,428 shares of our common stock. The underwriters exercised the option to purchase additional warrants to purchase 4,821,428 shares of Common Stock. The aggregate net proceeds received by us from the offering was $208.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us and excluding the net proceeds, if any, from the exercise of the common warrants. The warrants are immediately exercisable and will expire two years from the date of issuance, at an exercise price of $9.00 per share, which may provide us with additional funding, if such warrants are exercised by their holders.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On March 19, 2023, we entered into a Securities Purchase Agreement, pursuant to which the Company agreed to issue and sell, in a registered direct offering, 12,205,000 shares of common stock, pre-funded warrants to purchase up to an aggregate of 20,965,747 shares of Common Stock, and warrants to purchase up to 33,170,747 shares of Common Stock. The combined purchase price of each share of Common Stock and accompanying Warrant is $1.675 per share. The purchase price of each Pre-Funded Warrant and the accompanying Warrant is $1.674 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $0.001). The Offering closed on March 22, 2023. Each Warrant is exercisable for one share of Common Stock at an exercise price of $1.55 per share, which may provide us with additional funding, if such warrants are exercised by their holders. The Warrants are immediately exercisable and will expire 3.5 years from the original issuance date. Each Pre-Funded Warrant is exercisable for one share of Common Stock at an exercise price of $0.001 per share. The Pre-Funded Warrants are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. In connection with the Offering, we amended certain existing warrants to purchase up to an aggregate of 9,024,212 shares of the Company's common stock that were previously issued in December 2021 at an exercise price of $9.00 per share and had an expiration date of December 7, 2023, effective upon the closing of the Offering, such that the amended warrants have a reduced exercise price of $1.55 per share and expire three and one half years following the closing of the Offering, for additional consideration of $0.125 per amended warrant. We received net proceeds of approximately $51.3 million related to the offering after deducting placement agent fees and related offering expenses of $4.2 million and approximately $1.1 million in connection with the amended warrants after deducting placement fees of $0.1 million. Refer to Note 13 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">"Stockholders' Deficit" in our condensed financial statements included in this Form 10-Q for the quarter ended March 31, 2023 for further information.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2019, we entered into a RIPA with Oberland. Pursuant to the RIPA, Oberland paid us $125.0 million at closing, less certain issuance costs, and, subject to the terms and conditions of the RIPA, we received an additional $25.0 million upon regulatory approval of NEXLETOL in 2020 and were eligible to receive an additional $50.0 million at our option upon reaching certain sales thresholds. In April 2021, we entered into Amendment No. 2 to the RIPA and Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50 million payment payable to us under the terms of the RIPA. The amendment also updated the tiered payment percentage. As the quarterly net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States did not exceed $15.0 million for the quarter ended September 30, 2021, we deposited $50.0 million in a deposit account with Oberland, which reduced our unrestricted cash. On November 23, 2022, we entered into a waiver and amendment to the RIPA with Oberland, in which we agreed to make a one-time partial call payment with regards to the Revenue Interests (as defined in the RIPA) in an amount equal to $50 million from the restricted cash account (the &#8220;Partial Call&#8221;). Under this amendment, the amount of the Cumulative Purchaser Payments (as defined in the RIPA) was reduced to $177,777,778. As consideration for the payments, Oberland has the right to receive certain revenue interests from us based on the net sales of certain products which will be tiered payments ranging from 3.3% to 10% of our net sales in the covered territory (as detailed in the RIPA). Esperion reacquires 100% revenue rights upon repayment completion. We recorded the proceeds from the RIPA as a liability on the balance sheets and are accounting for the RIPA under the effective-interest method over the estimated life of the RIPA. Future payments under the RIPA may range from $26.9 million in the next year to a maximum total payment of $358.1 million beyond one year. Per the terms of the agreement, every $100 million of net sales generated, less than or equal to $250 million in an annual aggregate, would result in a repayment obligation of approximately $10.0 million or 10% at the stated repayment rate in the first year. In the future, as net sales thresholds set forth in the agreement are met and the repayment percentage rate changes, the amount of the obligation and timing of payment is likely to change. As the U.S. net sales were less than $350 million for the year ended December 31, 2021, the Covered Territory was expanded to include worldwide sales beginning in 2022. A significant increase or decrease in net sales will materially impact the revenue interest liability, interest expense and the time period for repayment. Refer to Note 8 "Liability Related to the Revenue Interest Purchase Agreement" in our condensed financial statements included in this Form 10-Q for the quarter ended March 31, 2023 for further information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On November 16, 2020, we issued $250.0 million aggregate principal amount of 4.00% convertible senior subordinated notes due 2025 to certain financial institutions as the initial purchasers of the convertible notes. An additional $30.0 million of additional convertible notes (collectively, the "Convertible Notes"), which were issued pursuant to the exercise of the initial purchasers' option to purchase such convertible notes, closed on November 18, 2020. On October 22, 2021, we entered into the Exchange Agreement with the Holders of our Convertible Notes. Under the terms of the Exchange Agreement the Holders agreed to exchange with us $15.0&#160;million aggregate principal amount of Convertible Notes held in the aggregate by them (and accrued interest thereon) for shares of our common stock, which closed on November 3, 2021. Future payments under the convertible notes include annual interest of $10.6 million and a principal payment of $265.0 million in 2025. Refer to Note 9 "Convertible Notes" in our condensed financial statements included in this Form 10-Q for the quarter ended March 31, 2023 for further information.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plan of Operations and Funding Requirements</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to incur significant expenses and operating losses for the foreseeable future in connection with study completion activities for our ongoing CLEAR Outcomes CVOT and our continued commercialization activities associated with NEXLETOL and NEXLIZET in the U.S. Pursuant to the license and collaboration agreements with DSE, Otsuka, and DS, we are eligible for substantial additional sales and regulatory milestone payments and royalties. We estimate that current cash resources, proceeds to be received in the future for product sales and proceeds under the collaboration agreements with Daiichi Sankyo and Otsuka are sufficient to allow us to fund continuing operations for the foreseeable future. We have based these estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. We may need to secure additional cash resources or implement certain additional cost reduction initiatives to continue to fund the commercialization and further development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet, particularly if our net product sales do not meet our expectations. We</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> caution that receipt of any milestone payment amounts is subject to risks and uncertainties, including the Company obtaining the relevant regulatory approvals and marketing authorizations, the approval of the required EU and US labels, the absence of any material disagreements or disputes with regulators or our collaboration partners and the ultimate timing and payment of such milestone payment amounts by our collaboration partners. In addition, while we expect that we will be entitled to the foregoing milestone payments, our inability to receive or a delay in receipt of some or all of our milestone payments and other royalty amounts from our collaboration partners may significantly impact our future capital needs and ability to fund operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Because of the numerous risks and uncertainties associated with the development and ongoing commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablet and the extent to which we entered and may enter into collaborations with pharmaceutical partners regarding the development and commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablet, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development and commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablet. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to successfully develop and commercialize NEXLETOL and NEXLIZET or other product candidates;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs, timing and outcomes of our ongoing clinical studies of bempedoic acid and the bempedoic acid / ezetimibe combination tablet;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the time and cost necessary to obtain regulatory approvals for bempedoic acid and the bempedoic acid / ezetimibe combination tablet outside the U.S. and Europe and regulatory approvals for cardiovascular risk reduction in the U.S. and Europe;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to establish any future collaboration or commercialization arrangements on favorable terms, if at all;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">our ability to realize the intended benefits of our existing and future collaboration and partnerships, including receiving potential milestone payments from collaboration partners;</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and</span></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:32.5pt">the implementation of operational and financial information technology.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Until such time, if ever, as we can generate U.S. substantial product revenues, we expect to finance our cash needs through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings and equity offerings or other sources. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available and permitted under the terms of our RIPA, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with pharmaceutical partners or royalty-based financing arrangements, such as the collaboration arrangement with DSE, Otsuka and DS, and the RIPA with Oberland, we may have to relinquish valuable rights to our technologies, future revenue streams or grant licenses on terms that may not be favorable to us. For instance, as part of the RIPA with Oberland, Oberland has the right to receive certain revenue interests from us based on the net sales of certain products, and we have granted Oberland a senior security interest in certain of our assets. If our cash flows and capital resources are insufficient to allow us to make required payments, we may have to reduce or delay capital expenditures, sell assets or seek additional capital. If we raise funds by selling additional equity, such sale would result in dilution to our stockholders. If we are unable to raise additional funds through equity or permitted debt financings or through collaborations, strategic alliances or licensing arrangements or permitted royalty-based financing arrangements when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market bempedoic acid and the bempedoic acid / ezetimibe combination tablet that we would otherwise prefer to develop and market ourselves. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We do not currently have, nor did we have during the periods presented, any off-balance sheet arrangements as defined by Securities and Exchange Commission rules.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_97"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes with respect to the information appearing in Part II, Item 7A, &#8220;Quantitative and Qualitative Disclosures About Market Risk,&#8221; in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_100"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities and Exchange Act of 1934 is (1)&#160;recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and forms and (2)&#160;accumulated and communicated to our management, including our President and Chief Executive Officer, who is our principal executive officer, and our Chief Financial Officer, who is our principal financial officer, to allow timely decisions regarding required disclosure.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of March&#160;31, 2023, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes to our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II &#8212; OTHER INFORMATION</span></div><div><span><br/></span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_106"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required with respect to this item can be found under &#8220;Commitments and Contingencies&#8221; in Note 5 to our condensed financial statements included elsewhere in this Form 10-Q and is incorporated by reference into this Item 1.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may become party to legal matters and claims arising in the ordinary course of business, the resolution of which we do not anticipate would have a material adverse impact on our financial position, results of operations or cash flows.</span></div><div id="i9237fb157928404b96a8fc7ef6f6efba_109"></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Except for the historical information contained herein or incorporated by reference, this report and the information incorporated by reference contains forward-looking statements that involve risks and uncertainties. These statements include projections about our accounting and finances, plans and objectives for the future, future operating and economic performance and other statements regarding future performance. These statements are not guarantees of future performance or events. Our actual results could differ materially from those discussed in this report. Factors that could cause or contribute to these differences include, but are not limited to, those discussed in Part I, Item 2 entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere throughout this report and in any documents incorporated in this report by reference.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should consider carefully the following risk factors, together with those set forth in Part I, Item 1A in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and in all of the other information included or incorporated in this report. The following risk factors represent new risk factors or those containing changes, including material changes, to the risk factors set forth in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. If any of the previously identified or following risks, either alone or taken together, or other risks not presently known to us or that we currently believe to not be significant, develop into actual events, then our business, financial condition, results of operations or prospects could be materially adversely affected. If that happens, the market price of our common stock could decline, and stockholders may lose all or part of their investment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a collaborative partner terminates or fails to perform its obligations under an agreement with us, the commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablet could be delayed or terminated, and the receipt of any milestone payment could be delayed.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2019, we entered into a license and collaboration agreement with Daiichi Sankyo Europe GmbH, or DSE, pursuant to which DSE will be responsible for the commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablet in the DSE Territory. In April 2020, we entered into a license and collaboration agreement with Otsuka Pharmaceutical Co., Ltd., or Otsuka, pursuant to which Otsuka will be responsible for the commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination tablet in Japan. Otsuka will be responsible for all development and regulatory activities in Japan. In addition, Otsuka will fund all clinical development costs associated with the program in Japan, if approved. In April 2021, we entered into a license and collaboration agreement with Daiichi Sankyo Co. Ltd, or DS, pursuant to which DS will be responsible for the commercialization of bempedoic acid and the bempedoic acid / ezetimibe combination in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar, or the DS Territory. Except for certain development activities in South Korea and Taiwan, DS will be responsible for development and commercialization in these territories. We may also enter into similar arrangements with other partners or collaborators to commercialize bempedoic acid and the bempedoic acid / ezetimibe combination tablet, outside of the United States, Europe, Japan, or the DS Territory, or to further commercialize bempedoic acid or the bempedoic acid / ezetimibe combination tablet in the broader cholesterol modifying market in the United States. If DSE, Otsuka, DS or any of our future collaborative partners does not devote sufficient time and resources to the collaboration arrangement with us, we may not realize the potential commercial benefits of the arrangement, and our results of operations may be materially adversely affected. In addition, if DSE, Otsuka or DS or any such future collaboration partner were to breach or terminate its arrangements with us, the commercialization of bempedoic acid or the bempedoic acid / ezetimibe combination tablet could be delayed, curtailed or terminated because we may not have sufficient financial resources or capabilities to continue commercialization of bempedoic acid or the bempedoic acid / ezetimibe combination tablet on our own in such locations. On March 27, 2023, we filed a complaint in the United States District Court for the Southern District of New York seeking declaratory judgment against DSE regarding the Company&#8217;s right to receive a $300 million milestone payment upon inclusion of cardiovascular risk reduction in the EU label that correlates with a relative risk reduction rate of at least 20%, based on the results of the CLEAR Outcomes. On May 4, 2023, we filed an amended complaint against DSE in the Southern District of New York which seeks a judicial declaration, on an expedited basis, that DSE is contractually required to make a $300&#160;million milestone payment to the Company upon applicable regulatory approval. Even </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if we are successful in enforcing our rights, there could be a delay in our receipt of the milestone payments as a result of this or any other dispute relating to such payments. Any failure to receive or any delay in receipt of the milestone payments may significantly impact our future capital needs. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the collaboration arrangement with DSE, we will receive significant commercial and regulatory milestone payments, as well as tiered fifteen percent (15%) to twenty-five percent (25%) royalties on certain net DSE Territory sales. Pursuant to the collaboration arrangement with Otsuka, we will receive significant commercial and regulatory milestone payments, as well as tiered fifteen percent (15%) to thirty percent (30%) royalties on certain net sales in Japan. Pursuant to the collaboration agreement with DS, we will receive significant commercial milestone payments, as well as tiered royalties ranging from five percent (5%) to twenty percent (20%) on net sales in the DS Territory. Similar to these collaboration arrangements, much of the potential revenue from future collaborations may consist of contingent payments, such as payments for achieving regulatory milestones or royalties payable on sales of drugs. The milestone and royalty revenue that we may receive under these collaborations will depend upon our collaborators&#8217; ability to successfully introduce, market and sell new products, and on our ability to obtain the relevant regulatory approvals. In addition, collaborators may decide to enter into arrangements with third parties to commercialize products developed under collaborations using our technologies, which could reduce the milestone and royalty revenue that we may receive, if any. DSE, Otsuka, DS and our future collaboration partners may fail to develop or effectively commercialize products using our products or technologies because they:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decide not to devote the necessary resources due to internal constraints, such as limited personnel with the requisite expertise, limited cash resources or specialized equipment limitations, or the belief that other drug development programs may have a higher likelihood of obtaining marketing approval or may potentially generate a greater return on investment;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decide to pursue other technologies or develop other product candidates, either on their own or in collaboration with others, including our competitors, to treat the same diseases targeted by our own collaborative programs;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">do not have sufficient resources necessary to carry the product candidate through clinical development, marketing approval and commercialization; or</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cannot obtain the necessary marketing approvals.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receipt of any milestone payment amounts is subject to risks and uncertainties, including our obtaining the relevant regulatory approvals and marketing authorizations, the approval of the required EU and US labels, the absence of any material disagreements or disputes with regulators or our collaboration partners and the ultimate timing and payment of such milestone payment amounts by our collaboration partners. In addition, while we expect that we will be entitled to the foregoing milestone payments, our inability to receive some or all of our milestone payments and other royalty amounts from our collaboration partners may significantly impact our future capital needs.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition may negatively impact a partner&#8217;s focus on and commitment to bempedoic acid or the bempedoic acid / ezetimibe combination tablet and, as a result, could delay or otherwise negatively affect the commercialization of bempedoic acid or the bempedoic acid / ezetimibe combination tablet outside of the United States or in the broader cholesterol modifying market in the United States. If DSE, Otsuka, DS and our future collaboration partners fail to develop or effectively commercialize bempedoic acid or the bempedoic acid / ezetimibe combination tablet for any of these reasons, our sales of bempedoic acid or the bempedoic acid / ezetimibe combination tablet may be limited, which would have a material adverse effect on our operating results and financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conditions in the banking system and financial markets, including the failure of banks and financial institutions, could have an adverse effect on our operations and financial results.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10 and March 12, 2023, the Federal Deposit Insurance Corporation took control and was appointed receiver of Silicon Valley Bank, or SVB, and Signature Bank and Silvergate Capital Corp, or Silvergate Capital, respectively, after each bank was unable to continue their operations. These events exposed vulnerabilities in the banking sector, including legal uncertainties, significant volatility and contagion risk, and caused market prices of regional bank stocks to plummet. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of the date of this Quarterly Report on Form 10-Q, we have no exposure to SVB, Signature Bank and Silvergate Capital; however, we are unable to predict the extent or nature of the impacts of these evolving circumstances at this time. If, for example, other banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access our existing cash, cash equivalents and investments may be threatened. While it is not possible at this time to predict the extent of the impact that the failure of SVB, Signature Bank and Silvergate Capital or the high market volatility and instability of the banking sector could have on economic activity and our business in particular, the failure of other banks and financial institutions and the measures taken by governments, businesses and other organizations in response to these events could adversely impact our business, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_112"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed or furnished as part of this Quarterly Report on Form&#160;10-Q are set forth on the Exhibit&#160;Index, which Exhibit&#160;Index is incorporated herein by reference.</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:8.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.362%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.918%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated&#160;by&#160;Reference&#160;to:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form&#160;or<br/>Schedule</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>No.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing<br/>Date&#160;with<br/>SEC</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC&#160;File<br/>Number</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000104746913006896/a2215641zex-3_2.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000104746913006896/a2215641zex-3_2.htm">Amended and Restated Certificate of Incorporation of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 12, 2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-188595</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000162828022015488/exhibit31.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000162828022015488/exhibit31.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation of the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 26, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-35986</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000162828022025245/exhibit31certificateofvali.htm">3.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000162828022025245/exhibit31certificateofvali.htm">Certificate of Validation relating to Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant dated May 26, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 20, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-35986</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000162828021008918/ex31-secondamendedandresta.htm">3.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000162828021008918/ex31-secondamendedandresta.htm">Second Amended and Restated Bylaws of the Registrant dated April 29, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 4, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-35986</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000104746913006896/a2215641zex-4_1.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000104746913006896/a2215641zex-4_1.htm">Specimen Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">June 12, 2013</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-188595</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000110465923035634/tm2310183d1_ex10-1.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000110465923035634/tm2310183d1_ex10-1.htm">Form of Securities Purchase Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 22, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-35986</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000110465923035634/tm2310183d1_ex10-2.htm">10.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1434868/000110465923035634/tm2310183d1_ex10-2.htm">Form of Warrant Amendment Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 22, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-35986</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex311x03312023.htm">31.1*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex311x03312023.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex312x03312023.htm">31.2*</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex312x03312023.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex321x03312023.htm">32.1</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex321x03312023.htm">+</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="espr-ex321x03312023.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</span></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Filed herewith.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="padding-left:49.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;The certification furnished in Exhibit&#160;32.1 hereto is deemed to be furnished with this Quarterly Report on Form&#160;10-Q and will not be deemed to be &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i9237fb157928404b96a8fc7ef6f6efba_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i9237fb157928404b96a8fc7ef6f6efba_7">Table of Contents </a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPERION THERAPEUTICS,&#160;INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Sheldon L. Koenig</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sheldon L. Koenig</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Benjamin Halladay</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benjamin Halladay</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</span></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>espr-ex311x03312023.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2c266d44f9234ffd8ebdd6918afd90a2_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:center"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="margin-bottom:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sheldon L. Koenig, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form&#160;10-Q for the period ended March 31, 2023, of Esperion Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sheldon L. Koenig</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sheldon L. Koenig</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>espr-ex312x03312023.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia5ed269d5f9a4485afab2b604833699e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:center"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certification</font></div><div style="margin-bottom:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Benjamin Halladay, certify that&#58;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form&#160;10-Q for the period ended March 31, 2023, of Esperion Therapeutics,&#160;Inc.&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.610%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.781%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Benjamin Halladay</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benjamin Halladay</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr></table></div><div><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>espr-ex321x03312023.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8775c0253a554f5f9fa16025d2cb9662_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="text-align:right"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report on Form&#160;10-Q of Esperion Therapeutics,&#160;Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;each of the undersigned officers of Esperion Therapeutics, Inc., hereby certify, pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section&#160;1350, that, to my knowledge as of the date hereof&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the Report which this statement accompanies fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.515%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.834%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 9, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Sheldon L. Koenig</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sheldon L. Koenig</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:14pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Benjamin Halladay</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benjamin Halladay</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer and Principal Accounting Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>espr-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7abd0a45-1af4-4bbb-ab52-3d00de73fc2d,g:05387136-6cd8-4464-bd5b-5fa183ea52d1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:espr="http://www.esperion.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.esperion.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="espr-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="espr-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="espr-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="espr-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.esperion.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheets" roleURI="http://www.esperion.com/role/CondensedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedBalanceSheetsParenthetical" roleURI="http://www.esperion.com/role/CondensedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofStockholdersDeficit" roleURI="http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit">
        <link:definition>0000005 - Statement - Condensed Statements of Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedStatementsofCashFlows" roleURI="http://www.esperion.com/role/CondensedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandBasisofPresentation" roleURI="http://www.esperion.com/role/TheCompanyandBasisofPresentation">
        <link:definition>0000007 - Disclosure - The Company and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationswithThirdParties" roleURI="http://www.esperion.com/role/CollaborationswithThirdParties">
        <link:definition>0000009 - Disclosure - Collaborations with Third Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventoriesnet" roleURI="http://www.esperion.com/role/Inventoriesnet">
        <link:definition>0000010 - Disclosure - Inventories, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.esperion.com/role/CommitmentsandContingencies">
        <link:definition>0000011 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.esperion.com/role/Investments">
        <link:definition>0000012 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.esperion.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheRevenueInterestPurchaseAgreement" roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement">
        <link:definition>0000014 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotes" roleURI="http://www.esperion.com/role/ConvertibleNotes">
        <link:definition>0000015 - Disclosure - Convertible Notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedLiabilities" roleURI="http://www.esperion.com/role/OtherAccruedLiabilities">
        <link:definition>0000016 - Disclosure - Other Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensation" roleURI="http://www.esperion.com/role/StockCompensation">
        <link:definition>0000017 - Disclosure - Stock Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.esperion.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficit" roleURI="http://www.esperion.com/role/StockholdersDeficit">
        <link:definition>0000019 - Disclosure - Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShare" roleURI="http://www.esperion.com/role/NetLossPerCommonShare">
        <link:definition>0000020 - Disclosure - Net Loss Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlowsandRestrictedCash" roleURI="http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCash">
        <link:definition>0000021 - Disclosure - Statements of Cash Flows and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000022 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetTables" roleURI="http://www.esperion.com/role/InventoriesnetTables">
        <link:definition>0000023 - Disclosure - Inventories, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.esperion.com/role/InvestmentsTables">
        <link:definition>0000024 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.esperion.com/role/FairValueMeasurementsTables">
        <link:definition>0000025 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables" roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables">
        <link:definition>0000026 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedLiabilitiesTables" roleURI="http://www.esperion.com/role/OtherAccruedLiabilitiesTables">
        <link:definition>0000027 - Disclosure - Other Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationTables" roleURI="http://www.esperion.com/role/StockCompensationTables">
        <link:definition>0000028 - Disclosure - Stock Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitTables" roleURI="http://www.esperion.com/role/StockholdersDeficitTables">
        <link:definition>0000029 - Disclosure - Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareTables" roleURI="http://www.esperion.com/role/NetLossPerCommonShareTables">
        <link:definition>0000030 - Disclosure - Net Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlowsandRestrictedCashTables" roleURI="http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables">
        <link:definition>0000031 - Disclosure - Statements of Cash Flows and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TheCompanyandBasisofPresentationDetails" roleURI="http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails">
        <link:definition>0000032 - Disclosure - The Company and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000033 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationswithThirdPartiesDetails" roleURI="http://www.esperion.com/role/CollaborationswithThirdPartiesDetails">
        <link:definition>0000034 - Disclosure - Collaborations with Third Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetDetails" roleURI="http://www.esperion.com/role/InventoriesnetDetails">
        <link:definition>0000035 - Disclosure - Inventories, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.esperion.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000036 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" roleURI="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails">
        <link:definition>0000037 - Disclosure - Investments - Summary of Cash Equivalents and Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.esperion.com/role/InvestmentsNarrativeDetails">
        <link:definition>0000038 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.esperion.com/role/FairValueMeasurementsDetails">
        <link:definition>0000039 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails">
        <link:definition>0000040 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails">
        <link:definition>0000041 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConvertibleNotesDetails" roleURI="http://www.esperion.com/role/ConvertibleNotesDetails">
        <link:definition>0000042 - Disclosure - Convertible Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAccruedLiabilitiesDetails" roleURI="http://www.esperion.com/role/OtherAccruedLiabilitiesDetails">
        <link:definition>0000043 - Disclosure - Other Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationStockOptionsAdditionalInformationDetails" roleURI="http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails">
        <link:definition>0000044 - Disclosure - Stock Compensation - Stock Options Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationScheduleofStockOptionsDetails" roleURI="http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails">
        <link:definition>0000045 - Disclosure - Stock Compensation - Schedule of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationPBSOsDetails" roleURI="http://www.esperion.com/role/StockCompensationPBSOsDetails">
        <link:definition>0000046 - Disclosure - Stock Compensation - PBSOs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationRSUsDetails" roleURI="http://www.esperion.com/role/StockCompensationRSUsDetails">
        <link:definition>0000047 - Disclosure - Stock Compensation - RSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockCompensationPBRSUsDetails" roleURI="http://www.esperion.com/role/StockCompensationPBRSUsDetails">
        <link:definition>0000048 - Disclosure - Stock Compensation - PBRSUs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.esperion.com/role/IncomeTaxesDetails">
        <link:definition>0000049 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitDetails" roleURI="http://www.esperion.com/role/StockholdersDeficitDetails">
        <link:definition>0000050 - Disclosure - Stockholders' Deficit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails" roleURI="http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails">
        <link:definition>0000051 - Disclosure - Stockholders' Deficit - Summary of Warrants and Pre-funded Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerCommonShareDetails" roleURI="http://www.esperion.com/role/NetLossPerCommonShareDetails">
        <link:definition>0000052 - Disclosure - Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlowsandRestrictedCashDetails" roleURI="http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails">
        <link:definition>0000053 - Disclosure - Statements of Cash Flows and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="espr_NumberOfBusinessDays" abstract="false" name="NumberOfBusinessDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="espr_RoyaltyRevenueAndProductSalesBulkTabletsMember" abstract="true" name="RoyaltyRevenueAndProductSalesBulkTabletsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" abstract="false" name="FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_AccruedClinicalDevelopmentCostsCurrent" abstract="false" name="AccruedClinicalDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock" abstract="false" name="ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" abstract="false" name="MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" abstract="false" name="PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_RevenueInterestPurchaseAgreementAmendmentMember" abstract="true" name="RevenueInterestPurchaseAgreementAmendmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_ConcentrationRiskNumberOfMajorCustomers" abstract="false" name="ConcentrationRiskNumberOfMajorCustomers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="espr_OtsukaPharmaceuticalCoLtdMember" abstract="true" name="OtsukaPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" abstract="false" name="AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" abstract="false" name="AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_AtTheMarketProgramMember" abstract="true" name="AtTheMarketProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_CardiovascularRiskMember" abstract="true" name="CardiovascularRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_LiabilityFromSaleOfFutureRevenuesLineItems" abstract="true" name="LiabilityFromSaleOfFutureRevenuesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_SaleOfStockAuthorizedAmount" abstract="false" name="SaleOfStockAuthorizedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" abstract="false" name="HypotheticalRepaymentObligationBasedOnSalesGenerated" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" abstract="false" name="TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" abstract="false" name="PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_ProceedsFromRevenueInterestPurchaseAgreement" abstract="false" name="ProceedsFromRevenueInterestPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" abstract="false" name="AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NonCashRightOfUseAsset" abstract="false" name="NonCashRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RevenueInterestPaymentsRemainingRedemptionValue" abstract="false" name="RevenueInterestPaymentsRemainingRedemptionValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_CollaborationRevenueMember" abstract="true" name="CollaborationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember" abstract="true" name="PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" abstract="false" name="PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" abstract="false" name="ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" abstract="false" name="RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" abstract="false" name="LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="espr_NetSalesThresholdOneMember" abstract="true" name="NetSalesThresholdOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_CommonStockPurchasableUnderWarrants" abstract="false" name="CommonStockPurchasableUnderWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="espr_CollaborativeArrangementAbstract" abstract="true" name="CollaborativeArrangementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_FairValueMeasurementAssetTransfersBetweenLevels" abstract="false" name="FairValueMeasurementAssetTransfersBetweenLevels" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_WarrantAmendmentAgreementsMember" abstract="true" name="WarrantAmendmentAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" abstract="false" name="PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_NetSalesThresholdDomain" abstract="true" name="NetSalesThresholdDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" abstract="false" name="EmployeeStockPurchasePlanDurationOfOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="espr_CappedCallMember" abstract="true" name="CappedCallMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_PotentialProceedsFromPartnerMilestonePayments" abstract="false" name="PotentialProceedsFromPartnerMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" abstract="false" name="NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember" abstract="true" name="ShareBasedPaymentArrangementOptionPerformanceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_RevenueInterestPaymentsRedemptionValue" abstract="false" name="RevenueInterestPaymentsRedemptionValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember" abstract="true" name="CardiovascularRiskOutcomeGreaterThanTwentyPercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_SignificantAccountingPoliciesLineItems" abstract="true" name="SignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" abstract="false" name="FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NumberOfStudyPatients" abstract="false" name="NumberOfStudyPatients" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="espr_TypeOfRiskAxis" abstract="true" name="TypeOfRiskAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" abstract="false" name="RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_GrossProceedsFromRevenueInterestPurchaseAgreement" abstract="false" name="GrossProceedsFromRevenueInterestPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" abstract="false" name="SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NetSalesThresholdTwoMember" abstract="true" name="NetSalesThresholdTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_RevenueInterestRateTierThree" abstract="false" name="RevenueInterestRateTierThree" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" abstract="false" name="EmployeeStockPurchasePlanPercentageDiscountOnShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_RevenueInterestLiability" abstract="false" name="RevenueInterestLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary" abstract="false" name="PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_CommonStockAndAccompanyingWarrantMember" abstract="true" name="CommonStockAndAccompanyingWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" abstract="false" name="PercentageOfRoyaltiesToBeReceivedOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_DebtInstrumentCovenantRequiredAmountOutstanding" abstract="false" name="DebtInstrumentCovenantRequiredAmountOutstanding" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_TypeOfRiskDomain" abstract="true" name="TypeOfRiskDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_PreFundedWarrantAndAccompanyingWarrantMember" abstract="true" name="PreFundedWarrantAndAccompanyingWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" abstract="false" name="BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock" abstract="false" name="SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="espr_PrepaidClinicalDevelopmentCostsCurrent" abstract="false" name="PrepaidClinicalDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_ClassOfWarrantOrRightExercised" abstract="false" name="ClassOfWarrantOrRightExercised" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" abstract="false" name="CashPaymentToBeReceivedUponCertainCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_SignificantAccountingPoliciesTable" abstract="true" name="SignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="espr_DeferredUpFrontPayment" abstract="false" name="DeferredUpFrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_OneTimePartialCall" abstract="false" name="OneTimePartialCall" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_PercentageOfCumulativePurchaserPaymentsGuarantee" abstract="false" name="PercentageOfCumulativePurchaserPaymentsGuarantee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_StockOptionAndIncentivePlan2022Member" abstract="true" name="StockOptionAndIncentivePlan2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" abstract="true" name="RIPAAmendmentToTheSecurityAgreementAndWaiverMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" abstract="false" name="AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="espr_RevenueInterestsPaymentOnWhichAgreementTerminates" abstract="false" name="RevenueInterestsPaymentOnWhichAgreementTerminates" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RevenueInterestLiabilityCurrent" abstract="false" name="RevenueInterestLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_PercentageOfRiskReduction" abstract="false" name="PercentageOfRiskReduction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_RevenueInterestPaymentsRedemptionPercentage" abstract="false" name="RevenueInterestPaymentsRedemptionPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_NumberOfConsecutiveTradingDays" abstract="false" name="NumberOfConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" abstract="false" name="MilestoneAmountForWorldwideSalesToReceiveThirdPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_ExclusiveDevelopmentalActivitiesMember" abstract="true" name="ExclusiveDevelopmentalActivitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_UpFrontPayment" abstract="false" name="UpFrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_AccruedVariableConsiderationCurrent" abstract="false" name="AccruedVariableConsiderationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_PaymentsFromRevenueInterestPurchaseAgreement" abstract="false" name="PaymentsFromRevenueInterestPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" abstract="false" name="NonCashInterestExpenseRelatedToRevenueInterestLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RelativeRiskMember" abstract="true" name="RelativeRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_NetSalesThresholdAxis" abstract="true" name="NetSalesThresholdAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="espr_FutureUpFrontPayment" abstract="false" name="FutureUpFrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" abstract="false" name="PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" abstract="false" name="DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_HypotheticalSalesGeneratedAmount" abstract="false" name="HypotheticalSalesGeneratedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_CommonStockPurchasableUnderPrefundedWarrants" abstract="false" name="CommonStockPurchasableUnderPrefundedWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" abstract="false" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" abstract="false" name="MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_TheWarrantsMember" abstract="true" name="TheWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization" abstract="false" name="AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_EigerIiiSaLlcMember" abstract="true" name="EigerIiiSaLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_PreFundedWarrantMember" abstract="true" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" abstract="true" name="UnvestedRestrictedStockAndRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" abstract="false" name="PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration" abstract="false" name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="espr_LiabilityFromSaleOfFutureRevenuesRollForward" abstract="true" name="LiabilityFromSaleOfFutureRevenuesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays" abstract="false" name="DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" abstract="false" name="FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RevenueInterestRateInitialRate" abstract="false" name="RevenueInterestRateInitialRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_DaiichiSankyoCoLtdMember" abstract="true" name="DaiichiSankyoCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor" abstract="false" name="DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" abstract="true" name="LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" abstract="false" name="RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_NumberOfSourcesOfRevenue" abstract="false" name="NumberOfSourcesOfRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="espr_DaiichiSankyoEuropeGmbhMember" abstract="true" name="DaiichiSankyoEuropeGmbhMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" abstract="false" name="UnamortizedTransactionCostsOnRevenueInterestAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_LiabilityFromSaleOfFutureRevenuesTable" abstract="true" name="LiabilityFromSaleOfFutureRevenuesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" abstract="false" name="ScheduleOfRevenueInterestLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="espr_FuturePaymentMilestoneSalesMilestones" abstract="false" name="FuturePaymentMilestoneSalesMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_CommonStockIssuanceCostsIncurredNotYetPaid" abstract="false" name="CommonStockIssuanceCostsIncurredNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_RevenueInterestPurchaseAgreementMember" abstract="true" name="RevenueInterestPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_ConvertibleSeniorNotesDue2025Member" abstract="true" name="ConvertibleSeniorNotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_SecuritiesPurchaseAgreementMember" abstract="true" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember" abstract="true" name="CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_RevenueInterestLiabilityNoncurrent" abstract="false" name="RevenueInterestLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_RevenueInterestRateTierTwo" abstract="false" name="RevenueInterestRateTierTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="espr_WainwrightMember" abstract="true" name="WainwrightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="espr_CashPaymentToBeReceivedUponFirstCommercialSales" abstract="false" name="CashPaymentToBeReceivedUponFirstCommercialSales" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>espr-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7abd0a45-1af4-4bbb-ab52-3d00de73fc2d,g:05387136-6cd8-4464-bd5b-5fa183ea52d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="espr-20230331.xsd#CondensedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1b934fb4-e00e-43ae-855f-4e936bb02271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_47c25c48-6083-40b5-93a9-54adfbca59b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1b934fb4-e00e-43ae-855f-4e936bb02271" xlink:to="loc_us-gaap_AccountsPayableCurrent_47c25c48-6083-40b5-93a9-54adfbca59b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedClinicalDevelopmentCostsCurrent_e86604e8-b139-4b16-bc6c-4c62200589c5" xlink:href="espr-20230331.xsd#espr_AccruedClinicalDevelopmentCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1b934fb4-e00e-43ae-855f-4e936bb02271" xlink:to="loc_espr_AccruedClinicalDevelopmentCostsCurrent_e86604e8-b139-4b16-bc6c-4c62200589c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_ffb6fdf5-f88f-4727-bca7-b0f15a200832" xlink:href="espr-20230331.xsd#espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1b934fb4-e00e-43ae-855f-4e936bb02271" xlink:to="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_ffb6fdf5-f88f-4727-bca7-b0f15a200832" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityCurrent_1dc4bc0a-9492-4321-a975-253ee295c756" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1b934fb4-e00e-43ae-855f-4e936bb02271" xlink:to="loc_espr_RevenueInterestLiabilityCurrent_1dc4bc0a-9492-4321-a975-253ee295c756" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c6fbf4a6-9a46-42fc-a2bc-3282cdb3edc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1b934fb4-e00e-43ae-855f-4e936bb02271" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_c6fbf4a6-9a46-42fc-a2bc-3282cdb3edc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8950d709-9aaa-4040-95c7-c35d7fe98992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1b934fb4-e00e-43ae-855f-4e936bb02271" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8950d709-9aaa-4040-95c7-c35d7fe98992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fd879d8f-96f1-43fa-b02d-08ac0ea90c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b099a660-eff6-4df8-9ae3-37223072ecb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd879d8f-96f1-43fa-b02d-08ac0ea90c0d" xlink:to="loc_us-gaap_PreferredStockValue_b099a660-eff6-4df8-9ae3-37223072ecb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ff64d703-9468-4b7a-b29e-20bd986d527b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd879d8f-96f1-43fa-b02d-08ac0ea90c0d" xlink:to="loc_us-gaap_CommonStockValue_ff64d703-9468-4b7a-b29e-20bd986d527b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ebcc334a-0313-4629-982e-f1b8dd2963d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd879d8f-96f1-43fa-b02d-08ac0ea90c0d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ebcc334a-0313-4629-982e-f1b8dd2963d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_342bc093-5044-4afc-9083-9fd575a3034c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd879d8f-96f1-43fa-b02d-08ac0ea90c0d" xlink:to="loc_us-gaap_TreasuryStockValue_342bc093-5044-4afc-9083-9fd575a3034c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_80d2484a-8c38-4f23-924a-1d1a299c61a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd879d8f-96f1-43fa-b02d-08ac0ea90c0d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_80d2484a-8c38-4f23-924a-1d1a299c61a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_11363fbb-a98b-4a3c-9e0e-a24d1d227025" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_fd879d8f-96f1-43fa-b02d-08ac0ea90c0d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_11363fbb-a98b-4a3c-9e0e-a24d1d227025" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_cb8d650a-8bb9-4752-ab35-1133eaa835f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_0b534483-3728-48ae-9938-0496b622dc81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cb8d650a-8bb9-4752-ab35-1133eaa835f4" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_0b534483-3728-48ae-9938-0496b622dc81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_833f424f-7bb1-49e2-a0ed-4c2addc89dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cb8d650a-8bb9-4752-ab35-1133eaa835f4" xlink:to="loc_us-gaap_AssetsCurrent_833f424f-7bb1-49e2-a0ed-4c2addc89dd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_607b5c89-cfd0-41c0-bb13-91202a537a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cb8d650a-8bb9-4752-ab35-1133eaa835f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_607b5c89-cfd0-41c0-bb13-91202a537a02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_80a95e34-9188-4bb9-a0b2-037d28298af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_cb8d650a-8bb9-4752-ab35-1133eaa835f4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_80a95e34-9188-4bb9-a0b2-037d28298af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c1373359-910f-4510-ba6e-b879b2708787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d402fde1-0eed-4767-be13-1d5566432aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c1373359-910f-4510-ba6e-b879b2708787" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d402fde1-0eed-4767-be13-1d5566432aa2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_13982ec6-fcb0-409b-ac06-c13ac27f3a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c1373359-910f-4510-ba6e-b879b2708787" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_13982ec6-fcb0-409b-ac06-c13ac27f3a88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PrepaidClinicalDevelopmentCostsCurrent_07c9128c-4c91-41c5-af62-4597dddd78af" xlink:href="espr-20230331.xsd#espr_PrepaidClinicalDevelopmentCostsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c1373359-910f-4510-ba6e-b879b2708787" xlink:to="loc_espr_PrepaidClinicalDevelopmentCostsCurrent_07c9128c-4c91-41c5-af62-4597dddd78af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2e412952-0e8f-4858-bd4c-ea99ba18ba60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c1373359-910f-4510-ba6e-b879b2708787" xlink:to="loc_us-gaap_InventoryNet_2e412952-0e8f-4858-bd4c-ea99ba18ba60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_91e70d56-0a6c-49c8-8b64-08af3f473de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c1373359-910f-4510-ba6e-b879b2708787" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_91e70d56-0a6c-49c8-8b64-08af3f473de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_abce63a7-005d-4f02-a207-3d37f9a28e02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_c1373359-910f-4510-ba6e-b879b2708787" xlink:to="loc_us-gaap_ShortTermInvestments_abce63a7-005d-4f02-a207-3d37f9a28e02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1437ef15-1e88-4e3b-ae93-0078b38ae2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_af434597-e9bf-45f4-b130-dc0805267790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1437ef15-1e88-4e3b-ae93-0078b38ae2c5" xlink:to="loc_us-gaap_Liabilities_af434597-e9bf-45f4-b130-dc0805267790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6d5c799a-7962-4735-b45d-f0e3a80433a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1437ef15-1e88-4e3b-ae93-0078b38ae2c5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6d5c799a-7962-4735-b45d-f0e3a80433a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_56656d3d-c3bd-42ea-8145-9d1220ebf848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1437ef15-1e88-4e3b-ae93-0078b38ae2c5" xlink:to="loc_us-gaap_StockholdersEquity_56656d3d-c3bd-42ea-8145-9d1220ebf848" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3a94d48b-808a-48d8-9d6f-7e1002a4d597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_832239e2-9275-4e9e-9928-36d5372e9e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3a94d48b-808a-48d8-9d6f-7e1002a4d597" xlink:to="loc_us-gaap_LiabilitiesCurrent_832239e2-9275-4e9e-9928-36d5372e9e35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_8b94d5ea-bd76-437c-8855-7b617f0c4482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3a94d48b-808a-48d8-9d6f-7e1002a4d597" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_8b94d5ea-bd76-437c-8855-7b617f0c4482" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityNoncurrent_3852ce5d-29cb-4b8e-a7a9-7fe60cc1397f" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3a94d48b-808a-48d8-9d6f-7e1002a4d597" xlink:to="loc_espr_RevenueInterestLiabilityNoncurrent_3852ce5d-29cb-4b8e-a7a9-7fe60cc1397f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4c9115d4-1969-4982-87a6-6bac24613a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_3a94d48b-808a-48d8-9d6f-7e1002a4d597" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4c9115d4-1969-4982-87a6-6bac24613a2e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="espr-20230331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_75885eb3-d28d-42f9-9d4b-1caa00bd91f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_5bb37c6e-196c-4169-8457-7873f0fdcf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_75885eb3-d28d-42f9-9d4b-1caa00bd91f4" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_5bb37c6e-196c-4169-8457-7873f0fdcf2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a4dcb2a2-1124-4270-8d3f-6a43cc773200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_75885eb3-d28d-42f9-9d4b-1caa00bd91f4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_a4dcb2a2-1124-4270-8d3f-6a43cc773200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_26172071-681c-4cf8-9732-17a2e1af19eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_75885eb3-d28d-42f9-9d4b-1caa00bd91f4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_26172071-681c-4cf8-9732-17a2e1af19eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_41caffa5-bb98-4396-b536-a4d986313204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0861e53a-db6b-4b42-8e4a-2f4210e2772f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_41caffa5-bb98-4396-b536-a4d986313204" xlink:to="loc_us-gaap_OperatingIncomeLoss_0861e53a-db6b-4b42-8e4a-2f4210e2772f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_eff25e7b-39c0-46c0-905c-e90b69c8a3dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_41caffa5-bb98-4396-b536-a4d986313204" xlink:to="loc_us-gaap_InterestExpense_eff25e7b-39c0-46c0-905c-e90b69c8a3dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3c9d6d5e-a28f-4cda-9e96-4e8703ad13d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_41caffa5-bb98-4396-b536-a4d986313204" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3c9d6d5e-a28f-4cda-9e96-4e8703ad13d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8e6bd048-aa8f-43d7-8a2f-0c94e83c9cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56be577d-d519-4079-9a87-e940bcac52c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8e6bd048-aa8f-43d7-8a2f-0c94e83c9cc9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_56be577d-d519-4079-9a87-e940bcac52c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a21b1a7d-445e-438b-baf7-4a7f02d8fde2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8e6bd048-aa8f-43d7-8a2f-0c94e83c9cc9" xlink:to="loc_us-gaap_OperatingExpenses_a21b1a7d-445e-438b-baf7-4a7f02d8fde2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_43944834-5b0a-4441-a83e-b11d53d60952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21379659-9636-4651-9548-802513e9f644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_43944834-5b0a-4441-a83e-b11d53d60952" xlink:to="loc_us-gaap_NetIncomeLoss_21379659-9636-4651-9548-802513e9f644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed91761b-c33d-4d80-a096-319479942482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_43944834-5b0a-4441-a83e-b11d53d60952" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ed91761b-c33d-4d80-a096-319479942482" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="espr-20230331.xsd#CondensedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed14ac99-ced3-42c6-b73c-fc655114cfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_87742d8d-e14b-4822-94e8-89047c10989f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed14ac99-ced3-42c6-b73c-fc655114cfa5" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_87742d8d-e14b-4822-94e8-89047c10989f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_42fc43f7-e0c4-4e40-964f-90ab9421738b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ed14ac99-ced3-42c6-b73c-fc655114cfa5" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_42fc43f7-e0c4-4e40-964f-90ab9421738b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ba060b1-a232-466a-9703-7e9e5b818ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cf897aa0-a617-40a9-8738-088f39124ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ba060b1-a232-466a-9703-7e9e5b818ce8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_cf897aa0-a617-40a9-8738-088f39124ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7febdb2-72e9-42c3-a8c5-347aba367f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ba060b1-a232-466a-9703-7e9e5b818ce8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7febdb2-72e9-42c3-a8c5-347aba367f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_378dea0d-235b-4d0f-9095-f668abe3e80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1ba060b1-a232-466a-9703-7e9e5b818ce8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_378dea0d-235b-4d0f-9095-f668abe3e80a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bc4c4a75-1faa-47d8-944a-a11d10020995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_us-gaap_NetIncomeLoss_bc4c4a75-1faa-47d8-944a-a11d10020995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b3986d15-f22f-403d-b021-e62db4d09c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_us-gaap_Depreciation_b3986d15-f22f-403d-b021-e62db4d09c6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d7c65fbd-eace-46a9-90ba-1ab98d1fcf12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d7c65fbd-eace-46a9-90ba-1ab98d1fcf12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_f8ab96ab-099a-448b-b0aa-ed39659160ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_f8ab96ab-099a-448b-b0aa-ed39659160ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_b2833170-c5ea-4428-bdc6-0e415768ba3f" xlink:href="espr-20230331.xsd#espr_NonCashInterestExpenseRelatedToRevenueInterestLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_b2833170-c5ea-4428-bdc6-0e415768ba3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0cf1322e-95ea-4b33-97db-7ed78dbc6402" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_us-gaap_ShareBasedCompensation_0cf1322e-95ea-4b33-97db-7ed78dbc6402" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b7c79162-5b92-4175-b61f-3db2025a0b27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_b7c79162-5b92-4175-b61f-3db2025a0b27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3eddb793-5182-4736-9b18-08149f70a93d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3eddb793-5182-4736-9b18-08149f70a93d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b5be7ae7-2e2a-489a-9ed4-c311a7bda29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b5be7ae7-2e2a-489a-9ed4-c311a7bda29d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_849e9b2b-01fa-4270-b2f8-08894f038c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_849e9b2b-01fa-4270-b2f8-08894f038c26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_080362c2-9755-41b8-b1cc-0168cd9e9d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_080362c2-9755-41b8-b1cc-0168cd9e9d14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2ff8972e-d336-46e1-bf5c-5418dee33fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_71ec6a7d-bbbc-4adb-9319-69aafc3bcd8a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_2ff8972e-d336-46e1-bf5c-5418dee33fa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5c76735-b760-4482-b645-84d1ffd43b25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d09aea90-8bed-44c8-8955-0ad8c8172049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5c76735-b760-4482-b645-84d1ffd43b25" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d09aea90-8bed-44c8-8955-0ad8c8172049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_d0d513fe-cd7f-49ce-a791-1ac4b76dfc6d" xlink:href="espr-20230331.xsd#espr_PaymentsFromRevenueInterestPurchaseAgreement"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5c76735-b760-4482-b645-84d1ffd43b25" xlink:to="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_d0d513fe-cd7f-49ce-a791-1ac4b76dfc6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_82abc0dc-8f62-4978-9113-4b63031ee0c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b5c76735-b760-4482-b645-84d1ffd43b25" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_82abc0dc-8f62-4978-9113-4b63031ee0c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InventoriesnetDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#InventoriesnetDetails"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/InventoriesnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_73646ced-5140-41d7-94ee-57f686ee7b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_92c9a4b1-4386-43eb-81bb-fdb728c5e1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_73646ced-5140-41d7-94ee-57f686ee7b7d" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_92c9a4b1-4386-43eb-81bb-fdb728c5e1e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f8a871c9-83ed-450b-a4c0-e03bd00956a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_73646ced-5140-41d7-94ee-57f686ee7b7d" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f8a871c9-83ed-450b-a4c0-e03bd00956a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d6ba6e09-2d1b-4db6-959a-eb42a43336b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_73646ced-5140-41d7-94ee-57f686ee7b7d" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d6ba6e09-2d1b-4db6-959a-eb42a43336b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3244ee36-f9e7-4149-bc42-dc90bc66db98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e5ac2a0d-0607-4888-807d-509c0dd65146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3244ee36-f9e7-4149-bc42-dc90bc66db98" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e5ac2a0d-0607-4888-807d-509c0dd65146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_731dd403-f64f-4980-a503-e01ea98189f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3244ee36-f9e7-4149-bc42-dc90bc66db98" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_731dd403-f64f-4980-a503-e01ea98189f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f3491239-4c25-4191-9cb5-ca9c3aa9f068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3244ee36-f9e7-4149-bc42-dc90bc66db98" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f3491239-4c25-4191-9cb5-ca9c3aa9f068" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#OtherAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_07396127-8f90-4c90-ba6c-b0ea82e1537f" xlink:href="espr-20230331.xsd#espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dc02a872-4cb2-48ca-8e37-ec1871c1000b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_07396127-8f90-4c90-ba6c-b0ea82e1537f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_dc02a872-4cb2-48ca-8e37-ec1871c1000b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedVariableConsiderationCurrent_69ee5753-9c5f-4a36-ac70-23cc9c86cb03" xlink:href="espr-20230331.xsd#espr_AccruedVariableConsiderationCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_07396127-8f90-4c90-ba6c-b0ea82e1537f" xlink:to="loc_espr_AccruedVariableConsiderationCurrent_69ee5753-9c5f-4a36-ac70-23cc9c86cb03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_a133a588-19f3-402b-a1d6-621f894bbb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_07396127-8f90-4c90-ba6c-b0ea82e1537f" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_a133a588-19f3-402b-a1d6-621f894bbb2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_57db8984-ce3a-45a2-aac0-3a87ddd7e018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_07396127-8f90-4c90-ba6c-b0ea82e1537f" xlink:to="loc_us-gaap_InterestPayableCurrent_57db8984-ce3a-45a2-aac0-3a87ddd7e018" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cbe0a7eb-9c3e-4aca-91c6-0efefc94c1a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_07396127-8f90-4c90-ba6c-b0ea82e1537f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_cbe0a7eb-9c3e-4aca-91c6-0efefc94c1a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StatementsofCashFlowsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22cafd86-3326-45af-a645-1cb8ff365af1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_114537da-e5cd-48d5-a219-2a19ab1641cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22cafd86-3326-45af-a645-1cb8ff365af1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_114537da-e5cd-48d5-a219-2a19ab1641cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_ce1ca983-a1f3-4928-9fc1-b1495e22244b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_22cafd86-3326-45af-a645-1cb8ff365af1" xlink:to="loc_us-gaap_RestrictedCash_ce1ca983-a1f3-4928-9fc1-b1495e22244b" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>espr-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7abd0a45-1af4-4bbb-ab52-3d00de73fc2d,g:05387136-6cd8-4464-bd5b-5fa183ea52d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="espr-20230331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended" id="i4a947eff4aab44f3a7d8f0905d32be30_CondensedStatementsofOperationsandComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_4fb15009-9c0f-4568-8f50-351ede88a20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_RevenuesAbstract_4fb15009-9c0f-4568-8f50-351ede88a20f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37542ea4-c7cf-446c-86ee-990458e8245f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_4fb15009-9c0f-4568-8f50-351ede88a20f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37542ea4-c7cf-446c-86ee-990458e8245f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_af8c190d-3fad-4eb6-8d8f-9de8f3945fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_af8c190d-3fad-4eb6-8d8f-9de8f3945fa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e16cb32f-6517-4a05-beb4-d8dc156c2ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e16cb32f-6517-4a05-beb4-d8dc156c2ad3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_69ea7ccb-37d4-424d-aacf-5167f7e32e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_69ea7ccb-37d4-424d-aacf-5167f7e32e89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9ea5a7c6-9bcd-472b-a41f-28021616a2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:to="loc_us-gaap_OperatingExpenses_9ea5a7c6-9bcd-472b-a41f-28021616a2c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e3ea1bea-6c59-4120-9ac9-5d42f0548474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_OperatingIncomeLoss_e3ea1bea-6c59-4120-9ac9-5d42f0548474" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a1154d99-87b2-47c2-9562-b525df73eafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_InterestExpense_a1154d99-87b2-47c2-9562-b525df73eafc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0c215154-65d3-4ce5-8211-d8d03584bcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0c215154-65d3-4ce5-8211-d8d03584bcfa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b793488-c555-49f4-ae2b-1919dd97449c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_NetIncomeLoss_4b793488-c555-49f4-ae2b-1919dd97449c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_128d77ff-d960-45f7-8a0d-cff519af4879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_EarningsPerShareBasic_128d77ff-d960-45f7-8a0d-cff519af4879" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1e71abeb-3c2f-477a-99ca-d4f03c406962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1e71abeb-3c2f-477a-99ca-d4f03c406962" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfe71592-7e28-4d54-9920-b122578a5422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfe71592-7e28-4d54-9920-b122578a5422" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1afe13d-548e-4595-9196-12416a1a8163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1afe13d-548e-4595-9196-12416a1a8163" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3d789959-42e0-4306-b794-586805934437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3d789959-42e0-4306-b794-586805934437" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_522fefbf-7c98-416b-8262-8b4336fe4c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3d789959-42e0-4306-b794-586805934437" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_522fefbf-7c98-416b-8262-8b4336fe4c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fc0029b5-c586-475a-9e08-4701be719b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fc0029b5-c586-475a-9e08-4701be719b47" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2e652654-efbb-44d1-81df-8e53ce8f8339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_StatementTable_2e652654-efbb-44d1-81df-8e53ce8f8339" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8cc0d05e-6db0-4d20-8f80-265f1ed7503a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2e652654-efbb-44d1-81df-8e53ce8f8339" xlink:to="loc_srt_ProductOrServiceAxis_8cc0d05e-6db0-4d20-8f80-265f1ed7503a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8cc0d05e-6db0-4d20-8f80-265f1ed7503a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8cc0d05e-6db0-4d20-8f80-265f1ed7503a" xlink:to="loc_srt_ProductsAndServicesDomain_8cc0d05e-6db0-4d20-8f80-265f1ed7503a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e16505e5-aa99-4d0f-9c2a-e3e3821ff66a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8cc0d05e-6db0-4d20-8f80-265f1ed7503a" xlink:to="loc_srt_ProductsAndServicesDomain_e16505e5-aa99-4d0f-9c2a-e3e3821ff66a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8026c516-39fe-4baf-bd06-eee7f35aedd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e16505e5-aa99-4d0f-9c2a-e3e3821ff66a" xlink:to="loc_us-gaap_ProductMember_8026c516-39fe-4baf-bd06-eee7f35aedd7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborationRevenueMember_9dcdae11-5203-46bb-a6df-62655f558de7" xlink:href="espr-20230331.xsd#espr_CollaborationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e16505e5-aa99-4d0f-9c2a-e3e3821ff66a" xlink:to="loc_espr_CollaborationRevenueMember_9dcdae11-5203-46bb-a6df-62655f558de7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" xlink:type="simple" xlink:href="espr-20230331.xsd#CondensedStatementsofStockholdersDeficit"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" xlink:type="extended" id="ic97636c8d74748a7a3c3fe0ad4d5e194_CondensedStatementsofStockholdersDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5ad1769d-9dfa-45c2-81cc-b434948fd17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5ad1769d-9dfa-45c2-81cc-b434948fd17c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e1b98203-80f3-4bc5-b162-168b89bd5a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_SharesOutstanding_e1b98203-80f3-4bc5-b162-168b89bd5a97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f0e906c1-3589-4b60-9c37-d48c78a93af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockholdersEquity_f0e906c1-3589-4b60-9c37-d48c78a93af7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ac00e5c1-16c9-4c56-a4fa-9a8d6750a4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ac00e5c1-16c9-4c56-a4fa-9a8d6750a4ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5381a01e-e21f-4603-b06d-f3a3015e0b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5381a01e-e21f-4603-b06d-f3a3015e0b19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5b0afa5f-6302-411d-b1b6-e9a25a7bff12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5b0afa5f-6302-411d-b1b6-e9a25a7bff12" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0a6fd6c3-00e1-44c8-9e93-e15050677136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0a6fd6c3-00e1-44c8-9e93-e15050677136" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e3cdcfe8-c3cd-4b92-9f7a-7053a6e58f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e3cdcfe8-c3cd-4b92-9f7a-7053a6e58f4b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c833b2ac-569c-4733-b7a0-cce3e6947b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c833b2ac-569c-4733-b7a0-cce3e6947b15" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_94876de3-0a23-48c2-9b58-a33431905e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_94876de3-0a23-48c2-9b58-a33431905e50" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ef55c10-a0ac-412a-bc3c-dc6ed53cfee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_NetIncomeLoss_0ef55c10-a0ac-412a-bc3c-dc6ed53cfee0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a4a08a72-bf9c-4927-9f18-86cd59041ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac7378d4-f93c-43c3-81bf-a209b21b8f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_74d3f5ef-27c7-438f-83ce-99a39261adb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5ad1769d-9dfa-45c2-81cc-b434948fd17c" xlink:to="loc_us-gaap_StatementTable_74d3f5ef-27c7-438f-83ce-99a39261adb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9423d450-062a-4860-8a5c-64481b98f543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_74d3f5ef-27c7-438f-83ce-99a39261adb3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9423d450-062a-4860-8a5c-64481b98f543" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9423d450-062a-4860-8a5c-64481b98f543_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9423d450-062a-4860-8a5c-64481b98f543" xlink:to="loc_us-gaap_EquityComponentDomain_9423d450-062a-4860-8a5c-64481b98f543_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9423d450-062a-4860-8a5c-64481b98f543" xlink:to="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_422300ac-cd29-47ad-9444-fc86359ca2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:to="loc_us-gaap_CommonStockMember_422300ac-cd29-47ad-9444-fc86359ca2b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d2f19b23-5371-495b-a6f2-a5475d40f32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d2f19b23-5371-495b-a6f2-a5475d40f32a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dc1c594e-cd02-4324-9619-6999339cba7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:to="loc_us-gaap_RetainedEarningsMember_dc1c594e-cd02-4324-9619-6999339cba7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_29db93bd-082f-49fa-b2b7-5177ce643aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_29db93bd-082f-49fa-b2b7-5177ce643aeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ec70435c-f03f-459c-bd10-b1371d4349da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:to="loc_us-gaap_TreasuryStockMember_ec70435c-f03f-459c-bd10-b1371d4349da" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#TheCompanyandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="extended" id="i1724e6ffc04a4e908f8efc6aff70b693_TheCompanyandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfStudyPatients_08d03986-507d-49f4-ab3a-3d7ff93add64" xlink:href="espr-20230331.xsd#espr_NumberOfStudyPatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_espr_NumberOfStudyPatients_08d03986-507d-49f4-ab3a-3d7ff93add64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_38938dee-9649-4695-8bdc-a5a30c66177f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_CommonStockSharesIssued_38938dee-9649-4695-8bdc-a5a30c66177f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2a4e2e37-f4cf-4f7f-a772-ce251089d122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2a4e2e37-f4cf-4f7f-a772-ce251089d122" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockPurchasableUnderPrefundedWarrants_bb62ce2e-7cf6-430b-89ab-365aaf2b85f3" xlink:href="espr-20230331.xsd#espr_CommonStockPurchasableUnderPrefundedWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_espr_CommonStockPurchasableUnderPrefundedWarrants_bb62ce2e-7cf6-430b-89ab-365aaf2b85f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockPurchasableUnderWarrants_8d4ef3a2-93fe-4107-9fc4-9f8e0859d37f" xlink:href="espr-20230331.xsd#espr_CommonStockPurchasableUnderWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_espr_CommonStockPurchasableUnderWarrants_8d4ef3a2-93fe-4107-9fc4-9f8e0859d37f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_901c76e6-3b60-482c-870d-a61f50f6b39e" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_901c76e6-3b60-482c-870d-a61f50f6b39e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_cbb84374-ab99-4880-be61-0076dd9c5af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_cbb84374-ab99-4880-be61-0076dd9c5af7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights_da01b814-c1fa-4424-95cb-468e8c52930d" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights_da01b814-c1fa-4424-95cb-468e8c52930d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7ee6ea81-3811-425c-8080-174132d758cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7ee6ea81-3811-425c-8080-174132d758cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4ef48bc3-f68a-4f4e-90c7-c3210b42dc29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4ef48bc3-f68a-4f4e-90c7-c3210b42dc29" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_4a8cde93-94ff-420b-a866-cdf11a2abf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_4a8cde93-94ff-420b-a866-cdf11a2abf8a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_282a758b-7f18-446a-8402-ef24c2b85321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_282a758b-7f18-446a-8402-ef24c2b85321" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1d71cf45-6e18-457f-89b9-4cd3caa05669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_282a758b-7f18-446a-8402-ef24c2b85321" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1d71cf45-6e18-457f-89b9-4cd3caa05669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d71cf45-6e18-457f-89b9-4cd3caa05669_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d71cf45-6e18-457f-89b9-4cd3caa05669" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1d71cf45-6e18-457f-89b9-4cd3caa05669_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9183bd23-d816-463a-a618-682b5ce32322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d71cf45-6e18-457f-89b9-4cd3caa05669" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9183bd23-d816-463a-a618-682b5ce32322" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SecuritiesPurchaseAgreementMember_8933733a-3033-432f-8410-accc882dcc4f" xlink:href="espr-20230331.xsd#espr_SecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9183bd23-d816-463a-a618-682b5ce32322" xlink:to="loc_espr_SecuritiesPurchaseAgreementMember_8933733a-3033-432f-8410-accc882dcc4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WarrantAmendmentAgreementsMember_a644daba-20c3-4b66-a256-311954a4dda9" xlink:href="espr-20230331.xsd#espr_WarrantAmendmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9183bd23-d816-463a-a618-682b5ce32322" xlink:to="loc_espr_WarrantAmendmentAgreementsMember_a644daba-20c3-4b66-a256-311954a4dda9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9e4c482e-3506-489c-b03f-3fc8fe23f2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_282a758b-7f18-446a-8402-ef24c2b85321" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9e4c482e-3506-489c-b03f-3fc8fe23f2e6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9e4c482e-3506-489c-b03f-3fc8fe23f2e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9e4c482e-3506-489c-b03f-3fc8fe23f2e6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9e4c482e-3506-489c-b03f-3fc8fe23f2e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c921754f-50fa-4cae-b37b-bfbf920d9cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9e4c482e-3506-489c-b03f-3fc8fe23f2e6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c921754f-50fa-4cae-b37b-bfbf920d9cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockAndAccompanyingWarrantMember_fea418c8-7f1a-4120-bfaa-83f870cdc856" xlink:href="espr-20230331.xsd#espr_CommonStockAndAccompanyingWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c921754f-50fa-4cae-b37b-bfbf920d9cd2" xlink:to="loc_espr_CommonStockAndAccompanyingWarrantMember_fea418c8-7f1a-4120-bfaa-83f870cdc856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PreFundedWarrantAndAccompanyingWarrantMember_f3fde740-c675-4a37-8d8d-5bc9dea6b41d" xlink:href="espr-20230331.xsd#espr_PreFundedWarrantAndAccompanyingWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c921754f-50fa-4cae-b37b-bfbf920d9cd2" xlink:to="loc_espr_PreFundedWarrantAndAccompanyingWarrantMember_f3fde740-c675-4a37-8d8d-5bc9dea6b41d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i07fa987bbb934f03b8d6bf4f2c067d4c_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesLineItems_f9522495-2a3d-4acc-bfeb-ce2e5608e67a" xlink:href="espr-20230331.xsd#espr_SignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConcentrationRiskNumberOfMajorCustomers_e96a6ba1-3af8-4b06-beca-4ab193a07e26" xlink:href="espr-20230331.xsd#espr_ConcentrationRiskNumberOfMajorCustomers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_f9522495-2a3d-4acc-bfeb-ce2e5608e67a" xlink:to="loc_espr_ConcentrationRiskNumberOfMajorCustomers_e96a6ba1-3af8-4b06-beca-4ab193a07e26" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfSourcesOfRevenue_27f7cff7-0962-4aeb-a543-8f2bc25e52aa" xlink:href="espr-20230331.xsd#espr_NumberOfSourcesOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_f9522495-2a3d-4acc-bfeb-ce2e5608e67a" xlink:to="loc_espr_NumberOfSourcesOfRevenue_27f7cff7-0962-4aeb-a543-8f2bc25e52aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de907c78-0bd1-452d-8c57-80847231d29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_f9522495-2a3d-4acc-bfeb-ce2e5608e67a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de907c78-0bd1-452d-8c57-80847231d29d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesTable_6d561e02-ff83-4c84-beb0-b50f3a76c00c" xlink:href="espr-20230331.xsd#espr_SignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_f9522495-2a3d-4acc-bfeb-ce2e5608e67a" xlink:to="loc_espr_SignificantAccountingPoliciesTable_6d561e02-ff83-4c84-beb0-b50f3a76c00c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0649d06-7731-4566-acc6-f9b4319abb74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_SignificantAccountingPoliciesTable_6d561e02-ff83-4c84-beb0-b50f3a76c00c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0649d06-7731-4566-acc6-f9b4319abb74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c0649d06-7731-4566-acc6-f9b4319abb74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0649d06-7731-4566-acc6-f9b4319abb74" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_c0649d06-7731-4566-acc6-f9b4319abb74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3daf74a-4bb5-43d1-b30e-c44b544408d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0649d06-7731-4566-acc6-f9b4319abb74" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3daf74a-4bb5-43d1-b30e-c44b544408d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_dc057bb6-3232-4ebc-8e6d-2477f0e12fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3daf74a-4bb5-43d1-b30e-c44b544408d9" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_dc057bb6-3232-4ebc-8e6d-2477f0e12fc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fb4e2eb5-c84b-494e-ba70-33fbf99bbdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_SignificantAccountingPoliciesTable_6d561e02-ff83-4c84-beb0-b50f3a76c00c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fb4e2eb5-c84b-494e-ba70-33fbf99bbdf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fb4e2eb5-c84b-494e-ba70-33fbf99bbdf9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fb4e2eb5-c84b-494e-ba70-33fbf99bbdf9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fb4e2eb5-c84b-494e-ba70-33fbf99bbdf9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_280948f8-d86f-4044-8fab-4cf9715456d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fb4e2eb5-c84b-494e-ba70-33fbf99bbdf9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_280948f8-d86f-4044-8fab-4cf9715456d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d414076e-ab8e-4221-9acf-d24a5fc11835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_280948f8-d86f-4044-8fab-4cf9715456d4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d414076e-ab8e-4221-9acf-d24a5fc11835" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9030ff5e-08ab-45f9-a3dc-53a5d7766517" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_SignificantAccountingPoliciesTable_6d561e02-ff83-4c84-beb0-b50f3a76c00c" xlink:to="loc_srt_ProductOrServiceAxis_9030ff5e-08ab-45f9-a3dc-53a5d7766517" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9030ff5e-08ab-45f9-a3dc-53a5d7766517_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9030ff5e-08ab-45f9-a3dc-53a5d7766517" xlink:to="loc_srt_ProductsAndServicesDomain_9030ff5e-08ab-45f9-a3dc-53a5d7766517_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4ec0033-6b32-4564-bfaa-36a2cd84a3fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9030ff5e-08ab-45f9-a3dc-53a5d7766517" xlink:to="loc_srt_ProductsAndServicesDomain_a4ec0033-6b32-4564-bfaa-36a2cd84a3fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_03be7e9c-c652-41b1-91ac-54741d6a90ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4ec0033-6b32-4564-bfaa-36a2cd84a3fe" xlink:to="loc_us-gaap_ProductMember_03be7e9c-c652-41b1-91ac-54741d6a90ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#CollaborationswithThirdPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" xlink:type="extended" id="i05886c2e02814bf1a183a525e6c6553b_CollaborationswithThirdPartiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UpFrontPayment_0129eb59-16eb-4f69-b0a8-dd66cce0c343" xlink:href="espr-20230331.xsd#espr_UpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_UpFrontPayment_0129eb59-16eb-4f69-b0a8-dd66cce0c343" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales_3090c570-082e-48b4-a4c5-42c215c60139" xlink:href="espr-20230331.xsd#espr_CashPaymentToBeReceivedUponFirstCommercialSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales_3090c570-082e-48b4-a4c5-42c215c60139" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization_a057e927-8c81-4400-8ec5-5f97fd01241e" xlink:href="espr-20230331.xsd#espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization_a057e927-8c81-4400-8ec5-5f97fd01241e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_f93e0178-9f92-4d01-b57f-a9f6df7cf2fe" xlink:href="espr-20230331.xsd#espr_PercentageOfRoyaltiesToBeReceivedOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_f93e0178-9f92-4d01-b57f-a9f6df7cf2fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c2bab203-5472-433e-a193-e9114aeebc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c2bab203-5472-433e-a193-e9114aeebc5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_8934be6a-cba9-493b-939b-a118fdffe7d8" xlink:href="espr-20230331.xsd#espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_8934be6a-cba9-493b-939b-a118fdffe7d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_5112cac6-4ae7-476a-94e5-89459479ca95" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_5112cac6-4ae7-476a-94e5-89459479ca95" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_4ecdcea4-532e-4928-8285-68a7443415d7" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_4ecdcea4-532e-4928-8285-68a7443415d7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_b089f9f4-eec0-4be4-b398-de84b9733d52" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_b089f9f4-eec0-4be4-b398-de84b9733d52" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneSalesMilestones_58eb7cfe-20a1-4927-9c9f-d384a8cdae3f" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneSalesMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_FuturePaymentMilestoneSalesMilestones_58eb7cfe-20a1-4927-9c9f-d384a8cdae3f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FutureUpFrontPayment_9d51d260-706a-4acf-bcb7-e081013ce4e8" xlink:href="espr-20230331.xsd#espr_FutureUpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_FutureUpFrontPayment_9d51d260-706a-4acf-bcb7-e081013ce4e8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_bf9f9c84-f8b8-448b-bea6-19497f03e314" xlink:href="espr-20230331.xsd#espr_CashPaymentToBeReceivedUponCertainCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_bf9f9c84-f8b8-448b-bea6-19497f03e314" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DeferredUpFrontPayment_aac72abd-eac1-48be-88eb-7a2b11582d6b" xlink:href="espr-20230331.xsd#espr_DeferredUpFrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_DeferredUpFrontPayment_aac72abd-eac1-48be-88eb-7a2b11582d6b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aa68f27d-99cc-4388-8886-8723968f1748" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:to="loc_srt_CounterpartyNameAxis_aa68f27d-99cc-4388-8886-8723968f1748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa68f27d-99cc-4388-8886-8723968f1748_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_aa68f27d-99cc-4388-8886-8723968f1748" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_aa68f27d-99cc-4388-8886-8723968f1748_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_daffe351-a548-462c-8979-480197b09243" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_aa68f27d-99cc-4388-8886-8723968f1748" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_daffe351-a548-462c-8979-480197b09243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoEuropeGmbhMember_75dda351-d246-47d1-b8a9-8a9f3fe14b5c" xlink:href="espr-20230331.xsd#espr_DaiichiSankyoEuropeGmbhMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_daffe351-a548-462c-8979-480197b09243" xlink:to="loc_espr_DaiichiSankyoEuropeGmbhMember_75dda351-d246-47d1-b8a9-8a9f3fe14b5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_OtsukaPharmaceuticalCoLtdMember_e5171c66-abe5-42b1-8ee9-fc2d930b68b3" xlink:href="espr-20230331.xsd#espr_OtsukaPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_daffe351-a548-462c-8979-480197b09243" xlink:to="loc_espr_OtsukaPharmaceuticalCoLtdMember_e5171c66-abe5-42b1-8ee9-fc2d930b68b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoCoLtdMember_e3d1cc24-510f-40de-9bf6-5c2f5216e1ba" xlink:href="espr-20230331.xsd#espr_DaiichiSankyoCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_daffe351-a548-462c-8979-480197b09243" xlink:to="loc_espr_DaiichiSankyoCoLtdMember_e3d1cc24-510f-40de-9bf6-5c2f5216e1ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_065734a3-3462-4ba8-a561-64d2d4e62127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_065734a3-3462-4ba8-a561-64d2d4e62127" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_065734a3-3462-4ba8-a561-64d2d4e62127_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_065734a3-3462-4ba8-a561-64d2d4e62127" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_065734a3-3462-4ba8-a561-64d2d4e62127_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76ee3877-d540-4a31-9b7a-453db3ba339a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_065734a3-3462-4ba8-a561-64d2d4e62127" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76ee3877-d540-4a31-9b7a-453db3ba339a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_d7422f0b-bd0f-461f-960f-6d251c2aa661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76ee3877-d540-4a31-9b7a-453db3ba339a" xlink:to="loc_us-gaap_CollaborativeArrangementMember_d7422f0b-bd0f-461f-960f-6d251c2aa661" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ExclusiveDevelopmentalActivitiesMember_cba5890e-6c5e-4602-ae29-85103a09812e" xlink:href="espr-20230331.xsd#espr_ExclusiveDevelopmentalActivitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76ee3877-d540-4a31-9b7a-453db3ba339a" xlink:to="loc_espr_ExclusiveDevelopmentalActivitiesMember_cba5890e-6c5e-4602-ae29-85103a09812e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_30fe3685-9af8-4b10-a90c-1f0372e2be7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:to="loc_srt_RangeAxis_30fe3685-9af8-4b10-a90c-1f0372e2be7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_30fe3685-9af8-4b10-a90c-1f0372e2be7e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_30fe3685-9af8-4b10-a90c-1f0372e2be7e" xlink:to="loc_srt_RangeMember_30fe3685-9af8-4b10-a90c-1f0372e2be7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5dae5d87-bb60-4517-90b4-9c3aaf262ef1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_30fe3685-9af8-4b10-a90c-1f0372e2be7e" xlink:to="loc_srt_RangeMember_5dae5d87-bb60-4517-90b4-9c3aaf262ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_de9ff825-d593-43a7-b69a-419d52813c36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5dae5d87-bb60-4517-90b4-9c3aaf262ef1" xlink:to="loc_srt_MinimumMember_de9ff825-d593-43a7-b69a-419d52813c36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3d5bb4da-8f02-4447-81e4-0634c0a55539" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5dae5d87-bb60-4517-90b4-9c3aaf262ef1" xlink:to="loc_srt_MaximumMember_3d5bb4da-8f02-4447-81e4-0634c0a55539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe0c1a39-d404-44e4-9261-3fe1fe3c20ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:to="loc_srt_ProductOrServiceAxis_fe0c1a39-d404-44e4-9261-3fe1fe3c20ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe0c1a39-d404-44e4-9261-3fe1fe3c20ce_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fe0c1a39-d404-44e4-9261-3fe1fe3c20ce" xlink:to="loc_srt_ProductsAndServicesDomain_fe0c1a39-d404-44e4-9261-3fe1fe3c20ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c39bf6b9-762d-4c52-b82c-21844306b209" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fe0c1a39-d404-44e4-9261-3fe1fe3c20ce" xlink:to="loc_srt_ProductsAndServicesDomain_c39bf6b9-762d-4c52-b82c-21844306b209" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember_bf90e0b4-8c47-4779-9bbd-115fec3859af" xlink:href="espr-20230331.xsd#espr_RoyaltyRevenueAndProductSalesBulkTabletsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c39bf6b9-762d-4c52-b82c-21844306b209" xlink:to="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember_bf90e0b4-8c47-4779-9bbd-115fec3859af" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i7884d978ab354cfeb889e9d423b08024_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c00ab9f3-9f87-4e3a-acfd-83060a7ba8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PotentialProceedsFromPartnerMilestonePayments_88f65fb8-e00d-4f4d-880e-711f60273073" xlink:href="espr-20230331.xsd#espr_PotentialProceedsFromPartnerMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c00ab9f3-9f87-4e3a-acfd-83060a7ba8ef" xlink:to="loc_espr_PotentialProceedsFromPartnerMilestonePayments_88f65fb8-e00d-4f4d-880e-711f60273073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRiskReduction_a46a6912-77a3-440e-a941-37c5296dfa2a" xlink:href="espr-20230331.xsd#espr_PercentageOfRiskReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c00ab9f3-9f87-4e3a-acfd-83060a7ba8ef" xlink:to="loc_espr_PercentageOfRiskReduction_a46a6912-77a3-440e-a941-37c5296dfa2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e39b10d4-d54f-49be-8843-6e28586c89cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_c00ab9f3-9f87-4e3a-acfd-83060a7ba8ef" xlink:to="loc_us-gaap_LossContingenciesTable_e39b10d4-d54f-49be-8843-6e28586c89cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TypeOfRiskAxis_9a4b84b9-24ff-4467-8c2d-17518c60a31c" xlink:href="espr-20230331.xsd#espr_TypeOfRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e39b10d4-d54f-49be-8843-6e28586c89cf" xlink:to="loc_espr_TypeOfRiskAxis_9a4b84b9-24ff-4467-8c2d-17518c60a31c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TypeOfRiskDomain_9a4b84b9-24ff-4467-8c2d-17518c60a31c_default" xlink:href="espr-20230331.xsd#espr_TypeOfRiskDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_espr_TypeOfRiskAxis_9a4b84b9-24ff-4467-8c2d-17518c60a31c" xlink:to="loc_espr_TypeOfRiskDomain_9a4b84b9-24ff-4467-8c2d-17518c60a31c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TypeOfRiskDomain_ad1937e4-4275-4a0e-a3dd-7b70146334c4" xlink:href="espr-20230331.xsd#espr_TypeOfRiskDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_espr_TypeOfRiskAxis_9a4b84b9-24ff-4467-8c2d-17518c60a31c" xlink:to="loc_espr_TypeOfRiskDomain_ad1937e4-4275-4a0e-a3dd-7b70146334c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CardiovascularRiskMember_bad056d5-577e-4f81-a561-d4c76f5b944d" xlink:href="espr-20230331.xsd#espr_CardiovascularRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_TypeOfRiskDomain_ad1937e4-4275-4a0e-a3dd-7b70146334c4" xlink:to="loc_espr_CardiovascularRiskMember_bad056d5-577e-4f81-a561-d4c76f5b944d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember_7969fc54-5b3c-4913-88cf-37284a9c5953" xlink:href="espr-20230331.xsd#espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_CardiovascularRiskMember_bad056d5-577e-4f81-a561-d4c76f5b944d" xlink:to="loc_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember_7969fc54-5b3c-4913-88cf-37284a9c5953" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember_1ec204a0-dc8e-43ac-80a7-98c52425d91f" xlink:href="espr-20230331.xsd#espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_CardiovascularRiskMember_bad056d5-577e-4f81-a561-d4c76f5b944d" xlink:to="loc_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember_1ec204a0-dc8e-43ac-80a7-98c52425d91f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RelativeRiskMember_ea0ede4e-c935-451d-8541-e053e947b03e" xlink:href="espr-20230331.xsd#espr_RelativeRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_TypeOfRiskDomain_ad1937e4-4275-4a0e-a3dd-7b70146334c4" xlink:to="loc_espr_RelativeRiskMember_ea0ede4e-c935-451d-8541-e053e947b03e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_03682b1f-323c-458d-82db-749c14e7d913" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e39b10d4-d54f-49be-8843-6e28586c89cf" xlink:to="loc_srt_RangeAxis_03682b1f-323c-458d-82db-749c14e7d913" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03682b1f-323c-458d-82db-749c14e7d913_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_03682b1f-323c-458d-82db-749c14e7d913" xlink:to="loc_srt_RangeMember_03682b1f-323c-458d-82db-749c14e7d913_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_868bf4bf-cfa9-42b5-a627-03e14ac80b37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_03682b1f-323c-458d-82db-749c14e7d913" xlink:to="loc_srt_RangeMember_868bf4bf-cfa9-42b5-a627-03e14ac80b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_961f69c9-0fe4-418a-b83f-245c659791b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_868bf4bf-cfa9-42b5-a627-03e14ac80b37" xlink:to="loc_srt_MinimumMember_961f69c9-0fe4-418a-b83f-245c659791b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6830f424-4fb4-43de-aebc-63292b85dd46" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_868bf4bf-cfa9-42b5-a627-03e14ac80b37" xlink:to="loc_srt_MaximumMember_6830f424-4fb4-43de-aebc-63292b85dd46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_84407f2a-d7e0-4c3f-b0cc-5df80d567186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_e39b10d4-d54f-49be-8843-6e28586c89cf" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_84407f2a-d7e0-4c3f-b0cc-5df80d567186" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_84407f2a-d7e0-4c3f-b0cc-5df80d567186_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_84407f2a-d7e0-4c3f-b0cc-5df80d567186" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_84407f2a-d7e0-4c3f-b0cc-5df80d567186_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ee7e208d-ce14-4fcd-846f-84fab484755c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_84407f2a-d7e0-4c3f-b0cc-5df80d567186" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ee7e208d-ce14-4fcd-846f-84fab484755c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bd031dc5-f20c-42b6-9ed5-075044d933c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ee7e208d-ce14-4fcd-846f-84fab484755c" xlink:to="loc_us-gaap_SubsequentEventMember_bd031dc5-f20c-42b6-9ed5-075044d933c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="extended" id="i6b7cfbd80d2c4d468bf6621bd1bfc35d_InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_626c59ae-35d5-4acd-9c03-cf1bcb717067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_626c59ae-35d5-4acd-9c03-cf1bcb717067" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6809215b-123e-408a-a326-fe7ebc58922c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6809215b-123e-408a-a326-fe7ebc58922c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4c2004d9-0d96-44d6-ac1e-708d41570526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4c2004d9-0d96-44d6-ac1e-708d41570526" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_553d2311-e0ee-4a3f-bbfd-6f23a37e3c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_553d2311-e0ee-4a3f-bbfd-6f23a37e3c16" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_398c5987-6d54-4d20-8bdf-010e73bb4223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_398c5987-6d54-4d20-8bdf-010e73bb4223" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ffbcd676-9312-4b0f-ad4a-cc2da238a512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_398c5987-6d54-4d20-8bdf-010e73bb4223" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ffbcd676-9312-4b0f-ad4a-cc2da238a512" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffbcd676-9312-4b0f-ad4a-cc2da238a512_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ffbcd676-9312-4b0f-ad4a-cc2da238a512" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ffbcd676-9312-4b0f-ad4a-cc2da238a512_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bf0a567-d156-4a6d-b47a-077339ed0eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ffbcd676-9312-4b0f-ad4a-cc2da238a512" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bf0a567-d156-4a6d-b47a-077339ed0eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4266ca26-e2ca-44ff-87c2-1560656f5afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bf0a567-d156-4a6d-b47a-077339ed0eea" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4266ca26-e2ca-44ff-87c2-1560656f5afc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a0c1c3e8-c1e6-4e5e-97bb-9151ced2a4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bf0a567-d156-4a6d-b47a-077339ed0eea" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a0c1c3e8-c1e6-4e5e-97bb-9151ced2a4ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_c0b737e3-f89f-41a7-9f74-79d1345fc98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bf0a567-d156-4a6d-b47a-077339ed0eea" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_c0b737e3-f89f-41a7-9f74-79d1345fc98a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_94385619-2d42-405e-80e3-59227385d724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_398c5987-6d54-4d20-8bdf-010e73bb4223" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_94385619-2d42-405e-80e3-59227385d724" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_94385619-2d42-405e-80e3-59227385d724_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_94385619-2d42-405e-80e3-59227385d724" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_94385619-2d42-405e-80e3-59227385d724_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_52572841-f149-4c3b-abc3-1077f8cc2a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_94385619-2d42-405e-80e3-59227385d724" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_52572841-f149-4c3b-abc3-1077f8cc2a37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_c1d59312-acad-4f0e-b245-cdd4d19540c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_52572841-f149-4c3b-abc3-1077f8cc2a37" xlink:to="loc_us-gaap_CashEquivalentsMember_c1d59312-acad-4f0e-b245-cdd4d19540c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_20564f51-f6db-41f1-84fe-41d513cbc53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_52572841-f149-4c3b-abc3-1077f8cc2a37" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_20564f51-f6db-41f1-84fe-41d513cbc53c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#InvestmentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/InvestmentsNarrativeDetails" xlink:type="extended" id="i9c30fe54ae144864bfbd9dca49d8eafd_InvestmentsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b7c40739-49db-4f49-a039-c090645c6a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b7c40739-49db-4f49-a039-c090645c6a65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_344e4e46-b6b3-489e-aec2-c16b462b3177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_344e4e46-b6b3-489e-aec2-c16b462b3177" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_0dcabc9b-00c8-4d3b-b66d-50b058df6440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_0dcabc9b-00c8-4d3b-b66d-50b058df6440" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable_0dd58c65-06eb-4414-8a8e-e62a005c274a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:to="loc_us-gaap_AccruedInvestmentIncomeReceivable_0dd58c65-06eb-4414-8a8e-e62a005c274a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_dada737c-f43c-49b2-ab37-942ddccf9f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_dada737c-f43c-49b2-ab37-942ddccf9f40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ebb0eff4-d731-49a9-923b-2235d9c80976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ebb0eff4-d731-49a9-923b-2235d9c80976" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4bb23b69-6a8a-46b8-b035-386b47b69ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ebb0eff4-d731-49a9-923b-2235d9c80976" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4bb23b69-6a8a-46b8-b035-386b47b69ff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4bb23b69-6a8a-46b8-b035-386b47b69ff0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bb23b69-6a8a-46b8-b035-386b47b69ff0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4bb23b69-6a8a-46b8-b035-386b47b69ff0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_91473876-8bde-4a57-9260-76d42ecff409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bb23b69-6a8a-46b8-b035-386b47b69ff0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_91473876-8bde-4a57-9260-76d42ecff409" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_c35f9343-7ecb-4f14-a1eb-fe9f1259b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_91473876-8bde-4a57-9260-76d42ecff409" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_c35f9343-7ecb-4f14-a1eb-fe9f1259b30c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_647a05e2-0901-4cca-a3fa-ae6e4ceb9f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ebb0eff4-d731-49a9-923b-2235d9c80976" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_647a05e2-0901-4cca-a3fa-ae6e4ceb9f02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_647a05e2-0901-4cca-a3fa-ae6e4ceb9f02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_647a05e2-0901-4cca-a3fa-ae6e4ceb9f02" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_647a05e2-0901-4cca-a3fa-ae6e4ceb9f02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a9f9ae53-bb1b-4534-adcc-c572cedb2d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_647a05e2-0901-4cca-a3fa-ae6e4ceb9f02" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a9f9ae53-bb1b-4534-adcc-c572cedb2d26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_4efcaf84-49a9-4ef6-a989-2b1455d8ee8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a9f9ae53-bb1b-4534-adcc-c572cedb2d26" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_4efcaf84-49a9-4ef6-a989-2b1455d8ee8d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i81d1ac74f9bd4534975a79de53fe3de0_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c940f688-2f83-4b45-8960-c95ad886b9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f5e3ccdb-2bf1-40e7-a791-22f643fb9566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c940f688-2f83-4b45-8960-c95ad886b9db" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f5e3ccdb-2bf1-40e7-a791-22f643fb9566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FairValueMeasurementAssetTransfersBetweenLevels_fcb21d93-0f87-416b-9dcf-16a53e1ff8d6" xlink:href="espr-20230331.xsd#espr_FairValueMeasurementAssetTransfersBetweenLevels"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c940f688-2f83-4b45-8960-c95ad886b9db" xlink:to="loc_espr_FairValueMeasurementAssetTransfersBetweenLevels_fcb21d93-0f87-416b-9dcf-16a53e1ff8d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_980c2c9e-542d-460b-a916-c1eef7a9dd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c940f688-2f83-4b45-8960-c95ad886b9db" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_980c2c9e-542d-460b-a916-c1eef7a9dd6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d2c61723-700d-43da-91da-af5319f54109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_980c2c9e-542d-460b-a916-c1eef7a9dd6d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d2c61723-700d-43da-91da-af5319f54109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d2c61723-700d-43da-91da-af5319f54109_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d2c61723-700d-43da-91da-af5319f54109" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d2c61723-700d-43da-91da-af5319f54109_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b35c6971-7f78-4ee8-8ee8-e304acad8905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d2c61723-700d-43da-91da-af5319f54109" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b35c6971-7f78-4ee8-8ee8-e304acad8905" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d64fc902-a55e-4a73-90da-395bf0f8abdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b35c6971-7f78-4ee8-8ee8-e304acad8905" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d64fc902-a55e-4a73-90da-395bf0f8abdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9fcdafed-b9db-488b-818c-5592e58ea6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_980c2c9e-542d-460b-a916-c1eef7a9dd6d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9fcdafed-b9db-488b-818c-5592e58ea6f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9fcdafed-b9db-488b-818c-5592e58ea6f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9fcdafed-b9db-488b-818c-5592e58ea6f9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9fcdafed-b9db-488b-818c-5592e58ea6f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9c7d4e-e762-45ca-8c88-246f0647f868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9fcdafed-b9db-488b-818c-5592e58ea6f9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9c7d4e-e762-45ca-8c88-246f0647f868" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9a465e6a-0b69-4f92-ba47-a6936b9fdd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9c7d4e-e762-45ca-8c88-246f0647f868" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9a465e6a-0b69-4f92-ba47-a6936b9fdd16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e524d338-9929-4bfd-beb4-bb9f93941ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9c7d4e-e762-45ca-8c88-246f0647f868" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e524d338-9929-4bfd-beb4-bb9f93941ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_134c015d-447a-4819-944b-b95d24bc4ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9c7d4e-e762-45ca-8c88-246f0647f868" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_134c015d-447a-4819-944b-b95d24bc4ba8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_941542e2-3742-42a7-8292-165385157434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_980c2c9e-542d-460b-a916-c1eef7a9dd6d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_941542e2-3742-42a7-8292-165385157434" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_941542e2-3742-42a7-8292-165385157434_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_941542e2-3742-42a7-8292-165385157434" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_941542e2-3742-42a7-8292-165385157434_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8976f2f3-9630-4df9-af8d-5c4a2c4d2e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_941542e2-3742-42a7-8292-165385157434" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8976f2f3-9630-4df9-af8d-5c4a2c4d2e6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a237c033-ed2a-4547-b727-5f0687ade8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8976f2f3-9630-4df9-af8d-5c4a2c4d2e6c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a237c033-ed2a-4547-b727-5f0687ade8eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d3859b9f-f0ed-4b96-9fab-72f89ee00375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8976f2f3-9630-4df9-af8d-5c4a2c4d2e6c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d3859b9f-f0ed-4b96-9fab-72f89ee00375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_dfb48db4-dc75-4c18-812b-b3990c712109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8976f2f3-9630-4df9-af8d-5c4a2c4d2e6c" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_dfb48db4-dc75-4c18-812b-b3990c712109" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" xlink:type="extended" id="ic9beb6ccca804e758eeb80d8d8832bb6_LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_9cb3dbf1-ca36-4e90-846f-7faad264558d" xlink:href="espr-20230331.xsd#espr_GrossProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_9cb3dbf1-ca36-4e90-846f-7faad264558d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_1e95146c-3471-4951-b24c-8c71500b0a5b" xlink:href="espr-20230331.xsd#espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_1e95146c-3471-4951-b24c-8c71500b0a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_bd7b654e-7f2a-4bae-967e-70857861641b" xlink:href="espr-20230331.xsd#espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_bd7b654e-7f2a-4bae-967e-70857861641b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_7461f6ef-af6f-4428-8f5c-99a58000492c" xlink:href="espr-20230331.xsd#espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_7461f6ef-af6f-4428-8f5c-99a58000492c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_e1f4df9c-3113-44ca-8189-70dadfdbd005" xlink:href="espr-20230331.xsd#espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_e1f4df9c-3113-44ca-8189-70dadfdbd005" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_8b1a49c7-3619-411b-87de-8cd42f5ad3c7" xlink:href="espr-20230331.xsd#espr_ProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_8b1a49c7-3619-411b-87de-8cd42f5ad3c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierTwo_edf582e8-1493-49fd-ae6f-db74fd0ce76d" xlink:href="espr-20230331.xsd#espr_RevenueInterestRateTierTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestRateTierTwo_edf582e8-1493-49fd-ae6f-db74fd0ce76d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateInitialRate_29652c1b-8a46-46e4-ba02-38b951ae6f2e" xlink:href="espr-20230331.xsd#espr_RevenueInterestRateInitialRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestRateInitialRate_29652c1b-8a46-46e4-ba02-38b951ae6f2e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_977e3e5d-5bc8-481e-9588-63c43620c97a" xlink:href="espr-20230331.xsd#espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_977e3e5d-5bc8-481e-9588-63c43620c97a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierThree_6f25ee4b-a9a1-4608-a4fb-c9c83a31a5c0" xlink:href="espr-20230331.xsd#espr_RevenueInterestRateTierThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestRateTierThree_6f25ee4b-a9a1-4608-a4fb-c9c83a31a5c0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_13030a1b-9048-4db8-b3b4-ec1a7e38b7f5" xlink:href="espr-20230331.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_13030a1b-9048-4db8-b3b4-ec1a7e38b7f5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_9fca1d9a-d83a-456f-8f5b-68c26ed8f7f1" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_9fca1d9a-d83a-456f-8f5b-68c26ed8f7f1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_255f1630-9805-4117-b029-8ada9d4f0f21" xlink:href="espr-20230331.xsd#espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_255f1630-9805-4117-b029-8ada9d4f0f21" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_7f90f710-2812-45d3-a7e5-4c3549a4829f" xlink:href="espr-20230331.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_7f90f710-2812-45d3-a7e5-4c3549a4829f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_bc038c46-29e2-46f1-aebb-92a5d839f636" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_bc038c46-29e2-46f1-aebb-92a5d839f636" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_faff725a-fa51-4b78-8f18-21ec88a6b143" xlink:href="espr-20230331.xsd#espr_PercentageOfCumulativePurchaserPaymentsGuarantee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_faff725a-fa51-4b78-8f18-21ec88a6b143" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_2528948d-16c0-41cb-966c-98858bb22514" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_2528948d-16c0-41cb-966c-98858bb22514" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_1ec0d8c2-7dc6-44aa-a022-105fd506d249" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_1ec0d8c2-7dc6-44aa-a022-105fd506d249" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_9475877e-86e1-4dba-ae0f-3feb68438107" xlink:href="espr-20230331.xsd#espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_9475877e-86e1-4dba-ae0f-3feb68438107" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_3f18c77a-0f96-4fde-a493-e120bf7b3e65" xlink:href="espr-20230331.xsd#espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_3f18c77a-0f96-4fde-a493-e120bf7b3e65" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_fa544fde-d144-4b8e-af6f-cde457b3b064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_us-gaap_RestrictedCash_fa544fde-d144-4b8e-af6f-cde457b3b064" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_OneTimePartialCall_6914bf06-396c-4e46-ae8d-86d1d3948ee2" xlink:href="espr-20230331.xsd#espr_OneTimePartialCall"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_OneTimePartialCall_6914bf06-396c-4e46-ae8d-86d1d3948ee2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestsPaymentOnWhichAgreementTerminates_94f0d35d-2713-48bf-9bee-f1937f4bbd22" xlink:href="espr-20230331.xsd#espr_RevenueInterestsPaymentOnWhichAgreementTerminates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestsPaymentOnWhichAgreementTerminates_94f0d35d-2713-48bf-9bee-f1937f4bbd22" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_78180844-72b8-4450-b44b-7fd4c3b779ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_78180844-72b8-4450-b44b-7fd4c3b779ec" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_d1a2fb42-4641-4401-b2ab-42610a71e7e2" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestLiability_d1a2fb42-4641-4401-b2ab-42610a71e7e2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_ca3743cb-2c8c-41f7-a3c2-e0e89ef7fe73" xlink:href="espr-20230331.xsd#espr_UnamortizedTransactionCostsOnRevenueInterestAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_ca3743cb-2c8c-41f7-a3c2-e0e89ef7fe73" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPaymentsRedemptionPercentage_3b0a4afd-79f7-47ba-802b-0592ed2bc99f" xlink:href="espr-20230331.xsd#espr_RevenueInterestPaymentsRedemptionPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestPaymentsRedemptionPercentage_3b0a4afd-79f7-47ba-802b-0592ed2bc99f" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPaymentsRedemptionValue_75097d41-c5dd-4a0c-bf14-3d803d79018f" xlink:href="espr-20230331.xsd#espr_RevenueInterestPaymentsRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestPaymentsRedemptionValue_75097d41-c5dd-4a0c-bf14-3d803d79018f" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPaymentsRemainingRedemptionValue_9617d5e6-e55a-411c-8160-6fb9cd75d0fc" xlink:href="espr-20230331.xsd#espr_RevenueInterestPaymentsRemainingRedemptionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestPaymentsRemainingRedemptionValue_9617d5e6-e55a-411c-8160-6fb9cd75d0fc" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b9ea361d-e268-4d42-a66f-4260f4988152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_us-gaap_InterestExpense_b9ea361d-e268-4d42-a66f-4260f4988152" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary_2a07fc28-3a4a-475a-9fd1-ae7119f3a361" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary_2a07fc28-3a4a-475a-9fd1-ae7119f3a361" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalSalesGeneratedAmount_71b2108b-fd6b-481b-8af2-8e63f57026cd" xlink:href="espr-20230331.xsd#espr_HypotheticalSalesGeneratedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_HypotheticalSalesGeneratedAmount_71b2108b-fd6b-481b-8af2-8e63f57026cd" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_863c6b0c-e736-4acf-95c8-c934110980d3" xlink:href="espr-20230331.xsd#espr_HypotheticalRepaymentObligationBasedOnSalesGenerated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_863c6b0c-e736-4acf-95c8-c934110980d3" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_f6de699e-db3a-40e2-925e-dc050cbf612b" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_f6de699e-db3a-40e2-925e-dc050cbf612b" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_76467c6e-5728-4ae7-8bb5-2c19bd0ee531" xlink:href="espr-20230331.xsd#espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_76467c6e-5728-4ae7-8bb5-2c19bd0ee531" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_0f2f38cd-6bdc-4dcc-b83d-e31c3590b8fc" xlink:href="espr-20230331.xsd#espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_0f2f38cd-6bdc-4dcc-b83d-e31c3590b8fc" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_444a91b9-df03-49a6-b2f4-5bf1d128461b" xlink:href="espr-20230331.xsd#espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_444a91b9-df03-49a6-b2f4-5bf1d128461b" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_aed7173c-d952-4c1d-ac7a-1e23a2cc2120" xlink:href="espr-20230331.xsd#espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_aed7173c-d952-4c1d-ac7a-1e23a2cc2120" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_a3f705b0-3634-4373-a01a-e761c3287008" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_a3f705b0-3634-4373-a01a-e761c3287008" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1525316c-8dbb-433c-a64f-d5cf141150d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_a3f705b0-3634-4373-a01a-e761c3287008" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1525316c-8dbb-433c-a64f-d5cf141150d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1525316c-8dbb-433c-a64f-d5cf141150d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1525316c-8dbb-433c-a64f-d5cf141150d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1525316c-8dbb-433c-a64f-d5cf141150d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_109bc29b-963c-4288-aa9d-8be46e995b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1525316c-8dbb-433c-a64f-d5cf141150d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_109bc29b-963c-4288-aa9d-8be46e995b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementMember_bef9cfa1-ed27-4073-8087-c8d4167567a7" xlink:href="espr-20230331.xsd#espr_RevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_109bc29b-963c-4288-aa9d-8be46e995b6d" xlink:to="loc_espr_RevenueInterestPurchaseAgreementMember_bef9cfa1-ed27-4073-8087-c8d4167567a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_56b88ec8-3af7-4e2b-bb6f-f7065d08c16a" xlink:href="espr-20230331.xsd#espr_RevenueInterestPurchaseAgreementAmendmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_109bc29b-963c-4288-aa9d-8be46e995b6d" xlink:to="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_56b88ec8-3af7-4e2b-bb6f-f7065d08c16a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_d0ccdb08-ac55-484a-acc8-0c8b3e18eb83" xlink:href="espr-20230331.xsd#espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_109bc29b-963c-4288-aa9d-8be46e995b6d" xlink:to="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_d0ccdb08-ac55-484a-acc8-0c8b3e18eb83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_517ef87c-a329-4b85-8cbb-28c5a014cade" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_a3f705b0-3634-4373-a01a-e761c3287008" xlink:to="loc_srt_CounterpartyNameAxis_517ef87c-a329-4b85-8cbb-28c5a014cade" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_517ef87c-a329-4b85-8cbb-28c5a014cade_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_517ef87c-a329-4b85-8cbb-28c5a014cade" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_517ef87c-a329-4b85-8cbb-28c5a014cade_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97a4471b-2ff2-4771-8348-53f25313ec7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_517ef87c-a329-4b85-8cbb-28c5a014cade" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97a4471b-2ff2-4771-8348-53f25313ec7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EigerIiiSaLlcMember_aebb30d8-7331-468c-8668-4208b3147051" xlink:href="espr-20230331.xsd#espr_EigerIiiSaLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97a4471b-2ff2-4771-8348-53f25313ec7c" xlink:to="loc_espr_EigerIiiSaLlcMember_aebb30d8-7331-468c-8668-4208b3147051" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdAxis_a785b8cd-3e8a-4253-9932-7721f45ae8fa" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_a3f705b0-3634-4373-a01a-e761c3287008" xlink:to="loc_espr_NetSalesThresholdAxis_a785b8cd-3e8a-4253-9932-7721f45ae8fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdDomain_a785b8cd-3e8a-4253-9932-7721f45ae8fa_default" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_espr_NetSalesThresholdAxis_a785b8cd-3e8a-4253-9932-7721f45ae8fa" xlink:to="loc_espr_NetSalesThresholdDomain_a785b8cd-3e8a-4253-9932-7721f45ae8fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdDomain_5b8338a6-5ab1-40bc-8624-cea075701e6c" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_espr_NetSalesThresholdAxis_a785b8cd-3e8a-4253-9932-7721f45ae8fa" xlink:to="loc_espr_NetSalesThresholdDomain_5b8338a6-5ab1-40bc-8624-cea075701e6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdOneMember_218838f6-d6d1-4fca-ad2d-ecb3b458b856" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_NetSalesThresholdDomain_5b8338a6-5ab1-40bc-8624-cea075701e6c" xlink:to="loc_espr_NetSalesThresholdOneMember_218838f6-d6d1-4fca-ad2d-ecb3b458b856" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdTwoMember_757b50d9-e461-492f-acfd-3957a2b447b2" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_NetSalesThresholdDomain_5b8338a6-5ab1-40bc-8624-cea075701e6c" xlink:to="loc_espr_NetSalesThresholdTwoMember_757b50d9-e461-492f-acfd-3957a2b447b2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" xlink:type="extended" id="i8494f9409141447c810d4766f162f7ce_LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_241e3748-4a2e-4240-b392-668993e00690" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_804dbaa2-b0a7-4a62-883e-9cdc3da0e5ba" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_241e3748-4a2e-4240-b392-668993e00690" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_804dbaa2-b0a7-4a62-883e-9cdc3da0e5ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_26d8b37b-da73-47cb-888b-77522bbd75c1" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_804dbaa2-b0a7-4a62-883e-9cdc3da0e5ba" xlink:to="loc_espr_RevenueInterestLiability_26d8b37b-da73-47cb-888b-77522bbd75c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_6be02a9b-0079-4a69-af9a-a422608810ec" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_804dbaa2-b0a7-4a62-883e-9cdc3da0e5ba" xlink:to="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_6be02a9b-0079-4a69-af9a-a422608810ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_a447aaf8-d42d-45ef-be21-5e30b71203d0" xlink:href="espr-20230331.xsd#espr_PaymentsFromRevenueInterestPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_804dbaa2-b0a7-4a62-883e-9cdc3da0e5ba" xlink:to="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_a447aaf8-d42d-45ef-be21-5e30b71203d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_312e2658-2d4c-4700-8bfc-f9fc59ffb931" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_f5545cf1-d059-4a73-b6f2-0dd2d71258dc" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_241e3748-4a2e-4240-b392-668993e00690" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_f5545cf1-d059-4a73-b6f2-0dd2d71258dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3c28ff42-2215-4f84-bb3c-53d4e020912b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_f5545cf1-d059-4a73-b6f2-0dd2d71258dc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3c28ff42-2215-4f84-bb3c-53d4e020912b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c28ff42-2215-4f84-bb3c-53d4e020912b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3c28ff42-2215-4f84-bb3c-53d4e020912b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3c28ff42-2215-4f84-bb3c-53d4e020912b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8a8996d-0aac-4c40-be5a-801aedf3f2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3c28ff42-2215-4f84-bb3c-53d4e020912b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8a8996d-0aac-4c40-be5a-801aedf3f2e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementMember_26e2378a-4b7a-453a-a575-0a5f83a779aa" xlink:href="espr-20230331.xsd#espr_RevenueInterestPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8a8996d-0aac-4c40-be5a-801aedf3f2e8" xlink:to="loc_espr_RevenueInterestPurchaseAgreementMember_26e2378a-4b7a-453a-a575-0a5f83a779aa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/ConvertibleNotesDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#ConvertibleNotesDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/ConvertibleNotesDetails" xlink:type="extended" id="i4e119ac480774f4cbe6ce4a1a8f13402_ConvertibleNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_425a7d3b-21b5-4565-8de3-fb6c34e2b1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_425a7d3b-21b5-4565-8de3-fb6c34e2b1e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_71c0b4e3-cdc6-45e2-a827-33f0bde04499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_71c0b4e3-cdc6-45e2-a827-33f0bde04499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0398fe36-9452-421b-8de6-44a052fb5857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0398fe36-9452-421b-8de6-44a052fb5857" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1819d228-4dd4-4c97-a5f2-c8f51a17a31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1819d228-4dd4-4c97-a5f2-c8f51a17a31b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_98821bd7-1fec-47ad-a817-34db6b989efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_98821bd7-1fec-47ad-a817-34db6b989efb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_49b8062f-c36f-4c0d-b02f-10b855647c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_49b8062f-c36f-4c0d-b02f-10b855647c2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_a583d5db-e1c3-45bd-8310-9ddcd2f33727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_a583d5db-e1c3-45bd-8310-9ddcd2f33727" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7160d5b1-6565-4fae-bbc6-2f37fc7d031c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7160d5b1-6565-4fae-bbc6-2f37fc7d031c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ffe1717a-2294-4f23-80d0-3dbc1b449c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ffe1717a-2294-4f23-80d0-3dbc1b449c66" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_ce2e655e-9980-474d-af4d-517e05f2d2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_ce2e655e-9980-474d-af4d-517e05f2d2f2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3b62bf48-da5b-4011-a1a5-33d74bdd71a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3b62bf48-da5b-4011-a1a5-33d74bdd71a2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_75e828db-48fa-49c3-a13c-7d9999ddd909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_75e828db-48fa-49c3-a13c-7d9999ddd909" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfBusinessDays_05916cd8-0f6b-418a-b38b-82ea42c6bed1" xlink:href="espr-20230331.xsd#espr_NumberOfBusinessDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_NumberOfBusinessDays_05916cd8-0f6b-418a-b38b-82ea42c6bed1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfConsecutiveTradingDays_fb85e2bc-ff93-435f-bb49-85f5959bd0da" xlink:href="espr-20230331.xsd#espr_NumberOfConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_NumberOfConsecutiveTradingDays_fb85e2bc-ff93-435f-bb49-85f5959bd0da" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_bc4517d7-3c61-4df6-9ddb-24978b039ef4" xlink:href="espr-20230331.xsd#espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_bc4517d7-3c61-4df6-9ddb-24978b039ef4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d6a2c1cc-ce89-46b6-8e57-e8c00e15cc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d6a2c1cc-ce89-46b6-8e57-e8c00e15cc9f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding_829eca64-4039-4d43-9e50-2724555fea81" xlink:href="espr-20230331.xsd#espr_DebtInstrumentCovenantRequiredAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding_829eca64-4039-4d43-9e50-2724555fea81" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6414d0cd-a694-4c93-9f6c-5a6dcf15e5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6414d0cd-a694-4c93-9f6c-5a6dcf15e5bb" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor_c6b46c73-b9fc-4505-bf9a-a31666aa9529" xlink:href="espr-20230331.xsd#espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor_c6b46c73-b9fc-4505-bf9a-a31666aa9529" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays_8205d7e3-e9a5-448a-ae55-55430b611224" xlink:href="espr-20230331.xsd#espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays_8205d7e3-e9a5-448a-ae55-55430b611224" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_50709a94-7388-4b33-a34c-01396ec0887e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_50709a94-7388-4b33-a34c-01396ec0887e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1abeb204-4a44-4e54-a9d4-ae4cf71bb37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1abeb204-4a44-4e54-a9d4-ae4cf71bb37f" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_ba2bc097-c2a9-4ede-99b1-8724a9e80701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_ba2bc097-c2a9-4ede-99b1-8724a9e80701" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0ba1b6a3-630c-4aea-bda8-d9c37d30e16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_LongTermDebt_0ba1b6a3-630c-4aea-bda8-d9c37d30e16a" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_2010f8bd-950f-4b13-ac76-94433bcca5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_InterestExpenseDebt_2010f8bd-950f-4b13-ac76-94433bcca5f2" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6d8048ed-ac74-4feb-8133-89ebeb89d78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6d8048ed-ac74-4feb-8133-89ebeb89d78d" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72cf172f-a5ca-44e2-beff-c99ea7fa5790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72cf172f-a5ca-44e2-beff-c99ea7fa5790" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_ca81518e-bb09-48a1-a813-57a95ccde289" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_ca81518e-bb09-48a1-a813-57a95ccde289" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7adbbc5c-2dc5-4b55-ac3d-f28c1594d080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7adbbc5c-2dc5-4b55-ac3d-f28c1594d080" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_abafb84a-ea42-41f7-8936-20361ae37859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_abafb84a-ea42-41f7-8936-20361ae37859" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ec2186c2-8a4e-4aa8-9a6c-589c8eee70af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_DebtInstrumentAxis_ec2186c2-8a4e-4aa8-9a6c-589c8eee70af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ec2186c2-8a4e-4aa8-9a6c-589c8eee70af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ec2186c2-8a4e-4aa8-9a6c-589c8eee70af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ec2186c2-8a4e-4aa8-9a6c-589c8eee70af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0cb8904a-209a-4113-bd5c-d24a51766043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ec2186c2-8a4e-4aa8-9a6c-589c8eee70af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0cb8904a-209a-4113-bd5c-d24a51766043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConvertibleSeniorNotesDue2025Member_6a953ae2-ea2f-40a3-88bd-15080358f403" xlink:href="espr-20230331.xsd#espr_ConvertibleSeniorNotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cb8904a-209a-4113-bd5c-d24a51766043" xlink:to="loc_espr_ConvertibleSeniorNotesDue2025Member_6a953ae2-ea2f-40a3-88bd-15080358f403" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fd6a3d25-b87e-4384-b812-73f62b64dc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fd6a3d25-b87e-4384-b812-73f62b64dc76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fd6a3d25-b87e-4384-b812-73f62b64dc76_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fd6a3d25-b87e-4384-b812-73f62b64dc76" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fd6a3d25-b87e-4384-b812-73f62b64dc76_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f185cb92-a1f9-42a0-9d0a-2fd0dfbcab92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fd6a3d25-b87e-4384-b812-73f62b64dc76" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f185cb92-a1f9-42a0-9d0a-2fd0dfbcab92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d3237138-b94b-4685-b88d-c46734393210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f185cb92-a1f9-42a0-9d0a-2fd0dfbcab92" xlink:to="loc_us-gaap_ConvertibleDebtMember_d3237138-b94b-4685-b88d-c46734393210" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4ce3988b-f197-4a45-9188-a047dd7ea7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4ce3988b-f197-4a45-9188-a047dd7ea7f7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4ce3988b-f197-4a45-9188-a047dd7ea7f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ce3988b-f197-4a45-9188-a047dd7ea7f7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4ce3988b-f197-4a45-9188-a047dd7ea7f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ac8c07f2-b794-4b4d-905e-c6761816dede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ce3988b-f197-4a45-9188-a047dd7ea7f7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ac8c07f2-b794-4b4d-905e-c6761816dede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_230c7611-d4a4-4c15-b689-68aab220f6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ac8c07f2-b794-4b4d-905e-c6761816dede" xlink:to="loc_us-gaap_ConvertibleDebtMember_230c7611-d4a4-4c15-b689-68aab220f6b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bb93c109-5da5-43a9-a31f-5e5d2fe09289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bb93c109-5da5-43a9-a31f-5e5d2fe09289" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_bb93c109-5da5-43a9-a31f-5e5d2fe09289_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bb93c109-5da5-43a9-a31f-5e5d2fe09289" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_bb93c109-5da5-43a9-a31f-5e5d2fe09289_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9c1c6faa-e5cd-4df3-ae71-7f1d6e2f8f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bb93c109-5da5-43a9-a31f-5e5d2fe09289" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9c1c6faa-e5cd-4df3-ae71-7f1d6e2f8f66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6cc72565-869b-4ca1-a185-d921f67cbdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9c1c6faa-e5cd-4df3-ae71-7f1d6e2f8f66" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6cc72565-869b-4ca1-a185-d921f67cbdc9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_16bca17c-f0bd-4198-8af9-3da628e1c5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9c1c6faa-e5cd-4df3-ae71-7f1d6e2f8f66" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_16bca17c-f0bd-4198-8af9-3da628e1c5c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_13f35982-6a01-4e47-9d65-d9422ac9aad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_13f35982-6a01-4e47-9d65-d9422ac9aad0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_13f35982-6a01-4e47-9d65-d9422ac9aad0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13f35982-6a01-4e47-9d65-d9422ac9aad0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_13f35982-6a01-4e47-9d65-d9422ac9aad0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c5c8c511-4960-42a4-a975-2d65728e6751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13f35982-6a01-4e47-9d65-d9422ac9aad0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c5c8c511-4960-42a4-a975-2d65728e6751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CappedCallMember_41264e63-f991-45af-b3d0-194788b8499a" xlink:href="espr-20230331.xsd#espr_CappedCallMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c5c8c511-4960-42a4-a975-2d65728e6751" xlink:to="loc_espr_CappedCallMember_41264e63-f991-45af-b3d0-194788b8499a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9c007e98-98c4-4a5e-8f1a-4ad74383f765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9c007e98-98c4-4a5e-8f1a-4ad74383f765" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9c007e98-98c4-4a5e-8f1a-4ad74383f765_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9c007e98-98c4-4a5e-8f1a-4ad74383f765" xlink:to="loc_us-gaap_ClassOfStockDomain_9c007e98-98c4-4a5e-8f1a-4ad74383f765_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_449c5823-e353-43f0-9212-aca07a95357f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9c007e98-98c4-4a5e-8f1a-4ad74383f765" xlink:to="loc_us-gaap_ClassOfStockDomain_449c5823-e353-43f0-9212-aca07a95357f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_6fd77df6-6ae4-435e-8304-a2e74f4a847b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_449c5823-e353-43f0-9212-aca07a95357f" xlink:to="loc_us-gaap_CommonClassAMember_6fd77df6-6ae4-435e-8304-a2e74f4a847b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_5b8e36b3-7f75-42c5-99e3-d79a7b7485b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_NatureOfExpenseAxis_5b8e36b3-7f75-42c5-99e3-d79a7b7485b0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_5b8e36b3-7f75-42c5-99e3-d79a7b7485b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NatureOfExpenseAxis_5b8e36b3-7f75-42c5-99e3-d79a7b7485b0" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_5b8e36b3-7f75-42c5-99e3-d79a7b7485b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9e5d62cd-a6aa-4109-bfee-2c1c861f91be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NatureOfExpenseAxis_5b8e36b3-7f75-42c5-99e3-d79a7b7485b0" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9e5d62cd-a6aa-4109-bfee-2c1c861f91be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember_867b906e-99be-4920-a9c0-0618e9a3228d" xlink:href="espr-20230331.xsd#espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9e5d62cd-a6aa-4109-bfee-2c1c861f91be" xlink:to="loc_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember_867b906e-99be-4920-a9c0-0618e9a3228d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockCompensationStockOptionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" xlink:type="extended" id="i6d648bb3642c47efa5c3aba204831eab_StockCompensationStockOptionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bd1cc0a1-e484-4463-8dbb-f1db05d0644f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bd1cc0a1-e484-4463-8dbb-f1db05d0644f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_0298fd55-eb43-4930-bca4-145707ab7aff" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_0298fd55-eb43-4930-bca4-145707ab7aff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_a9ef2713-f896-4604-bd72-70bd05a3913a" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_a9ef2713-f896-4604-bd72-70bd05a3913a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_421e8266-0f66-4cf0-860b-8c2c691daa5d" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanPercentageDiscountOnShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_421e8266-0f66-4cf0-860b-8c2c691daa5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_62aab540-d5a0-4f47-a410-d112cbe1df80" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_62aab540-d5a0-4f47-a410-d112cbe1df80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3789fc93-3fec-4a36-a0ef-e4619bd11e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3789fc93-3fec-4a36-a0ef-e4619bd11e96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_deca0ded-59e6-4655-8691-444535113480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_deca0ded-59e6-4655-8691-444535113480" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bcfdcd0f-e8b7-4553-86b7-04e062c977b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bcfdcd0f-e8b7-4553-86b7-04e062c977b2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a94b32ea-7948-4aa1-9774-75d9a2f43096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a94b32ea-7948-4aa1-9774-75d9a2f43096" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fe710d51-2117-4e77-9e07-a1e9652db893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fe710d51-2117-4e77-9e07-a1e9652db893" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf48c7c-f262-4fc5-badc-a383e5cabe74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf48c7c-f262-4fc5-badc-a383e5cabe74" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8a7547d0-9076-4540-97c7-cc657cd19132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8a7547d0-9076-4540-97c7-cc657cd19132" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b9dc3c2-d50a-4ffd-bd39-02cb3d2a2252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b9dc3c2-d50a-4ffd-bd39-02cb3d2a2252" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d858c1b0-223b-4f23-ac87-b9bee4e55a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b9dc3c2-d50a-4ffd-bd39-02cb3d2a2252" xlink:to="loc_us-gaap_AwardTypeAxis_d858c1b0-223b-4f23-ac87-b9bee4e55a95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d858c1b0-223b-4f23-ac87-b9bee4e55a95_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d858c1b0-223b-4f23-ac87-b9bee4e55a95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d858c1b0-223b-4f23-ac87-b9bee4e55a95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d858c1b0-223b-4f23-ac87-b9bee4e55a95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_68850a5a-5585-41c7-a6fc-f4aa4ffea141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:to="loc_us-gaap_EmployeeStockMember_68850a5a-5585-41c7-a6fc-f4aa4ffea141" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4a31d150-6a83-40e5-8df8-604affcb5944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4a31d150-6a83-40e5-8df8-604affcb5944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_060791f5-9fd6-4905-a1ba-16ba6299a16a" xlink:href="espr-20230331.xsd#espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:to="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_060791f5-9fd6-4905-a1ba-16ba6299a16a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aaa30f00-595a-4f90-a326-799c4b1ef980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aaa30f00-595a-4f90-a326-799c4b1ef980" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c746dc26-a7e3-4454-ab00-46e2574e0e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:to="loc_us-gaap_PerformanceSharesMember_c746dc26-a7e3-4454-ab00-46e2574e0e3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ab97c127-1f81-4ed8-a02a-40eb721b2106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b9dc3c2-d50a-4ffd-bd39-02cb3d2a2252" xlink:to="loc_us-gaap_PlanNameAxis_ab97c127-1f81-4ed8-a02a-40eb721b2106" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ab97c127-1f81-4ed8-a02a-40eb721b2106_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_ab97c127-1f81-4ed8-a02a-40eb721b2106" xlink:to="loc_us-gaap_PlanNameDomain_ab97c127-1f81-4ed8-a02a-40eb721b2106_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3a191f24-cff4-45d8-98ce-937aae298ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_ab97c127-1f81-4ed8-a02a-40eb721b2106" xlink:to="loc_us-gaap_PlanNameDomain_3a191f24-cff4-45d8-98ce-937aae298ac4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_StockOptionAndIncentivePlan2022Member_1e45af2f-5a12-4a7e-a1d4-207018deb4c5" xlink:href="espr-20230331.xsd#espr_StockOptionAndIncentivePlan2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_3a191f24-cff4-45d8-98ce-937aae298ac4" xlink:to="loc_espr_StockOptionAndIncentivePlan2022Member_1e45af2f-5a12-4a7e-a1d4-207018deb4c5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationPBSOsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockCompensationPBSOsDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/StockCompensationPBSOsDetails" xlink:type="extended" id="id3d5ad8ee24f46b8971eb1f1b15c9ca5_StockCompensationPBSOsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d8f92cd-2084-43a9-8873-79aa1e4e6709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d8f92cd-2084-43a9-8873-79aa1e4e6709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_079efd7a-4c39-4b82-bdf2-3d19afa5d20d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_079efd7a-4c39-4b82-bdf2-3d19afa5d20d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5b89e2f4-ceef-45c1-9fbf-cbb9aee86601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5b89e2f4-ceef-45c1-9fbf-cbb9aee86601" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_82040897-95a4-4324-b1cb-5820f11aa80f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_82040897-95a4-4324-b1cb-5820f11aa80f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6be94aed-a03b-4bf7-aa73-27985f884318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fc5ba4d8-6537-423c-b93a-79ebaca9b398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fc5ba4d8-6537-423c-b93a-79ebaca9b398" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d3074897-0737-4496-9523-d80b3cfe0e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d3074897-0737-4496-9523-d80b3cfe0e40" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5895fb84-6b5a-4127-b65b-62fa344e622b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5895fb84-6b5a-4127-b65b-62fa344e622b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4cd3a709-5e0b-45ad-9584-11d0668fea93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4cd3a709-5e0b-45ad-9584-11d0668fea93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_861cc14e-697b-49d3-9042-a6ce5a2a74a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_861cc14e-697b-49d3-9042-a6ce5a2a74a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d09ad22e-fb07-487f-b473-ee1531cabc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d09ad22e-fb07-487f-b473-ee1531cabc14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6ef7be9c-14db-4553-b161-0799916a4801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_344c8cfb-1b98-4dcb-88f3-3c9915a36dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_344c8cfb-1b98-4dcb-88f3-3c9915a36dac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_564be09f-a053-4b27-a659-f1e480c9f374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_564be09f-a053-4b27-a659-f1e480c9f374" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_12017c79-d26b-46c8-9549-85367535556d" xlink:href="espr-20230331.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:to="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_12017c79-d26b-46c8-9549-85367535556d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e988d92d-a656-41cb-a80d-6b155129a1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_12017c79-d26b-46c8-9549-85367535556d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e988d92d-a656-41cb-a80d-6b155129a1ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7459560a-3347-4753-9e88-f0036bd063c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_12017c79-d26b-46c8-9549-85367535556d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7459560a-3347-4753-9e88-f0036bd063c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f744bc30-4706-485c-b9cd-7deb1e2bcec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_12017c79-d26b-46c8-9549-85367535556d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f744bc30-4706-485c-b9cd-7deb1e2bcec2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_2ae2fcc9-a984-450f-966b-1a10dd9308c4" xlink:href="espr-20230331.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:to="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_2ae2fcc9-a984-450f-966b-1a10dd9308c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f49023f1-2d8c-4440-8466-75cbdb6868ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_2ae2fcc9-a984-450f-966b-1a10dd9308c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f49023f1-2d8c-4440-8466-75cbdb6868ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_64ba5f50-64cf-408f-9c2c-fea91c81c4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_2ae2fcc9-a984-450f-966b-1a10dd9308c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_64ba5f50-64cf-408f-9c2c-fea91c81c4e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1c4033c3-c009-4506-b879-ce82e42b013f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_2ae2fcc9-a984-450f-966b-1a10dd9308c4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1c4033c3-c009-4506-b879-ce82e42b013f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17e1e9b3-bc11-4ef2-85d8-1c4b0395aeca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17e1e9b3-bc11-4ef2-85d8-1c4b0395aeca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d7c6729b-d1de-49f0-8821-fdb0e9a94ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17e1e9b3-bc11-4ef2-85d8-1c4b0395aeca" xlink:to="loc_us-gaap_AwardTypeAxis_d7c6729b-d1de-49f0-8821-fdb0e9a94ae0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7c6729b-d1de-49f0-8821-fdb0e9a94ae0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d7c6729b-d1de-49f0-8821-fdb0e9a94ae0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d7c6729b-d1de-49f0-8821-fdb0e9a94ae0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e35d187f-ecbe-4432-97a8-c3a6d1e99321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d7c6729b-d1de-49f0-8821-fdb0e9a94ae0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e35d187f-ecbe-4432-97a8-c3a6d1e99321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_ba9a0166-6553-47e4-b7d4-54b205a8025f" xlink:href="espr-20230331.xsd#espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e35d187f-ecbe-4432-97a8-c3a6d1e99321" xlink:to="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_ba9a0166-6553-47e4-b7d4-54b205a8025f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationRSUsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockCompensationRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/StockCompensationRSUsDetails" xlink:type="extended" id="i817e9c4729cf4f839321119fda929c3a_StockCompensationRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd2aae-b4a7-49b8-8bfc-668b120aa8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd2aae-b4a7-49b8-8bfc-668b120aa8d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cfd4bb02-d3bc-46b3-8c3b-af3f6430cbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cfd4bb02-d3bc-46b3-8c3b-af3f6430cbc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9fbbc41c-932a-4047-a0ad-d25a4e83c09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9fbbc41c-932a-4047-a0ad-d25a4e83c09a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ed78e9b-6529-41b3-874e-5a8e77a54500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ed78e9b-6529-41b3-874e-5a8e77a54500" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_edd4dde8-54be-40fa-a7a3-a567b18a925b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_edd4dde8-54be-40fa-a7a3-a567b18a925b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8676eb6f-1bed-4378-92d4-dfc8b577cf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd2aae-b4a7-49b8-8bfc-668b120aa8d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3f91adbb-82a7-4ee6-bdf3-bbb3144c4c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3f91adbb-82a7-4ee6-bdf3-bbb3144c4c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_174634b1-cd38-40e2-8505-2c5815dfc8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_174634b1-cd38-40e2-8505-2c5815dfc8ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1d4b821c-2cd8-4187-8563-5616ca4e72dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1d4b821c-2cd8-4187-8563-5616ca4e72dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ef52066f-fa2a-4859-90a8-fac13e971356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ef52066f-fa2a-4859-90a8-fac13e971356" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9f363e68-768f-4211-892e-d16124bec9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b10b1c57-5834-4279-9c63-0fb73c0188ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd2aae-b4a7-49b8-8bfc-668b120aa8d6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b10b1c57-5834-4279-9c63-0fb73c0188ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6accee1a-e198-4a65-b8c4-f35cf7a441f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b10b1c57-5834-4279-9c63-0fb73c0188ec" xlink:to="loc_us-gaap_AwardTypeAxis_6accee1a-e198-4a65-b8c4-f35cf7a441f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6accee1a-e198-4a65-b8c4-f35cf7a441f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6accee1a-e198-4a65-b8c4-f35cf7a441f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6accee1a-e198-4a65-b8c4-f35cf7a441f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3bc513c-eceb-4851-904c-c49dd2c9847b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6accee1a-e198-4a65-b8c4-f35cf7a441f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3bc513c-eceb-4851-904c-c49dd2c9847b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_084b55ba-8806-42c4-9e6a-1e68fb24b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3bc513c-eceb-4851-904c-c49dd2c9847b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_084b55ba-8806-42c4-9e6a-1e68fb24b30c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationPBRSUsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockCompensationPBRSUsDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/StockCompensationPBRSUsDetails" xlink:type="extended" id="i4eb5ac6e791d4564ac7da6fa6c7fd8df_StockCompensationPBRSUsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ebf3a55-7b1f-44d1-8ddf-1dcda9d78276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ebf3a55-7b1f-44d1-8ddf-1dcda9d78276" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d25a5a60-20f7-4589-8de1-b6a6a7f3c00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d25a5a60-20f7-4589-8de1-b6a6a7f3c00b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75e5f6a6-90db-4688-9895-47790e6ed1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75e5f6a6-90db-4688-9895-47790e6ed1ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c19ebb4-822c-44b3-b2f5-a852c9222935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c19ebb4-822c-44b3-b2f5-a852c9222935" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0e6a6c2a-8376-42fd-999b-d3d38dada192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0e6a6c2a-8376-42fd-999b-d3d38dada192" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_27d19054-6988-4066-94d6-d22fe7fc946f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ebf3a55-7b1f-44d1-8ddf-1dcda9d78276" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_53753da5-a6e4-4639-a7bf-09f79cf310d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_53753da5-a6e4-4639-a7bf-09f79cf310d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f639fd19-d7fb-4c1c-9eea-eb38e55cb474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f639fd19-d7fb-4c1c-9eea-eb38e55cb474" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1117400d-9cf9-4cba-96f3-6e418c0f8e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1117400d-9cf9-4cba-96f3-6e418c0f8e2e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_288e8a66-38ca-49c6-baad-9e0bc5c3a9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_288e8a66-38ca-49c6-baad-9e0bc5c3a9ac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_be542791-1cad-402b-974a-9da78e29ed94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10db98c4-8c21-40ab-9d7d-d2d8e20ac66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ebf3a55-7b1f-44d1-8ddf-1dcda9d78276" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10db98c4-8c21-40ab-9d7d-d2d8e20ac66a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_112247fa-b8d7-4d2e-a0f9-0315f07280da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10db98c4-8c21-40ab-9d7d-d2d8e20ac66a" xlink:to="loc_us-gaap_AwardTypeAxis_112247fa-b8d7-4d2e-a0f9-0315f07280da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_112247fa-b8d7-4d2e-a0f9-0315f07280da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_112247fa-b8d7-4d2e-a0f9-0315f07280da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_112247fa-b8d7-4d2e-a0f9-0315f07280da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2291e4d-0156-40ab-8f4c-b9be30224a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_112247fa-b8d7-4d2e-a0f9-0315f07280da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2291e4d-0156-40ab-8f4c-b9be30224a67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1ae92d78-204e-4701-bab8-046241e53df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2291e4d-0156-40ab-8f4c-b9be30224a67" xlink:to="loc_us-gaap_PerformanceSharesMember_1ae92d78-204e-4701-bab8-046241e53df8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockholdersDeficitDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockholdersDeficitDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/StockholdersDeficitDetails" xlink:type="extended" id="ib3e39ee80bd14c0a83ab3e929c63d952_StockholdersDeficitDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bb4fbb8c-3ed8-46a2-a426-332cd403b384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bb4fbb8c-3ed8-46a2-a426-332cd403b384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_69f1b3cb-c20b-4125-a996-da6656b560a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_69f1b3cb-c20b-4125-a996-da6656b560a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e218fc8e-2275-4fac-abc4-8ded2565e59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e218fc8e-2275-4fac-abc4-8ded2565e59c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SaleOfStockAuthorizedAmount_d31c6f56-c831-4bb1-8ba7-990f5462b33e" xlink:href="espr-20230331.xsd#espr_SaleOfStockAuthorizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_SaleOfStockAuthorizedAmount_d31c6f56-c831-4bb1-8ba7-990f5462b33e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_33b570bd-1825-4d87-a77c-531f3b5e58cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_33b570bd-1825-4d87-a77c-531f3b5e58cd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9c6f7029-4769-4abd-8455-3a83d9943ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9c6f7029-4769-4abd-8455-3a83d9943ec1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_fdf72a5a-7623-46a0-80a9-7fdc48ab919c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_fdf72a5a-7623-46a0-80a9-7fdc48ab919c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_417503ba-1be3-4d97-861a-e67234fa4623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_CommonStockSharesIssued_417503ba-1be3-4d97-861a-e67234fa4623" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_73d4a0cd-4b52-4f56-b726-0aa02648651b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_73d4a0cd-4b52-4f56-b726-0aa02648651b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockPurchasableUnderPrefundedWarrants_b55c2be4-f569-4ffa-af60-f33e1cb8831d" xlink:href="espr-20230331.xsd#espr_CommonStockPurchasableUnderPrefundedWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_CommonStockPurchasableUnderPrefundedWarrants_b55c2be4-f569-4ffa-af60-f33e1cb8831d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockPurchasableUnderWarrants_a9a19b4d-a420-484b-be77-503bfd586702" xlink:href="espr-20230331.xsd#espr_CommonStockPurchasableUnderWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_CommonStockPurchasableUnderWarrants_a9a19b4d-a420-484b-be77-503bfd586702" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_febf4272-18e5-4f5b-9bc2-69201c1faed8" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_febf4272-18e5-4f5b-9bc2-69201c1faed8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_af4030ac-e071-4771-9442-1957bb598964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_af4030ac-e071-4771-9442-1957bb598964" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration_7160218d-c435-46ce-a3be-a996b34ffb6c" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration_7160218d-c435-46ce-a3be-a996b34ffb6c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_e28da491-7794-4984-aacf-ae93c541bc48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_e28da491-7794-4984-aacf-ae93c541bc48" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_f84f57a4-4bfa-4c2b-9e11-0de87b1f84a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_PaymentsForCommissions_f84f57a4-4bfa-4c2b-9e11-0de87b1f84a2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f22d2229-b015-457b-a726-d291a5761988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f22d2229-b015-457b-a726-d291a5761988" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfPrivatePlacement_f25fa1b0-5f76-434d-90cd-33f16cff70c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfPrivatePlacement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfPrivatePlacement_f25fa1b0-5f76-434d-90cd-33f16cff70c1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_4c02d921-6eb2-4206-8c23-1bd45725ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_4c02d921-6eb2-4206-8c23-1bd45725ca7b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercised_396adb4f-45af-4b10-b81d-8b31cd22a559" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_ClassOfWarrantOrRightExercised_396adb4f-45af-4b10-b81d-8b31cd22a559" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c2ceb905-851e-4d45-8f82-c3a1cb732925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c2ceb905-851e-4d45-8f82-c3a1cb732925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2ceb905-851e-4d45-8f82-c3a1cb732925_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c2ceb905-851e-4d45-8f82-c3a1cb732925" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c2ceb905-851e-4d45-8f82-c3a1cb732925_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81380166-c207-44ea-b618-6ecaa017eef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c2ceb905-851e-4d45-8f82-c3a1cb732925" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81380166-c207-44ea-b618-6ecaa017eef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AtTheMarketProgramMember_18fc2228-07fa-4571-a1ee-2757c608a57f" xlink:href="espr-20230331.xsd#espr_AtTheMarketProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81380166-c207-44ea-b618-6ecaa017eef1" xlink:to="loc_espr_AtTheMarketProgramMember_18fc2228-07fa-4571-a1ee-2757c608a57f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_386f359d-6b76-49c4-b25d-6bd0c350dd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_386f359d-6b76-49c4-b25d-6bd0c350dd35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386f359d-6b76-49c4-b25d-6bd0c350dd35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_386f359d-6b76-49c4-b25d-6bd0c350dd35" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_386f359d-6b76-49c4-b25d-6bd0c350dd35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8f34958-2ea2-41df-9465-4297b67ce245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_386f359d-6b76-49c4-b25d-6bd0c350dd35" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8f34958-2ea2-41df-9465-4297b67ce245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WainwrightMember_f6a0cfaa-68d0-40f3-868f-e549555ea946" xlink:href="espr-20230331.xsd#espr_WainwrightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8f34958-2ea2-41df-9465-4297b67ce245" xlink:to="loc_espr_WainwrightMember_f6a0cfaa-68d0-40f3-868f-e549555ea946" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SecuritiesPurchaseAgreementMember_640a79df-f317-44ef-b624-bab1d2da5c5b" xlink:href="espr-20230331.xsd#espr_SecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8f34958-2ea2-41df-9465-4297b67ce245" xlink:to="loc_espr_SecuritiesPurchaseAgreementMember_640a79df-f317-44ef-b624-bab1d2da5c5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WarrantAmendmentAgreementsMember_25a376d1-3899-4b88-afd8-899f655b710c" xlink:href="espr-20230331.xsd#espr_WarrantAmendmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8f34958-2ea2-41df-9465-4297b67ce245" xlink:to="loc_espr_WarrantAmendmentAgreementsMember_25a376d1-3899-4b88-afd8-899f655b710c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f15f8323-dd54-4739-9f79-67129634a4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f15f8323-dd54-4739-9f79-67129634a4ee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f15f8323-dd54-4739-9f79-67129634a4ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f15f8323-dd54-4739-9f79-67129634a4ee" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f15f8323-dd54-4739-9f79-67129634a4ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f15f8323-dd54-4739-9f79-67129634a4ee" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockAndAccompanyingWarrantMember_1b7ce10c-80d7-4e8b-b6c9-3aaf8d56f00f" xlink:href="espr-20230331.xsd#espr_CommonStockAndAccompanyingWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:to="loc_espr_CommonStockAndAccompanyingWarrantMember_1b7ce10c-80d7-4e8b-b6c9-3aaf8d56f00f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TheWarrantsMember_0e61af01-9f8c-4ba7-aaae-4265ddc8ae85" xlink:href="espr-20230331.xsd#espr_TheWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:to="loc_espr_TheWarrantsMember_0e61af01-9f8c-4ba7-aaae-4265ddc8ae85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PreFundedWarrantAndAccompanyingWarrantMember_50a60d6a-c70a-4799-a1e1-2f857adbee3a" xlink:href="espr-20230331.xsd#espr_PreFundedWarrantAndAccompanyingWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:to="loc_espr_PreFundedWarrantAndAccompanyingWarrantMember_50a60d6a-c70a-4799-a1e1-2f857adbee3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PreFundedWarrantMember_8dc60c8a-f61c-49ab-a6a4-60130dd0a1c4" xlink:href="espr-20230331.xsd#espr_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:to="loc_espr_PreFundedWarrantMember_8dc60c8a-f61c-49ab-a6a4-60130dd0a1c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e9a36e4b-294c-49ca-8a4d-2f78cf976593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e9a36e4b-294c-49ca-8a4d-2f78cf976593" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e9a36e4b-294c-49ca-8a4d-2f78cf976593_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e9a36e4b-294c-49ca-8a4d-2f78cf976593" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e9a36e4b-294c-49ca-8a4d-2f78cf976593_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_97c6ebd6-40ef-4982-bfbe-58252d551f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e9a36e4b-294c-49ca-8a4d-2f78cf976593" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_97c6ebd6-40ef-4982-bfbe-58252d551f8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_38cad24e-17a6-4c8c-8cba-21175c7a8f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_97c6ebd6-40ef-4982-bfbe-58252d551f8b" xlink:to="loc_us-gaap_SubsequentEventMember_38cad24e-17a6-4c8c-8cba-21175c7a8f88" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails" xlink:type="extended" id="i3092a5ec02cd44058771c0607d8b3ad6_StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_75b52301-fe2c-4efa-938d-06b2786023ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_14666c95-ef13-4427-94b0-4460076a9307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_75b52301-fe2c-4efa-938d-06b2786023ee" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_14666c95-ef13-4427-94b0-4460076a9307" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8d3b03c0-2151-463a-9642-bbdb3375a0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_75b52301-fe2c-4efa-938d-06b2786023ee" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8d3b03c0-2151-463a-9642-bbdb3375a0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c22f3ad0-ba1f-4dfa-88b9-31554dd422bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_75b52301-fe2c-4efa-938d-06b2786023ee" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c22f3ad0-ba1f-4dfa-88b9-31554dd422bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3a24f1aa-00e5-447a-ba9c-53d517f7374f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c22f3ad0-ba1f-4dfa-88b9-31554dd422bc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3a24f1aa-00e5-447a-ba9c-53d517f7374f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a24f1aa-00e5-447a-ba9c-53d517f7374f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3a24f1aa-00e5-447a-ba9c-53d517f7374f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a24f1aa-00e5-447a-ba9c-53d517f7374f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b272dbd-b6b8-4862-bba0-0a6f2deb7961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3a24f1aa-00e5-447a-ba9c-53d517f7374f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b272dbd-b6b8-4862-bba0-0a6f2deb7961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WainwrightMember_1795ff62-13df-49b2-9707-fc7c9468ed0a" xlink:href="espr-20230331.xsd#espr_WainwrightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b272dbd-b6b8-4862-bba0-0a6f2deb7961" xlink:to="loc_espr_WainwrightMember_1795ff62-13df-49b2-9707-fc7c9468ed0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WarrantAmendmentAgreementsMember_6fdde9d9-f463-40ad-a095-ab6b72835c30" xlink:href="espr-20230331.xsd#espr_WarrantAmendmentAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b272dbd-b6b8-4862-bba0-0a6f2deb7961" xlink:to="loc_espr_WarrantAmendmentAgreementsMember_6fdde9d9-f463-40ad-a095-ab6b72835c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SecuritiesPurchaseAgreementMember_6eddff04-bd58-4810-baa6-553ed11a0a7d" xlink:href="espr-20230331.xsd#espr_SecuritiesPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b272dbd-b6b8-4862-bba0-0a6f2deb7961" xlink:to="loc_espr_SecuritiesPurchaseAgreementMember_6eddff04-bd58-4810-baa6-553ed11a0a7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b11e915f-7756-40bb-aa70-0eb64605c92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c22f3ad0-ba1f-4dfa-88b9-31554dd422bc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b11e915f-7756-40bb-aa70-0eb64605c92f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b11e915f-7756-40bb-aa70-0eb64605c92f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b11e915f-7756-40bb-aa70-0eb64605c92f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b11e915f-7756-40bb-aa70-0eb64605c92f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_78cfe8e3-fba2-4202-9442-feb156862160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b11e915f-7756-40bb-aa70-0eb64605c92f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_78cfe8e3-fba2-4202-9442-feb156862160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PreFundedWarrantMember_e22ec8cb-59c4-42dc-964e-c161c2126d54" xlink:href="espr-20230331.xsd#espr_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_78cfe8e3-fba2-4202-9442-feb156862160" xlink:to="loc_espr_PreFundedWarrantMember_e22ec8cb-59c4-42dc-964e-c161c2126d54" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.esperion.com/role/NetLossPerCommonShareDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#NetLossPerCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.esperion.com/role/NetLossPerCommonShareDetails" xlink:type="extended" id="i16875c9464ba4885bb542b233b61b971_NetLossPerCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11ab5d6c-beb8-4fe8-ac8c-41693e325b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_417869cc-5812-4da7-8e67-6f1434b40082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11ab5d6c-beb8-4fe8-ac8c-41693e325b9a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_417869cc-5812-4da7-8e67-6f1434b40082" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c33570b9-c9fd-412a-9dca-5f12b8f42897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11ab5d6c-beb8-4fe8-ac8c-41693e325b9a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c33570b9-c9fd-412a-9dca-5f12b8f42897" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5e35071-2fdb-48e5-a147-3973e8e9ee00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c33570b9-c9fd-412a-9dca-5f12b8f42897" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5e35071-2fdb-48e5-a147-3973e8e9ee00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5e35071-2fdb-48e5-a147-3973e8e9ee00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5e35071-2fdb-48e5-a147-3973e8e9ee00" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_b5e35071-2fdb-48e5-a147-3973e8e9ee00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5e35071-2fdb-48e5-a147-3973e8e9ee00" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2b237418-9fa1-4de9-8d9a-853c5afd95e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2b237418-9fa1-4de9-8d9a-853c5afd95e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_3efed304-b823-489c-8804-313ebf96e5f5" xlink:href="espr-20230331.xsd#espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_3efed304-b823-489c-8804-313ebf96e5f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_89fe0a4e-344f-48e4-9529-b7371b8f1c7c" xlink:href="espr-20230331.xsd#espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_89fe0a4e-344f-48e4-9529-b7371b8f1c7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9e5447c1-04f4-4fff-a7bf-3a1c9566ba08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_us-gaap_PerformanceSharesMember_9e5447c1-04f4-4fff-a7bf-3a1c9566ba08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7a7e5d98-b090-4137-bb29-6c0ea88418b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_us-gaap_EmployeeStockMember_7a7e5d98-b090-4137-bb29-6c0ea88418b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_9ea5dd5e-7c67-4719-b55c-0061ae17873c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_9ea5dd5e-7c67-4719-b55c-0061ae17873c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b3d1d2fc-6505-4d2c-b9ec-0a2e4c8b8f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_us-gaap_WarrantMember_b3d1d2fc-6505-4d2c-b9ec-0a2e4c8b8f4b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5b20ed09-73db-4ff3-92d2-a137586a5b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c33570b9-c9fd-412a-9dca-5f12b8f42897" xlink:to="loc_us-gaap_AwardTypeAxis_5b20ed09-73db-4ff3-92d2-a137586a5b72" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b20ed09-73db-4ff3-92d2-a137586a5b72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5b20ed09-73db-4ff3-92d2-a137586a5b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5b20ed09-73db-4ff3-92d2-a137586a5b72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae68508b-2e8d-4f3d-aa6f-390af472d98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5b20ed09-73db-4ff3-92d2-a137586a5b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae68508b-2e8d-4f3d-aa6f-390af472d98d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0ec31d97-d0ce-4f06-be40-faba01bf456c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae68508b-2e8d-4f3d-aa6f-390af472d98d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0ec31d97-d0ce-4f06-be40-faba01bf456c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3544bbc1-4a87-4e5d-8d10-7968af1e873e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c33570b9-c9fd-412a-9dca-5f12b8f42897" xlink:to="loc_srt_CounterpartyNameAxis_3544bbc1-4a87-4e5d-8d10-7968af1e873e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3544bbc1-4a87-4e5d-8d10-7968af1e873e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3544bbc1-4a87-4e5d-8d10-7968af1e873e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3544bbc1-4a87-4e5d-8d10-7968af1e873e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2368dc2-1daf-4241-b10b-3c3b449b3007" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3544bbc1-4a87-4e5d-8d10-7968af1e873e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2368dc2-1daf-4241-b10b-3c3b449b3007" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoCoLtdMember_ad109f3e-464a-49ab-bcae-394169194049" xlink:href="espr-20230331.xsd#espr_DaiichiSankyoCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2368dc2-1daf-4241-b10b-3c3b449b3007" xlink:to="loc_espr_DaiichiSankyoCoLtdMember_ad109f3e-464a-49ab-bcae-394169194049" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>espr-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7abd0a45-1af4-4bbb-ab52-3d00de73fc2d,g:05387136-6cd8-4464-bd5b-5fa183ea52d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_cb7df5a8-beb1-4e96-a9a9-5a617114f904_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PrepaidClinicalDevelopmentCostsCurrent_ee12ba8c-6290-4120-a229-649dd5ff7fc9_terseLabel_en-US" xlink:label="lab_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical development costs</link:label>
    <link:label id="lab_espr_PrepaidClinicalDevelopmentCostsCurrent_label_en-US" xlink:label="lab_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical Development Costs, Current</link:label>
    <link:label id="lab_espr_PrepaidClinicalDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:href="espr-20230331.xsd#espr_PrepaidClinicalDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:to="lab_espr_PrepaidClinicalDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_c2d9fd4b-6840-4c17-9a8a-4a830442010c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of convertible notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6193bdbf-e4e9-40c0-b582-322da24fd02d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DaiichiSankyoEuropeGmbhMember_0cba3086-5def-45b1-a5f0-097e61ae85c5_terseLabel_en-US" xlink:label="lab_espr_DaiichiSankyoEuropeGmbhMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo Europe GmbH ("DSE")</link:label>
    <link:label id="lab_espr_DaiichiSankyoEuropeGmbhMember_label_en-US" xlink:label="lab_espr_DaiichiSankyoEuropeGmbhMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo Europe Gmbh [Member]</link:label>
    <link:label id="lab_espr_DaiichiSankyoEuropeGmbhMember_documentation_en-US" xlink:label="lab_espr_DaiichiSankyoEuropeGmbhMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member stands for the Daiichi Sankyo Europe GmbH ("DSE").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoEuropeGmbhMember" xlink:href="espr-20230331.xsd#espr_DaiichiSankyoEuropeGmbhMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DaiichiSankyoEuropeGmbhMember" xlink:to="lab_espr_DaiichiSankyoEuropeGmbhMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ExclusiveDevelopmentalActivitiesMember_5d036a41-9f67-4e18-be72-7affff477825_terseLabel_en-US" xlink:label="lab_espr_ExclusiveDevelopmentalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Developmental Activities</link:label>
    <link:label id="lab_espr_ExclusiveDevelopmentalActivitiesMember_label_en-US" xlink:label="lab_espr_ExclusiveDevelopmentalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exclusive Developmental Activities [Member]</link:label>
    <link:label id="lab_espr_ExclusiveDevelopmentalActivitiesMember_documentation_en-US" xlink:label="lab_espr_ExclusiveDevelopmentalActivitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to exclusive developmental activities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ExclusiveDevelopmentalActivitiesMember" xlink:href="espr-20230331.xsd#espr_ExclusiveDevelopmentalActivitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ExclusiveDevelopmentalActivitiesMember" xlink:to="lab_espr_ExclusiveDevelopmentalActivitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e6bef244-5902-4c58-bf62-be3f34175362_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c085458f-3ef5-4e79-81ae-a8e43cce46b2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_2be05e10-4de8-4ac7-aed7-1744ffc20fa7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average trading-day period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2f8d8613-0e52-4fed-ae86-fd0204943fa7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NumberOfConsecutiveTradingDays_4325364c-7b7a-4881-8358-02def8288c4f_terseLabel_en-US" xlink:label="lab_espr_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days</link:label>
    <link:label id="lab_espr_NumberOfConsecutiveTradingDays_label_en-US" xlink:label="lab_espr_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Consecutive Trading Days</link:label>
    <link:label id="lab_espr_NumberOfConsecutiveTradingDays_documentation_en-US" xlink:label="lab_espr_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfConsecutiveTradingDays" xlink:href="espr-20230331.xsd#espr_NumberOfConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NumberOfConsecutiveTradingDays" xlink:to="lab_espr_NumberOfConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9e99b320-b347-4c3f-a21c-aa7a1d5ec100_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_a0188045-e223-4923-bc23-3db962819e73_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_d72a91c2-5ccf-4b27-81ba-e4913268cd7d_terseLabel_en-US" xlink:label="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone amount for worldwide sales to receive the third payment</link:label>
    <link:label id="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_label_en-US" xlink:label="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Amount for Worldwide Sales to Receive Third Payment</link:label>
    <link:label id="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_documentation_en-US" xlink:label="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone amount for worldwide sales to receive the Third Payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:href="espr-20230331.xsd#espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:to="lab_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PreFundedWarrantMember_4fb533a1-dbb2-4004-b23d-4f577c374936_terseLabel_en-US" xlink:label="lab_espr_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant</link:label>
    <link:label id="lab_espr_PreFundedWarrantMember_label_en-US" xlink:label="lab_espr_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant [Member]</link:label>
    <link:label id="lab_espr_PreFundedWarrantMember_documentation_en-US" xlink:label="lab_espr_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PreFundedWarrantMember" xlink:href="espr-20230331.xsd#espr_PreFundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PreFundedWarrantMember" xlink:to="lab_espr_PreFundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4a5e7810-de21-4c45-bbb9-6659a8fbdf46_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1de3184d-c14a-43a5-9293-928f67603132_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_d2a9cc8e-b17b-41fc-afd9-8f1c24538503_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_867ab3a9-df0f-4e93-8518-416c681c52f6_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c005a3ec-87c4-473a-8eb3-c114b7a1bec5_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_3310cf5a-8cf5-4a8d-9cbb-f47c3cbc19a0_terseLabel_en-US" xlink:label="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of increase in royalty rate upon drawdown of third payment</link:label>
    <link:label id="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_label_en-US" xlink:label="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Increase in Royalty Rate Upon Drawdown of Third Payment</link:label>
    <link:label id="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_documentation_en-US" xlink:label="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of increase in the Royalty Rate upon drawdown of the Third Payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:href="espr-20230331.xsd#espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:to="lab_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b99fad9e-b1fe-4d16-89dc-16b22865b3c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, stated interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a74b2a6d-4cae-4b3c-a927-3f270db0659c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_654927a4-769f-4c01-90b6-06bb50dfe6cb_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_53a4578b-ef40-468e-af16-852113eb0aa0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_bb3f7f0e-12c8-43e1-a459-60e689eabbef_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_81510f83-5adc-4add-b7b6-f58298c04193_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (Loss) Income Per Common Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e34fb1b2-2e9f-4778-81a4-672d2f0ddad4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total potential dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_f0058554-6f9e-452c-ad01-cb45f885b634_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestsPaymentOnWhichAgreementTerminates_34fbe94f-a259-4a82-8da2-03a16b36a3cc_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestsPaymentOnWhichAgreementTerminates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative purchaser payment adjustment</link:label>
    <link:label id="lab_espr_RevenueInterestsPaymentOnWhichAgreementTerminates_label_en-US" xlink:label="lab_espr_RevenueInterestsPaymentOnWhichAgreementTerminates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interests Payment On Which Agreement Terminates</link:label>
    <link:label id="lab_espr_RevenueInterestsPaymentOnWhichAgreementTerminates_documentation_en-US" xlink:label="lab_espr_RevenueInterestsPaymentOnWhichAgreementTerminates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interests Payment On Which Agreement Terminates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestsPaymentOnWhichAgreementTerminates" xlink:href="espr-20230331.xsd#espr_RevenueInterestsPaymentOnWhichAgreementTerminates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestsPaymentOnWhichAgreementTerminates" xlink:to="lab_espr_RevenueInterestsPaymentOnWhichAgreementTerminates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_12d1be88-4cfb-43cc-864f-71605e2e6644_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_6d5187a9-0187-4648-806d-a7dc9c930e58_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_42a326cd-2cef-4e99-901b-94a99a12e66e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_3aee4ced-8f55-46d7-95dd-760d228e7520_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_121c69cf-7b42-4aae-83fa-bd16625578db_terseLabel_en-US" xlink:label="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:href="espr-20230331.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:to="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_63f94c1e-784e-46ff-bd5a-786d7b8b5318_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CollaborationRevenueMember_44a8bc76-58a9-440c-b695-1e08b34ae1e9_terseLabel_en-US" xlink:label="lab_espr_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_espr_CollaborationRevenueMember_label_en-US" xlink:label="lab_espr_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Revenue [Member]</link:label>
    <link:label id="lab_espr_CollaborationRevenueMember_documentation_en-US" xlink:label="lab_espr_CollaborationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to collaboration revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborationRevenueMember" xlink:href="espr-20230331.xsd#espr_CollaborationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CollaborationRevenueMember" xlink:to="lab_espr_CollaborationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5d4ef65e-c7c5-47b9-856f-eb7f2b02e959_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_4c57ad68-1b2e-4365-99ba-a0e8167ffd7d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f4b1a0cc-a429-4cf8-8e8a-635ab35cf13b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense, RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_b6cbf1e7-db75-40e3-85e3-d6c959d32149_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_471e8947-d56f-4417-b35d-469da5f3e83f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_FuturePaymentMilestoneSalesMilestones_46fc1f8a-b1ec-4ed5-b23b-a1c21030b417_terseLabel_en-US" xlink:label="lab_espr_FuturePaymentMilestoneSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments related to total net sales achievements</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneSalesMilestones_label_en-US" xlink:label="lab_espr_FuturePaymentMilestoneSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payment Milestone, Sales Milestones</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneSalesMilestones_documentation_en-US" xlink:label="lab_espr_FuturePaymentMilestoneSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amount of potential future payments related to total net sales achievements for Otsuka in Japan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneSalesMilestones" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_FuturePaymentMilestoneSalesMilestones" xlink:to="lab_espr_FuturePaymentMilestoneSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_3fc5c4cd-ee44-4dba-a4ad-bd6038453867_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_d306622b-75de-45f1-8966-75b0fe714c2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_6a189618-e711-411c-a837-42816ff52545_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_c165a0c4-bf95-447c-ad50-154c0321292a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable related to the ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_d08f4cc2-08ec-4e83-90b6-daa85f380dd9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_23cbff9c-800c-471a-a834-3465b425d243_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_6d71c23f-1d86-41c0-8701-a11d72db71ca_terseLabel_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of subsequent installment, subject to regulatory approval</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_label_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Subsequent Installment, Subject to Regulatory Approval</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_documentation_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of the subsequent installment which is subject to regulatory approval.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:href="espr-20230331.xsd#espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:to="lab_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestPaymentsRedemptionValue_ba5b9bae-43d5-4812-9a1e-d0c85820d0df_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestPaymentsRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption amount</link:label>
    <link:label id="lab_espr_RevenueInterestPaymentsRedemptionValue_label_en-US" xlink:label="lab_espr_RevenueInterestPaymentsRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Payments, Redemption Value</link:label>
    <link:label id="lab_espr_RevenueInterestPaymentsRedemptionValue_documentation_en-US" xlink:label="lab_espr_RevenueInterestPaymentsRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Payments, Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPaymentsRedemptionValue" xlink:href="espr-20230331.xsd#espr_RevenueInterestPaymentsRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestPaymentsRedemptionValue" xlink:to="lab_espr_RevenueInterestPaymentsRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a2b3acc2-b49b-4da1-a4fe-4755b748be7c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_521ee261-8852-4627-82fb-3ea8ad50bb4d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f73cb7f9-6986-494d-92c3-17f0b6dcb11d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_b9caded8-16da-499b-8ec4-bf9a49550ae8_terseLabel_en-US" xlink:label="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive number of months sales must be at or above milestone amount</link:label>
    <link:label id="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_label_en-US" xlink:label="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consecutive Number of Months Sales Must Be At or Above Milestone Amount</link:label>
    <link:label id="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_documentation_en-US" xlink:label="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The consecutive number of months sales must be at or above the milestone amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:href="espr-20230331.xsd#espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:to="lab_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_c079b9a6-a0ea-4985-97e6-cdce5639cad8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Relating to the Company's RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9095c1f3-ec08-42c0-bd8c-7b2c4d8a2793_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5953e9d2-309f-42d2-ab63-37529e8ae071_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_a10ce468-b748-456e-b37d-896b9941b7f3_terseLabel_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amount of subsequent installment, subject to RIPA terms and conditions</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_label_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Subsequent Installment, Subject to Revenue Interest Purchase Agreement Terms and Conditions</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_documentation_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The total amount of the subsequent installment, subject to the terms and conditions of the Revenue Interest Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:href="espr-20230331.xsd#espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:to="lab_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_FutureUpFrontPayment_46f991c5-6136-45bb-80a1-a413f8862eab_terseLabel_en-US" xlink:label="lab_espr_FutureUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration cash payment</link:label>
    <link:label id="lab_espr_FutureUpFrontPayment_label_en-US" xlink:label="lab_espr_FutureUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Up-Front Payment</link:label>
    <link:label id="lab_espr_FutureUpFrontPayment_documentation_en-US" xlink:label="lab_espr_FutureUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Up-Front Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FutureUpFrontPayment" xlink:href="espr-20230331.xsd#espr_FutureUpFrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_FutureUpFrontPayment" xlink:to="lab_espr_FutureUpFrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_ef67f1cc-5f18-4c3b-845d-f107b3f60e41_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_82bef331-8c28-4633-83fa-26ac97f509b0_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6267812d-d1b3-4a63-97ec-00f1c02911d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_fcf5778f-f60f-47e9-a3f9-9e7927bf0092_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CommonStockPurchasableUnderWarrants_c1522ab6-06b0-4575-ab9f-a9106bfb50ce_terseLabel_en-US" xlink:label="lab_espr_CommonStockPurchasableUnderWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchasable under warrants (in shares)</link:label>
    <link:label id="lab_espr_CommonStockPurchasableUnderWarrants_label_en-US" xlink:label="lab_espr_CommonStockPurchasableUnderWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchasable Under Warrants</link:label>
    <link:label id="lab_espr_CommonStockPurchasableUnderWarrants_documentation_en-US" xlink:label="lab_espr_CommonStockPurchasableUnderWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchasable Under Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockPurchasableUnderWarrants" xlink:href="espr-20230331.xsd#espr_CommonStockPurchasableUnderWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CommonStockPurchasableUnderWarrants" xlink:to="lab_espr_CommonStockPurchasableUnderWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_80a434e3-733b-4e30-ab0e-6208ea8f874a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, warrants, and pre-funded warrants, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_320e9d03-beea-4861-8ad3-46593a51dde7_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b322ca06-fbe8-4206-926f-637d27473ef1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_519b12ab-6abd-418c-8daf-7d696381ad06_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_1cb11c42-eb5b-48bd-b01d-a8392c67f1a7_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NumberOfBusinessDays_7a97519a-5cae-44aa-b270-57e9e283f6b6_terseLabel_en-US" xlink:label="lab_espr_NumberOfBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business days</link:label>
    <link:label id="lab_espr_NumberOfBusinessDays_label_en-US" xlink:label="lab_espr_NumberOfBusinessDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Business Days</link:label>
    <link:label id="lab_espr_NumberOfBusinessDays_documentation_en-US" xlink:label="lab_espr_NumberOfBusinessDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Business Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfBusinessDays" xlink:href="espr-20230331.xsd#espr_NumberOfBusinessDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NumberOfBusinessDays" xlink:to="lab_espr_NumberOfBusinessDays" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestRateTierTwo_f00ce7ec-fa7a-4946-93b1-7abbe34bba3c_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestRateTierTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021</link:label>
    <link:label id="lab_espr_RevenueInterestRateTierTwo_label_en-US" xlink:label="lab_espr_RevenueInterestRateTierTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Rate, Tier Two</link:label>
    <link:label id="lab_espr_RevenueInterestRateTierTwo_documentation_en-US" xlink:label="lab_espr_RevenueInterestRateTierTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Revenue Interest Rate which will take effect if annual net sales equal or exceed $350.0 million by December 31, 2021.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierTwo" xlink:href="espr-20230331.xsd#espr_RevenueInterestRateTierTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestRateTierTwo" xlink:to="lab_espr_RevenueInterestRateTierTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9d6e04aa-426f-4023-8377-5bfbb9e95209_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1b07db30-4a0b-4cbf-a35a-245d86a5bd2c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_30d48b76-0715-4cad-ba06-1db4e9371792_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of PBRSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_785155dd-5b0e-49be-8a06-2ac03c5550ea_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_bd050646-df1a-40e0-a80e-fbeebb18d19a_terseLabel_en-US" xlink:label="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of last reported sale price</link:label>
    <link:label id="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_label_en-US" xlink:label="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price</link:label>
    <link:label id="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_documentation_en-US" xlink:label="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:href="espr-20230331.xsd#espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:to="lab_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_a2d45856-ac9b-4add-b11c-fba32e9b512e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9489e305-ebf2-4047-bbd1-ab3e5b939d19_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and at the beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d28683d9-88ef-4ba2-9a66-72a2ac8bbc37_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at the at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_7661e834-8cd8-4555-9d12-d46135a261e3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_82287665-07be-4b2e-947b-2449cfeb6a66_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2f942137-27d6-4639-b53c-e9ea1f9d4000_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestRateTierThree_965ac171-53e9-4fe9-b88e-34c8e66d43f6_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestRateTierThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest rate if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024</link:label>
    <link:label id="lab_espr_RevenueInterestRateTierThree_label_en-US" xlink:label="lab_espr_RevenueInterestRateTierThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Rate, Tier Three</link:label>
    <link:label id="lab_espr_RevenueInterestRateTierThree_documentation_en-US" xlink:label="lab_espr_RevenueInterestRateTierThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Revenue Interest Rate which will take effect if annual net sales equals or exceeds the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierThree" xlink:href="espr-20230331.xsd#espr_RevenueInterestRateTierThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestRateTierThree" xlink:to="lab_espr_RevenueInterestRateTierThree" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CommonStockPurchasableUnderPrefundedWarrants_cffc3dd8-dcf1-4b16-ba77-2f33787dda03_terseLabel_en-US" xlink:label="lab_espr_CommonStockPurchasableUnderPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchasable under prefunded warrants (in shares)</link:label>
    <link:label id="lab_espr_CommonStockPurchasableUnderPrefundedWarrants_label_en-US" xlink:label="lab_espr_CommonStockPurchasableUnderPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchasable Under Prefunded Warrants</link:label>
    <link:label id="lab_espr_CommonStockPurchasableUnderPrefundedWarrants_documentation_en-US" xlink:label="lab_espr_CommonStockPurchasableUnderPrefundedWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchasable Under Prefunded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockPurchasableUnderPrefundedWarrants" xlink:href="espr-20230331.xsd#espr_CommonStockPurchasableUnderPrefundedWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CommonStockPurchasableUnderPrefundedWarrants" xlink:to="lab_espr_CommonStockPurchasableUnderPrefundedWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_364a9d76-8469-48e2-a92f-3b575148951c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of capped call options associated with convertible notes</link:label>
    <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Derivative Instrument, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:to="lab_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_442fe7b3-7a31-4dee-b7f8-6b4d5c29e393_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_label_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interests Payment on Which Agreement Terminates After the Third Anniversary Of Closing Date If Put Option Is Exercised</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_documentation_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:to="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_d393351a-160d-40c0-9dea-e691246b6056_terseLabel_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment, first JNDA submissions</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_label_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payment Milestone, First Submission of Japanese New Drug Application, Otsuka Territory</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_documentation_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:to="lab_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_2c947835-4765-441b-a12b-dc4a7a9829b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_9035d91c-de28-487c-b696-fac5049f2d81_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_b7db6f42-8fd0-46d4-ad0b-bf525a939f19_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_abcc46c0-8d52-48aa-a4c4-43ca0ef32e9e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_SecuritiesPurchaseAgreementMember_fdfed83c-ff11-499b-9a0e-5ffdb1b65f88_terseLabel_en-US" xlink:label="lab_espr_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:label id="lab_espr_SecuritiesPurchaseAgreementMember_label_en-US" xlink:label="lab_espr_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
    <link:label id="lab_espr_SecuritiesPurchaseAgreementMember_documentation_en-US" xlink:label="lab_espr_SecuritiesPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SecuritiesPurchaseAgreementMember" xlink:href="espr-20230331.xsd#espr_SecuritiesPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_SecuritiesPurchaseAgreementMember" xlink:to="lab_espr_SecuritiesPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_52bae477-f0ed-4425-a164-2a7ec1f16c6d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs to additional paid in capital</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_a79be3ea-ed01-4c83-b138-b2eca6da4127_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_3a07e60f-e9d5-41c0-8502-db78f90dac45_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember_2f9d8a94-f461-407f-8e9b-62cee4d0929d_terseLabel_en-US" xlink:label="lab_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchaser Discounts And Commissions And Offering Expenses Payable</link:label>
    <link:label id="lab_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember_label_en-US" xlink:label="lab_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchaser Discounts And Commissions And Offering Expenses Payable [Member]</link:label>
    <link:label id="lab_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember_documentation_en-US" xlink:label="lab_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchaser Discounts And Commissions And Offering Expenses Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember" xlink:href="espr-20230331.xsd#espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember" xlink:to="lab_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2813667b-c1f1-4b89-bee3-79f0fb76547d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_25cad05f-3334-4431-a1fb-a6691daca9a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0ac700cf-173a-4bdf-b6d3-626fc2242997_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_91cfe21a-92d9-4334-93a2-074c51cc4282_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PBRSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_3bfb8e66-f195-405c-af2a-eef144b398cb_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested PBRSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_4f41fe68-5f1d-4bdc-b0c0-acc6a75c6419_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Receivables</link:label>
    <link:label id="lab_us-gaap_TradeAccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_TradeAccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAccountsReceivableMember" xlink:to="lab_us-gaap_TradeAccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfPrivatePlacement_929c91c1-297b-4db4-8513-fcb1f07635bd_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Placement fees</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f81bafb5-9bef-4fe6-bcb5-7ec4fca4cf29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bb425215-aa89-4b6a-ba12-8d94a90b462b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5ade5183-7e7a-4bde-814d-f4f2736c9f8b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_ffa48ea2-c5a7-4edf-b644-f86af19fbdbe_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NumberOfStudyPatients_0c24daa3-0b68-4ecf-8327-bdaa6507a06d_terseLabel_en-US" xlink:label="lab_espr_NumberOfStudyPatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Study patients enrolled</link:label>
    <link:label id="lab_espr_NumberOfStudyPatients_label_en-US" xlink:label="lab_espr_NumberOfStudyPatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Study Patients</link:label>
    <link:label id="lab_espr_NumberOfStudyPatients_documentation_en-US" xlink:label="lab_espr_NumberOfStudyPatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Study Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfStudyPatients" xlink:href="espr-20230331.xsd#espr_NumberOfStudyPatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NumberOfStudyPatients" xlink:to="lab_espr_NumberOfStudyPatients" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_b02bc854-6a2b-47c5-b7e3-c986bb83269e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0b67d1d5-a6ec-4879-ab64-9ed7118c692a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3b16857c-0117-4f03-8a68-edd9e8366c8c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other prepaid and current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_7668471b-a245-4513-8c48-824670c0babb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesTable_83c8e574-f7fc-4847-9f4c-1f288d79de52_terseLabel_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability from Sale of Future Revenues [Table]</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesTable_label_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability from Sale of Future Revenues [Table]</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesTable_documentation_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about liabilities from the sale of future royalty revenues.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:to="lab_espr_LiabilityFromSaleOfFutureRevenuesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_f693522f-11aa-4aba-8567-cbe4ed8805fe_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_c8ad4ab4-ec80-4ba2-98a0-4091e816046b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5a11f15-a52d-4096-9a00-1980b1491054_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_980fcde4-32fc-4f55-a263-562eaa6fea06_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued for shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_878cf059-5b8a-42ea-88da-304aba039117_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period over which remaining unrecognized compensation cost will be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bc8131ec-bdb2-43eb-a22c-04ab98bd33e5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f5223df0-2854-4c17-9a58-21f180d66c55_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_cdaf4bb2-17f4-405d-8208-4f2daad2b4d0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, warrants, and pre-funded warrants, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock_16a721cb-9cfd-443d-87aa-a4b63db09522_terseLabel_en-US" xlink:label="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Revenue Interest Liability Activity During the Period</link:label>
    <link:label id="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock_label_en-US" xlink:label="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue Interest Liability [Table Text Block]</link:label>
    <link:label id="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of information pertaining to the revenue interest liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:href="espr-20230331.xsd#espr_ScheduleOfRevenueInterestLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:to="lab_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_64f3456d-77aa-4cce-b395-c9c16e93a850_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_1e8abe4f-f4c9-4c55-89c0-cc47bb34dcd2_terseLabel_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase discount</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_label_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Percentage Discount on Shares</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_documentation_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The discount at which shares may be purchased under the employee stock purchase plan, calculated as a stated percentage of the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanPercentageDiscountOnShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:to="lab_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7badb521-f73a-4ea2-96bb-5bd33ab91032_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_d65772dd-81c6-4867-93aa-3f26db1d756c_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interest payments to qualify for third payment applicable percentage</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_label_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_documentation_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:to="lab_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_28112f45-b4d0-4ab6-9426-8cef3681588b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_a08accc5-64ca-4a68-bbfe-eac4f7671b21_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrant amendment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_bb4c8530-b4cf-47fb-b2e7-c1befe3b5e98_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_c92fd2fb-a0f6-4dda-9366-e4d45a9fc9ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_151d0bf5-7f62-4d96-85d6-538432321b26_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_label_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interests Payment on Which Agreement Terminates Prior to the Third Anniversary Of Closing Date If Put Option Is Exercised</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_documentation_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:to="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_fa861039-f604-4aaa-ae5c-1ff4356be267_terseLabel_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of offering periods</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_label_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Duration of Offering Period</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_documentation_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The duration of offering periods in which employees may purchase stock, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:to="lab_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_928e86b3-60fa-442e-a8f0-30be01ae8b4e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8799ed60-4cac-4ee1-aad9-4cd79a775cd3_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_a825b3fb-6198-414e-b63b-9b7251512e11_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_04e937c1-da7b-4be8-9983-5ae3886568c7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_cae6f184-980a-4efd-96ef-8a90fb598064_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8b645138-6559-4fff-9633-041c557dd439_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_8fc9ebe5-dcc3-4996-a13b-54f677f1d2a2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_17835624-02ea-4ee9-8060-ff96d152d704_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_ed1b263e-d4d4-4dfc-9861-f34bd9fd40ae_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_9c541b42-1689-4661-8331-3ad2a610faa6_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issuable upon conversion of convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_78cc4f44-0841-4714-9417-c5772f6c621c_terseLabel_en-US" xlink:label="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="espr-20230331.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_UpFrontPayment_87b5b94b-dbdc-4f70-9723-48d40395585a_terseLabel_en-US" xlink:label="lab_espr_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront cash payment received (paid)</link:label>
    <link:label id="lab_espr_UpFrontPayment_label_en-US" xlink:label="lab_espr_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Up-Front Payment</link:label>
    <link:label id="lab_espr_UpFrontPayment_documentation_en-US" xlink:label="lab_espr_UpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of up-front payment received (paid) .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UpFrontPayment" xlink:href="espr-20230331.xsd#espr_UpFrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_UpFrontPayment" xlink:to="lab_espr_UpFrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_187bdf6d-1ae2-4e0f-8d46-5027cab2f65b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest on convertible notes</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2a47baae-26ca-493c-b9d9-7dc3f5842845_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_e47ade49-04a0-47be-9ae9-ad623f6580af_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_eb6cbfa0-2b2e-4746-b8f3-0d4456a912af_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_40e059b7-05d4-4cc6-9545-ad867fa6b88b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NetSalesThresholdAxis_037c0d17-f9af-479b-901e-4e27b7fdf38e_terseLabel_en-US" xlink:label="lab_espr_NetSalesThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold [Axis]</link:label>
    <link:label id="lab_espr_NetSalesThresholdAxis_label_en-US" xlink:label="lab_espr_NetSalesThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold [Axis]</link:label>
    <link:label id="lab_espr_NetSalesThresholdAxis_documentation_en-US" xlink:label="lab_espr_NetSalesThresholdAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdAxis" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NetSalesThresholdAxis" xlink:to="lab_espr_NetSalesThresholdAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_368c3678-cfd3-411c-8eb7-d0e4f7eea5b0_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PreFundedWarrantAndAccompanyingWarrantMember_4f69155d-0f1f-4b26-aae6-f9af73b6e858_terseLabel_en-US" xlink:label="lab_espr_PreFundedWarrantAndAccompanyingWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant And Accompanying Warrant</link:label>
    <link:label id="lab_espr_PreFundedWarrantAndAccompanyingWarrantMember_label_en-US" xlink:label="lab_espr_PreFundedWarrantAndAccompanyingWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant And Accompanying Warrant [Member]</link:label>
    <link:label id="lab_espr_PreFundedWarrantAndAccompanyingWarrantMember_documentation_en-US" xlink:label="lab_espr_PreFundedWarrantAndAccompanyingWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre Funded Warrant And Accompanying Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PreFundedWarrantAndAccompanyingWarrantMember" xlink:href="espr-20230331.xsd#espr_PreFundedWarrantAndAccompanyingWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PreFundedWarrantAndAccompanyingWarrantMember" xlink:to="lab_espr_PreFundedWarrantAndAccompanyingWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestLiabilityNoncurrent_4e399c7b-cc7c-41d9-94d5-ee22194f21cf_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest liability</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityNoncurrent_label_en-US" xlink:label="lab_espr_RevenueInterestLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Liability, NonCurrent</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityNoncurrent_documentation_en-US" xlink:label="lab_espr_RevenueInterestLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as noncurrent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityNoncurrent" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestLiabilityNoncurrent" xlink:to="lab_espr_RevenueInterestLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_5863cf6a-9372-4ddf-b915-4f507f528163_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_SignificantAccountingPoliciesTable_4cd2fbb3-284a-46e5-a2ec-e653e74ad8c7_terseLabel_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_espr_SignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_espr_SignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of information about significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesTable" xlink:href="espr-20230331.xsd#espr_SignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_SignificantAccountingPoliciesTable" xlink:to="lab_espr_SignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_1c9df4d0-8085-4bbc-9a67-0b32dab8b6d7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember_3a341532-b72e-4cfb-afff-6a75bd620267_terseLabel_en-US" xlink:label="lab_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular Risk Outcome Less than Twenty Percent</link:label>
    <link:label id="lab_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember_label_en-US" xlink:label="lab_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular Risk Outcome Greater Than Fifteen But Less Than Twenty Percent [Member]</link:label>
    <link:label id="lab_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember_documentation_en-US" xlink:label="lab_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular Risk Outcome Greater Than Fifteen But Less Than Twenty Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember" xlink:href="espr-20230331.xsd#espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember" xlink:to="lab_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_fd5e9d13-cf98-4b5d-9e14-7b7e901dc3d6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays_d84f8693-f2c7-469e-9888-9b9cb2f86bad_terseLabel_en-US" xlink:label="lab_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement, threshold trading days</link:label>
    <link:label id="lab_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days</link:label>
    <link:label id="lab_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays_documentation_en-US" xlink:label="lab_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays" xlink:href="espr-20230331.xsd#espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays" xlink:to="lab_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NumberOfSourcesOfRevenue_c66a3dee-2c96-4a6a-9b22-5855d1a36bb1_terseLabel_en-US" xlink:label="lab_espr_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of revenue sources</link:label>
    <link:label id="lab_espr_NumberOfSourcesOfRevenue_label_en-US" xlink:label="lab_espr_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sources Of Revenue</link:label>
    <link:label id="lab_espr_NumberOfSourcesOfRevenue_documentation_en-US" xlink:label="lab_espr_NumberOfSourcesOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Sources Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfSourcesOfRevenue" xlink:href="espr-20230331.xsd#espr_NumberOfSourcesOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NumberOfSourcesOfRevenue" xlink:to="lab_espr_NumberOfSourcesOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestPaymentsRemainingRedemptionValue_13f848f3-3c0e-4fe8-a72b-20dc78e4af08_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestPaymentsRemainingRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining redemption amount</link:label>
    <link:label id="lab_espr_RevenueInterestPaymentsRemainingRedemptionValue_label_en-US" xlink:label="lab_espr_RevenueInterestPaymentsRemainingRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Payments, Remaining Redemption Value</link:label>
    <link:label id="lab_espr_RevenueInterestPaymentsRemainingRedemptionValue_documentation_en-US" xlink:label="lab_espr_RevenueInterestPaymentsRemainingRedemptionValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Payments, Remaining Redemption Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPaymentsRemainingRedemptionValue" xlink:href="espr-20230331.xsd#espr_RevenueInterestPaymentsRemainingRedemptionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestPaymentsRemainingRedemptionValue" xlink:to="lab_espr_RevenueInterestPaymentsRemainingRedemptionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_9042c84f-79dc-4556-a5e4-1074587b117e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5bb5443b-e51a-4ec6-9f4a-42b8e9240850_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b8e8b666-3132-4a70-b730-5a15633be1b2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DaiichiSankyoCoLtdMember_bdf61c7f-fb78-476f-ae28-1748f5ee0ca3_terseLabel_en-US" xlink:label="lab_espr_DaiichiSankyoCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo Co. Ltd</link:label>
    <link:label id="lab_espr_DaiichiSankyoCoLtdMember_label_en-US" xlink:label="lab_espr_DaiichiSankyoCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo Co. Ltd [Member]</link:label>
    <link:label id="lab_espr_DaiichiSankyoCoLtdMember_documentation_en-US" xlink:label="lab_espr_DaiichiSankyoCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Daiichi Sankyo Co. Ltd</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoCoLtdMember" xlink:href="espr-20230331.xsd#espr_DaiichiSankyoCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DaiichiSankyoCoLtdMember" xlink:to="lab_espr_DaiichiSankyoCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_b0f09cfd-d881-4dd0-b618-502ff855ffad_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales_09093a41-33ab-4b30-bd43-79214d4e54a6_terseLabel_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment to the Company upon first commercial sales in the DSE Territory</link:label>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales_label_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payment to be Received upon First Commercial Sales</link:label>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales_documentation_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of cash payment to the Company upon first commercial sales in the DSE Territory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:href="espr-20230331.xsd#espr_CashPaymentToBeReceivedUponFirstCommercialSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:to="lab_espr_CashPaymentToBeReceivedUponFirstCommercialSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_03364235-854e-4596-95dd-5da4c581f49f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_aba9d9ee-7e1b-468c-ad85-a63d9349140e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember_4c24ee8a-ffd1-4349-82e6-5d9c7a805a0d_terseLabel_en-US" xlink:label="lab_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular Risk Outcome Greater than Twenty Percent</link:label>
    <link:label id="lab_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember_label_en-US" xlink:label="lab_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular Risk Outcome Greater Than Twenty Percent [Member]</link:label>
    <link:label id="lab_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember_documentation_en-US" xlink:label="lab_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular Risk Outcome Greater Than Twenty Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember" xlink:href="espr-20230331.xsd#espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember" xlink:to="lab_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_5b3caf1a-952a-4138-835c-9516bb2017c6_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a9edd2dd-4546-413a-bfcb-3fc88f0fbdf5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_31d815d3-fd0a-451b-af88-de151d6ace19_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_bcdade0a-0ad8-4da6-b08a-45edacd1102e_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_fda5f197-9136-4838-95ca-52958e3ef5b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_FairValueMeasurementAssetTransfersBetweenLevels_4d4bdc01-8835-4729-a2d8-05407909bb84_terseLabel_en-US" xlink:label="lab_espr_FairValueMeasurementAssetTransfersBetweenLevels" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of assets between levels</link:label>
    <link:label id="lab_espr_FairValueMeasurementAssetTransfersBetweenLevels_label_en-US" xlink:label="lab_espr_FairValueMeasurementAssetTransfersBetweenLevels" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Asset Transfers between Levels</link:label>
    <link:label id="lab_espr_FairValueMeasurementAssetTransfersBetweenLevels_documentation_en-US" xlink:label="lab_espr_FairValueMeasurementAssetTransfersBetweenLevels" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the transfer of assets between the levels of fair value hierarchy that have taken place during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FairValueMeasurementAssetTransfersBetweenLevels" xlink:href="espr-20230331.xsd#espr_FairValueMeasurementAssetTransfersBetweenLevels"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_FairValueMeasurementAssetTransfersBetweenLevels" xlink:to="lab_espr_FairValueMeasurementAssetTransfersBetweenLevels" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_3f5f5c23-20cd-4e1a-9444-b5b93404fc1e_terseLabel_en-US" xlink:label="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential additional future payments</link:label>
    <link:label id="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_label_en-US" xlink:label="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Amount of Potential Future Revenue, Total Development and Sales Milestones</link:label>
    <link:label id="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_documentation_en-US" xlink:label="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:href="espr-20230331.xsd#espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:to="lab_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_18b6a66b-3764-4b77-87a4-97e37edee2eb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_8548cf37-0b61-465f-a793-5ff89a7417d2_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_598db390-2a1c-4ec7-82f1-ca2471205cb8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c6ce0263-0e9d-4783-983c-b7979e04a6c6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_c2436f0e-e8bc-4370-ab60-c061283e7663_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_2d3a4e27-0c88-4e66-bf02-28e3de8e2625_terseLabel_en-US" xlink:label="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized issuance costs</link:label>
    <link:label id="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_label_en-US" xlink:label="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized Transaction Costs on Revenue Interest Agreement</link:label>
    <link:label id="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_documentation_en-US" xlink:label="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of transaction costs on revenue interest agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:href="espr-20230331.xsd#espr_UnamortizedTransactionCostsOnRevenueInterestAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:to="lab_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_TypeOfRiskAxis_2c8bb2a8-e608-459c-8ac9-0e0dd1ee2472_terseLabel_en-US" xlink:label="lab_espr_TypeOfRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Of Risk[Axis]</link:label>
    <link:label id="lab_espr_TypeOfRiskAxis_label_en-US" xlink:label="lab_espr_TypeOfRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Of Risk [Axis]</link:label>
    <link:label id="lab_espr_TypeOfRiskAxis_documentation_en-US" xlink:label="lab_espr_TypeOfRiskAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Of Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TypeOfRiskAxis" xlink:href="espr-20230331.xsd#espr_TypeOfRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_TypeOfRiskAxis" xlink:to="lab_espr_TypeOfRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9cc0ba28-a63d-4fab-adbd-d03b974f07f2_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_341d41b1-f04e-4855-9fa2-cb8c6456cbab_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized stock-based compensation expense, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock_d3b7b2df-009a-4999-b375-c03bf9c60643_terseLabel_en-US" xlink:label="lab_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrants and Pre-funded Warrants Outstanding</link:label>
    <link:label id="lab_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock_label_en-US" xlink:label="lab_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Warrants And Pre Funded Warrants Outstanding [Table Text Block]</link:label>
    <link:label id="lab_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock_documentation_en-US" xlink:label="lab_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Warrants And Pre Funded Warrants Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock" xlink:href="espr-20230331.xsd#espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock" xlink:to="lab_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_OneTimePartialCall_b15d1cb8-6dda-42c4-af2d-dd61a060e4cc_terseLabel_en-US" xlink:label="lab_espr_OneTimePartialCall" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One time partial call</link:label>
    <link:label id="lab_espr_OneTimePartialCall_label_en-US" xlink:label="lab_espr_OneTimePartialCall" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Partial Call</link:label>
    <link:label id="lab_espr_OneTimePartialCall_documentation_en-US" xlink:label="lab_espr_OneTimePartialCall" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time Partial Call</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_OneTimePartialCall" xlink:href="espr-20230331.xsd#espr_OneTimePartialCall"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_OneTimePartialCall" xlink:to="lab_espr_OneTimePartialCall" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_b7e25834-daa8-4054-83a2-c3767e283a7a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e08a3984-41c0-49ce-ac5c-32e74abf1974_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c062b640-3bea-4eab-8505-f003d4492e63_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_8e336ce2-4420-4a78-895d-a8b312c81071_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment of forward stock repurchase transaction</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_f66e4f5e-dce1-4880-92fe-498752204b8d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_feba257c-8042-43b8-99f8-934a125b1a93_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_8ef72861-75ee-4938-b313-dead1fe2ac74_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_bd334b0c-92ba-44af-b293-0f862af5b1ed_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_83495e54-3517-4af4-be78-fb45e85035dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_7ae35f22-50e3-4d79-9fdc-2630e1522157_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Relating to the Company's PBRSU's</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Performance-Based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary_9e2c19e6-8f15-4459-9926-a9c7afd9c733_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues interests payment on which agreement terminates, after third anniversary</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary_label_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interests Payment on Which Agreement Terminates, After Third Anniversary</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary_documentation_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interests Payment on Which Agreement Terminates, After Third Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary" xlink:to="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_dcc3531e-b5d7-4e6a-b9f8-fe94361c5433_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems_e1a8245b-ccdd-4563-8e9e-0b38fce35408_terseLabel_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems_label_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability from Sale of Future Revenues [Line Items]</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems_documentation_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:to="lab_espr_LiabilityFromSaleOfFutureRevenuesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b7694643-bf40-4fec-bd5f-730a3cabc741_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_02077aa7-949d-4011-929c-55ed652eb9b1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_OtsukaPharmaceuticalCoLtdMember_d6179155-f63b-4463-ae31-40c2561c419c_terseLabel_en-US" xlink:label="lab_espr_OtsukaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otsuka Pharmaceutical Co, Ltd.</link:label>
    <link:label id="lab_espr_OtsukaPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_espr_OtsukaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Otsuka Pharmaceutical Co Ltd [Member]</link:label>
    <link:label id="lab_espr_OtsukaPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_espr_OtsukaPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Otsuka Pharmaceutical Co, Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_OtsukaPharmaceuticalCoLtdMember" xlink:href="espr-20230331.xsd#espr_OtsukaPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_OtsukaPharmaceuticalCoLtdMember" xlink:to="lab_espr_OtsukaPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_a606c536-521b-45d3-8bcd-06767fb38745_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_d8fb7f5d-9d0a-47db-9081-1edbafcbe652_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_6e4e76cd-3016-4ed6-9b50-0587e789de44_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CollaborativeArrangementAbstract_017b6e0d-aca5-44c1-ac0e-06f9f62789db_terseLabel_en-US" xlink:label="lab_espr_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations with Third Parties</link:label>
    <link:label id="lab_espr_CollaborativeArrangementAbstract_label_en-US" xlink:label="lab_espr_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations with Third Parties</link:label>
    <link:label id="lab_espr_CollaborativeArrangementAbstract_documentation_en-US" xlink:label="lab_espr_CollaborativeArrangementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementAbstract" xlink:href="espr-20230331.xsd#espr_CollaborativeArrangementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CollaborativeArrangementAbstract" xlink:to="lab_espr_CollaborativeArrangementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_eca4573f-df69-498e-a468-05af099415a9_terseLabel_en-US" xlink:label="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RIPA Amendment To The Security Agreement And Waiver</link:label>
    <link:label id="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_label_en-US" xlink:label="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RIPA Amendment To The Security Agreement And Waiver [Member]</link:label>
    <link:label id="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_documentation_en-US" xlink:label="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RIPA Amendment To The Security Agreement And Waiver</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:href="espr-20230331.xsd#espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:to="lab_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_6aff99a0-dc66-4ee6-8b1d-aa43a92f322e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ConvertibleSeniorNotesDue2025Member_54dea6db-c98d-4369-bf07-f075cd789082_terseLabel_en-US" xlink:label="lab_espr_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025</link:label>
    <link:label id="lab_espr_ConvertibleSeniorNotesDue2025Member_label_en-US" xlink:label="lab_espr_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025 [Member]</link:label>
    <link:label id="lab_espr_ConvertibleSeniorNotesDue2025Member_documentation_en-US" xlink:label="lab_espr_ConvertibleSeniorNotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConvertibleSeniorNotesDue2025Member" xlink:href="espr-20230331.xsd#espr_ConvertibleSeniorNotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ConvertibleSeniorNotesDue2025Member" xlink:to="lab_espr_ConvertibleSeniorNotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_c177045d-04e3-412a-973a-1d27cca6f419_terseLabel_en-US" xlink:label="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount of US net sales to qualify for the Covered Territory expansion to include worldwide sales by December 31, 2021</link:label>
    <link:label id="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_label_en-US" xlink:label="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold To Include Worldwide Sales In Covered Territory</link:label>
    <link:label id="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_documentation_en-US" xlink:label="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold To Include Worldwide Sales In Covered Territory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:to="lab_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_26e1d2dc-08a4-4e2d-be00-e9716f4f0bc8_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_88698afd-d0a9-454a-b9b2-3f221fb96744_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_18553446-cbce-45cf-9c12-50e303eadf9a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring fair value measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_64e99c6a-ddef-4e3a-812a-264d9a83ce3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRiskReduction_1f13437c-43e9-40dc-9ea6-1686bedd38fc_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRiskReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of risk reduction</link:label>
    <link:label id="lab_espr_PercentageOfRiskReduction_label_en-US" xlink:label="lab_espr_PercentageOfRiskReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Risk Reduction</link:label>
    <link:label id="lab_espr_PercentageOfRiskReduction_documentation_en-US" xlink:label="lab_espr_PercentageOfRiskReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Risk Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRiskReduction" xlink:href="espr-20230331.xsd#espr_PercentageOfRiskReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRiskReduction" xlink:to="lab_espr_PercentageOfRiskReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestLiability_94556cee-8c40-41a0-9a0d-2436b2607211_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest liability</link:label>
    <link:label id="lab_espr_RevenueInterestLiability_3c9d0be0-8e14-4227-b397-c7c9f49a8788_periodStartLabel_en-US" xlink:label="lab_espr_RevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest liability, beginning balance</link:label>
    <link:label id="lab_espr_RevenueInterestLiability_9afd7066-7980-4265-b09c-e56de07ac207_periodEndLabel_en-US" xlink:label="lab_espr_RevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest liability, ending balance</link:label>
    <link:label id="lab_espr_RevenueInterestLiability_label_en-US" xlink:label="lab_espr_RevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Liability</link:label>
    <link:label id="lab_espr_RevenueInterestLiability_documentation_en-US" xlink:label="lab_espr_RevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the current and non-current portion of the Revenue Interest Liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestLiability" xlink:to="lab_espr_RevenueInterestLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_1469bd51-4432-4b77-9447-5cd3cf1f6e2e_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense recognized</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_label_en-US" xlink:label="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Liability, Increase for Interest Expense Recognized</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_documentation_en-US" xlink:label="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase in the revenue interest liability attributable to interest expense recognized during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:to="lab_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_63e26823-ac1a-412b-bacb-f778e724ba89_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_be08dd57-bfc8-4080-a825-19efc10d0d84_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7b838928-b79c-408a-866b-29c9d6b0b1e9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aef11566-1236-468c-9a24-45fbb2dbd4e2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_edf7cefa-b0de-44c4-a535-74660d660334_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding and unvested at the ending of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_96dbbd6c-b070-4118-84da-e14e6e19eda3_terseLabel_en-US" xlink:label="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_3f6bf4d3-205b-494c-ba81-5939ade92da7_totalLabel_en-US" xlink:label="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other accrued liabilities</link:label>
    <link:label id="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Employee-related Liabilities, Current</link:label>
    <link:label id="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_documentation_en-US" xlink:label="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:href="espr-20230331.xsd#espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:to="lab_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_9de60e31-6651-413a-b4b4-00167c5687e1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5ede2ffe-0b19-4c3e-bbed-f2853712658b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_c6f93fa0-492a-46e1-abfb-ef15ca536f31_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_be29667a-de19-4c85-92cf-6ca4577a1b9c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_0ac1ec68-894b-4625-9eca-6d17a1484e8f_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3cff6e9f-c27f-4997-ba42-d5f69b415112_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5402d48b-49c9-47c7-9711-8abdf937b2b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_0a369ca1-30da-4bbb-b865-300c0e53b710_terseLabel_en-US" xlink:label="lab_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing number of months sales must be at or above milestone amount</link:label>
    <link:label id="lab_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_label_en-US" xlink:label="lab_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing Number Of Months Sales Must Be At Or Above Milestone Amount</link:label>
    <link:label id="lab_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_documentation_en-US" xlink:label="lab_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The trailing number of months sales must be at or above the milestone amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:href="espr-20230331.xsd#espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:to="lab_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_ea37159a-2dbd-4df5-9afc-78c737dbf240_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock_59462574-93a0-48d7-9bcf-1c3160ba400b_terseLabel_en-US" xlink:label="lab_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]</link:label>
    <link:label id="lab_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock_documentation_en-US" xlink:label="lab_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of reconciliation of cash and cash equivalents and restricted cash presented on the Condensed Balance Sheets to the same amounts presented on the Condensed Statements of Cash Flows.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock" xlink:href="espr-20230331.xsd#espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock" xlink:to="lab_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e525b8d9-ba25-4a21-809b-b47db3d76f9d_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_59ceaa43-a62d-40ec-8c71-2bd094735351_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_ecdc5de1-c7fb-40e3-8fc5-c624d35f1054_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement, amount of principal amount converted into common stock</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9b3f3e0d-394c-4a42-90a3-90aeefa0fa9f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Relating to the Company's Options and Performance-Based Options to Purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1fe5d0e6-1a47-4fe0-9e99-6306549f0ee4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_d3d8042b-1faa-432b-a90f-4291d281e538_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_818c08c0-5b9c-44a1-ab82-f0d0042a2cf4_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Implemented Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_7c4cd2f5-eaf2-4afc-879b-a6e0e29b12bc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_b0c64f5c-1230-44d1-be78-aa2b70fc6ec3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock being exchanged (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_081d9c9e-8d7f-490b-97c7-51f4743853e3_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaids and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_d5d1b615-691b-4b87-9f5f-1191e47eb4f8_terseLabel_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:label id="lab_us-gaap_InterimPeriodCostsNotAllocableDomain_label_en-US" xlink:label="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="lab_us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ConcentrationRiskNumberOfMajorCustomers_42390457-f4d4-454f-b0dd-ae92452787bb_terseLabel_en-US" xlink:label="lab_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of major customers</link:label>
    <link:label id="lab_espr_ConcentrationRiskNumberOfMajorCustomers_label_en-US" xlink:label="lab_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Number of Major Customers</link:label>
    <link:label id="lab_espr_ConcentrationRiskNumberOfMajorCustomers_documentation_en-US" xlink:label="lab_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of the Company's major customers.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:href="espr-20230331.xsd#espr_ConcentrationRiskNumberOfMajorCustomers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:to="lab_espr_ConcentrationRiskNumberOfMajorCustomers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_01d1f103-64f7-4261-b372-37c74ec63b51_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestLiabilityCurrent_a0c686ed-f9d5-43d6-8dad-8f66665d454c_verboseLabel_en-US" xlink:label="lab_espr_RevenueInterestLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue interest liability</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityCurrent_label_en-US" xlink:label="lab_espr_RevenueInterestLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Liability, Current</link:label>
    <link:label id="lab_espr_RevenueInterestLiabilityCurrent_documentation_en-US" xlink:label="lab_espr_RevenueInterestLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityCurrent" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestLiabilityCurrent" xlink:to="lab_espr_RevenueInterestLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_f97ca835-45f0-4ee6-83d6-ed191e2492e7_terseLabel_en-US" xlink:label="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical repayment obligation</link:label>
    <link:label id="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_label_en-US" xlink:label="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical Repayment Obligation Based On Sales Generated</link:label>
    <link:label id="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_documentation_en-US" xlink:label="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical Repayment Obligation Based On Sales Generated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:href="espr-20230331.xsd#espr_HypotheticalRepaymentObligationBasedOnSalesGenerated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:to="lab_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_2270592a-9e02-4cb8-9b6e-ee65d8c68db1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement_d633b1da-6043-40dd-9c06-443211036999_negatedLabel_en-US" xlink:label="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on revenue interest liability</link:label>
    <link:label id="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement_9340a7ca-b259-4fc8-ab7d-7c03be0eb3c4_negatedTerseLabel_en-US" xlink:label="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interests payments</link:label>
    <link:label id="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement_label_en-US" xlink:label="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments From Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement_documentation_en-US" xlink:label="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow from a revenue interest purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:href="espr-20230331.xsd#espr_PaymentsFromRevenueInterestPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:to="lab_espr_PaymentsFromRevenueInterestPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8a31fccb-7dc5-4334-a09e-e46cddefae72_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_f51d1e02-a1ce-4987-8562-ef07b2418269_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e551a942-52bb-49d5-a8ed-7e4310851fdc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_52a1b307-503e-4074-835d-014a560a38a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9a7a818f-c43e-4ab7-ac6f-b4a093fb2d96_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_09413d5b-b781-47d8-93d8-0f30b09852c2_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_85565d9f-ff1f-4375-8fce-717bcdc6d898_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_907440c9-e129-4fd4-8ee8-acf8c4ef0d6e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_4bf67efc-ec7f-4b40-89c0-ef29530a41d8_terseLabel_en-US" xlink:label="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of cumulative purchaser payments</link:label>
    <link:label id="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_label_en-US" xlink:label="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Cumulative Purchaser Payments, Guarantee</link:label>
    <link:label id="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_documentation_en-US" xlink:label="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Cumulative Purchaser Payments, Guarantee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:href="espr-20230331.xsd#espr_PercentageOfCumulativePurchaserPaymentsGuarantee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:to="lab_espr_PercentageOfCumulativePurchaserPaymentsGuarantee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e2d6214b-85c5-4f54-8396-863c18a92758_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_78c98a59-5dbe-4536-8d88-85f92df8addf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_88a2f038-23ef-4108-8520-486dc47ad1fe_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalties to be received on the net sales</link:label>
    <link:label id="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_label_en-US" xlink:label="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Royalties to be Received on Net Sales</link:label>
    <link:label id="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_documentation_en-US" xlink:label="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of royalties to be received on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:href="espr-20230331.xsd#espr_PercentageOfRoyaltiesToBeReceivedOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:to="lab_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_3ab5ac3a-8946-4a6d-9420-b4479dbf1efc_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cabd2d52-bf04-4d29-919b-204c25cd8a53_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_724e251a-6d9c-475d-85ce-8b4e096e1e19_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9ac22538-7d63-43e7-ad00-811893d4812f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_0fb3e25e-d546-4f9f-adc7-59a84bd67aa5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_c5845208-85de-4d56-ab2b-28e80d47e71c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 240,000,000 shares authorized as of March&#160;31, 2023 and as of December&#160;31, 2022; 89,237,167 shares issued at March&#160;31, 2023 and 76,564,396 shares issued at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercised_65b0f2cc-3dbc-42d3-8c59-1431bc283e93_terseLabel_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercised_label_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercised_documentation_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercised" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ClassOfWarrantOrRightExercised" xlink:to="lab_espr_ClassOfWarrantOrRightExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_20fcc68f-64dd-4dee-b1af-fa49a2c97541_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6cd8f198-4be5-4a4f-a316-5d23c7b51f7f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor_91ee2a6c-f9d3-41bf-bc99-b17ed3387645_terseLabel_en-US" xlink:label="lab_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Agreement, weighted average price per share floor (in dollars per share)</link:label>
    <link:label id="lab_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor_label_en-US" xlink:label="lab_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor</link:label>
    <link:label id="lab_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor_documentation_en-US" xlink:label="lab_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor" xlink:href="espr-20230331.xsd#espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor" xlink:to="lab_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_bb47917d-81af-41ce-a322-0c35b45c9225_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of restricted stock units and performance-based restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_8461d1a9-a391-40f0-a49d-dede0b5cfb5b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_134ff279-61e6-495b-944b-92c83afb45ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Excluded From Calculation of Diluted Net (Loss) Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7a15ad1f-64f5-4309-a424-0a7dbdc9b082_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_fd4da866-a4e5-4824-98e8-4232f6551a41_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_TypeOfRiskDomain_760353ca-3aaf-4dec-9861-72a3ca11a6d6_terseLabel_en-US" xlink:label="lab_espr_TypeOfRiskDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Of Risk [Domain]</link:label>
    <link:label id="lab_espr_TypeOfRiskDomain_label_en-US" xlink:label="lab_espr_TypeOfRiskDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Of Risk [Domain]</link:label>
    <link:label id="lab_espr_TypeOfRiskDomain_documentation_en-US" xlink:label="lab_espr_TypeOfRiskDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type Of Event [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TypeOfRiskDomain" xlink:href="espr-20230331.xsd#espr_TypeOfRiskDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_TypeOfRiskDomain" xlink:to="lab_espr_TypeOfRiskDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d58363d1-bf83-4d4f-a670-f6802f73c4fa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ad961219-c0a2-406b-9420-297265763df8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f2ab633d-f3d2-43fd-8e41-fda6a4986418_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58aeb081-2343-4d8f-b900-67f47bbd6c82_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5d756afc-b744-4dd0-9bff-81f76f3e923b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RelativeRiskMember_8f0f6a04-6f03-425e-bece-691fa9776244_terseLabel_en-US" xlink:label="lab_espr_RelativeRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Risk</link:label>
    <link:label id="lab_espr_RelativeRiskMember_label_en-US" xlink:label="lab_espr_RelativeRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Risk [Member]</link:label>
    <link:label id="lab_espr_RelativeRiskMember_documentation_en-US" xlink:label="lab_espr_RelativeRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relative Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RelativeRiskMember" xlink:href="espr-20230331.xsd#espr_RelativeRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RelativeRiskMember" xlink:to="lab_espr_RelativeRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding_2c3b1d8c-ad8a-491f-8800-9a37c87ee35c_terseLabel_en-US" xlink:label="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, required amount outstanding</link:label>
    <link:label id="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding_label_en-US" xlink:label="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Required Amount Outstanding</link:label>
    <link:label id="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding_documentation_en-US" xlink:label="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Required Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:href="espr-20230331.xsd#espr_DebtInstrumentCovenantRequiredAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:to="lab_espr_DebtInstrumentCovenantRequiredAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_5175720a-c6c8-46bc-834f-233debcdbbe6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_dc8a8145-ad05-4b8a-826c-f75b83a8200d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_4db97664-c9f9-4b02-ba94-9f9eb5f73783_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8f88f9b4-3108-466f-863b-188f04e4710b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_71178fc4-1f3f-4dd9-b907-3a390be1681e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_0f013cb7-98be-4487-8650-36dbdc7a364f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue from collaborations</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_51a83172-4a3e-4516-a33e-af2559cfc074_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_26f1ac8a-7110-4154-9264-5e1532ee2c0d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Cash Equivalents and Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_3a91e551-f1ef-49dd-b2e4-653bf71ab12b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9de1e41e-ec7d-4a21-9d68-c2d5f51f4f10_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_760f1af1-b00f-48c0-8fe6-8d465840e083_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bd70d2da-080d-4271-8b06-3d0de05c2d25_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember_109f3b53-c92a-468a-9588-10c563f565e9_terseLabel_en-US" xlink:label="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue and product sales bulk tablets</link:label>
    <link:label id="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember_label_en-US" xlink:label="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue And Product Sales Bulk Tablets [Member]</link:label>
    <link:label id="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember_documentation_en-US" xlink:label="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue And Product Sales Bulk Tablets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember" xlink:href="espr-20230331.xsd#espr_RoyaltyRevenueAndProductSalesBulkTabletsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember" xlink:to="lab_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f2596ea4-2d4f-43b4-8117-1feb86bdac30_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b09c842-3206-42c0-ba88-3f1680b07e83_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0c0f9391-8817-4840-8ec1-d159c0e3a8ff_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7ee15e21-76ed-427e-b1bf-dbd0ffd32f9f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of ESPP Shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_103164f6-ea3b-4f4a-938e-4a2214a23c9d_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_8fc0efb0-5f1a-4ddd-a3ac-2e02f1bbdf9b_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective annual imputed interest rate (as a percent)</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_label_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Purchase Agreement, Effective Annual Imputed Interest Rate</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_documentation_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of effective annual imputed interest rate under the revenue interest purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:href="espr-20230331.xsd#espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:to="lab_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_984b1532-a769-4a3e-ad07-9d64d873a6c1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization_00192396-c617-4b06-9880-c610e0fd2037_terseLabel_en-US" xlink:label="lab_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash payment to the Company upon grant of marketing authorization</link:label>
    <link:label id="lab_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization_label_en-US" xlink:label="lab_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Payment To Be Received Upon Grant Of Marketing Authorization</link:label>
    <link:label id="lab_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization_documentation_en-US" xlink:label="lab_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash payment to the Company upon grant of marketing authorization dependent on the range of relative risk reduction in the CLEAR outcomes study.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization" xlink:href="espr-20230331.xsd#espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization" xlink:to="lab_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_17a8ceab-eb69-4abc-87cf-114a2b776667_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_80e92941-6ef4-4549-943e-00eea83558ed_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementMember_47a52b13-bfbe-4098-ba2c-5104e987f747_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Purchase Agreement (RIPA)</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementMember_label_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Purchase Agreement [Member]</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementMember_documentation_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to revenue interest purchase agreement ("RIPA").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementMember" xlink:href="espr-20230331.xsd#espr_RevenueInterestPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestPurchaseAgreementMember" xlink:to="lab_espr_RevenueInterestPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward_85543c95-5126-4204-b821-89489a269c05_terseLabel_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability From Sale Of Future Revenues [Roll Forward]</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward_label_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability From Sale Of Future Revenues [Roll Forward]</link:label>
    <link:label id="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward_documentation_en-US" xlink:label="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability From Sale Of Future Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:to="lab_espr_LiabilityFromSaleOfFutureRevenuesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_ad15b6a2-c2d3-4d43-9db7-8e3e642c9bc6_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of ESPP Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_22667cfb-66fc-487b-968a-b8d83c2b7bea_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights_c86bb2c8-abca-4124-b7ee-05f94b48ab69_terseLabel_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional consideration (in dollars per share)</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights_label_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant Or Right, Additional Consideration Of Warrants Or Rights</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights_documentation_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant Or Right, Additional Consideration Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights" xlink:to="lab_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9db0a657-03f3-4f9c-8023-92dee79e98de_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_401cfc81-dbe4-419d-952a-c0beee6a6ca8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCommissions_f41d4608-02b2-4912-befb-74541f7566f8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated offering expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions" xlink:to="lab_us-gaap_PaymentsForCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_620f2db5-71fd-4168-8689-812b8dd5da3f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2d31c5ff-28fb-402c-aefa-db73bce09941_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3040e8c8-c2d2-4371-a944-fbb7fe626876_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5bab548b-e311-46ae-bf31-46d265eb5a18_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations with Third Parties</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_eee9834a-2fc9-42d6-adc8-1a066b2a2e37_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_82c6e391-a14b-45da-9e30-78a9419d52cc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b61a0947-7eb4-4d40-996f-7771f91b3727_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_7e6af206-ed59-4988-b8e0-3ee6b505e277_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares under option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_66fcb233-fc7f-4af2-838f-1bb9d80a2051_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost; 1,994,198 shares at March&#160;31, 2023 and December 31, 2022</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration_43f1e830-8213-4d31-930a-2721144cfbac_terseLabel_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional consideration per amended warrant (in dollars per share)</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration_label_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights, Additional Consideration</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration_documentation_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights, Additional Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration" xlink:to="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_76d2e2ae-ed96-448e-81ad-46d94b823907_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_02b7ac47-c924-41a4-ad8e-daddd864eca7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_512b45af-382c-481a-9345-7b732d21d0b8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f7fba89d-daf6-45b7-a459-da7b18dd7067_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_e68fc370-6e1c-45c1-bfb4-0d7a11635ed3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_a608088b-e989-4a75-960a-cb7bfd229291_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_TheWarrantsMember_6f2ac80e-4f6a-413b-965e-381e6ff91150_terseLabel_en-US" xlink:label="lab_espr_TheWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Warrants</link:label>
    <link:label id="lab_espr_TheWarrantsMember_label_en-US" xlink:label="lab_espr_TheWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Warrants [Member]</link:label>
    <link:label id="lab_espr_TheWarrantsMember_documentation_en-US" xlink:label="lab_espr_TheWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TheWarrantsMember" xlink:href="espr-20230331.xsd#espr_TheWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_TheWarrantsMember" xlink:to="lab_espr_TheWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_e1b08f82-3ed8-45ec-8e9f-fe95957851ee_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_1daefb94-623a-41f5-8336-ecabdbcf41eb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0ad7a010-467a-4998-895c-13b4a7f0b15e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ed87df5c-3242-4643-957e-288fc960a1fa_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_50847663-54e4-4ea2-80fe-99f8ba917b78_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_46f59e73-f9cf-4950-ae55-dbbd5b759af2_terseLabel_en-US" xlink:label="lab_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PBSOs</link:label>
    <link:label id="lab_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_e7cf8237-e2d0-4e87-9739-f264102c205a_verboseLabel_en-US" xlink:label="lab_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares under PBSOs</link:label>
    <link:label id="lab_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_label_en-US" xlink:label="lab_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Payment Arrangement, Option, Performance Based [Member]</link:label>
    <link:label id="lab_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_documentation_en-US" xlink:label="lab_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Payment Arrangement, Option, Performance Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember" xlink:href="espr-20230331.xsd#espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember" xlink:to="lab_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_cbe0dbd0-82e8-4410-9359-e4ec6100d590_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement_85a9f372-92a6-4f76-948a-8833374596a4_terseLabel_en-US" xlink:label="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement_label_en-US" xlink:label="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement_documentation_en-US" xlink:label="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Revenue Interest Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:href="espr-20230331.xsd#espr_ProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:to="lab_espr_ProceedsFromRevenueInterestPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_b2ef3084-a150-4316-9611-adea44e20ff2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_afb83670-97e9-4081-bef1-4d3d8f548c60_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f3029096-91db-4b29-8fe8-45234036cc2f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_22850541-409e-4aaa-b550-317cca3b56da_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_9f858caa-511b-4f83-9d2f-e2694a3e4173_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0b0ee80b-077f-4bfd-a770-665d402a2d63_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_847232ba-145e-48dc-af4f-63ac88cc2b8a_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_997544c4-581f-4c0e-a858-8b7d30f4c557_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AccruedVariableConsiderationCurrent_d48be21e-a6c4-404e-8ae3-30d7849f29d8_terseLabel_en-US" xlink:label="lab_espr_AccruedVariableConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued variable consideration</link:label>
    <link:label id="lab_espr_AccruedVariableConsiderationCurrent_label_en-US" xlink:label="lab_espr_AccruedVariableConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Variable Consideration, Current</link:label>
    <link:label id="lab_espr_AccruedVariableConsiderationCurrent_documentation_en-US" xlink:label="lab_espr_AccruedVariableConsiderationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedVariableConsiderationCurrent" xlink:href="espr-20230331.xsd#espr_AccruedVariableConsiderationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AccruedVariableConsiderationCurrent" xlink:to="lab_espr_AccruedVariableConsiderationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_4b689275-6847-4c56-b35f-209c84520bb2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_f481d3fe-568b-4243-adfe-4c122887d35b_terseLabel_en-US" xlink:label="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified net revenue</link:label>
    <link:label id="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_label_en-US" xlink:label="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified Net Revenue Threshold Triggering Deposit In Blocked Account</link:label>
    <link:label id="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_documentation_en-US" xlink:label="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Amount of Net Revenue To Qualify For Deposit In Blocked Account</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:href="espr-20230331.xsd#espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:to="lab_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_8cb22dc6-5bc5-47c3-8685-190e6af2e2c2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_34034ccf-9e23-482d-b659-3885819da27c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_2edfb2db-a076-4473-ae00-e4f35b9fdb3c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_24080e2e-eeda-4489-bced-60845fe1c7c0_terseLabel_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, premium percentage</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_label_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_documentation_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:to="lab_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_e6e661f1-4b79-4a4b-8e17-9e6155ad8a30_terseLabel_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2024, contingent on 100% invested capital received</link:label>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_label_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold</link:label>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_documentation_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:href="espr-20230331.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:to="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d3b2d71b-65ea-4fc5-8d8e-92f61429d4d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestRateInitialRate_23314ff0-5cb9-47e4-a86d-6017daacb664_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestRateInitialRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial revenue interest rate</link:label>
    <link:label id="lab_espr_RevenueInterestRateInitialRate_label_en-US" xlink:label="lab_espr_RevenueInterestRateInitialRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Rate, Initial Rate</link:label>
    <link:label id="lab_espr_RevenueInterestRateInitialRate_documentation_en-US" xlink:label="lab_espr_RevenueInterestRateInitialRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The initial revenue interest rate, as a percentage of the Company's net sales in the Covered Territory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateInitialRate" xlink:href="espr-20230331.xsd#espr_RevenueInterestRateInitialRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestRateInitialRate" xlink:to="lab_espr_RevenueInterestRateInitialRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0e27873e-eb09-415e-b196-f568b7766bcc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CommonStockAndAccompanyingWarrantMember_916532e2-389c-4222-adfe-a03fdadfe528_terseLabel_en-US" xlink:label="lab_espr_CommonStockAndAccompanyingWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Accompanying Warrant</link:label>
    <link:label id="lab_espr_CommonStockAndAccompanyingWarrantMember_label_en-US" xlink:label="lab_espr_CommonStockAndAccompanyingWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Accompanying Warrant [Member]</link:label>
    <link:label id="lab_espr_CommonStockAndAccompanyingWarrantMember_documentation_en-US" xlink:label="lab_espr_CommonStockAndAccompanyingWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Accompanying Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockAndAccompanyingWarrantMember" xlink:href="espr-20230331.xsd#espr_CommonStockAndAccompanyingWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CommonStockAndAccompanyingWarrantMember" xlink:to="lab_espr_CommonStockAndAccompanyingWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_586ec05e-3a38-4beb-bf5b-8b8b53899176_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_101f0a02-6009-4692-8fbe-df14073b359a_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_793f203d-1d22-440a-847b-1e6b20c370d3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_31f236bb-3023-418c-8f74-43d86b80dde0_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_13c90e27-e41d-42fe-ad14-a2b8fe028999_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_23004bf0-5f21-43f0-83e5-a86db56da1eb_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_40e20669-d0f7-4dc5-9064-6041128840d2_verboseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums and discounts on investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3d6c2be8-4672-460a-8bd1-0f003f2f48fa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_20b30040-6fea-4d23-9c86-587b9cd0b0ee_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_StockOptionAndIncentivePlan2022Member_e983bbc4-fce5-434a-9f6a-3cef021de94f_terseLabel_en-US" xlink:label="lab_espr_StockOptionAndIncentivePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option And Incentive Plan 2022</link:label>
    <link:label id="lab_espr_StockOptionAndIncentivePlan2022Member_label_en-US" xlink:label="lab_espr_StockOptionAndIncentivePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option And Incentive Plan 2022 [Member]</link:label>
    <link:label id="lab_espr_StockOptionAndIncentivePlan2022Member_documentation_en-US" xlink:label="lab_espr_StockOptionAndIncentivePlan2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option And Incentive Plan 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_StockOptionAndIncentivePlan2022Member" xlink:href="espr-20230331.xsd#espr_StockOptionAndIncentivePlan2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_StockOptionAndIncentivePlan2022Member" xlink:to="lab_espr_StockOptionAndIncentivePlan2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AccruedClinicalDevelopmentCostsCurrent_cb08d299-44de-4555-916f-505e94a329a1_terseLabel_en-US" xlink:label="lab_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical development costs</link:label>
    <link:label id="lab_espr_AccruedClinicalDevelopmentCostsCurrent_label_en-US" xlink:label="lab_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Development Costs, Current</link:label>
    <link:label id="lab_espr_AccruedClinicalDevelopmentCostsCurrent_documentation_en-US" xlink:label="lab_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:href="espr-20230331.xsd#espr_AccruedClinicalDevelopmentCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:to="lab_espr_AccruedClinicalDevelopmentCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NonCashRightOfUseAsset_116316ad-2e0b-4128-ae61-64da37f5c7cd_terseLabel_en-US" xlink:label="lab_espr_NonCashRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non cash right of use asset</link:label>
    <link:label id="lab_espr_NonCashRightOfUseAsset_label_en-US" xlink:label="lab_espr_NonCashRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Right Of Use Asset</link:label>
    <link:label id="lab_espr_NonCashRightOfUseAsset_documentation_en-US" xlink:label="lab_espr_NonCashRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the difference between the lease asset and the lease liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NonCashRightOfUseAsset" xlink:href="espr-20230331.xsd#espr_NonCashRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NonCashRightOfUseAsset" xlink:to="lab_espr_NonCashRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_8a980de6-4ec7-49ba-abe5-35c401bc9ff2_terseLabel_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_label_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_documentation_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:href="espr-20230331.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:to="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2184c3ae-8a82-4dca-9f44-1e1473b2b440_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cb6072fb-c424-4f43-ab93-f8524b47ae9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_57a6d4b6-78fe-4cd4-8312-accecc0f5790_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e3b94785-fdb6-4d5c-8ab1-c5e466e13bcc_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1ddb5b55-be28-45fe-aad9-d05fbe61222b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_973bd69c-01eb-40d9-bc70-3d40ced0dd3f_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c261fdae-f209-44b9-9ece-2466b39aa51e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_07381ce3-2d09-4907-ba08-029ebe28eba4_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_974ded91-0cc4-4ddb-8fa3-9a03be2ad31b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NetSalesThresholdOneMember_dde0214a-446d-48fb-8f5b-1d638e2f457a_terseLabel_en-US" xlink:label="lab_espr_NetSalesThresholdOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Less Than $250 Million</link:label>
    <link:label id="lab_espr_NetSalesThresholdOneMember_label_en-US" xlink:label="lab_espr_NetSalesThresholdOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold One [Member]</link:label>
    <link:label id="lab_espr_NetSalesThresholdOneMember_documentation_en-US" xlink:label="lab_espr_NetSalesThresholdOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdOneMember" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NetSalesThresholdOneMember" xlink:to="lab_espr_NetSalesThresholdOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_c24d535d-2905-4963-b369-c4892ee7a2d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_514c66f4-e973-45c7-bf1d-c0728485eb16_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, convertible, threshold percentage of stock price trigger</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_89a43712-2866-4a45-a49e-006ba5f66a27_terseLabel_en-US" xlink:label="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate</link:label>
    <link:label id="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_label_en-US" xlink:label="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Invested Capital Received By December 31, 2024, To Qualify For Second Reduced Revenue Interest Rate</link:label>
    <link:label id="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_documentation_en-US" xlink:label="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:href="espr-20230331.xsd#espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:to="lab_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_e8d72271-5301-4a6b-a578-b0966d20aa09_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_fb8967c2-443b-4dca-bcdf-6efc74ba8b16_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1a6da787-9bd5-48f4-9dc3-7b32f445fb36_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a3bf151c-12f7-4db9-98fa-a670981a0411_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_DeferredUpFrontPayment_2b333b6b-6eab-44b0-b562-758c0ab2c2a0_terseLabel_en-US" xlink:label="lab_espr_DeferredUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred up-front payment</link:label>
    <link:label id="lab_espr_DeferredUpFrontPayment_label_en-US" xlink:label="lab_espr_DeferredUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Up-Front Payment</link:label>
    <link:label id="lab_espr_DeferredUpFrontPayment_documentation_en-US" xlink:label="lab_espr_DeferredUpFrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Up-Front Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DeferredUpFrontPayment" xlink:href="espr-20230331.xsd#espr_DeferredUpFrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_DeferredUpFrontPayment" xlink:to="lab_espr_DeferredUpFrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_d9a52c23-e08e-4211-9e03-cf6fcd298f89_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CommonStockIssuanceCostsIncurredNotYetPaid_c63fb656-666b-4779-aa17-f261271f1556_terseLabel_en-US" xlink:label="lab_espr_CommonStockIssuanceCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issuance, warrant, and pre-funded warrant issuance costs not yet paid</link:label>
    <link:label id="lab_espr_CommonStockIssuanceCostsIncurredNotYetPaid_label_en-US" xlink:label="lab_espr_CommonStockIssuanceCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issuance Costs Incurred, Not Yet Paid</link:label>
    <link:label id="lab_espr_CommonStockIssuanceCostsIncurredNotYetPaid_documentation_en-US" xlink:label="lab_espr_CommonStockIssuanceCostsIncurredNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issuance Costs Incurred, Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockIssuanceCostsIncurredNotYetPaid" xlink:href="espr-20230331.xsd#espr_CommonStockIssuanceCostsIncurredNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CommonStockIssuanceCostsIncurredNotYetPaid" xlink:to="lab_espr_CommonStockIssuanceCostsIncurredNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_c5a312c1-8369-4f12-99aa-5394bcdb4b72_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_4f2d0057-156f-4e86-9476-ee98f2a90179_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 5)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_bd690d84-a119-4b92-896b-cd8ee9e9dd1d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5bd58600-ca33-4086-aa40-9c8e7c203dd0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e70f9f82-cf2f-4467-9f46-acf92ac90353_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_99a651b4-5076-4105-ba5b-b1d7734ce376_terseLabel_en-US" xlink:label="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company deposit value in blocked account</link:label>
    <link:label id="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_label_en-US" xlink:label="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold</link:label>
    <link:label id="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_documentation_en-US" xlink:label="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:href="espr-20230331.xsd#espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:to="lab_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_c6f587bc-ce01-4989-96a6-e4ec0900a36f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_f89ac4b0-8a96-4959-b911-be0720c04b48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on modification of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_89706fc9-a6d7-4fb7-a9f3-a10871f2c9aa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March&#160;31, 2023 and December 31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PotentialProceedsFromPartnerMilestonePayments_65f0d8f6-ae3b-4e69-a922-19fbd5c5f803_terseLabel_en-US" xlink:label="lab_espr_PotentialProceedsFromPartnerMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Partner milestone payments</link:label>
    <link:label id="lab_espr_PotentialProceedsFromPartnerMilestonePayments_label_en-US" xlink:label="lab_espr_PotentialProceedsFromPartnerMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Proceeds From Partner Milestone Payments</link:label>
    <link:label id="lab_espr_PotentialProceedsFromPartnerMilestonePayments_documentation_en-US" xlink:label="lab_espr_PotentialProceedsFromPartnerMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Proceeds From Partner Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PotentialProceedsFromPartnerMilestonePayments" xlink:href="espr-20230331.xsd#espr_PotentialProceedsFromPartnerMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PotentialProceedsFromPartnerMilestonePayments" xlink:to="lab_espr_PotentialProceedsFromPartnerMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_fbfa5ad0-a382-41c3-8da7-8af5d8406318_terseLabel_en-US" xlink:label="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds from revenue interest liability</link:label>
    <link:label id="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_label_en-US" xlink:label="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Proceeds from Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_documentation_en-US" xlink:label="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash inflow from a revenue interest purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:href="espr-20230331.xsd#espr_GrossProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:to="lab_espr_GrossProceedsFromRevenueInterestPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37cf207b-0ca2-4eca-8d43-21e7258aa6b4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7a51e7d3-b354-421a-bb60-0a7f7bcb5bd1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_bf917f21-e700-4227-b72e-0687495ae790_terseLabel_en-US" xlink:label="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_label_en-US" xlink:label="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payment Milestone, Achievement of Drug Trial Outcomes Studies</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_documentation_en-US" xlink:label="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:to="lab_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b368d7d6-fc0a-49c0-a15f-ce04bd8e24e7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock_8614de99-fda1-4272-b18a-507fe81c4154_terseLabel_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Revenue Interest Purchase Agreement</link:label>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock_label_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to The Revenue Interest Purchase Agreement [Text Block]</link:label>
    <link:label id="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock_documentation_en-US" xlink:label="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure of liabilities related to the Revenue Interest Purchase Agreement entered into by the Company with Eiger III SA LLC ("Oberland").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:href="espr-20230331.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:to="lab_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_d5f8b47d-4f3b-4b04-9ff1-a44808d7a6a1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_91d087de-2486-4cff-a647-70c22778acc7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_75a4f6f3-ab03-4fbd-ad1b-ddf10ce7552c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7c844b66-3608-4a8a-843c-fdbc76f82c1f_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_fb0cb92d-934b-44e7-b1c5-20b5b3d2e605_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember_99c000f0-100f-4266-8404-034293a683c6_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RIPA Amendment</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember_label_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Purchase Agreement Amendment [Member]</link:label>
    <link:label id="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember_documentation_en-US" xlink:label="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Purchase Agreement Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:href="espr-20230331.xsd#espr_RevenueInterestPurchaseAgreementAmendmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:to="lab_espr_RevenueInterestPurchaseAgreementAmendmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_fdcc6350-1360-46d3-8b39-3676af6d6852_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period Two</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_4b6fc76d-0bd6-4c78-ad21-74178e1e12fc_terseLabel_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in dollars per share)</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Purchase Price Of Warrants Or Rights</link:label>
    <link:label id="lab_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Purchase Price Of Warrants Or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:to="lab_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_15c7ed14-a31f-4d1c-833e-ba06fc49dd66_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_58076bf8-b006-4667-ba55-cb6d7ab303b2_terseLabel_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee, as a percentage of base salary</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_documentation_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of employee gross pay the employee may contribute to an employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b4533db3-bbc3-4e42-abf6-dad9a96663d2_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_efbe57d8-6b0f-4fca-9ad9-0658793163df_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_32f3b0eb-a0f0-4ad9-8393-e4f07ee524a0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestPaymentsRedemptionPercentage_2c5d3a29-12ce-4cea-9e29-016dae595fa3_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestPaymentsRedemptionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption percentage</link:label>
    <link:label id="lab_espr_RevenueInterestPaymentsRedemptionPercentage_label_en-US" xlink:label="lab_espr_RevenueInterestPaymentsRedemptionPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Payments, Redemption Percentage</link:label>
    <link:label id="lab_espr_RevenueInterestPaymentsRedemptionPercentage_documentation_en-US" xlink:label="lab_espr_RevenueInterestPaymentsRedemptionPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest Payments, Redemption Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPaymentsRedemptionPercentage" xlink:href="espr-20230331.xsd#espr_RevenueInterestPaymentsRedemptionPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestPaymentsRedemptionPercentage" xlink:to="lab_espr_RevenueInterestPaymentsRedemptionPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f97d211-c16b-4433-80ef-b062a54abff9_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_7fa03d61-a301-4110-9d18-36684b9081a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares delivered to the company (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_83fd5ae5-e817-4cb1-9615-6f8fe1de55d7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_452d0a8c-899d-421c-86da-2c7514ea1334_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period One</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_5ceb1fab-ce92-451e-8c4e-07863c0011a1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_095ba85f-c364-4a21-8fbf-929f22f8abe6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_9b1c0273-1a4c-41f0-8e4f-3083310088bb_terseLabel_en-US" xlink:label="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment amount expected to pay in next twelve months</link:label>
    <link:label id="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_label_en-US" xlink:label="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months</link:label>
    <link:label id="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_documentation_en-US" xlink:label="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:href="espr-20230331.xsd#espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:to="lab_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5afcd728-f799-45a9-96a0-dcf40d415ca0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_7c2da7a8-8fb7-42c2-b3c5-98cf93481c78_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_f3a15572-bd86-4d1c-ac8b-3af49cc8eaf2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_8cc6b181-f719-4ce4-a229-4f1061569eb2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_cdee591f-a59d-48cf-a3c2-c315511ede2a_terseLabel_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of subsequent installment, subject to achievement of sales threshold</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_label_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Subsequent Installment, Subject to Achievement of Sales Threshold</link:label>
    <link:label id="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_documentation_en-US" xlink:label="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of the subsequent installment which is subject to the achievement of the Sales Threshold as defined in the Revenue Interest Purchase Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:href="espr-20230331.xsd#espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:to="lab_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_06d84fdf-0da3-4a3c-948b-9bc402293bf2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_c75507c4-d2d3-476a-afe0-12a65725d544_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e6446fab-7d69-4149-ad22-ecfe0c77eccf_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_a628795d-3008-45a3-bcce-bd0c847a838f_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_645644da-8483-4aa8-843d-d7f77b3c966a_terseLabel_en-US" xlink:label="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested RSUs</link:label>
    <link:label id="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_label_en-US" xlink:label="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Restricted Stock And Restricted Stock Units [Member]</link:label>
    <link:label id="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to unvested restricted stock and restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:href="espr-20230331.xsd#espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:to="lab_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_874a12b9-983d-44ee-af33-1ef21ecac64d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_HypotheticalSalesGeneratedAmount_498f473e-1c67-4d26-8fb4-37a7c1989e94_terseLabel_en-US" xlink:label="lab_espr_HypotheticalSalesGeneratedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical sales generated amount</link:label>
    <link:label id="lab_espr_HypotheticalSalesGeneratedAmount_label_en-US" xlink:label="lab_espr_HypotheticalSalesGeneratedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical Sales Generated Amount</link:label>
    <link:label id="lab_espr_HypotheticalSalesGeneratedAmount_documentation_en-US" xlink:label="lab_espr_HypotheticalSalesGeneratedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hypothetical Sales Generated Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalSalesGeneratedAmount" xlink:href="espr-20230331.xsd#espr_HypotheticalSalesGeneratedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_HypotheticalSalesGeneratedAmount" xlink:to="lab_espr_HypotheticalSalesGeneratedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_WainwrightMember_ddd99425-b448-4321-a006-37ab40eedcec_terseLabel_en-US" xlink:label="lab_espr_WainwrightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wainwright</link:label>
    <link:label id="lab_espr_WainwrightMember_label_en-US" xlink:label="lab_espr_WainwrightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wainwright [Member]</link:label>
    <link:label id="lab_espr_WainwrightMember_documentation_en-US" xlink:label="lab_espr_WainwrightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wainwright</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WainwrightMember" xlink:href="espr-20230331.xsd#espr_WainwrightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_WainwrightMember" xlink:to="lab_espr_WainwrightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_bc79201d-928f-4f2e-8ac3-8d4f8fc2c57f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_edf4f855-75cc-41ce-a25f-d01b67c9c755_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation capitalized into inventory</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CappedCallMember_6b1322f7-a534-4b8a-8052-d438fdd4bb05_terseLabel_en-US" xlink:label="lab_espr_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call</link:label>
    <link:label id="lab_espr_CappedCallMember_label_en-US" xlink:label="lab_espr_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call [Member]</link:label>
    <link:label id="lab_espr_CappedCallMember_documentation_en-US" xlink:label="lab_espr_CappedCallMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capped Call</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CappedCallMember" xlink:href="espr-20230331.xsd#espr_CappedCallMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CappedCallMember" xlink:to="lab_espr_CappedCallMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_2fb8f728-966e-42a7-81e3-a585aa794901_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3bacee43-af41-460c-9014-15624834d2f8_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_92216d33-03bc-4b29-b510-9e6c714cf5fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_9f97658d-82be-4fc9-bf2e-07e8e8ee820d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_647fd1cb-ee2c-4100-824d-86b7120e8380_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_ac8916b3-32e0-4419-b7a9-4308c1657210_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_c9dfb1f7-9e45-43af-9d28-e0db8a8b1b7e_terseLabel_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of maximum annual contributions per employee</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_label_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Amount</link:label>
    <link:label id="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_documentation_en-US" xlink:label="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum amount the employee may contribute to an employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="lab_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_ddbde41e-4710-4639-bdca-78690435ca1f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales/maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_3ffd362e-d313-451b-a6cd-d78745e60027_terseLabel_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payment to be received upon certain commercial milestones</link:label>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_label_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payment To Be Received Upon Certain Commercial Milestones</link:label>
    <link:label id="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_documentation_en-US" xlink:label="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Payment To Be Received Upon Certain Commercial Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:href="espr-20230331.xsd#espr_CashPaymentToBeReceivedUponCertainCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:to="lab_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_80a3f90e-6d17-4a67-951c-3e3d3a806969_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9c97b7ce-f3f4-419a-aa9c-4533dff8aa1c_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_bc179313-d3ad-4593-a553-a187c560607b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_b0998639-8be8-49bf-9032-fb23ac0c57cb_terseLabel_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_label_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Revenue Interests Payment on Which Agreement Terminates</link:label>
    <link:label id="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_documentation_en-US" xlink:label="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenue interests payment on which agreement terminates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:to="lab_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a17b4fbf-53ba-4d78-b9cc-55a8a4ef1923_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_cada86ab-d8c2-44c2-a12a-6f0a5f0989c7_terseLabel_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_label_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Payment Milestone, First National Health Insurance Price Listing, Otsuka Territory</link:label>
    <link:label id="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_documentation_en-US" xlink:label="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:to="lab_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_2c0e4592-3b57-4821-b62c-83de108cb7df_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2fd66e87-4290-4ffa-b847-bed83b355d3d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d83f3138-2869-4060-acbf-509e1d224b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of commons stock shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_EigerIiiSaLlcMember_3bde796a-37cc-46ab-8ccf-77f3b338d1af_terseLabel_en-US" xlink:label="lab_espr_EigerIiiSaLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oberland</link:label>
    <link:label id="lab_espr_EigerIiiSaLlcMember_label_en-US" xlink:label="lab_espr_EigerIiiSaLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eiger Iii Sa Llc [Member]</link:label>
    <link:label id="lab_espr_EigerIiiSaLlcMember_documentation_en-US" xlink:label="lab_espr_EigerIiiSaLlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to revenue interest purchase agreement ("RIPA") with Oberland.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EigerIiiSaLlcMember" xlink:href="espr-20230331.xsd#espr_EigerIiiSaLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_EigerIiiSaLlcMember" xlink:to="lab_espr_EigerIiiSaLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1dc4de41-56db-4154-80b7-767b9aac663a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_279fd654-3922-4fe0-acd7-5f4fd3dad0fe_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:label id="lab_us-gaap_NatureOfExpenseAxis_label_en-US" xlink:label="lab_us-gaap_NatureOfExpenseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfExpenseAxis" xlink:to="lab_us-gaap_NatureOfExpenseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_b6d31738-44f9-4733-a0a6-117cb327d528_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInvestmentIncomeReceivable_1f408b65-2720-4d5d-992e-0e5c6b8e2cce_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest receivable</link:label>
    <link:label id="lab_us-gaap_AccruedInvestmentIncomeReceivable_label_en-US" xlink:label="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Investment Income Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInvestmentIncomeReceivable" xlink:to="lab_us-gaap_AccruedInvestmentIncomeReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_SignificantAccountingPoliciesLineItems_6fa2f65e-2875-4e2d-bbe9-271820566128_terseLabel_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_espr_SignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_espr_SignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_espr_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesLineItems" xlink:href="espr-20230331.xsd#espr_SignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems" xlink:to="lab_espr_SignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_05058d29-1a6d-46cf-a5d3-973e00752a20_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Cash Flows and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_19aaaf28-52f0-4c92-ad25-54ac7cf010ab_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_288f03b6-3472-4c05-8772-ff699881b925_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_25d18935-2be0-4468-99b0-72cc645647fa_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income on investments</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_d9d8244c-235d-4fb8-a7dc-969b12ce5c31_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6b736c70-dc6a-49b8-b992-e6b437b7a2b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2cb3f436-d5fa-4650-b54c-337df47a9111_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_bc72815e-9209-4515-950b-1f014ca7f990_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborations with Third Parties</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_64716118-ed21-40f3-b41b-792a53b17418_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_419f8d6a-534b-4555-ba5d-bf60e8feb6c5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_SaleOfStockAuthorizedAmount_faf1fef0-5c90-4d4d-a823-47fe5a32cbc3_terseLabel_en-US" xlink:label="lab_espr_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate offering price shares</link:label>
    <link:label id="lab_espr_SaleOfStockAuthorizedAmount_label_en-US" xlink:label="lab_espr_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:label id="lab_espr_SaleOfStockAuthorizedAmount_documentation_en-US" xlink:label="lab_espr_SaleOfStockAuthorizedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SaleOfStockAuthorizedAmount" xlink:href="espr-20230331.xsd#espr_SaleOfStockAuthorizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_SaleOfStockAuthorizedAmount" xlink:to="lab_espr_SaleOfStockAuthorizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_9c9689e6-7c09-49c4-963a-19cb7e88a5c6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_9899a05e-e527-47e8-981c-281970175882_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b7e3fba9-d297-40a9-98dc-91b6bfad8c00_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_AtTheMarketProgramMember_dec84486-7fb6-40f9-ab17-a506395d1c92_terseLabel_en-US" xlink:label="lab_espr_AtTheMarketProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Program</link:label>
    <link:label id="lab_espr_AtTheMarketProgramMember_label_en-US" xlink:label="lab_espr_AtTheMarketProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Program [Member]</link:label>
    <link:label id="lab_espr_AtTheMarketProgramMember_documentation_en-US" xlink:label="lab_espr_AtTheMarketProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AtTheMarketProgramMember" xlink:href="espr-20230331.xsd#espr_AtTheMarketProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_AtTheMarketProgramMember" xlink:to="lab_espr_AtTheMarketProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_a522c725-d802-41ba-be1c-a286e327a2c6_terseLabel_en-US" xlink:label="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to the revenue interest liability</link:label>
    <link:label id="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_label_en-US" xlink:label="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Cash Interest Expense Related to Revenue Interest Liability</link:label>
    <link:label id="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_documentation_en-US" xlink:label="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of non-cash expense included in interest expense associated with the revenue interest liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:href="espr-20230331.xsd#espr_NonCashInterestExpenseRelatedToRevenueInterestLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:to="lab_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_3bd1a355-b989-4131-a477-0f806260a497_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3848312d-4ec6-47b1-86d5-889d8d9b14bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_29b5b139-b4c6-4976-a067-3f7d45c8e792_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_3e9ae643-f642-4092-86b0-a53d1cac6b68_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0150526-dbd1-4a03-8d66-5e1b25b04b16_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e4859f7d-8cd3-462d-80c8-556312329e83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_af6e053c-9a17-445d-afc3-90c7e04324f4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock from exercisable warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NetSalesThresholdDomain_63ad7656-14d8-4766-aa82-8d2a0180513e_terseLabel_en-US" xlink:label="lab_espr_NetSalesThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold [Domain]</link:label>
    <link:label id="lab_espr_NetSalesThresholdDomain_label_en-US" xlink:label="lab_espr_NetSalesThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold [Domain]</link:label>
    <link:label id="lab_espr_NetSalesThresholdDomain_documentation_en-US" xlink:label="lab_espr_NetSalesThresholdDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdDomain" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NetSalesThresholdDomain" xlink:to="lab_espr_NetSalesThresholdDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_NetSalesThresholdTwoMember_6e39abe2-ab3e-4d95-a3cd-b1dcf6edcd67_terseLabel_en-US" xlink:label="lab_espr_NetSalesThresholdTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Greater Than $250 Million But Less Than $350 Million</link:label>
    <link:label id="lab_espr_NetSalesThresholdTwoMember_label_en-US" xlink:label="lab_espr_NetSalesThresholdTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold Two [Member]</link:label>
    <link:label id="lab_espr_NetSalesThresholdTwoMember_documentation_en-US" xlink:label="lab_espr_NetSalesThresholdTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Sales Threshold Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdTwoMember" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_NetSalesThresholdTwoMember" xlink:to="lab_espr_NetSalesThresholdTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_CardiovascularRiskMember_efb85c97-d39c-4c00-a11c-d7c545696495_terseLabel_en-US" xlink:label="lab_espr_CardiovascularRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular Risk</link:label>
    <link:label id="lab_espr_CardiovascularRiskMember_label_en-US" xlink:label="lab_espr_CardiovascularRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular Risk [Member]</link:label>
    <link:label id="lab_espr_CardiovascularRiskMember_documentation_en-US" xlink:label="lab_espr_CardiovascularRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CardiovascularRiskMember" xlink:href="espr-20230331.xsd#espr_CardiovascularRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_CardiovascularRiskMember" xlink:to="lab_espr_CardiovascularRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_0bb92d8d-ed3f-4031-a21d-3a9b35531a7c_terseLabel_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021</link:label>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_label_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate</link:label>
    <link:label id="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_documentation_en-US" xlink:label="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:href="espr-20230331.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:to="lab_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_espr_WarrantAmendmentAgreementsMember_fc07dd04-10e4-44f1-b8ce-b9e92f7675bc_terseLabel_en-US" xlink:label="lab_espr_WarrantAmendmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Amendment Agreements</link:label>
    <link:label id="lab_espr_WarrantAmendmentAgreementsMember_label_en-US" xlink:label="lab_espr_WarrantAmendmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Amendment Agreements [Member]</link:label>
    <link:label id="lab_espr_WarrantAmendmentAgreementsMember_documentation_en-US" xlink:label="lab_espr_WarrantAmendmentAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Amendment Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WarrantAmendmentAgreementsMember" xlink:href="espr-20230331.xsd#espr_WarrantAmendmentAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_espr_WarrantAmendmentAgreementsMember" xlink:to="lab_espr_WarrantAmendmentAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_6abd0c99-8836-4a62-8fa2-e23e41a22e3c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Company and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>espr-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7abd0a45-1af4-4bbb-ab52-3d00de73fc2d,g:05387136-6cd8-4464-bd5b-5fa183ea52d1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.esperion.com/role/CoverPage" xlink:type="simple" xlink:href="espr-20230331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7d214dee-2d81-4ec6-b223-0ecda7f30514" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_DocumentType_7d214dee-2d81-4ec6-b223-0ecda7f30514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_2fd3cb46-a0f5-4d71-9cb0-cfa46230ec6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_DocumentQuarterlyReport_2fd3cb46-a0f5-4d71-9cb0-cfa46230ec6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e92086a1-2e66-4678-b69c-05510ebd2f35" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_DocumentPeriodEndDate_e92086a1-2e66-4678-b69c-05510ebd2f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c0b36a52-84df-4dc0-bc8e-bf5670a024cb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_DocumentTransitionReport_c0b36a52-84df-4dc0-bc8e-bf5670a024cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fef66193-d1e6-4e33-9217-5c216bab0304" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityFileNumber_fef66193-d1e6-4e33-9217-5c216bab0304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4f9ec63b-397e-4835-871a-f367aac04002" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityRegistrantName_4f9ec63b-397e-4835-871a-f367aac04002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_863c4f43-242a-4d91-98fc-1287e829a924" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_863c4f43-242a-4d91-98fc-1287e829a924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_b1997613-aa7c-4684-a3ae-cb3d5b6bcd56" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityTaxIdentificationNumber_b1997613-aa7c-4684-a3ae-cb3d5b6bcd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_28f3f57c-350e-4c8a-9147-022445f311c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityAddressAddressLine1_28f3f57c-350e-4c8a-9147-022445f311c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_ee7fa097-65dc-4e9a-84ac-fa36764cf3d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityAddressCityOrTown_ee7fa097-65dc-4e9a-84ac-fa36764cf3d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e4eda9e5-2166-42fb-bf2f-0550c66f88ce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityAddressStateOrProvince_e4eda9e5-2166-42fb-bf2f-0550c66f88ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f73f1a9f-71f4-44b6-a01c-6633bda1d337" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityAddressPostalZipCode_f73f1a9f-71f4-44b6-a01c-6633bda1d337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_71229680-50d5-40f7-82fa-97ceb6f6be74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_CityAreaCode_71229680-50d5-40f7-82fa-97ceb6f6be74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_f3a195e7-fe81-4fc3-a11e-728c1604c857" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_LocalPhoneNumber_f3a195e7-fe81-4fc3-a11e-728c1604c857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_08e112a3-fea0-4fb9-81ff-80df5b142fcd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_Security12bTitle_08e112a3-fea0-4fb9-81ff-80df5b142fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_c4846444-83a9-4e66-a122-2bb9dbe42eba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_TradingSymbol_c4846444-83a9-4e66-a122-2bb9dbe42eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_8b0f4e76-eafa-4aba-8edb-ddddeeee955d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_SecurityExchangeName_8b0f4e76-eafa-4aba-8edb-ddddeeee955d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a49b230b-50bc-48f2-b9bc-7f7013a2d941" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityCurrentReportingStatus_a49b230b-50bc-48f2-b9bc-7f7013a2d941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_32cecf9e-dd24-40a3-9a6e-a0999f8db244" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityInteractiveDataCurrent_32cecf9e-dd24-40a3-9a6e-a0999f8db244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7775ba61-8e15-466d-8433-234501b1524c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntitySmallBusiness_7775ba61-8e15-466d-8433-234501b1524c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_adc5989b-4a0c-4e93-bf18-814936902a13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityEmergingGrowthCompany_adc5989b-4a0c-4e93-bf18-814936902a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9b49bbda-7e60-4109-8319-a197948bebab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityShellCompany_9b49bbda-7e60-4109-8319-a197948bebab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_dca0efe2-8e74-4a16-864a-956bf8da8911" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_dca0efe2-8e74-4a16-864a-956bf8da8911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f1a6375b-1a6d-4335-803d-55890ec433ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityCentralIndexKey_f1a6375b-1a6d-4335-803d-55890ec433ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cf2a30fa-44b4-4411-89c3-77086bc72b20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_CurrentFiscalYearEndDate_cf2a30fa-44b4-4411-89c3-77086bc72b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_7189ffa1-9cf4-481c-ad15-b8c5ee7cbe9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_DocumentFiscalYearFocus_7189ffa1-9cf4-481c-ad15-b8c5ee7cbe9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_9e79f023-6f3e-4dfa-bb8d-85800f7aa3bc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_9e79f023-6f3e-4dfa-bb8d-85800f7aa3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e18e91bb-0cab-4194-b487-f7115fa94822" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_AmendmentFlag_e18e91bb-0cab-4194-b487-f7115fa94822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_953729c7-697f-443b-911b-46711ad15f95" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_afb92a72-e6fc-46b6-90ee-3ab1f31622b0" xlink:to="loc_dei_EntityFilerCategory_953729c7-697f-443b-911b-46711ad15f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedBalanceSheets" xlink:type="simple" xlink:href="espr-20230331.xsd#CondensedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CondensedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_162282db-47b5-4ae8-9808-82dcec077c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_c2111ebb-cb00-46de-9e80-883c869efa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_162282db-47b5-4ae8-9808-82dcec077c95" xlink:to="loc_us-gaap_AssetsAbstract_c2111ebb-cb00-46de-9e80-883c869efa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7605609d-e4ff-4bde-ab88-57796d9af29b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c2111ebb-cb00-46de-9e80-883c869efa6b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7605609d-e4ff-4bde-ab88-57796d9af29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_216ef244-5438-481c-a943-456a5a9481a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7605609d-e4ff-4bde-ab88-57796d9af29b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_216ef244-5438-481c-a943-456a5a9481a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_b56b8cb5-dc02-4f22-92fc-af8a55670da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7605609d-e4ff-4bde-ab88-57796d9af29b" xlink:to="loc_us-gaap_ShortTermInvestments_b56b8cb5-dc02-4f22-92fc-af8a55670da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2adefd11-af05-4248-bdaf-de437663b787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7605609d-e4ff-4bde-ab88-57796d9af29b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2adefd11-af05-4248-bdaf-de437663b787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PrepaidClinicalDevelopmentCostsCurrent_e21c0355-b4a1-4f55-bbf9-9d24e1d697b4" xlink:href="espr-20230331.xsd#espr_PrepaidClinicalDevelopmentCostsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7605609d-e4ff-4bde-ab88-57796d9af29b" xlink:to="loc_espr_PrepaidClinicalDevelopmentCostsCurrent_e21c0355-b4a1-4f55-bbf9-9d24e1d697b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d7e33c1d-3631-4019-bf6f-25ee4f79d1a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7605609d-e4ff-4bde-ab88-57796d9af29b" xlink:to="loc_us-gaap_InventoryNet_d7e33c1d-3631-4019-bf6f-25ee4f79d1a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e347f61e-c8a8-4514-a2a3-909200b0e5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7605609d-e4ff-4bde-ab88-57796d9af29b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_e347f61e-c8a8-4514-a2a3-909200b0e5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_838c96b9-6668-4cd1-8870-11c70e52d01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7605609d-e4ff-4bde-ab88-57796d9af29b" xlink:to="loc_us-gaap_AssetsCurrent_838c96b9-6668-4cd1-8870-11c70e52d01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15e417dc-2268-46b3-a3d0-1b70a6a58d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c2111ebb-cb00-46de-9e80-883c869efa6b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15e417dc-2268-46b3-a3d0-1b70a6a58d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_29e03d9d-ae24-471c-855c-19dd5c7d6daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c2111ebb-cb00-46de-9e80-883c869efa6b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_29e03d9d-ae24-471c-855c-19dd5c7d6daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_229f4526-031e-4990-9a9b-4cc4a5df8291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c2111ebb-cb00-46de-9e80-883c869efa6b" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_229f4526-031e-4990-9a9b-4cc4a5df8291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5b255cb4-24f6-4648-9297-1c91682d680e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_c2111ebb-cb00-46de-9e80-883c869efa6b" xlink:to="loc_us-gaap_Assets_5b255cb4-24f6-4648-9297-1c91682d680e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61e397b2-9ad7-4af8-89f4-4d4cda036f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_162282db-47b5-4ae8-9808-82dcec077c95" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61e397b2-9ad7-4af8-89f4-4d4cda036f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4a73f8b0-fc02-4ca7-949a-8251e08d4799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61e397b2-9ad7-4af8-89f4-4d4cda036f20" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4a73f8b0-fc02-4ca7-949a-8251e08d4799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_430f101c-060c-4b1b-8a6e-5a26f9f13acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4a73f8b0-fc02-4ca7-949a-8251e08d4799" xlink:to="loc_us-gaap_AccountsPayableCurrent_430f101c-060c-4b1b-8a6e-5a26f9f13acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedClinicalDevelopmentCostsCurrent_82883ebb-9019-4ff3-8c3f-84c98b3dc432" xlink:href="espr-20230331.xsd#espr_AccruedClinicalDevelopmentCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4a73f8b0-fc02-4ca7-949a-8251e08d4799" xlink:to="loc_espr_AccruedClinicalDevelopmentCostsCurrent_82883ebb-9019-4ff3-8c3f-84c98b3dc432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_e150e527-b430-4dac-ba7a-6a63873a82eb" xlink:href="espr-20230331.xsd#espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4a73f8b0-fc02-4ca7-949a-8251e08d4799" xlink:to="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_e150e527-b430-4dac-ba7a-6a63873a82eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityCurrent_975054e3-8462-4353-8608-e39957e7bb46" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4a73f8b0-fc02-4ca7-949a-8251e08d4799" xlink:to="loc_espr_RevenueInterestLiabilityCurrent_975054e3-8462-4353-8608-e39957e7bb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d9d32e36-c61b-4fce-a556-ad2c831fc5ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4a73f8b0-fc02-4ca7-949a-8251e08d4799" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d9d32e36-c61b-4fce-a556-ad2c831fc5ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_81f2c83f-e163-4406-9f5c-c3da49dea3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4a73f8b0-fc02-4ca7-949a-8251e08d4799" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_81f2c83f-e163-4406-9f5c-c3da49dea3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d4eec49e-2363-4968-97cc-d33175414eda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4a73f8b0-fc02-4ca7-949a-8251e08d4799" xlink:to="loc_us-gaap_LiabilitiesCurrent_d4eec49e-2363-4968-97cc-d33175414eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_267a014b-9509-49a0-a9bf-ee78fb0b2006" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61e397b2-9ad7-4af8-89f4-4d4cda036f20" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_267a014b-9509-49a0-a9bf-ee78fb0b2006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityNoncurrent_1c049bc6-bb14-4a48-aaba-38559440b979" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61e397b2-9ad7-4af8-89f4-4d4cda036f20" xlink:to="loc_espr_RevenueInterestLiabilityNoncurrent_1c049bc6-bb14-4a48-aaba-38559440b979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a158563e-baab-442c-973b-7489b8834dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61e397b2-9ad7-4af8-89f4-4d4cda036f20" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a158563e-baab-442c-973b-7489b8834dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fab40060-9a85-410d-88a3-fef0f549395b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61e397b2-9ad7-4af8-89f4-4d4cda036f20" xlink:to="loc_us-gaap_Liabilities_fab40060-9a85-410d-88a3-fef0f549395b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d039cbba-ea33-407e-9a85-f43632045e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61e397b2-9ad7-4af8-89f4-4d4cda036f20" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d039cbba-ea33-407e-9a85-f43632045e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4eb86f3c-4cfd-4c64-a546-007b80deef40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61e397b2-9ad7-4af8-89f4-4d4cda036f20" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4eb86f3c-4cfd-4c64-a546-007b80deef40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a3f5badb-70e5-4533-8d22-ca33412c5f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4eb86f3c-4cfd-4c64-a546-007b80deef40" xlink:to="loc_us-gaap_PreferredStockValue_a3f5badb-70e5-4533-8d22-ca33412c5f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3e88579c-288c-47e6-92cc-97f01593af11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4eb86f3c-4cfd-4c64-a546-007b80deef40" xlink:to="loc_us-gaap_CommonStockValue_3e88579c-288c-47e6-92cc-97f01593af11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_24985741-605d-4ae6-857e-9e1e26ff46db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4eb86f3c-4cfd-4c64-a546-007b80deef40" xlink:to="loc_us-gaap_AdditionalPaidInCapital_24985741-605d-4ae6-857e-9e1e26ff46db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_75fb4c79-b3aa-4aa9-bede-7e2ea8e49916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4eb86f3c-4cfd-4c64-a546-007b80deef40" xlink:to="loc_us-gaap_TreasuryStockValue_75fb4c79-b3aa-4aa9-bede-7e2ea8e49916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8d5c3a21-a93a-42b1-8f31-99fe69b8b44d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4eb86f3c-4cfd-4c64-a546-007b80deef40" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8d5c3a21-a93a-42b1-8f31-99fe69b8b44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_78ef919b-40a2-4af9-b951-e2ec0abdad1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4eb86f3c-4cfd-4c64-a546-007b80deef40" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_78ef919b-40a2-4af9-b951-e2ec0abdad1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd7e4462-840e-4022-885d-570da0d0f3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4eb86f3c-4cfd-4c64-a546-007b80deef40" xlink:to="loc_us-gaap_StockholdersEquity_cd7e4462-840e-4022-885d-570da0d0f3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d79c53e4-6289-48f7-bcb1-228c48850d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_61e397b2-9ad7-4af8-89f4-4d4cda036f20" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_d79c53e4-6289-48f7-bcb1-228c48850d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="espr-20230331.xsd#CondensedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CondensedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_101d9b63-069e-4e0c-a357-86a74a4c118a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_435bdeb9-1b71-48ab-b6fa-953b2d756e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_101d9b63-069e-4e0c-a357-86a74a4c118a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_435bdeb9-1b71-48ab-b6fa-953b2d756e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a4736632-2b9d-4826-b4da-62e1092bb292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_101d9b63-069e-4e0c-a357-86a74a4c118a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a4736632-2b9d-4826-b4da-62e1092bb292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_29f6c677-2293-4ecf-87f1-bc0b033e0964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_101d9b63-069e-4e0c-a357-86a74a4c118a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_29f6c677-2293-4ecf-87f1-bc0b033e0964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_158751ce-53ee-431f-a2dc-f29f9247f18f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_101d9b63-069e-4e0c-a357-86a74a4c118a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_158751ce-53ee-431f-a2dc-f29f9247f18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_211798c9-8b8c-4f3b-b0bc-fd68822854a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_101d9b63-069e-4e0c-a357-86a74a4c118a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_211798c9-8b8c-4f3b-b0bc-fd68822854a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c8f54d56-5930-49ed-90f0-9e9fd8914d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_101d9b63-069e-4e0c-a357-86a74a4c118a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c8f54d56-5930-49ed-90f0-9e9fd8914d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_52c51182-77e1-4395-9ddc-8cbf18dc204a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_101d9b63-069e-4e0c-a357-86a74a4c118a" xlink:to="loc_us-gaap_CommonStockSharesIssued_52c51182-77e1-4395-9ddc-8cbf18dc204a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_69e7c862-674e-4985-8025-22d9dc7c39e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_101d9b63-069e-4e0c-a357-86a74a4c118a" xlink:to="loc_us-gaap_TreasuryStockShares_69e7c862-674e-4985-8025-22d9dc7c39e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="espr-20230331.xsd#CondensedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4b0bb443-b804-471d-b97f-4a4fcae7a9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2e652654-efbb-44d1-81df-8e53ce8f8339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4b0bb443-b804-471d-b97f-4a4fcae7a9ad" xlink:to="loc_us-gaap_StatementTable_2e652654-efbb-44d1-81df-8e53ce8f8339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8cc0d05e-6db0-4d20-8f80-265f1ed7503a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e652654-efbb-44d1-81df-8e53ce8f8339" xlink:to="loc_srt_ProductOrServiceAxis_8cc0d05e-6db0-4d20-8f80-265f1ed7503a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e16505e5-aa99-4d0f-9c2a-e3e3821ff66a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8cc0d05e-6db0-4d20-8f80-265f1ed7503a" xlink:to="loc_srt_ProductsAndServicesDomain_e16505e5-aa99-4d0f-9c2a-e3e3821ff66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_8026c516-39fe-4baf-bd06-eee7f35aedd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e16505e5-aa99-4d0f-9c2a-e3e3821ff66a" xlink:to="loc_us-gaap_ProductMember_8026c516-39fe-4baf-bd06-eee7f35aedd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborationRevenueMember_9dcdae11-5203-46bb-a6df-62655f558de7" xlink:href="espr-20230331.xsd#espr_CollaborationRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e16505e5-aa99-4d0f-9c2a-e3e3821ff66a" xlink:to="loc_espr_CollaborationRevenueMember_9dcdae11-5203-46bb-a6df-62655f558de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e652654-efbb-44d1-81df-8e53ce8f8339" xlink:to="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_4fb15009-9c0f-4568-8f50-351ede88a20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_RevenuesAbstract_4fb15009-9c0f-4568-8f50-351ede88a20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37542ea4-c7cf-446c-86ee-990458e8245f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_4fb15009-9c0f-4568-8f50-351ede88a20f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_37542ea4-c7cf-446c-86ee-990458e8245f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_af8c190d-3fad-4eb6-8d8f-9de8f3945fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_af8c190d-3fad-4eb6-8d8f-9de8f3945fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e16cb32f-6517-4a05-beb4-d8dc156c2ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e16cb32f-6517-4a05-beb4-d8dc156c2ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_69ea7ccb-37d4-424d-aacf-5167f7e32e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_69ea7ccb-37d4-424d-aacf-5167f7e32e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9ea5a7c6-9bcd-472b-a41f-28021616a2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_c6a61ffc-19bf-4802-85ee-50fa92a9576a" xlink:to="loc_us-gaap_OperatingExpenses_9ea5a7c6-9bcd-472b-a41f-28021616a2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e3ea1bea-6c59-4120-9ac9-5d42f0548474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_OperatingIncomeLoss_e3ea1bea-6c59-4120-9ac9-5d42f0548474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a1154d99-87b2-47c2-9562-b525df73eafc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_InterestExpense_a1154d99-87b2-47c2-9562-b525df73eafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0c215154-65d3-4ce5-8211-d8d03584bcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0c215154-65d3-4ce5-8211-d8d03584bcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b793488-c555-49f4-ae2b-1919dd97449c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_NetIncomeLoss_4b793488-c555-49f4-ae2b-1919dd97449c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_128d77ff-d960-45f7-8a0d-cff519af4879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_EarningsPerShareBasic_128d77ff-d960-45f7-8a0d-cff519af4879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1e71abeb-3c2f-477a-99ca-d4f03c406962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1e71abeb-3c2f-477a-99ca-d4f03c406962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfe71592-7e28-4d54-9920-b122578a5422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_dfe71592-7e28-4d54-9920-b122578a5422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1afe13d-548e-4595-9196-12416a1a8163" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1afe13d-548e-4595-9196-12416a1a8163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3d789959-42e0-4306-b794-586805934437" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3d789959-42e0-4306-b794-586805934437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_522fefbf-7c98-416b-8262-8b4336fe4c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3d789959-42e0-4306-b794-586805934437" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_522fefbf-7c98-416b-8262-8b4336fe4c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fc0029b5-c586-475a-9e08-4701be719b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b188f486-9897-4d35-9116-6bf68200de0b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_fc0029b5-c586-475a-9e08-4701be719b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" xlink:type="simple" xlink:href="espr-20230331.xsd#CondensedStatementsofStockholdersDeficit"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_197d0068-6d9e-4246-9b37-835dc873bc1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_74d3f5ef-27c7-438f-83ce-99a39261adb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_197d0068-6d9e-4246-9b37-835dc873bc1d" xlink:to="loc_us-gaap_StatementTable_74d3f5ef-27c7-438f-83ce-99a39261adb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9423d450-062a-4860-8a5c-64481b98f543" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_74d3f5ef-27c7-438f-83ce-99a39261adb3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9423d450-062a-4860-8a5c-64481b98f543" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9423d450-062a-4860-8a5c-64481b98f543" xlink:to="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_422300ac-cd29-47ad-9444-fc86359ca2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:to="loc_us-gaap_CommonStockMember_422300ac-cd29-47ad-9444-fc86359ca2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d2f19b23-5371-495b-a6f2-a5475d40f32a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d2f19b23-5371-495b-a6f2-a5475d40f32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_dc1c594e-cd02-4324-9619-6999339cba7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:to="loc_us-gaap_RetainedEarningsMember_dc1c594e-cd02-4324-9619-6999339cba7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_29db93bd-082f-49fa-b2b7-5177ce643aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_29db93bd-082f-49fa-b2b7-5177ce643aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_ec70435c-f03f-459c-bd10-b1371d4349da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_01e6e977-44b7-48ef-8aa6-e37d2de7bbed" xlink:to="loc_us-gaap_TreasuryStockMember_ec70435c-f03f-459c-bd10-b1371d4349da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5ad1769d-9dfa-45c2-81cc-b434948fd17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_74d3f5ef-27c7-438f-83ce-99a39261adb3" xlink:to="loc_us-gaap_StatementLineItems_5ad1769d-9dfa-45c2-81cc-b434948fd17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5ad1769d-9dfa-45c2-81cc-b434948fd17c" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_e1b98203-80f3-4bc5-b162-168b89bd5a97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_SharesOutstanding_e1b98203-80f3-4bc5-b162-168b89bd5a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f0e906c1-3589-4b60-9c37-d48c78a93af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockholdersEquity_f0e906c1-3589-4b60-9c37-d48c78a93af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ac00e5c1-16c9-4c56-a4fa-9a8d6750a4ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_ac00e5c1-16c9-4c56-a4fa-9a8d6750a4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5381a01e-e21f-4603-b06d-f3a3015e0b19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5381a01e-e21f-4603-b06d-f3a3015e0b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5b0afa5f-6302-411d-b1b6-e9a25a7bff12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5b0afa5f-6302-411d-b1b6-e9a25a7bff12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0a6fd6c3-00e1-44c8-9e93-e15050677136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0a6fd6c3-00e1-44c8-9e93-e15050677136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e3cdcfe8-c3cd-4b92-9f7a-7053a6e58f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_e3cdcfe8-c3cd-4b92-9f7a-7053a6e58f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c833b2ac-569c-4733-b7a0-cce3e6947b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_c833b2ac-569c-4733-b7a0-cce3e6947b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_94876de3-0a23-48c2-9b58-a33431905e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_94876de3-0a23-48c2-9b58-a33431905e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ef55c10-a0ac-412a-bc3c-dc6ed53cfee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_NetIncomeLoss_0ef55c10-a0ac-412a-bc3c-dc6ed53cfee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a4a08a72-bf9c-4927-9f18-86cd59041ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_SharesOutstanding_a4a08a72-bf9c-4927-9f18-86cd59041ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ac7378d4-f93c-43c3-81bf-a209b21b8f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03b0635d-1af9-45ff-a4e0-464b374f07cb" xlink:to="loc_us-gaap_StockholdersEquity_ac7378d4-f93c-43c3-81bf-a209b21b8f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CondensedStatementsofCashFlows" xlink:type="simple" xlink:href="espr-20230331.xsd#CondensedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CondensedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_760b4239-a13e-42f2-ac8f-c3d111834210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d326a889-0f2e-4feb-adb2-30e7c66a2ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_760b4239-a13e-42f2-ac8f-c3d111834210" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d326a889-0f2e-4feb-adb2-30e7c66a2ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4ebb227a-a292-46b1-9251-c5b0e0db3a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d326a889-0f2e-4feb-adb2-30e7c66a2ca2" xlink:to="loc_us-gaap_NetIncomeLoss_4ebb227a-a292-46b1-9251-c5b0e0db3a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7132827-4c0f-4e6b-a50d-7245f082a89a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d326a889-0f2e-4feb-adb2-30e7c66a2ca2" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7132827-4c0f-4e6b-a50d-7245f082a89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_fb6412dd-9a74-4422-ac4f-dcb7f782b02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7132827-4c0f-4e6b-a50d-7245f082a89a" xlink:to="loc_us-gaap_Depreciation_fb6412dd-9a74-4422-ac4f-dcb7f782b02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2554b1a5-1dc8-45a5-ae96-99464d69ee2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7132827-4c0f-4e6b-a50d-7245f082a89a" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2554b1a5-1dc8-45a5-ae96-99464d69ee2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a421cef1-5888-462f-a798-7e8823252d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7132827-4c0f-4e6b-a50d-7245f082a89a" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a421cef1-5888-462f-a798-7e8823252d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_e721d088-dc77-45d3-a59b-99cb8641cd9c" xlink:href="espr-20230331.xsd#espr_NonCashInterestExpenseRelatedToRevenueInterestLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7132827-4c0f-4e6b-a50d-7245f082a89a" xlink:to="loc_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability_e721d088-dc77-45d3-a59b-99cb8641cd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bde20dfa-6df3-4d95-8752-f180530dc186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7132827-4c0f-4e6b-a50d-7245f082a89a" xlink:to="loc_us-gaap_ShareBasedCompensation_bde20dfa-6df3-4d95-8752-f180530dc186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4f068014-cf2e-4378-bfd0-e73a015d5109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e7132827-4c0f-4e6b-a50d-7245f082a89a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4f068014-cf2e-4378-bfd0-e73a015d5109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4ffe35d2-0ce6-4f17-b751-a8d93b35a5dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4f068014-cf2e-4378-bfd0-e73a015d5109" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4ffe35d2-0ce6-4f17-b751-a8d93b35a5dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fb3e690c-2ebf-412b-965a-a19a75fd321c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4f068014-cf2e-4378-bfd0-e73a015d5109" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fb3e690c-2ebf-412b-965a-a19a75fd321c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d7a74ce4-1b3c-47ad-b822-b9b4352ce7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4f068014-cf2e-4378-bfd0-e73a015d5109" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_d7a74ce4-1b3c-47ad-b822-b9b4352ce7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_13102dcf-76a8-4fef-9450-a7620ea133ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4f068014-cf2e-4378-bfd0-e73a015d5109" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_13102dcf-76a8-4fef-9450-a7620ea133ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ce3998a8-a9cb-4bfb-8238-b60176aa3e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4f068014-cf2e-4378-bfd0-e73a015d5109" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ce3998a8-a9cb-4bfb-8238-b60176aa3e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_ca176caa-4c6b-4b39-a7c3-6bd01ac8ba97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4f068014-cf2e-4378-bfd0-e73a015d5109" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_ca176caa-4c6b-4b39-a7c3-6bd01ac8ba97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_40011040-43ff-4f6d-a96c-ce488189d9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d326a889-0f2e-4feb-adb2-30e7c66a2ca2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_40011040-43ff-4f6d-a96c-ce488189d9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f93502b1-8f8f-4423-afe2-6e2e422a01bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_760b4239-a13e-42f2-ac8f-c3d111834210" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f93502b1-8f8f-4423-afe2-6e2e422a01bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_95620cbc-fcfa-46c8-a2d3-0e5de47ca13b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f93502b1-8f8f-4423-afe2-6e2e422a01bb" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_95620cbc-fcfa-46c8-a2d3-0e5de47ca13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5ea84df0-62ad-452a-ace8-7de30a070505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f93502b1-8f8f-4423-afe2-6e2e422a01bb" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_5ea84df0-62ad-452a-ace8-7de30a070505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54ae1426-e630-45d2-beae-da904af8ce7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_f93502b1-8f8f-4423-afe2-6e2e422a01bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54ae1426-e630-45d2-beae-da904af8ce7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66c569fd-65ba-46b9-aa70-84a47c1bf15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_760b4239-a13e-42f2-ac8f-c3d111834210" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66c569fd-65ba-46b9-aa70-84a47c1bf15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_18c29481-732f-4979-9336-54e3f3f095e3" xlink:href="espr-20230331.xsd#espr_PaymentsFromRevenueInterestPurchaseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66c569fd-65ba-46b9-aa70-84a47c1bf15c" xlink:to="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_18c29481-732f-4979-9336-54e3f3f095e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a5a109dd-6e90-452a-9928-818cfdc9312b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66c569fd-65ba-46b9-aa70-84a47c1bf15c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_a5a109dd-6e90-452a-9928-818cfdc9312b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_abedd644-80dc-4b85-b1c8-a182f98737f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66c569fd-65ba-46b9-aa70-84a47c1bf15c" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_abedd644-80dc-4b85-b1c8-a182f98737f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e2022794-d2a8-49f7-9a09-9a9c4da30a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_66c569fd-65ba-46b9-aa70-84a47c1bf15c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e2022794-d2a8-49f7-9a09-9a9c4da30a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_714d55ad-ed7e-4390-8f8e-59c44e640b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_760b4239-a13e-42f2-ac8f-c3d111834210" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_714d55ad-ed7e-4390-8f8e-59c44e640b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_09576a87-f4a4-46ac-b8b4-b5f29553f307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_760b4239-a13e-42f2-ac8f-c3d111834210" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_09576a87-f4a4-46ac-b8b4-b5f29553f307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2276890b-9fb9-416e-a42a-65a9d3d8f91d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_760b4239-a13e-42f2-ac8f-c3d111834210" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2276890b-9fb9-416e-a42a-65a9d3d8f91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_12c4f180-9324-43ee-b47d-9b43a8371f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_760b4239-a13e-42f2-ac8f-c3d111834210" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_12c4f180-9324-43ee-b47d-9b43a8371f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockIssuanceCostsIncurredNotYetPaid_cdbb7adb-1433-485e-ad84-9c7236be954f" xlink:href="espr-20230331.xsd#espr_CommonStockIssuanceCostsIncurredNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_12c4f180-9324-43ee-b47d-9b43a8371f1d" xlink:to="loc_espr_CommonStockIssuanceCostsIncurredNotYetPaid_cdbb7adb-1433-485e-ad84-9c7236be954f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NonCashRightOfUseAsset_120410c9-6a86-47e2-9b77-bd5567dedd9e" xlink:href="espr-20230331.xsd#espr_NonCashRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_12c4f180-9324-43ee-b47d-9b43a8371f1d" xlink:to="loc_espr_NonCashRightOfUseAsset_120410c9-6a86-47e2-9b77-bd5567dedd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/TheCompanyandBasisofPresentation" xlink:type="simple" xlink:href="espr-20230331.xsd#TheCompanyandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/TheCompanyandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_576b66d1-9dce-473a-af37-1e8feba3d4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7cfc1ac7-ff3b-4691-849c-cc4523add905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_576b66d1-9dce-473a-af37-1e8feba3d4d9" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_7cfc1ac7-ff3b-4691-849c-cc4523add905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="espr-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6e845446-b819-4ebe-a3c7-aecc0e0f4084" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0ded7084-d3bd-4d27-805a-a07a950d2e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6e845446-b819-4ebe-a3c7-aecc0e0f4084" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_0ded7084-d3bd-4d27-805a-a07a950d2e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CollaborationswithThirdParties" xlink:type="simple" xlink:href="espr-20230331.xsd#CollaborationswithThirdParties"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CollaborationswithThirdParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementAbstract_e5236b12-44aa-43b3-825e-1e6a1fc29849" xlink:href="espr-20230331.xsd#espr_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_171f2a97-4c81-414d-a5cc-77607b7ae747" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_CollaborativeArrangementAbstract_e5236b12-44aa-43b3-825e-1e6a1fc29849" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_171f2a97-4c81-414d-a5cc-77607b7ae747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/Inventoriesnet" xlink:type="simple" xlink:href="espr-20230331.xsd#Inventoriesnet"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/Inventoriesnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b86288e8-4829-403f-b3dd-9f2821ded57f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_5840ff2a-7446-47d4-ba70-17203700d3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b86288e8-4829-403f-b3dd-9f2821ded57f" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_5840ff2a-7446-47d4-ba70-17203700d3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="espr-20230331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b86d292a-2195-4ff0-b2ca-3582687e2137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a09dafe7-2ea9-48a3-8009-03fb9abba37c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b86d292a-2195-4ff0-b2ca-3582687e2137" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a09dafe7-2ea9-48a3-8009-03fb9abba37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/Investments" xlink:type="simple" xlink:href="espr-20230331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9f3d3297-f286-4e78-94fb-5ef7a7d50ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_731c7152-f487-44a9-b7ce-f6e13cf5e453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9f3d3297-f286-4e78-94fb-5ef7a7d50ee0" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_731c7152-f487-44a9-b7ce-f6e13cf5e453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="espr-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ceaff50b-315e-4326-a767-6068c30cca01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_ef1504e5-4d1a-4ef3-a782-867f7aa6d06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ceaff50b-315e-4326-a767-6068c30cca01" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_ef1504e5-4d1a-4ef3-a782-867f7aa6d06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement" xlink:type="simple" xlink:href="espr-20230331.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreement"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_4a736190-62de-4ed5-b5aa-27e903ff98c2" xlink:href="espr-20230331.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock_c55119b1-d257-41ca-84fb-1e565b8e2706" xlink:href="espr-20230331.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_4a736190-62de-4ed5-b5aa-27e903ff98c2" xlink:to="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock_c55119b1-d257-41ca-84fb-1e565b8e2706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/ConvertibleNotes" xlink:type="simple" xlink:href="espr-20230331.xsd#ConvertibleNotes"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/ConvertibleNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_229c2adb-94ba-485e-9ce8-13bc1a51490d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_fa6a9d55-6002-423f-9a57-1a71c114be65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_229c2adb-94ba-485e-9ce8-13bc1a51490d" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_fa6a9d55-6002-423f-9a57-1a71c114be65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/OtherAccruedLiabilities" xlink:type="simple" xlink:href="espr-20230331.xsd#OtherAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/OtherAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_69365ac1-936d-4722-94a6-f3479433552a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_e42c120c-0e39-4ca0-b055-8d4ba394c932" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_69365ac1-936d-4722-94a6-f3479433552a" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_e42c120c-0e39-4ca0-b055-8d4ba394c932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensation" xlink:type="simple" xlink:href="espr-20230331.xsd#StockCompensation"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e58671ea-3721-4ed5-8c8b-ba4e16a43609" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4f7b18b6-ad31-4b8b-9b10-e17743a2702d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e58671ea-3721-4ed5-8c8b-ba4e16a43609" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4f7b18b6-ad31-4b8b-9b10-e17743a2702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/IncomeTaxes" xlink:type="simple" xlink:href="espr-20230331.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4a07d4b4-1bbd-4749-a3d8-e296db5d4d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_704facc3-ac31-4950-afe1-37ea99821da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4a07d4b4-1bbd-4749-a3d8-e296db5d4d8b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_704facc3-ac31-4950-afe1-37ea99821da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockholdersDeficit" xlink:type="simple" xlink:href="espr-20230331.xsd#StockholdersDeficit"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_be6259e2-1838-401c-9fe8-08b395047e90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b77b22fa-5ed4-411e-baaa-33f00c499df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_be6259e2-1838-401c-9fe8-08b395047e90" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_b77b22fa-5ed4-411e-baaa-33f00c499df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/NetLossPerCommonShare" xlink:type="simple" xlink:href="espr-20230331.xsd#NetLossPerCommonShare"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/NetLossPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c1d124ad-0f8f-4344-a8bf-dc9314d479b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2878db17-03cf-40ed-bbd0-8b732b87ef5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c1d124ad-0f8f-4344-a8bf-dc9314d479b7" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2878db17-03cf-40ed-bbd0-8b732b87ef5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCash" xlink:type="simple" xlink:href="espr-20230331.xsd#StatementsofCashFlowsandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cf1c22bb-dca1-4e5c-a963-6e1af46dea6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_309394d0-1020-4528-bb8b-79a3c403c5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_cf1c22bb-dca1-4e5c-a963-6e1af46dea6e" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_309394d0-1020-4528-bb8b-79a3c403c5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="espr-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0460ed6d-5bc5-4119-b698-2d8cd3a109c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9a0fb3e9-ea51-4411-8023-0006c50c98bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0460ed6d-5bc5-4119-b698-2d8cd3a109c2" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9a0fb3e9-ea51-4411-8023-0006c50c98bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_700f8b79-f96d-4390-9f7d-85c862685098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0460ed6d-5bc5-4119-b698-2d8cd3a109c2" xlink:to="loc_us-gaap_UseOfEstimates_700f8b79-f96d-4390-9f7d-85c862685098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9b97bbeb-6f1e-4ece-bee2-d9b8d8e21053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0460ed6d-5bc5-4119-b698-2d8cd3a109c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_9b97bbeb-6f1e-4ece-bee2-d9b8d8e21053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_c1099b4f-21b7-495c-8ac8-2c7f01f4f057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0460ed6d-5bc5-4119-b698-2d8cd3a109c2" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_c1099b4f-21b7-495c-8ac8-2c7f01f4f057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_031c7093-6a02-48a6-b239-4995b8611c50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0460ed6d-5bc5-4119-b698-2d8cd3a109c2" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_031c7093-6a02-48a6-b239-4995b8611c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3c1438a1-530b-4e16-ad25-d6727aaa9c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0460ed6d-5bc5-4119-b698-2d8cd3a109c2" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_3c1438a1-530b-4e16-ad25-d6727aaa9c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_7d447eef-dd64-4f3f-b4f0-51bd28d9e04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0460ed6d-5bc5-4119-b698-2d8cd3a109c2" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_7d447eef-dd64-4f3f-b4f0-51bd28d9e04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bd8c7647-72a2-4c0b-afed-1c6cdaf9295d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0460ed6d-5bc5-4119-b698-2d8cd3a109c2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bd8c7647-72a2-4c0b-afed-1c6cdaf9295d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InventoriesnetTables" xlink:type="simple" xlink:href="espr-20230331.xsd#InventoriesnetTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/InventoriesnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_19b09730-46c3-4383-a1b2-c6b4e18de974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9b441d67-ab65-40ca-a507-a5573d095c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_19b09730-46c3-4383-a1b2-c6b4e18de974" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_9b441d67-ab65-40ca-a507-a5573d095c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsTables" xlink:type="simple" xlink:href="espr-20230331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1d8cf34c-eba8-48cb-9dac-79484baa8cef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_861e3460-f6a9-4d01-b68e-314701d00734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1d8cf34c-eba8-48cb-9dac-79484baa8cef" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_861e3460-f6a9-4d01-b68e-314701d00734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="espr-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5d55980c-d2e7-4244-8f89-7823e173eca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4c23e540-1432-404b-a1f4-da93422d48d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5d55980c-d2e7-4244-8f89-7823e173eca7" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4c23e540-1432-404b-a1f4-da93422d48d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables" xlink:type="simple" xlink:href="espr-20230331.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_32ff87b1-8144-4a32-9fc3-b988e105bb0b" xlink:href="espr-20230331.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock_833e5f6b-d384-4530-b5f9-d481072e8a11" xlink:href="espr-20230331.xsd#espr_ScheduleOfRevenueInterestLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_32ff87b1-8144-4a32-9fc3-b988e105bb0b" xlink:to="loc_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock_833e5f6b-d384-4530-b5f9-d481072e8a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/OtherAccruedLiabilitiesTables" xlink:type="simple" xlink:href="espr-20230331.xsd#OtherAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/OtherAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_dacfec55-a98a-46c0-a720-5ddd77fd8d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6e1b9e81-4f00-4fcc-9064-85871223a9af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_dacfec55-a98a-46c0-a720-5ddd77fd8d4e" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6e1b9e81-4f00-4fcc-9064-85871223a9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationTables" xlink:type="simple" xlink:href="espr-20230331.xsd#StockCompensationTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a1108e8-1326-4f93-afb9-b8ca62857111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f05c7623-cb4e-470e-bbc0-b348e6987eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a1108e8-1326-4f93-afb9-b8ca62857111" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f05c7623-cb4e-470e-bbc0-b348e6987eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_154d202b-b07e-4f2b-b930-26264b07f4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a1108e8-1326-4f93-afb9-b8ca62857111" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_154d202b-b07e-4f2b-b930-26264b07f4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_4e654f4f-b780-4417-9c79-f077d6ab6914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a1108e8-1326-4f93-afb9-b8ca62857111" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_4e654f4f-b780-4417-9c79-f077d6ab6914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockholdersDeficitTables" xlink:type="simple" xlink:href="espr-20230331.xsd#StockholdersDeficitTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockholdersDeficitTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3ca1bca5-cc02-4ac7-b94c-10d20187b535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock_d95249ba-9c80-480c-a89e-1dde6d617ef8" xlink:href="espr-20230331.xsd#espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3ca1bca5-cc02-4ac7-b94c-10d20187b535" xlink:to="loc_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock_d95249ba-9c80-480c-a89e-1dde6d617ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/NetLossPerCommonShareTables" xlink:type="simple" xlink:href="espr-20230331.xsd#NetLossPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/NetLossPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3e8c9d9e-cee7-4f16-92d0-884983b68aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_48298cc3-9172-4b12-880e-08c0ea2a3049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3e8c9d9e-cee7-4f16-92d0-884983b68aa0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_48298cc3-9172-4b12-880e-08c0ea2a3049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables" xlink:type="simple" xlink:href="espr-20230331.xsd#StatementsofCashFlowsandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_6bf0ce11-1ab7-41e6-a998-43cbf006464b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock_ec4c3c8a-1622-4ad1-8546-418ba9c6d7a8" xlink:href="espr-20230331.xsd#espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_6bf0ce11-1ab7-41e6-a998-43cbf006464b" xlink:to="loc_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock_ec4c3c8a-1622-4ad1-8546-418ba9c6d7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#TheCompanyandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68353c22-da9b-46bc-83c9-5206dcb108f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_282a758b-7f18-446a-8402-ef24c2b85321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68353c22-da9b-46bc-83c9-5206dcb108f1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_282a758b-7f18-446a-8402-ef24c2b85321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1d71cf45-6e18-457f-89b9-4cd3caa05669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_282a758b-7f18-446a-8402-ef24c2b85321" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1d71cf45-6e18-457f-89b9-4cd3caa05669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9183bd23-d816-463a-a618-682b5ce32322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1d71cf45-6e18-457f-89b9-4cd3caa05669" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9183bd23-d816-463a-a618-682b5ce32322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SecuritiesPurchaseAgreementMember_8933733a-3033-432f-8410-accc882dcc4f" xlink:href="espr-20230331.xsd#espr_SecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9183bd23-d816-463a-a618-682b5ce32322" xlink:to="loc_espr_SecuritiesPurchaseAgreementMember_8933733a-3033-432f-8410-accc882dcc4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WarrantAmendmentAgreementsMember_a644daba-20c3-4b66-a256-311954a4dda9" xlink:href="espr-20230331.xsd#espr_WarrantAmendmentAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9183bd23-d816-463a-a618-682b5ce32322" xlink:to="loc_espr_WarrantAmendmentAgreementsMember_a644daba-20c3-4b66-a256-311954a4dda9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9e4c482e-3506-489c-b03f-3fc8fe23f2e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_282a758b-7f18-446a-8402-ef24c2b85321" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9e4c482e-3506-489c-b03f-3fc8fe23f2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c921754f-50fa-4cae-b37b-bfbf920d9cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9e4c482e-3506-489c-b03f-3fc8fe23f2e6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c921754f-50fa-4cae-b37b-bfbf920d9cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockAndAccompanyingWarrantMember_fea418c8-7f1a-4120-bfaa-83f870cdc856" xlink:href="espr-20230331.xsd#espr_CommonStockAndAccompanyingWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c921754f-50fa-4cae-b37b-bfbf920d9cd2" xlink:to="loc_espr_CommonStockAndAccompanyingWarrantMember_fea418c8-7f1a-4120-bfaa-83f870cdc856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PreFundedWarrantAndAccompanyingWarrantMember_f3fde740-c675-4a37-8d8d-5bc9dea6b41d" xlink:href="espr-20230331.xsd#espr_PreFundedWarrantAndAccompanyingWarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c921754f-50fa-4cae-b37b-bfbf920d9cd2" xlink:to="loc_espr_PreFundedWarrantAndAccompanyingWarrantMember_f3fde740-c675-4a37-8d8d-5bc9dea6b41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_282a758b-7f18-446a-8402-ef24c2b85321" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfStudyPatients_08d03986-507d-49f4-ab3a-3d7ff93add64" xlink:href="espr-20230331.xsd#espr_NumberOfStudyPatients"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_espr_NumberOfStudyPatients_08d03986-507d-49f4-ab3a-3d7ff93add64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_38938dee-9649-4695-8bdc-a5a30c66177f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_CommonStockSharesIssued_38938dee-9649-4695-8bdc-a5a30c66177f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2a4e2e37-f4cf-4f7f-a772-ce251089d122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2a4e2e37-f4cf-4f7f-a772-ce251089d122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockPurchasableUnderPrefundedWarrants_bb62ce2e-7cf6-430b-89ab-365aaf2b85f3" xlink:href="espr-20230331.xsd#espr_CommonStockPurchasableUnderPrefundedWarrants"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_espr_CommonStockPurchasableUnderPrefundedWarrants_bb62ce2e-7cf6-430b-89ab-365aaf2b85f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockPurchasableUnderWarrants_8d4ef3a2-93fe-4107-9fc4-9f8e0859d37f" xlink:href="espr-20230331.xsd#espr_CommonStockPurchasableUnderWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_espr_CommonStockPurchasableUnderWarrants_8d4ef3a2-93fe-4107-9fc4-9f8e0859d37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_901c76e6-3b60-482c-870d-a61f50f6b39e" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_901c76e6-3b60-482c-870d-a61f50f6b39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_cbb84374-ab99-4880-be61-0076dd9c5af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_cbb84374-ab99-4880-be61-0076dd9c5af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights_da01b814-c1fa-4424-95cb-468e8c52930d" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights_da01b814-c1fa-4424-95cb-468e8c52930d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7ee6ea81-3811-425c-8080-174132d758cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_7ee6ea81-3811-425c-8080-174132d758cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4ef48bc3-f68a-4f4e-90c7-c3210b42dc29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_4ef48bc3-f68a-4f4e-90c7-c3210b42dc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_4a8cde93-94ff-420b-a866-cdf11a2abf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_34888ce9-9e0b-494c-bfcb-0a4c53efd4c8" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_4a8cde93-94ff-420b-a866-cdf11a2abf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f9d20f21-4981-4fa4-b192-4648696453e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesTable_6d561e02-ff83-4c84-beb0-b50f3a76c00c" xlink:href="espr-20230331.xsd#espr_SignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f9d20f21-4981-4fa4-b192-4648696453e2" xlink:to="loc_espr_SignificantAccountingPoliciesTable_6d561e02-ff83-4c84-beb0-b50f3a76c00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0649d06-7731-4566-acc6-f9b4319abb74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesTable_6d561e02-ff83-4c84-beb0-b50f3a76c00c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0649d06-7731-4566-acc6-f9b4319abb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3daf74a-4bb5-43d1-b30e-c44b544408d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_c0649d06-7731-4566-acc6-f9b4319abb74" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3daf74a-4bb5-43d1-b30e-c44b544408d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAccountsReceivableMember_dc057bb6-3232-4ebc-8e6d-2477f0e12fc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeAccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d3daf74a-4bb5-43d1-b30e-c44b544408d9" xlink:to="loc_us-gaap_TradeAccountsReceivableMember_dc057bb6-3232-4ebc-8e6d-2477f0e12fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fb4e2eb5-c84b-494e-ba70-33fbf99bbdf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesTable_6d561e02-ff83-4c84-beb0-b50f3a76c00c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fb4e2eb5-c84b-494e-ba70-33fbf99bbdf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_280948f8-d86f-4044-8fab-4cf9715456d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fb4e2eb5-c84b-494e-ba70-33fbf99bbdf9" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_280948f8-d86f-4044-8fab-4cf9715456d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_d414076e-ab8e-4221-9acf-d24a5fc11835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_280948f8-d86f-4044-8fab-4cf9715456d4" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_d414076e-ab8e-4221-9acf-d24a5fc11835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9030ff5e-08ab-45f9-a3dc-53a5d7766517" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesTable_6d561e02-ff83-4c84-beb0-b50f3a76c00c" xlink:to="loc_srt_ProductOrServiceAxis_9030ff5e-08ab-45f9-a3dc-53a5d7766517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4ec0033-6b32-4564-bfaa-36a2cd84a3fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9030ff5e-08ab-45f9-a3dc-53a5d7766517" xlink:to="loc_srt_ProductsAndServicesDomain_a4ec0033-6b32-4564-bfaa-36a2cd84a3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_03be7e9c-c652-41b1-91ac-54741d6a90ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4ec0033-6b32-4564-bfaa-36a2cd84a3fe" xlink:to="loc_us-gaap_ProductMember_03be7e9c-c652-41b1-91ac-54741d6a90ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SignificantAccountingPoliciesLineItems_f9522495-2a3d-4acc-bfeb-ce2e5608e67a" xlink:href="espr-20230331.xsd#espr_SignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesTable_6d561e02-ff83-4c84-beb0-b50f3a76c00c" xlink:to="loc_espr_SignificantAccountingPoliciesLineItems_f9522495-2a3d-4acc-bfeb-ce2e5608e67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConcentrationRiskNumberOfMajorCustomers_e96a6ba1-3af8-4b06-beca-4ab193a07e26" xlink:href="espr-20230331.xsd#espr_ConcentrationRiskNumberOfMajorCustomers"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_f9522495-2a3d-4acc-bfeb-ce2e5608e67a" xlink:to="loc_espr_ConcentrationRiskNumberOfMajorCustomers_e96a6ba1-3af8-4b06-beca-4ab193a07e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfSourcesOfRevenue_27f7cff7-0962-4aeb-a543-8f2bc25e52aa" xlink:href="espr-20230331.xsd#espr_NumberOfSourcesOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_f9522495-2a3d-4acc-bfeb-ce2e5608e67a" xlink:to="loc_espr_NumberOfSourcesOfRevenue_27f7cff7-0962-4aeb-a543-8f2bc25e52aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de907c78-0bd1-452d-8c57-80847231d29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_SignificantAccountingPoliciesLineItems_f9522495-2a3d-4acc-bfeb-ce2e5608e67a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_de907c78-0bd1-452d-8c57-80847231d29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#CollaborationswithThirdPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CollaborationswithThirdPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_CollaborativeArrangementAbstract_0964c133-f409-4249-8c6f-63997d0dd7bd" xlink:href="espr-20230331.xsd#espr_CollaborativeArrangementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_CollaborativeArrangementAbstract_0964c133-f409-4249-8c6f-63997d0dd7bd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_aa68f27d-99cc-4388-8886-8723968f1748" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:to="loc_srt_CounterpartyNameAxis_aa68f27d-99cc-4388-8886-8723968f1748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_daffe351-a548-462c-8979-480197b09243" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_aa68f27d-99cc-4388-8886-8723968f1748" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_daffe351-a548-462c-8979-480197b09243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoEuropeGmbhMember_75dda351-d246-47d1-b8a9-8a9f3fe14b5c" xlink:href="espr-20230331.xsd#espr_DaiichiSankyoEuropeGmbhMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_daffe351-a548-462c-8979-480197b09243" xlink:to="loc_espr_DaiichiSankyoEuropeGmbhMember_75dda351-d246-47d1-b8a9-8a9f3fe14b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_OtsukaPharmaceuticalCoLtdMember_e5171c66-abe5-42b1-8ee9-fc2d930b68b3" xlink:href="espr-20230331.xsd#espr_OtsukaPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_daffe351-a548-462c-8979-480197b09243" xlink:to="loc_espr_OtsukaPharmaceuticalCoLtdMember_e5171c66-abe5-42b1-8ee9-fc2d930b68b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoCoLtdMember_e3d1cc24-510f-40de-9bf6-5c2f5216e1ba" xlink:href="espr-20230331.xsd#espr_DaiichiSankyoCoLtdMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_daffe351-a548-462c-8979-480197b09243" xlink:to="loc_espr_DaiichiSankyoCoLtdMember_e3d1cc24-510f-40de-9bf6-5c2f5216e1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_065734a3-3462-4ba8-a561-64d2d4e62127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_065734a3-3462-4ba8-a561-64d2d4e62127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76ee3877-d540-4a31-9b7a-453db3ba339a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_065734a3-3462-4ba8-a561-64d2d4e62127" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76ee3877-d540-4a31-9b7a-453db3ba339a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_d7422f0b-bd0f-461f-960f-6d251c2aa661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76ee3877-d540-4a31-9b7a-453db3ba339a" xlink:to="loc_us-gaap_CollaborativeArrangementMember_d7422f0b-bd0f-461f-960f-6d251c2aa661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ExclusiveDevelopmentalActivitiesMember_cba5890e-6c5e-4602-ae29-85103a09812e" xlink:href="espr-20230331.xsd#espr_ExclusiveDevelopmentalActivitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_76ee3877-d540-4a31-9b7a-453db3ba339a" xlink:to="loc_espr_ExclusiveDevelopmentalActivitiesMember_cba5890e-6c5e-4602-ae29-85103a09812e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_30fe3685-9af8-4b10-a90c-1f0372e2be7e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:to="loc_srt_RangeAxis_30fe3685-9af8-4b10-a90c-1f0372e2be7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5dae5d87-bb60-4517-90b4-9c3aaf262ef1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_30fe3685-9af8-4b10-a90c-1f0372e2be7e" xlink:to="loc_srt_RangeMember_5dae5d87-bb60-4517-90b4-9c3aaf262ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_de9ff825-d593-43a7-b69a-419d52813c36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5dae5d87-bb60-4517-90b4-9c3aaf262ef1" xlink:to="loc_srt_MinimumMember_de9ff825-d593-43a7-b69a-419d52813c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3d5bb4da-8f02-4447-81e4-0634c0a55539" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5dae5d87-bb60-4517-90b4-9c3aaf262ef1" xlink:to="loc_srt_MaximumMember_3d5bb4da-8f02-4447-81e4-0634c0a55539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe0c1a39-d404-44e4-9261-3fe1fe3c20ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:to="loc_srt_ProductOrServiceAxis_fe0c1a39-d404-44e4-9261-3fe1fe3c20ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c39bf6b9-762d-4c52-b82c-21844306b209" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fe0c1a39-d404-44e4-9261-3fe1fe3c20ce" xlink:to="loc_srt_ProductsAndServicesDomain_c39bf6b9-762d-4c52-b82c-21844306b209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember_bf90e0b4-8c47-4779-9bbd-115fec3859af" xlink:href="espr-20230331.xsd#espr_RoyaltyRevenueAndProductSalesBulkTabletsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c39bf6b9-762d-4c52-b82c-21844306b209" xlink:to="loc_espr_RoyaltyRevenueAndProductSalesBulkTabletsMember_bf90e0b4-8c47-4779-9bbd-115fec3859af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_cc21b1e5-d1f9-4daa-ab89-4ebf12ce239c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UpFrontPayment_0129eb59-16eb-4f69-b0a8-dd66cce0c343" xlink:href="espr-20230331.xsd#espr_UpFrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_UpFrontPayment_0129eb59-16eb-4f69-b0a8-dd66cce0c343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales_3090c570-082e-48b4-a4c5-42c215c60139" xlink:href="espr-20230331.xsd#espr_CashPaymentToBeReceivedUponFirstCommercialSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_CashPaymentToBeReceivedUponFirstCommercialSales_3090c570-082e-48b4-a4c5-42c215c60139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization_a057e927-8c81-4400-8ec5-5f97fd01241e" xlink:href="espr-20230331.xsd#espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization_a057e927-8c81-4400-8ec5-5f97fd01241e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_f93e0178-9f92-4d01-b57f-a9f6df7cf2fe" xlink:href="espr-20230331.xsd#espr_PercentageOfRoyaltiesToBeReceivedOnNetSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales_f93e0178-9f92-4d01-b57f-a9f6df7cf2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c2bab203-5472-433e-a193-e9114aeebc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c2bab203-5472-433e-a193-e9114aeebc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_8934be6a-cba9-493b-939b-a118fdffe7d8" xlink:href="espr-20230331.xsd#espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones_8934be6a-cba9-493b-939b-a118fdffe7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_5112cac6-4ae7-476a-94e5-89459479ca95" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory_5112cac6-4ae7-476a-94e5-89459479ca95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_4ecdcea4-532e-4928-8285-68a7443415d7" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory_4ecdcea4-532e-4928-8285-68a7443415d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_b089f9f4-eec0-4be4-b398-de84b9733d52" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies_b089f9f4-eec0-4be4-b398-de84b9733d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FuturePaymentMilestoneSalesMilestones_58eb7cfe-20a1-4927-9c9f-d384a8cdae3f" xlink:href="espr-20230331.xsd#espr_FuturePaymentMilestoneSalesMilestones"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_FuturePaymentMilestoneSalesMilestones_58eb7cfe-20a1-4927-9c9f-d384a8cdae3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FutureUpFrontPayment_9d51d260-706a-4acf-bcb7-e081013ce4e8" xlink:href="espr-20230331.xsd#espr_FutureUpFrontPayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_FutureUpFrontPayment_9d51d260-706a-4acf-bcb7-e081013ce4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_bf9f9c84-f8b8-448b-bea6-19497f03e314" xlink:href="espr-20230331.xsd#espr_CashPaymentToBeReceivedUponCertainCommercialMilestones"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones_bf9f9c84-f8b8-448b-bea6-19497f03e314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DeferredUpFrontPayment_aac72abd-eac1-48be-88eb-7a2b11582d6b" xlink:href="espr-20230331.xsd#espr_DeferredUpFrontPayment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_20c8a222-32ec-47f7-b3a5-cb2c5a0813bb" xlink:to="loc_espr_DeferredUpFrontPayment_aac72abd-eac1-48be-88eb-7a2b11582d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InventoriesnetDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#InventoriesnetDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/InventoriesnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8650d581-885b-4f44-8105-bed499cddd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9f7c7e2b-0f98-4c1e-b9ad-ba6ef92aeb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8650d581-885b-4f44-8105-bed499cddd6e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_9f7c7e2b-0f98-4c1e-b9ad-ba6ef92aeb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_84058829-121b-4858-8bcd-6498c3194536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8650d581-885b-4f44-8105-bed499cddd6e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_84058829-121b-4858-8bcd-6498c3194536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0bf6cb66-0456-4104-b1e4-3fffcdf561ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8650d581-885b-4f44-8105-bed499cddd6e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_0bf6cb66-0456-4104-b1e4-3fffcdf561ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2e081bd3-654f-4a6e-a283-51678c149a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8650d581-885b-4f44-8105-bed499cddd6e" xlink:to="loc_us-gaap_InventoryNet_2e081bd3-654f-4a6e-a283-51678c149a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b6f824e1-f4ab-4424-a07b-d7332b6d47d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_e39b10d4-d54f-49be-8843-6e28586c89cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b6f824e1-f4ab-4424-a07b-d7332b6d47d9" xlink:to="loc_us-gaap_LossContingenciesTable_e39b10d4-d54f-49be-8843-6e28586c89cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TypeOfRiskAxis_9a4b84b9-24ff-4467-8c2d-17518c60a31c" xlink:href="espr-20230331.xsd#espr_TypeOfRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e39b10d4-d54f-49be-8843-6e28586c89cf" xlink:to="loc_espr_TypeOfRiskAxis_9a4b84b9-24ff-4467-8c2d-17518c60a31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TypeOfRiskDomain_ad1937e4-4275-4a0e-a3dd-7b70146334c4" xlink:href="espr-20230331.xsd#espr_TypeOfRiskDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_TypeOfRiskAxis_9a4b84b9-24ff-4467-8c2d-17518c60a31c" xlink:to="loc_espr_TypeOfRiskDomain_ad1937e4-4275-4a0e-a3dd-7b70146334c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CardiovascularRiskMember_bad056d5-577e-4f81-a561-d4c76f5b944d" xlink:href="espr-20230331.xsd#espr_CardiovascularRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_TypeOfRiskDomain_ad1937e4-4275-4a0e-a3dd-7b70146334c4" xlink:to="loc_espr_CardiovascularRiskMember_bad056d5-577e-4f81-a561-d4c76f5b944d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember_7969fc54-5b3c-4913-88cf-37284a9c5953" xlink:href="espr-20230331.xsd#espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_CardiovascularRiskMember_bad056d5-577e-4f81-a561-d4c76f5b944d" xlink:to="loc_espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember_7969fc54-5b3c-4913-88cf-37284a9c5953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember_1ec204a0-dc8e-43ac-80a7-98c52425d91f" xlink:href="espr-20230331.xsd#espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_CardiovascularRiskMember_bad056d5-577e-4f81-a561-d4c76f5b944d" xlink:to="loc_espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember_1ec204a0-dc8e-43ac-80a7-98c52425d91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RelativeRiskMember_ea0ede4e-c935-451d-8541-e053e947b03e" xlink:href="espr-20230331.xsd#espr_RelativeRiskMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_TypeOfRiskDomain_ad1937e4-4275-4a0e-a3dd-7b70146334c4" xlink:to="loc_espr_RelativeRiskMember_ea0ede4e-c935-451d-8541-e053e947b03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_03682b1f-323c-458d-82db-749c14e7d913" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e39b10d4-d54f-49be-8843-6e28586c89cf" xlink:to="loc_srt_RangeAxis_03682b1f-323c-458d-82db-749c14e7d913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_868bf4bf-cfa9-42b5-a627-03e14ac80b37" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_03682b1f-323c-458d-82db-749c14e7d913" xlink:to="loc_srt_RangeMember_868bf4bf-cfa9-42b5-a627-03e14ac80b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_961f69c9-0fe4-418a-b83f-245c659791b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_868bf4bf-cfa9-42b5-a627-03e14ac80b37" xlink:to="loc_srt_MinimumMember_961f69c9-0fe4-418a-b83f-245c659791b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6830f424-4fb4-43de-aebc-63292b85dd46" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_868bf4bf-cfa9-42b5-a627-03e14ac80b37" xlink:to="loc_srt_MaximumMember_6830f424-4fb4-43de-aebc-63292b85dd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_84407f2a-d7e0-4c3f-b0cc-5df80d567186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e39b10d4-d54f-49be-8843-6e28586c89cf" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_84407f2a-d7e0-4c3f-b0cc-5df80d567186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ee7e208d-ce14-4fcd-846f-84fab484755c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_84407f2a-d7e0-4c3f-b0cc-5df80d567186" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ee7e208d-ce14-4fcd-846f-84fab484755c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_bd031dc5-f20c-42b6-9ed5-075044d933c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ee7e208d-ce14-4fcd-846f-84fab484755c" xlink:to="loc_us-gaap_SubsequentEventMember_bd031dc5-f20c-42b6-9ed5-075044d933c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c00ab9f3-9f87-4e3a-acfd-83060a7ba8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_e39b10d4-d54f-49be-8843-6e28586c89cf" xlink:to="loc_us-gaap_LossContingenciesLineItems_c00ab9f3-9f87-4e3a-acfd-83060a7ba8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PotentialProceedsFromPartnerMilestonePayments_88f65fb8-e00d-4f4d-880e-711f60273073" xlink:href="espr-20230331.xsd#espr_PotentialProceedsFromPartnerMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c00ab9f3-9f87-4e3a-acfd-83060a7ba8ef" xlink:to="loc_espr_PotentialProceedsFromPartnerMilestonePayments_88f65fb8-e00d-4f4d-880e-711f60273073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRiskReduction_a46a6912-77a3-440e-a941-37c5296dfa2a" xlink:href="espr-20230331.xsd#espr_PercentageOfRiskReduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c00ab9f3-9f87-4e3a-acfd-83060a7ba8ef" xlink:to="loc_espr_PercentageOfRiskReduction_a46a6912-77a3-440e-a941-37c5296dfa2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4bd14a0f-4b73-4692-9ac0-dc4c178736ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_398c5987-6d54-4d20-8bdf-010e73bb4223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4bd14a0f-4b73-4692-9ac0-dc4c178736ea" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_398c5987-6d54-4d20-8bdf-010e73bb4223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_ffbcd676-9312-4b0f-ad4a-cc2da238a512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_398c5987-6d54-4d20-8bdf-010e73bb4223" xlink:to="loc_us-gaap_FinancialInstrumentAxis_ffbcd676-9312-4b0f-ad4a-cc2da238a512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bf0a567-d156-4a6d-b47a-077339ed0eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_ffbcd676-9312-4b0f-ad4a-cc2da238a512" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bf0a567-d156-4a6d-b47a-077339ed0eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4266ca26-e2ca-44ff-87c2-1560656f5afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bf0a567-d156-4a6d-b47a-077339ed0eea" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4266ca26-e2ca-44ff-87c2-1560656f5afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a0c1c3e8-c1e6-4e5e-97bb-9151ced2a4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bf0a567-d156-4a6d-b47a-077339ed0eea" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a0c1c3e8-c1e6-4e5e-97bb-9151ced2a4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_c0b737e3-f89f-41a7-9f74-79d1345fc98a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0bf0a567-d156-4a6d-b47a-077339ed0eea" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_c0b737e3-f89f-41a7-9f74-79d1345fc98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_94385619-2d42-405e-80e3-59227385d724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_398c5987-6d54-4d20-8bdf-010e73bb4223" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_94385619-2d42-405e-80e3-59227385d724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_52572841-f149-4c3b-abc3-1077f8cc2a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_94385619-2d42-405e-80e3-59227385d724" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_52572841-f149-4c3b-abc3-1077f8cc2a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_c1d59312-acad-4f0e-b245-cdd4d19540c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_52572841-f149-4c3b-abc3-1077f8cc2a37" xlink:to="loc_us-gaap_CashEquivalentsMember_c1d59312-acad-4f0e-b245-cdd4d19540c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_20564f51-f6db-41f1-84fe-41d513cbc53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_52572841-f149-4c3b-abc3-1077f8cc2a37" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_20564f51-f6db-41f1-84fe-41d513cbc53c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_398c5987-6d54-4d20-8bdf-010e73bb4223" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_626c59ae-35d5-4acd-9c03-cf1bcb717067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_626c59ae-35d5-4acd-9c03-cf1bcb717067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6809215b-123e-408a-a326-fe7ebc58922c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6809215b-123e-408a-a326-fe7ebc58922c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4c2004d9-0d96-44d6-ac1e-708d41570526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4c2004d9-0d96-44d6-ac1e-708d41570526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_553d2311-e0ee-4a3f-bbfd-6f23a37e3c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25b3fead-ee9a-426e-af20-4eb7c64e6ea0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_553d2311-e0ee-4a3f-bbfd-6f23a37e3c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8da3225d-fdd2-4938-9332-d9778bfc70de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ebb0eff4-d731-49a9-923b-2235d9c80976" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8da3225d-fdd2-4938-9332-d9778bfc70de" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ebb0eff4-d731-49a9-923b-2235d9c80976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4bb23b69-6a8a-46b8-b035-386b47b69ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ebb0eff4-d731-49a9-923b-2235d9c80976" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4bb23b69-6a8a-46b8-b035-386b47b69ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_91473876-8bde-4a57-9260-76d42ecff409" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4bb23b69-6a8a-46b8-b035-386b47b69ff0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_91473876-8bde-4a57-9260-76d42ecff409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_c35f9343-7ecb-4f14-a1eb-fe9f1259b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_91473876-8bde-4a57-9260-76d42ecff409" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_c35f9343-7ecb-4f14-a1eb-fe9f1259b30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_647a05e2-0901-4cca-a3fa-ae6e4ceb9f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ebb0eff4-d731-49a9-923b-2235d9c80976" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_647a05e2-0901-4cca-a3fa-ae6e4ceb9f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a9f9ae53-bb1b-4534-adcc-c572cedb2d26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_647a05e2-0901-4cca-a3fa-ae6e4ceb9f02" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a9f9ae53-bb1b-4534-adcc-c572cedb2d26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_4efcaf84-49a9-4ef6-a989-2b1455d8ee8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_a9f9ae53-bb1b-4534-adcc-c572cedb2d26" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_4efcaf84-49a9-4ef6-a989-2b1455d8ee8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_ebb0eff4-d731-49a9-923b-2235d9c80976" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_b7c40739-49db-4f49-a039-c090645c6a65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:to="loc_us-gaap_InvestmentIncomeInterest_b7c40739-49db-4f49-a039-c090645c6a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_344e4e46-b6b3-489e-aec2-c16b462b3177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_344e4e46-b6b3-489e-aec2-c16b462b3177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_0dcabc9b-00c8-4d3b-b66d-50b058df6440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_0dcabc9b-00c8-4d3b-b66d-50b058df6440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInvestmentIncomeReceivable_0dd58c65-06eb-4414-8a8e-e62a005c274a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedInvestmentIncomeReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:to="loc_us-gaap_AccruedInvestmentIncomeReceivable_0dd58c65-06eb-4414-8a8e-e62a005c274a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_dada737c-f43c-49b2-ab37-942ddccf9f40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e1e14e48-63b7-4374-92b5-5ea62ddb4a98" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_dada737c-f43c-49b2-ab37-942ddccf9f40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c1d71648-ebbc-455a-aa60-dfc949ce60e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_980c2c9e-542d-460b-a916-c1eef7a9dd6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c1d71648-ebbc-455a-aa60-dfc949ce60e9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_980c2c9e-542d-460b-a916-c1eef7a9dd6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d2c61723-700d-43da-91da-af5319f54109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_980c2c9e-542d-460b-a916-c1eef7a9dd6d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d2c61723-700d-43da-91da-af5319f54109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b35c6971-7f78-4ee8-8ee8-e304acad8905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_d2c61723-700d-43da-91da-af5319f54109" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b35c6971-7f78-4ee8-8ee8-e304acad8905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_d64fc902-a55e-4a73-90da-395bf0f8abdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_b35c6971-7f78-4ee8-8ee8-e304acad8905" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_d64fc902-a55e-4a73-90da-395bf0f8abdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9fcdafed-b9db-488b-818c-5592e58ea6f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_980c2c9e-542d-460b-a916-c1eef7a9dd6d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9fcdafed-b9db-488b-818c-5592e58ea6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9c7d4e-e762-45ca-8c88-246f0647f868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_9fcdafed-b9db-488b-818c-5592e58ea6f9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9c7d4e-e762-45ca-8c88-246f0647f868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9a465e6a-0b69-4f92-ba47-a6936b9fdd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9c7d4e-e762-45ca-8c88-246f0647f868" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9a465e6a-0b69-4f92-ba47-a6936b9fdd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_e524d338-9929-4bfd-beb4-bb9f93941ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9c7d4e-e762-45ca-8c88-246f0647f868" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_e524d338-9929-4bfd-beb4-bb9f93941ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_134c015d-447a-4819-944b-b95d24bc4ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3c9c7d4e-e762-45ca-8c88-246f0647f868" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_134c015d-447a-4819-944b-b95d24bc4ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_941542e2-3742-42a7-8292-165385157434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_980c2c9e-542d-460b-a916-c1eef7a9dd6d" xlink:to="loc_us-gaap_FinancialInstrumentAxis_941542e2-3742-42a7-8292-165385157434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8976f2f3-9630-4df9-af8d-5c4a2c4d2e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_941542e2-3742-42a7-8292-165385157434" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8976f2f3-9630-4df9-af8d-5c4a2c4d2e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a237c033-ed2a-4547-b727-5f0687ade8eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8976f2f3-9630-4df9-af8d-5c4a2c4d2e6c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a237c033-ed2a-4547-b727-5f0687ade8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_d3859b9f-f0ed-4b96-9fab-72f89ee00375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8976f2f3-9630-4df9-af8d-5c4a2c4d2e6c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_d3859b9f-f0ed-4b96-9fab-72f89ee00375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_dfb48db4-dc75-4c18-812b-b3990c712109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8976f2f3-9630-4df9-af8d-5c4a2c4d2e6c" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_dfb48db4-dc75-4c18-812b-b3990c712109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c940f688-2f83-4b45-8960-c95ad886b9db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_980c2c9e-542d-460b-a916-c1eef7a9dd6d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c940f688-2f83-4b45-8960-c95ad886b9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f5e3ccdb-2bf1-40e7-a791-22f643fb9566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c940f688-2f83-4b45-8960-c95ad886b9db" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f5e3ccdb-2bf1-40e7-a791-22f643fb9566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_FairValueMeasurementAssetTransfersBetweenLevels_fcb21d93-0f87-416b-9dcf-16a53e1ff8d6" xlink:href="espr-20230331.xsd#espr_FairValueMeasurementAssetTransfersBetweenLevels"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_c940f688-2f83-4b45-8960-c95ad886b9db" xlink:to="loc_espr_FairValueMeasurementAssetTransfersBetweenLevels_fcb21d93-0f87-416b-9dcf-16a53e1ff8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_822cbaf0-42d5-4b31-9efa-d8ca6ae6373e" xlink:href="espr-20230331.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_a3f705b0-3634-4373-a01a-e761c3287008" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_822cbaf0-42d5-4b31-9efa-d8ca6ae6373e" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_a3f705b0-3634-4373-a01a-e761c3287008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1525316c-8dbb-433c-a64f-d5cf141150d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_a3f705b0-3634-4373-a01a-e761c3287008" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1525316c-8dbb-433c-a64f-d5cf141150d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_109bc29b-963c-4288-aa9d-8be46e995b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1525316c-8dbb-433c-a64f-d5cf141150d6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_109bc29b-963c-4288-aa9d-8be46e995b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementMember_bef9cfa1-ed27-4073-8087-c8d4167567a7" xlink:href="espr-20230331.xsd#espr_RevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_109bc29b-963c-4288-aa9d-8be46e995b6d" xlink:to="loc_espr_RevenueInterestPurchaseAgreementMember_bef9cfa1-ed27-4073-8087-c8d4167567a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_56b88ec8-3af7-4e2b-bb6f-f7065d08c16a" xlink:href="espr-20230331.xsd#espr_RevenueInterestPurchaseAgreementAmendmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_109bc29b-963c-4288-aa9d-8be46e995b6d" xlink:to="loc_espr_RevenueInterestPurchaseAgreementAmendmentMember_56b88ec8-3af7-4e2b-bb6f-f7065d08c16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_d0ccdb08-ac55-484a-acc8-0c8b3e18eb83" xlink:href="espr-20230331.xsd#espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_109bc29b-963c-4288-aa9d-8be46e995b6d" xlink:to="loc_espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember_d0ccdb08-ac55-484a-acc8-0c8b3e18eb83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_517ef87c-a329-4b85-8cbb-28c5a014cade" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_a3f705b0-3634-4373-a01a-e761c3287008" xlink:to="loc_srt_CounterpartyNameAxis_517ef87c-a329-4b85-8cbb-28c5a014cade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97a4471b-2ff2-4771-8348-53f25313ec7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_517ef87c-a329-4b85-8cbb-28c5a014cade" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97a4471b-2ff2-4771-8348-53f25313ec7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EigerIiiSaLlcMember_aebb30d8-7331-468c-8668-4208b3147051" xlink:href="espr-20230331.xsd#espr_EigerIiiSaLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_97a4471b-2ff2-4771-8348-53f25313ec7c" xlink:to="loc_espr_EigerIiiSaLlcMember_aebb30d8-7331-468c-8668-4208b3147051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdAxis_a785b8cd-3e8a-4253-9932-7721f45ae8fa" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_a3f705b0-3634-4373-a01a-e761c3287008" xlink:to="loc_espr_NetSalesThresholdAxis_a785b8cd-3e8a-4253-9932-7721f45ae8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdDomain_5b8338a6-5ab1-40bc-8624-cea075701e6c" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_NetSalesThresholdAxis_a785b8cd-3e8a-4253-9932-7721f45ae8fa" xlink:to="loc_espr_NetSalesThresholdDomain_5b8338a6-5ab1-40bc-8624-cea075701e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdOneMember_218838f6-d6d1-4fca-ad2d-ecb3b458b856" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_NetSalesThresholdDomain_5b8338a6-5ab1-40bc-8624-cea075701e6c" xlink:to="loc_espr_NetSalesThresholdOneMember_218838f6-d6d1-4fca-ad2d-ecb3b458b856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdTwoMember_757b50d9-e461-492f-acfd-3957a2b447b2" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_NetSalesThresholdDomain_5b8338a6-5ab1-40bc-8624-cea075701e6c" xlink:to="loc_espr_NetSalesThresholdTwoMember_757b50d9-e461-492f-acfd-3957a2b447b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_a3f705b0-3634-4373-a01a-e761c3287008" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_9cb3dbf1-ca36-4e90-846f-7faad264558d" xlink:href="espr-20230331.xsd#espr_GrossProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_GrossProceedsFromRevenueInterestPurchaseAgreement_9cb3dbf1-ca36-4e90-846f-7faad264558d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_1e95146c-3471-4951-b24c-8c71500b0a5b" xlink:href="espr-20230331.xsd#espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions_1e95146c-3471-4951-b24c-8c71500b0a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_bd7b654e-7f2a-4bae-967e-70857861641b" xlink:href="espr-20230331.xsd#espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval_bd7b654e-7f2a-4bae-967e-70857861641b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_7461f6ef-af6f-4428-8f5c-99a58000492c" xlink:href="espr-20230331.xsd#espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold_7461f6ef-af6f-4428-8f5c-99a58000492c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_e1f4df9c-3113-44ca-8189-70dadfdbd005" xlink:href="espr-20230331.xsd#espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment_e1f4df9c-3113-44ca-8189-70dadfdbd005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_8b1a49c7-3619-411b-87de-8cd42f5ad3c7" xlink:href="espr-20230331.xsd#espr_ProceedsFromRevenueInterestPurchaseAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_ProceedsFromRevenueInterestPurchaseAgreement_8b1a49c7-3619-411b-87de-8cd42f5ad3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierTwo_edf582e8-1493-49fd-ae6f-db74fd0ce76d" xlink:href="espr-20230331.xsd#espr_RevenueInterestRateTierTwo"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestRateTierTwo_edf582e8-1493-49fd-ae6f-db74fd0ce76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateInitialRate_29652c1b-8a46-46e4-ba02-38b951ae6f2e" xlink:href="espr-20230331.xsd#espr_RevenueInterestRateInitialRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestRateInitialRate_29652c1b-8a46-46e4-ba02-38b951ae6f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_977e3e5d-5bc8-481e-9588-63c43620c97a" xlink:href="espr-20230331.xsd#espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate_977e3e5d-5bc8-481e-9588-63c43620c97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRateTierThree_6f25ee4b-a9a1-4608-a4fb-c9c83a31a5c0" xlink:href="espr-20230331.xsd#espr_RevenueInterestRateTierThree"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestRateTierThree_6f25ee4b-a9a1-4608-a4fb-c9c83a31a5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_13030a1b-9048-4db8-b3b4-ec1a7e38b7f5" xlink:href="espr-20230331.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate_13030a1b-9048-4db8-b3b4-ec1a7e38b7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_9fca1d9a-d83a-456f-8f5b-68c26ed8f7f1" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates_9fca1d9a-d83a-456f-8f5b-68c26ed8f7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_255f1630-9805-4117-b029-8ada9d4f0f21" xlink:href="espr-20230331.xsd#espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_255f1630-9805-4117-b029-8ada9d4f0f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_7f90f710-2812-45d3-a7e5-4c3549a4829f" xlink:href="espr-20230331.xsd#espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold_7f90f710-2812-45d3-a7e5-4c3549a4829f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_bc038c46-29e2-46f1-aebb-92a5d839f636" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage_bc038c46-29e2-46f1-aebb-92a5d839f636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_faff725a-fa51-4b78-8f18-21ec88a6b143" xlink:href="espr-20230331.xsd#espr_PercentageOfCumulativePurchaserPaymentsGuarantee"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfCumulativePurchaserPaymentsGuarantee_faff725a-fa51-4b78-8f18-21ec88a6b143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_2528948d-16c0-41cb-966c-98858bb22514" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised_2528948d-16c0-41cb-966c-98858bb22514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_1ec0d8c2-7dc6-44aa-a022-105fd506d249" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised_1ec0d8c2-7dc6-44aa-a022-105fd506d249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_9475877e-86e1-4dba-ae0f-3feb68438107" xlink:href="espr-20230331.xsd#espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount_9475877e-86e1-4dba-ae0f-3feb68438107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_3f18c77a-0f96-4fde-a493-e120bf7b3e65" xlink:href="espr-20230331.xsd#espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold_3f18c77a-0f96-4fde-a493-e120bf7b3e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_fa544fde-d144-4b8e-af6f-cde457b3b064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_us-gaap_RestrictedCash_fa544fde-d144-4b8e-af6f-cde457b3b064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_OneTimePartialCall_6914bf06-396c-4e46-ae8d-86d1d3948ee2" xlink:href="espr-20230331.xsd#espr_OneTimePartialCall"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_OneTimePartialCall_6914bf06-396c-4e46-ae8d-86d1d3948ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestsPaymentOnWhichAgreementTerminates_94f0d35d-2713-48bf-9bee-f1937f4bbd22" xlink:href="espr-20230331.xsd#espr_RevenueInterestsPaymentOnWhichAgreementTerminates"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestsPaymentOnWhichAgreementTerminates_94f0d35d-2713-48bf-9bee-f1937f4bbd22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_78180844-72b8-4450-b44b-7fd4c3b779ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_78180844-72b8-4450-b44b-7fd4c3b779ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_d1a2fb42-4641-4401-b2ab-42610a71e7e2" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiability"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestLiability_d1a2fb42-4641-4401-b2ab-42610a71e7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_ca3743cb-2c8c-41f7-a3c2-e0e89ef7fe73" xlink:href="espr-20230331.xsd#espr_UnamortizedTransactionCostsOnRevenueInterestAgreement"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement_ca3743cb-2c8c-41f7-a3c2-e0e89ef7fe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPaymentsRedemptionPercentage_3b0a4afd-79f7-47ba-802b-0592ed2bc99f" xlink:href="espr-20230331.xsd#espr_RevenueInterestPaymentsRedemptionPercentage"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestPaymentsRedemptionPercentage_3b0a4afd-79f7-47ba-802b-0592ed2bc99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPaymentsRedemptionValue_75097d41-c5dd-4a0c-bf14-3d803d79018f" xlink:href="espr-20230331.xsd#espr_RevenueInterestPaymentsRedemptionValue"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestPaymentsRedemptionValue_75097d41-c5dd-4a0c-bf14-3d803d79018f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPaymentsRemainingRedemptionValue_9617d5e6-e55a-411c-8160-6fb9cd75d0fc" xlink:href="espr-20230331.xsd#espr_RevenueInterestPaymentsRemainingRedemptionValue"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestPaymentsRemainingRedemptionValue_9617d5e6-e55a-411c-8160-6fb9cd75d0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b9ea361d-e268-4d42-a66f-4260f4988152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_us-gaap_InterestExpense_b9ea361d-e268-4d42-a66f-4260f4988152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary_2a07fc28-3a4a-475a-9fd1-ae7119f3a361" xlink:href="espr-20230331.xsd#espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary_2a07fc28-3a4a-475a-9fd1-ae7119f3a361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalSalesGeneratedAmount_71b2108b-fd6b-481b-8af2-8e63f57026cd" xlink:href="espr-20230331.xsd#espr_HypotheticalSalesGeneratedAmount"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_HypotheticalSalesGeneratedAmount_71b2108b-fd6b-481b-8af2-8e63f57026cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_863c6b0c-e736-4acf-95c8-c934110980d3" xlink:href="espr-20230331.xsd#espr_HypotheticalRepaymentObligationBasedOnSalesGenerated"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated_863c6b0c-e736-4acf-95c8-c934110980d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_f6de699e-db3a-40e2-925e-dc050cbf612b" xlink:href="espr-20230331.xsd#espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory_f6de699e-db3a-40e2-925e-dc050cbf612b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_76467c6e-5728-4ae7-8bb5-2c19bd0ee531" xlink:href="espr-20230331.xsd#espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths_76467c6e-5728-4ae7-8bb5-2c19bd0ee531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_0f2f38cd-6bdc-4dcc-b83d-e31c3590b8fc" xlink:href="espr-20230331.xsd#espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate_0f2f38cd-6bdc-4dcc-b83d-e31c3590b8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_444a91b9-df03-49a6-b2f4-5bf1d128461b" xlink:href="espr-20230331.xsd#espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount_444a91b9-df03-49a6-b2f4-5bf1d128461b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_aed7173c-d952-4c1d-ac7a-1e23a2cc2120" xlink:href="espr-20230331.xsd#espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_d18d4d8d-17bf-4ffd-9743-dc940ad5bccf" xlink:to="loc_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment_aed7173c-d952-4c1d-ac7a-1e23a2cc2120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_1a0f458e-a613-4543-8a97-3c5d67785417" xlink:href="espr-20230331.xsd#espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_f5545cf1-d059-4a73-b6f2-0dd2d71258dc" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract_1a0f458e-a613-4543-8a97-3c5d67785417" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_f5545cf1-d059-4a73-b6f2-0dd2d71258dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3c28ff42-2215-4f84-bb3c-53d4e020912b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_f5545cf1-d059-4a73-b6f2-0dd2d71258dc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3c28ff42-2215-4f84-bb3c-53d4e020912b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8a8996d-0aac-4c40-be5a-801aedf3f2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3c28ff42-2215-4f84-bb3c-53d4e020912b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8a8996d-0aac-4c40-be5a-801aedf3f2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestPurchaseAgreementMember_26e2378a-4b7a-453a-a575-0a5f83a779aa" xlink:href="espr-20230331.xsd#espr_RevenueInterestPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c8a8996d-0aac-4c40-be5a-801aedf3f2e8" xlink:to="loc_espr_RevenueInterestPurchaseAgreementMember_26e2378a-4b7a-453a-a575-0a5f83a779aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_241e3748-4a2e-4240-b392-668993e00690" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesTable_f5545cf1-d059-4a73-b6f2-0dd2d71258dc" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_241e3748-4a2e-4240-b392-668993e00690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_804dbaa2-b0a7-4a62-883e-9cdc3da0e5ba" xlink:href="espr-20230331.xsd#espr_LiabilityFromSaleOfFutureRevenuesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesLineItems_241e3748-4a2e-4240-b392-668993e00690" xlink:to="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_804dbaa2-b0a7-4a62-883e-9cdc3da0e5ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_26d8b37b-da73-47cb-888b-77522bbd75c1" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_804dbaa2-b0a7-4a62-883e-9cdc3da0e5ba" xlink:to="loc_espr_RevenueInterestLiability_26d8b37b-da73-47cb-888b-77522bbd75c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_6be02a9b-0079-4a69-af9a-a422608810ec" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_804dbaa2-b0a7-4a62-883e-9cdc3da0e5ba" xlink:to="loc_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized_6be02a9b-0079-4a69-af9a-a422608810ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_a447aaf8-d42d-45ef-be21-5e30b71203d0" xlink:href="espr-20230331.xsd#espr_PaymentsFromRevenueInterestPurchaseAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_804dbaa2-b0a7-4a62-883e-9cdc3da0e5ba" xlink:to="loc_espr_PaymentsFromRevenueInterestPurchaseAgreement_a447aaf8-d42d-45ef-be21-5e30b71203d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_RevenueInterestLiability_312e2658-2d4c-4700-8bfc-f9fc59ffb931" xlink:href="espr-20230331.xsd#espr_RevenueInterestLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_LiabilityFromSaleOfFutureRevenuesRollForward_804dbaa2-b0a7-4a62-883e-9cdc3da0e5ba" xlink:to="loc_espr_RevenueInterestLiability_312e2658-2d4c-4700-8bfc-f9fc59ffb931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/ConvertibleNotesDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#ConvertibleNotesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/ConvertibleNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8db9812c-5dfa-4d67-9449-5a93bb979885" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8db9812c-5dfa-4d67-9449-5a93bb979885" xlink:to="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ec2186c2-8a4e-4aa8-9a6c-589c8eee70af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_DebtInstrumentAxis_ec2186c2-8a4e-4aa8-9a6c-589c8eee70af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0cb8904a-209a-4113-bd5c-d24a51766043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ec2186c2-8a4e-4aa8-9a6c-589c8eee70af" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0cb8904a-209a-4113-bd5c-d24a51766043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ConvertibleSeniorNotesDue2025Member_6a953ae2-ea2f-40a3-88bd-15080358f403" xlink:href="espr-20230331.xsd#espr_ConvertibleSeniorNotesDue2025Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0cb8904a-209a-4113-bd5c-d24a51766043" xlink:to="loc_espr_ConvertibleSeniorNotesDue2025Member_6a953ae2-ea2f-40a3-88bd-15080358f403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fd6a3d25-b87e-4384-b812-73f62b64dc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fd6a3d25-b87e-4384-b812-73f62b64dc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_f185cb92-a1f9-42a0-9d0a-2fd0dfbcab92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fd6a3d25-b87e-4384-b812-73f62b64dc76" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_f185cb92-a1f9-42a0-9d0a-2fd0dfbcab92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_d3237138-b94b-4685-b88d-c46734393210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_f185cb92-a1f9-42a0-9d0a-2fd0dfbcab92" xlink:to="loc_us-gaap_ConvertibleDebtMember_d3237138-b94b-4685-b88d-c46734393210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_4ce3988b-f197-4a45-9188-a047dd7ea7f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_4ce3988b-f197-4a45-9188-a047dd7ea7f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ac8c07f2-b794-4b4d-905e-c6761816dede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_4ce3988b-f197-4a45-9188-a047dd7ea7f7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ac8c07f2-b794-4b4d-905e-c6761816dede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_230c7611-d4a4-4c15-b689-68aab220f6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_ac8c07f2-b794-4b4d-905e-c6761816dede" xlink:to="loc_us-gaap_ConvertibleDebtMember_230c7611-d4a4-4c15-b689-68aab220f6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bb93c109-5da5-43a9-a31f-5e5d2fe09289" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bb93c109-5da5-43a9-a31f-5e5d2fe09289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9c1c6faa-e5cd-4df3-ae71-7f1d6e2f8f66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_bb93c109-5da5-43a9-a31f-5e5d2fe09289" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9c1c6faa-e5cd-4df3-ae71-7f1d6e2f8f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6cc72565-869b-4ca1-a185-d921f67cbdc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9c1c6faa-e5cd-4df3-ae71-7f1d6e2f8f66" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_6cc72565-869b-4ca1-a185-d921f67cbdc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_16bca17c-f0bd-4198-8af9-3da628e1c5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_9c1c6faa-e5cd-4df3-ae71-7f1d6e2f8f66" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_16bca17c-f0bd-4198-8af9-3da628e1c5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_13f35982-6a01-4e47-9d65-d9422ac9aad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_13f35982-6a01-4e47-9d65-d9422ac9aad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_c5c8c511-4960-42a4-a975-2d65728e6751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13f35982-6a01-4e47-9d65-d9422ac9aad0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_c5c8c511-4960-42a4-a975-2d65728e6751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CappedCallMember_41264e63-f991-45af-b3d0-194788b8499a" xlink:href="espr-20230331.xsd#espr_CappedCallMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_c5c8c511-4960-42a4-a975-2d65728e6751" xlink:to="loc_espr_CappedCallMember_41264e63-f991-45af-b3d0-194788b8499a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9c007e98-98c4-4a5e-8f1a-4ad74383f765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9c007e98-98c4-4a5e-8f1a-4ad74383f765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_449c5823-e353-43f0-9212-aca07a95357f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9c007e98-98c4-4a5e-8f1a-4ad74383f765" xlink:to="loc_us-gaap_ClassOfStockDomain_449c5823-e353-43f0-9212-aca07a95357f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_6fd77df6-6ae4-435e-8304-a2e74f4a847b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_449c5823-e353-43f0-9212-aca07a95357f" xlink:to="loc_us-gaap_CommonClassAMember_6fd77df6-6ae4-435e-8304-a2e74f4a847b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfExpenseAxis_5b8e36b3-7f75-42c5-99e3-d79a7b7485b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfExpenseAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_NatureOfExpenseAxis_5b8e36b3-7f75-42c5-99e3-d79a7b7485b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9e5d62cd-a6aa-4109-bfee-2c1c861f91be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NatureOfExpenseAxis_5b8e36b3-7f75-42c5-99e3-d79a7b7485b0" xlink:to="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9e5d62cd-a6aa-4109-bfee-2c1c861f91be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember_867b906e-99be-4920-a9c0-0618e9a3228d" xlink:href="espr-20230331.xsd#espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterimPeriodCostsNotAllocableDomain_9e5d62cd-a6aa-4109-bfee-2c1c861f91be" xlink:to="loc_espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember_867b906e-99be-4920-a9c0-0618e9a3228d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e92b8d0-94ff-4ace-b5ea-2481fab3fb82" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_425a7d3b-21b5-4565-8de3-fb6c34e2b1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_425a7d3b-21b5-4565-8de3-fb6c34e2b1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_71c0b4e3-cdc6-45e2-a827-33f0bde04499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_71c0b4e3-cdc6-45e2-a827-33f0bde04499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0398fe36-9452-421b-8de6-44a052fb5857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0398fe36-9452-421b-8de6-44a052fb5857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1819d228-4dd4-4c97-a5f2-c8f51a17a31b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1819d228-4dd4-4c97-a5f2-c8f51a17a31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_98821bd7-1fec-47ad-a817-34db6b989efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForDerivativeInstrumentFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities_98821bd7-1fec-47ad-a817-34db6b989efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_49b8062f-c36f-4c0d-b02f-10b855647c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_49b8062f-c36f-4c0d-b02f-10b855647c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_a583d5db-e1c3-45bd-8310-9ddcd2f33727" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_a583d5db-e1c3-45bd-8310-9ddcd2f33727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7160d5b1-6565-4fae-bbc6-2f37fc7d031c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7160d5b1-6565-4fae-bbc6-2f37fc7d031c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ffe1717a-2294-4f23-80d0-3dbc1b449c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ffe1717a-2294-4f23-80d0-3dbc1b449c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_ce2e655e-9980-474d-af4d-517e05f2d2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_ce2e655e-9980-474d-af4d-517e05f2d2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3b62bf48-da5b-4011-a1a5-33d74bdd71a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_3b62bf48-da5b-4011-a1a5-33d74bdd71a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_75e828db-48fa-49c3-a13c-7d9999ddd909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_75e828db-48fa-49c3-a13c-7d9999ddd909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfBusinessDays_05916cd8-0f6b-418a-b38b-82ea42c6bed1" xlink:href="espr-20230331.xsd#espr_NumberOfBusinessDays"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_NumberOfBusinessDays_05916cd8-0f6b-418a-b38b-82ea42c6bed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_NumberOfConsecutiveTradingDays_fb85e2bc-ff93-435f-bb49-85f5959bd0da" xlink:href="espr-20230331.xsd#espr_NumberOfConsecutiveTradingDays"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_NumberOfConsecutiveTradingDays_fb85e2bc-ff93-435f-bb49-85f5959bd0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_bc4517d7-3c61-4df6-9ddb-24978b039ef4" xlink:href="espr-20230331.xsd#espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice_bc4517d7-3c61-4df6-9ddb-24978b039ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d6a2c1cc-ce89-46b6-8e57-e8c00e15cc9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d6a2c1cc-ce89-46b6-8e57-e8c00e15cc9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding_829eca64-4039-4d43-9e50-2724555fea81" xlink:href="espr-20230331.xsd#espr_DebtInstrumentCovenantRequiredAmountOutstanding"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_DebtInstrumentCovenantRequiredAmountOutstanding_829eca64-4039-4d43-9e50-2724555fea81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6414d0cd-a694-4c93-9f6c-5a6dcf15e5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_6414d0cd-a694-4c93-9f6c-5a6dcf15e5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor_c6b46c73-b9fc-4505-bf9a-a31666aa9529" xlink:href="espr-20230331.xsd#espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor_c6b46c73-b9fc-4505-bf9a-a31666aa9529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays_8205d7e3-e9a5-448a-ae55-55430b611224" xlink:href="espr-20230331.xsd#espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays_8205d7e3-e9a5-448a-ae55-55430b611224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_50709a94-7388-4b33-a34c-01396ec0887e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_50709a94-7388-4b33-a34c-01396ec0887e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_1abeb204-4a44-4e54-a9d4-ae4cf71bb37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_1abeb204-4a44-4e54-a9d4-ae4cf71bb37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_ba2bc097-c2a9-4ede-99b1-8724a9e80701" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_ba2bc097-c2a9-4ede-99b1-8724a9e80701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0ba1b6a3-630c-4aea-bda8-d9c37d30e16a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_LongTermDebt_0ba1b6a3-630c-4aea-bda8-d9c37d30e16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_2010f8bd-950f-4b13-ac76-94433bcca5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_InterestExpenseDebt_2010f8bd-950f-4b13-ac76-94433bcca5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_6d8048ed-ac74-4feb-8133-89ebeb89d78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_DebtInstrumentFairValue_6d8048ed-ac74-4feb-8133-89ebeb89d78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72cf172f-a5ca-44e2-beff-c99ea7fa5790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_72cf172f-a5ca-44e2-beff-c99ea7fa5790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_ca81518e-bb09-48a1-a813-57a95ccde289" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage_ca81518e-bb09-48a1-a813-57a95ccde289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7adbbc5c-2dc5-4b55-ac3d-f28c1594d080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7adbbc5c-2dc5-4b55-ac3d-f28c1594d080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_abafb84a-ea42-41f7-8936-20361ae37859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e778208d-3ba0-4fdd-b53a-f65a16c936ff" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_abafb84a-ea42-41f7-8936-20361ae37859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#OtherAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/OtherAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f0a34a49-9bf5-4e5d-a1ce-0123e2109e16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_83f7d52b-8cf9-454a-8de2-a53d185d8212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f0a34a49-9bf5-4e5d-a1ce-0123e2109e16" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_83f7d52b-8cf9-454a-8de2-a53d185d8212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedVariableConsiderationCurrent_21af4ea9-7eb9-4bc5-abbd-a9229f7819a9" xlink:href="espr-20230331.xsd#espr_AccruedVariableConsiderationCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f0a34a49-9bf5-4e5d-a1ce-0123e2109e16" xlink:to="loc_espr_AccruedVariableConsiderationCurrent_21af4ea9-7eb9-4bc5-abbd-a9229f7819a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_625679ee-9f07-4cbd-aeb1-73dd59ee07ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f0a34a49-9bf5-4e5d-a1ce-0123e2109e16" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_625679ee-9f07-4cbd-aeb1-73dd59ee07ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_a34b35bb-cbca-430f-bf24-7d8daecfc0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f0a34a49-9bf5-4e5d-a1ce-0123e2109e16" xlink:to="loc_us-gaap_InterestPayableCurrent_a34b35bb-cbca-430f-bf24-7d8daecfc0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d2761c32-c997-4540-906a-b55f37bd5894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f0a34a49-9bf5-4e5d-a1ce-0123e2109e16" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_d2761c32-c997-4540-906a-b55f37bd5894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_060a051d-004c-441f-acb6-7a3f9b45f36c" xlink:href="espr-20230331.xsd#espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f0a34a49-9bf5-4e5d-a1ce-0123e2109e16" xlink:to="loc_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent_060a051d-004c-441f-acb6-7a3f9b45f36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockCompensationStockOptionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e22718f-cc39-40f1-870c-827c92113ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b9dc3c2-d50a-4ffd-bd39-02cb3d2a2252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0e22718f-cc39-40f1-870c-827c92113ee7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b9dc3c2-d50a-4ffd-bd39-02cb3d2a2252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d858c1b0-223b-4f23-ac87-b9bee4e55a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b9dc3c2-d50a-4ffd-bd39-02cb3d2a2252" xlink:to="loc_us-gaap_AwardTypeAxis_d858c1b0-223b-4f23-ac87-b9bee4e55a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d858c1b0-223b-4f23-ac87-b9bee4e55a95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_68850a5a-5585-41c7-a6fc-f4aa4ffea141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:to="loc_us-gaap_EmployeeStockMember_68850a5a-5585-41c7-a6fc-f4aa4ffea141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4a31d150-6a83-40e5-8df8-604affcb5944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4a31d150-6a83-40e5-8df8-604affcb5944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_060791f5-9fd6-4905-a1ba-16ba6299a16a" xlink:href="espr-20230331.xsd#espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:to="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_060791f5-9fd6-4905-a1ba-16ba6299a16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_aaa30f00-595a-4f90-a326-799c4b1ef980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_aaa30f00-595a-4f90-a326-799c4b1ef980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_c746dc26-a7e3-4454-ab00-46e2574e0e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_430698de-2c60-41ee-ad80-6447ae8cc0f1" xlink:to="loc_us-gaap_PerformanceSharesMember_c746dc26-a7e3-4454-ab00-46e2574e0e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_ab97c127-1f81-4ed8-a02a-40eb721b2106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b9dc3c2-d50a-4ffd-bd39-02cb3d2a2252" xlink:to="loc_us-gaap_PlanNameAxis_ab97c127-1f81-4ed8-a02a-40eb721b2106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_3a191f24-cff4-45d8-98ce-937aae298ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_ab97c127-1f81-4ed8-a02a-40eb721b2106" xlink:to="loc_us-gaap_PlanNameDomain_3a191f24-cff4-45d8-98ce-937aae298ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_StockOptionAndIncentivePlan2022Member_1e45af2f-5a12-4a7e-a1d4-207018deb4c5" xlink:href="espr-20230331.xsd#espr_StockOptionAndIncentivePlan2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_3a191f24-cff4-45d8-98ce-937aae298ac4" xlink:to="loc_espr_StockOptionAndIncentivePlan2022Member_1e45af2f-5a12-4a7e-a1d4-207018deb4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6b9dc3c2-d50a-4ffd-bd39-02cb3d2a2252" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bd1cc0a1-e484-4463-8dbb-f1db05d0644f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bd1cc0a1-e484-4463-8dbb-f1db05d0644f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_0298fd55-eb43-4930-bca4-145707ab7aff" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_0298fd55-eb43-4930-bca4-145707ab7aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_a9ef2713-f896-4604-bd72-70bd05a3913a" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount_a9ef2713-f896-4604-bd72-70bd05a3913a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_421e8266-0f66-4cf0-860b-8c2c691daa5d" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanPercentageDiscountOnShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares_421e8266-0f66-4cf0-860b-8c2c691daa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_62aab540-d5a0-4f47-a410-d112cbe1df80" xlink:href="espr-20230331.xsd#espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod_62aab540-d5a0-4f47-a410-d112cbe1df80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_3789fc93-3fec-4a36-a0ef-e4619bd11e96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_3789fc93-3fec-4a36-a0ef-e4619bd11e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_deca0ded-59e6-4655-8691-444535113480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_deca0ded-59e6-4655-8691-444535113480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bcfdcd0f-e8b7-4553-86b7-04e062c977b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_bcfdcd0f-e8b7-4553-86b7-04e062c977b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a94b32ea-7948-4aa1-9774-75d9a2f43096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_a94b32ea-7948-4aa1-9774-75d9a2f43096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fe710d51-2117-4e77-9e07-a1e9652db893" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_fe710d51-2117-4e77-9e07-a1e9652db893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf48c7c-f262-4fc5-badc-a383e5cabe74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_bdf48c7c-f262-4fc5-badc-a383e5cabe74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8a7547d0-9076-4540-97c7-cc657cd19132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e57735b3-ee70-41ed-96fd-67aa0c14d8d3" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8a7547d0-9076-4540-97c7-cc657cd19132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockCompensationScheduleofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ccfa75-584d-452c-a591-c6ab6590967a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0d3efe-211c-4369-b3a5-55d9b9d8ecb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ccfa75-584d-452c-a591-c6ab6590967a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0d3efe-211c-4369-b3a5-55d9b9d8ecb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8658c130-731d-47c3-9c2e-461944309ac9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0d3efe-211c-4369-b3a5-55d9b9d8ecb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8658c130-731d-47c3-9c2e-461944309ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_acd003f5-4e8d-4b45-8788-b4a078baf78f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0d3efe-211c-4369-b3a5-55d9b9d8ecb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_acd003f5-4e8d-4b45-8788-b4a078baf78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3f88e1ca-b62b-42bf-9ffc-2af0f675e04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0d3efe-211c-4369-b3a5-55d9b9d8ecb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_3f88e1ca-b62b-42bf-9ffc-2af0f675e04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_124051b4-0831-4002-b027-17b5bf00a868" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0d3efe-211c-4369-b3a5-55d9b9d8ecb0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_124051b4-0831-4002-b027-17b5bf00a868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12bcb268-1bab-4022-bc5d-052c85cdc04e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a0d3efe-211c-4369-b3a5-55d9b9d8ecb0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_12bcb268-1bab-4022-bc5d-052c85cdc04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_dd816efc-a623-45d2-8539-c3e8ea26fe7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ccfa75-584d-452c-a591-c6ab6590967a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_dd816efc-a623-45d2-8539-c3e8ea26fe7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_33e3523f-c81a-4b87-aed0-26c9dd0b2ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ccfa75-584d-452c-a591-c6ab6590967a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_33e3523f-c81a-4b87-aed0-26c9dd0b2ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_282cf847-7100-41fe-9fcb-52b563d82240" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ccfa75-584d-452c-a591-c6ab6590967a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_282cf847-7100-41fe-9fcb-52b563d82240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31a38b77-9a71-4c20-8cad-bc5ae7bf8f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_282cf847-7100-41fe-9fcb-52b563d82240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_31a38b77-9a71-4c20-8cad-bc5ae7bf8f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3de374d5-8f8c-4c82-9351-74a62a10e903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_282cf847-7100-41fe-9fcb-52b563d82240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3de374d5-8f8c-4c82-9351-74a62a10e903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_0e67207e-3a26-4bd4-8d5f-e378905f8b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_282cf847-7100-41fe-9fcb-52b563d82240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_0e67207e-3a26-4bd4-8d5f-e378905f8b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1394941e-d9af-4d8e-b1a1-c8bb5d61adf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_282cf847-7100-41fe-9fcb-52b563d82240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1394941e-d9af-4d8e-b1a1-c8bb5d61adf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_77989d21-f80a-46fb-a46f-8ae71f0eac53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_282cf847-7100-41fe-9fcb-52b563d82240" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_77989d21-f80a-46fb-a46f-8ae71f0eac53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c7b32b74-43ac-436c-bcff-814b3674e2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ccfa75-584d-452c-a591-c6ab6590967a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c7b32b74-43ac-436c-bcff-814b3674e2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_301b8b3d-6e1d-436b-9874-62a237f9d274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ccfa75-584d-452c-a591-c6ab6590967a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_301b8b3d-6e1d-436b-9874-62a237f9d274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_22c13a52-5177-4f7e-847c-31d27632deab" xlink:href="espr-20230331.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ccfa75-584d-452c-a591-c6ab6590967a" xlink:to="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_22c13a52-5177-4f7e-847c-31d27632deab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3d62e8a9-c9bb-408e-8117-00ece940b4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_22c13a52-5177-4f7e-847c-31d27632deab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3d62e8a9-c9bb-408e-8117-00ece940b4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_09afc479-2ca6-4280-b387-9235af901063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_22c13a52-5177-4f7e-847c-31d27632deab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_09afc479-2ca6-4280-b387-9235af901063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_494d0f9a-e383-4a3c-b61f-19d8e192e4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_22c13a52-5177-4f7e-847c-31d27632deab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_494d0f9a-e383-4a3c-b61f-19d8e192e4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_8b7fd39d-043b-469c-b009-da65661a427f" xlink:href="espr-20230331.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_06ccfa75-584d-452c-a591-c6ab6590967a" xlink:to="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_8b7fd39d-043b-469c-b009-da65661a427f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7a9918e7-8e09-48a3-9c76-9842d447bc99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_8b7fd39d-043b-469c-b009-da65661a427f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7a9918e7-8e09-48a3-9c76-9842d447bc99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e6e4f0e9-e0a5-4da6-b743-875b7b11f869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_8b7fd39d-043b-469c-b009-da65661a427f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e6e4f0e9-e0a5-4da6-b743-875b7b11f869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b6a980cd-e230-4afc-8e3d-f78c689f6d86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_8b7fd39d-043b-469c-b009-da65661a427f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b6a980cd-e230-4afc-8e3d-f78c689f6d86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationPBSOsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockCompensationPBSOsDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationPBSOsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41e2f428-b806-4ba5-a100-1b565d74c173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17e1e9b3-bc11-4ef2-85d8-1c4b0395aeca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_41e2f428-b806-4ba5-a100-1b565d74c173" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17e1e9b3-bc11-4ef2-85d8-1c4b0395aeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d7c6729b-d1de-49f0-8821-fdb0e9a94ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17e1e9b3-bc11-4ef2-85d8-1c4b0395aeca" xlink:to="loc_us-gaap_AwardTypeAxis_d7c6729b-d1de-49f0-8821-fdb0e9a94ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e35d187f-ecbe-4432-97a8-c3a6d1e99321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d7c6729b-d1de-49f0-8821-fdb0e9a94ae0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e35d187f-ecbe-4432-97a8-c3a6d1e99321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_ba9a0166-6553-47e4-b7d4-54b205a8025f" xlink:href="espr-20230331.xsd#espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e35d187f-ecbe-4432-97a8-c3a6d1e99321" xlink:to="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_ba9a0166-6553-47e4-b7d4-54b205a8025f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_17e1e9b3-bc11-4ef2-85d8-1c4b0395aeca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d8f92cd-2084-43a9-8873-79aa1e4e6709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d8f92cd-2084-43a9-8873-79aa1e4e6709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_079efd7a-4c39-4b82-bdf2-3d19afa5d20d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_079efd7a-4c39-4b82-bdf2-3d19afa5d20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5b89e2f4-ceef-45c1-9fbf-cbb9aee86601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_5b89e2f4-ceef-45c1-9fbf-cbb9aee86601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_82040897-95a4-4324-b1cb-5820f11aa80f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_82040897-95a4-4324-b1cb-5820f11aa80f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6be94aed-a03b-4bf7-aa73-27985f884318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6be94aed-a03b-4bf7-aa73-27985f884318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fc5ba4d8-6537-423c-b93a-79ebaca9b398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_fc5ba4d8-6537-423c-b93a-79ebaca9b398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d3074897-0737-4496-9523-d80b3cfe0e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_dfaf401e-bafe-454b-8131-e2981c7fd213" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d3074897-0737-4496-9523-d80b3cfe0e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5895fb84-6b5a-4127-b65b-62fa344e622b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5895fb84-6b5a-4127-b65b-62fa344e622b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4cd3a709-5e0b-45ad-9584-11d0668fea93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4cd3a709-5e0b-45ad-9584-11d0668fea93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_861cc14e-697b-49d3-9042-a6ce5a2a74a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_861cc14e-697b-49d3-9042-a6ce5a2a74a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d09ad22e-fb07-487f-b473-ee1531cabc14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d09ad22e-fb07-487f-b473-ee1531cabc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6ef7be9c-14db-4553-b161-0799916a4801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6ef7be9c-14db-4553-b161-0799916a4801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_344c8cfb-1b98-4dcb-88f3-3c9915a36dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_344c8cfb-1b98-4dcb-88f3-3c9915a36dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_564be09f-a053-4b27-a659-f1e480c9f374" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3f68885b-82d3-44e8-82a0-4ab5524378cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_564be09f-a053-4b27-a659-f1e480c9f374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_12017c79-d26b-46c8-9549-85367535556d" xlink:href="espr-20230331.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:to="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_12017c79-d26b-46c8-9549-85367535556d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e988d92d-a656-41cb-a80d-6b155129a1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_12017c79-d26b-46c8-9549-85367535556d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e988d92d-a656-41cb-a80d-6b155129a1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7459560a-3347-4753-9e88-f0036bd063c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_12017c79-d26b-46c8-9549-85367535556d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_7459560a-3347-4753-9e88-f0036bd063c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f744bc30-4706-485c-b9cd-7deb1e2bcec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_12017c79-d26b-46c8-9549-85367535556d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_f744bc30-4706-485c-b9cd-7deb1e2bcec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_2ae2fcc9-a984-450f-966b-1a10dd9308c4" xlink:href="espr-20230331.xsd#espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3d269b68-f730-4093-b69b-7d721e0b761e" xlink:to="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_2ae2fcc9-a984-450f-966b-1a10dd9308c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f49023f1-2d8c-4440-8466-75cbdb6868ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_2ae2fcc9-a984-450f-966b-1a10dd9308c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f49023f1-2d8c-4440-8466-75cbdb6868ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_64ba5f50-64cf-408f-9c2c-fea91c81c4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_2ae2fcc9-a984-450f-966b-1a10dd9308c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_64ba5f50-64cf-408f-9c2c-fea91c81c4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1c4033c3-c009-4506-b879-ce82e42b013f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract_2ae2fcc9-a984-450f-966b-1a10dd9308c4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1c4033c3-c009-4506-b879-ce82e42b013f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationRSUsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockCompensationRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d98f8c73-0486-4769-a0d8-30a63c910a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b10b1c57-5834-4279-9c63-0fb73c0188ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d98f8c73-0486-4769-a0d8-30a63c910a4a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b10b1c57-5834-4279-9c63-0fb73c0188ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6accee1a-e198-4a65-b8c4-f35cf7a441f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b10b1c57-5834-4279-9c63-0fb73c0188ec" xlink:to="loc_us-gaap_AwardTypeAxis_6accee1a-e198-4a65-b8c4-f35cf7a441f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3bc513c-eceb-4851-904c-c49dd2c9847b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6accee1a-e198-4a65-b8c4-f35cf7a441f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3bc513c-eceb-4851-904c-c49dd2c9847b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_084b55ba-8806-42c4-9e6a-1e68fb24b30c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b3bc513c-eceb-4851-904c-c49dd2c9847b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_084b55ba-8806-42c4-9e6a-1e68fb24b30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd2aae-b4a7-49b8-8bfc-668b120aa8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b10b1c57-5834-4279-9c63-0fb73c0188ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd2aae-b4a7-49b8-8bfc-668b120aa8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd2aae-b4a7-49b8-8bfc-668b120aa8d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cfd4bb02-d3bc-46b3-8c3b-af3f6430cbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_cfd4bb02-d3bc-46b3-8c3b-af3f6430cbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9fbbc41c-932a-4047-a0ad-d25a4e83c09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9fbbc41c-932a-4047-a0ad-d25a4e83c09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ed78e9b-6529-41b3-874e-5a8e77a54500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_2ed78e9b-6529-41b3-874e-5a8e77a54500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_edd4dde8-54be-40fa-a7a3-a567b18a925b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_edd4dde8-54be-40fa-a7a3-a567b18a925b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8676eb6f-1bed-4378-92d4-dfc8b577cf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4e2c51da-ee96-4c52-ba58-02c1b4766d14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8676eb6f-1bed-4378-92d4-dfc8b577cf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f6dd2aae-b4a7-49b8-8bfc-668b120aa8d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3f91adbb-82a7-4ee6-bdf3-bbb3144c4c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3f91adbb-82a7-4ee6-bdf3-bbb3144c4c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_174634b1-cd38-40e2-8505-2c5815dfc8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_174634b1-cd38-40e2-8505-2c5815dfc8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1d4b821c-2cd8-4187-8563-5616ca4e72dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1d4b821c-2cd8-4187-8563-5616ca4e72dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ef52066f-fa2a-4859-90a8-fac13e971356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ef52066f-fa2a-4859-90a8-fac13e971356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9f363e68-768f-4211-892e-d16124bec9d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_83442931-50ed-467b-8793-be1a31bc0b37" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9f363e68-768f-4211-892e-d16124bec9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockCompensationPBRSUsDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockCompensationPBRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockCompensationPBRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2884de25-4644-42c2-ac96-b78b25387624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10db98c4-8c21-40ab-9d7d-d2d8e20ac66a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2884de25-4644-42c2-ac96-b78b25387624" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10db98c4-8c21-40ab-9d7d-d2d8e20ac66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_112247fa-b8d7-4d2e-a0f9-0315f07280da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10db98c4-8c21-40ab-9d7d-d2d8e20ac66a" xlink:to="loc_us-gaap_AwardTypeAxis_112247fa-b8d7-4d2e-a0f9-0315f07280da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2291e4d-0156-40ab-8f4c-b9be30224a67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_112247fa-b8d7-4d2e-a0f9-0315f07280da" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2291e4d-0156-40ab-8f4c-b9be30224a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_1ae92d78-204e-4701-bab8-046241e53df8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2291e4d-0156-40ab-8f4c-b9be30224a67" xlink:to="loc_us-gaap_PerformanceSharesMember_1ae92d78-204e-4701-bab8-046241e53df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ebf3a55-7b1f-44d1-8ddf-1dcda9d78276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_10db98c4-8c21-40ab-9d7d-d2d8e20ac66a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ebf3a55-7b1f-44d1-8ddf-1dcda9d78276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ebf3a55-7b1f-44d1-8ddf-1dcda9d78276" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d25a5a60-20f7-4589-8de1-b6a6a7f3c00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d25a5a60-20f7-4589-8de1-b6a6a7f3c00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75e5f6a6-90db-4688-9895-47790e6ed1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_75e5f6a6-90db-4688-9895-47790e6ed1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c19ebb4-822c-44b3-b2f5-a852c9222935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_3c19ebb4-822c-44b3-b2f5-a852c9222935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0e6a6c2a-8376-42fd-999b-d3d38dada192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0e6a6c2a-8376-42fd-999b-d3d38dada192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_27d19054-6988-4066-94d6-d22fe7fc946f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_06d3d450-e14b-4ffa-b617-044d1dfe49f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_27d19054-6988-4066-94d6-d22fe7fc946f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_3ebf3a55-7b1f-44d1-8ddf-1dcda9d78276" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_53753da5-a6e4-4639-a7bf-09f79cf310d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_53753da5-a6e4-4639-a7bf-09f79cf310d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f639fd19-d7fb-4c1c-9eea-eb38e55cb474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f639fd19-d7fb-4c1c-9eea-eb38e55cb474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1117400d-9cf9-4cba-96f3-6e418c0f8e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1117400d-9cf9-4cba-96f3-6e418c0f8e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_288e8a66-38ca-49c6-baad-9e0bc5c3a9ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_288e8a66-38ca-49c6-baad-9e0bc5c3a9ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_be542791-1cad-402b-974a-9da78e29ed94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a62b5a77-b99f-409f-a2de-120c8ca066c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_be542791-1cad-402b-974a-9da78e29ed94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e01fc9ce-c283-4920-bd1c-124262416537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_8ff27e71-43c0-4caf-8bef-cb4fb3e9f2cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e01fc9ce-c283-4920-bd1c-124262416537" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_8ff27e71-43c0-4caf-8bef-cb4fb3e9f2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c6b547e4-32ec-4cfb-a421-91bc69bccc15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_8ff27e71-43c0-4caf-8bef-cb4fb3e9f2cc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c6b547e4-32ec-4cfb-a421-91bc69bccc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockholdersDeficitDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockholdersDeficitDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockholdersDeficitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_778c6636-8401-4d6f-aceb-a63609c5fd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_778c6636-8401-4d6f-aceb-a63609c5fd14" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_c2ceb905-851e-4d45-8f82-c3a1cb732925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_c2ceb905-851e-4d45-8f82-c3a1cb732925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81380166-c207-44ea-b618-6ecaa017eef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_c2ceb905-851e-4d45-8f82-c3a1cb732925" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81380166-c207-44ea-b618-6ecaa017eef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_AtTheMarketProgramMember_18fc2228-07fa-4571-a1ee-2757c608a57f" xlink:href="espr-20230331.xsd#espr_AtTheMarketProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_81380166-c207-44ea-b618-6ecaa017eef1" xlink:to="loc_espr_AtTheMarketProgramMember_18fc2228-07fa-4571-a1ee-2757c608a57f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_386f359d-6b76-49c4-b25d-6bd0c350dd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_386f359d-6b76-49c4-b25d-6bd0c350dd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8f34958-2ea2-41df-9465-4297b67ce245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_386f359d-6b76-49c4-b25d-6bd0c350dd35" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8f34958-2ea2-41df-9465-4297b67ce245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WainwrightMember_f6a0cfaa-68d0-40f3-868f-e549555ea946" xlink:href="espr-20230331.xsd#espr_WainwrightMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8f34958-2ea2-41df-9465-4297b67ce245" xlink:to="loc_espr_WainwrightMember_f6a0cfaa-68d0-40f3-868f-e549555ea946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SecuritiesPurchaseAgreementMember_640a79df-f317-44ef-b624-bab1d2da5c5b" xlink:href="espr-20230331.xsd#espr_SecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8f34958-2ea2-41df-9465-4297b67ce245" xlink:to="loc_espr_SecuritiesPurchaseAgreementMember_640a79df-f317-44ef-b624-bab1d2da5c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WarrantAmendmentAgreementsMember_25a376d1-3899-4b88-afd8-899f655b710c" xlink:href="espr-20230331.xsd#espr_WarrantAmendmentAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e8f34958-2ea2-41df-9465-4297b67ce245" xlink:to="loc_espr_WarrantAmendmentAgreementsMember_25a376d1-3899-4b88-afd8-899f655b710c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_f15f8323-dd54-4739-9f79-67129634a4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_f15f8323-dd54-4739-9f79-67129634a4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_f15f8323-dd54-4739-9f79-67129634a4ee" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockAndAccompanyingWarrantMember_1b7ce10c-80d7-4e8b-b6c9-3aaf8d56f00f" xlink:href="espr-20230331.xsd#espr_CommonStockAndAccompanyingWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:to="loc_espr_CommonStockAndAccompanyingWarrantMember_1b7ce10c-80d7-4e8b-b6c9-3aaf8d56f00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_TheWarrantsMember_0e61af01-9f8c-4ba7-aaae-4265ddc8ae85" xlink:href="espr-20230331.xsd#espr_TheWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:to="loc_espr_TheWarrantsMember_0e61af01-9f8c-4ba7-aaae-4265ddc8ae85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PreFundedWarrantAndAccompanyingWarrantMember_50a60d6a-c70a-4799-a1e1-2f857adbee3a" xlink:href="espr-20230331.xsd#espr_PreFundedWarrantAndAccompanyingWarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:to="loc_espr_PreFundedWarrantAndAccompanyingWarrantMember_50a60d6a-c70a-4799-a1e1-2f857adbee3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PreFundedWarrantMember_8dc60c8a-f61c-49ab-a6a4-60130dd0a1c4" xlink:href="espr-20230331.xsd#espr_PreFundedWarrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_18ca3714-8f59-4b7c-9a67-5b991d83e77a" xlink:to="loc_espr_PreFundedWarrantMember_8dc60c8a-f61c-49ab-a6a4-60130dd0a1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_e9a36e4b-294c-49ca-8a4d-2f78cf976593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_e9a36e4b-294c-49ca-8a4d-2f78cf976593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_97c6ebd6-40ef-4982-bfbe-58252d551f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_e9a36e4b-294c-49ca-8a4d-2f78cf976593" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_97c6ebd6-40ef-4982-bfbe-58252d551f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_38cad24e-17a6-4c8c-8cba-21175c7a8f88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_97c6ebd6-40ef-4982-bfbe-58252d551f8b" xlink:to="loc_us-gaap_SubsequentEventMember_38cad24e-17a6-4c8c-8cba-21175c7a8f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_f4d270a7-dfcb-455a-b6e0-afbc1f6444b2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bb4fbb8c-3ed8-46a2-a426-332cd403b384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_bb4fbb8c-3ed8-46a2-a426-332cd403b384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_69f1b3cb-c20b-4125-a996-da6656b560a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_69f1b3cb-c20b-4125-a996-da6656b560a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_e218fc8e-2275-4fac-abc4-8ded2565e59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_e218fc8e-2275-4fac-abc4-8ded2565e59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SaleOfStockAuthorizedAmount_d31c6f56-c831-4bb1-8ba7-990f5462b33e" xlink:href="espr-20230331.xsd#espr_SaleOfStockAuthorizedAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_SaleOfStockAuthorizedAmount_d31c6f56-c831-4bb1-8ba7-990f5462b33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_33b570bd-1825-4d87-a77c-531f3b5e58cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_33b570bd-1825-4d87-a77c-531f3b5e58cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9c6f7029-4769-4abd-8455-3a83d9943ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9c6f7029-4769-4abd-8455-3a83d9943ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_fdf72a5a-7623-46a0-80a9-7fdc48ab919c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_fdf72a5a-7623-46a0-80a9-7fdc48ab919c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_417503ba-1be3-4d97-861a-e67234fa4623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_CommonStockSharesIssued_417503ba-1be3-4d97-861a-e67234fa4623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_73d4a0cd-4b52-4f56-b726-0aa02648651b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_73d4a0cd-4b52-4f56-b726-0aa02648651b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockPurchasableUnderPrefundedWarrants_b55c2be4-f569-4ffa-af60-f33e1cb8831d" xlink:href="espr-20230331.xsd#espr_CommonStockPurchasableUnderPrefundedWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_CommonStockPurchasableUnderPrefundedWarrants_b55c2be4-f569-4ffa-af60-f33e1cb8831d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_CommonStockPurchasableUnderWarrants_a9a19b4d-a420-484b-be77-503bfd586702" xlink:href="espr-20230331.xsd#espr_CommonStockPurchasableUnderWarrants"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_CommonStockPurchasableUnderWarrants_a9a19b4d-a420-484b-be77-503bfd586702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_febf4272-18e5-4f5b-9bc2-69201c1faed8" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights_febf4272-18e5-4f5b-9bc2-69201c1faed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_af4030ac-e071-4771-9442-1957bb598964" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_af4030ac-e071-4771-9442-1957bb598964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration_7160218d-c435-46ce-a3be-a996b34ffb6c" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration_7160218d-c435-46ce-a3be-a996b34ffb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_e28da491-7794-4984-aacf-ae93c541bc48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_e28da491-7794-4984-aacf-ae93c541bc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_f84f57a4-4bfa-4c2b-9e11-0de87b1f84a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForCommissions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_PaymentsForCommissions_f84f57a4-4bfa-4c2b-9e11-0de87b1f84a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f22d2229-b015-457b-a726-d291a5761988" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f22d2229-b015-457b-a726-d291a5761988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfPrivatePlacement_f25fa1b0-5f76-434d-90cd-33f16cff70c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfPrivatePlacement"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfPrivatePlacement_f25fa1b0-5f76-434d-90cd-33f16cff70c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_4c02d921-6eb2-4206-8c23-1bd45725ca7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_4c02d921-6eb2-4206-8c23-1bd45725ca7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ClassOfWarrantOrRightExercised_396adb4f-45af-4b10-b81d-8b31cd22a559" xlink:href="espr-20230331.xsd#espr_ClassOfWarrantOrRightExercised"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_60a625b5-e29f-410c-beb5-8a20fc3ba710" xlink:to="loc_espr_ClassOfWarrantOrRightExercised_396adb4f-45af-4b10-b81d-8b31cd22a559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_eeb01095-e1a1-4776-bf42-a8c9001fe6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c22f3ad0-ba1f-4dfa-88b9-31554dd422bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_eeb01095-e1a1-4776-bf42-a8c9001fe6b5" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c22f3ad0-ba1f-4dfa-88b9-31554dd422bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3a24f1aa-00e5-447a-ba9c-53d517f7374f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c22f3ad0-ba1f-4dfa-88b9-31554dd422bc" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3a24f1aa-00e5-447a-ba9c-53d517f7374f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b272dbd-b6b8-4862-bba0-0a6f2deb7961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3a24f1aa-00e5-447a-ba9c-53d517f7374f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b272dbd-b6b8-4862-bba0-0a6f2deb7961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WainwrightMember_1795ff62-13df-49b2-9707-fc7c9468ed0a" xlink:href="espr-20230331.xsd#espr_WainwrightMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b272dbd-b6b8-4862-bba0-0a6f2deb7961" xlink:to="loc_espr_WainwrightMember_1795ff62-13df-49b2-9707-fc7c9468ed0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_WarrantAmendmentAgreementsMember_6fdde9d9-f463-40ad-a095-ab6b72835c30" xlink:href="espr-20230331.xsd#espr_WarrantAmendmentAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b272dbd-b6b8-4862-bba0-0a6f2deb7961" xlink:to="loc_espr_WarrantAmendmentAgreementsMember_6fdde9d9-f463-40ad-a095-ab6b72835c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_SecuritiesPurchaseAgreementMember_6eddff04-bd58-4810-baa6-553ed11a0a7d" xlink:href="espr-20230331.xsd#espr_SecuritiesPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1b272dbd-b6b8-4862-bba0-0a6f2deb7961" xlink:to="loc_espr_SecuritiesPurchaseAgreementMember_6eddff04-bd58-4810-baa6-553ed11a0a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_b11e915f-7756-40bb-aa70-0eb64605c92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c22f3ad0-ba1f-4dfa-88b9-31554dd422bc" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_b11e915f-7756-40bb-aa70-0eb64605c92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_78cfe8e3-fba2-4202-9442-feb156862160" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_b11e915f-7756-40bb-aa70-0eb64605c92f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_78cfe8e3-fba2-4202-9442-feb156862160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_PreFundedWarrantMember_e22ec8cb-59c4-42dc-964e-c161c2126d54" xlink:href="espr-20230331.xsd#espr_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_78cfe8e3-fba2-4202-9442-feb156862160" xlink:to="loc_espr_PreFundedWarrantMember_e22ec8cb-59c4-42dc-964e-c161c2126d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_75b52301-fe2c-4efa-938d-06b2786023ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_c22f3ad0-ba1f-4dfa-88b9-31554dd422bc" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_75b52301-fe2c-4efa-938d-06b2786023ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_14666c95-ef13-4427-94b0-4460076a9307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_75b52301-fe2c-4efa-938d-06b2786023ee" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_14666c95-ef13-4427-94b0-4460076a9307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8d3b03c0-2151-463a-9642-bbdb3375a0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_75b52301-fe2c-4efa-938d-06b2786023ee" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_8d3b03c0-2151-463a-9642-bbdb3375a0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/NetLossPerCommonShareDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#NetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/NetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8a7fa7e7-7370-4939-9ec1-8a84c9c0bafd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c33570b9-c9fd-412a-9dca-5f12b8f42897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8a7fa7e7-7370-4939-9ec1-8a84c9c0bafd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c33570b9-c9fd-412a-9dca-5f12b8f42897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5e35071-2fdb-48e5-a147-3973e8e9ee00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c33570b9-c9fd-412a-9dca-5f12b8f42897" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5e35071-2fdb-48e5-a147-3973e8e9ee00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b5e35071-2fdb-48e5-a147-3973e8e9ee00" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2b237418-9fa1-4de9-8d9a-853c5afd95e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2b237418-9fa1-4de9-8d9a-853c5afd95e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_3efed304-b823-489c-8804-313ebf96e5f5" xlink:href="espr-20230331.xsd#espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember_3efed304-b823-489c-8804-313ebf96e5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_89fe0a4e-344f-48e4-9529-b7371b8f1c7c" xlink:href="espr-20230331.xsd#espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember_89fe0a4e-344f-48e4-9529-b7371b8f1c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9e5447c1-04f4-4fff-a7bf-3a1c9566ba08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_us-gaap_PerformanceSharesMember_9e5447c1-04f4-4fff-a7bf-3a1c9566ba08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_7a7e5d98-b090-4137-bb29-6c0ea88418b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_us-gaap_EmployeeStockMember_7a7e5d98-b090-4137-bb29-6c0ea88418b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_9ea5dd5e-7c67-4719-b55c-0061ae17873c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_9ea5dd5e-7c67-4719-b55c-0061ae17873c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b3d1d2fc-6505-4d2c-b9ec-0a2e4c8b8f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_540adc6b-1c96-49e3-8811-35c3b819e3ad" xlink:to="loc_us-gaap_WarrantMember_b3d1d2fc-6505-4d2c-b9ec-0a2e4c8b8f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5b20ed09-73db-4ff3-92d2-a137586a5b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c33570b9-c9fd-412a-9dca-5f12b8f42897" xlink:to="loc_us-gaap_AwardTypeAxis_5b20ed09-73db-4ff3-92d2-a137586a5b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae68508b-2e8d-4f3d-aa6f-390af472d98d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5b20ed09-73db-4ff3-92d2-a137586a5b72" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae68508b-2e8d-4f3d-aa6f-390af472d98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0ec31d97-d0ce-4f06-be40-faba01bf456c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ae68508b-2e8d-4f3d-aa6f-390af472d98d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0ec31d97-d0ce-4f06-be40-faba01bf456c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3544bbc1-4a87-4e5d-8d10-7968af1e873e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c33570b9-c9fd-412a-9dca-5f12b8f42897" xlink:to="loc_srt_CounterpartyNameAxis_3544bbc1-4a87-4e5d-8d10-7968af1e873e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2368dc2-1daf-4241-b10b-3c3b449b3007" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3544bbc1-4a87-4e5d-8d10-7968af1e873e" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2368dc2-1daf-4241-b10b-3c3b449b3007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_espr_DaiichiSankyoCoLtdMember_ad109f3e-464a-49ab-bcae-394169194049" xlink:href="espr-20230331.xsd#espr_DaiichiSankyoCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2368dc2-1daf-4241-b10b-3c3b449b3007" xlink:to="loc_espr_DaiichiSankyoCoLtdMember_ad109f3e-464a-49ab-bcae-394169194049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11ab5d6c-beb8-4fe8-ac8c-41693e325b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_c33570b9-c9fd-412a-9dca-5f12b8f42897" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11ab5d6c-beb8-4fe8-ac8c-41693e325b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_417869cc-5812-4da7-8e67-6f1434b40082" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_11ab5d6c-beb8-4fe8-ac8c-41693e325b9a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_417869cc-5812-4da7-8e67-6f1434b40082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails" xlink:type="simple" xlink:href="espr-20230331.xsd#StatementsofCashFlowsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8510b0d5-6154-4630-9a9b-07997b72452f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f48c91bf-5a47-4e58-bb1e-f3629fc634e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8510b0d5-6154-4630-9a9b-07997b72452f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f48c91bf-5a47-4e58-bb1e-f3629fc634e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_6612f953-3903-4db5-bb55-be8be803682f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8510b0d5-6154-4630-9a9b-07997b72452f" xlink:to="loc_us-gaap_RestrictedCash_6612f953-3903-4db5-bb55-be8be803682f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_97ee7fd9-e6aa-4287-940a-47cd33f7e4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8510b0d5-6154-4630-9a9b-07997b72452f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_97ee7fd9-e6aa-4287-940a-47cd33f7e4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976781640064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Esperion Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1870780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3891 Ranchero Drive, Suite&#160;150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ann Arbor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">48108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">887-3903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ESPR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,712,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001434868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976781369920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 144,911<span></span>
</td>
<td class="nump">$ 124,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">17,427<span></span>
</td>
<td class="nump">42,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">36,415<span></span>
</td>
<td class="nump">33,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PrepaidClinicalDevelopmentCostsCurrent', window );">Prepaid clinical development costs</a></td>
<td class="nump">6,916<span></span>
</td>
<td class="nump">1,026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">39,352<span></span>
</td>
<td class="nump">35,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other prepaid and current assets</a></td>
<td class="nump">5,584<span></span>
</td>
<td class="nump">9,866<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">250,605<span></span>
</td>
<td class="nump">246,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use operating lease assets</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">251,819<span></span>
</td>
<td class="nump">247,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">17,065<span></span>
</td>
<td class="nump">23,040<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_AccruedClinicalDevelopmentCostsCurrent', window );">Accrued clinical development costs</a></td>
<td class="nump">4,617<span></span>
</td>
<td class="nump">5,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">34,421<span></span>
</td>
<td class="nump">35,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestLiabilityCurrent', window );">Revenue interest liability</a></td>
<td class="nump">26,921<span></span>
</td>
<td class="nump">24,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue from collaborations</a></td>
<td class="nump">12,157<span></span>
</td>
<td class="nump">3,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">384<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">95,486<span></span>
</td>
<td class="nump">92,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes, net of issuance costs</a></td>
<td class="nump">260,316<span></span>
</td>
<td class="nump">259,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestLiabilityNoncurrent', window );">Revenue interest liability</a></td>
<td class="nump">224,898<span></span>
</td>
<td class="nump">218,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">782<span></span>
</td>
<td class="nump">665<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">581,482<span></span>
</td>
<td class="nump">571,717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March&#160;31, 2023 and December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 240,000,000 shares authorized as of March&#160;31, 2023 and as of December&#160;31, 2022; 89,237,167 shares issued at March&#160;31, 2023 and 76,564,396 shares issued at December&#160;31, 2022</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,127,004<span></span>
</td>
<td class="nump">1,071,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 1,994,198 shares at March&#160;31, 2023 and December 31, 2022</a></td>
<td class="num">(54,998)<span></span>
</td>
<td class="num">(54,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,401,755)<span></span>
</td>
<td class="num">(1,340,036)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(329,663)<span></span>
</td>
<td class="num">(323,778)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">$ 251,819<span></span>
</td>
<td class="nump">$ 247,939<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AccruedClinicalDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AccruedClinicalDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PrepaidClinicalDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PrepaidClinicalDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability related to Revenue Interest Purchase Agreement ("RIPA"), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976781762896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">240,000,000<span></span>
</td>
<td class="nump">240,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">89,237,167<span></span>
</td>
<td class="nump">76,564,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">1,994,198<span></span>
</td>
<td class="nump">1,994,198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782048608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 24,329<span></span>
</td>
<td class="nump">$ 18,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Cost of goods sold</a></td>
<td class="nump">11,652<span></span>
</td>
<td class="nump">7,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">31,381<span></span>
</td>
<td class="nump">24,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">29,901<span></span>
</td>
<td class="nump">30,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">72,934<span></span>
</td>
<td class="nump">61,825<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(48,605)<span></span>
</td>
<td class="num">(42,989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(14,387)<span></span>
</td>
<td class="num">(14,062)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (61,719)<span></span>
</td>
<td class="num">$ (56,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.79)<span></span>
</td>
<td class="num">$ (0.93)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - basic (in shares)</a></td>
<td class="nump">78,440,266<span></span>
</td>
<td class="nump">60,954,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - diluted (in shares)</a></td>
<td class="nump">78,440,266<span></span>
</td>
<td class="nump">60,954,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain (loss) on investments</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">$ (232)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(61,718)<span></span>
</td>
<td class="num">(56,963)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">17,031<span></span>
</td>
<td class="nump">13,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=espr_CollaborationRevenueMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 7,298<span></span>
</td>
<td class="nump">$ 5,482<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=espr_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=espr_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976781407584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,879,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="num">$ (196,944)<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">$ 964,401<span></span>
</td>
<td class="num">$ (1,106,377)<span></span>
</td>
<td class="num">$ (31)<span></span>
</td>
<td class="num">$ (54,998)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units and performance-based restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Vesting of ESPP Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Vesting of ESPP Shares</a></td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">4,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain (loss)</a></td>
<td class="num">(232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(56,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,058,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="num">(249,040)<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
<td class="nump">969,268<span></span>
</td>
<td class="num">(1,163,108)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
<td class="num">(54,998)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,570,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="num">(323,778)<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">1,071,183<span></span>
</td>
<td class="num">(1,340,036)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="num">(54,998)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units and performance-based restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Vesting of ESPP Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Vesting of ESPP Shares</a></td>
<td class="nump">502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, warrants, and pre-funded warrants, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, warrants, and pre-funded warrants, net of issuance costs</a></td>
<td class="nump">52,428<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">52,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain (loss)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(61,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,242,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="num">$ (329,663)<span></span>
</td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 1,127,004<span></span>
</td>
<td class="num">$ (1,401,755)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="num">$ (54,998)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782587568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (61,719)<span></span>
</td>
<td class="num">$ (56,731)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">153<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on investments</a></td>
<td class="num">(339)<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability', window );">Non-cash interest expense related to the revenue interest liability</a></td>
<td class="nump">11,320<span></span>
</td>
<td class="nump">11,015<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,903<span></span>
</td>
<td class="nump">4,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(2,686)<span></span>
</td>
<td class="num">(2,182)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaids and other assets</a></td>
<td class="num">(1,608)<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">8,650<span></span>
</td>
<td class="num">(2,100)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(4,151)<span></span>
</td>
<td class="num">(1,260)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(5,975)<span></span>
</td>
<td class="nump">9,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued liabilities</a></td>
<td class="num">(1,249)<span></span>
</td>
<td class="num">(3,049)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(54,356)<span></span>
</td>
<td class="num">(38,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales/maturities of investments</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="num">(18,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PaymentsFromRevenueInterestPurchaseAgreement', window );">Payments on revenue interest liability</a></td>
<td class="num">(3,106)<span></span>
</td>
<td class="num">(1,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">52,598<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(219)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">49,492<span></span>
</td>
<td class="num">(1,436)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">20,136<span></span>
</td>
<td class="num">(58,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">124,775<span></span>
</td>
<td class="nump">258,892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">144,911<span></span>
</td>
<td class="nump">200,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_CommonStockIssuanceCostsIncurredNotYetPaid', window );">Common stock issuance, warrant, and pre-funded warrant issuance costs not yet paid</a></td>
<td class="nump">170<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_NonCashRightOfUseAsset', window );">Non cash right of use asset</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_CommonStockIssuanceCostsIncurredNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issuance Costs Incurred, Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_CommonStockIssuanceCostsIncurredNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NonCashInterestExpenseRelatedToRevenueInterestLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash expense included in interest expense associated with the revenue interest liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NonCashInterestExpenseRelatedToRevenueInterestLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NonCashRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the difference between the lease asset and the lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NonCashRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PaymentsFromRevenueInterestPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from a revenue interest purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PaymentsFromRevenueInterestPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976787020272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">The Company and Basis of Presentation</a></td>
<td class="text">The Company and Basis of Presentation<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Esperion Therapeutics, Inc. ("the Company&#8221;) is a pharmaceutical company singularly focused on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol ("LDL-C"). Through commercial execution and completion of the CLEAR Outcomes trial as well as advancing the Company's pre-clinical pipeline, the Company continues to evolve into a differentiated, global cardiometabolic biotech. The Esperion team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. The Company's first two products were approved by the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Swiss Agency for Therapeutic Products ("Swissmedic") in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease ("ASCVD") or heterozygous familial hypercholesterolemia ("HeFH").</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company recently completed a global cardiovascular outcomes trial, or CVOT,&#8201;&#8212;&#8201;known as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">holesterol </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">L</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">owering via B</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">E</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mpedoic Acid, an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CL-inhibiting </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">R</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">egimen (CLEAR) Outcomes. The trial was designed to evaluate whether treatment with bempedoic acid reduced the risk of cardiovascular events in patients who are statin averse and who have CVD or are at high risk for CVD. The Company initiated the CLEAR Outcomes CVOT in December 2016 and fully enrolled the study with over 14,000 patients in August 2019. The primary endpoint of the study was the effect of bempedoic acid on four types of major adverse cardiovascular events, or MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization; also referred to as &#8220;four-component MACE&#8221;). CLEAR Outcomes was an event-driven trial and concluded once the predetermined number of MACE endpoints occurred. On December 7, 2022, the Company announced that the study had met its primary endpoint.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 4, 2023, the Company announced the full results from the CLEAR Outcomes trial. The study showed that bempedoic acid demonstrated significant</span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">cardiovascular risk reductions and significantly reduced the risk of heart attack and coronary revascularization as compared to placebo. These results were seen in a broad population of primary and secondary prevention patients who are unable to maximize or tolerate a statin. The proportions of patients experiencing adverse events and serious adverse events were similar between the active and placebo treatment groups. Bempedoic acid (contained in NEXLETOL&#174; and NEXLIZET&#174; (bempedoic acid and ezetimibe) tablets) now becomes the first LDL-C lowering therapy since statins proven to lower hard ischemic events, not only in those with ASCVD but also in the large number of primary prevention patients for whom limited therapies exist. The Company believes that it remains on track to submit regulatory filings to the FDA and EMA in the first half of 2023 with expected inclusion in the U.S. and EMA labels in the first half of 2024. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 19, 2023, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers named therein (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the &#8220;Offering&#8221;), 12,205,000 shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), pre-funded warrants to purchase up to an aggregate of 20,965,747 shares of Common Stock (the &#8220;Pre-Funded Warrants&#8221;) in lieu of shares of Common Stock, and warrants to purchase up to 33,170,747 shares of Common Stock (the &#8220;Warrants&#8221;). The combined purchase price of each share of Common Stock and accompanying Warrant is $1.675 per share. The purchase price of each Pre-Funded Warrant and the accompanying Warrant is $1.674 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $0.001). The Purchase Agreement contains customary representations, warranties, covenants and indemnification rights and obligations of the Company and the Purchasers. The Offering closed on March 22, 2023. In connection with the Offering, the Company amended, pursuant to Warrant Amendment Agreements (the &#8220;Warrant Amendment Agreements&#8221;), certain existing warrants to purchase up to an aggregate of 9,024,212 shares of the Company's common stock that were previously issued in December 2021 at an exercise price of $9.00 per share and had an expiration date of December 7, 2023, effective upon the closing of the Offering, such that the amended warrants have a reduced exercise price of $1.55 per share and expire three and one half years following the closing of the Offering, for additional consideration of $0.125 per amended warrant. The Company received gross proceeds of approximately $55.5&#160;million from the Offering, before deducting placement agent fees and related offering expenses. The net proceeds to the Company from the Offering, after deducting the placement agent fees and expenses and the Company&#8217;s estimated offering expenses, are approximately $51.3&#160;million. In addition, the Company received approximately $1.2&#160;million as the gross consideration in connection with the Warrant Amendment Agreements. The net proceeds of the Warrant Amendment Agreements after deducting placement fees were approximately $1.1&#160;million. Refer to Note 13 "Stockholders' Deficit" for further information.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's primary activities since incorporation have been conducting research and development activities, including nonclinical, preclinical and clinical testing, gaining commercial approval of its products, developing a commercial sales team, performing business and financial planning, recruiting personnel, and raising capital. The Company received approval by the FDA in February 2020 to commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablet in the U.S., and accordingly commenced principal operations on March 30, 2020 with the commercialization of NEXLETOL. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is subject to risks and uncertainties which include the need to successfully commercialize its products, research, develop, and clinically test therapeutic products; obtain regulatory approvals for its products (or additional or expanded indications for approved products); manage its management, commercial and scientific staff; and finance its operations with an ultimate goal of achieving profitable operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has sustained annual operating losses since inception and expects such losses to continue over the foreseeable future. While management believes current cash resources and future cash received from the Company's net product sales and collaboration agreements with Daiichi Sankyo Europe GmbH ("DSE"), Otsuka Pharmaceutical Co., Ltd ("Otsuka"), and Daiichi Sankyo Co. Ltd ("DS"), entered into on January 2, 2019, April 17, 2020 and April 26, 2021, respectively, will fund operations for the foreseeable future, management may continue to fund operations and advance the development of the Company's products and product candidates through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, and permitted private and public equity offerings or through other sources. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funds are not available, the Company may not be able to continue the development of its current products or future product candidates, or to commercialize its current or future product candidates, if approved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2022, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976866893248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in bank deposits, money market accounts, and short-term investments. The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents are reported at fair value.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are considered to be available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are reported in accumulated other comprehensive income (loss). The cost of investments classified as available-for-sale are adjusted for the amortization of premiums and accretion of discounts to maturity and recorded in other income, net. Realized gains and losses, if any, are determined using the specific identification method and recorded in other income, net. Investments with original maturities beyond 90 days at the date of purchase and which mature at, or less than twelve months from, the balance sheet date are classified as current. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of March&#160;31, 2023, eleven customers accounted for all of the </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company's net trade receivables and as of December 31, 2022, eleven customers accounted for all the Company's net trade receivables.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones as consideration when it is probable that a future reversal is unlikely to occur. For sales-based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (&#8220;API&#8221;) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt">Product Sales, Net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $17.0 million for the three months ended March&#160;31, 2023, and $13.4 million for the three months ended March&#160;31, 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers&#8217; distribution facilities, or free on board (&#8220;FOB&#8221;) destination, the terms of which are designated in the contract.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company&#8217;s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as &#8220;Other accrued liabilities&#8221; in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forms of Variable Consideration</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-pay assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company generally offers a right of return based on the product&#8217;s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company&#8217;s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company&#8217;s expectations regarding future payment patterns.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Implemented Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976866893248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations with Third Parties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_CollaborativeArrangementAbstract', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborations with Third Parties</a></td>
<td class="text">Collaborations with Third Parties<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DSE Agreement Terms</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2019, the Company entered into a license and collaboration agreement with DSE, which was furthered amended on June 18, 2020. Pursuant to the amended agreement, the Company granted DSE exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablet in the European Economic Area, Turkey, and Switzerland (&#8220;DSE Territory&#8221;). DSE will be responsible for commercialization in the DSE Territory. DSE's designated affiliate in Turkey will be solely responsible, at its sole cost and expense, for all regulatory matters relating to such products in Turkey, including obtaining regulatory approval for such products in Turkey. The Company remains responsible for clinical development, regulatory and manufacturing activities for the licensed products globally, including in the DSE Territory outside of Turkey.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the Company received upfront cash of $150.0 million in 2019 and a $150.0 million cash milestone payment in 2020 following the completion of the NUSTENDI&#174; Marketing Authorisation Applications ("MAA"). The Company is responsible for supplying DSE with certain manufacturing supply of the API or bulk tablets. The Company is also eligible to receive an additional regulatory milestone payment of either $200&#160;million or $300&#160;million upon the grant of the marketing authorisation in the European Union for the CV risk reduction label, depending on the range of relative risk reduction in the CLEAR Outcomes study. Refer to Note 5 "Commitments and Contingencies" for further information. In addition, the Company is eligible to receive additional sales milestone payments related to total net sales achievements for DSE in the DSE Territory. Finally, the Company receives tiered fifteen percent (15%) to twenty-five percent (25%) royalties on net DSE Territory sales.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement calls for both parties to participate in a Joint Collaboration Committee (the &#8220;DSE JCC&#8221;). The DSE JCC is comprised of executive management from each company and the Company will lead in all aspects related to development and DSE will lead in all aspects related to commercialization in the DSE Territory.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March&#160;31, 2023 and 2022, the Company recognized collaboration revenue of approximately $7.1&#160;million and $5.3 million related to royalty revenue from DSE from the sales of NILEMDO&#174; and NUSTENDI as well as the sales of bulk tablets to DSE pursuant to the supply agreement that was executed with DSE. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All remaining future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to sales-based milestones will be recognized when the subsequent sales occur.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Otsuka Agreement Terms</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 17, 2020, the Company entered into a license and collaboration agreement (the "Otsuka Agreement") with Otsuka. Pursuant to the Otsuka Agreement, the Company granted Otsuka exclusive development and commercialization rights to NEXLETOL and NEXLIZET in Japan. Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan. In addition, Otsuka will fund all clinical development costs associated with the program in Japan.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the consideration consists of a $60.0 million upfront cash payment and the Company will be eligible to receive additional payments of up to $450.0 million if certain regulatory and commercial milestones are achieved by Otsuka. The potential future milestone payments include up to $20.0 million upon first JNDA submissions in the Otsuka Territory, up to $70.0 million upon the first NHI Price Listing for NEXLETOL in the Otsuka Territory, and up to $50.0 million upon the achievement of the primary major adverse cardiovascular events (&#8220;MACE&#8221;) in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments up to $310.0 million related to total net sales achievements for Otsuka in Japan. Finally, the Company will receive tiered fifteen percent (15%) to thirty percent (30%) royalties on net sales in Japan.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company did not have any collaboration revenue from the Otsuka Agreement during the three months ended March 31, 2023 and 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not yet recognized any revenue for milestone payments as the related regulatory and commercial milestones have not yet been achieved.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DS Agreement Terms</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Co. Ltd (the "DS Agreement"). Pursuant to the DS Agreement, the Company granted DS exclusive rights to develop and commercialize bempedoic acid and the bempedoic acid / ezetimibe combination tablet in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. Except for certain development activities in South Korea and Taiwan, DS will be responsible for development and commercialization in these territories. In addition, DS will fund all development costs associated with the program in the DS Territory. Pursuant to the agreement, the consideration consists of a $30.0&#160;million upfront cash payment that is non-refundable, non-reimbursable and non-creditable. The Company also will be eligible to receive additional one-time payments of up to $175.0&#160;million if certain commercial milestones are achieved by DS. Also, the Company will receive tiered royalties of five percent (5%) to twenty percent (20%) of net sales in the DS Territory.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $30.0&#160;million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company&#8217;s intellectual property and 2) the obligation to provide ongoing development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company&#8217;s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company&#8217;s obligation to provide ongoing development activities. For the three months ended March 31, 2023 and 2022, the Company recognized $0.2&#160;million and $0.2&#160;million, respectively of collaboration revenue related to the ongoing regulatory and development activities. The remaining $0.5&#160;million of the upfront payment was deferred as of March 31, 2023 due to an on-going performance obligation related to the developmental activities in South Korea and Taiwan. This deferred revenue will be recognized ratably over the period leading up to the completion of these developmental activities.</span></div>All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_CollaborativeArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_CollaborativeArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976784699232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories, net</a></td>
<td class="text">Inventories, net<div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,090&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,558&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,548&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,352&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,201&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976893689760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="text-indent:18pt"><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 4, 2023, the Company announced the full results from its Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial. Based on the terms of the contract with DSE, the Company is eligible for partner milestone payments upon inclusion of cardiovascular risk reduction data in the EU label, for which payment is tied to the magnitude of the risk percentage reduction included in the label (among other requirements) and ranges from $200&#160;million for the inclusion of cardiovascular risk reduction in the EU label that correlates with a relative risk reduction rate that, based on the CLEAR Outcomes data, is equal or greater than 15% but less than 20%, to $300&#160;million if such risk reduction in the EU label that correlates with a relative risk reduction rate is equal or greater than 20%. Based on the CLEAR Outcomes data, the Company believes it would be entitled to receive $300&#160;million in partner milestone payments upon inclusion of cardiovascular risk reduction data in the EU label. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has had communications with DSE regarding potential milestone payments in which DSE has conveyed that it disagrees with the Company&#8217;s assessment that the CLEAR Outcomes data would support the Company&#8217;s right to receive any milestone payments upon inclusion of certain required cardiovascular risk reduction data in the EU label. Even if the Company is successful in enforcing its rights, there could be a delay in the Company&#8217;s receipt of the milestone payments as a result of any dispute relating to such payments. Any failure to receive or any delay in receipt of the milestone payments may significantly impact the Company&#8217;s future capital needs, ability to recognize revenue for the milestone upon inclusion of cardiovascular risk reduction data in the EU label, and ability to fund operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2023, the Company filed a complaint in the United States District Court for the Southern District of New York seeking declaratory judgment against DSE regarding the Company&#8217;s right to receive a $300&#160;million milestone payment upon inclusion of cardiovascular risk reduction in the EU label that correlates with a relative risk reduction rate of at least 20%, based on the CLEAR Outcomes trial demonstrating significant cardiovascular risk reductions.</span></div>On May 4, 2023, the Company filed an amended complaint against DSE in the Southern District of New York. The complaint seeks a judicial declaration, on an expedited basis, that DSE is contractually required to make a $300&#160;million milestone payment to the Company upon applicable regulatory approval.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786054576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s cash equivalents and short-term investments (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,395&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,394&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and March&#160;31, 2022, other income, net in the statements of operations includes interest income on investments of $0.9 million and $0.3 million. During the three months ended March&#160;31, 2023, other income, net in the statements of operations includes accretion of premiums and discounts on investments of $0.3&#160;million. During the three months ended March 31, 2022, other income, net in the statements of operations includes amortization of premiums and discounts on investments of $0.2&#160;million.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no unrealized gains or losses on investments reclassified from accumulated other comprehensive income (loss) to other income in the statements of operations during the three months ended March&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March&#160;31, 2023 and 2022, there were no allowances for credit losses and all unrealized gains (losses) for available-for-sale securities were recognized in accumulated other comprehensive income (loss). As of March&#160;31, 2023, the Company had no accrued interest receivables.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786072944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as &#8220;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#8221; Fair value measurements are defined on a three level hierarchy:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:12.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:81.159%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;1 inputs:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices for identical assets or liabilities in active markets;</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;2 inputs:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level&#160;1 prices, such as quoted market prices for similar assets or liabilities or other inputs that are observable or can be corroborated by market data; and</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level&#160;3 inputs:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs that are supported by little or no market activity and require the reporting entity to develop assumptions that market participants would use when pricing the asset or liability.</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets that have been measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,394&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,394&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels 1, 2 or 3 during the three months ended March&#160;31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786062752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Revenue Interest Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock', window );">Liability Related to the Revenue Interest Purchase Agreement</a></td>
<td class="text">Liability Related to the Revenue Interest Purchase Agreement<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2019, the Company entered into a Revenue Interest Purchase Agreement ("RIPA") with Oberland, as agent for purchasers party thereto (the &#8220;Purchasers&#8221;), and the Purchasers named therein, to obtain financing in respect to the commercialization and further development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet and other working capital needs. Pursuant to the RIPA, the Company received $125.0 million at closing, less certain issuance costs. The Company was entitled to receive up to approximately $75.0 million in subsequent installments subject to the terms and conditions set forth in the RIPA: (i) $25.0 million upon certain regulatory approval of its product candidates and (ii) $50.0 million, at the Company&#8217;s option, upon reaching $100.0 million trailing worldwide six-month net sales any time prior to December 31, 2021 (the &#8220;Third Payment&#8221;). In March 2020, the Company received $25.0 million from Oberland upon receiving regulatory approval of NEXLETOL.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As consideration for such payments, the Purchasers will have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from the Company based upon net sales of the Company&#8217;s certain products, once approved, which will be tiered payments initially ranging from 2.5% to 7.5% of the Company&#8217;s net sales in the covered territory (the &#8220;Covered Territory&#8221;); provided that if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024, the revenue interest rate will be decreased to a single rate of 0.4% of the Company&#8217;s net sales in the Covered Territory beginning on January 1, 2025. If the Third Payment is drawn down by the Company, the applicable royalty rates will increase by one-third. The Covered Territory is the United States, but is subject to expand to include the world-wide net sales if the Company&#8217;s annual U.S. net sales are less than $350.0&#160;million for the year ended December 31, 2021. The U.S. net sales milestone thresholds are not to be taken as financial guidance. The Purchasers&#8217; rights to receive the Revenue Interests shall terminate on the date on which the Purchasers have received Revenue Interests payments of 195% of the then aggregate purchase price (the &#8220;Cumulative Purchaser Payments&#8221;) paid to the Company, unless the RIPA is terminated earlier.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RIPA, the Company has an option (the &#8220;Call Option&#8221;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#8220;Put Option&#8221;) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the RIPA contains various representations and warranties, information rights, non-financial covenants, indemnification obligations and other provisions that are customary for a transaction of this nature.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RIPA Amendments</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 26, 2021, the Company entered into Amendment No. 2 (the &#8220;RIPA Amendment 2&#8221;) to the RIPA with Oberland, as agent for the purchaser parties thereto. Pursuant to the RIPA Amendment 2, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50&#160;million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA such that the purchasers will have a right to receive certain revenue interests (the &#8220;Revenue Interests&#8221;) from the Company based on net sales of the Company&#8217;s certain products, once approved, which will be tiered payments ranging from 3.33% to 10% (the &#8220;Third Payment Applicable Percentage&#8221;) of the Company&#8217;s net sales in the covered territory (the &#8220;Covered Territory&#8221;); provided that (a) prior to December 31, 2024, with respect to each country defined in the Daiichi Territory, if the percentage of net sales that Company receives from Daiichi (the &#8220;Receivables Percentage&#8221;) is less than the Third Payment Applicable Percentage, then the Revenue Interest for such country payable to the purchasers will be equal to the Receivables Percentages, (b) if annual net sales equal or exceed $350&#160;million and if the Purchasers receive 100% of their invested capital (Cumulative Purchaser Payments") by December 31, 2024, the revenue interest rate will be decreased to a single rate of 3.33% of the Company&#8217;s net sales in the Covered Territory for all subsequent calendar quarters and (c) if the Purchasers receive Revenue Interest payments less than 100% of Cumulative Purchaser Payments by December 31, 2024, the Third Payment Applicable Percentage will be increased to a single rate of the Company&#8217;s net sales that would have provided 100% of Cumulative Purchaser Payments had such rate applied from the initial funding by the Purchasers. The Covered Territory was originally the United States, but has been expanded to worldwide for all calendar years beginning on or after January 1, 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the RIPA Amendment 2, the Company has an option (the &#8220;Call Option&#8221;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#8220;Put Option&#8221;) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option or the Call Option are exercised, the required repurchase price will be 200% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 16, 2021, the Company entered into an Amendment to the Security Agreement and Waiver ("Amendment and Waiver") with the same parties to the Security Agreement, by and among the Company, Eiger Partners II LP (the "Purchaser") and Eiger III SA LLC (the "Purchaser Agent"), dated as of June 26, 2019 (the "Security Agreement"). Pursuant to the Amendment and Waiver, if (i) the net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States (as reported in the Company&#8217;s financial statements as &#8220;product sales, net&#8221; in accordance with GAAP and excluding, for the avoidance of doubt, upfront or milestone payments and other collaboration revenue) (the &#8220;Specified Net Revenue&#8221;) for the calendar quarter ended September 30, 2021 does not exceed $15.0&#160;million, or (ii) the Specified Net Revenue for any calendar quarter ending after September 30, 2021 does not exceed $15.0&#160;million, then the Company shall deposit $50.0&#160;million in a deposit account that is subject to a block account control agreement in favor of the Purchase Agent, no later than the earlier of (x) the date the Specified Net Revenue for such calendar quarter has been determined and (y) 45 days after the last day of such calendar quarter. Since the Specified Net Revenue for the calendar quarter ended September 30, 2021 did not exceed $15.0&#160;million, the Company deposited $50.0&#160;million in a deposit account that is subject to a block account control agreement, which is classified as restricted cash on the balance sheets. The Purchaser Agent shall have sole dominion and control over all funds deposited in the deposited account and such funds may be withdrawn therefrom only with the consent of the Purchaser Agent. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall have the right to apply amounts held in the deposit account in payment of certain secured obligations in the manner provided for in the Security Agreement. The Amendment and Wavier does not substitute, replace or release the Pledgors from any other obligations under the RIPA or Security Agreement.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 23, 2022, the Company entered into Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement (the &#8220;RIPA Amendment 3&#8221;), by and among the Company, the Purchasers and the Purchaser Agent, which amends (i) the Revenue Interest Purchase Agreement, by and among the Company, the Purchasers, and the Purchaser Agent, dated effective as of June 26, 2019 (as amended by Amendment No. 1 to Revenue Interest Purchase Agreement dated as of November 9, 2020 and Amendment No. 2 to Revenue Interest Purchase Agreement dated as of April 26, 2021, and as may be further amended, restated, supplemented or modified from time to time, the &#8220;RIPA&#8221;) and (ii) the Security Agreement, by the Company in favor of the Purchaser Agent, dated as of June 28, 2019 (as amended by the Amendment to Security Agreement and Waiver by and among the Company, the Purchaser and the Purchaser Agent, effective as of May 16, 2021, and as may be further amended, restated, supplemented or modified from time to time, the &#8220;Security Agreement&#8221;). Pursuant to the RIPA Amendment 3, among other things, (a) the Company agreed to make a one-time partial call payment with regards to the Revenue Interests (as defined in the RIPA) in an amount equal to $50&#160;million from the restricted cash account (the &#8220;Partial Call&#8221;), (b) the amount of the Cumulative Purchaser Payments (as defined in the RIPA) was reduced to </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$177,777,778, and (c) the Purchasers and Purchaser Agent waived certain claimed defaults, breaches and Put Option Events under the RIPA and other related documents that may have occurred as a result of the Company&#8217;s opening of a new bank account.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the guidance in ASC 470&#8209;50, &#8220;Debt&#8212;Modifications and Extinguishments,&#8221; the RIPA Amendment 3 was accounted for as a debt modification. The amendment resulted in a less than $0.1&#160;million loss on modification of debt, consisting of third-party fees associated with the transaction, which is included in selling, general, and administrative expenses in the statements of operations for the year ended December 31, 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the arrangement, as of March 31, 2023, the Company has recorded a liability, referred to as the &#8220;Revenue interest liability&#8221; on the balance sheet, of $251.8&#160;million, net of $0.3&#160;million of capitalized issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. The total redemption amount is equal to 225% of the Cumulative Purchaser Payments, or $400&#160;million. At March 31, 2023, the remaining redemption amount is $385.0&#160;million. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The Company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant increase or decrease in future net sales will materially impact the revenue interest liability, interest expense and the time period for repayment. The Company recorded approximately $11.3&#160;million and $11.0&#160;million in interest expense related to this arrangement for the three months ended March 31, 2023 and 2022, respectively.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The repayment of the RIPA to Oberland does not have a fixed repayment schedule, rather it will be completely repaid and extinguished when the Company has repaid 225% of the Cumulative Purchaser Payments. Since there is not a fixed repayment schedule, the Company does not project its future repayments by year. Each period, the Company estimates the future expected sales of its products in the covered territory and determines the effective annual imputed interest rate, which updates and changes the timing of the Company&#8217;s payments. Under the terms of the agreement, every $100&#160;million of net sales generated, less than or equal to $250&#160;million in an annual aggregate year, would result in a repayment obligation of approximately $10.0&#160;million or 10.0% at the stated repayment rate in the first year. Annual net sales for a calendar year exceeding $250&#160;million would result in a repayment obligation of approximately $3.3&#160;million or 3.3% for every $100&#160;million of sales above the threshold. As the U.S. net sales were less than $350&#160;million for the year ended December 31, 2021, the Covered Territory was expanded to include worldwide sales beginning in 2022. The Company&#8217;s repayments of the RIPA are directly tied to the growth of its net sales, and as the Company&#8217;s net sales grow, the Company expects the related repayments of the RIPA to grow as well. The Company currently expects to repay $26.9&#160;million in the next twelve months.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective annual imputed interest rate is 18.2% as of March&#160;31, 2023. Payments made to Oberland as a result of the Company&#8217;s net sales will reduce the revenue interest liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue interest liability activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interests payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,819&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No definition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of liabilities related to the Revenue Interest Purchase Agreement entered into by the Company with Eiger III SA LLC ("Oberland").</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786920432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Convertible Notes</a></td>
<td class="text">Convertible NotesIn November 2020, the Company issued $280.0&#160;million aggregate principal amount of 4.0% senior subordinated convertible notes due November 2025. The net proceeds the Company received from the offering was approximately $271.1&#160;million, after deducting the initial purchasers&#8217; discounts and commissions and offering expenses payable by the Company (the "Convertible Notes") of $8.9&#160;million. The Company used approximately $46.0&#160;million of the net proceeds from the offering of the notes to pay the cost of the Capped Call (as defined below) and $55.0&#160;million of the net proceeds from the offering of the initial notes to finance the Prepaid Forward (as defined below). The Convertible Notes are the Company's senior unsecured obligations and mature on November 15, 2025 (the &#8220;Maturity Date&#8221;), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Convertible Notes are convertible into shares of the <div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s common stock, can be repurchased for cash, or a combination thereof, at the Company&#8217;s election, at an initial conversion rate of 30.2151 shares of common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $33.096 per share of common stock, subject to adjustment. The Company will pay interest on the Convertible Notes semi-annually in arrears on May 15 and November 15 of each year.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes are general unsecured obligations of the Company that are subordinated in right of payment to indebtedness, obligations and other liabilities under the Company&#8217;s RIPA, the revenue interests issued pursuant to such agreement, and any refinancing of the foregoing.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding August 15, 2025 in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ended on March 31, 2021 (and only during such calendar quarter), if the last reported sale price per share of the Company&#8217;s common stock, par value $0.001 per share (&#8220;common stock&#8221;), is greater than or equal to 130% of the conversion price for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five business days after any five consecutive trading day period (such five consecutive trading day period, the &#8220;measurement period&#8221;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company&#8217;s common stock and the conversion rate for the notes on each such trading day; (3) if the Company calls such notes for redemption, any such notes that have been called for redemption may be converted at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, but only with respect to the notes called for redemption; and (4) upon the occurrence of specified corporate events, as provided in the Indenture. On or after August 15, 2025, to the close of business on the second scheduled trading day immediately before the maturity date, holders may convert all or any portion of their notes at the applicable conversion rate at any time at the option of the holder regardless of the foregoing conditions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, following certain corporate events or following issuance of a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a corporate event or to convert its notes called (or deemed called) for redemption during the related redemption period, as the case may be.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Convertible Notes will be redeemable, in whole or in part, at the Company&#8217;s option at any time, and from time to time, on or after November 20, 2023 and before the 41st scheduled trading day immediately before the maturity date, at a cash redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company&#8217;s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date the Company sends the related redemption notice, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company sends such redemption notice. No sinking fund is provided for the notes. If the Company redeems less than all the outstanding notes, at least $125.0&#160;million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company undergoes a &#8220;fundamental change&#8221; (as defined in the Indenture), holders may require the Company to repurchase their notes for cash all or any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the fundamental change repurchase date. The Indenture includes customary terms and covenants, including certain events of default.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2021, the Company entered into a privately negotiated exchange agreement (the &#8220;Exchange Agreement&#8221;) with two co-managed holders (the &#8220;Holders&#8221;) of its Convertible Notes. Under the terms of the Exchange Agreement the Holders agreed to exchange (the &#8220;Exchange&#8221;) with the Company $15.0&#160;million aggregate principal amount of the Convertible Notes held in the aggregate by them (and accrued interest thereon) for shares of the Company&#8217;s common stock. Pursuant to the Exchange Agreement, the number of shares of common stock to be issued by the Company to the Holders upon consummation of the Exchange was determined based upon the volume-weighted-average-price per share of common stock, subject to a floor of $5.62 per share, during the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODIwOA_adc66ab1-dedb-4d22-80ef-7e400f74515e">five</span> trading-day averaging period, commencing on the trading day immediately following the date of the Exchange Agreement. The Exchange closed on November 3, 2021, with 1,094,848 shares of the Company's common stock being exchanged.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of March 31, 2023, the principal amount of convertible notes was $265.0&#160;million, and the unamortized debt discount and issuance costs were $4.7&#160;million, for a net carrying amount of $260.3&#160;million.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company recorded $3.1&#160;million of interest expense during the three months ended March 31, 2023, and $3.0&#160;million of interest expense during the three months ended March 31, 2022, relating to the cash interest on the convertible notes due semi-annually and amortization of the debt issuance costs. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of March 31, 2023, no Convertible Notes were convertible pursuant to their terms. The estimated fair value of the Convertible Notes was $123.2&#160;million as of March 31, 2023 and $145.9&#160;million as of December 31, 2022. The estimated fair value of the Convertible Notes was determined through consideration of quoted market prices. As of March 31, 2023, the if-converted value of the Convertible Notes did not exceed the principal value of those notes.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capped Call Transactions</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the Convertible Notes, the Company entered into privately-negotiated capped call transactions with one of the initial purchasers of the convertible notes or its affiliate and certain other financial institutions. The Company used approximately $46.0&#160;million of the net proceeds from the offering of the Convertible Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce potential dilution to the Company&#8217;s common stock upon any conversion of the Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, in the event that the market value per share of the Company&#8217;s common stock, as measured under the terms of the capped call transactions at the time of exercise, is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the Convertible Notes, and is subject to certain adjustments), with such reduction and/or offset subject to a cap initially equal to approximately $55.16 (which represents a premium of approximately 100% over the last reported sale price of the Company&#8217;s common stock on November 11, 2020), subject to certain adjustments. The capped call transactions are separate transactions, entered into by the Company and are not part of the terms of the Convertible Notes.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that the transactions meet certain accounting criteria, the convertible note capped call transactions are recorded in stockholders&#8217; equity, and they are not accounted for as derivatives and are not remeasured each reporting period. As of March&#160;31, 2023 and December 31, 2022, the Company had not purchased any shares under the convertible note capped call transactions.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prepaid Forward</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the offering of the Convertible Notes, the Company entered into a prepaid forward stock repurchase transaction (&#8220;Prepaid Forward&#8221;) with a financial institution (&#8220;Forward Counterparty&#8221;). Pursuant to the Prepaid Forward, the Company used approximately $55.0&#160;million of the net proceeds from the offering of the Convertible Notes to fund the Prepaid Forward. The aggregate number of shares of the Company&#8217;s common stock underlying the Prepaid Forward was approximately 1,994,198. The expiration date for the Prepaid Forward is November 15, 2025, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders&#8217; votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. As of March 31, 2023, 165,540 shares had been delivered to the Company. The Company&#8217;s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786826016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Accrued Liabilities</a></td>
<td class="text">Other Accrued Liabilities<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued variable consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest on convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,191&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976785994384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Compensation</a></td>
<td class="text">Stock Compensation<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Stock Option and Incentive Plan</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022, the Company's stockholders approved the 2022 Stock Option and Incentive Plan (the "2022 Plan"). The number of shares of common stock available for awards under the 2022 Plan was set to 4,400,000, with any shares underlying awards that are forfeited, canceled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance or shares, or otherwise terminated (other than by exercise) under the 2022 Plan may be added back to the shares of common stock available for issuance under the 2022 Plan. The 2022 Plan provides for the award of stock options (both incentive and non-qualified options), stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. Following the approval of the 2022 Plan, no further awards will be issued under the Company&#8217;s 2013 Stock Option and Incentive Plan (the &#8220;2013 Plan&#8221;). </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the board of directors approved the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP") which was approved by the Company's shareholders on May 28, 2020. The ESPP allows eligible employees to authorize payroll deductions of up to 10% of their base salary or wages up to $25,000 annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to 15% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Offering periods under the ESPP will generally be in six months increments, commencing on September 1 and March 1 of each calendar year with the administrator having the right to establish different offering periods. In the three months ended March&#160;31, 2023 and 2022, the Company recognized $0.1&#160;million and approximately $0.1&#160;million of stock compensation expense related to the ESPP. As of March&#160;31, 2023, there have been 435,076 shares issued and 389,924 shares reserved for future issuance under the ESPP.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s options to purchase common stock for the three months ended March&#160;31, 2023:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,842,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited&#160;or&#160;expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(622,585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374,452&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to stock options was $1.0 million for the three months ended March&#160;31, 2023, including $0.1 million that was capitalized into inventory, and $1.5 million for the three months ended March&#160;31, 2022, including $0.1 million that was capitalized into inventory. As of March&#160;31, 2023, there was $9.0 million of unrecognized stock-based compensation expense related to unvested options, which will be recognized over a weighted-average period of 2.9 years. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-Based Stock Options ("PBSOs")</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company granted PBSOs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company granted PBSOs from the 2022 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met. </span></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s PBSOs for the three months ended March&#160;31, 2023:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited&#160;or&#160;expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,950&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to PBSOs was $0.2&#160;million for the three months ended March&#160;31, 2023 and $0.1&#160;million for the three months ended March 31, 2022. As of March 31, 2023, there was approximately $1.0&#160;million of unrecognized stock-based compensation expense related to unvested PBSOs, which will be recognized over a weighted-average period of approximately 1.2 years. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units (or RSUs)</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s RSUs for the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.004%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Fair Value Per <br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622,485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,392)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to RSUs was approximately $1.5 million for the three months ended March&#160;31, 2023, including $0.1&#160;million that was capitalized into inventory, and approximately $1.9 million for the three months ended March 31, 2022, including $0.1 million that was capitalized into inventory. As of March&#160;31, 2023, there was $18.6 million of unrecognized stock-based compensation expense related to unvested RSUs, which will be recognized over a weighted-average period of 3.0 years.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Performance-based Restricted Stock Units ("PBRSUs")</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Company granted PBRSUs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined milestones based on the Company's U.S. net product sales or clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBRSUs based on the expected performance period to achieve the performance milestone. The fair value of the PBRSUs is based on the quoted market price of the Company's common stock on the date of grant. The Company expects the performance criteria to be met. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company's PBRSUs for the three months ended March 31, 2023:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:67.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PBRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average fair value per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,725)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation related to the PBRSUs was $0.1&#160;million for the three months ended March 31, 2023, including less than $0.1&#160;million that was capitalized into inventory, and $0.8&#160;million for the three months ended March 31, 2022, including $0.1&#160;million that was capitalized into inventory. As of March 31, 2023, there was approximately $0.8&#160;million of unrecognized stock-based compensation expense related to unvested PBRSUs, which will be recognized over a weighted-average period of approximately 1.2 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786027712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesThere was no provision for income taxes for the three months ended March&#160;31, 2023 and 2022, because the Company has incurred annual operating losses since inception. At March&#160;31, 2023, the Company continues to conclude that it is not more likely than not that the Company will realize the benefit of its deferred tax assets due to its history of losses. Accordingly, a full valuation allowance has been applied against the net deferred tax assets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786902560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text">Stockholders' Deficit<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 15, 2022, the Company filed a new registration statement on Form S-3 to replace its prior automatically effective registration statement on Form S-3ASR filed on August 3, 2021, which registers the offering, issuance and sale of up to $239&#160;million of common stock from time to time in &#8220;at-the-market&#8221; offerings (the &#8220;New ATM Program&#8221;). On February 21, 2023, the Company terminated the open market sales agreement with Jefferies LLC and entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald &amp; Co., as sales agent, to provide for the issuance and sale by the Company of up to $70&#160;million of common stock from time to time in &#8220;at-the-market&#8221; offerings (the "2023 ATM Program"), pursuant to its existing Form S-3 and the prospectus supplement filed on February 21, 2023. The Company may continue to use the 2023 ATM Program to address potential short-term or long-term funding requirements that may arise. Such program will continue to be subject to the volatility of the price of the Company's common stock and general market conditions. During the year ended December 31, 2022, the Company issued 13,043,797 shares of common stock resulting in net proceeds of approximately $90.8&#160;million after deducting $3.1&#160;million of underwriting discounts and commissions and other expenses, pursuant to the New ATM Program. No shares have been issued under the 2023 ATM Program as of the date of this quarterly report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with an underwriting agreement with H.C. Wainwright &amp; Co., LLC ("Wainwright") on December 2, 2021, the Company issued warrants to purchase 36,964,286 shares of common stock at an exercise price of $9.00. The warrants will terminate on December 7, 2023. The warrants were recorded at fair value of $61.9&#160;million to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the proceeds between the common shares issued with the Offering and the warrants. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registered Direct Offering and Warrant Amendment</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2023, the Company entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) with certain purchasers named therein (the &#8220;Purchasers&#8221;), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the &#8220;Offering&#8221;), 12,205,000 shares of its common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), pre-funded warrants to purchase up to an aggregate of 20,965,747 shares of Common Stock (the &#8220;Pre-Funded Warrants&#8221;) in lieu of shares of Common Stock, and warrants to purchase up to 33,170,747 shares of Common Stock (the &#8220;Warrants&#8221;). The combined purchase price of each share of Common Stock and accompanying Warrant is $1.675 per share. The Warrants expire on September 22, 2026 and have an exercise price of $1.55. The purchase price of each Pre-Funded Warrant is $1.674 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $0.001). The Purchase Agreement contains customary representations, warranties, covenants and indemnification rights and obligations of the Company and the Purchasers. The Offering closed on March 22, 2023. The warrants and pre-funded warrants were recorded at fair value of $22.8&#160;million to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the proceeds between the common shares issued with the Offering and the warrants and pre-funded warrants. The Company estimated the fair value of the warrants using a Black-Scholes option-pricing model, which is based, in part, upon subjective assumptions including but not limited to stock price volatility, the expected life of the warrant, the risk-free interest rate and the fair value of the common stock underlying the warrant. The Company estimates the volatility based on its historical volatility that is in line with the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury daily rate for a maturity similar to the expected remaining life of the warrants. The expected remaining life of the warrants is assumed to be equivalent to its remaining contractual term. The Company estimated the fair value of the pre-funded warrants based on the market price of the Company's common stock at issuance. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Offering, the Company amended, pursuant to Warrant Amendment Agreements (the &#8220;Warrant Amendment Agreements&#8221;), certain existing warrants to purchase up to an aggregate of 9,024,212 shares of the Company's common stock that were previously issued in December 2021 at an exercise price of $9.00 per share and had an expiration date of December 7, 2023, effective upon the closing of the Offering, such that the amended warrants have a reduced exercise price of $1.55 per share and expire three and one half years following the closing of the Offering, or September 22, 2026, for additional consideration of $0.125 per amended warrant. Based on the change in the fair value of the amended warrants, the Company recorded issuance costs to additional paid-in capital of $2.9&#160;million.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received gross proceeds of approximately $55.5&#160;million from the Offering, before deducting placement agent fees and related offering expenses. The net proceeds to the Company from the Offering, after deducting the placement agent fees and expenses and the Company&#8217;s estimated offering expenses of $4.2&#160;million, were approximately $51.3&#160;million. In addition, the Company received approximately $1.2&#160;million as the gross consideration in connection with the Warrant </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amendment Agreements. The net proceeds of the Warrant Amendment Agreements after deducting placement fees of $0.1&#160;million were approximately $1.1&#160;million.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the warrants and pre-funded warrants outstanding for the Company as of March 31, 2023 and December 31, 2022:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"/><td style="width:53.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.389%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding from 2021 agreement, expiring December 7, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,940,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,964,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding from Warrant Amendment Agreements, expiring September 22, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding from Purchase Agreement, expiring September 22, 2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,170,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded warrants outstanding, no expiration date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,965,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total warrants and pre-funded warrants outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,100,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,964,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2023, on April 24, 2023, 5,865,747 shares of pre-funded warrants were exercised.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976781566736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text">Net Loss Per Common Share<div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Pre-Funded Warrants are included in the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period, including shares that potentially could be dilutive if they were exercised or vested during the period, determined using the treasury-stock method. For purposes of this calculation, warrants for common stock, stock options, PBSOs, unvested RSUs and PBRSUs, shares issuable under the ESPP and shares issuable upon conversion of the convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"><tr><td style="width:1.0%"/><td style="width:57.421%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,101,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under PBSOs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested PBRSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable related to the ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,007,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,007,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,135,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,964,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,292,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,816,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786679760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Statements of Cash Flows and Restricted Cash</a></td>
<td class="text">Statements of Cash Flows and Restricted CashThe following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on March 31, 2023 and 2022 and December 31, 2022 and 2021 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:42.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.492%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782076288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company&#8217;s financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2022, and the notes thereto, which are included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in bank deposits, money market accounts, and short-term investments. The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents are reported at fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are considered to be available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are reported in accumulated other comprehensive income (loss). The cost of investments classified as available-for-sale are adjusted for the amortization of premiums and accretion of discounts to maturity and recorded in other income, net. Realized gains and losses, if any, are determined using the specific identification method and recorded in other income, net. Investments with original maturities beyond 90 days at the date of purchase and which mature at, or less than twelve months from, the balance sheet date are classified as current. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risk</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Risk</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of March&#160;31, 2023, eleven customers accounted for all of the </span></div>Company's net trade receivables and as of December 31, 2022, eleven customers accounted for all the Company's net trade receivables.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Collaboration Revenue</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones as consideration when it is probable that a future reversal is unlikely to occur. For sales-based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (&#8220;API&#8221;) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.</span></div><div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt">Product Sales, Net</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $17.0 million for the three months ended March&#160;31, 2023, and $13.4 million for the three months ended March&#160;31, 2022.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers&#8217; distribution facilities, or free on board (&#8220;FOB&#8221;) destination, the terms of which are designated in the contract.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company&#8217;s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as &#8220;Other accrued liabilities&#8221; in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forms of Variable Consideration</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates and Chargebacks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-pay assistance:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distribution Fees:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company generally offers a right of return based on the product&#8217;s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company&#8217;s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discounts:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company&#8217;s expectations regarding future payment patterns.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. </span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Implemented Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Implemented Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no other material changes to the significant accounting policies previously disclosed in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786860192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventories</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,090&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,558&#160;</span></td><td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,697&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,548&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,352&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,201&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786682192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Company's Cash Equivalents and Short-Term Investments</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s cash equivalents and short-term investments (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,566&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,395&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,394&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated <br/>Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,078&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,995&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,562&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,560&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786670176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s financial assets that have been measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,394&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,394&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,078&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">401&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,560&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782014720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Revenue Interest Purchase Agreement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock', window );">Summary of Revenue Interest Liability Activity During the Period</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the revenue interest liability activity during the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:12pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense recognized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue Interests payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue interest liability at March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,819&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No definition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ScheduleOfRevenueInterestLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to the revenue interest liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ScheduleOfRevenueInterestLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786702608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,565&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,053&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued variable consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,987&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued interest on convertible notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,421&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,191&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782089776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Activity Relating to the Company's Options and Performance-Based Options to Purchase Common Stock</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s options to purchase common stock for the three months ended March&#160;31, 2023:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,842,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,154,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited&#160;or&#160;expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(622,585)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374,452&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.18</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,194,004&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.99</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s PBSOs for the three months ended March&#160;31, 2023:</span></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.32</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited&#160;or&#160;expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,250)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,950&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Activity Relating to the Company's RSUs</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company&#8217;s RSUs for the three months ended March&#160;31, 2023:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:68.254%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.004%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Fair Value Per <br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,768,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.80&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,622,485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.13&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101,881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171,392)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Summary of Activity Relating to the Company's PBRSU's</a></td>
<td class="text"><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity relating to the Company's PBRSUs for the three months ended March 31, 2023:</span></div><div style="margin-bottom:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:67.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of <br/>PBRSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average fair value per share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">461,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(200,725)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding and unvested March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,375&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786860192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock', window );">Summary of Warrants and Pre-funded Warrants Outstanding</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes the warrants and pre-funded warrants outstanding for the Company as of March 31, 2023 and December 31, 2022:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"><tr><td style="width:1.0%"/><td style="width:53.261%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.385%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.890%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.389%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding from 2021 agreement, expiring December 7, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,940,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,964,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding from Warrant Amendment Agreements, expiring September 22, 2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding from Purchase Agreement, expiring September 22, 2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,170,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-funded warrants outstanding, no expiration date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,965,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total warrants and pre-funded warrants outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,100,780&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,964,286&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Warrants And Pre Funded Warrants Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976785994384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Shares Excluded From Calculation of Diluted Net (Loss) Income Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"><tr><td style="width:1.0%"/><td style="width:57.421%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.612%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under option</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,374,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,101,259&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares under PBSOs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433,950&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested RSUs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,978,717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested PBRSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable related to the ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issuable upon conversion of convertible notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,007,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,007,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,135,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,964,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total potential dilutive shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,292,792&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,816,979&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976786054576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock', window );">Reconciliation of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text">The following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on March 31, 2023 and 2022 and December 31, 2022 and 2021 (in thousands): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:42.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.492%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,911&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258,892&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reconciliation of cash and cash equivalents and restricted cash presented on the Condensed Balance Sheets to the same amounts presented on the Condensed Statements of Cash Flows.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782781552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company and Basis of Presentation (Details)<br> $ / shares in Units, patient in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 22, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 19, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>patient</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 23, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_NumberOfStudyPatients', window );">Study patients enrolled | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,237,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,564,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,598<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_CommonStockPurchasableUnderPrefundedWarrants', window );">Common stock purchasable under prefunded warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,965,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_CommonStockPurchasableUnderWarrants', window );">Common stock purchasable under warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,170,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Common Stock And Accompanying Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Pre Funded Warrant And Accompanying Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_WarrantAmendmentAgreementsMember', window );">Warrant Amendment Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>The Company and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_CommonStockPurchasableUnderWarrants', window );">Common stock purchasable under warrants (in shares) | shares</a></td>
<td class="nump">9,024,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights', window );">Additional consideration (in dollars per share)</a></td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds | $</a></td>
<td class="nump">$ 55,500<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from warrant amendment | $</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant Or Right, Additional Consideration Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Purchase Price Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_CommonStockPurchasableUnderPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Purchasable Under Prefunded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_CommonStockPurchasableUnderPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_CommonStockPurchasableUnderWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Purchasable Under Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_CommonStockPurchasableUnderWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NumberOfStudyPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Study Patients</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NumberOfStudyPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=espr_CommonStockAndAccompanyingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=espr_CommonStockAndAccompanyingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=espr_PreFundedWarrantAndAccompanyingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=espr_PreFundedWarrantAndAccompanyingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_WarrantAmendmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_WarrantAmendmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976781489728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>revenue_source </div>
<div>customer</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>customer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_SignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_NumberOfSourcesOfRevenue', window );">Number of revenue sources | revenue_source</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 24,329<span></span>
</td>
<td class="nump">$ 18,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_SignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Revenues</a></td>
<td class="nump">$ 17,031<span></span>
</td>
<td class="nump">$ 13,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember', window );">Trade Receivables | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_SignificantAccountingPoliciesLineItems', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ConcentrationRiskNumberOfMajorCustomers', window );">Number of major customers | customer</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ConcentrationRiskNumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of the Company's major customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ConcentrationRiskNumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NumberOfSourcesOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Sources Of Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NumberOfSourcesOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_TradeAccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976778974368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborations with Third Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2021</div></th>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,329<span></span>
</td>
<td class="nump">$ 18,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember', window );">Daiichi Sankyo Europe GmbH ("DSE") | Royalty revenue and product sales bulk tablets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">5,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember', window );">Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_UpFrontPayment', window );">Upfront cash payment received (paid)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_CashPaymentToBeReceivedUponFirstCommercialSales', window );">Cash payment to the Company upon first commercial sales in the DSE Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember', window );">Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization', window );">Additional cash payment to the Company upon grant of marketing authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember', window );">Daiichi Sankyo Europe GmbH ("DSE") | License and Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization', window );">Additional cash payment to the Company upon grant of marketing authorization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_OtsukaPharmaceuticalCoLtdMember', window );">Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_UpFrontPayment', window );">Upfront cash payment received (paid)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones', window );">Potential additional future payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_OtsukaPharmaceuticalCoLtdMember', window );">Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_OtsukaPharmaceuticalCoLtdMember', window );">Otsuka Pharmaceutical Co, Ltd. | Exclusive Developmental Activities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory', window );">Milestone payment, first JNDA submissions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory', window );">Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies', window );">Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_FuturePaymentMilestoneSalesMilestones', window );">Milestone payments related to total net sales achievements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoCoLtdMember', window );">Daiichi Sankyo Co. Ltd | License and Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_FutureUpFrontPayment', window );">Consideration cash payment</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones', window );">Cash payment to be received upon certain commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_DeferredUpFrontPayment', window );">Deferred up-front payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoCoLtdMember', window );">Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoCoLtdMember', window );">Daiichi Sankyo Co. Ltd | License and Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborations with Third Parties</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales', window );">Percentage of royalties to be received on the net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional cash payment to the Company upon grant of marketing authorization dependent on the range of relative risk reduction in the CLEAR outcomes study.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_CashPaymentToBeReceivedUponCertainCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Payment To Be Received Upon Certain Commercial Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_CashPaymentToBeReceivedUponCertainCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_CashPaymentToBeReceivedUponFirstCommercialSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash payment to the Company upon first commercial sales in the DSE Territory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_CashPaymentToBeReceivedUponFirstCommercialSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_DeferredUpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Up-Front Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_DeferredUpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_FuturePaymentMilestoneSalesMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of potential future payments related to total net sales achievements for Otsuka in Japan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_FuturePaymentMilestoneSalesMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_FutureUpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future Up-Front Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_FutureUpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRoyaltiesToBeReceivedOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalties to be received on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRoyaltiesToBeReceivedOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_UpFrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of up-front payment received (paid) .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_UpFrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=espr_DaiichiSankyoEuropeGmbhMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=espr_RoyaltyRevenueAndProductSalesBulkTabletsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=espr_RoyaltyRevenueAndProductSalesBulkTabletsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=espr_OtsukaPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=espr_OtsukaPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_ExclusiveDevelopmentalActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_ExclusiveDevelopmentalActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=espr_DaiichiSankyoCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=espr_DaiichiSankyoCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782554832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 35,090<span></span>
</td>
<td class="nump">$ 26,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">1,697<span></span>
</td>
<td class="nump">6,548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">2,565<span></span>
</td>
<td class="nump">2,095<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Inventory</a></td>
<td class="nump">$ 39,352<span></span>
</td>
<td class="nump">$ 35,201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976778990592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>May 04, 2023</div></th>
<th class="th"><div>Mar. 27, 2023</div></th>
<th class="th"><div>Mar. 04, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PotentialProceedsFromPartnerMilestonePayments', window );">Partner milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PotentialProceedsFromPartnerMilestonePayments', window );">Partner milestone payments</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_TypeOfRiskAxis=espr_CardiovascularRiskMember', window );">Cardiovascular Risk | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRiskReduction', window );">Percentage of risk reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_TypeOfRiskAxis=espr_CardiovascularRiskMember', window );">Cardiovascular Risk | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRiskReduction', window );">Percentage of risk reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_TypeOfRiskAxis=espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember', window );">Cardiovascular Risk Outcome Less than Twenty Percent | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PotentialProceedsFromPartnerMilestonePayments', window );">Partner milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_TypeOfRiskAxis=espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember', window );">Cardiovascular Risk Outcome Greater than Twenty Percent | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PotentialProceedsFromPartnerMilestonePayments', window );">Partner milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_TypeOfRiskAxis=espr_RelativeRiskMember', window );">Relative Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRiskReduction', window );">Percentage of risk reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRiskReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Risk Reduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRiskReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PotentialProceedsFromPartnerMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Proceeds From Partner Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PotentialProceedsFromPartnerMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_TypeOfRiskAxis=espr_CardiovascularRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_TypeOfRiskAxis=espr_CardiovascularRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_TypeOfRiskAxis=espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_TypeOfRiskAxis=espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_TypeOfRiskAxis=espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_TypeOfRiskAxis=espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_TypeOfRiskAxis=espr_RelativeRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_TypeOfRiskAxis=espr_RelativeRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976781689072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Cash Equivalents and Short-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 131,395<span></span>
</td>
<td class="nump">$ 152,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities, Available-for-Sale</a></td>
<td class="nump">131,394<span></span>
</td>
<td class="nump">152,560<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">113,566<span></span>
</td>
<td class="nump">105,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities, Available-for-Sale</a></td>
<td class="nump">113,566<span></span>
</td>
<td class="nump">105,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities, Available-for-Sale</a></td>
<td class="nump">401<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities, Available-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. treasury notes | Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">17,428<span></span>
</td>
<td class="nump">42,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities, Available-for-Sale</a></td>
<td class="nump">$ 17,427<span></span>
</td>
<td class="nump">$ 42,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976778979552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">$ 1,273,000<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedInvestmentIncomeReceivable', window );">Accrued interest receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on investments</a></td>
<td class="nump">339,000<span></span>
</td>
<td class="num">(173,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income on investments</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on investments</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="num">$ (200,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInvestmentIncomeReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInvestmentIncomeReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976779227296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_FairValueMeasurementAssetTransfersBetweenLevels', window );">Transfer of assets between levels</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">131,394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152,560,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">113,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,078,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">17,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,081,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">131,394,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,560,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">113,566,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,078,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;1 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">401,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">401,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;1 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">17,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,081,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;2 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;2 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;3 | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring fair value measurement | Level&#160;3 | U.S. treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair value measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_FairValueMeasurementAssetTransfersBetweenLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the transfer of assets between the levels of fair value hierarchy that have taken place during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_FairValueMeasurementAssetTransfersBetweenLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976776472640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 23, 2022</div></th>
<th class="th"><div>May 16, 2021</div></th>
<th class="th"><div>Apr. 26, 2021</div></th>
<th class="th"><div>Jun. 26, 2019</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_OneTimePartialCall', window );">One time partial call</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestPaymentsRedemptionPercentage', window );">Redemption percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestPaymentsRedemptionValue', window );">Redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestPaymentsRemainingRedemptionValue', window );">Remaining redemption amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,387,000<span></span>
</td>
<td class="nump">14,062,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement (RIPA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestLiability', window );">Revenue interest liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,819,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243,605,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement', window );">Capitalized issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300,000<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement (RIPA) | Oberland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_GrossProceedsFromRevenueInterestPurchaseAgreement', window );">Gross proceeds from revenue interest liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions', window );">Total amount of subsequent installment, subject to RIPA terms and conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval', window );">Amount of subsequent installment, subject to regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold', window );">Amount of subsequent installment, subject to achievement of sales threshold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment', window );">Milestone amount for worldwide sales to receive the third payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ProceedsFromRevenueInterestPurchaseAgreement', window );">Proceeds from Revenue Interest Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestRateTierTwo', window );">Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestRateInitialRate', window );">Initial revenue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate', window );">Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestRateTierThree', window );">Revenue interest rate if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate', window );">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates', window );">Percentage of revenue interests payment on which agreement terminates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount', window );">Trailing number of months sales must be at or above milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestsPaymentOnWhichAgreementTerminates', window );">Cumulative purchaser payment adjustment</a></td>
<td class="nump">$ 177,777,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary', window );">Percentage of revenues interests payment on which agreement terminates, after third anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory', window );">Maximum amount of US net sales to qualify for the Covered Territory expansion to include worldwide sales by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths', window );">Repayment amount expected to pay in next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate', window );">Effective annual imputed interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount', window );">Consecutive number of months sales must be at or above milestone amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment', window );">Percentage of increase in royalty rate upon drawdown of third payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement (RIPA) | Oberland | Net Sales Less Than $250 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestRateInitialRate', window );">Initial revenue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate', window );">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_HypotheticalSalesGeneratedAmount', window );">Hypothetical sales generated amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated', window );">Hypothetical repayment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement (RIPA) | Oberland | Net Sales Greater Than $250 Million But Less Than $350 Million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestRateTierTwo', window );">Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate', window );">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_HypotheticalSalesGeneratedAmount', window );">Hypothetical sales generated amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated', window );">Hypothetical repayment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementAmendmentMember', window );">RIPA Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Loss on modification of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementAmendmentMember', window );">RIPA Amendment | Oberland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestRateTierTwo', window );">Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestRateInitialRate', window );">Initial revenue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate', window );">Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold', window );">Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2024, contingent on 100% invested capital received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage', window );">Percentage of revenue interest payments to qualify for third payment applicable percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfCumulativePurchaserPaymentsGuarantee', window );">Percentage of cumulative purchaser payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised', window );">Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised', window );">Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember', window );">RIPA Amendment To The Security Agreement And Waiver | Oberland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems', window );"><strong>Liability Related to the Revenue Interest Purchase Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount', window );">Specified net revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold', window );">Company deposit value in blocked account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the subsequent installment which is subject to the achievement of the Sales Threshold as defined in the Revenue Interest Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the subsequent installment which is subject to regulatory approval.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the subsequent installment, subject to the terms and conditions of the Revenue Interest Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consecutive number of months sales must be at or above the milestone amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_GrossProceedsFromRevenueInterestPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a revenue interest purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_GrossProceedsFromRevenueInterestPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_HypotheticalRepaymentObligationBasedOnSalesGenerated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Hypothetical Repayment Obligation Based On Sales Generated</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_HypotheticalRepaymentObligationBasedOnSalesGenerated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_HypotheticalSalesGeneratedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Hypothetical Sales Generated Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_HypotheticalSalesGeneratedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_LiabilityFromSaleOfFutureRevenuesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_LiabilityFromSaleOfFutureRevenuesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone amount for worldwide sales to receive the Third Payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Sales Threshold To Include Worldwide Sales In Covered Territory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_OneTimePartialCall">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>One Time Partial Call</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_OneTimePartialCall</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfCumulativePurchaserPaymentsGuarantee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Cumulative Purchaser Payments, Guarantee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfCumulativePurchaserPaymentsGuarantee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of increase in the Royalty Rate upon drawdown of the Third Payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue interests payment on which agreement terminates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Revenue Interests Payment on Which Agreement Terminates, After Third Anniversary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ProceedsFromRevenueInterestPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Revenue Interest Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ProceedsFromRevenueInterestPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the current and non-current portion of the Revenue Interest Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestPaymentsRedemptionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Payments, Redemption Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestPaymentsRedemptionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestPaymentsRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Payments, Redemption Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestPaymentsRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestPaymentsRemainingRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest Payments, Remaining Redemption Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestPaymentsRemainingRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of effective annual imputed interest rate under the revenue interest purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestRateInitialRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The initial revenue interest rate, as a percentage of the Company's net sales in the Covered Territory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestRateInitialRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestRateTierThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Revenue Interest Rate which will take effect if annual net sales equals or exceeds the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestRateTierThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestRateTierTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Revenue Interest Rate which will take effect if annual net sales equal or exceed $350.0 million by December 31, 2021.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestRateTierTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestsPaymentOnWhichAgreementTerminates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Interests Payment On Which Agreement Terminates</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestsPaymentOnWhichAgreementTerminates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Amount of Net Revenue To Qualify For Deposit In Blocked Account</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The trailing number of months sales must be at or above the milestone amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_UnamortizedTransactionCostsOnRevenueInterestAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction costs on revenue interest agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_UnamortizedTransactionCostsOnRevenueInterestAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=espr_EigerIiiSaLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NetSalesThresholdAxis=espr_NetSalesThresholdOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NetSalesThresholdAxis=espr_NetSalesThresholdOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NetSalesThresholdAxis=espr_NetSalesThresholdTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NetSalesThresholdAxis=espr_NetSalesThresholdTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976778904576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesRollForward', window );"><strong>Liability From Sale Of Future Revenues [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PaymentsFromRevenueInterestPurchaseAgreement', window );">Revenue Interests payments</a></td>
<td class="num">$ (3,106)<span></span>
</td>
<td class="num">$ (1,217)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember', window );">Revenue Interest Purchase Agreement (RIPA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_LiabilityFromSaleOfFutureRevenuesRollForward', window );"><strong>Liability From Sale Of Future Revenues [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestLiability', window );">Revenue interest liability, beginning balance</a></td>
<td class="nump">243,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized', window );">Interest expense recognized</a></td>
<td class="nump">11,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_PaymentsFromRevenueInterestPurchaseAgreement', window );">Revenue Interests payments</a></td>
<td class="num">(3,106)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_RevenueInterestLiability', window );">Revenue interest liability, ending balance</a></td>
<td class="nump">$ 251,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_LiabilityFromSaleOfFutureRevenuesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability From Sale Of Future Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_LiabilityFromSaleOfFutureRevenuesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_PaymentsFromRevenueInterestPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from a revenue interest purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_PaymentsFromRevenueInterestPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the current and non-current portion of the Revenue Interest Liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in the revenue interest liability attributable to interest expense recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_RevenueInterestPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976778137152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Notes (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 03, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 22, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 16, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($) </div>
<div>day </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities', window );">Purchase of capped call options associated with convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000,000<span></span>
</td>
<td class="nump">$ 46,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Prepayment of forward stock repurchase transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Underlying common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,994,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Shares delivered to the company (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=espr_CappedCallMember', window );">Capped Call | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage', window );">Class of warrant or right, premium percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025 | Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 280,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, stated interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Debt instrument, convertible, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.2151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Exchange Agreement, amount of principal amount converted into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor', window );">Exchange Agreement, weighted average price per share floor (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays', window );">Exchange Agreement, threshold trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Common stock being exchanged (in shares) | shares</a></td>
<td class="nump">1,094,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Debt interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 145,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025 | Convertible Debt | Purchaser Discounts And Commissions And Offering Expenses Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt discount and issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025 | Convertible Debt | Period One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Average trading-day period | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_NumberOfBusinessDays', window );">Number of business days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice', window );">Debt instrument, convertible, threshold percentage of last reported sale price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member', window );">Convertible Senior Notes Due 2025 | Convertible Debt | Period Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Debt instrument, convertible, threshold percentage of stock price trigger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays', window );">Debt instrument, convertible, threshold trading days | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Average trading-day period | day</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_DebtInstrumentCovenantRequiredAmountOutstanding', window );">Debt instrument, required amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_DebtInstrumentCovenantRequiredAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Required Amount Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_DebtInstrumentCovenantRequiredAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NumberOfBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Business Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NumberOfBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3505-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=espr_CappedCallMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=espr_CappedCallMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=espr_ConvertibleSeniorNotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782721088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 5,565<span></span>
</td>
<td class="nump">$ 9,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_AccruedVariableConsiderationCurrent', window );">Accrued variable consideration</a></td>
<td class="nump">21,313<span></span>
</td>
<td class="nump">21,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">3,446<span></span>
</td>
<td class="nump">2,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest on convertible notes</a></td>
<td class="nump">3,975<span></span>
</td>
<td class="nump">1,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">122<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent', window );">Total other accrued liabilities</a></td>
<td class="nump">$ 34,421<span></span>
</td>
<td class="nump">$ 35,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_AccruedVariableConsiderationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_AccruedVariableConsiderationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782503072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Stock Options Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=espr_StockOptionAndIncentivePlan2022Member', window );">Stock Option And Incentive Plan 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of commons stock shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee, as a percentage of base salary</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount', window );">Amount of maximum annual contributions per employee</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares', window );">Purchase discount</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod', window );">Duration of offering periods</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">389,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized into inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which remaining unrecognized compensation cost will be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember', window );">PBSOs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which remaining unrecognized compensation cost will be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized into inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense, options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which remaining unrecognized compensation cost will be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PBRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Stock-based compensation capitalized into inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which remaining unrecognized compensation cost will be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation expense, RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The duration of offering periods in which employees may purchase stock, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_EmployeeStockPurchasePlanPercentageDiscountOnShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The discount at which shares may be purchased under the employee stock purchase plan, calculated as a stated percentage of the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_EmployeeStockPurchasePlanPercentageDiscountOnShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=espr_StockOptionAndIncentivePlan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=espr_StockOptionAndIncentivePlan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782619312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - Schedule of Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of period (in shares)</a></td>
<td class="nump">3,842,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,154,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(622,585)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">4,374,452<span></span>
</td>
<td class="nump">3,842,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">4,374,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,194,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of period (in dollars per share)</a></td>
<td class="nump">$ 27.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">4.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">38.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">19.98<span></span>
</td>
<td class="nump">$ 27.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">19.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 33.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">4 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">2 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782474512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - PBSOs (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of period (in shares)</a></td>
<td class="nump">3,842,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,154,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(622,585)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">4,374,452<span></span>
</td>
<td class="nump">3,842,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">4,374,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,194,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of period (in dollars per share)</a></td>
<td class="nump">$ 27.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">4.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">38.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">19.98<span></span>
</td>
<td class="nump">$ 27.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">19.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 33.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">4 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">6 years 2 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">2 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember', window );">PBSOs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of period (in shares)</a></td>
<td class="nump">499,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(65,250)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">433,950<span></span>
</td>
<td class="nump">499,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">433,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">48,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of period (in dollars per share)</a></td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (in dollars per share)</a></td>
<td class="nump">6.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">6.72<span></span>
</td>
<td class="nump">$ 6.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">6.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 8.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
<td class="text">9 years 3 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">6 years 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976782031632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - RSUs (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning of period (in shares) | shares</a></td>
<td class="nump">1,768,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,622,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(101,881)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(171,392)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested at the ending of period (in shares) | shares</a></td>
<td class="nump">3,117,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and at the beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">4.13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">9.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">9.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at the at the end of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976778979808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Compensation - PBRSUs (Details) - PBRSUs<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of PBRSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning of period (in shares) | shares</a></td>
<td class="nump">461,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(69,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(200,725)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding and unvested at the ending of period (in shares) | shares</a></td>
<td class="nump">191,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and at the beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">12.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">8.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding and unvested at the at the end of the period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976866964992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Provision for income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976775085552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Mar. 19, 2023</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Apr. 15, 2022</div></th>
<th class="th"><div>Dec. 02, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 24, 2023</div></th>
<th class="th"><div>Mar. 23, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total shares of common stock from exercisable warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,100,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,964,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,237,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,564,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs to additional paid in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,598<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=espr_TheWarrantsMember', window );">The Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=espr_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total shares of common stock from exercisable warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,965,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=espr_PreFundedWarrantMember', window );">Pre Funded Warrant | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,865,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_WainwrightMember', window );">Wainwright</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total shares of common stock from exercisable warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,964,286<span></span>
</td>
<td class="nump">27,940,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,964,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total shares of common stock from exercisable warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,170,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_CommonStockPurchasableUnderPrefundedWarrants', window );">Common stock purchasable under prefunded warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,965,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_CommonStockPurchasableUnderWarrants', window );">Common stock purchasable under warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,170,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Common Stock And Accompanying Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement | Pre Funded Warrant And Accompanying Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights', window );">Purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_WarrantAmendmentAgreementsMember', window );">Warrant Amendment Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="nump">$ 55,500<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total shares of common stock from exercisable warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,024,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_CommonStockPurchasableUnderWarrants', window );">Common stock purchasable under warrants (in shares)</a></td>
<td class="nump">9,024,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued for shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,024,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration', window );">Additional consideration per amended warrant (in dollars per share)</a></td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Estimated offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfPrivatePlacement', window );">Placement fees</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from warrant amendment</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=espr_AtTheMarketProgramMember', window );">At The Market Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issued stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,043,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_espr_SaleOfStockAuthorizedAmount', window );">Aggregate offering price shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercise Price of Warrants or Rights, Additional Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Purchase Price Of Warrants Or Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_CommonStockPurchasableUnderPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Purchasable Under Prefunded Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_CommonStockPurchasableUnderPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_CommonStockPurchasableUnderWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Purchasable Under Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_CommonStockPurchasableUnderWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_espr_SaleOfStockAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">espr_SaleOfStockAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>espr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=espr_TheWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=espr_TheWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=espr_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=espr_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_WainwrightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_WainwrightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=espr_CommonStockAndAccompanyingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=espr_CommonStockAndAccompanyingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=espr_PreFundedWarrantAndAccompanyingWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=espr_PreFundedWarrantAndAccompanyingWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_WarrantAmendmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_WarrantAmendmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=espr_AtTheMarketProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=espr_AtTheMarketProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976781508320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Deficit - Summary of Warrants and Pre-funded Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 23, 2023</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total shares of common stock from exercisable warrants outstanding (in shares)</a></td>
<td class="nump">91,100,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,964,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=espr_PreFundedWarrantMember', window );">Pre Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total shares of common stock from exercisable warrants outstanding (in shares)</a></td>
<td class="nump">20,965,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_WainwrightMember', window );">Wainwright</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total shares of common stock from exercisable warrants outstanding (in shares)</a></td>
<td class="nump">27,940,074<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,964,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,964,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_WarrantAmendmentAgreementsMember', window );">Warrant Amendment Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total shares of common stock from exercisable warrants outstanding (in shares)</a></td>
<td class="nump">9,024,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Total shares of common stock from exercisable warrants outstanding (in shares)</a></td>
<td class="nump">33,170,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=espr_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=espr_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_WainwrightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_WainwrightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_WarrantAmendmentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_WarrantAmendmentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=espr_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976781562256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Common Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">86,292,792<span></span>
</td>
<td class="nump">51,816,979<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common shares under option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">4,374,452<span></span>
</td>
<td class="nump">4,101,259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember', window );">Common shares under PBSOs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">433,950<span></span>
</td>
<td class="nump">122,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember', window );">Unvested RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">3,117,397<span></span>
</td>
<td class="nump">1,978,717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">Unvested PBRSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">191,375<span></span>
</td>
<td class="nump">602,750<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Shares issuable related to the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">33,575<span></span>
</td>
<td class="nump">40,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Shares issuable upon conversion of convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">8,007,010<span></span>
</td>
<td class="nump">8,007,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net (Loss) Income Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total potential dilutive shares (in shares)</a></td>
<td class="nump">70,135,033<span></span>
</td>
<td class="nump">36,964,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139976784485872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Cash Flows and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 144,911<span></span>
</td>
<td class="nump">$ 124,775<span></span>
</td>
<td class="nump">$ 150,364<span></span>
</td>
<td class="nump">$ 208,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows</a></td>
<td class="nump">$ 144,911<span></span>
</td>
<td class="nump">$ 124,775<span></span>
</td>
<td class="nump">$ 200,364<span></span>
</td>
<td class="nump">$ 258,892<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>espr-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:espr="http://www.esperion.com/20230331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="espr-20230331.xsd" xlink:type="simple"/>
    <context id="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i138e5960375b40e09f319237f97dcd65_I20230501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="id6505e18f8b44bb1be4b3c88b659408a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i914746ebf548485ab38582d5985e0ada_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2b77b80c5d249d29e61285804d99500_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i27f18e48d6294e8b944c473a6e0492ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6db3ef3bcd8641beb4f52ba5d002ddb4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i465260a8cedb484e9ea4a4a8159d8ed6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id6e2ffdc00584f51b68b18c17fd34cd7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96cd74dcb04940069b98e07d316c536b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13fe6538e08e4e9e95c7d4ea4d868263_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i00efd75341744eafa3659cc293e6f016_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i735d7eb128bb425881b2106dba0bc826_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ed0b5ab60804e7ba2963330f6311982_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ied4203a5755144439c1cc7549b1adda6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib3682159d79c4bc58c63d3f05153448b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i65b2edc7703246bb9244d72048a96b56_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i85ece9e3706a4128875ddb42c594ca79_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7ac34f1300344bff8cbb530bbc966b3a_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5c5aee48198c4721a9a6396775fbc9df_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id5d8ac1d3b1f4bfd9174292f26013954_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6c4384b7bf6a4a13a1b8e29a389fa42c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5617bf716d28411ebabd53cd816b47f0_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i99f951895edd442e82a9307c2fd15632_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i9df09bf3eb9f4d92a8093c27cf22cb5a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2b8c5a52c3b749aaa0e91a6da46ae301_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i530db00620494f0d8c03838ac8b04a07_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26d56f0010704f36816774ad7c5f40f4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d5484c9784f4fd1aa72d1ad735a068e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idb28160fa7384975be907af6cd2a9f51_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i69cd4c90044a41f7861387a767ee94d2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia012cc762a894ec387428edb3a5b3bac_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8a9f1879a9d4499392ef45ea2e774ecb_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib55dcb7213154d228df81b8e761f46b0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1f4442b575984c518a0936302e598e13_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i97c9874b2c3a4d5a806023ad434054ce_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i834d7e9dd8044b26a5dda1d39659e958_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia033e96d244b4ac48293f47e9660b8be_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i55f6734ada96468a9b81e77531464725_D20190801-20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="idabb0477bfa648dab7fecedc64128780_I20230319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-19</instant>
        </period>
    </context>
    <context id="i2d316e7178014207990f50547c020dad_D20230319-20230319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-19</startDate>
            <endDate>2023-03-19</endDate>
        </period>
    </context>
    <context id="i97a34cf836d84f4fadef4d721fab3698_I20230319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:CommonStockAndAccompanyingWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-19</instant>
        </period>
    </context>
    <context id="ice6f0592c1f54f6b9a640b944432f3be_I20230319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:PreFundedWarrantAndAccompanyingWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-19</instant>
        </period>
    </context>
    <context id="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="i7ce060f7a8354b51af7f71258119d414_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2905ddfb2a734b91a7b4f966c0bb65da_I20230323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-23</instant>
        </period>
    </context>
    <context id="i90c4fbf04c494d99bd37f6e4eb559905_I20230322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-22</instant>
        </period>
    </context>
    <context id="i5664faaee9574db4a202135e028596c8_D20230319-20230319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-19</startDate>
            <endDate>2023-03-19</endDate>
        </period>
    </context>
    <context id="i82aa535e66f84394b33629688b89827e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i13c84429beb04adb81c5c0e8a4fa22d3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:TradeAccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib0dc2923eba0447ab555feccec765db2_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="i5784cd2d48204ab3a25a3176ccbe3451_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="ia4e347119af144cd8d92b13e2b6c5387_D20190102-20190102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-02</startDate>
            <endDate>2019-01-02</endDate>
        </period>
    </context>
    <context id="i437ec51f9da947e4957d1c78257d41ca_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RoyaltyRevenueAndProductSalesBulkTabletsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icc5c8e4669ee430eb7fd9eb3d5682fcc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoEuropeGmbhMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">espr:RoyaltyRevenueAndProductSalesBulkTabletsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia37f88e1d6334cd4988043aa29cb8d9d_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="icbe99073da5e4665be166412628cfbc6_I20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-17</instant>
        </period>
    </context>
    <context id="i774e2569416f4db59556c5fcd4cc0597_I20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-17</instant>
        </period>
    </context>
    <context id="ia9838052375c4929b5e4b845fe66da84_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="i556e6b8f854a4c16bc7335cde1d58ab3_D20200417-20200417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:OtsukaPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:ExclusiveDevelopmentalActivitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="ic913c0c79880452395a8e14c510b4c70_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ifa13681c34ae4d84ab904e7d74d950a1_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ic924dfffa02f4560877a7d949f08cede_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i58cea3ac6b01461cab29af950aeb53a8_D20210426-20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="if38679db574c48ac84aa03b68471cdff_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie63bcb21a66346609cd8f6ef61fbffb7_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:DaiichiSankyoCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i7d6b22f936e84b6e9cadcd7659d06dc6_D20230304-20230304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-04</startDate>
            <endDate>2023-03-04</endDate>
        </period>
    </context>
    <context id="ica364f56b4754e2fb33645747ebebdba_I20230304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:CardiovascularRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-04</instant>
        </period>
    </context>
    <context id="i0ff170b7510847eeb8c913c0268553d5_I20230304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:CardiovascularRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-04</instant>
        </period>
    </context>
    <context id="i5eb81084a86e42b49fbea9ece7638ea5_D20230304-20230304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:CardiovascularRiskOutcomeGreaterThanTwentyPercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-04</startDate>
            <endDate>2023-03-04</endDate>
        </period>
    </context>
    <context id="i9e14be02d3004562870df907dec00d77_I20230304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:RelativeRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-04</instant>
        </period>
    </context>
    <context id="i6dc542279e7e464ca12100e49501610e_D20230304-20230304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2023-03-04</startDate>
            <endDate>2023-03-04</endDate>
        </period>
    </context>
    <context id="ia2442189a4e04c14866e4ca5dbe37ae7_D20230327-20230327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2023-03-27</startDate>
            <endDate>2023-03-27</endDate>
        </period>
    </context>
    <context id="i77154455e27741eea8b7382d7bae0ad0_I20230327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:TypeOfRiskAxis">espr:CardiovascularRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-27</instant>
        </period>
    </context>
    <context id="ic6cf6eadd1ee45ffbf7b12713791e2c9_D20230504-20230504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-04</startDate>
            <endDate>2023-05-04</endDate>
        </period>
    </context>
    <context id="iddba95e9a591432fb6bb68b9d99fc675_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4446c0fdb9a84cc7ae17ac1fc0e8e0a0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaee3d89d3ffc4d01a13615bb5476bcf1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if2b452feddd34bfab04830af609fee01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70000ff4cfcc4e379e6941a6be6de6ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bf5212861014a2a90c4514e738c57eb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7636ce535be94232b11a93a9e2d54623_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i96447b072e33476da43830de87cc58b4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib0a643f6059d440590c4f9ef231a9a6a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic4a1c26e2f864ba39b7dc746fa87291e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9c9a60f0eede463fa23b607d23c6f990_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8cadd97215ba4500883c87f85dc8fa2d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if1ca33a8008147d78bca5e8eed93423d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5fe88940f17f4e6792cd87aaa54541dd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7471d3b7a6ba4353b8cbc8d3e9345bfe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia9834c756a92466abb333281240e95ae_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if15b9c81ed564487bd38021a6515575e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2a3337053c7d484984eb254e5738a3a5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i20434c7136b44164a04d244e3105f708_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1f55c80accfb4964b37eccb272c3ab19_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8b4f98b104bb49ccbbb686e748c86c53_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4dc441d33315499aaa534c51197956c9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie25bd0065058415581124c3cefc0bc4b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2df84ce791dd48a0a34c0e850ff9e8ea_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ief6c1f5d0ae340d8af91af461c6b1b1a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie13c0a874a8e4068b43b96843795daac_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1185e14b22bb4ad8b91ff702b16b3dbe_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6f66dcce3270487dac3d302e1c309b3f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i293919219d734293958f10064d773142_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i37331eb822c14332aecf98c4a60c9a83_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i62ae5ff6d06c466e9f4d59d506da6f7e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18c2947b9df14b23b8cc09df417e317f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4b0c9a8dfde64edbbed9fa7ad3f7e105_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id23e5091216b49dfac7f65fdd88e2a1f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd852d52cb6c4999a5a4f084a7dabb24_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75e3b605ec754126b40578f924de207a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i88342aa86a3b4d5eada1ac9c12a8b565_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3543312988354b0d860025f4d82f6d5a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a04e27d9c67411db002887f7c2f4e82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4189fded356d43ba84b628246a86e8bd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6b58988234e7462d88cabcc48176e5cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if5dc67741b7147d48b9de0788cbe4d92_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia22b6d1eb1714222833742d1f5e85b9a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-26</startDate>
            <endDate>2019-06-26</endDate>
        </period>
    </context>
    <context id="if514492bc1304c3e88a7d73b880162d6_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i39c7a52f49de44809d9de735fcdb4259_D20210426-20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-26</startDate>
            <endDate>2021-04-26</endDate>
        </period>
    </context>
    <context id="i6754f51923214db89d9e97a310f8cc9f_D20210516-20210516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RIPAAmendmentToTheSecurityAgreementAndWaiverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-16</startDate>
            <endDate>2021-05-16</endDate>
        </period>
    </context>
    <context id="i05a73c2f8f9840268e786ffef237f263_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RIPAAmendmentToTheSecurityAgreementAndWaiverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia380cab0f6c44c18a991dc9247a9f988_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i62091633ce8842d79fd91f8dcc5437c7_D20221123-20221123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-23</startDate>
            <endDate>2022-11-23</endDate>
        </period>
    </context>
    <context id="i593d725af50a4b0091e208f4866fe4d9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8971caf868ca48d4bb6027c5bcbc4c0d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i60257fb8aa8e4bae83973ec6daf04c7f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if7b64718731d44238127edb9d9fdb04b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i60e0844b890e44459d45cfea66deae41_D20210516-20210516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-16</startDate>
            <endDate>2021-05-16</endDate>
        </period>
    </context>
    <context id="ia26aa17e92c241019a3310efe812d480_D20210516-20210516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-16</startDate>
            <endDate>2021-05-16</endDate>
        </period>
    </context>
    <context id="i9977b26c9b394f16bbdfa5a9ea8bc078_I20210516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-16</instant>
        </period>
    </context>
    <context id="if4567f7a9b074360b5b429789676c1b0_D20210516-20210516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-16</startDate>
            <endDate>2021-05-16</endDate>
        </period>
    </context>
    <context id="i2677ac65322b4743a3ca63339e6ecf73_I20210516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="espr:NetSalesThresholdAxis">espr:NetSalesThresholdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-16</instant>
        </period>
    </context>
    <context id="i282b2fae645341849445d9da9274fa5e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic5ce29780ee048d2a07167f083638b4e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9672d71ca80348519f56b4e7a065e01c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">espr:EigerIiiSaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if3be96d871a141f89c4e0d00a0a0b2ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:RevenueInterestPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie9d604cc8ce549efb8eacca20225427d_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i558c1c82e52841cd910a7702549badd5_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i77878605a83847e6b08dc2b1e23c3d3c_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">espr:PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i3e9376bd36d849ffb4316ffe1b5485a7_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i443e0a08bb4a4888a6d5462309e5dc2b_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="id505115d3ec947189265eca782d4648d_D20201101-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="ic5eeddb8167c498c8696923171b62eb4_I20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="i20ddb90b5807415aa23e0e6e68488a19_D20211022-20211022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-22</startDate>
            <endDate>2021-10-22</endDate>
        </period>
    </context>
    <context id="idef44d4d210a42b4b9aa0ab56e93f3ea_I20211022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-22</instant>
        </period>
    </context>
    <context id="i80cfd1f853144d49b1d183168049513c_D20211103-20211103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-03</startDate>
            <endDate>2021-11-03</endDate>
        </period>
    </context>
    <context id="i50721021131b4d71b50fa66d28915b11_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i85e1a076c7ee4e17907f790ab9bf3c54_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i921ae98ba14c414092902fd6b4401923_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i1696b3ebb44147b9a3cbeaecc46fbd18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">espr:ConvertibleSeniorNotesDue2025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icae7497a06dd4ecf932d2ce48689f651_D20201116-20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2020-11-16</startDate>
            <endDate>2020-11-16</endDate>
        </period>
    </context>
    <context id="iaa0efd686a824365a3cc55c8e2d823d9_I20201116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:CappedCallMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-16</instant>
        </period>
    </context>
    <context id="i99ff79bbd6b34af19e4c4f5ffd0dd8bd_I20220531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">espr:StockOptionAndIncentivePlan2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="ic8d1aec6f0a243debcdc270c1c4783d6_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i88cb7b840c98434489e5ae6882bf0bde_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2ed983231e1c4e1e9acf5a3984e776a1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3ddb347cbc7e4b08b9ec62540ce50d3e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i66bec0e27b1b48d1bcd58ded58c2e003_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7b0445354f6f4558904c97d5373f8c53_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i60d797f24c2c4a04b4ff42bb670e3cc1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9b9c918318b245b38e4e0d3ba2428dba_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i162d9a4406ca467199ca052182157c66_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i012dbf6545a3491b9f6f9fab381db389_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5e9dfbd0c5a54147bd3f860e7e9511c2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i83fd6d470bf4439baf8eaf859c790c76_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8632a444e79c46f1a18e5bc0a4625f88_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if882eb7b96d54916b14a19ce79b2ec18_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7e0291a026d743f2b05b3fe91e58229b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i11f403f253414aff975722250ebed665_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6f7bbae10a6e443e8fc0880b3115a1d0_D20220415-20220415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">espr:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-15</startDate>
            <endDate>2022-04-15</endDate>
        </period>
    </context>
    <context id="i5746fa6ad7264580a9b24d5d4c46caa2_D20230221-20230223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">espr:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-21</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <context id="i3456d874c623457a8adcfaacbaeb0697_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">espr:AtTheMarketProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib488c87ccc86426b94cb6b54cc339eab_I20211202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-02</instant>
        </period>
    </context>
    <context id="i65f77ad90bd045109470849cecbc6ea3_D20211202-20211202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-02</startDate>
            <endDate>2021-12-02</endDate>
        </period>
    </context>
    <context id="i326e6c7729314df9be278a89e941857f_I20230319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:TheWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-19</instant>
        </period>
    </context>
    <context id="ife8d4c895c31407d94cb9c6ff1903a1a_D20230319-20230319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-19</startDate>
            <endDate>2023-03-19</endDate>
        </period>
    </context>
    <context id="i9d4d2015f62f45aaa2e5addfd39b96f2_I20230319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-19</instant>
        </period>
    </context>
    <context id="i46d8059776cc44b2bb584005f975602b_D20230319-20230319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
        </entity>
        <period>
            <startDate>2023-03-19</startDate>
            <endDate>2023-03-19</endDate>
        </period>
    </context>
    <context id="if7e3ecf1db13427a96c7342395cd96b9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if3cca07e819f46e68cad7cce1b9900cb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WainwrightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia89bfe8a898240809b23c12addd330c2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="icc92509623704e8fa809dc4a3cd974f3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:WarrantAmendmentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if4d3e30f8f084676b1159f8204cf214e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i39d14dea4b5f4437b4a560e299ef1164_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">espr:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie5ade988872643258980d4d742f28c71_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iedd2a0c27a144f8f80418aaca97d59de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3dc5d334d016420f99299c9b501f60ff_I20230424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">espr:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-24</instant>
        </period>
    </context>
    <context id="id729569cba9c49bfb3259c1d0b23594b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4b19c75cff2843b98e3df4b11681f893_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic416a391bdff493fbefe5822e04c52ed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i364cd2415d994d3e85d93df2f35e189e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:ShareBasedPaymentArrangementOptionPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0616f511266b4f73a0978adcfd5aaa0a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i4f5e3f1ac3ab4878bb7bbbf20e6fe992_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">espr:UnvestedRestrictedStockAndRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0bb62ba99eea46949781dcab102b26a1_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i92b532ab4d724df2b12bf304d0f7d08a_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if2e830b24c974bfb99c9f7bd46ee28b5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i03a5a3f73f214702aafb0c19d871baab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ief954accff7948b38b762497cb61309d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ied19a86173ab476f92091aa5b22ef096_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if98ef8167c62483b9317f69d35a8b12b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5c01babe5a404671aaf5f037534a61fc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001434868</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="patient">
        <measure>espr:patient</measure>
    </unit>
    <unit id="customer">
        <measure>espr:customer</measure>
    </unit>
    <unit id="revenue_source">
        <measure>espr:revenue_source</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>espr:day</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80L2ZyYWc6YTJkM2NiNDFkN2Q5NGIxODk4NDRmZDg1NmQ0ODg1NmYvdGFibGU6OTEwYWI4ZjRkYzM0NGMxNjhlYTRiMjI5Yjk1OTdhNTMvdGFibGVyYW5nZTo5MTBhYjhmNGRjMzQ0YzE2OGVhNGIyMjliOTU5N2E1M18zLTEtMS0xLTY1Mjcz_0ebe5e1f-be55-433b-aaf8-b4adcdcbd788">0001434868</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80L2ZyYWc6YTJkM2NiNDFkN2Q5NGIxODk4NDRmZDg1NmQ0ODg1NmYvdGFibGU6OTEwYWI4ZjRkYzM0NGMxNjhlYTRiMjI5Yjk1OTdhNTMvdGFibGVyYW5nZTo5MTBhYjhmNGRjMzQ0YzE2OGVhNGIyMjliOTU5N2E1M180LTEtMS0xLTY1Mjcz_5bf5d28c-ecd9-43df-bb9f-3f5f314ca4e4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80L2ZyYWc6YTJkM2NiNDFkN2Q5NGIxODk4NDRmZDg1NmQ0ODg1NmYvdGFibGU6OTEwYWI4ZjRkYzM0NGMxNjhlYTRiMjI5Yjk1OTdhNTMvdGFibGVyYW5nZTo5MTBhYjhmNGRjMzQ0YzE2OGVhNGIyMjliOTU5N2E1M181LTEtMS0xLTY1Mjcz_5a1c58cd-a76f-480b-a1c9-5ad35e7a6feb">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80L2ZyYWc6YTJkM2NiNDFkN2Q5NGIxODk4NDRmZDg1NmQ0ODg1NmYvdGFibGU6OTEwYWI4ZjRkYzM0NGMxNjhlYTRiMjI5Yjk1OTdhNTMvdGFibGVyYW5nZTo5MTBhYjhmNGRjMzQ0YzE2OGVhNGIyMjliOTU5N2E1M182LTEtMS0xLTY1Mjcz_472b67fe-4533-48c9-9803-6ad6ed3d9b64">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80L2ZyYWc6YTJkM2NiNDFkN2Q5NGIxODk4NDRmZDg1NmQ0ODg1NmYvdGFibGU6OTEwYWI4ZjRkYzM0NGMxNjhlYTRiMjI5Yjk1OTdhNTMvdGFibGVyYW5nZTo5MTBhYjhmNGRjMzQ0YzE2OGVhNGIyMjliOTU5N2E1M183LTEtMS0xLTY1Mjcz_b1f04915-157c-4c36-93d5-449e0db3c442">false</dei:AmendmentFlag>
    <espr:ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81NS9mcmFnOjgyODBlZTExMDViODQ2NjE5NGZiOTE0M2U5MDA3ODY3L3RhYmxlOjY2NTA4NmU4MDdlNDQ5Y2Y5MDczNTEwOTk4NzhhNWQzL3RhYmxlcmFuZ2U6NjY1MDg2ZTgwN2U0NDljZjkwNzM1MTA5OTg3OGE1ZDNfMTMtMS0xLTEtNjUyNzM_c52b541e-4ad8-4737-a2af-34559298fcba">P6M</espr:ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount>
    <espr:PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81NS9mcmFnOjgyODBlZTExMDViODQ2NjE5NGZiOTE0M2U5MDA3ODY3L3RhYmxlOjY2NTA4NmU4MDdlNDQ5Y2Y5MDczNTEwOTk4NzhhNWQzL3RhYmxlcmFuZ2U6NjY1MDg2ZTgwN2U0NDljZjkwNzM1MTA5OTg3OGE1ZDNfMTQtMS0xLTEtNjUyNzM_6c41105f-5a64-477b-926c-7c356e5663ec"
      unitRef="number">0.3333</espr:PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment>
    <espr:DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays
      contextRef="i20ddb90b5807415aa23e0e6e68488a19_D20211022-20211022"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODIwOA_adc66ab1-dedb-4d22-80ef-7e400f74515e">P5D</espr:DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays>
    <dei:DocumentType
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE1_361a3510-0fda-4c82-8dd1-5ccdcebf40b6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6ZjI2Y2Q5ZTc0YTVjNDcyZjg0MTVlNmE5OGI1M2NmYzQvdGFibGVyYW5nZTpmMjZjZDllNzRhNWM0NzJmODQxNWU2YTk4YjUzY2ZjNF8wLTAtMS0xLTY1Mjcz_13309141-b3cf-4618-84b2-bb04eea618d7">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8xMjg_b5f7fce3-7b98-4782-9889-95e199a44aa8">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NDM5Zjc4MGU5ZDNjNDRiNGI0ZDA2ZjBkNzc5Y2U0MTMvdGFibGVyYW5nZTo0MzlmNzgwZTlkM2M0NGI0YjRkMDZmMGQ3NzljZTQxM18wLTAtMS0xLTY1Mjcz_30f8f722-3692-40e6-9d22-610f8b07a601">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTA4_be948e41-bfa5-422c-801a-f4faf56fc1d0">001-35986</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTA5_abfb0e84-3ef3-48b4-bf0e-31f67498f7a0">Esperion Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NTdiZGE4YmJmMDFkNGU2YThlNzM1Y2JkNzExM2FjYzgvdGFibGVyYW5nZTo1N2JkYThiYmYwMWQ0ZTZhOGU3MzVjYmQ3MTEzYWNjOF8wLTAtMS0xLTY1Mjcz_6d944ac5-0544-4558-91b8-5419ba993487">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NTdiZGE4YmJmMDFkNGU2YThlNzM1Y2JkNzExM2FjYzgvdGFibGVyYW5nZTo1N2JkYThiYmYwMWQ0ZTZhOGU3MzVjYmQ3MTEzYWNjOF8wLTItMS0xLTY1Mjcz_be163861-597f-4246-98e4-8976b14d1c56">26-1870780</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE2_33f796a4-1455-4229-a59f-39e6e6263abd">3891 Ranchero Drive, Suite&#160;150</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTEw_1d6b304c-9be0-4c02-9962-70a65c1b4a3b">Ann Arbor</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTEx_b65523a0-bf78-4432-99a6-b6695ccacbab">MI</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTEy_b413bf9a-daf8-4f1e-bd4f-06afaa7e0ec9">48108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE3_a5b4ad83-0d7b-4588-a715-1321bde07acb">734</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTEz_8121ccdc-3160-47b6-93f3-30805eee4c6d">887-3903</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NDZiMTJmMWI0OWY0NGMyYjhjYjMwOGRhNDUzOTFiODgvdGFibGVyYW5nZTo0NmIxMmYxYjQ5ZjQ0YzJiOGNiMzA4ZGE0NTM5MWI4OF8xLTAtMS0xLTY1Mjcz_ef234387-4628-4ab4-b316-cf4193be13c8">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NDZiMTJmMWI0OWY0NGMyYjhjYjMwOGRhNDUzOTFiODgvdGFibGVyYW5nZTo0NmIxMmYxYjQ5ZjQ0YzJiOGNiMzA4ZGE0NTM5MWI4OF8xLTItMS0xLTY1Mjcz_8215f14f-7650-4bbd-8242-4fdfff6fe51f">ESPR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6NDZiMTJmMWI0OWY0NGMyYjhjYjMwOGRhNDUzOTFiODgvdGFibGVyYW5nZTo0NmIxMmYxYjQ5ZjQ0YzJiOGNiMzA4ZGE0NTM5MWI4OF8xLTQtMS0xLTY1MjczL3RleHRyZWdpb246NjhjY2I3NTAzYWQ5NDIyYWEwMmNhZjRmZjQ3M2QyNWJfNQ_3fe00bc9-feb6-42fc-8555-38f50cc301af">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE4_4b6f4be4-1e77-451c-af94-12a7487dd87f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE5_993fa042-0d96-4f88-8693-8c967196d397">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6YTI3ZjIzYjViYWUyNDMyZjgwZGY1NzA2NzVkNzA1MWMvdGFibGVyYW5nZTphMjdmMjNiNWJhZTI0MzJmODBkZjU3MDY3NWQ3MDUxY18yLTAtMS0xLTY3Mjkw_3886e0e1-e895-403c-a7c7-e6aec2ad25cf">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6YTI3ZjIzYjViYWUyNDMyZjgwZGY1NzA2NzVkNzA1MWMvdGFibGVyYW5nZTphMjdmMjNiNWJhZTI0MzJmODBkZjU3MDY3NWQ3MDUxY18yLTQtMS0xLTY1Mjcz_515c28ed-0142-4926-a866-f060ce9ee244">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGFibGU6YTI3ZjIzYjViYWUyNDMyZjgwZGY1NzA2NzVkNzA1MWMvdGFibGVyYW5nZTphMjdmMjNiNWJhZTI0MzJmODBkZjU3MDY3NWQ3MDUxY180LTQtMS0xLTY1Mjcz_d0d49c81-e4ee-4866-b7a7-f09c6b0cc7b3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMTE0_5771652b-3c6c-4417-aaad-e38e66a44a8d">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i138e5960375b40e09f319237f97dcd65_I20230501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xL2ZyYWc6NWFiYTYyZGM2ZjlhNGEyN2EwZjZiMTU4NTU5ODdlYTUvdGV4dHJlZ2lvbjo1YWJhNjJkYzZmOWE0YTI3YTBmNmIxNTg1NTk4N2VhNV8yMDE3_2d3b0792-6dba-4f7d-933e-09b10de1c190"
      unitRef="shares">94712657</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNC0xLTEtMS02NTI3Mw_52522d78-3b24-4553-8f64-9a8ea841c1a6"
      unitRef="usd">144911000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNC0zLTEtMS02NTI3Mw_24bb49fb-aacf-468d-a95e-0824262abcff"
      unitRef="usd">124775000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNS0xLTEtMS02NTI3Mw_923d7430-f6a5-4fe3-a931-fddde4e508c9"
      unitRef="usd">17427000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNS0zLTEtMS02NTI3Mw_7805a0ea-7a60-43e3-9b9c-122ec078d07a"
      unitRef="usd">42086000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNi0xLTEtMS02NTI3Mw_9795a55e-2945-483f-a88a-6517b1cb38b9"
      unitRef="usd">36415000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNi0zLTEtMS02NTI3Mw_f93c924b-00b4-49ac-be88-0ddbac09beb7"
      unitRef="usd">33729000</us-gaap:AccountsReceivableNetCurrent>
    <espr:PrepaidClinicalDevelopmentCostsCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNy0xLTEtMS02NTI3Mw_25e5dd21-d0df-47aa-886c-4a2bab7595ca"
      unitRef="usd">6916000</espr:PrepaidClinicalDevelopmentCostsCurrent>
    <espr:PrepaidClinicalDevelopmentCostsCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNy0zLTEtMS02NTI3Mw_0cb1aca2-7f3d-41d4-8078-3675e8ca282d"
      unitRef="usd">1026000</espr:PrepaidClinicalDevelopmentCostsCurrent>
    <us-gaap:InventoryNet
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfOC0xLTEtMS02NTI3Mw_142796da-eac7-4040-8690-fed3d8c5e111"
      unitRef="usd">39352000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfOC0zLTEtMS02NTI3Mw_8bdb9510-ea87-4879-a239-9e32f6272fc7"
      unitRef="usd">35201000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfOS0xLTEtMS02NTI3Mw_05a81f49-1473-4ffd-a004-586c926629f9"
      unitRef="usd">5584000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfOS0zLTEtMS02NTI3Mw_bce990a7-746e-4280-bb88-b3a6094d3a2b"
      unitRef="usd">9866000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTAtMS0xLTEtNjUyNzM_09f7d1ec-3d12-4ead-87fd-df79c1ad6d3a"
      unitRef="usd">250605000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTAtMy0xLTEtNjUyNzM_5e0adbd3-ac16-4f99-8933-9093152ddcbf"
      unitRef="usd">246683000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTMtMS0xLTEtNjUyNzM_95b9f8ff-584f-46ed-b980-9dd7d7bf8130"
      unitRef="usd">83000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTMtMy0xLTEtNjUyNzM_a15dbfda-96ea-4812-85f6-5c7c1be5dbd1"
      unitRef="usd">164000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTQtMS0xLTEtNjUyNzM_a73cfef9-2886-4cb2-93e2-1b5d390ee449"
      unitRef="usd">1075000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTQtMy0xLTEtNjUyNzM_79d5e61e-7bfb-412b-a640-e49374ceb452"
      unitRef="usd">1036000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTUtMS0xLTEtNjUyNzM_45a5eca7-6d14-4e11-88b7-4cced0824938"
      unitRef="usd">56000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTUtMy0xLTEtNjUyNzM_71b7641a-9bc9-4adf-b94a-36d8ab4d6ff2"
      unitRef="usd">56000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:Assets
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTYtMS0xLTEtNjUyNzM_6733acbd-294d-4384-822a-4d99b31586c6"
      unitRef="usd">251819000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMTYtMy0xLTEtNjUyNzM_c32daa8f-fe7a-4deb-a5a5-98fb7cfe71bf"
      unitRef="usd">247939000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjAtMS0xLTEtNjUyNzM_d69a4ef5-87e2-49d3-b43d-8685973b8746"
      unitRef="usd">17065000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjAtMy0xLTEtNjUyNzM_497a2ab0-a80d-4829-ae11-8eb8bf08e079"
      unitRef="usd">23040000</us-gaap:AccountsPayableCurrent>
    <espr:AccruedClinicalDevelopmentCostsCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjEtMS0xLTEtNjUyNzM_f9602472-346d-45b4-ba2b-6d06e0c21dd7"
      unitRef="usd">4617000</espr:AccruedClinicalDevelopmentCostsCurrent>
    <espr:AccruedClinicalDevelopmentCostsCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjEtMy0xLTEtNjUyNzM_7c182a81-5401-4bfd-936b-093b61d2af82"
      unitRef="usd">5426000</espr:AccruedClinicalDevelopmentCostsCurrent>
    <espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjItMS0xLTEtNjUyNzM_ce83254d-bae6-49c9-a316-55f505034112"
      unitRef="usd">34421000</espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjItMy0xLTEtNjUyNzM_31364864-5c74-490f-aa89-d964d22e983c"
      unitRef="usd">35191000</espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <espr:RevenueInterestLiabilityCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjMtMS0xLTEtNjUyNzM_dd3f4c68-4708-4815-a7c0-d6940c703bb6"
      unitRef="usd">26921000</espr:RevenueInterestLiabilityCurrent>
    <espr:RevenueInterestLiabilityCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjMtMy0xLTEtNjUyNzM_fa3a5c1e-d6ef-4a12-8078-d15d116f30d3"
      unitRef="usd">24760000</espr:RevenueInterestLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjQtMS0xLTEtNjUyNzM_4590251d-9398-43be-a227-73355061d201"
      unitRef="usd">12157000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjQtMy0xLTEtNjUyNzM_243e30cf-6ddd-4c9c-90f0-39a8aa04475e"
      unitRef="usd">3507000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjUtMS0xLTEtNjUyNzM_6e59b46f-f0be-4c66-9e12-5af958b70d6f"
      unitRef="usd">305000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjUtMy0xLTEtNjUyNzM_e7af4f41-cb5d-4d4a-9c32-5575c14c913f"
      unitRef="usd">384000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjYtMS0xLTEtNjUyNzM_67db23cd-ef98-4d1c-aa80-28082a520509"
      unitRef="usd">95486000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjYtMy0xLTEtNjUyNzM_e8d930a3-a6c9-4348-81d2-a2da0aa7b2b3"
      unitRef="usd">92308000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjgtMS0xLTEtNjUyNzM_ab4ad564-9b24-474a-85fa-d129d23c618c"
      unitRef="usd">260316000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjgtMy0xLTEtNjUyNzM_efcf1d51-4eee-47d2-a24b-1111ab581600"
      unitRef="usd">259899000</us-gaap:ConvertibleLongTermNotesPayable>
    <espr:RevenueInterestLiabilityNoncurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjktMS0xLTEtNjUyNzM_ca3635e3-66fb-4efe-9853-d48c84ae296d"
      unitRef="usd">224898000</espr:RevenueInterestLiabilityNoncurrent>
    <espr:RevenueInterestLiabilityNoncurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMjktMy0xLTEtNjUyNzM_08e3ab21-0089-4b1d-88b1-f872393b4b0e"
      unitRef="usd">218845000</espr:RevenueInterestLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzAtMS0xLTEtNjUyNzM_d923fa57-e760-4071-bbb3-75170a2c62da"
      unitRef="usd">782000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzAtMy0xLTEtNjUyNzM_88450900-6157-4365-b647-cb422db3392b"
      unitRef="usd">665000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzMtMS0xLTEtNjUyNzM_8b80cfb2-d0af-47d6-a80a-f1572b892d5a"
      unitRef="usd">581482000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzMtMy0xLTEtNjUyNzM_7d3f822b-c97f-4fd2-8c07-485c1a729321"
      unitRef="usd">571717000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzQtMS0xLTEtNjUyNzM_091b5e43-7085-446b-a999-a41a20edd312"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzQtMy0xLTEtNjUyNzM_e3bd58b9-ae1b-40fe-857e-e366682cca46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF8yMQ_3f62342f-c57f-4a6a-93bf-893833381ceb"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF8yMQ_5d7d3d28-c313-4674-b2c1-75f3bef44276"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF8zNQ_79d087fc-1e3f-4d6c-8aac-97ed6883a580"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF8zNQ_c9af3fcd-23ae-4fd8-b853-6554d716dd0a"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF82MA_18f86288-8829-4fd2-a4c1-690b735bde01"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF82MA_67d7290a-2cf6-43c7-adab-5c78c25c9984"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF82MA_8d075764-a81e-413c-b9f9-7f4ce56bbed0"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjo3NDA1YTkzNjBiYTE0ZWE4ODQ1OWIwMDY2MmZiNjhjNF82MA_9c07af7c-b233-4f6b-a64b-4a612131652a"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMS0xLTEtNjUyNzM_5d460864-2f2a-4adc-bc39-7530303bea9c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzYtMy0xLTEtNjUyNzM_00cf12c9-fc4c-4985-b418-dc839fddfbc4"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18xOA_af0cf932-03fb-40c1-a7ab-674f3164b803"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18xOA_e6a71bdc-cbad-4266-8116-17dcc363915e"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18zMg_50a3b7e2-6c81-436e-a462-5b29b3da155d"
      unitRef="shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18zMg_5416d906-be40-415c-b14c-a6fb1ce937ee"
      unitRef="shares">240000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18xMTI_afa6f588-b8ae-4c09-b12e-0328503d3464"
      unitRef="shares">89237167</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjplMTkxMmQ1OTQyMzk0ZGM4OWFjZWViNDY5NTBlMDUzM18xMzk_04d10912-c38a-489c-ba90-0b4a03be4162"
      unitRef="shares">76564396</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMS0xLTEtNjUyNzM_413ea19f-c00f-4624-8683-4fb7d4f7faf6"
      unitRef="usd">87000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzctMy0xLTEtNjUyNzM_16444ca2-a78b-4e5b-91bc-348b02691ee8"
      unitRef="usd">75000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzgtMS0xLTEtNjUyNzM_eecca7ec-e8af-41e7-85cd-65ebd19c5893"
      unitRef="usd">1127004000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzgtMy0xLTEtNjUyNzM_6929adf6-16e8-4750-ba5f-05847ac95ec1"
      unitRef="usd">1071183000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockShares
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzktMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjpjOWQ0YTdiZjUyMTg0NjZmYTk5N2E0NDY5NDEwN2FiY18yOQ_6f19d6f5-ebc1-470d-9d2f-b8d9e60a1809"
      unitRef="shares">1994198</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzktMC0xLTEtNjUyNzMvdGV4dHJlZ2lvbjpjOWQ0YTdiZjUyMTg0NjZmYTk5N2E0NDY5NDEwN2FiY18yOQ_d1c84a78-11bb-493d-b42d-8201eeeea1a3"
      unitRef="shares">1994198</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzktMS0xLTEtNjUyNzM_ee899319-a238-43f0-9afe-2528d04928f2"
      unitRef="usd">54998000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfMzktMy0xLTEtNjUyNzM_4f797686-b747-4763-9e02-a3b36d344aa6"
      unitRef="usd">54998000</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDAtMS0xLTEtNjUyNzM_c2640e39-9d91-4559-8b4e-2f3dbc3153a4"
      unitRef="usd">-1000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDAtMy0xLTEtNjUyNzM_6b9521c8-9f1e-43c3-a28c-51e80f0973c7"
      unitRef="usd">-2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDEtMS0xLTEtNjUyNzM_0c6c6137-0f86-45e3-a926-121931e4d9a4"
      unitRef="usd">-1401755000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDEtMy0xLTEtNjUyNzM_85bc791c-d747-46dd-ad0b-a8da21b5dc92"
      unitRef="usd">-1340036000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDItMS0xLTEtNjUyNzM_2a0e4500-5646-4e43-a7e9-4e841dd38ca1"
      unitRef="usd">-329663000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDItMy0xLTEtNjUyNzM_2e234d92-cb54-4f77-9388-6cb762aea7ab"
      unitRef="usd">-323778000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDMtMS0xLTEtNjUyNzM_873a1ba1-ad42-44f3-8df2-689f96d5a521"
      unitRef="usd">251819000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xNi9mcmFnOjk0MmUyNzc5MGI4ZTQ3MGFhODY1Mzc2ZmY5NjYyMjg2L3RhYmxlOjBhNzRiNjUxMDBiYzQ0ZDdiMGUzOTZkMGIzNmVjNzQ4L3RhYmxlcmFuZ2U6MGE3NGI2NTEwMGJjNDRkN2IwZTM5NmQwYjM2ZWM3NDhfNDMtMy0xLTEtNjUyNzM_ef9c033e-8e50-4eb0-8e1c-2da5cc42b557"
      unitRef="usd">247939000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2b77b80c5d249d29e61285804d99500_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMy0xLTEtMS02NTI3Mw_d57d7a08-caa6-4d16-9959-3ee08814da42"
      unitRef="usd">17031000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27f18e48d6294e8b944c473a6e0492ed_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMy0zLTEtMS02NTI3Mw_fcd356c1-d9a7-4049-98f8-73d5be05a264"
      unitRef="usd">13354000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6db3ef3bcd8641beb4f52ba5d002ddb4_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfNC0xLTEtMS02NTI3Mw_9f7f6a10-f209-4208-a839-d869b144ca51"
      unitRef="usd">7298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i465260a8cedb484e9ea4a4a8159d8ed6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfNC0zLTEtMS02NTI3Mw_2f70bbcf-bdc9-4f7c-84e4-dfbd838ea23f"
      unitRef="usd">5482000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfNS0xLTEtMS02NTI3Mw_4cd8c1a6-59ed-4c2a-bbb4-cab6452b0ba2"
      unitRef="usd">24329000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfNS0zLTEtMS02NTI3Mw_e2aa44ad-3c83-4cb0-8c03-f3b5f335bdd6"
      unitRef="usd">18836000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfOC0xLTEtMS02NTI3Mw_4c67bc35-42a8-4812-9888-f2b312c64391"
      unitRef="usd">11652000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfOC0zLTEtMS02NTI3Mw_b340ec30-a136-4f80-81be-2d4e558929fb"
      unitRef="usd">7125000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfOS0xLTEtMS02NTI3Mw_b55db6d5-fe01-4f03-82b2-1e9f6f334c68"
      unitRef="usd">31381000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfOS0zLTEtMS02NTI3Mw_2cef134b-06ac-4f02-97cf-ec4187ab9daf"
      unitRef="usd">24319000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTAtMS0xLTEtNjUyNzM_c5187e73-f3b0-4d6f-a4d1-91bd64ca7cf9"
      unitRef="usd">29901000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTAtMy0xLTEtNjUyNzM_1387df6d-5de7-470d-9e64-e55632095f2d"
      unitRef="usd">30381000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTEtMS0xLTEtNjUyNzM_b8ea61b5-7b47-4a64-8b7d-4a1a73ab244b"
      unitRef="usd">72934000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTEtMy0xLTEtNjUyNzM_05941154-ecfb-4578-b9ec-ec509c4f77f1"
      unitRef="usd">61825000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTMtMS0xLTEtNjUyNzM_8980281c-4503-4c75-bf13-2be6cbc88195"
      unitRef="usd">-48605000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTMtMy0xLTEtNjUyNzM_5aba8171-fac3-496f-af60-f597a90ee48f"
      unitRef="usd">-42989000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTUtMS0xLTEtNjUyNzM_f21c0262-aa55-4176-8c4c-f56f4178d737"
      unitRef="usd">14387000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTUtMy0xLTEtNjUyNzM_23199a2e-6c50-4daa-be98-74b045e90407"
      unitRef="usd">14062000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTYtMS0xLTEtNjUyNzM_69c1c29e-2f70-4b49-9214-83e2a2835429"
      unitRef="usd">1273000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTYtMy0xLTEtNjUyNzM_5ee7a395-ea3b-49c9-bbdc-862e69798cf2"
      unitRef="usd">320000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTctMS0xLTEtNjUyNzM_af5e3b3a-0986-4c08-b2ae-275a150d8f0b"
      unitRef="usd">-61719000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTctMy0xLTEtNjUyNzM_f792266a-a04b-44ed-a31a-89e585b4d0ca"
      unitRef="usd">-56731000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTktMS0xLTEtNjUyNzM_1bcaa1d2-164f-4e0b-a8fb-4d7f76ab6b6f"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTktMS0xLTEtNjUyNzM_56f21b0e-290b-401a-bdc0-6b0444cfbb37"
      unitRef="usdPerShare">-0.79</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTktMy0xLTEtNjUyNzM_3407284c-51b2-4afd-81c0-4a1b24c7178c"
      unitRef="usdPerShare">-0.93</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMTktMy0xLTEtNjUyNzM_d1f22d5f-5dee-4403-98fb-88ddc24c19cb"
      unitRef="usdPerShare">-0.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjEtMS0xLTEtNjUyNzM_6a7937b2-d169-4e16-bc39-c5a75539163d"
      unitRef="shares">78440266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjEtMS0xLTEtNjUyNzM_bb9f3946-17af-4651-bf69-579b31662fb0"
      unitRef="shares">78440266</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjEtMy0xLTEtNjUyNzM_2603a1b5-5bed-4024-8f8a-9d3149078ed9"
      unitRef="shares">60954755</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjEtMy0xLTEtNjUyNzM_bce0d1f4-7253-4aba-95c3-1289fa72148e"
      unitRef="shares">60954755</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjQtMS0xLTEtNjUyNzM_7cd2db96-3d57-40e5-aea9-a66428bee017"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjQtMy0xLTEtNjUyNzM_3d9f0e76-9382-4d89-a840-fdd3eec68ddc"
      unitRef="usd">-232000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjUtMS0xLTEtNjUyNzM_7ebd266d-643b-4361-b05e-92b7eed6c7b7"
      unitRef="usd">-61718000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8xOS9mcmFnOjU0NjU1NzQ4ZTI3ZTRkMGM4NDNkN2E5NzVjOTEzZDExL3RhYmxlOjRhMWI2YzYzYjNmNzRhZDc5YmZiNTE1NjVjZWIwNmQ4L3RhYmxlcmFuZ2U6NGExYjZjNjNiM2Y3NGFkNzliZmI1MTU2NWNlYjA2ZDhfMjUtMy0xLTEtNjUyNzM_fccc367b-263c-4e29-afd5-6bae00dc2673"
      unitRef="usd">-56963000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="id6e2ffdc00584f51b68b18c17fd34cd7_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi0xLTEtMS02NTU1MA_cf7e9974-8596-4b5f-b389-b28c131ce5eb"
      unitRef="shares">60879496</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id6e2ffdc00584f51b68b18c17fd34cd7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi0zLTEtMS02NTU1MA_72c29db2-0207-4717-9986-9ec0e4578a20"
      unitRef="usd">61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i96cd74dcb04940069b98e07d316c536b_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi01LTEtMS02NTU1MA_5a5904f7-5b4d-4187-ad76-962d90c26593"
      unitRef="usd">964401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i13fe6538e08e4e9e95c7d4ea4d868263_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi03LTEtMS02NTU1MA_901f2638-5df8-4db2-a994-38abcee8a378"
      unitRef="usd">-1106377000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i00efd75341744eafa3659cc293e6f016_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi05LTEtMS02NTU1MA_21a5a64c-1dd8-4667-94a6-91c82a02617a"
      unitRef="usd">-31000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i735d7eb128bb425881b2106dba0bc826_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi0xMS0xLTEtNjU1NTA_389af8e5-6f68-4930-857e-35084e6489da"
      unitRef="usd">-54998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8ed0b5ab60804e7ba2963330f6311982_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfMi0xMy0xLTEtNjU1NTA_ebf913f0-29fc-40cc-bf08-e2499e99cbfd"
      unitRef="usd">-196944000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="ied4203a5755144439c1cc7549b1adda6_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNC0xLTEtMS02NTU1MA_1de0be03-f2b3-45d7-844b-5b04a848694a"
      unitRef="shares">55286</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ied4203a5755144439c1cc7549b1adda6_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNS0xLTEtMS02NTU1MA_1ad84145-f06d-4031-aa5b-ecd012d075e4"
      unitRef="shares">123785</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ib3682159d79c4bc58c63d3f05153448b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNS01LTEtMS02NTU1MA_3c8f2fc0-321e-4bd4-8c9f-b8ec25373522"
      unitRef="usd">431000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNS0xMy0xLTEtNjU1NTA_92800397-0724-4ded-bba2-c2210e1251d1"
      unitRef="usd">431000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib3682159d79c4bc58c63d3f05153448b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNi01LTEtMS02NTU1MA_2a59a9fe-78d6-48ff-bc70-9c1363a5f78d"
      unitRef="usd">4436000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNi0xMy0xLTEtNjU1NTA_8f79762c-d95c-4d86-833f-6d6d045b643d"
      unitRef="usd">4436000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i65b2edc7703246bb9244d72048a96b56_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNy05LTEtMS02NTU1MA_1742ca2a-628e-4a37-b2aa-256f333cc07c"
      unitRef="usd">-232000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfNy0xMy0xLTEtNjU1NTA_39b6d6d6-0d7a-4815-80cb-cc0ed158a034"
      unitRef="usd">-232000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i85ece9e3706a4128875ddb42c594ca79_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOC03LTEtMS02NTU1MA_ce927e8c-8993-43a2-909b-8358ee756035"
      unitRef="usd">-56731000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOC0xMy0xLTEtNjU1NTA_3a5b63ea-aac0-4d7c-9e8e-9bdbac8b46bb"
      unitRef="usd">-56731000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i7ac34f1300344bff8cbb530bbc966b3a_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS0xLTEtMS02NTU1MA_53a3bdb1-7793-426f-8409-b589dfbc5063"
      unitRef="shares">61058567</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7ac34f1300344bff8cbb530bbc966b3a_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS0zLTEtMS02NTU1MA_093795b5-d637-4f21-9b03-5e8e8219cf5c"
      unitRef="usd">61000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c5aee48198c4721a9a6396775fbc9df_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS01LTEtMS02NTU1MA_eaa35de2-1db2-4229-b073-d7c51bf05fcf"
      unitRef="usd">969268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id5d8ac1d3b1f4bfd9174292f26013954_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS03LTEtMS02NTU1MA_a428fbb1-f127-4c4c-a462-51e8fcb09566"
      unitRef="usd">-1163108000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c4384b7bf6a4a13a1b8e29a389fa42c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS05LTEtMS02NTU1MA_19a0397a-f41a-433d-b48f-bb426327e8e4"
      unitRef="usd">-263000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5617bf716d28411ebabd53cd816b47f0_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS0xMS0xLTEtNjU1NTA_842cea10-fb49-4fd2-b110-312e3d094a5b"
      unitRef="usd">-54998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99f951895edd442e82a9307c2fd15632_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOjZjNjFiYzcxYjc5MTRiNGRhODljY2IzMjFjODA2MTU4L3RhYmxlcmFuZ2U6NmM2MWJjNzFiNzkxNGI0ZGE4OWNjYjMyMWM4MDYxNThfOS0xMy0xLTEtNjU1NTA_d95acbb7-2817-40eb-9c4b-a7207a1895a8"
      unitRef="usd">-249040000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i9df09bf3eb9f4d92a8093c27cf22cb5a_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi0xLTEtMS02NTI3Mw_fac6b1cd-7e05-481a-85bf-71186f1717dc"
      unitRef="shares">74570198</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9df09bf3eb9f4d92a8093c27cf22cb5a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi0zLTEtMS02NTI3Mw_cd22c516-70b5-46c0-8569-d936b7cfa9a3"
      unitRef="usd">75000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2b8c5a52c3b749aaa0e91a6da46ae301_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi01LTEtMS02NTI3Mw_c68393e8-8326-4379-b1a1-a3122b82a4a0"
      unitRef="usd">1071183000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i530db00620494f0d8c03838ac8b04a07_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi03LTEtMS02NTI3Mw_5a045525-72d3-4c6c-8c52-2ae18f7a6c14"
      unitRef="usd">-1340036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i26d56f0010704f36816774ad7c5f40f4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi05LTEtMS02NTI3Mw_05abd944-8aa1-4139-b666-5b1adddc06e5"
      unitRef="usd">-2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0d5484c9784f4fd1aa72d1ad735a068e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi0xMS0xLTEtNjUyNzM_b37e1022-84cb-4dda-9ec9-58001043463c"
      unitRef="usd">-54998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMi0xMy0xLTEtNjUyNzM_ebb93337-d882-4015-bacf-a4e42507aa0f"
      unitRef="usd">-323778000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="idb28160fa7384975be907af6cd2a9f51_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNC0xLTEtMS02NTI3Mw_566b5d9f-ac2f-44e1-bfc0-5873bf8be724"
      unitRef="shares">372117</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="idb28160fa7384975be907af6cd2a9f51_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNS0xLTEtMS02NTI3Mw_ae38b61d-7423-4e1b-921f-cb38ed9ff8be"
      unitRef="shares">95654</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i69cd4c90044a41f7861387a767ee94d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNS01LTEtMS02NTI3Mw_59252173-6dc3-41cb-8294-fa410b84400f"
      unitRef="usd">502000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNS0xMy0xLTEtNjUyNzM_80d9f809-92a5-4814-a799-9ddb7880b100"
      unitRef="usd">502000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i69cd4c90044a41f7861387a767ee94d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNi01LTEtMS02NTI3Mw_60a4c754-3aed-4b3e-8ea2-5f1403dabee7"
      unitRef="usd">2903000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNi0xMy0xLTEtNjUyNzM_523857f7-b2a7-41c7-9285-445668138af5"
      unitRef="usd">2903000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="idb28160fa7384975be907af6cd2a9f51_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy0xLTEtMS02NTYyNw_2a22c084-52c8-4fbd-af04-b13027464d16"
      unitRef="shares">12205000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idb28160fa7384975be907af6cd2a9f51_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy0zLTEtMS02NTYyNw_7cd18f38-2de8-4242-94a2-de55e3d86f40"
      unitRef="usd">12000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i69cd4c90044a41f7861387a767ee94d2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy01LTEtMS02NTYyNw_19caeccb-6c62-4075-af6e-891a0f3ab564"
      unitRef="usd">52416000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy0xMy0xLTEtNjU2Mjc_2c1bc93c-9409-4fa5-8303-b050a4b27eee"
      unitRef="usd">52428000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia012cc762a894ec387428edb3a5b3bac_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy05LTEtMS02NTI3Mw_d4331e22-2698-43b4-94c8-2b08a055ec05"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfNy0xMy0xLTEtNjUyNzM_56b041b6-becb-48fc-b6ce-d9f90c7755d4"
      unitRef="usd">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i8a9f1879a9d4499392ef45ea2e774ecb_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfOC03LTEtMS02NTI3Mw_3d6b0459-d7b8-416d-b575-0680f93157ea"
      unitRef="usd">-61719000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfOC0xMy0xLTEtNjUyNzM_976face0-67e4-4a8f-a6e3-21379e653be9"
      unitRef="usd">-61719000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="ib55dcb7213154d228df81b8e761f46b0_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtMS0xLTEtNjUyNzM_b885a4ed-42dc-4164-9067-a34a96f60bc3"
      unitRef="shares">87242969</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib55dcb7213154d228df81b8e761f46b0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtMy0xLTEtNjUyNzM_97f3ddf1-21e1-4c18-944b-66cf483fb287"
      unitRef="usd">87000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1f4442b575984c518a0936302e598e13_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtNS0xLTEtNjUyNzM_6891a0fb-f875-46d1-b93c-bea8e1b692cc"
      unitRef="usd">1127004000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i97c9874b2c3a4d5a806023ad434054ce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtNy0xLTEtNjUyNzM_9df20987-6658-4091-bf2f-0d9245c6f877"
      unitRef="usd">-1401755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i834d7e9dd8044b26a5dda1d39659e958_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtOS0xLTEtNjUyNzM_f7023d2c-ffc1-4625-b60c-ff832dabcbbc"
      unitRef="usd">-1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia033e96d244b4ac48293f47e9660b8be_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtMTEtMS0xLTY1Mjcz_90b74cf7-3d83-4849-86f8-8eff6397b6a1"
      unitRef="usd">-54998000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yMi9mcmFnOmNjZjkyYjI3N2E5YzRiZTM4N2ExZmMzMDgxZWJhYWJkL3RhYmxlOmU1NjdlZmVmMjg3MzRhMzA5ZDkxNjgzODk5OWYxYjg2L3RhYmxlcmFuZ2U6ZTU2N2VmZWYyODczNGEzMDlkOTE2ODM4OTk5ZjFiODZfMjMtMTMtMS0xLTY1Mjcz_82b3a20c-4d78-49b2-8eef-384892b86745"
      unitRef="usd">-329663000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMy01LTEtMS02NTI3Mw_54e8a7af-bff6-49a8-be33-010d6d11a19c"
      unitRef="usd">-61719000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMy03LTEtMS02NTI3Mw_4154aed7-2a85-483a-a3c3-dacd46532655"
      unitRef="usd">-56731000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNS01LTEtMS02NTI3Mw_540f753a-e7e1-4662-b06c-a1c278dcbf42"
      unitRef="usd">81000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNS03LTEtMS02NTI3Mw_1a3dcc6d-b3b2-467d-a31e-293ea85b0f95"
      unitRef="usd">153000</us-gaap:Depreciation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNi01LTEtMS02NTI3Mw_0eb80208-db06-4703-b2e4-45d10135bcc8"
      unitRef="usd">339000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNi03LTEtMS02NTI3Mw_b9fad5f5-c640-4e2e-b5d5-5077d7655c75"
      unitRef="usd">-173000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNy01LTEtMS02NTI3Mw_d36e65a1-2ca4-4319-8c49-9978da77fe8c"
      unitRef="usd">417000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNy03LTEtMS02NTI3Mw_d95ccafa-14a1-4267-94d6-b3f4925051ef"
      unitRef="usd">398000</us-gaap:AmortizationOfFinancingCosts>
    <espr:NonCashInterestExpenseRelatedToRevenueInterestLiability
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfOS01LTEtMS02NTI3Mw_882e26b5-47bd-42fb-a99d-281d29f8d255"
      unitRef="usd">11320000</espr:NonCashInterestExpenseRelatedToRevenueInterestLiability>
    <espr:NonCashInterestExpenseRelatedToRevenueInterestLiability
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfOS03LTEtMS02NTI3Mw_3e1bb964-03b6-4bbc-ae55-67357fa87991"
      unitRef="usd">11015000</espr:NonCashInterestExpenseRelatedToRevenueInterestLiability>
    <us-gaap:ShareBasedCompensation
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTEtNS0xLTEtNjUyNzM_dcc3913c-3b56-4340-ab66-2ebbecde3f2d"
      unitRef="usd">2903000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTEtNy0xLTEtNjUyNzM_2e466d47-d2bf-4ce8-941c-344438411a45"
      unitRef="usd">4436000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTMtNS0xLTEtNjUyNzM_d382c13e-113c-4e06-98b9-f8918044c14b"
      unitRef="usd">2686000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTMtNy0xLTEtNjUyNzM_a579eda7-5235-438f-b026-fb9df720014d"
      unitRef="usd">2182000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTQtNS0xLTEtNjUyNzM_4a2969cc-f31d-4d91-b48d-3e07affa43bf"
      unitRef="usd">1608000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTQtNy0xLTEtNjUyNzM_21019f19-018b-4349-8ac9-1023d03fa06b"
      unitRef="usd">-764000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTUtNS0xLTEtNjUyNzM_3ca06894-de09-41f6-b952-adf91f2e500c"
      unitRef="usd">8650000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTUtNy0xLTEtNjUyNzM_50c94aa3-2684-456a-8272-2ab694f28886"
      unitRef="usd">-2100000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTYtNS0xLTEtNjUyNzM_9f016829-c35d-419c-bd0b-85801ae7eca6"
      unitRef="usd">4151000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTYtNy0xLTEtNjUyNzM_3a159d23-0fe5-4bc1-a18f-b00e7c9f2aac"
      unitRef="usd">1260000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTgtNS0xLTEtNjUyNzM_5e1f1110-90fb-4897-a9e2-33b49b46276a"
      unitRef="usd">-5975000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTgtNy0xLTEtNjUyNzM_d167256c-3390-4b59-9687-288d3ce60180"
      unitRef="usd">9393000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTktNS0xLTEtNjUyNzM_868a5cc1-b8e3-48fb-a63f-b078b2870d6e"
      unitRef="usd">-1249000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMTktNy0xLTEtNjUyNzM_f253c63b-3a30-4e64-88ef-1e46c2f823ef"
      unitRef="usd">-3049000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjAtNS0xLTEtNjUyNzM_27a21692-0d5a-450b-a38f-8ff790f74950"
      unitRef="usd">-54356000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjAtNy0xLTEtNjUyNzM_df36df70-c3e3-45e0-923f-a07bebf47533"
      unitRef="usd">-38990000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjMtNS0xLTEtNjUyNzM_9e3ed085-a3ba-417d-9281-f604d8565178"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjMtNy0xLTEtNjUyNzM_1e6b7bc1-0fd0-45df-b526-4c98dc8825fe"
      unitRef="usd">18102000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjQtNS0xLTEtNjUyNzM_8bbc9d68-66e4-4c3d-a7da-ede947d1ffa8"
      unitRef="usd">25000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjQtNy0xLTEtNjUyNzM_ff349685-9295-436d-ae7d-621fcbf3b8e1"
      unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjYtNS0xLTEtNjUyNzM_3ed06409-a1ea-4d50-949b-24195c25404c"
      unitRef="usd">25000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMjYtNy0xLTEtNjUyNzM_0f8c539b-a241-4d48-807a-32d34d3f74e8"
      unitRef="usd">-18102000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <espr:PaymentsFromRevenueInterestPurchaseAgreement
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzMtNS0xLTEtNjUyNzM_880d1946-7f48-4b98-bef6-97d331872312"
      unitRef="usd">3106000</espr:PaymentsFromRevenueInterestPurchaseAgreement>
    <espr:PaymentsFromRevenueInterestPurchaseAgreement
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzMtNy0xLTEtNjUyNzM_5a879c61-a021-4789-9825-8e9a169fd2ce"
      unitRef="usd">1217000</espr:PaymentsFromRevenueInterestPurchaseAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNS0xLTEtNjczMTE_af37741c-bbcc-4006-9bd7-27d8277756dc"
      unitRef="usd">52598000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNS0xLTEtNjczMTE_f59f957b-9608-4bc1-9c73-86683bed32a9"
      unitRef="usd">52598000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNy0xLTEtNjczMTI_daa2fba1-2da9-4232-9080-c08ce979d039"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNy0xLTEtNjczMTI_e031100f-fbd3-424f-ba23-a9b8bff8187d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNS0xLTEtNjUyNzM_59b36f2f-54b4-4ab6-9adc-01710c48c009"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzQtNy0xLTEtNjUyNzM_80b4168f-22fd-43f6-87f8-314fa753cc6e"
      unitRef="usd">219000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzUtNS0xLTEtNjUyNzM_19f22ee2-52c4-4eb7-a31b-3bccf10098cd"
      unitRef="usd">49492000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzUtNy0xLTEtNjUyNzM_dc869c5c-dbec-4972-af7c-fcc93b5b5170"
      unitRef="usd">-1436000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzctNS0xLTEtNjUyNzM_b303859a-1be7-4d24-b5c0-fcf2bf7968bc"
      unitRef="usd">20136000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzctNy0xLTEtNjUyNzM_17f89a1a-5c85-4cf4-93eb-66729cd6d333"
      unitRef="usd">-58528000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzgtNS0xLTEtNjUyNzM_96fa62e4-641d-46db-88bc-641dcb5f8955"
      unitRef="usd">124775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8ed0b5ab60804e7ba2963330f6311982_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzgtNy0xLTEtNjUyNzM_fdbecfa4-5e7c-40bd-b8b0-b86b15d653de"
      unitRef="usd">258892000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzktNS0xLTEtNjUyNzM_01e28c48-dc1c-48b5-92b8-d3896c576c3c"
      unitRef="usd">144911000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i99f951895edd442e82a9307c2fd15632_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfMzktNy0xLTEtNjUyNzM_9b6a4fcc-9e86-4103-ad58-b267a0a76c55"
      unitRef="usd">200364000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <espr:CommonStockIssuanceCostsIncurredNotYetPaid
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNDEtNS0xLTEtNjUyNzM_ff5f95f3-71b0-467c-8d78-d3fd71459542"
      unitRef="usd">170000</espr:CommonStockIssuanceCostsIncurredNotYetPaid>
    <espr:CommonStockIssuanceCostsIncurredNotYetPaid
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNDEtNy0xLTEtNjUyNzM_54f7cbe7-5b24-4fbf-8f15-ba4cf133a873"
      unitRef="usd">0</espr:CommonStockIssuanceCostsIncurredNotYetPaid>
    <espr:NonCashRightOfUseAsset
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNDQtNS0xLTEtNjUyNzM_b5e42548-f3ac-459d-a3c6-ef800495f1ab"
      unitRef="usd">1000</espr:NonCashRightOfUseAsset>
    <espr:NonCashRightOfUseAsset
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8yNS9mcmFnOjJhNjgyMzA4NzBmZDRlYzVhODg3YzkyNDkzZjFiNzk1L3RhYmxlOmZmMjI1MjhiMGEyMDRlMWViZDlmZTk4OGVmM2UyZWZjL3RhYmxlcmFuZ2U6ZmYyMjUyOGIwYTIwNGUxZWJkOWZlOTg4ZWYzZTJlZmNfNDQtNy0xLTEtNjUyNzM_57044358-c59b-45a4-9899-b18a746f1dac"
      unitRef="usd">6000</espr:NonCashRightOfUseAsset>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTMxMA_f1775f2f-a12a-4a83-9071-6f7038c5a97b">The Company and Basis of Presentation&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Esperion Therapeutics, Inc. ("the Company&#x201d;) is a pharmaceutical company singularly focused on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol ("LDL-C"). Through commercial execution and completion of the CLEAR Outcomes trial as well as advancing the Company's pre-clinical pipeline, the Company continues to evolve into a differentiated, global cardiometabolic biotech. The Esperion team of lipid experts are dedicated to lowering bad cholesterol through the discovery, development and commercialization of innovative medicines and their combinations with established medicines. The Company's first two products were approved by the U.S. Food and Drug Administration ("FDA"), European Medicines Agency ("EMA") and Swiss Agency for Therapeutic Products ("Swissmedic") in 2020. Bempedoic acid and the bempedoic acid / ezetimibe combination tablet are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease ("ASCVD") or heterozygous familial hypercholesterolemia ("HeFH").&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company recently completed a global cardiovascular outcomes trial, or CVOT,&#x2009;&#x2014;&#x2009;known as &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;C&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;holesterol &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;L&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;owering via B&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;E&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;mpedoic Acid, an &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;A&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;CL-inhibiting &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;R&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;egimen (CLEAR) Outcomes. The trial was designed to evaluate whether treatment with bempedoic acid reduced the risk of cardiovascular events in patients who are statin averse and who have CVD or are at high risk for CVD. The Company initiated the CLEAR Outcomes CVOT in December 2016 and fully enrolled the study with over 14,000 patients in August 2019. The primary endpoint of the study was the effect of bempedoic acid on four types of major adverse cardiovascular events, or MACE (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization; also referred to as &#x201c;four-component MACE&#x201d;). CLEAR Outcomes was an event-driven trial and concluded once the predetermined number of MACE endpoints occurred. On December 7, 2022, the Company announced that the study had met its primary endpoint.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 4, 2023, the Company announced the full results from the CLEAR Outcomes trial. The study showed that bempedoic acid demonstrated significant&lt;/span&gt;&lt;span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;cardiovascular risk reductions and significantly reduced the risk of heart attack and coronary revascularization as compared to placebo. These results were seen in a broad population of primary and secondary prevention patients who are unable to maximize or tolerate a statin. The proportions of patients experiencing adverse events and serious adverse events were similar between the active and placebo treatment groups. Bempedoic acid (contained in NEXLETOL&#xae; and NEXLIZET&#xae; (bempedoic acid and ezetimibe) tablets) now becomes the first LDL-C lowering therapy since statins proven to lower hard ischemic events, not only in those with ASCVD but also in the large number of primary prevention patients for whom limited therapies exist. The Company believes that it remains on track to submit regulatory filings to the FDA and EMA in the first half of 2023 with expected inclusion in the U.S. and EMA labels in the first half of 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 19, 2023, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain purchasers named therein (the &#x201c;Purchasers&#x201d;), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the &#x201c;Offering&#x201d;), 12,205,000 shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), pre-funded warrants to purchase up to an aggregate of 20,965,747 shares of Common Stock (the &#x201c;Pre-Funded Warrants&#x201d;) in lieu of shares of Common Stock, and warrants to purchase up to 33,170,747 shares of Common Stock (the &#x201c;Warrants&#x201d;). The combined purchase price of each share of Common Stock and accompanying Warrant is $1.675 per share. The purchase price of each Pre-Funded Warrant and the accompanying Warrant is $1.674 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $0.001). The Purchase Agreement contains customary representations, warranties, covenants and indemnification rights and obligations of the Company and the Purchasers. The Offering closed on March 22, 2023. In connection with the Offering, the Company amended, pursuant to Warrant Amendment Agreements (the &#x201c;Warrant Amendment Agreements&#x201d;), certain existing warrants to purchase up to an aggregate of 9,024,212 shares of the Company's common stock that were previously issued in December 2021 at an exercise price of $9.00 per share and had an expiration date of December 7, 2023, effective upon the closing of the Offering, such that the amended warrants have a reduced exercise price of $1.55 per share and expire three and one half years following the closing of the Offering, for additional consideration of $0.125 per amended warrant. The Company received gross proceeds of approximately $55.5&#160;million from the Offering, before deducting placement agent fees and related offering expenses. The net proceeds to the Company from the Offering, after deducting the placement agent fees and expenses and the Company&#x2019;s estimated offering expenses, are approximately $51.3&#160;million. In addition, the Company received approximately $1.2&#160;million as the gross consideration in connection with the Warrant Amendment Agreements. The net proceeds of the Warrant Amendment Agreements after deducting placement fees were approximately $1.1&#160;million. Refer to Note 13 "Stockholders' Deficit" for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company's primary activities since incorporation have been conducting research and development activities, including nonclinical, preclinical and clinical testing, gaining commercial approval of its products, developing a commercial sales team, performing business and financial planning, recruiting personnel, and raising capital. The Company received approval by the FDA in February 2020 to commercialize NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablet in the U.S., and accordingly commenced principal operations on March 30, 2020 with the commercialization of NEXLETOL. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is subject to risks and uncertainties which include the need to successfully commercialize its products, research, develop, and clinically test therapeutic products; obtain regulatory approvals for its products (or additional or expanded indications for approved products); manage its management, commercial and scientific staff; and finance its operations with an ultimate goal of achieving profitable operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has sustained annual operating losses since inception and expects such losses to continue over the foreseeable future. While management believes current cash resources and future cash received from the Company's net product sales and collaboration agreements with Daiichi Sankyo Europe GmbH ("DSE"), Otsuka Pharmaceutical Co., Ltd ("Otsuka"), and Daiichi Sankyo Co. Ltd ("DS"), entered into on January 2, 2019, April 17, 2020 and April 26, 2021, respectively, will fund operations for the foreseeable future, management may continue to fund operations and advance the development of the Company's products and product candidates through a combination of collaborations with third parties, strategic alliances, licensing arrangements, permitted debt financings, permitted royalty-based financings, and permitted private and public equity offerings or through other sources. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If adequate funds are not available, the Company may not be able to continue the development of its current products or future product candidates, or to commercialize its current or future product candidates, if approved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2022, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <espr:NumberOfStudyPatients
      contextRef="i55f6734ada96468a9b81e77531464725_D20190801-20190831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzM2_fd8a6b34-2b4f-4ca1-8151-b0bb6806bdf0"
      unitRef="patient">14000</espr:NumberOfStudyPatients>
    <us-gaap:CommonStockSharesIssued
      contextRef="idabb0477bfa648dab7fecedc64128780_I20230319"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzQ0_ea7df3e3-3ea0-40cc-ac4b-ac09e9909258"
      unitRef="shares">12205000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idabb0477bfa648dab7fecedc64128780_I20230319"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzU2_1bd40b02-bea2-4a7d-a2c2-9e777ce26b62"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <espr:CommonStockPurchasableUnderPrefundedWarrants
      contextRef="i2d316e7178014207990f50547c020dad_D20230319-20230319"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzY0_67c6e16d-71e7-4572-acd9-649f9cd99bba"
      unitRef="shares">20965747</espr:CommonStockPurchasableUnderPrefundedWarrants>
    <espr:CommonStockPurchasableUnderWarrants
      contextRef="i2d316e7178014207990f50547c020dad_D20230319-20230319"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzc2_34e7f861-424a-49ba-ac33-22202858b6b5"
      unitRef="shares">33170747</espr:CommonStockPurchasableUnderWarrants>
    <espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights
      contextRef="i97a34cf836d84f4fadef4d721fab3698_I20230319"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzg4_fb4a8cbb-39bf-4bbb-9fa8-9fe549e2707d"
      unitRef="usdPerShare">1.675</espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights>
    <espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights
      contextRef="ice6f0592c1f54f6b9a640b944432f3be_I20230319"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxMzk2_49d2b3a2-a363-4cf0-9260-4a050ddc1f89"
      unitRef="usdPerShare">1.674</espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idabb0477bfa648dab7fecedc64128780_I20230319"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMxNDA0_86387ad6-e39a-4c26-b588-880bcb6598f3"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <espr:CommonStockPurchasableUnderWarrants
      contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODM0NjE5_16c0d97f-632f-44d1-80e7-237923dca99d"
      unitRef="shares">9024212</espr:CommonStockPurchasableUnderWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7ce060f7a8354b51af7f71258119d414_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODM0NjM3_57584d4e-941d-4627-bc49-9a9e9e42162b"
      unitRef="usdPerShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i2905ddfb2a734b91a7b4f966c0bb65da_I20230323"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODM0NjMw_69da0eb8-6b18-4cc2-a4fa-2832d4c513b1"
      unitRef="usdPerShare">1.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <espr:ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights
      contextRef="i90c4fbf04c494d99bd37f6e4eb559905_I20230322"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODM0NjQ0_adc194ab-b7d7-4c72-8dd1-c6fe49b05d53"
      unitRef="usdPerShare">0.125</espr:ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfMjE5OTAyMzI3MzM2Nw_bf49bfbf-249c-4b0c-9e77-0193569ce032"
      unitRef="usd">55500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5664faaee9574db4a202135e028596c8_D20230319-20230319"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfMjE5OTAyMzI3MzYyOQ_81836684-c76b-4491-b188-3e7ce82ba3cb"
      unitRef="usd">51300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5664faaee9574db4a202135e028596c8_D20230319-20230319"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfMjE5OTAyMzI3MzY4Mg_2595d9ab-0dfb-408c-b25f-ee8ea08c232c"
      unitRef="usd">1200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTQ5NzU1ODMzNTM4_eb4bbd2b-1b7c-4655-80c0-a2985ee26a4e"
      unitRef="usd">1100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zMS9mcmFnOjcxMzlhM2EwOGY4NDQzNWZhNzU1ZWJiYjY5YzlkYjNjL3RleHRyZWdpb246NzEzOWEzYTA4Zjg0NDM1ZmE3NTVlYmJiNjljOWRiM2NfNTMxMQ_fb3a7551-abf2-427a-8cfc-004d5694ca63">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed interim financial statements are unaudited and were prepared by the Company in accordance with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). In the opinion of management, the Company has made all adjustments, which include only normal recurring adjustments necessary for a fair presentation of the Company&#x2019;s financial position and results of operations for the interim periods presented. Certain information and disclosures normally included in the annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, have been condensed or omitted. These condensed interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December&#160;31, 2022, and the notes thereto, which are included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2022. The results of operations for the interim periods are not necessarily indicative of the results to be expected for a full year, any other interim periods or any future year or period.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwNzc_3fdb15e7-a17d-4cd9-be36-4fe5543d7438">Summary of Significant Accounting Policies&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in bank deposits, money market accounts, and short-term investments. The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents are reported at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments are considered to be available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are reported in accumulated other comprehensive income (loss). The cost of investments classified as available-for-sale are adjusted for the amortization of premiums and accretion of discounts to maturity and recorded in other income, net. Realized gains and losses, if any, are determined using the specific identification method and recorded in other income, net. Investments with original maturities beyond 90 days at the date of purchase and which mature at, or less than twelve months from, the balance sheet date are classified as current. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of March&#160;31, 2023, eleven customers accounted for all of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company's net trade receivables and as of December 31, 2022, eleven customers accounted for all the Company's net trade receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones as consideration when it is probable that a future reversal is unlikely to occur. For sales-based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (&#x201c;API&#x201d;) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $17.0 million for the three months ended March&#160;31, 2023, and $13.4 million for the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers&#x2019; distribution facilities, or free on board (&#x201c;FOB&#x201d;) destination, the terms of which are designated in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company&#x2019;s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as &#x201c;Other accrued liabilities&#x201d; in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forms of Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-pay assistance:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company generally offers a right of return based on the product&#x2019;s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company&#x2019;s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company&#x2019;s expectations regarding future payment patterns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Implemented Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes to the significant accounting policies previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwNzg_5f3fa0ba-28ab-48cb-8dda-303df9b4e53d">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, net revenues, expenses and related disclosures. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwNzQ_cbcb6858-5ad9-41c0-9a58-dc2e3393968a">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in bank deposits, money market accounts, and short-term investments. The Company considers all highly liquid investments with an original maturity of 90 days or less at the time of purchase to be cash equivalents. Cash equivalents are reported at fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwODE_40f3daec-831f-494a-a707-640e1e033cb8">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments are considered to be available-for-sale and are carried at fair value. Unrealized gains and losses, if any, are reported in accumulated other comprehensive income (loss). The cost of investments classified as available-for-sale are adjusted for the amortization of premiums and accretion of discounts to maturity and recorded in other income, net. Realized gains and losses, if any, are determined using the specific identification method and recorded in other income, net. Investments with original maturities beyond 90 days at the date of purchase and which mature at, or less than twelve months from, the balance sheet date are classified as current. Investments with a maturity beyond twelve months from the balance sheet date are classified as long-term.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwODI_e5e6c463-5a08-4bb0-9e05-dde9235a6c99">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into a limited number of distribution agreements with distributors and specialty pharmacies. The Company's net product sales are with these customers. As of March&#160;31, 2023, eleven customers accounted for all of the &lt;/span&gt;&lt;/div&gt;Company's net trade receivables and as of December 31, 2022, eleven customers accounted for all the Company's net trade receivables.</us-gaap:ConcentrationRiskCreditRisk>
    <espr:ConcentrationRiskNumberOfMajorCustomers
      contextRef="i82aa535e66f84394b33629688b89827e_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMjMzNA_2ebedcc9-5837-4527-8743-da6bf48c0d4c"
      unitRef="customer">11</espr:ConcentrationRiskNumberOfMajorCustomers>
    <espr:ConcentrationRiskNumberOfMajorCustomers
      contextRef="i13c84429beb04adb81c5c0e8a4fa22d3_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMjQzMw_078f37da-bf2d-49a8-9397-3a1477f952d2"
      unitRef="customer">11</espr:ConcentrationRiskNumberOfMajorCustomers>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwNzk_e338e422-a665-4a4e-869a-cc0a926c46c1">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 606, Revenue from Contracts with Customers, the Company recognizes revenue when a customer obtains control of promised goods or services, in an amount that reflects the consideration the Company expects to receive in exchange for the goods or services provided. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: identify the contracts with a customer; identify the performance obligations in the contract; determine the transaction price; allocate the transaction price to the performance obligations in the contract; and recognize revenue when or as the entity satisfies a performance obligation. At contract inception the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. The Company derives revenue through two primary sources: collaboration revenue and product sales. Collaboration revenue consists of the collaboration payments to the Company for collaboration arrangements outside of the United States for the development, manufacturing and commercialization, including royalties, of the Company's product candidates by the Company's partners and product sales consists of sales of NEXLETOL and NEXLIZET.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into agreements related to its activities to develop, manufacture, and commercialize its product candidates. The Company earns collaboration revenue in connection with a collaboration agreement to develop and/or commercialize product candidates where the Company deems the collaborator to be the customer. Revenue is recognized when (or as) the Company satisfies performance obligations under the terms of a contract. Depending on the terms of the arrangement, the Company may defer the recognition of all or a portion of the consideration received as the performance obligations are satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreements may require the Company to deliver various rights, services, and/or goods across the entire life cycle of a product or product candidate. In an agreement involving multiple goods or services promised to be transferred to a customer, the Company must assess, at the inception of the contract, whether each promise represents a separate performance obligation (i.e., is "distinct"), or whether such promises should be combined as a single performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the agreement typically include consideration to be provided to the Company in the form of non-refundable up-front payments, development milestones, sales milestones, and royalties on sales of products within a respective territory. The Company recognizes regulatory and approval milestones as consideration when it is probable that a future reversal is unlikely to occur. For sales-based milestones and royalties based on sales of product in a territory, the Company applies the sales-based royalty exception in ASC 606-10-55-65 to all of these milestones and royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the contract, the transaction price reflects the amount of consideration the Company expects to be entitled to in exchange for transferring promised goods or services to its customer. In the arrangement where the Company satisfies performance obligation(s) during the regulatory phase over time, the Company recognizes collaboration revenue typically using an input method on the basis of regulatory costs incurred relative to the total expected cost which determines the extent of progress toward completion. The Company reviews the estimate of the transaction price and the total expected cost each period and makes revisions to such estimates as necessary. Under contracted supply agreements with collaborators, the Company, through its third party contract manufacturing partners, may manufacture and supply quantities of active pharmaceutical ingredient (&#x201c;API&#x201d;) or bulk tablets reasonably required by collaboration partners for the development or sale of licensed products in their respective territory. The Company recognizes revenue when the collaboration partner has obtained control of the API or bulk tablets. The Company records the costs related to the supply agreement in cost of goods sold on the condensed statements of operations and comprehensive (loss) income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company's collaboration agreements, product sales and cost of sales may be recorded by the Company's collaborators as they are deemed to be the principal in the transaction. The Company receives royalties from the commercialization of such products, and records its share of the variable consideration, representing a percentage of net product sales, as collaboration revenue in the period in which such underlying sales occur and costs are incurred by the collaborator.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.94pt"&gt;Product Sales, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 21, 2020, the Company announced that the FDA approved NEXLETOL as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On February 26, 2020, the Company announced that the FDA approved NEXLIZET as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or established ASCVD who require additional lowering of LDL-C. On March 30, 2020, NEXLETOL was commercially available in the U.S. through prescription and on June 4, 2020, NEXLIZET was commercially available in the U.S. through prescription. Net product sales totaled $17.0 million for the three months ended March&#160;31, 2023, and $13.4 million for the three months ended March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells NEXLETOL and NEXLIZET to wholesalers in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time when the customer is deemed to have obtained control of the product. The customer is deemed to have obtained control of the product at the time of physical receipt of the product at the customers&#x2019; distribution facilities, or free on board (&#x201c;FOB&#x201d;) destination, the terms of which are designated in the contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product sales are recorded at the net selling price, which includes estimates of variable consideration for which reserves are established for (a) rebates and chargebacks, (b) co-pay assistance programs, (c) distribution fees, (d) product returns, and (e) other discounts. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as current contractual and statutory requirements, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company's best estimates of the amount of consideration to which it is entitled based on the terms of the applicable contract. The amount of variable consideration may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Given the early stage of the Company&#x2019;s commercial operations it has provided constraint of its variable consideration due to its potential consumption trends. Actual amounts of consideration ultimately received may differ from the Company's estimates. If actual results in the future vary from estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees are classified as &#x201c;Other accrued liabilities&#x201d; in the condensed balance sheets. Discounts, such as prompt pay discounts, and chargebacks are recorded as a reduction to trade accounts receivable in the condensed balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forms of Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rebates and Chargebacks:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company estimates reductions to product sales for Public Health Service Institutions, such as Medicaid, Medicare and Veterans' Administration ("VA") programs, as well as certain other qualifying federal and state government programs, and other group purchasing organizations. The Company estimates these reductions based upon the Company's contracts with government agencies and other organizations, statutorily defined discounts and estimated payor mix. These organizations purchase directly from the Company's wholesalers at a discount and the wholesalers charge the Company back the difference between the wholesaler price and the discounted price. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for a current quarter. The Company's reserve for this discounted pricing is based on expected sales to qualified healthcare providers and the chargebacks that customers have already claimed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Co-pay assistance:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Eligible patients who have commercial insurance may receive assistance from the Company to reduce the patient's out of pocket costs. The Company will buy down the difference between the amount of the eligible patient's co-pay when the drug is purchased at the pharmacy at a determined price. Liabilities for co-pay assistance are calculated by actual program participation from third-party administrators.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Distribution Fees:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has written contracts with its customers that include terms for distribution fees and costs for inventory management. The Company estimates and records distribution fees due to its customers based on gross sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Returns:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company generally offers a right of return based on the product&#x2019;s expiration date and certain spoilage and damaged instances. The Company estimates the amount of product sales that may be returned and records the estimate as a reduction of product sales in the period the related product sales is recognized. The Company&#x2019;s estimates for expected returns are based primarily on an ongoing analysis of sales information and visibility into the inventory remaining in the distribution channel.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discounts:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company provides product discounts, such as prompt pay discounts, to its customers. The Company estimates cash discounts based on terms in negotiated contracts and the Company&#x2019;s expectations regarding future payment patterns.&lt;/span&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <espr:NumberOfSourcesOfRevenue
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMzY1Mw_774b5c04-c3f3-4afe-a751-20c9387e47c6"
      unitRef="revenue_source">2</espr:NumberOfSourcesOfRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie2b77b80c5d249d29e61285804d99500_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfODI0NQ_44d9aed9-6886-44be-8d45-ee6d425be94e"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i27f18e48d6294e8b944c473a6e0492ed_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfODI4OA_33fe4396-099c-4da2-b65d-39fa16a6795a"
      unitRef="usd">13400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwODA_85e9130c-ebfa-4e65-b295-3bb89865af00">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value and recognized on a first-in, first-out ("FIFO") method. The Company uses standard cost to determine the cost basis for inventory. Inventory is capitalized based on when future economic benefit is expected to be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its inventory levels on a periodic basis to determine if any inventory is at risk for expiration prior to sale or has a cost basis that is greater than its estimated future net realizable value. Any adjustments are recognized through cost of goods sold in the period in which they are incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNC9mcmFnOmRkNWNjYzMzMzI5NDQxY2Q5YmMwMWUyOTlmOTk4NjI5L3RleHRyZWdpb246ZGQ1Y2NjMzMzMjk0NDFjZDliYzAxZTI5OWY5OTg2MjlfMTQwNzY_bf846fd7-b1b8-47a0-8d33-7d980d0d47aa">&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Implemented Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no other material changes to the significant accounting policies previously disclosed in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfOTIxNQ_848328e8-e7c5-496d-88e7-a673ba9903e6">Collaborations with Third Parties&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DSE Agreement Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 2, 2019, the Company entered into a license and collaboration agreement with DSE, which was furthered amended on June 18, 2020. Pursuant to the amended agreement, the Company granted DSE exclusive commercialization rights to bempedoic acid and the bempedoic acid / ezetimibe combination tablet in the European Economic Area, Turkey, and Switzerland (&#x201c;DSE Territory&#x201d;). DSE will be responsible for commercialization in the DSE Territory. DSE's designated affiliate in Turkey will be solely responsible, at its sole cost and expense, for all regulatory matters relating to such products in Turkey, including obtaining regulatory approval for such products in Turkey. The Company remains responsible for clinical development, regulatory and manufacturing activities for the licensed products globally, including in the DSE Territory outside of Turkey.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the agreement, the Company received upfront cash of $150.0 million in 2019 and a $150.0 million cash milestone payment in 2020 following the completion of the NUSTENDI&#xae; Marketing Authorisation Applications ("MAA"). The Company is responsible for supplying DSE with certain manufacturing supply of the API or bulk tablets. The Company is also eligible to receive an additional regulatory milestone payment of either $200&#160;million or $300&#160;million upon the grant of the marketing authorisation in the European Union for the CV risk reduction label, depending on the range of relative risk reduction in the CLEAR Outcomes study. Refer to Note 5 "Commitments and Contingencies" for further information. In addition, the Company is eligible to receive additional sales milestone payments related to total net sales achievements for DSE in the DSE Territory. Finally, the Company receives tiered fifteen percent (15%) to twenty-five percent (25%) royalties on net DSE Territory sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement calls for both parties to participate in a Joint Collaboration Committee (the &#x201c;DSE JCC&#x201d;). The DSE JCC is comprised of executive management from each company and the Company will lead in all aspects related to development and DSE will lead in all aspects related to commercialization in the DSE Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three months ended March&#160;31, 2023 and 2022, the Company recognized collaboration revenue of approximately $7.1&#160;million and $5.3 million related to royalty revenue from DSE from the sales of NILEMDO&#xae; and NUSTENDI as well as the sales of bulk tablets to DSE pursuant to the supply agreement that was executed with DSE. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All remaining future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to sales-based milestones will be recognized when the subsequent sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Otsuka Agreement Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 17, 2020, the Company entered into a license and collaboration agreement (the "Otsuka Agreement") with Otsuka. Pursuant to the Otsuka Agreement, the Company granted Otsuka exclusive development and commercialization rights to NEXLETOL and NEXLIZET in Japan. Otsuka will be responsible for all development, regulatory, and commercialization activities in Japan. In addition, Otsuka will fund all clinical development costs associated with the program in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the agreement, the consideration consists of a $60.0 million upfront cash payment and the Company will be eligible to receive additional payments of up to $450.0 million if certain regulatory and commercial milestones are achieved by Otsuka. The potential future milestone payments include up to $20.0 million upon first JNDA submissions in the Otsuka Territory, up to $70.0 million upon the first NHI Price Listing for NEXLETOL in the Otsuka Territory, and up to $50.0 million upon the achievement of the primary major adverse cardiovascular events (&#x201c;MACE&#x201d;) in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study. In addition, the Company is eligible to receive additional sales milestone payments up to $310.0 million related to total net sales achievements for Otsuka in Japan. Finally, the Company will receive tiered fifteen percent (15%) to thirty percent (30%) royalties on net sales in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company did not have any collaboration revenue from the Otsuka Agreement during the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not yet recognized any revenue for milestone payments as the related regulatory and commercial milestones have not yet been achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DS Agreement Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2021, the Company entered into a license and collaboration agreement with Daiichi Sankyo Co. Ltd (the "DS Agreement"). Pursuant to the DS Agreement, the Company granted DS exclusive rights to develop and commercialize bempedoic acid and the bempedoic acid / ezetimibe combination tablet in South Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia and Myanmar (collectively the "DS Territory"). The agreement allows for potential expansion across geographies including Saudi Arabia, Kuwait, Oman, UAE, Qatar, Bahrain, Yemen, Colombia and other Latin American countries. Except for certain development activities in South Korea and Taiwan, DS will be responsible for development and commercialization in these territories. In addition, DS will fund all development costs associated with the program in the DS Territory. Pursuant to the agreement, the consideration consists of a $30.0&#160;million upfront cash payment that is non-refundable, non-reimbursable and non-creditable. The Company also will be eligible to receive additional one-time payments of up to $175.0&#160;million if certain commercial milestones are achieved by DS. Also, the Company will receive tiered royalties of five percent (5%) to twenty percent (20%) of net sales in the DS Territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considered the guidance under ASC 606 and concluded that the agreement was in the scope of ASC 606. The Company concluded that the upfront payment of $30.0&#160;million should be included in the transaction price and related to the following performance obligations under the agreement: 1) the license to the Company&#x2019;s intellectual property and 2) the obligation to provide ongoing development activities. The Company used the adjusted market assessment approach in determining the standalone selling price of the Company&#x2019;s intellectual property and the expected cost plus margin approach in determining the standalone selling price of the Company&#x2019;s obligation to provide ongoing development activities. For the three months ended March 31, 2023 and 2022, the Company recognized $0.2&#160;million and $0.2&#160;million, respectively of collaboration revenue related to the ongoing regulatory and development activities. The remaining $0.5&#160;million of the upfront payment was deferred as of March 31, 2023 due to an on-going performance obligation related to the developmental activities in South Korea and Taiwan. This deferred revenue will be recognized ratably over the period leading up to the completion of these developmental activities.&lt;/span&gt;&lt;/div&gt;All future potential milestone amounts were not included in the transaction price, as they were all determined to be fully constrained following the concepts of ASC 606 due to the fact that such amounts hinge on development activities, regulatory approvals and sales-based milestones. Additionally, the Company expects that any consideration related to royalties and sales-based milestones will be recognized when the subsequent sales occur.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <espr:UpFrontPayment
      contextRef="ib0dc2923eba0447ab555feccec765db2_D20190102-20190102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfOTg1_6eb30394-a8e9-4c45-96f7-fcd69d3754b2"
      unitRef="usd">150000000</espr:UpFrontPayment>
    <espr:CashPaymentToBeReceivedUponFirstCommercialSales
      contextRef="ib0dc2923eba0447ab555feccec765db2_D20190102-20190102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMTAwMg_227ee460-354c-4476-919b-f1ee1cdb7b7e"
      unitRef="usd">150000000</espr:CashPaymentToBeReceivedUponFirstCommercialSales>
    <espr:AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization
      contextRef="i5784cd2d48204ab3a25a3176ccbe3451_D20190102-20190102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNTQ5NzU1ODI1Mzcz_5ffbd79e-c1ae-431d-a266-82fc50cf9d01"
      unitRef="usd">200000000</espr:AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization>
    <espr:AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization
      contextRef="ia4e347119af144cd8d92b13e2b6c5387_D20190102-20190102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNTQ5NzU1ODI1Mzg3_401237fa-c763-459f-b5d2-156a858c956b"
      unitRef="usd">300000000</espr:AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="i5784cd2d48204ab3a25a3176ccbe3451_D20190102-20190102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMTcxNg_08713d95-b7af-41d1-ac74-22baf0e45c2e"
      unitRef="number">0.15</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="ia4e347119af144cd8d92b13e2b6c5387_D20190102-20190102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMTc0NA_24276632-230b-4490-8258-5d4377e4e4c3"
      unitRef="number">0.25</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i437ec51f9da947e4957d1c78257d41ca_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMjIxNg_20b58648-4ce5-4cb7-a2fe-d43db22277de"
      unitRef="usd">7100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc5c8e4669ee430eb7fd9eb3d5682fcc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMjMzMg_75edbf9a-7a00-4e63-ad7f-2dbb51765f63"
      unitRef="usd">5300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <espr:UpFrontPayment
      contextRef="ia37f88e1d6334cd4988043aa29cb8d9d_D20200417-20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMzUzNQ_911a7780-97d5-45da-b952-35e69658be44"
      unitRef="usd">60000000</espr:UpFrontPayment>
    <espr:AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones
      contextRef="icbe99073da5e4665be166412628cfbc6_I20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMzYzMg_5116dd89-41df-457e-972c-e7a040d38d7d"
      unitRef="usd">450000000</espr:AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones>
    <espr:FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory
      contextRef="i774e2569416f4db59556c5fcd4cc0597_I20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMzc2MQ_dd9d5a34-29d4-49ff-a2cd-012a8dca33b3"
      unitRef="usd">20000000</espr:FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory>
    <espr:FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory
      contextRef="i774e2569416f4db59556c5fcd4cc0597_I20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMzgyMw_8e3cbb4b-d3bd-4d92-a7aa-56bea8b0daa0"
      unitRef="usd">70000000</espr:FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory>
    <espr:FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies
      contextRef="i774e2569416f4db59556c5fcd4cc0597_I20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfMzkwNw_2ed8aefd-b1a3-44ae-ba06-a795252725a9"
      unitRef="usd">50000000</espr:FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies>
    <espr:FuturePaymentMilestoneSalesMilestones
      contextRef="i774e2569416f4db59556c5fcd4cc0597_I20200417"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNDIzOA_b8fd49da-1e00-4068-ad84-436a3963b741"
      unitRef="usd">310000000</espr:FuturePaymentMilestoneSalesMilestones>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="ia9838052375c4929b5e4b845fe66da84_D20200417-20200417"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNDM2MA_6cf2c764-59f6-4ec7-85ec-f367ca2d482b"
      unitRef="number">0.15</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="i556e6b8f854a4c16bc7335cde1d58ab3_D20200417-20200417"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNDM4Mw_58c0cb47-f9ce-4877-b22e-f5a5bc6b8c4e"
      unitRef="number">0.30</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:FutureUpFrontPayment
      contextRef="ic913c0c79880452395a8e14c510b4c70_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNjQxOA_c79caa04-0a4c-4d97-99b6-13e8a5c29a04"
      unitRef="usd">30000000</espr:FutureUpFrontPayment>
    <espr:CashPaymentToBeReceivedUponCertainCommercialMilestones
      contextRef="ic913c0c79880452395a8e14c510b4c70_D20210401-20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNjU4Ng_5e656119-ece7-45a4-9ba2-3c4a88376568"
      unitRef="usd">175000000</espr:CashPaymentToBeReceivedUponCertainCommercialMilestones>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="ifa13681c34ae4d84ab904e7d74d950a1_D20210401-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNjcwNw_9b4e0ab3-f726-490f-89d6-cbe16cc6e824"
      unitRef="number">0.05</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:PercentageOfRoyaltiesToBeReceivedOnNetSales
      contextRef="ic924dfffa02f4560877a7d949f08cede_D20210401-20210430"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNjczMA_d8373c94-d9a2-4cab-bcf1-f4957277313e"
      unitRef="number">0.20</espr:PercentageOfRoyaltiesToBeReceivedOnNetSales>
    <espr:FutureUpFrontPayment
      contextRef="i58cea3ac6b01461cab29af950aeb53a8_D20210426-20210426"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNjk1Mw_bfc470e6-f073-4448-9e04-48ffb1e69fc9"
      unitRef="usd">30000000</espr:FutureUpFrontPayment>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if38679db574c48ac84aa03b68471cdff_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNTQ5NzU1ODI0OTIy_d4c68b78-be62-44cc-be18-8e6fd7cf216a"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie63bcb21a66346609cd8f6ef61fbffb7_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfNTQ5NzU1ODI0OTM2_2673b800-4dad-4fd9-bd85-74ee2abd6e86"
      unitRef="usd">200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <espr:DeferredUpFrontPayment
      contextRef="if38679db574c48ac84aa03b68471cdff_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV8zNy9mcmFnOmMyZWNmNjY5ZjBkYTQ4ZjRiYjE5ZWMyYTlmODBkOGFmL3RleHRyZWdpb246YzJlY2Y2NjlmMGRhNDhmNGJiMTllYzJhOWY4MGQ4YWZfODQ3Mg_b760bd00-3a4f-4a47-976f-b3229bed9c7e"
      unitRef="usd">500000</espr:DeferredUpFrontPayment>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RleHRyZWdpb246MzExYjE5YmM0MWU2NDg1YTkwMzBjMTI2ZmEzZWZiOTBfODU_3d232829-6787-43f6-8500-ba6995ffb7f5">Inventories, net&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RleHRyZWdpb246MzExYjE5YmM0MWU2NDg1YTkwMzBjMTI2ZmEzZWZiOTBfODY_251fed92-c40d-4530-bed3-a4ace2c3bff3">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMS0xLTEtMS02NTI3Mw_d1880c28-012e-4a15-bc56-544c4b4d5c27"
      unitRef="usd">35090000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMS0zLTEtMS02NTI3Mw_4aa381c0-54d6-4bdd-ad56-3443a67dd24f"
      unitRef="usd">26558000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMi0xLTEtMS02NTI3Mw_5f4725b8-de6d-48c6-8a3c-c13d1503a4d8"
      unitRef="usd">1697000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMi0zLTEtMS02NTI3Mw_ac6191cd-a2c4-4d07-b56c-c6f18403898a"
      unitRef="usd">6548000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMy0xLTEtMS02NTI3Mw_8e7bcc35-566a-4e26-b159-abf19133b2aa"
      unitRef="usd">2565000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfMy0zLTEtMS02NTI3Mw_acc45ffe-1402-46dc-b42e-ac4addecafa3"
      unitRef="usd">2095000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfNS0xLTEtMS02NTI3Mw_bfa2d20c-d961-467d-9729-25445e3bedf7"
      unitRef="usd">39352000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80MC9mcmFnOjMxMWIxOWJjNDFlNjQ4NWE5MDMwYzEyNmZhM2VmYjkwL3RhYmxlOmJjYTQ0ODM4NzA2YTQ1NTM5Mjk0NTZjOTY3NDhhNTQyL3RhYmxlcmFuZ2U6YmNhNDQ4Mzg3MDZhNDU1MzkyOTQ1NmM5Njc0OGE1NDJfNS0zLTEtMS02NTI3Mw_d086244f-65b9-4046-9f92-7148960558b9"
      unitRef="usd">35201000</us-gaap:InventoryNet>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMjA3MQ_91b5ba98-3437-45f1-9dac-76ab5a795de0">Commitments and Contingencies &lt;div style="text-indent:18pt"&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"/&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 4, 2023, the Company announced the full results from its Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen (CLEAR) Outcomes trial. Based on the terms of the contract with DSE, the Company is eligible for partner milestone payments upon inclusion of cardiovascular risk reduction data in the EU label, for which payment is tied to the magnitude of the risk percentage reduction included in the label (among other requirements) and ranges from $200&#160;million for the inclusion of cardiovascular risk reduction in the EU label that correlates with a relative risk reduction rate that, based on the CLEAR Outcomes data, is equal or greater than 15% but less than 20%, to $300&#160;million if such risk reduction in the EU label that correlates with a relative risk reduction rate is equal or greater than 20%. Based on the CLEAR Outcomes data, the Company believes it would be entitled to receive $300&#160;million in partner milestone payments upon inclusion of cardiovascular risk reduction data in the EU label. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has had communications with DSE regarding potential milestone payments in which DSE has conveyed that it disagrees with the Company&#x2019;s assessment that the CLEAR Outcomes data would support the Company&#x2019;s right to receive any milestone payments upon inclusion of certain required cardiovascular risk reduction data in the EU label. Even if the Company is successful in enforcing its rights, there could be a delay in the Company&#x2019;s receipt of the milestone payments as a result of any dispute relating to such payments. Any failure to receive or any delay in receipt of the milestone payments may significantly impact the Company&#x2019;s future capital needs, ability to recognize revenue for the milestone upon inclusion of cardiovascular risk reduction data in the EU label, and ability to fund operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2023, the Company filed a complaint in the United States District Court for the Southern District of New York seeking declaratory judgment against DSE regarding the Company&#x2019;s right to receive a $300&#160;million milestone payment upon inclusion of cardiovascular risk reduction in the EU label that correlates with a relative risk reduction rate of at least 20%, based on the CLEAR Outcomes trial demonstrating significant cardiovascular risk reductions.&lt;/span&gt;&lt;/div&gt;On May 4, 2023, the Company filed an amended complaint against DSE in the Southern District of New York. The complaint seeks a judicial declaration, on an expedited basis, that DSE is contractually required to make a $300&#160;million milestone payment to the Company upon applicable regulatory approval.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <espr:PotentialProceedsFromPartnerMilestonePayments
      contextRef="i7d6b22f936e84b6e9cadcd7659d06dc6_D20230304-20230304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMTQ2MDA_4ee328af-44f2-412e-a92d-4a2aa0ab6458"
      unitRef="usd">200000000</espr:PotentialProceedsFromPartnerMilestonePayments>
    <espr:PercentageOfRiskReduction
      contextRef="ica364f56b4754e2fb33645747ebebdba_I20230304"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMTQ2MDQ_72852af6-2a39-40d1-95fe-3a96927e24c8"
      unitRef="number">0.15</espr:PercentageOfRiskReduction>
    <espr:PercentageOfRiskReduction
      contextRef="i0ff170b7510847eeb8c913c0268553d5_I20230304"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMTQ2MDg_8fdcb75d-5b1c-4bf4-89ba-dbc42683e4d1"
      unitRef="number">0.20</espr:PercentageOfRiskReduction>
    <espr:PotentialProceedsFromPartnerMilestonePayments
      contextRef="i5eb81084a86e42b49fbea9ece7638ea5_D20230304-20230304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMTQ2MzY_a67a00a6-ab1f-48e3-a2c8-348b36d987ab"
      unitRef="usd">300000000</espr:PotentialProceedsFromPartnerMilestonePayments>
    <espr:PercentageOfRiskReduction
      contextRef="i9e14be02d3004562870df907dec00d77_I20230304"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfMTQ2MzI_7d7dd1f8-62ad-4531-aec7-8068d2da762e"
      unitRef="number">0.20</espr:PercentageOfRiskReduction>
    <espr:PotentialProceedsFromPartnerMilestonePayments
      contextRef="i6dc542279e7e464ca12100e49501610e_D20230304-20230304"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfNTQ5NzU1ODI0MjUy_3f3de592-f842-4f5f-bef2-a9c4b685c4b0"
      unitRef="usd">300000000</espr:PotentialProceedsFromPartnerMilestonePayments>
    <espr:PotentialProceedsFromPartnerMilestonePayments
      contextRef="ia2442189a4e04c14866e4ca5dbe37ae7_D20230327-20230327"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfNTQ5NzU1ODI0MzA4_b8e05b57-c588-4a99-8250-dc7b0d77dce0"
      unitRef="usd">300000000</espr:PotentialProceedsFromPartnerMilestonePayments>
    <espr:PercentageOfRiskReduction
      contextRef="i77154455e27741eea8b7382d7bae0ad0_I20230327"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfNTQ5NzU1ODI0Mzc1_cd9482e2-6b14-4e6f-987e-27b0abf4b348"
      unitRef="number">0.20</espr:PercentageOfRiskReduction>
    <espr:PotentialProceedsFromPartnerMilestonePayments
      contextRef="ic6cf6eadd1ee45ffbf7b12713791e2c9_D20230504-20230504"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80My9mcmFnOmJjN2I3ODhlY2ZlNDRmOTJhOGQ5YmQzMDUxOTIyMTM5L3RleHRyZWdpb246YmM3Yjc4OGVjZmU0NGY5MmE4ZDliZDMwNTE5MjIxMzlfNTQ5NzU1ODI4NTI3_7c47462c-5e2d-44b6-8306-3ed6bc7ebe49"
      unitRef="usd">300000000</espr:PotentialProceedsFromPartnerMilestonePayments>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfMTI3MA_d610d324-f91b-47f1-aab4-8cb22ca087d9">Investments&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s cash equivalents and short-term investments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and March&#160;31, 2022, other income, net in the statements of operations includes interest income on investments of $0.9 million and $0.3 million. During the three months ended March&#160;31, 2023, other income, net in the statements of operations includes accretion of premiums and discounts on investments of $0.3&#160;million. During the three months ended March 31, 2022, other income, net in the statements of operations includes amortization of premiums and discounts on investments of $0.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no unrealized gains or losses on investments reclassified from accumulated other comprehensive income (loss) to other income in the statements of operations during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three months ended March&#160;31, 2023 and 2022, there were no allowances for credit losses and all unrealized gains (losses) for available-for-sale securities were recognized in accumulated other comprehensive income (loss). As of March&#160;31, 2023, the Company had no accrued interest receivables.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfMTI3MQ_fff61389-4ec5-480e-b960-fbb2985427df">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s cash equivalents and short-term investments (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized &lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated &lt;br/&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iddba95e9a591432fb6bb68b9d99fc675_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfMy0xLTEtMS02NTI3Mw_adbfe1db-0456-4683-bab8-ea5649e1166b"
      unitRef="usd">113566000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iddba95e9a591432fb6bb68b9d99fc675_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfMy0zLTEtMS02NTI3Mw_437f34fc-2dd9-46a9-8c66-1d894405a04c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iddba95e9a591432fb6bb68b9d99fc675_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfMy01LTEtMS02NTI3Mw_41d14eca-7c7f-42da-951e-a662672e7abe"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iddba95e9a591432fb6bb68b9d99fc675_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfMy03LTEtMS02NTI3Mw_88ceac55-35b9-4b8d-a2f5-0430da543a5d"
      unitRef="usd">113566000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4446c0fdb9a84cc7ae17ac1fc0e8e0a0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNC0xLTEtMS02NTI3Mw_c60a691c-db34-4538-afeb-fdb3d96f8efa"
      unitRef="usd">401000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4446c0fdb9a84cc7ae17ac1fc0e8e0a0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNC0zLTEtMS02NTI3Mw_a432ad73-b654-411a-babe-bc22968e3cef"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4446c0fdb9a84cc7ae17ac1fc0e8e0a0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNC01LTEtMS02NTI3Mw_c8d0bb74-1b0b-4286-a7ff-ce54f29b680f"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4446c0fdb9a84cc7ae17ac1fc0e8e0a0_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNC03LTEtMS02NTI3Mw_8bb8e02b-4c27-4542-8ad1-bac1b08ce529"
      unitRef="usd">401000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaee3d89d3ffc4d01a13615bb5476bcf1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNi0xLTEtMS02NTI3Mw_e56ced06-6c53-4668-b255-fb73e9cfbc51"
      unitRef="usd">17428000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaee3d89d3ffc4d01a13615bb5476bcf1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNi0zLTEtMS02NTI3Mw_062bdb81-059f-4c09-819b-a6b25b90a91e"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaee3d89d3ffc4d01a13615bb5476bcf1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNi01LTEtMS02NTI3Mw_27137017-203d-41c9-a0e9-3355021c1304"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaee3d89d3ffc4d01a13615bb5476bcf1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNi03LTEtMS02NTI3Mw_bdeeb898-3c64-40be-abb3-9f6e2d1b07c4"
      unitRef="usd">17427000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNy0xLTEtMS02NTI3Mw_986038b9-f576-48fb-b88b-d741bd659d61"
      unitRef="usd">131395000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNy0zLTEtMS02NTI3Mw_f6255796-0702-4863-88f6-f36efe6d3917"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNy01LTEtMS02NTI3Mw_70c78e6d-2d3a-4a5b-9e36-14cba2bc65e3"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjZkYzQ1NDVjY2Q3YzRhNzQ4N2Q1MmQ2N2VjMTdmYjQzL3RhYmxlcmFuZ2U6NmRjNDU0NWNjZDdjNGE3NDg3ZDUyZDY3ZWMxN2ZiNDNfNy03LTEtMS02NTI3Mw_3a3bd02c-e342-4df6-8b33-628eb2b4b668"
      unitRef="usd">131394000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if2b452feddd34bfab04830af609fee01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMy0xLTEtMS02NTI3Mw_7743d6c6-b4b8-4036-aab5-3ffbf0b77ced"
      unitRef="usd">105078000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if2b452feddd34bfab04830af609fee01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMy0zLTEtMS02NTI3Mw_4481ac3f-d902-4624-bbe1-9a4d458363ed"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if2b452feddd34bfab04830af609fee01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMy01LTEtMS02NTI3Mw_0a6aa179-d257-4fc8-83d3-d9caa6158fe1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if2b452feddd34bfab04830af609fee01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMy03LTEtMS02NTI3Mw_a337f1b8-2364-4471-95be-fa82b2f2b686"
      unitRef="usd">105078000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i70000ff4cfcc4e379e6941a6be6de6ab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNC0xLTEtMS02NTI3Mw_2c084fc7-a838-41cd-8a2f-60acd1d80a00"
      unitRef="usd">4994000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i70000ff4cfcc4e379e6941a6be6de6ab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNC0zLTEtMS02NTI3Mw_c6bed803-e472-43ae-ad6d-4db3f7430e93"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i70000ff4cfcc4e379e6941a6be6de6ab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNC01LTEtMS02NTI3Mw_5a91984d-6b31-4fb5-80d7-5a96b9f346a3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i70000ff4cfcc4e379e6941a6be6de6ab_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNC03LTEtMS02NTI3Mw_4ddf0283-22fc-4812-9341-dd8a0c36a466"
      unitRef="usd">4995000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i1bf5212861014a2a90c4514e738c57eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNi0xLTEtMS02NTI3Mw_cffce752-fa2c-414a-934f-4b64cd9d0e10"
      unitRef="usd">401000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i1bf5212861014a2a90c4514e738c57eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNi0zLTEtMS02NTI3Mw_d36b711f-e442-48f2-8044-5800e82e39a5"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i1bf5212861014a2a90c4514e738c57eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNi01LTEtMS02NTI3Mw_f9cc6d4f-0e9e-46b6-8540-d90f2ba22ce9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1bf5212861014a2a90c4514e738c57eb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfNi03LTEtMS02NTI3Mw_8edd5757-f102-4e42-8175-72edb726da70"
      unitRef="usd">401000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7636ce535be94232b11a93a9e2d54623_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfOS0xLTEtMS02NTI3Mw_6a69c52d-ae2a-4dc4-a9c7-7decbd57be62"
      unitRef="usd">42089000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7636ce535be94232b11a93a9e2d54623_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfOS0zLTEtMS02NTI3Mw_f45faadb-3d7e-4690-a4db-67f802206c9b"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7636ce535be94232b11a93a9e2d54623_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfOS01LTEtMS02NTI3Mw_5296bc18-610e-4591-8fca-c7c2488c248f"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7636ce535be94232b11a93a9e2d54623_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfOS03LTEtMS02NTI3Mw_58a0705f-9b1d-4347-bc45-f16fda0960bd"
      unitRef="usd">42086000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMTEtMS0xLTEtNjUyNzM_e4a60cf0-57aa-4a77-8528-1b7bfac7d4c1"
      unitRef="usd">152562000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMTEtMy0xLTEtNjUyNzM_b1b9eb58-196f-42c3-9450-c61d6e5514a5"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMTEtNS0xLTEtNjUyNzM_9d90bf95-577c-4f36-8d7c-84b4a9a8270b"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RhYmxlOjMyYzk4NDdjN2EwNjRiNWNiZGM0YmRmNDBiMTVjN2M1L3RhYmxlcmFuZ2U6MzJjOTg0N2M3YTA2NGI1Y2JkYzRiZGY0MGIxNWM3YzVfMTEtNy0xLTEtNjUyNzM_64009b7f-eb6a-4331-a85f-61617c6058ec"
      unitRef="usd">152560000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i96447b072e33476da43830de87cc58b4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfMjcx_29d96f0a-035a-4ca6-94bf-2157e0baf32a"
      unitRef="usd">900000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib0a643f6059d440590c4f9ef231a9a6a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfNDQz_4f750b97-28ed-42be-a2b7-4fd599c9ac10"
      unitRef="usd">300000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i96447b072e33476da43830de87cc58b4_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfNjQx_9d99007c-bb0f-4c42-9b54-57ab7d67c2e4"
      unitRef="usd">300000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ib0a643f6059d440590c4f9ef231a9a6a_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfNTQ5NzU1ODE1NTU3_428ef2b5-d30c-4438-8d13-9edc94a23fae"
      unitRef="usd">-200000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic4a1c26e2f864ba39b7dc746fa87291e_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfODAw_193dfc97-d6df-4c1f-b5a2-166a35d297dc"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i9c9a60f0eede463fa23b607d23c6f990_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfODAw_4c5b9ac8-447e-47c5-8b8f-410c46c7f8b0"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfMTA0Mg_1753be44-5194-4d0f-a4c4-81108498f6b6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i99f951895edd442e82a9307c2fd15632_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfMTA0Mg_7c0b5a01-647a-407c-a686-679b4b3b6234"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:AccruedInvestmentIncomeReceivable
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80Ni9mcmFnOmUxNjg4ODExMjY0YjQ1Y2I5MGNmMTQyZWUzM2JiYmYwL3RleHRyZWdpb246ZTE2ODg4MTEyNjRiNDVjYjkwY2YxNDJlZTMzYmJiZjBfNTQ5NzU1ODE1NTg5_42585964-254c-4182-a273-b84f1c2e9cd8"
      unitRef="usd">0</us-gaap:AccruedInvestmentIncomeReceivable>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RleHRyZWdpb246YzJhMTVhNzMwODI4NDMwMjg3ZGE3YjFiYzMzNWFiYTlfNjUw_d3c498ce-d74a-489d-89bf-bbfbecdfb53f">Fair Value Measurements&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows accounting guidance that emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Fair value is defined as &#x201c;the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.&#x201d; Fair value measurements are defined on a three level hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;1 inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quoted prices for identical assets or liabilities in active markets;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;2 inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Observable inputs other than Level&#160;1 prices, such as quoted market prices for similar assets or liabilities or other inputs that are observable or can be corroborated by market data; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level&#160;3 inputs:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unobservable inputs that are supported by little or no market activity and require the reporting entity to develop assumptions that market participants would use when pricing the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s financial assets that have been measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Levels 1, 2 or 3 during the three months ended March&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RleHRyZWdpb246YzJhMTVhNzMwODI4NDMwMjg3ZGE3YjFiYzMzNWFiYTlfNjUx_6adda092-c99e-438a-acdd-ff39d5a694dd">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s financial assets that have been measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8cadd97215ba4500883c87f85dc8fa2d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNC0yLTEtMS02NTI3Mw_ab2c2a8c-0030-4c2d-bdfa-e682d77ab4c0"
      unitRef="usd">113566000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if1ca33a8008147d78bca5e8eed93423d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNC00LTEtMS02NTI3Mw_cb57af8f-a2c4-4c7e-a378-f9750162f5aa"
      unitRef="usd">113566000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5fe88940f17f4e6792cd87aaa54541dd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNC02LTEtMS02NTI3Mw_727120a8-810d-4259-8618-63381a4a6dd4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7471d3b7a6ba4353b8cbc8d3e9345bfe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNC04LTEtMS02NTI3Mw_3eb17271-8cc2-434a-a0da-48604005fba5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia9834c756a92466abb333281240e95ae_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNS0yLTEtMS02NTI3Mw_a6ed63f2-b52e-45e2-b777-bdd8ec675de3"
      unitRef="usd">401000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if15b9c81ed564487bd38021a6515575e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNS00LTEtMS02NTI3Mw_dea7a04f-8c80-48dc-a16a-3bbc3da2628e"
      unitRef="usd">401000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2a3337053c7d484984eb254e5738a3a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNS02LTEtMS02NTI3Mw_1c82b5b1-0ea7-4aaa-b94e-1e88bc4466f3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i20434c7136b44164a04d244e3105f708_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNS04LTEtMS02NTI3Mw_c430f937-d437-41d4-817b-e7a97147544b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1f55c80accfb4964b37eccb272c3ab19_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNy0yLTEtMS02NTI3Mw_f9bd0d0a-de72-44e4-98fd-665cedf37087"
      unitRef="usd">17427000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8b4f98b104bb49ccbbb686e748c86c53_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNy00LTEtMS02NTI3Mw_9cb02a99-b962-489e-a249-670f5d2676be"
      unitRef="usd">17427000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4dc441d33315499aaa534c51197956c9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNy02LTEtMS02NTI3Mw_dbb64de3-5209-4ddb-a186-2b78521ebe6d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie25bd0065058415581124c3cefc0bc4b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfNy04LTEtMS02NTI3Mw_746005d0-7e99-45d9-9581-300ecdfcb59b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2df84ce791dd48a0a34c0e850ff9e8ea_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfOC0yLTEtMS02NTI3Mw_4ffdb399-7e65-469c-b601-8e7f78b9d300"
      unitRef="usd">131394000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ief6c1f5d0ae340d8af91af461c6b1b1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfOC00LTEtMS02NTI3Mw_aac7cb45-6b32-4fb4-b3e1-cec4f0f282f6"
      unitRef="usd">131394000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ie13c0a874a8e4068b43b96843795daac_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfOC02LTEtMS02NTI3Mw_d23f6541-a903-44a6-a055-639ae9953b22"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1185e14b22bb4ad8b91ff702b16b3dbe_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfOC04LTEtMS02NTI3Mw_552cb455-17bd-4b43-8f03-dc2425cdf5cc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f66dcce3270487dac3d302e1c309b3f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTEtMi0xLTEtNjUyNzM_33dcb484-d3c7-4901-bc3b-3521c7038de7"
      unitRef="usd">105078000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i293919219d734293958f10064d773142_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTEtNC0xLTEtNjUyNzM_f259cd9e-75f1-448f-b669-a6176685f7db"
      unitRef="usd">105078000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i37331eb822c14332aecf98c4a60c9a83_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTEtNi0xLTEtNjUyNzM_e2be2da3-0181-43c8-95c5-4c677e5a8c7e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i62ae5ff6d06c466e9f4d59d506da6f7e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTEtOC0xLTEtNjUyNzM_5c2ff03e-5188-48a8-bf32-b35e0418fe78"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i18c2947b9df14b23b8cc09df417e317f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTItMi0xLTEtNjUyNzM_90b74bd5-6477-4d6b-b89a-45bf99978529"
      unitRef="usd">401000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4b0c9a8dfde64edbbed9fa7ad3f7e105_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTItNC0xLTEtNjUyNzM_4e2176a3-01ac-4b30-adad-72c9e451268c"
      unitRef="usd">401000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id23e5091216b49dfac7f65fdd88e2a1f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTItNi0xLTEtNjUyNzM_71a204a9-9e22-408b-b67d-2389cf0a65c4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibd852d52cb6c4999a5a4f084a7dabb24_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTItOC0xLTEtNjUyNzM_c30dc51a-e999-4beb-bed3-0baed770d7a6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i75e3b605ec754126b40578f924de207a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTUtMi0xLTEtNjUyNzM_04e859bf-f118-4ef3-9c21-b08495e4c4fd"
      unitRef="usd">47081000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i88342aa86a3b4d5eada1ac9c12a8b565_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTUtNC0xLTEtNjUyNzM_b626cc12-cd76-4acd-9062-40a5444a7af7"
      unitRef="usd">47081000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3543312988354b0d860025f4d82f6d5a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTUtNi0xLTEtNjUyNzM_ed3de3ee-db95-4da9-8b0c-152accd0fa3b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8a04e27d9c67411db002887f7c2f4e82_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTUtOC0xLTEtNjUyNzM_c2ffc57d-ba01-44f0-bbbd-7ae047fbb39b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4189fded356d43ba84b628246a86e8bd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTctMi0xLTEtNjUyNzM_9419aa3b-d06f-42c4-8888-e83161ab5975"
      unitRef="usd">152560000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6b58988234e7462d88cabcc48176e5cd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTctNC0xLTEtNjUyNzM_7170eee9-1f0e-4b5d-a7bc-9be3893b51e1"
      unitRef="usd">152560000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if5dc67741b7147d48b9de0788cbe4d92_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTctNi0xLTEtNjUyNzM_63c26dae-1c87-411f-ba29-e4b0a2f12a2b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia22b6d1eb1714222833742d1f5e85b9a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RhYmxlOjc1ZDI2ODQ0M2M0ZjQzMGQ4OWNiNzJkODdlYTVmZDhjL3RhYmxlcmFuZ2U6NzVkMjY4NDQzYzRmNDMwZDg5Y2I3MmQ4N2VhNWZkOGNfMTctOC0xLTEtNjUyNzM_d336cc21-8747-4f10-a2f6-e5a4d76446c7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <espr:FairValueMeasurementAssetTransfersBetweenLevels
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RleHRyZWdpb246YzJhMTVhNzMwODI4NDMwMjg3ZGE3YjFiYzMzNWFiYTlfNTc1_82cc3393-792b-492d-b127-a5697ed63806"
      unitRef="usd">0</espr:FairValueMeasurementAssetTransfersBetweenLevels>
    <espr:FairValueMeasurementAssetTransfersBetweenLevels
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV80OS9mcmFnOmMyYTE1YTczMDgyODQzMDI4N2RhN2IxYmMzMzVhYmE5L3RleHRyZWdpb246YzJhMTVhNzMwODI4NDMwMjg3ZGE3YjFiYzMzNWFiYTlfNTc1_b025e3fc-c591-4cb0-bb32-7ca55db47ea9"
      unitRef="usd">0</espr:FairValueMeasurementAssetTransfersBetweenLevels>
    <espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTI5Njk_9d192f35-0fec-46a9-b381-250412ede512">Liability Related to the Revenue Interest Purchase Agreement&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 26, 2019, the Company entered into a Revenue Interest Purchase Agreement ("RIPA") with Oberland, as agent for purchasers party thereto (the &#x201c;Purchasers&#x201d;), and the Purchasers named therein, to obtain financing in respect to the commercialization and further development of bempedoic acid and the bempedoic acid / ezetimibe combination tablet and other working capital needs. Pursuant to the RIPA, the Company received $125.0 million at closing, less certain issuance costs. The Company was entitled to receive up to approximately $75.0 million in subsequent installments subject to the terms and conditions set forth in the RIPA: (i) $25.0 million upon certain regulatory approval of its product candidates and (ii) $50.0 million, at the Company&#x2019;s option, upon reaching $100.0 million trailing worldwide six-month net sales any time prior to December 31, 2021 (the &#x201c;Third Payment&#x201d;). In March 2020, the Company received $25.0 million from Oberland upon receiving regulatory approval of NEXLETOL.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As consideration for such payments, the Purchasers will have a right to receive certain revenue interests (the &#x201c;Revenue Interests&#x201d;) from the Company based upon net sales of the Company&#x2019;s certain products, once approved, which will be tiered payments initially ranging from 2.5% to 7.5% of the Company&#x2019;s net sales in the covered territory (the &#x201c;Covered Territory&#x201d;); provided that if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024, the revenue interest rate will be decreased to a single rate of 0.4% of the Company&#x2019;s net sales in the Covered Territory beginning on January 1, 2025. If the Third Payment is drawn down by the Company, the applicable royalty rates will increase by one-third. The Covered Territory is the United States, but is subject to expand to include the world-wide net sales if the Company&#x2019;s annual U.S. net sales are less than $350.0&#160;million for the year ended December 31, 2021. The U.S. net sales milestone thresholds are not to be taken as financial guidance. The Purchasers&#x2019; rights to receive the Revenue Interests shall terminate on the date on which the Purchasers have received Revenue Interests payments of 195% of the then aggregate purchase price (the &#x201c;Cumulative Purchaser Payments&#x201d;) paid to the Company, unless the RIPA is terminated earlier.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the RIPA, the Company has an option (the &#x201c;Call Option&#x201d;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#x201c;Put Option&#x201d;) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the RIPA contains various representations and warranties, information rights, non-financial covenants, indemnification obligations and other provisions that are customary for a transaction of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RIPA Amendments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 26, 2021, the Company entered into Amendment No. 2 (the &#x201c;RIPA Amendment 2&#x201d;) to the RIPA with Oberland, as agent for the purchaser parties thereto. Pursuant to the RIPA Amendment 2, Oberland waived the original trailing six-month world-wide net sales condition to the third installment payment under the RIPA and released the final $50&#160;million payment payable to the Company under the terms of the RIPA. The Company and Oberland also agreed to amend additional terms of the RIPA such that the purchasers will have a right to receive certain revenue interests (the &#x201c;Revenue Interests&#x201d;) from the Company based on net sales of the Company&#x2019;s certain products, once approved, which will be tiered payments ranging from 3.33% to 10% (the &#x201c;Third Payment Applicable Percentage&#x201d;) of the Company&#x2019;s net sales in the covered territory (the &#x201c;Covered Territory&#x201d;); provided that (a) prior to December 31, 2024, with respect to each country defined in the Daiichi Territory, if the percentage of net sales that Company receives from Daiichi (the &#x201c;Receivables Percentage&#x201d;) is less than the Third Payment Applicable Percentage, then the Revenue Interest for such country payable to the purchasers will be equal to the Receivables Percentages, (b) if annual net sales equal or exceed $350&#160;million and if the Purchasers receive 100% of their invested capital (Cumulative Purchaser Payments") by December 31, 2024, the revenue interest rate will be decreased to a single rate of 3.33% of the Company&#x2019;s net sales in the Covered Territory for all subsequent calendar quarters and (c) if the Purchasers receive Revenue Interest payments less than 100% of Cumulative Purchaser Payments by December 31, 2024, the Third Payment Applicable Percentage will be increased to a single rate of the Company&#x2019;s net sales that would have provided 100% of Cumulative Purchaser Payments had such rate applied from the initial funding by the Purchasers. The Covered Territory was originally the United States, but has been expanded to worldwide for all calendar years beginning on or after January 1, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the RIPA Amendment 2, the Company has an option (the &#x201c;Call Option&#x201d;) to terminate the RIPA and repurchase future Revenue Interests at any time upon advance written notice. Additionally, the Purchasers have an option (the &#x201c;Put Option&#x201d;) to terminate the RIPA and to require the Company to repurchase future Revenue Interests upon enumerated events such as a bankruptcy event, an uncured material breach, a material adverse effect or a change of control. If the Put Option or the Call Option are exercised, the required repurchase price will be 200% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised prior to the third anniversary of the closing date, and 225% of the Cumulative Purchaser Payments (minus all payments Company has made to the Purchasers in connection with the Revenue Interests), if such option is exercised thereafter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 16, 2021, the Company entered into an Amendment to the Security Agreement and Waiver ("Amendment and Waiver") with the same parties to the Security Agreement, by and among the Company, Eiger Partners II LP (the "Purchaser") and Eiger III SA LLC (the "Purchaser Agent"), dated as of June 26, 2019 (the "Security Agreement"). Pursuant to the Amendment and Waiver, if (i) the net revenue from sales of NEXLETOL and NEXLIZET and certain other products in the United States (as reported in the Company&#x2019;s financial statements as &#x201c;product sales, net&#x201d; in accordance with GAAP and excluding, for the avoidance of doubt, upfront or milestone payments and other collaboration revenue) (the &#x201c;Specified Net Revenue&#x201d;) for the calendar quarter ended September 30, 2021 does not exceed $15.0&#160;million, or (ii) the Specified Net Revenue for any calendar quarter ending after September 30, 2021 does not exceed $15.0&#160;million, then the Company shall deposit $50.0&#160;million in a deposit account that is subject to a block account control agreement in favor of the Purchase Agent, no later than the earlier of (x) the date the Specified Net Revenue for such calendar quarter has been determined and (y) 45 days after the last day of such calendar quarter. Since the Specified Net Revenue for the calendar quarter ended September 30, 2021 did not exceed $15.0&#160;million, the Company deposited $50.0&#160;million in a deposit account that is subject to a block account control agreement, which is classified as restricted cash on the balance sheets. The Purchaser Agent shall have sole dominion and control over all funds deposited in the deposited account and such funds may be withdrawn therefrom only with the consent of the Purchaser Agent. Upon the occurrence and during the continuance of a Put Option Event, the Purchaser Agent shall have the right to apply amounts held in the deposit account in payment of certain secured obligations in the manner provided for in the Security Agreement. The Amendment and Wavier does not substitute, replace or release the Pledgors from any other obligations under the RIPA or Security Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 23, 2022, the Company entered into Waiver and Amendment No. 3 to Revenue Interest Purchase Agreement and Amendment No. 2 to Security Agreement (the &#x201c;RIPA Amendment 3&#x201d;), by and among the Company, the Purchasers and the Purchaser Agent, which amends (i) the Revenue Interest Purchase Agreement, by and among the Company, the Purchasers, and the Purchaser Agent, dated effective as of June 26, 2019 (as amended by Amendment No. 1 to Revenue Interest Purchase Agreement dated as of November 9, 2020 and Amendment No. 2 to Revenue Interest Purchase Agreement dated as of April 26, 2021, and as may be further amended, restated, supplemented or modified from time to time, the &#x201c;RIPA&#x201d;) and (ii) the Security Agreement, by the Company in favor of the Purchaser Agent, dated as of June 28, 2019 (as amended by the Amendment to Security Agreement and Waiver by and among the Company, the Purchaser and the Purchaser Agent, effective as of May 16, 2021, and as may be further amended, restated, supplemented or modified from time to time, the &#x201c;Security Agreement&#x201d;). Pursuant to the RIPA Amendment 3, among other things, (a) the Company agreed to make a one-time partial call payment with regards to the Revenue Interests (as defined in the RIPA) in an amount equal to $50&#160;million from the restricted cash account (the &#x201c;Partial Call&#x201d;), (b) the amount of the Cumulative Purchaser Payments (as defined in the RIPA) was reduced to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$177,777,778, and (c) the Purchasers and Purchaser Agent waived certain claimed defaults, breaches and Put Option Events under the RIPA and other related documents that may have occurred as a result of the Company&#x2019;s opening of a new bank account.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the guidance in ASC 470&#x2011;50, &#x201c;Debt&#x2014;Modifications and Extinguishments,&#x201d; the RIPA Amendment 3 was accounted for as a debt modification. The amendment resulted in a less than $0.1&#160;million loss on modification of debt, consisting of third-party fees associated with the transaction, which is included in selling, general, and administrative expenses in the statements of operations for the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the arrangement, as of March 31, 2023, the Company has recorded a liability, referred to as the &#x201c;Revenue interest liability&#x201d; on the balance sheet, of $251.8&#160;million, net of $0.3&#160;million of capitalized issuance costs in connection with the RIPA, which will be amortized to interest expense over the estimated term of the RIPA. The total redemption amount is equal to 225% of the Cumulative Purchaser Payments, or $400&#160;million. At March 31, 2023, the remaining redemption amount is $385.0&#160;million. The Company imputes interest expense associated with this liability using the effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate on this liability may vary during the term of the agreement depending on a number of factors, including the level of forecasted net sales. The Company evaluates the interest rate quarterly based on its current net sales forecasts utilizing the prospective method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant increase or decrease in future net sales will materially impact the revenue interest liability, interest expense and the time period for repayment. The Company recorded approximately $11.3&#160;million and $11.0&#160;million in interest expense related to this arrangement for the three months ended March 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The repayment of the RIPA to Oberland does not have a fixed repayment schedule, rather it will be completely repaid and extinguished when the Company has repaid 225% of the Cumulative Purchaser Payments. Since there is not a fixed repayment schedule, the Company does not project its future repayments by year. Each period, the Company estimates the future expected sales of its products in the covered territory and determines the effective annual imputed interest rate, which updates and changes the timing of the Company&#x2019;s payments. Under the terms of the agreement, every $100&#160;million of net sales generated, less than or equal to $250&#160;million in an annual aggregate year, would result in a repayment obligation of approximately $10.0&#160;million or 10.0% at the stated repayment rate in the first year. Annual net sales for a calendar year exceeding $250&#160;million would result in a repayment obligation of approximately $3.3&#160;million or 3.3% for every $100&#160;million of sales above the threshold. As the U.S. net sales were less than $350&#160;million for the year ended December 31, 2021, the Covered Territory was expanded to include worldwide sales beginning in 2022. The Company&#x2019;s repayments of the RIPA are directly tied to the growth of its net sales, and as the Company&#x2019;s net sales grow, the Company expects the related repayments of the RIPA to grow as well. The Company currently expects to repay $26.9&#160;million in the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective annual imputed interest rate is 18.2% as of March&#160;31, 2023. Payments made to Oberland as a result of the Company&#x2019;s net sales will reduce the revenue interest liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the revenue interest liability activity during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue interest liability at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue Interests payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue interest liability at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock>
    <espr:GrossProceedsFromRevenueInterestPurchaseAgreement
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNDk0_52731a75-13cd-4796-b3f1-4c89bc2458a5"
      unitRef="usd">125000000.0</espr:GrossProceedsFromRevenueInterestPurchaseAgreement>
    <espr:AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTk0_f1bd4be9-3bc5-4502-b07b-782f4806c792"
      unitRef="usd">75000000.0</espr:AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions>
    <espr:AmountOfSubsequentInstallmentSubjectToRegulatoryApproval
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNjg3_6a134fdc-87f0-4350-99b9-bc884cce87b2"
      unitRef="usd">25000000.0</espr:AmountOfSubsequentInstallmentSubjectToRegulatoryApproval>
    <espr:AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNzU4_b22fb0c5-a473-4952-8860-d24f2283c560"
      unitRef="usd">50000000.0</espr:AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold>
    <espr:MilestoneAmountForWorldwideSalesToReceiveThirdPayment
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfODAx_8596ac15-8ed2-4844-921a-837261ce7467"
      unitRef="usd">100000000.0</espr:MilestoneAmountForWorldwideSalesToReceiveThirdPayment>
    <espr:ProceedsFromRevenueInterestPurchaseAgreement
      contextRef="if514492bc1304c3e88a7d73b880162d6_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfOTM4_8657788e-bbda-4db1-82e5-0de37a8c78de"
      unitRef="usd">25000000.0</espr:ProceedsFromRevenueInterestPurchaseAgreement>
    <espr:RevenueInterestRateTierTwo
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1ODIxOQ_b00d970f-095d-4681-b637-bb4a2c99a5af"
      unitRef="number">0.025</espr:RevenueInterestRateTierTwo>
    <espr:RevenueInterestRateInitialRate
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1ODIyNg_b2db2de4-ecfc-4bff-a201-bd67451c1403"
      unitRef="number">0.075</espr:RevenueInterestRateInitialRate>
    <espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1ODQwOQ_da90a6cf-b56d-4eab-9c39-3e46af76c14e"
      unitRef="number">1</espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate>
    <espr:RevenueInterestRateTierThree
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1ODUyNQ_42d4b03d-e2e4-4027-9311-7ef04e9250ed"
      unitRef="number">0.004</espr:RevenueInterestRateTierThree>
    <espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1ODg3Nw_20073147-df38-4625-b6da-84755d1b725b"
      unitRef="usd">350000000</espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates
      contextRef="i53741d99778440d2934aa2f5b54eab6f_D20190626-20190626"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ1OTE1NA_778cf08f-fac2-4cb3-8fd4-0588ed2d47d9"
      unitRef="number">1.95</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates>
    <espr:TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount
      contextRef="i39c7a52f49de44809d9de735fcdb4259_D20210426-20210426"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwMjEx_6f147f11-a7b1-4fc7-bfa3-66c71917ed88">P6M</espr:TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount>
    <espr:ProceedsFromRevenueInterestPurchaseAgreement
      contextRef="i39c7a52f49de44809d9de735fcdb4259_D20210426-20210426"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2ODAzMw_428f741f-416a-41c4-a4e0-bae8947b6fdb"
      unitRef="usd">50000000</espr:ProceedsFromRevenueInterestPurchaseAgreement>
    <espr:RevenueInterestRateTierTwo
      contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2ODQwNw_f066780d-1613-4c36-92af-b2b60fd0598f"
      unitRef="number">0.0333</espr:RevenueInterestRateTierTwo>
    <espr:RevenueInterestRateInitialRate
      contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2ODQxNA_3ff8139a-2999-4dc0-b8b7-875991b638db"
      unitRef="number">0.10</espr:RevenueInterestRateInitialRate>
    <espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold
      contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2ODk1Ng_8314aaa9-e2a8-4288-b648-f4904d36051a"
      unitRef="usd">350000000</espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold>
    <espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate
      contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2ODk5MA_4998758c-1915-47d0-976a-b829ba8e4078"
      unitRef="number">1</espr:PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate>
    <espr:RevenueInterestRateTierTwo
      contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2OTEzOQ_72220e37-4b3b-480f-bef4-f87f739dfae9"
      unitRef="number">0.0333</espr:RevenueInterestRateTierTwo>
    <espr:PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage
      contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2OTMwMg_b1341f26-684e-4786-bbcc-f4db6da42e0d"
      unitRef="number">1</espr:PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage>
    <espr:PercentageOfCumulativePurchaserPaymentsGuarantee
      contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ2OTQ4OA_51cd714a-012f-4b8e-8dad-96741606f79d"
      unitRef="number">1</espr:PercentageOfCumulativePurchaserPaymentsGuarantee>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised
      contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MDI5MQ_9a3bbf5c-c06a-4cee-97c4-5e07ae578cb5"
      unitRef="number">2</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised
      contextRef="i03a9d94fbf34429c8a0fb41c0c38b4e0_D20210426-20210426"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MDUxNA_9ada2d03-0704-4ff2-b593-1ccd4b2875f0"
      unitRef="number">2.25</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised>
    <espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount
      contextRef="i6754f51923214db89d9e97a310f8cc9f_D20210516-20210516"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MTg4NQ_a9e21669-7ae0-4c1f-99df-7cd990b58625"
      unitRef="usd">15000000</espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount>
    <espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount
      contextRef="i6754f51923214db89d9e97a310f8cc9f_D20210516-20210516"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MTk5Nw_9b2e358d-e1fc-462f-ba99-ddff5605b4b1"
      unitRef="usd">15000000</espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount>
    <espr:BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold
      contextRef="i6754f51923214db89d9e97a310f8cc9f_D20210516-20210516"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MjAzMw_311d9eff-b886-4551-add3-a37c3f08a120"
      unitRef="usd">50000000</espr:BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold>
    <espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount
      contextRef="i6754f51923214db89d9e97a310f8cc9f_D20210516-20210516"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MjQxNQ_0e278763-4602-4f9f-aea5-6d079286de40"
      unitRef="usd">15000000</espr:SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount>
    <us-gaap:RestrictedCash
      contextRef="i05a73c2f8f9840268e786ffef237f263_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3MjQ0Mg_68e87eec-2c11-49dd-b431-19368857927a"
      unitRef="usd">50000000</us-gaap:RestrictedCash>
    <espr:OneTimePartialCall
      contextRef="ia380cab0f6c44c18a991dc9247a9f988_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NDQ0Mw_402fde08-88cb-4e42-afdb-9bdf4be6687e"
      unitRef="usd">50000000</espr:OneTimePartialCall>
    <espr:RevenueInterestsPaymentOnWhichAgreementTerminates
      contextRef="i62091633ce8842d79fd91f8dcc5437c7_D20221123-20221123"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NDU5NA_d855ac26-a1e5-42c3-8083-5918cbe6d445"
      unitRef="usd">177777778</espr:RevenueInterestsPaymentOnWhichAgreementTerminates>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="i593d725af50a4b0091e208f4866fe4d9_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NTAyMg_e68e77f9-c149-4a0f-833a-9f64e832f219"
      unitRef="usd">-100000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <espr:RevenueInterestLiability
      contextRef="i8971caf868ca48d4bb6027c5bcbc4c0d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwNDIy_fd120f6f-2ab2-48b9-9d08-c1a302712ce3"
      unitRef="usd">251800000</espr:RevenueInterestLiability>
    <espr:UnamortizedTransactionCostsOnRevenueInterestAgreement
      contextRef="i60257fb8aa8e4bae83973ec6daf04c7f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwNDM4_5fd762a8-9756-475e-8b9b-473c963d64ec"
      unitRef="usd">300000</espr:UnamortizedTransactionCostsOnRevenueInterestAgreement>
    <espr:RevenueInterestPaymentsRedemptionPercentage
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NTYxMQ_c555b3b5-cd8c-4c68-a3ab-31b1f124a8ed"
      unitRef="number">2.25</espr:RevenueInterestPaymentsRedemptionPercentage>
    <espr:RevenueInterestPaymentsRedemptionValue
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NTY1Ng_1667d489-e8db-4316-8ee3-603d576b406c"
      unitRef="usd">400000000</espr:RevenueInterestPaymentsRedemptionValue>
    <espr:RevenueInterestPaymentsRemainingRedemptionValue
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUxMTE0_8b0116df-3f61-46ac-9d9f-06f492082a00"
      unitRef="usd">385000000</espr:RevenueInterestPaymentsRemainingRedemptionValue>
    <us-gaap:InterestExpense
      contextRef="i60257fb8aa8e4bae83973ec6daf04c7f_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwMzky_16fe846d-a9b4-4ff3-95c5-2eb447eee61e"
      unitRef="usd">11300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="if7b64718731d44238127edb9d9fdb04b_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwMjEz_ae156b41-89b9-499a-8c8c-a14e728e1108"
      unitRef="usd">11000000</us-gaap:InterestExpense>
    <espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary
      contextRef="i60e0844b890e44459d45cfea66deae41_D20210516-20210516"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NjY3Mw_e1381108-9727-4679-8a1c-9c012c9cf6a1"
      unitRef="number">2.25</espr:PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary>
    <espr:HypotheticalSalesGeneratedAmount
      contextRef="ia26aa17e92c241019a3310efe812d480_D20210516-20210516"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzA4Nw_b1815e18-ea0a-4676-ab96-d119b143787e"
      unitRef="usd">100000000</espr:HypotheticalSalesGeneratedAmount>
    <espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate
      contextRef="ia26aa17e92c241019a3310efe812d480_D20210516-20210516"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzEzNw_578c0a91-733f-406f-ac88-0c65bce06c2e"
      unitRef="usd">250000000</espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate>
    <espr:HypotheticalRepaymentObligationBasedOnSalesGenerated
      contextRef="i9977b26c9b394f16bbdfa5a9ea8bc078_I20210516"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzIyNg_0deaea78-73c3-45be-921a-112ba4fe5877"
      unitRef="usd">10000000</espr:HypotheticalRepaymentObligationBasedOnSalesGenerated>
    <espr:RevenueInterestRateInitialRate
      contextRef="ia26aa17e92c241019a3310efe812d480_D20210516-20210516"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzIzMw_940ca7f4-acb0-477b-81d8-85e4128c02f4"
      unitRef="number">0.100</espr:RevenueInterestRateInitialRate>
    <espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate
      contextRef="if4567f7a9b074360b5b429789676c1b0_D20210516-20210516"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzMzMg_4c32d15f-d511-4015-85dd-2dd84e6a68f9"
      unitRef="usd">250000000</espr:MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate>
    <espr:HypotheticalRepaymentObligationBasedOnSalesGenerated
      contextRef="i2677ac65322b4743a3ca63339e6ecf73_I20210516"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzM5Mg_6aff7574-77a3-4eec-a59e-0cb0923e3bfa"
      unitRef="usd">3300000</espr:HypotheticalRepaymentObligationBasedOnSalesGenerated>
    <espr:RevenueInterestRateTierTwo
      contextRef="if4567f7a9b074360b5b429789676c1b0_D20210516-20210516"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzM5OQ_481cc653-6ee2-4aa0-b0ef-817ad43e3650"
      unitRef="number">0.033</espr:RevenueInterestRateTierTwo>
    <espr:HypotheticalSalesGeneratedAmount
      contextRef="if4567f7a9b074360b5b429789676c1b0_D20210516-20210516"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzQxMw_5db5e05a-ab48-4fc4-bd68-3145386f5b80"
      unitRef="usd">100000000</espr:HypotheticalSalesGeneratedAmount>
    <espr:NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory
      contextRef="i282b2fae645341849445d9da9274fa5e_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTY0OTI2NzQ3NzQ4NA_6706dbf3-06df-4cff-a5df-706a34e57846"
      unitRef="usd">350000000</espr:NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory>
    <espr:RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths
      contextRef="ic5ce29780ee048d2a07167f083638b4e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwMzcw_5bca9d5e-2c83-423d-a599-a7e3239eb9a7"
      unitRef="usd">26900000</espr:RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths>
    <espr:RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate
      contextRef="i9672d71ca80348519f56b4e7a065e01c_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfNTQ5NzU1ODUwMzg1_5b2ac53b-be56-4797-8dab-54707eb372d5"
      unitRef="number">0.182</espr:RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate>
    <espr:ScheduleOfRevenueInterestLiabilityTableTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RleHRyZWdpb246ZmFjZmRjM2JlYTg3NGRkMjljYTc3NjhiODcwN2U4NzlfMTI5NzA_5cea289f-60ab-4df4-a4b9-5758db9de752">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the revenue interest liability activity during the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue interest liability at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243,605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue Interests payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,106)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue interest liability at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</espr:ScheduleOfRevenueInterestLiabilityTableTextBlock>
    <espr:RevenueInterestLiability
      contextRef="if3be96d871a141f89c4e0d00a0a0b2ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RhYmxlOjA2YzUxMzBkYjI3NzRjYmM5YjQ0MGI1ZGZlOWE5MmZmL3RhYmxlcmFuZ2U6MDZjNTEzMGRiMjc3NGNiYzliNDQwYjVkZmU5YTkyZmZfMS0xLTEtMS02NTI3Mw_a5f9d2a4-9be5-44f5-840a-0acbba195022"
      unitRef="usd">243605000</espr:RevenueInterestLiability>
    <espr:RevenueInterestLiabilityIncreaseForInterestExpenseRecognized
      contextRef="i60257fb8aa8e4bae83973ec6daf04c7f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RhYmxlOjA2YzUxMzBkYjI3NzRjYmM5YjQ0MGI1ZGZlOWE5MmZmL3RhYmxlcmFuZ2U6MDZjNTEzMGRiMjc3NGNiYzliNDQwYjVkZmU5YTkyZmZfMi0xLTEtMS02NTI3Mw_668707b0-96e9-42fc-9d12-40399214320b"
      unitRef="usd">11320000</espr:RevenueInterestLiabilityIncreaseForInterestExpenseRecognized>
    <espr:PaymentsFromRevenueInterestPurchaseAgreement
      contextRef="i60257fb8aa8e4bae83973ec6daf04c7f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RhYmxlOjA2YzUxMzBkYjI3NzRjYmM5YjQ0MGI1ZGZlOWE5MmZmL3RhYmxlcmFuZ2U6MDZjNTEzMGRiMjc3NGNiYzliNDQwYjVkZmU5YTkyZmZfMy0xLTEtMS02NTI3Mw_7a11b378-7439-4974-898f-51b69e9c7eaf"
      unitRef="usd">3106000</espr:PaymentsFromRevenueInterestPurchaseAgreement>
    <espr:RevenueInterestLiability
      contextRef="i8971caf868ca48d4bb6027c5bcbc4c0d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81Mi9mcmFnOmZhY2ZkYzNiZWE4NzRkZDI5Y2E3NzY4Yjg3MDdlODc5L3RhYmxlOjA2YzUxMzBkYjI3NzRjYmM5YjQ0MGI1ZGZlOWE5MmZmL3RhYmxlcmFuZ2U6MDZjNTEzMGRiMjc3NGNiYzliNDQwYjVkZmU5YTkyZmZfNC0xLTEtMS02NTI3Mw_ff3ff8e5-004d-42cb-a9f4-0f263970c7f2"
      unitRef="usd">251819000</espr:RevenueInterestLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTI4MDM_2c42ce79-832c-45af-b739-22c648b229ab">Convertible NotesIn November 2020, the Company issued $280.0&#160;million aggregate principal amount of 4.0% senior subordinated convertible notes due November 2025. The net proceeds the Company received from the offering was approximately $271.1&#160;million, after deducting the initial purchasers&#x2019; discounts and commissions and offering expenses payable by the Company (the "Convertible Notes") of $8.9&#160;million. The Company used approximately $46.0&#160;million of the net proceeds from the offering of the notes to pay the cost of the Capped Call (as defined below) and $55.0&#160;million of the net proceeds from the offering of the initial notes to finance the Prepaid Forward (as defined below). The Convertible Notes are the Company's senior unsecured obligations and mature on November 15, 2025 (the &#x201c;Maturity Date&#x201d;), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Convertible Notes are convertible into shares of the &lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s common stock, can be repurchased for cash, or a combination thereof, at the Company&#x2019;s election, at an initial conversion rate of 30.2151 shares of common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $33.096 per share of common stock, subject to adjustment. The Company will pay interest on the Convertible Notes semi-annually in arrears on May 15 and November 15 of each year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Convertible Notes are general unsecured obligations of the Company that are subordinated in right of payment to indebtedness, obligations and other liabilities under the Company&#x2019;s RIPA, the revenue interests issued pursuant to such agreement, and any refinancing of the foregoing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders may convert their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding August 15, 2025 in the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ended on March 31, 2021 (and only during such calendar quarter), if the last reported sale price per share of the Company&#x2019;s common stock, par value $0.001 per share (&#x201c;common stock&#x201d;), is greater than or equal to 130% of the conversion price for each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter; (2) during the five business days after any five consecutive trading day period (such five consecutive trading day period, the &#x201c;measurement period&#x201d;) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company&#x2019;s common stock and the conversion rate for the notes on each such trading day; (3) if the Company calls such notes for redemption, any such notes that have been called for redemption may be converted at any time prior to the close of business on the second scheduled trading day immediately preceding the redemption date, but only with respect to the notes called for redemption; and (4) upon the occurrence of specified corporate events, as provided in the Indenture. On or after August 15, 2025, to the close of business on the second scheduled trading day immediately before the maturity date, holders may convert all or any portion of their notes at the applicable conversion rate at any time at the option of the holder regardless of the foregoing conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, following certain corporate events or following issuance of a notice of redemption, the Company will, in certain circumstances, increase the conversion rate for a holder who elects to convert its notes in connection with such a corporate event or to convert its notes called (or deemed called) for redemption during the related redemption period, as the case may be.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Convertible Notes will be redeemable, in whole or in part, at the Company&#x2019;s option at any time, and from time to time, on or after November 20, 2023 and before the 41st scheduled trading day immediately before the maturity date, at a cash redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, but only if the last reported sale price per share of the Company&#x2019;s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive), including the trading day immediately preceding the date the Company sends the related redemption notice, during any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company sends such redemption notice. No sinking fund is provided for the notes. If the Company redeems less than all the outstanding notes, at least $125.0&#160;million aggregate principal amount of notes must be outstanding and not subject to redemption as of the relevant redemption notice date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company undergoes a &#x201c;fundamental change&#x201d; (as defined in the Indenture), holders may require the Company to repurchase their notes for cash all or any portion of their notes at a fundamental change repurchase price equal to 100% of the principal amount of the notes to be repurchased, plus accrued and unpaid interest, to, but excluding, the fundamental change repurchase date. The Indenture includes customary terms and covenants, including certain events of default.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 22, 2021, the Company entered into a privately negotiated exchange agreement (the &#x201c;Exchange Agreement&#x201d;) with two co-managed holders (the &#x201c;Holders&#x201d;) of its Convertible Notes. Under the terms of the Exchange Agreement the Holders agreed to exchange (the &#x201c;Exchange&#x201d;) with the Company $15.0&#160;million aggregate principal amount of the Convertible Notes held in the aggregate by them (and accrued interest thereon) for shares of the Company&#x2019;s common stock. Pursuant to the Exchange Agreement, the number of shares of common stock to be issued by the Company to the Holders upon consummation of the Exchange was determined based upon the volume-weighted-average-price per share of common stock, subject to a floor of $5.62 per share, during the &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODIwOA_adc66ab1-dedb-4d22-80ef-7e400f74515e"&gt;five&lt;/span&gt; trading-day averaging period, commencing on the trading day immediately following the date of the Exchange Agreement. The Exchange closed on November 3, 2021, with 1,094,848 shares of the Company's common stock being exchanged.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of March 31, 2023, the principal amount of convertible notes was $265.0&#160;million, and the unamortized debt discount and issuance costs were $4.7&#160;million, for a net carrying amount of $260.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company recorded $3.1&#160;million of interest expense during the three months ended March 31, 2023, and $3.0&#160;million of interest expense during the three months ended March 31, 2022, relating to the cash interest on the convertible notes due semi-annually and amortization of the debt issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;As of March 31, 2023, no Convertible Notes were convertible pursuant to their terms. The estimated fair value of the Convertible Notes was $123.2&#160;million as of March 31, 2023 and $145.9&#160;million as of December 31, 2022. The estimated fair value of the Convertible Notes was determined through consideration of quoted market prices. As of March 31, 2023, the if-converted value of the Convertible Notes did not exceed the principal value of those notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capped Call Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the offering of the Convertible Notes, the Company entered into privately-negotiated capped call transactions with one of the initial purchasers of the convertible notes or its affiliate and certain other financial institutions. The Company used approximately $46.0&#160;million of the net proceeds from the offering of the Convertible Notes to pay the cost of the capped call transactions. The capped call transactions are expected generally to reduce potential dilution to the Company&#x2019;s common stock upon any conversion of the Convertible Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted notes, as the case may be, in the event that the market value per share of the Company&#x2019;s common stock, as measured under the terms of the capped call transactions at the time of exercise, is greater than the strike price of the capped call transactions (which initially corresponds to the initial conversion price of the Convertible Notes, and is subject to certain adjustments), with such reduction and/or offset subject to a cap initially equal to approximately $55.16 (which represents a premium of approximately 100% over the last reported sale price of the Company&#x2019;s common stock on November 11, 2020), subject to certain adjustments. The capped call transactions are separate transactions, entered into by the Company and are not part of the terms of the Convertible Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Given that the transactions meet certain accounting criteria, the convertible note capped call transactions are recorded in stockholders&#x2019; equity, and they are not accounted for as derivatives and are not remeasured each reporting period. As of March&#160;31, 2023 and December 31, 2022, the Company had not purchased any shares under the convertible note capped call transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prepaid Forward&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the offering of the Convertible Notes, the Company entered into a prepaid forward stock repurchase transaction (&#x201c;Prepaid Forward&#x201d;) with a financial institution (&#x201c;Forward Counterparty&#x201d;). Pursuant to the Prepaid Forward, the Company used approximately $55.0&#160;million of the net proceeds from the offering of the Convertible Notes to fund the Prepaid Forward. The aggregate number of shares of the Company&#x2019;s common stock underlying the Prepaid Forward was approximately 1,994,198. The expiration date for the Prepaid Forward is November 15, 2025, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders&#x2019; votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. As of March 31, 2023, 165,540 shares had been delivered to the Company. The Company&#x2019;s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie9d604cc8ce549efb8eacca20225427d_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNjM_b9b5e13e-41ba-4017-9d9c-07c5201d8827"
      unitRef="usd">280000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie9d604cc8ce549efb8eacca20225427d_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfOTY_4d71092f-43a0-4fa8-afdb-c8183f50f1bf"
      unitRef="number">0.040</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i558c1c82e52841cd910a7702549badd5_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjMw_457d8bf7-14a2-4aab-a478-789e5555bb0a"
      unitRef="usd">271100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i77878605a83847e6b08dc2b1e23c3d3c_I20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNTQ5NzU1ODI4OTg2_f3a57149-1009-4e5f-a561-0ab903b2c075"
      unitRef="usd">8900000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="i3e9376bd36d849ffb4316ffe1b5485a7_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDAz_32ad7fdd-a4d6-4b35-9550-c90f46d8d6d1"
      unitRef="usd">46000000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3e9376bd36d849ffb4316ffe1b5485a7_D20201101-20201130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNTE1_aa5381a4-ec72-4230-a9ae-dd793c64b0d4"
      unitRef="usd">55000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="i558c1c82e52841cd910a7702549badd5_D20201101-20201130"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTA2MQ_5ff40c68-0c48-45eb-b50a-db40dfae8505"
      unitRef="number">30.2151</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="ie9d604cc8ce549efb8eacca20225427d_I20201130"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTIwOQ_02357c09-7c23-45af-8538-b9e647ecc42c"
      unitRef="usdPerShare">33.096</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i443e0a08bb4a4888a6d5462309e5dc2b_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjA3OA_9b1360f8-26fc-4d2e-82e9-4dff86074bd6"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjEzNw_148ebe1a-236f-44cf-9f86-02501ed5a4f5"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjE4NQ_577b47da-dde1-48d3-a30d-ed1bbc9a2964"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjI0MQ_b04bd503-fb3d-4f46-a265-dfe219a4b792"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <espr:NumberOfBusinessDays
      contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjM3OA_8cadf069-6da8-45d3-9fed-6b1862aef218"
      unitRef="day">5</espr:NumberOfBusinessDays>
    <espr:NumberOfConsecutiveTradingDays
      contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjQwNQ_783f8994-62e7-488a-bddc-e64ba07298d3"
      unitRef="day">5</espr:NumberOfConsecutiveTradingDays>
    <espr:NumberOfConsecutiveTradingDays
      contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjQ0NQ_ea697fb4-9e40-469a-a1a3-6d557bb8754f"
      unitRef="day">5</espr:NumberOfConsecutiveTradingDays>
    <espr:DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice
      contextRef="i1bf59e45fa034c3a99b59b8f90f1865e_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMjYzMQ_ebd10924-5712-43bf-98b9-d98cddc264fa"
      unitRef="number">0.98</espr:DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="id505115d3ec947189265eca782d4648d_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDEyMA_19998f13-9d35-42a5-b797-2844a11353a9"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="id505115d3ec947189265eca782d4648d_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDMxNw_193c9aa0-af84-49aa-b143-4e0775deb2fd"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <us-gaap:DebtInstrumentConvertibleThresholdTradingDays
      contextRef="id505115d3ec947189265eca782d4648d_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDM3Mg_7d0584d6-6f84-47e6-aae9-62a02d413c51"
      unitRef="day">20</us-gaap:DebtInstrumentConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="id505115d3ec947189265eca782d4648d_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDUzNQ_5d877a6d-b68a-42ca-b4b7-5093c7e3563f"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <espr:DebtInstrumentCovenantRequiredAmountOutstanding
      contextRef="ic5eeddb8167c498c8696923171b62eb4_I20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNDgwNQ_f7f61dd4-d5ba-43c6-babb-e32869b28178"
      unitRef="usd">125000000</espr:DebtInstrumentCovenantRequiredAmountOutstanding>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i558c1c82e52841cd910a7702549badd5_D20201101-20201130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNTE2Nw_cafc0254-07fd-410f-8850-6ad5bcdeebe8"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i20ddb90b5807415aa23e0e6e68488a19_D20211022-20211022"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfNzc2Ng_8eaebe94-bdc1-434e-b5e5-72b4f4712a31"
      unitRef="usd">15000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <espr:DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor
      contextRef="idef44d4d210a42b4b9aa0ab56e93f3ea_I20211022"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODE4Mw_740aa1e5-0a12-46df-a36b-36b2eacff88b"
      unitRef="usdPerShare">5.62</espr:DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="i80cfd1f853144d49b1d183168049513c_D20211103-20211103"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODM3NQ_de78063e-9627-4a8a-b130-4a5efc633435"
      unitRef="shares">1094848</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i50721021131b4d71b50fa66d28915b11_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODUwNA_4cf73999-637a-4fb1-b830-d71aa68aa7cd"
      unitRef="usd">265000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="i50721021131b4d71b50fa66d28915b11_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODU2Ng_6b59ee2e-e599-4553-a00f-8480ab477b79"
      unitRef="usd">4700000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:LongTermDebt
      contextRef="i50721021131b4d71b50fa66d28915b11_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODU5OQ_33855ff6-b7b7-4f8c-9037-1d0468f727d8"
      unitRef="usd">260300000</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i85e1a076c7ee4e17907f790ab9bf3c54_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODYyNQ_6ab6f4aa-08c4-473a-869b-02c3d4ef175e"
      unitRef="usd">3100000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="i921ae98ba14c414092902fd6b4401923_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfODczMg_85ec962b-f41f-498f-9379-717d7c3223a8"
      unitRef="usd">3000000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i50721021131b4d71b50fa66d28915b11_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfOTA5OA_ec79fe0f-8e81-4a21-8c46-f53ffcb05b88"
      unitRef="usd">123200000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i1696b3ebb44147b9a3cbeaecc46fbd18_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfOTEzMA_aaed2cd0-9ca8-4e43-94f5-3a533fec2aa3"
      unitRef="usd">145900000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:PaymentsForDerivativeInstrumentFinancingActivities
      contextRef="icae7497a06dd4ecf932d2ce48689f651_D20201116-20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfOTcwMA_124c2fea-7fa0-491e-bbe3-b7c5bf1f0fdd"
      unitRef="usd">46000000</us-gaap:PaymentsForDerivativeInstrumentFinancingActivities>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iaa0efd686a824365a3cc55c8e2d823d9_I20201116"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTA1NDY_47a9d057-ce57-4fb2-853d-1cedfecf787c"
      unitRef="usdPerShare">55.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <espr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage
      contextRef="iaa0efd686a824365a3cc55c8e2d823d9_I20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTA1OTQ_b5b9f14c-ece0-423d-a587-b639616aaf11"
      unitRef="number">1</espr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="icae7497a06dd4ecf932d2ce48689f651_D20201116-20201116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTE1MDU_8b5b485e-5241-4c68-8c4e-c461f0caa1a3"
      unitRef="usd">55000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="icae7497a06dd4ecf932d2ce48689f651_D20201116-20201116"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTE3MTA_0f0e884c-a990-4f60-99ff-b9eefbb06fce"
      unitRef="shares">1994198</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV81OC9mcmFnOjY2ZmFhNjg2YmE2MTQ1MjE5NzEzOWU1Yzc5MzQ2ZGI3L3RleHRyZWdpb246NjZmYWE2ODZiYTYxNDUyMTk3MTM5ZTVjNzkzNDZkYjdfMTI0OTM_002bbfbb-445c-40fe-a28a-272d96415990"
      unitRef="shares">165540</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RleHRyZWdpb246NzlkZmNlOTFlOGIxNGFmN2FjNzYwMTY5MDc5MWY0NjhfMTAy_32dbd942-c2c6-48c4-82d0-94095243314c">Other Accrued Liabilities&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RleHRyZWdpb246NzlkZmNlOTFlOGIxNGFmN2FjNzYwMTY5MDc5MWY0NjhfMTAz_cfd5f110-f768-4d30-aeb2-b6a2bf1d948e">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued interest on convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMS0xLTEtMS02NTI3Mw_3956c980-664f-4c78-84c5-40a54ca70a45"
      unitRef="usd">5565000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMS0zLTEtMS02NTI3Mw_f0a8d401-43c9-4251-8053-3cabd7d34b71"
      unitRef="usd">9053000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <espr:AccruedVariableConsiderationCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMi0xLTEtMS02NTI3Mw_bd61a656-e174-4b31-af96-e0e38fc5a7d5"
      unitRef="usd">21313000</espr:AccruedVariableConsiderationCurrent>
    <espr:AccruedVariableConsiderationCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMi0zLTEtMS02NTI3Mw_d1aeecdb-b349-4e5a-8226-e47414538059"
      unitRef="usd">21987000</espr:AccruedVariableConsiderationCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMy0xLTEtMS02NTI3Mw_c34a53a3-8aa3-4dbd-8904-00559770372d"
      unitRef="usd">3446000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfMy0zLTEtMS02NTI3Mw_0fc11cd2-8d25-4cf6-be55-834d2d6c27bf"
      unitRef="usd">2547000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNC0xLTEtMS02NTI3Mw_b809f174-5f72-47b6-b194-e00183bddd77"
      unitRef="usd">3975000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNC0zLTEtMS02NTI3Mw_63f03c8e-c790-4915-a670-3147388aa031"
      unitRef="usd">1325000</us-gaap:InterestPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNS0xLTEtMS02NTI3Mw_a6b88814-041b-4de1-bda9-634515e297df"
      unitRef="usd">122000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNS0zLTEtMS02NTI3Mw_8e20ec96-ae34-4038-a551-34f4b242f89d"
      unitRef="usd">279000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNi0xLTEtMS02NTI3Mw_188f2a55-afbf-41b4-90c5-3acaff886e21"
      unitRef="usd">34421000</espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82MS9mcmFnOjc5ZGZjZTkxZThiMTRhZjdhYzc2MDE2OTA3OTFmNDY4L3RhYmxlOjJkMmQzMmRhZGJlNzRlNDQ4NmNjMzJkNTExNDEzM2I3L3RhYmxlcmFuZ2U6MmQyZDMyZGFkYmU3NGU0NDg2Y2MzMmQ1MTE0MTMzYjdfNi0zLTEtMS02NTI3Mw_35a4eedd-3580-4380-a374-47988d832514"
      unitRef="usd">35191000</espr:AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNzA3Mw_17ac589e-7830-4e63-aa4c-58cfa4ebd22c">Stock Compensation&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2022 Stock Option and Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In May 2022, the Company's stockholders approved the 2022 Stock Option and Incentive Plan (the "2022 Plan"). The number of shares of common stock available for awards under the 2022 Plan was set to 4,400,000, with any shares underlying awards that are forfeited, canceled, held back upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance or shares, or otherwise terminated (other than by exercise) under the 2022 Plan may be added back to the shares of common stock available for issuance under the 2022 Plan. The 2022 Plan provides for the award of stock options (both incentive and non-qualified options), stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. Following the approval of the 2022 Plan, no further awards will be issued under the Company&#x2019;s 2013 Stock Option and Incentive Plan (the &#x201c;2013 Plan&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the board of directors approved the Esperion Therapeutics, Inc. 2020 Employee Stock Purchase Plan (the "ESPP") which was approved by the Company's shareholders on May 28, 2020. The ESPP allows eligible employees to authorize payroll deductions of up to 10% of their base salary or wages up to $25,000 annually to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period. Participating employees will purchase shares of the Company's common stock at a discount of up to 15% on the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period. Offering periods under the ESPP will generally be in six months increments, commencing on September 1 and March 1 of each calendar year with the administrator having the right to establish different offering periods. In the three months ended March&#160;31, 2023 and 2022, the Company recognized $0.1&#160;million and approximately $0.1&#160;million of stock compensation expense related to the ESPP. As of March&#160;31, 2023, there have been 435,076 shares issued and 389,924 shares reserved for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company&#x2019;s options to purchase common stock for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,842,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&#160;or&#160;expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(622,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,374,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,374,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,194,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation related to stock options was $1.0 million for the three months ended March&#160;31, 2023, including $0.1 million that was capitalized into inventory, and $1.5 million for the three months ended March&#160;31, 2022, including $0.1 million that was capitalized into inventory. As of March&#160;31, 2023, there was $9.0 million of unrecognized stock-based compensation expense related to unvested options, which will be recognized over a weighted-average period of 2.9 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-Based Stock Options ("PBSOs")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company granted PBSOs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company granted PBSOs from the 2022 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBSOs based on the expected performance period to achieve the performance milestone. The Company expects the performance criteria to be met. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company&#x2019;s PBSOs for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&#160;or&#160;expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation related to PBSOs was $0.2&#160;million for the three months ended March&#160;31, 2023 and $0.1&#160;million for the three months ended March 31, 2022. As of March 31, 2023, there was approximately $1.0&#160;million of unrecognized stock-based compensation expense related to unvested PBSOs, which will be recognized over a weighted-average period of approximately 1.2 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units (or RSUs)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company&#x2019;s RSUs for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Fair Value Per &lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,622,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation related to RSUs was approximately $1.5 million for the three months ended March&#160;31, 2023, including $0.1&#160;million that was capitalized into inventory, and approximately $1.9 million for the three months ended March 31, 2022, including $0.1 million that was capitalized into inventory. As of March&#160;31, 2023, there was $18.6 million of unrecognized stock-based compensation expense related to unvested RSUs, which will be recognized over a weighted-average period of 3.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Performance-based Restricted Stock Units ("PBRSUs")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2021, the Company granted PBRSUs from the 2013 Plan that vest upon various performance-based milestones as set forth in the individual grant agreements, such as achievement of predetermined milestones based on the Company's U.S. net product sales or clinical or regulatory outcomes. The actual number of units (if any) received under these awards will depend on continued employment and actual performance over the performance period. Each quarter, the Company updates their assessment of the probability that the performance milestone will be achieved. The Company amortizes the fair value of the PBRSUs based on the expected performance period to achieve the performance milestone. The fair value of the PBRSUs is based on the quoted market price of the Company's common stock on the date of grant. The Company expects the performance criteria to be met. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company's PBRSUs for the three months ended March 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;PBRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average fair value per share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation related to the PBRSUs was $0.1&#160;million for the three months ended March 31, 2023, including less than $0.1&#160;million that was capitalized into inventory, and $0.8&#160;million for the three months ended March 31, 2022, including $0.1&#160;million that was capitalized into inventory. As of March 31, 2023, there was approximately $0.8&#160;million of unrecognized stock-based compensation expense related to unvested PBRSUs, which will be recognized over a weighted-average period of approximately 1.2 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i99ff79bbd6b34af19e4c4f5ffd0dd8bd_I20220531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjYz_5badeebf-7041-4f95-a199-ef5f96fe426b"
      unitRef="shares">4400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ic8d1aec6f0a243debcdc270c1c4783d6_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMTM3Ng_d73951d5-3210-4bbd-ad91-ef4a5631b4b3"
      unitRef="number">0.10</espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
    <espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="ic8d1aec6f0a243debcdc270c1c4783d6_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMTQxNQ_d32e1f52-5ab9-4577-bdee-f97b9105b15b"
      unitRef="usd">25000</espr:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount>
    <espr:EmployeeStockPurchasePlanPercentageDiscountOnShares
      contextRef="ic8d1aec6f0a243debcdc270c1c4783d6_D20200401-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMTY0Nw_3f41667b-117f-43f1-a301-965888fc0268"
      unitRef="number">0.15</espr:EmployeeStockPurchasePlanPercentageDiscountOnShares>
    <espr:EmployeeStockPurchasePlanDurationOfOfferingPeriod
      contextRef="ic8d1aec6f0a243debcdc270c1c4783d6_D20200401-20200430"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMTkwMA_1fef0693-2d2a-43d9-8ae6-f0527548c00d">P6M</espr:EmployeeStockPurchasePlanDurationOfOfferingPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i88cb7b840c98434489e5ae6882bf0bde_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjEwNw_8c4f7f8f-3d79-43db-81f5-67148f9f3c40"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2ed983231e1c4e1e9acf5a3984e776a1_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfODA5MQ_3b8fcc6e-b015-4398-87c1-cdeeb4f57ee1"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i88cb7b840c98434489e5ae6882bf0bde_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjM3NQ_810e0b07-3e39-4f67-bf17-ae8d53fba015"
      unitRef="shares">435076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i3ddb347cbc7e4b08b9ec62540ce50d3e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjM5Ng_d1c58980-e8b8-47fe-994e-9fc4e5783b45"
      unitRef="shares">389924</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNzA2Nw_38def785-d1ee-4a9e-b65f-30700034bc94">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company&#x2019;s options to purchase common stock for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,842,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,154,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&#160;or&#160;expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(622,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,374,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,374,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,194,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company&#x2019;s PBSOs for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.32&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&#160;or&#160;expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,250)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMi0xLTEtMS02NTI3Mw_5444e75a-dc1d-47cd-a154-cddf5ea89373"
      unitRef="shares">3842737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMi0zLTEtMS02NTI3Mw_a84263ab-2686-4024-836b-fb519ea8ab97"
      unitRef="usdPerShare">27.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ia380cab0f6c44c18a991dc9247a9f988_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMi01LTEtMS02NTI3Mw_0dfaf409-4672-468b-8ead-a027770eae0e">P4Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMi03LTEtMS02NTI3Mw_4f9032ab-3ad9-4375-92d6-023cd2224983"
      unitRef="usd">1658000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMy0xLTEtMS02NTI3Mw_f52e8b6b-bec4-4077-8c86-502b3c14ba7c"
      unitRef="shares">1154300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfMy0zLTEtMS02NTI3Mw_c606c6a7-4272-4f20-b9e5-4cc6c48fe442"
      unitRef="usdPerShare">4.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNC0xLTEtMS02NTI3Mw_55663a50-a160-44d4-a14d-03d74ca54798"
      unitRef="shares">622585</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNC0zLTEtMS02NTI3Mw_ffec8130-6ee6-45ee-bcad-722126bc5e9d"
      unitRef="usdPerShare">38.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNS0xLTEtMS02NTI3Mw_599a4a1b-58d8-4150-8de3-1d1a4f541901"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNS0zLTEtMS02NTI3Mw_4d15425e-a2bf-41e3-ada9-012e7bc95939"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNi0xLTEtMS02NTI3Mw_5b732024-4b8c-49b9-ad23-c9f686c7187a"
      unitRef="shares">4374452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNi0zLTEtMS02NTI3Mw_edc4a605-accc-4366-96d0-99257623c5a1"
      unitRef="usdPerShare">19.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNi01LTEtMS02NTI3Mw_6cfcf63f-48de-4f11-9afd-c6b1a5a30398">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNi03LTEtMS02NTI3Mw_66c0ff5e-9edf-41ef-a6f8-bcdf150d3831"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNy0xLTEtMS02NTI3Mw_882e6364-b4f5-4298-95b6-2435625f1a85"
      unitRef="shares">4374452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNy0zLTEtMS02NTI3Mw_7bd24d30-bec3-479a-bc58-fcd58da96bad"
      unitRef="usdPerShare">19.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNy01LTEtMS02NTI3Mw_5d13e4f2-c2fc-4794-9cb9-64b9f43c3cf7">P6Y2M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfNy03LTEtMS02NTI3Mw_9b1b6b8d-c838-43f8-9a14-3eb40bdc2aa9"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfOC0xLTEtMS02NTI3Mw_d481604a-74cc-43c4-b305-37212e69e70b"
      unitRef="shares">2194004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfOC0zLTEtMS02NTI3Mw_8475ca9d-a2f6-487a-8dea-9eb416366e6e"
      unitRef="usdPerShare">33.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfOC01LTEtMS02NTI3Mw_e5d85a1f-a185-404f-8a31-2897273129a1">P2Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOmQ1MmNkMzZiMDM1MjQwMmJiM2Y2ZmMzYTIzMzkwNDc2L3RhYmxlcmFuZ2U6ZDUyY2QzNmIwMzUyNDAyYmIzZjZmYzNhMjMzOTA0NzZfOC03LTEtMS02NTI3Mw_b05c471b-fc58-4e1f-b0ca-a6cba21cceaf"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i66bec0e27b1b48d1bcd58ded58c2e003_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjY0Mg_7b817c8a-b243-4594-bd16-ed7c2696b7c1"
      unitRef="usd">1000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i66bec0e27b1b48d1bcd58ded58c2e003_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjcxMg_ff8295e5-c05e-4508-b9fa-205e558d5781"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7b0445354f6f4558904c97d5373f8c53_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjc2NA_e6b91619-9fb5-49b3-adee-89ae6dda583e"
      unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i7b0445354f6f4558904c97d5373f8c53_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjgyMQ_2d1d2767-62a0-405c-9550-6ca4fe6a09cf"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i60d797f24c2c4a04b4ff42bb670e3cc1_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjg5Nw_ef305607-34b3-48e5-b49c-f3e6595ed529"
      unitRef="usd">9000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i66bec0e27b1b48d1bcd58ded58c2e003_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfMjE5OTAyMzI2MzMyMg_66ef6ccd-d4d8-4779-90e6-7ed9b3676432">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9b9c918318b245b38e4e0d3ba2428dba_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMi0xLTEtMS02NTI3Mw_83fc31ec-85aa-4a85-ac5a-3d4a2babb8c4"
      unitRef="shares">499200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9b9c918318b245b38e4e0d3ba2428dba_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMi0zLTEtMS02NTI3Mw_9de0c2aa-5fc0-48ea-8a44-e8f7080833df"
      unitRef="usdPerShare">6.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i162d9a4406ca467199ca052182157c66_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMi01LTEtMS02NTI3Mw_aa79983e-6589-4b9b-8392-b46d9f0ec516">P9Y3M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9b9c918318b245b38e4e0d3ba2428dba_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMi03LTEtMS02NTI3Mw_65813544-dc6a-4cc1-bfdd-750391e0c0d7"
      unitRef="usd">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMy0xLTEtMS02NTI3Mw_94ab67d4-4256-4e1f-88b6-f625f1d9cee7"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfMy0zLTEtMS02NTI3Mw_eeab7d5a-fcec-4a3c-a86d-45972e436cdf"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNC0xLTEtMS02NTI3Mw_25dce33f-b178-4f43-84d7-135a5f0e372f"
      unitRef="shares">65250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNC0zLTEtMS02NTI3Mw_a0d4ea45-07ce-481c-b317-60040c55d274"
      unitRef="usdPerShare">6.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNS0xLTEtMS02NTI3Mw_a0c1aef5-09be-4a6d-a758-3ad8f0887d66"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNS0zLTEtMS02NTI3Mw_f1082615-6470-49e8-a693-04433754fcc9"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNi0xLTEtMS02NTI3Mw_4ca856ac-1af3-4e9f-bae2-fa6a15811912"
      unitRef="shares">433950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNi0zLTEtMS02NTI3Mw_1c86494c-2142-4b3a-b7dc-769f1f88ed22"
      unitRef="usdPerShare">6.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNi01LTEtMS02NTI3Mw_7b6f16eb-0c6c-417f-9c44-34b9850efb56">P8Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNi03LTEtMS02NTI3Mw_2c30d8be-e35f-44b9-aac0-f951459c06a0"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNy0xLTEtMS02NTI3Mw_b0d99bde-4429-44a9-87f3-91b37b444c6c"
      unitRef="shares">433950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNy0zLTEtMS02NTI3Mw_338d8f87-15ef-49b2-82d3-353eebc495cd"
      unitRef="usdPerShare">6.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNy01LTEtMS02NTI3Mw_f5cae3b5-bfa2-4a21-951a-04a66d5210ce">P8Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfNy03LTEtMS02NTI3Mw_51238878-d930-45c5-a230-3e93382aa520"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfOC0xLTEtMS02NTI3Mw_364c091b-4a6e-438b-bbce-a955ab29b4c1"
      unitRef="shares">48100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfOC0zLTEtMS02NTI3Mw_7b0ca256-aec1-4998-91e0-bad405ef8ebc"
      unitRef="usdPerShare">8.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfOC01LTEtMS02NTI3Mw_28e2adac-e6f4-47b5-aa42-fb14f5768036">P6Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjgyMmNhMWRmMTYyNjRkZmJiMzhhZGFkM2M0YzdiMmJiL3RhYmxlcmFuZ2U6ODIyY2ExZGYxNjI2NGRmYmIzOGFkYWQzYzRjN2IyYmJfOC03LTEtMS02NTI3Mw_77874825-a86e-4acc-a775-73392828c701"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNDU5MA_35f21d3e-7970-435a-a1bc-d0e7d7e9dbc4"
      unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i012dbf6545a3491b9f6f9fab381db389_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTQ5NzU1ODIxNjA0_d18de68e-f395-4885-a6bd-4be3106d2a82"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="ifc3f9aea2e044968a4fd796455e4dbdb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNDY5Mg_39798614-f80e-4d74-9988-e74a5feede8a"
      unitRef="usd">1000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNDg0NA_32a554fe-aa8d-435a-8d64-f9415c47d0fa">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNzA3Mg_052ca2ff-68f9-4a0d-be24-ee966a80580d">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company&#x2019;s RSUs for the three months ended March&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Fair Value Per &lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,768,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,622,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101,881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171,392)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5e9dfbd0c5a54147bd3f860e7e9511c2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMS0xLTEtMS02NTI3Mw_2b04828e-3952-4afd-9f78-9535a8b5df82"
      unitRef="shares">1768185</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5e9dfbd0c5a54147bd3f860e7e9511c2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMS0zLTEtMS02NTI3Mw_0f347300-747d-4c27-be11-18b6efd122ed"
      unitRef="usdPerShare">8.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMi0xLTEtMS02NTI3Mw_28734999-a052-46c0-a1eb-e32c5cfc3dff"
      unitRef="shares">1622485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMi0zLTEtMS02NTI3Mw_b08be4ed-c5be-4bd4-9bea-14decd883ed4"
      unitRef="usdPerShare">4.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMy0xLTEtMS02NTI3Mw_da36cab2-ffbf-4b79-8e55-781d7600fcff"
      unitRef="shares">101881</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfMy0zLTEtMS02NTI3Mw_a4ff2ef8-e864-4a7f-9f2a-0378d4599887"
      unitRef="usdPerShare">9.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfNC0xLTEtMS02NTI3Mw_74df753c-ea63-47ea-b8a1-551d57cf42ef"
      unitRef="shares">171392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfNC0zLTEtMS02NTI3Mw_388c4938-a337-4335-a96b-e1b08f51944a"
      unitRef="usdPerShare">9.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i83fd6d470bf4439baf8eaf859c790c76_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfNS0xLTEtMS02NTI3Mw_fd5e7d76-b78f-4de8-887c-6e34dd82bb3b"
      unitRef="shares">3117397</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i83fd6d470bf4439baf8eaf859c790c76_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjAzZTBiNzAyMzY5OTQxN2VhOTgwODJlN2I4NjAyMDU2L3RhYmxlcmFuZ2U6MDNlMGI3MDIzNjk5NDE3ZWE5ODA4MmU3Yjg2MDIwNTZfNS0zLTEtMS02NTI3Mw_b7f9b9b4-d1ac-426a-bd18-33de132a2c4f"
      unitRef="usdPerShare">6.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTAzNA_5d2c3880-f2fb-4144-bc49-9854f57ba42f"
      unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTA5Ng_449a5b0f-f84c-4cf5-82b8-0314c561b4a0"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8632a444e79c46f1a18e5bc0a4625f88_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTE2MQ_90d95be2-d131-43d9-bb75-e5f5a5e8a186"
      unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i8632a444e79c46f1a18e5bc0a4625f88_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTI2Nw_968644aa-be2d-4d3d-821d-1c624ce277a2"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i83fd6d470bf4439baf8eaf859c790c76_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTM1MA_2d8dc05a-10a8-40b2-abdb-98309940b172"
      unitRef="usd">18600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic5d2974b7d614bcaa563e8c3af491fbd_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTQ4Nw_5dc8825c-ce24-4fec-806d-5a046541eafb">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNzA3MA_658a09ed-0bc2-4fbd-87d3-46dae7bd1428">&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity relating to the Company's PBRSUs for the three months ended March 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.203%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.507%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of &lt;br/&gt;PBRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-average fair value per share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;461,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(200,725)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding and unvested March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if882eb7b96d54916b14a19ce79b2ec18_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMS0xLTEtMS02NTI3Mw_a69694a0-51be-489c-ad62-2ab90938a2e6"
      unitRef="shares">461250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="if882eb7b96d54916b14a19ce79b2ec18_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMS0yLTEtMS02NTI3Mw_c56ca1d3-590a-4ba3-9604-41f843d1628a"
      unitRef="usdPerShare">9.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMi0xLTEtMS02NTI3Mw_d81c3cc7-f651-41fd-bbab-d9a2cd27dd35"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMi0yLTEtMS02NTI3Mw_a515bf8a-8062-48b4-9f08-644bf014871d"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMy0xLTEtMS02NTI3Mw_341eb8d6-16d7-4538-ac44-7d764eb01141"
      unitRef="shares">69150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfMy0yLTEtMS02NTI3Mw_c56de891-5b8c-478f-bc7f-ae2a2138f1e1"
      unitRef="usdPerShare">12.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfNC0xLTEtMS02NzA5OA_7ed5a45c-950d-407e-bb45-bd1c1fbcb269"
      unitRef="shares">200725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfNC0yLTEtMS02NzEwOQ_50fe9bf5-97c8-40cd-a1b6-6764a66cf71f"
      unitRef="usdPerShare">8.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i7e0291a026d743f2b05b3fe91e58229b_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfNC0xLTEtMS02NTI3Mw_7a7a24d0-eb4b-4da8-95c9-78c9cca49df2"
      unitRef="shares">191375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i7e0291a026d743f2b05b3fe91e58229b_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RhYmxlOjc0ZTFlMWNjZjM5ZjRmNGJiNjBlZmNmNGYwMzQ2MGU5L3RhYmxlcmFuZ2U6NzRlMWUxY2NmMzlmNGY0YmI2MGVmY2Y0ZjAzNDYwZTlfNC0yLTEtMS02NTI3Mw_db46dc49-67cc-4216-9f69-eea8b7f0116f"
      unitRef="usdPerShare">8.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNjU5NA_529fff40-9a77-4b9e-af03-3844e0e9aedf"
      unitRef="usd">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNjY5NA_6d2640a5-068b-442d-92e3-7fe7d9cbdc50"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i11f403f253414aff975722250ebed665_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNjgwMg_2a2489b3-5236-409a-955a-8c4e578d5acc"
      unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i11f403f253414aff975722250ebed665_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNTQ5NzU1ODIxNjE4_cb9b7366-5891-4d28-88ba-97f63e52203b"
      unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i7e0291a026d743f2b05b3fe91e58229b_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNjkxMQ_ee5f48ef-f665-480c-8564-cbb1f0e08247"
      unitRef="usd">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic515ce14af2d40d483b0f3bf7c0ab0ea_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82NC9mcmFnOmZjY2ZhYjYzMmIyNDRiYzNhNTllNWVmMGQ1OGRhZDVlL3RleHRyZWdpb246ZmNjZmFiNjMyYjI0NGJjM2E1OWU1ZWYwZDU4ZGFkNWVfNzA2NA_b77ea84b-21ca-4e44-b52d-efdae8bde12f">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82Ny9mcmFnOjBmZjA4OGUwMzdlYzRkZGRhNzI2NjI4ODg3YTg4Mzk5L3RleHRyZWdpb246MGZmMDg4ZTAzN2VjNGRkZGE3MjY2Mjg4ODdhODgzOTlfNDQx_86696f93-4317-49be-bf2f-ddd44d8b8c76">Income TaxesThere was no provision for income taxes for the three months ended March&#160;31, 2023 and 2022, because the Company has incurred annual operating losses since inception. At March&#160;31, 2023, the Company continues to conclude that it is not more likely than not that the Company will realize the benefit of its deferred tax assets due to its history of losses. Accordingly, a full valuation allowance has been applied against the net deferred tax assets.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82Ny9mcmFnOjBmZjA4OGUwMzdlYzRkZGRhNzI2NjI4ODg3YTg4Mzk5L3RleHRyZWdpb246MGZmMDg4ZTAzN2VjNGRkZGE3MjY2Mjg4ODdhODgzOTlfMzI_44fd0903-1b92-4f97-9f0d-0f6a047b77af"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV82Ny9mcmFnOjBmZjA4OGUwMzdlYzRkZGRhNzI2NjI4ODg3YTg4Mzk5L3RleHRyZWdpb246MGZmMDg4ZTAzN2VjNGRkZGE3MjY2Mjg4ODdhODgzOTlfMzI_7ab08ab6-0854-4226-a467-f2046b79b2e9"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMzM5Ng_cfabf5db-6a96-45e0-9acf-e2a4e8fde18c">Stockholders' Deficit&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ATM Offering &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On April 15, 2022, the Company filed a new registration statement on Form S-3 to replace its prior automatically effective registration statement on Form S-3ASR filed on August 3, 2021, which registers the offering, issuance and sale of up to $239&#160;million of common stock from time to time in &#x201c;at-the-market&#x201d; offerings (the &#x201c;New ATM Program&#x201d;). On February 21, 2023, the Company terminated the open market sales agreement with Jefferies LLC and entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald &amp;amp; Co., as sales agent, to provide for the issuance and sale by the Company of up to $70&#160;million of common stock from time to time in &#x201c;at-the-market&#x201d; offerings (the "2023 ATM Program"), pursuant to its existing Form S-3 and the prospectus supplement filed on February 21, 2023. The Company may continue to use the 2023 ATM Program to address potential short-term or long-term funding requirements that may arise. Such program will continue to be subject to the volatility of the price of the Company's common stock and general market conditions. During the year ended December 31, 2022, the Company issued 13,043,797 shares of common stock resulting in net proceeds of approximately $90.8&#160;million after deducting $3.1&#160;million of underwriting discounts and commissions and other expenses, pursuant to the New ATM Program. No shares have been issued under the 2023 ATM Program as of the date of this quarterly report.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with an underwriting agreement with H.C. Wainwright &amp;amp; Co., LLC ("Wainwright") on December 2, 2021, the Company issued warrants to purchase 36,964,286 shares of common stock at an exercise price of $9.00. The warrants will terminate on December 7, 2023. The warrants were recorded at fair value of $61.9&#160;million to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the proceeds between the common shares issued with the Offering and the warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Registered Direct Offering and Warrant Amendment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 19, 2023, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) with certain purchasers named therein (the &#x201c;Purchasers&#x201d;), pursuant to which the Company agreed to issue and sell, in a registered direct offering (the &#x201c;Offering&#x201d;), 12,205,000 shares of its common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), pre-funded warrants to purchase up to an aggregate of 20,965,747 shares of Common Stock (the &#x201c;Pre-Funded Warrants&#x201d;) in lieu of shares of Common Stock, and warrants to purchase up to 33,170,747 shares of Common Stock (the &#x201c;Warrants&#x201d;). The combined purchase price of each share of Common Stock and accompanying Warrant is $1.675 per share. The Warrants expire on September 22, 2026 and have an exercise price of $1.55. The purchase price of each Pre-Funded Warrant is $1.674 (equal to the combined purchase price per share of Common Stock and accompanying Warrant, minus $0.001). The Purchase Agreement contains customary representations, warranties, covenants and indemnification rights and obligations of the Company and the Purchasers. The Offering closed on March 22, 2023. The warrants and pre-funded warrants were recorded at fair value of $22.8&#160;million to additional-paid-in-capital in accordance with ASC 815-10 based upon the allocation of the proceeds between the common shares issued with the Offering and the warrants and pre-funded warrants. The Company estimated the fair value of the warrants using a Black-Scholes option-pricing model, which is based, in part, upon subjective assumptions including but not limited to stock price volatility, the expected life of the warrant, the risk-free interest rate and the fair value of the common stock underlying the warrant. The Company estimates the volatility based on its historical volatility that is in line with the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury daily rate for a maturity similar to the expected remaining life of the warrants. The expected remaining life of the warrants is assumed to be equivalent to its remaining contractual term. The Company estimated the fair value of the pre-funded warrants based on the market price of the Company's common stock at issuance. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Offering, the Company amended, pursuant to Warrant Amendment Agreements (the &#x201c;Warrant Amendment Agreements&#x201d;), certain existing warrants to purchase up to an aggregate of 9,024,212 shares of the Company's common stock that were previously issued in December 2021 at an exercise price of $9.00 per share and had an expiration date of December 7, 2023, effective upon the closing of the Offering, such that the amended warrants have a reduced exercise price of $1.55 per share and expire three and one half years following the closing of the Offering, or September 22, 2026, for additional consideration of $0.125 per amended warrant. Based on the change in the fair value of the amended warrants, the Company recorded issuance costs to additional paid-in capital of $2.9&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received gross proceeds of approximately $55.5&#160;million from the Offering, before deducting placement agent fees and related offering expenses. The net proceeds to the Company from the Offering, after deducting the placement agent fees and expenses and the Company&#x2019;s estimated offering expenses of $4.2&#160;million, were approximately $51.3&#160;million. In addition, the Company received approximately $1.2&#160;million as the gross consideration in connection with the Warrant &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amendment Agreements. The net proceeds of the Warrant Amendment Agreements after deducting placement fees of $0.1&#160;million were approximately $1.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the warrants and pre-funded warrants outstanding for the Company as of March 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding from 2021 agreement, expiring December 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,940,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,964,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding from Warrant Amendment Agreements, expiring September 22, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,024,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding from Purchase Agreement, expiring September 22, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,170,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-funded warrants outstanding, no expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,965,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total warrants and pre-funded warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,100,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,964,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to March 31, 2023, on April 24, 2023, 5,865,747 shares of pre-funded warrants were exercised.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <espr:SaleOfStockAuthorizedAmount
      contextRef="i6f7bbae10a6e443e8fc0880b3115a1d0_D20220415-20220415"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ0NjMwMA_3741ee92-77e8-4e71-8aa0-7a7e9c852a31"
      unitRef="usd">239000000</espr:SaleOfStockAuthorizedAmount>
    <espr:SaleOfStockAuthorizedAmount
      contextRef="i5746fa6ad7264580a9b24d5d4c46caa2_D20230221-20230223"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ0NjY0OA_153942b7-0938-4ddc-9138-a6d444e336e7"
      unitRef="usd">70000000</espr:SaleOfStockAuthorizedAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3456d874c623457a8adcfaacbaeb0697_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ0NzE2Nw_d7b60087-044f-49ca-863b-64c435badf7c"
      unitRef="shares">13043797</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i3456d874c623457a8adcfaacbaeb0697_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ0NzIzNw_fa2ac0b8-9537-4377-a388-58f65b715dc4"
      unitRef="usd">90800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i3456d874c623457a8adcfaacbaeb0697_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ0NzI1Nw_24823bdd-bee8-464c-9a1e-7827a87841e2"
      unitRef="usd">3100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib488c87ccc86426b94cb6b54cc339eab_I20211202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ1MjE4MA_d2e5c8ad-60d1-49c0-a70d-6e3ce68f14f7"
      unitRef="shares">36964286</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ib488c87ccc86426b94cb6b54cc339eab_I20211202"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ1MjIzMQ_72474769-8311-4e87-83e4-036709407814"
      unitRef="usdPerShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i65f77ad90bd045109470849cecbc6ea3_D20211202-20211202"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfMTY0OTI2NzQ1MjMyOQ_6495481d-52d0-4aa2-a9e9-a315855dfe50"
      unitRef="usd">61900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="idabb0477bfa648dab7fecedc64128780_I20230319"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzEz_3cb54cfc-181b-4813-903e-81d672584e13"
      unitRef="shares">12205000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idabb0477bfa648dab7fecedc64128780_I20230319"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzI1_a9477061-9038-4399-bc71-1f9175731cd9"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <espr:CommonStockPurchasableUnderPrefundedWarrants
      contextRef="i2d316e7178014207990f50547c020dad_D20230319-20230319"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzMz_72bbb5ef-7578-4862-9936-b26007324dfd"
      unitRef="shares">20965747</espr:CommonStockPurchasableUnderPrefundedWarrants>
    <espr:CommonStockPurchasableUnderWarrants
      contextRef="i2d316e7178014207990f50547c020dad_D20230319-20230319"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzQ1_ea1d6322-c65b-42e8-a9c1-5769e2438bf8"
      unitRef="shares">33170747</espr:CommonStockPurchasableUnderWarrants>
    <espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights
      contextRef="i97a34cf836d84f4fadef4d721fab3698_I20230319"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzU3_566067bc-aee8-4cef-a41c-64c589a7a430"
      unitRef="usdPerShare">1.675</espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i326e6c7729314df9be278a89e941857f_I20230319"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM4Mjk4_dc8f9381-81a4-4a1a-ad1e-6ad76e95ff18"
      unitRef="usdPerShare">1.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights
      contextRef="ice6f0592c1f54f6b9a640b944432f3be_I20230319"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzY1_44bd7fe5-1fac-44da-bb0d-1be6702e5d26"
      unitRef="usdPerShare">1.674</espr:ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="idabb0477bfa648dab7fecedc64128780_I20230319"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzcz_c31ac576-bea8-4679-998b-7bed0852346f"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="ife8d4c895c31407d94cb9c6ff1903a1a_D20230319-20230319"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM2ODE4_836889b3-2713-4074-9fcb-214a4c8cea5b"
      unitRef="usd">22800000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i9d4d2015f62f45aaa2e5addfd39b96f2_I20230319"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzgx_b498e4cb-17a8-477c-86ea-e0abee4f5760"
      unitRef="shares">9024212</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7ce060f7a8354b51af7f71258119d414_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzky_e35d5ce4-c236-4208-857f-e2e52ebc027f"
      unitRef="usdPerShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i90c4fbf04c494d99bd37f6e4eb559905_I20230322"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzMzk5_33689106-0d01-4c4f-953e-c8b5bc6faa7d"
      unitRef="usdPerShare">1.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <espr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration
      contextRef="i90c4fbf04c494d99bd37f6e4eb559905_I20230322"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzNDA2_e26b1fae-eaf8-436b-9bc7-d9f214fb8052"
      unitRef="usdPerShare">0.125</espr:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i46d8059776cc44b2bb584005f975602b_D20230319-20230319"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM2ODMz_c119b868-9832-4fff-b042-4c85eae5c8d0"
      unitRef="usd">2900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzNDE0_bf49bfbf-249c-4b0c-9e77-0193569ce032"
      unitRef="usd">55500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsForCommissions
      contextRef="i5664faaee9574db4a202135e028596c8_D20230319-20230319"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM4MzA1_b551750c-3922-4251-99cd-46b525a87646"
      unitRef="usd">4200000</us-gaap:PaymentsForCommissions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i5664faaee9574db4a202135e028596c8_D20230319-20230319"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzNDI5_81836684-c76b-4491-b188-3e7ce82ba3cb"
      unitRef="usd">51300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i5664faaee9574db4a202135e028596c8_D20230319-20230319"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODMzNDQ0_2595d9ab-0dfb-408c-b25f-ee8ea08c232c"
      unitRef="usd">1200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsForRepurchaseOfPrivatePlacement
      contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM4MzE5_97b6afe4-3e0e-4f9f-8b3b-6dda712f776e"
      unitRef="usd">100000</us-gaap:PaymentsForRepurchaseOfPrivatePlacement>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i84f90717ce174411be734d0d3fc6f97c_D20230322-20230322"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM2ODQ3_32285709-8645-42ed-914d-1af35bf642cd"
      unitRef="usd">1100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <espr:SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM4MzMy_3448f718-a738-4c14-aee8-6c24d31708c0">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes the warrants and pre-funded warrants outstanding for the Company as of March 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.859%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.261%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.890%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding from 2021 agreement, expiring December 7, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,940,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,964,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding from Warrant Amendment Agreements, expiring September 22, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,024,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding from Purchase Agreement, expiring September 22, 2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,170,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pre-funded warrants outstanding, no expiration date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,965,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total warrants and pre-funded warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91,100,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,964,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</espr:SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if7e3ecf1db13427a96c7342395cd96b9_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMS0xLTEtMS03Mjc4NA_da7b6f6b-4a1a-437f-b3e3-d491dcb9245e"
      unitRef="shares">27940074</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if3cca07e819f46e68cad7cce1b9900cb_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMS0zLTEtMS03Mjc4Ng_94bd83a5-3d54-4116-bebe-918bf61b14aa"
      unitRef="shares">36964286</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if7e3ecf1db13427a96c7342395cd96b9_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMS01LTEtMS03Mjc4OA_5adad30b-4a26-4f0a-85a5-c66e5baa32bd"
      unitRef="usdPerShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia89bfe8a898240809b23c12addd330c2_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMi0xLTEtMS03Mjc4NA_2d042afc-c261-4088-859c-9c95a146fce6"
      unitRef="shares">9024212</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="icc92509623704e8fa809dc4a3cd974f3_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMi0zLTEtMS03Mjc4Ng_85a4e132-65bc-460d-8384-a877289e6730"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia89bfe8a898240809b23c12addd330c2_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMi01LTEtMS03Mjc4OA_402f20fd-8a70-4b92-b9d6-a8baff126c5b"
      unitRef="usdPerShare">1.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if4d3e30f8f084676b1159f8204cf214e_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMy0xLTEtMS03Mjc4NA_5635616d-6dbe-4e0b-97d8-088bd5d2f6fe"
      unitRef="shares">33170747</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i39d14dea4b5f4437b4a560e299ef1164_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMy0zLTEtMS03Mjc4Ng_3730f220-f9ef-448e-aa04-938d93b30530"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if4d3e30f8f084676b1159f8204cf214e_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfMy01LTEtMS03Mjc4OA_26883406-fe4e-4876-bddc-d2272527c1e0"
      unitRef="usdPerShare">1.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ie5ade988872643258980d4d742f28c71_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfNC0xLTEtMS03Mjc4NA_8e25a3fb-6168-4300-af1b-54346e511f6e"
      unitRef="shares">20965747</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="iedd2a0c27a144f8f80418aaca97d59de_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfNC0zLTEtMS03Mjc4Ng_100a7639-d1e7-4d5c-8ac8-a776496bc353"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie5ade988872643258980d4d742f28c71_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfNC01LTEtMS03Mjc4OA_0e5f1f6f-2590-4197-a53a-05155387c87b"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfNS0xLTEtMS03Mjc4NA_6c96334b-ce02-4bbf-8a73-f92e3273b4fd"
      unitRef="shares">91100780</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RhYmxlOmJkMzEzN2QyZTYzYTQ4MmJiYTQ2ZmE1MDg3YjI2ZWY5L3RhYmxlcmFuZ2U6YmQzMTM3ZDJlNjNhNDgyYmJhNDZmYTUwODdiMjZlZjlfNS0zLTEtMS03Mjc4Ng_9ab1d426-8e79-4545-868d-2bb1f3d8f6c7"
      unitRef="shares">36964286</us-gaap:ClassOfWarrantOrRightOutstanding>
    <espr:ClassOfWarrantOrRightExercised
      contextRef="i3dc5d334d016420f99299c9b501f60ff_I20230424"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83MC9mcmFnOjE2OTYzZmEwNGU0ZjQ1OTk5YmYyZDdkYmY1Y2FkNDg0L3RleHRyZWdpb246MTY5NjNmYTA0ZTRmNDU5OTliZjJkN2RiZjVjYWQ0ODRfNTQ5NzU1ODM4MzM0_8627f4c5-052e-4fcc-84ec-88fd84a5984e"
      unitRef="shares">5865747</espr:ClassOfWarrantOrRightExercised>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RleHRyZWdpb246NTc1MGY1ZWUxN2FlNDFhNjg5ZmQwNDU5ZDFkMmUzZmNfMTA1MA_a6c1a906-c619-4d54-b741-014341625d99">Net Loss Per Common Share&lt;div style="margin-bottom:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Pre-Funded Warrants are included in the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period, including shares that potentially could be dilutive if they were exercised or vested during the period, determined using the treasury-stock method. For purposes of this calculation, warrants for common stock, stock options, PBSOs, unvested RSUs and PBRSUs, shares issuable under the ESPP and shares issuable upon conversion of the convertible notes are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares under option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,374,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,101,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares under PBSOs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested PBRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable related to the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon conversion of convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,007,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,007,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,135,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,964,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total potential dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,292,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,816,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RleHRyZWdpb246NTc1MGY1ZWUxN2FlNDFhNjg5ZmQwNDU5ZDFkMmUzZmNfMTA1Mg_509e6d30-b8d3-41c5-9272-585cf50e6041">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The shares outstanding at the end of the respective periods presented below were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.421%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.612%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares under option&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,374,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,101,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common shares under PBSOs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,978,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested PBRSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable related to the ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares issuable upon conversion of convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,007,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,007,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,135,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,964,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total potential dilutive shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,292,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,816,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id729569cba9c49bfb3259c1d0b23594b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfMi0yLTEtMS02NTI3Mw_caa56884-ad1d-44bd-b114-67ae6e2e4569"
      unitRef="shares">4374452</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4b19c75cff2843b98e3df4b11681f893_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfMi00LTEtMS02NTI3Mw_3f996c62-8cfa-499c-af88-cb0d233a54d1"
      unitRef="shares">4101259</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic416a391bdff493fbefe5822e04c52ed_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfMy0yLTEtMS02NTI3Mw_59f29234-a89d-425a-ba98-837578f7b7a2"
      unitRef="shares">433950</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i364cd2415d994d3e85d93df2f35e189e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfMy00LTEtMS02NTI3Mw_23b77c3b-bb13-44b9-9e9c-81fce718842c"
      unitRef="shares">122700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0616f511266b4f73a0978adcfd5aaa0a_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNC0yLTEtMS02NTI3Mw_f8ad737c-7378-4324-953d-17f24b9abf77"
      unitRef="shares">3117397</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4f5e3f1ac3ab4878bb7bbbf20e6fe992_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNC00LTEtMS02NTI3Mw_84a91a3c-c020-4745-97e5-c2f4b984dc27"
      unitRef="shares">1978717</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0bb62ba99eea46949781dcab102b26a1_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNS0yLTEtMS02NTI3Mw_b61b156f-3d4e-43c0-9bff-5e1eb0cb8cea"
      unitRef="shares">191375</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i92b532ab4d724df2b12bf304d0f7d08a_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNS00LTEtMS02NTI3Mw_4af78722-3d0a-4b87-bebd-66e732d76562"
      unitRef="shares">602750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if2e830b24c974bfb99c9f7bd46ee28b5_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNi0yLTEtMS02NTI3Mw_18294965-149b-43ad-8821-a9279ee2201e"
      unitRef="shares">33575</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i03a5a3f73f214702aafb0c19d871baab_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNi00LTEtMS02NTI3Mw_d19f627f-a7a3-43a9-82f2-3d51a6e1b5e0"
      unitRef="shares">40257</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ief954accff7948b38b762497cb61309d_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNy0yLTEtMS02NTI3Mw_e3a8997b-ae52-4d3e-9400-552d973e3b80"
      unitRef="shares">8007010</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ied19a86173ab476f92091aa5b22ef096_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfNy00LTEtMS02NTI3Mw_fc5fce5a-f048-4d8d-b805-e7db0a656990"
      unitRef="shares">8007010</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if98ef8167c62483b9317f69d35a8b12b_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfOC0yLTEtMS02NTI3Mw_50ab71be-a29b-4957-b7dd-386824584b8f"
      unitRef="shares">70135033</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5c01babe5a404671aaf5f037534a61fc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfOC00LTEtMS02NTI3Mw_9d0ad376-e6b7-482b-b78f-83e991de7789"
      unitRef="shares">36964286</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfOS0yLTEtMS02NTI3Mw_745d4aef-388d-48b1-a5ee-1b1f7027e032"
      unitRef="shares">86292792</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2e33009a89c14e0f989708532696e7e5_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83My9mcmFnOjU3NTBmNWVlMTdhZTQxYTY4OWZkMDQ1OWQxZDJlM2ZjL3RhYmxlOmVmMzczMWY4ZmRkZTRhMDViNGZiOWNjOWYxZjkxZGU1L3RhYmxlcmFuZ2U6ZWYzNzMxZjhmZGRlNGEwNWI0ZmI5Y2M5ZjFmOTFkZTVfOS00LTEtMS02NTI3Mw_54d642b2-1db7-484a-a878-fdd659ea3dca"
      unitRef="shares">51816979</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RleHRyZWdpb246OTdhODZmODAzOTczNGIzMjgwZDJiYmJkYjdhOTM4YTlfMzI2_b4d2d389-c9d7-4e46-b0cf-42787f45ff86">Statements of Cash Flows and Restricted CashThe following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on March 31, 2023 and 2022 and December 31, 2022 and 2021 (in thousands): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <espr:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock
      contextRef="i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RleHRyZWdpb246OTdhODZmODAzOTczNGIzMjgwZDJiYmJkYjdhOTM4YTlfMzI3_ad856a4e-b939-4a9a-b52b-a15c49dad61e">The following table provides a reconciliation of cash and cash equivalents and restricted cash presented on the balance sheets to the same amounts presented on the statements of cash flows on March 31, 2023 and 2022 and December 31, 2022 and 2021 (in thousands): &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.258%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.487%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;258,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</espr:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMS0xLTEtMS02NTI3Mw_c0bf36cd-4c5a-4453-a1d0-28e890ecb966"
      unitRef="usd">144911000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i99f951895edd442e82a9307c2fd15632_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMS0zLTEtMS02NTI3Mw_a70e9117-1aba-4e33-a78c-f434ba9bd904"
      unitRef="usd">150364000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMS01LTEtMS02NTI3Mw_8a0238a0-5489-433f-8b6c-b789ba761664"
      unitRef="usd">124775000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8ed0b5ab60804e7ba2963330f6311982_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMS03LTEtMS02NTI3Mw_2c9954ce-df45-460f-a991-915ee77bafc0"
      unitRef="usd">208892000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMi0xLTEtMS02NTI3Mw_810dbf38-9e91-4b77-80c0-6ea1116c1047"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i99f951895edd442e82a9307c2fd15632_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMi0zLTEtMS02NTI3Mw_9e3b0127-22b1-4806-92d4-0ec0e5c235da"
      unitRef="usd">50000000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMi01LTEtMS02NTI3Mw_40df5de1-282f-4fd3-9a4b-92753954c654"
      unitRef="usd">0</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i8ed0b5ab60804e7ba2963330f6311982_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMi03LTEtMS02NTI3Mw_844b433b-c462-42ef-8e61-e00764e882d8"
      unitRef="usd">50000000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id6505e18f8b44bb1be4b3c88b659408a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMy0xLTEtMS02NTI3Mw_33c3fee0-1fa3-4f6f-8621-d20f5ae7e852"
      unitRef="usd">144911000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i99f951895edd442e82a9307c2fd15632_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMy0zLTEtMS02NTI3Mw_0ecc2552-8029-4cc7-8545-052c665f31fa"
      unitRef="usd">200364000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i914746ebf548485ab38582d5985e0ada_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMy01LTEtMS02NTI3Mw_135acddc-988e-4f9a-b9b3-4ac3e3c38ef0"
      unitRef="usd">124775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8ed0b5ab60804e7ba2963330f6311982_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjkyMzdmYjE1NzkyODQwNGI5NmE4ZmM3ZWY2ZjZlZmJhL3NlYzo5MjM3ZmIxNTc5Mjg0MDRiOTZhOGZjN2VmNmY2ZWZiYV83Ni9mcmFnOjk3YTg2ZjgwMzk3MzRiMzI4MGQyYmJiZGI3YTkzOGE5L3RhYmxlOjRmM2ZlYjA5ODQ5ZDQ3OWM4Nzk1ZGJmOTRhZjkzYWRjL3RhYmxlcmFuZ2U6NGYzZmViMDk4NDlkNDc5Yzg3OTVkYmY5NGFmOTNhZGNfMy03LTEtMS02NTI3Mw_9ca01dbf-6d08-4d4c-b797-175777710040"
      unitRef="usd">258892000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M#^#]4@AUN-'_H#C5'O\'4$L#!!0    ( !!(J59K[JY\QP8  -X<   8
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M,!^'&0WB.-R;'2$-]D@#+]*;C:SUB19U"=VV$TJ74S"[..'A^^. QB.4ME5
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MVC+ N7KYJL[BQRM48([6F): +DB.$D8IY@(5P.L7?]FW&O44036%_M-81];
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MZO8&7 >HYTO&Y$M'WP_:^V#T!U!+ P04    "  02*E6R-C^82T%  !.%@
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MAF*Z"?<I^U \_T;;#C4-C(JT:OZBY]96FZ%H7[$B:YUY"[(D/_P/O[4#<>*
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M6I3M8(.@9+SY3WZV$W$PP/CQ#T#M #0<$(\,P.V >N9F#;(ZK/=$D]6%% ]
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MWIIT+ Y&54?CQQ]^GLVF%X<"1*0HUQ)AEO)RZ#F-YWAM5G4N7;X52XN(4)D
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M*.3[@_!9 E!-T#OU_'XXK^CC1,@6G,@I!5&6ITQ&@)7M- BS*74=5*=^I5E
MWUV?/!M30]#Z$]F""D=>7.K8D&>1PYU*%' ?^@ J&>K2AD1!UB+)(_>=+7S-
M.!N+U&B-3D'<*,FVHMO#ZW1\=K;#*S-)I35,$?S,J)"DMJ@"*1/GJ ":R<^#
MK"VY1<DT2<MS-.-UIEQ;W2%LIK-P]@[?][MH3;,.E$J>RY 4F80MR6,0U'E0
M)>STY.QL?(:8S',ZH:VI.XX6"CSQ,(B*7_#,Y5B8ZZSH[U+%H8U3.=?1;1*B
M]&Y\TQ@;M  M'Q%7&G;WG"N7R&R]8[EI>>CHYJ0VA'M#RNGYA:?!$4N\A[LD
M=,,[6IF.3QJM<'0W1AE&<JOFG>W3\:S5:6Q4@R&&!M7[4>.Q"-^CR^A$CP+(
MKC8[3;(.N_E87X9IIX%/U*&2U7ZSB,#IB1@QS*]M#F'\3PA(8*VN1NS R]KQ
MC .-,;]\80K#&5W;I5#,AE(L%,[X8QTZC* @#L4%]034R$3>*0DP_)*Q!W/&
MEE@2*LJ,EAMJ?L-HE:N2=L[*'5ES42F&R42L@)J,]=W4-PP.\2-62<U8,1E,
MLOL[O,RIC%:R2"A620T\.T6-:Y0/;KILWTK &,;PX>#.U6',A&V>?",/=8J3
MFA$C1?5>-?WM?C<D3N.(DVIQ.-EKM7 UJ9LFC63%_C16M9W2;D-T.&B:OJ]=
MZA?P25L%.+)$F.G!4H2J<  (7Y)2RQ@.ODNL)Y,D\-K&Q-[Y<</XSMC*4Y/R
MA>IAB$K->% XS1$X*;*[A6H[N$D8B9A8:R,]T N(,,8::FIH_<816S](!CZ%
MW>15L><*4^!F\P7J$,[/O3ZJ,5YHV_I'B8-A6L 5T$LR_*/4B55.V-=.N9O-
MAQ?HZPT DTF&GQ0NR<#%J;-(J6FDHHG:U^7RHN>F87//5&% ;$2=!V 5*QL"
M!&4GFDCV8&>7FKVBMW%H*A0A4+>/33NBH.X< A20)7T?&539OGL)K:,/N3RN
M8\<.;TG"F)';14MF4LS&LJYJJIC_7&M<=:KH.E^>=O'\QZ_)OA:54DPK87/S
M) 9<-X1JH2UB,^D^XD 8_>1H8QM<DQTRLR*OI(8W:G$CS>W6QM<-XM=B\48<
MC*YNKND=Q(?*U[=2?!R^:;NT"+-W589U80$MY?<90Y)8%Y==W="204L,COXF
M34"(A$>PB9@C0G,Q/8^!2"3#K=E3OC5E_R]#T44O&3;(%8(ZOKZ;D$?NMT+2
MUW\ANQ=<9,9=,HPC_.XLA&H?]>\5IVW4\/ H6B+%!;TCYNE&>&,E!R]0:,+>
MMY%OL$>[C#KAD%;"K'!%$(C,2/S@9HZZT# Z<PH.,GE&_D)75'1D:E$U@&]6
M@T?.;F5>;8_H\X1LL(;9;]=!]W<\CJ.[]8)>Z*%%HU>9347C>6P7A;.<@:/_
MHH)!8&;4TE6*E1O>\-'<2=Y)G4M^V=JO;,@B]'B!$^-TL#/0?0OP\"#&3JM_
M+@4X:.Y;(0DSQCWXVI!Y?+=>MD@W?N!5]N?=+I=J""KYV.NALJ*7@WWW94"<
MB:)ZX)=/-"2(S4T8S\;<VKTEB2F.O9.=!L4I7)<2 +W++ID,EM0F9/:0^@@9
MFF1I^"C^.H'E0 V'9D.*@]CS_3J??^P&"V_#+JH[HN?V4;W:P=<"AB=OA0-\
M =1&WQRF/QX^&BK6:+Y.%@ACW'8#4(UR(B$$)QFQE-J)<N=#BWV5=Z_,0<_3
MXG<ST<:N/7#1V(??46>^.8AL?1D;VUYQ&0I![:FKJJE?#9+P/#6^]XB*CAEF
MK]E;^^XQ*.D_X4EL&(UZC@U' 4@[.%]'ED&%YN-DYQJ%+#<8PS(VN""VV!#:
MS9#_.]W3KVV=9Q28]"%7["&^H+@9-A&-_^YW\= )FJS5.'6I(C24;7,=/]F9
M)6U;!:G##-RIRC9.1/&RJ^A=+Y@'Q7]BY5"^H<^RQ'1R]/?OXB!4#?^=SS0
MUWBN9G\(Q=*=:MRUH0DH@D;;@71T<GK?1'R1!K814W?/H974P@:L8BGH33H_
M'>_['.BX]\47XGS%W[51:PA\"!]_M7?;3^?FX8NQ;GGX[@[5\HJ&9+E:8NMD
M?'XV"K.NYJ*R)7\_MK!590O^N8;7*$<+SJA=@T7C!1W0?E#X\C]02P,$%
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M#,%[71S3/">R :7U'1DG-W)9PRD1ER25WRL[UE75/Y R, 2?LIGATZXSOZ7
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M.4N=F&DE+=/1)9K<Q[++-+=<8^4W<&+#2BQU3R2&IT@/3:@,7Z;PTUB.6/;
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MW8RH70*MYTK9_<1M,-RUR4]02P,$%     @ $$BI5A6,950F!0  \0T  !D
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M8H!&0J +DE,MUYQX(U+XGK:#2J$5;-B*<>$;T"'M#BWSG6C;BT,@8E,O5'#
MU=N8[,!9X.II'>QT."A8'G*A^UV&$'5%4EBDUY&@V<Z^YAWO#%H2S2*,D]0H
M_=6J9JY&VDRL9]6@ME6OQEV"M_#,")R3:=(Y'D1@JA&RVCB]#&/;3#L: L.R
MH*D;C5>@\[FF%[#>^ #-'#_]!U!+ P04    "  02*E6IH4]&:<$  !."P
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M ._7!@[F?] !S6?OK_X'4$L#!!0    ( !!(J5;,3(&1LP(  !L&   9
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M%X'!<YDY9+E7;)V"29 G%VLS>6%THFA6*:\X0DHK0@I >3+Y7&F#S([7FQM
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M'8 &X/VD /GX&W+0_$KL]#]02P,$%     @ $$BI5K^)>$38 @  6P8  !D
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M CU&44=K^R<!H4M>9 -882$ZAP%\99I6Z"W45([8.VL)+K3NA *:'U9XJ==
MM^^HHJ,,Y#1LN3&'L/#'2@U>,!<D3.J.X-[PIE!=R;6%!TE_[-*3>K*LY".J
M+1_I$ PYAU0;J13-$Z'DGZA^A1HK8C$5<3GN:0P&Z() D&2.=<B%^;B6U)1V
MR]G1$!DH"F-+LJBV Q!0=53@2:A.Q,&C:/()]LS7LT*D4-LJR5>TIK'IHCQ-
M$_A(Z>&Q;U5ZT/ -VG48:X[NI=,^]GX?[2?G(@Z,?^EQ[-+-KTD#**P(.AI^
M.$O QE$6-]ZT87RLC*=A%)8U37^TG$#GE3%^O^$"_>_)_"]02P,$%     @
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MH;+]PC2\GZ(VU53S7;J\<C'I9B'@@HPQ@V84!$)TPU8G@:B'WKM8_D/_]GU
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MF!SMSY7@X!5:@.>+HC#-!1W0?E6^^0]02P,$%     @ $$BI5A2'A A0!
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M122[1=A[-]0536'LX<72H%;@38X_1:?AQ8$2D[;$Y!#[?Y_P0?;=VC^2\K$
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MD%T5*U.1^GRO^.CSU=%)$KBPQT;3S#2\UP\<2USZ#19OY@S:<TVL=KA/O7*
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MF-/3C,H&T'PF25YGV 7ZQW[Y+U!+ P04    "  02*E6,?LI9BL#  "R!P
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MM86!DW001^-_8_%2B*,PB@?G\2<XU!#AW@"H49=^S!G(52.IG07];C])Y^T
M>79OQ[#-6W)I0.#:AD:G9Z, =#O:6H/4QH^3E2([G/RRLG\#U,[!GJ^5HIWA
M$O3_E^PO4$L#!!0    ( !!(J5:G&ZAFOP(  !8&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(W+GAM;'U5;6_:,!#^*U9639V$FG<H#"+1=M,FK1IJN^W#
MM \FN1"KCIW9#K3_?F<GI$P"OF"?_=QSSYUSQWPGU;.N  QYJ;G0"Z\RIIGY
MOLXKJ*F^D@T(O"FEJJE!4VU\W2B@A7.JN1\%P=BO*1->-G=G*Y7-96LX$[!2
M1+=U3=7K#7"Y6WBAMS]X8)O*V ,_FS=T X]@?C0KA98_L!2L!J&9%$1!N?"6
MX>PFL7@'^,E@IP_VQ&:REO+9&E^+A1=80< A-Y:!XK*%6^#<$J&,OSVG-X2T
MCH?[/?MGESOFLJ8:;B7_Q0I3+;QKCQ10TI:;![G[ GT^J>7+)=?NE^PZ;(S@
MO-5&UKTS*JB9Z%;ZTM?AP.$Z..$0]0Z1T]T%<BKOJ*'97,D=41:-;';C4G7>
M*(X)^RB/1N$M0S^3?3<5*++,<]5"0;XQNF:<&0::7#[1-0?]8>X;C&/1?MYS
MWG2<T0G.F-Q+82I-/HD"BO_]?=0WB(SV(F^BLX3W5%V1.!R1*(CB,WSQD'3L
M^.(3?"OZZG(C5!1=[I1K\GNYUD;A9_+G6,H=8W*<T;;.3#<TAX6'O:%!;<'+
MWK\+Q\'',WJ306]RCCU[Q%8L6@Y$EN3D@QT3?9;VN.B.G_;\_."#R"6VHC96
M!&)(*3EV-!,;<LD$GLA68SGUAQG!Y\HK]UYWD$.]1CYK[#7GLL:1HJGKR@N2
MCM)QBNMT%*3Q -I2Q>P;=5$+4!T\"D=Q&-ME>CT9P(V2)6@[)R@G):#6>)0D
M8Q*-TN0-Q80!3!,3$)9U"\HP&T%(XSRFDY0@?90.'M+5(HPB$DVFY$D:I)<G
MZW-!XF241*'=I*-P&I)C3^\?]&H-:N,FDBUN*TS7ML/I,/267:^_P;N)B77>
M,*$)AQ)=@ZM)ZA'53:'.,+)QG;^6!N>(VU8XN$%9 -Z7$E/O#1M@^"O(_@%0
M2P,$%     @ $$BI5N4]X"Z3!   2 X  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C@N>&ULY5=;;]LV%/XK!^K0.H J2]0]30S8:;?UH:N1I"F&80^,?&P+
ME42/I'/9K]\A=:G;.$:1MD][27@YE^_P?/PLGMP*^4FM$37<U56C3IVUUIOC
M\5@5:ZRY\L0&&]I9"EES35.Y&JN-1+ZP3G4U9KZ?C&M>-L[DQ*[-Y>1$;'55
M-CB7H+9US>7]#"MQ>^H$3K]P7J[6VBR,)R<;OL(+U!\V<TFS\1!E4=;8J%(T
M('%YZDR#XUEB[*W!58FW:F<,II)K(3Z9R=O%J>,;0%AAH4T$3O]N\ RKR@0B
M&/]T,9TAI7'<'??1?[6U4RW77.&9J#Z6"[T^=3('%KCDVTJ?B]O?L:LG-O$*
M42G[%VX[6]^!8JNTJ#MG0E"73?N?WW7G\"T.K'-@%G>;R*)\S36?G$AQ"])8
M4S0SL*5:;P)7-J8I%UK2;DE^>G*A1?$)SD1-75;<'M3HDE]7J(Y.QIH2&+-Q
MT06;M<'8(\%">"<:O5;PIEG@XDO_,0$;T+$>W8P=#/B.2P_"P 7FL_! O'"H
M-K3QPL>J77.)+V?4Q07,^3V12\-42MZLT([_FEXK+8DI?^\KOHT=[8]M;L^Q
MVO "3QVZ'@KE#3J3Y\^"Q']U 'DT((\.19]<M)<&Q!*FALBEOH=SK*ACS0JT
M +U&VT7>W+]0\'YC.JF -U0G2GMWFZ*OO-\EM_E6%FM:-+XU]=[285_M!]'M
MK_V2("U%1=?>8C2DZNY^^2\JBYCWI<C]I3Q_EK$@?:5 ?(:\Z2$7+61E&4PE
M6D>]EHA0MS1$0T,@$A7K@47'\,>VOD9I3K(_B(_V[N+BY?0&)4D1O+E#6924
M8R[+ LT1@J7.0\MS-,IGD)]13D.=+:_@$F4-HS^12W4$T]5*XHIKA+=D49*>
M%7#%JRW"J&P(L-@JZA,9OM]JI6EHHG$-K[% B[2#SB!TLXBY:9C"+\!2+XTA
M\K*$)H&;Q!G\1D0F;#0+XL@-?9]V(H^%0/JUQ-)LT2GAW::4-!PEC+EQ%A^1
M59AY*1NJ7H ]=_:*=OK15]B^/%.@;&GD1C$S6'(OSR#Q@FS'_0J526_X2/E)
MD6E"O;RAY:>$ZY!:2CUT9VZ01Z[O1Z:RT(LB8%Z>[[C_2&;.9Q?OU?^#?E&>
MN\RR*O'2$'(OM UB _$>TN81YL4NB_VC-E#R/;P+0S>/.T0,LO8V/)%T!V,=
M9ER4N8$]F,S+(_)/V([K ?6/!_6/?Z#ZGU]\4/LT_&".GZ_A!M;3+LH#VG_!
M"FKOMKEI>_V0M(&;)M2=++;=R?P=E30"&-F-R MV57(4^(&;98%A:.ZQJ&?2
M*$@#-\Q9MQX^CN,K?H1N$*3DF5IVA=$A3B0#)Y(?R(GYC([_Q5Y:'$SSTVC1
M8_I>2O".$DM>2KBQNK8A$V7U<K<_>_0L"8P.V6;&_C>IV"C)Z<?52E? O"0>
MF$&ZZ*;,_IA:#?A69@0Y,2J->[=]O!CO?-W7*%?V#:/H\V?;Z/9#?U@=GDG3
M]G7PV;Q]8U'R%?T"0(5+<O7I"\(!V;Y;VHD6&_M6N!::7AYVN*:G'DIC0/M+
M(70_,0F&Q^/D/U!+ P04    "  02*E6X>S\W1H#  !@!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6R55=MNVS@0_96!NDA;0+5NOJ:V >=2;!^*
M->JT>5CL RV-+"*2J))4G.S7[Y"292?K".B+1')FSCDS)(?SO9 /*D/4\%3D
MI5HXF=;5I>>I.,."J8&HL"1+*F3!-$WESE.51);8H"+W0M\?>P7CI;.<V[6U
M7,Y%K7->XEJ"JHN"R><KS,5^X03.8>$[WV7:+'C+><5VN$']HUI+FGD=2L(+
M+!47)4A,%\XJN+P:&G_K\)/C7IV,P62R%>+!3+XF"\<W@C#'6!L$1K]'O,8\
M-T DXU>+Z724)O!T?$#_8G.G7+9,X;7([WFBLX4S=2#!E-6Y_B[V?V*;S\C@
MQ2)7]@O[QG<T=B"NE19%&TP*"EXV?_;4UN$D8.J_$1"V :'5W1!9E3=,L^5<
MBCU(XTUH9F!3M=$DCI=F4S9:DI53G%YNM(@?,I$G*-5[N,&4QUS#ASNVS5%]
MG'N:.(RG%[=X5PU>^ 9>!-]$J3,%MV6"R<MXC[1U L.#P*NP%_ ;DP.( A="
M/XQZ\*(NX<CB16_@W?ZJN7Z&OU=;I26=B7_.Y=A #,]#F'MRJ2H6X\*ABZ!0
M/J*SO'@7C/W//0*'G<!A'_IRTUP/$"G<,RE9J16P,H&UQ$]I;:IZ7/^KUDJ3
MD9>[<VGT$IU/XRY#2$5.=Y4P09MCT%Y8_B\JT&3>GZJJCJJZ=7%415C2!EV+
MHF+E,S!E$J--C;-N5RW0#<98;%$>5L/+UU[_\X![>^>(FCVBI!8"^(0RY@I)
M%H_Q6*<7BJ0H3'@ ;"<1J<%HEP(K+HVU(YFTK.'$G0U]UY\,(1J[L_'0#:=C
M^ -F ]_O(6@ML"+\Q'# ZL"F3N@V6.F&+PPMX1AFKA\221#"Q;LI_3X363 8
MC7K(UC45BEK3D:.?(HK<8.*[D^'D-<>Z?SM=*$6#S&Q/39A&@J2RC%ZA^52>
M .Z$9OGO'9A9X 8^:9OZI_4^=Z^\DZY7H-S9WJX@%G6IFP;8K7;/QZKIFD?W
MYNVAD[;CI8(<4PKU!Y.1 [+IY\U$B\KVT*W0U)'M,*,G$*5Q('LJA#Y,#$'W
MJ"[_ U!+ P04    "  02*E6UG;K 5\#   D!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6R-56UOVS80_BL'%1A:0(NH%UMV:AN(TQ0KL&Y&G*P?
MAGZ@I;,EE")5DHJS?[\C)2LIYAK[(AW)N^>>YT@>%T>EOYD*T<)S(Z19!I6U
M[744F:+"AILKU:*DE;W2#;<TU(?(M!IYZ8,:$26,3:.&US)8+?S<1J\6JK.B
MEKC18+JFX?J?-0IU7 9Q<)JXKP^5=1/1:M'R V[1/K8;3:-H1"GK!J6IE02-
M^V5P$U^O,^?O'?ZJ\6A>V>"4[)3ZY@:?RF7 '"$46%B'P.GWA+<HA ,B&M\'
MS&!,Z0)?VR?TCUX[:=EQ@[=*?*E+6RV#60 E[GDG[+TZ_H:#GHG#*Y0P_@O'
MP9<%4'3&JF8()@9-+?L_?Q[J\'\"DB$@\;S[1)[E!V[Y:J'5$;3S)C1G>*D^
MFLC5TFW*UFI:K2G.KOZ@??]=&0,;U'"KFH8JM:VX1GC[P'<"S;M%9"F/\XZ*
M 7/=8R8_P4SALY*V,G G2RQ_C(^(WT@R.9%<)Q<!/W-]!6D<0L*2] )>.HI.
M/5[Z$[P[KF4M#[WH7NW?-SMC-9V1K^?T]G#9>3AW;ZY-RPM<!G0Q#.HG#%:_
MO(FG[/T%LME(-KN$OMK2/2P[@:#V/5>JZW,A.BHM?-2J@5LNBDYP?\C)YT,M
M.DMK;F??NJU]!Y]DH1I\47M.XD42YR4^5 BF9T37W5@N2ZHJ< N65E"6CHXS
MR:-%?_V@15VKTH!'D8[GSC4&.")M IYT[9TN%UG\J*T<M$G2)MRI);B> I0=
M@E4NJ-; I:U_]<XN)^[WE/T:Z!@5U7B.W"<Y'?E!1D<'5H-J?;XL3/,LS"8)
M63&+PV0R/^N^66__-)"E:3B?,(B3),P9@T?YA,9QO=\^&DC#.,[#=)Y#',[S
M69C'^8O'9NU]XGE,&2<P981 2,-FU\9T[B92%:D0Y-ZKA+OM9@.4=$(A&2-V
M^7\BNI:X%HKR:#-4L!_9VBU+9<E[%C*6ARQFKZPO7&NJH8&<A7$Z"5F:0CH-
MY],L3&93>%"6"V@IG.I,UECIH2ZS:9C,2<0\@4D<SF**S.=P[BY$KSI7@_K@
M^[,AEIVT?1,;9\<GX*;O?"_N_?M!NWNHI0&!>PIE5_DD -WWY'Y@5>O[X$Y9
MZJK>K.@90^T<:'VO2- P< G&AW'U+U!+ P04    "  02*E6Y2_G/_<"  !9
M!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6R55=]/VS 0_E>L#"&0
M(O*C+9321J(%M#T@H<*VAVD/;G)I+!P[V&[+_ON=G2:TI:VVE^3.Y_ONN[/O
M/%Q)]:H+ $/>2R[TR"N,J09!H-,"2JHO9 4"+;E4)36HJGF@*P4T<TXE#^(P
MO Q*RH27#-W:DTJ&<F$X$_"DB%Z4)55_QL#E:N1%7K,P9?/"V(4@&59T#L]@
MOE=/"K6@1<E8"4(S*8B"?.3=1H-QU^YW&WXP6.D-F=A,9E*^6N5;-O)"2P@X
MI,8B4/PM80*<6R"D\;;&]-J0UG%3;M ?7.Z8RXQJF$C^DV6F&'E]CV20TP4W
M4[GZ"NM\>A8OE5R[+UFM]X8>21?:R'+MC Q*)NH_?5_7X5\<XK5#['C7@1S+
M.VIH,E1R193=C6A6<*DZ;R3'A#V49Z/0RM#/),^&&L B&TUD3B94%^0!#TH3
M*C(R!6T42PUDM>7LA<XXZ/-A8#"T!0C2=9AQ'28^$*9#'J4PA2;W(H-LVS]
MRBWON.$]CH\"/E)U03J13^(P[AS!Z[1UZ#B\S@$\FY]?9WG_MF!+RFU-_-T2
M^'OKLN%!?MW.T(B7[?>^*M4DNOM)V 8<Z(JF,/*PPS2H)7C)Z9?H,KPYDF*W
M3;%[##V90BI%RCBCKA^:X[8)?<IB3Y;[TCD:<'\Z+P607'*\8TS,B;$7BE1*
M+ED&&!;[?)=DVI!T NR05!\DG=T%$E9%;X.Q9I13D0)Q+:*)D6Y5TQ((+>7"
MXGSRT5M-X7!SUQ1HQXN7%NW-<QQ0B)UP!RF4,U"-.6[,$3EC%EHN-*[H\\$&
MS(>TY;ZE3 [6(.IV_>LH(B<DZH5^Y[)KI;CK7UWU4(K#OM^_CC>/TB&<?NG'
M47Q#T"4,PUWU11K*_[/NNI KT=0/CS##N8VV@Y4\V6".#\AGYKV:^;Y['VR,
MNQ+4W UUC5'Q-.O)UZZV[\9M/2X_MM>/#A9_SH0F'')T#2^N>AY1]2"O%2,K
M-SQGTN H=F*!;Q\HNP'MN92F46R ]C5-_@)02P,$%     @ $$BI5BX3_!Z#
M!P  GDX  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULO9QK;YM(%(;_
MRL@;K;I2%</8^))-+"7A^J%2U+3;SP0F,2H&+X.35NJ/W^%B\/@RA?;U?DD
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ME[S5;;4!"38\3U=UL.C!*DJJ__ZW^D#L!(Q/!= Z@'8-&-4!H[T 2D\$C.N
M<=<,1AU@=,TPJ0,F^P'&B8!I'3#="QB=RC"K V9=,\SK@'DIA^K\E2??]'-_
M<9VE;R0K6@M:L5 JJ(P6YSQ*"K$_YIGX-!)Q^>+3DI'[=+7VD^_$3T)RY_.(
MD_29/&2,LR3W2TF^,UGN1S'_BUR0(>%+7WQ(HH1\3J*<OR=KT4JT+;9\6J8;
M+D!BZX6T?CW,17>+I,.@[II9=8V>Z)I./J1)ON3$2D(6'HFWU/$C1?Q0'*;F
M6-'ML;JC2N '/[LDE+XG5*,C\OG1).\NI"-2_3O2T_L.8'W^"V!3#;[=O%R2
MD5Z ]?GV-!T[DAWZ5V%Z]L_N#J9;\!&,T^7$C.K^M?TZ0G+5)),%.QWJLH=>
M=Z!^LFN2'$?-5W=4HD>_\]4]TN.["CL^CBVNKE=\[0?L9K N0-DK&RS^_$.?
M:'\?4S829B)A%A)F(V$.$N8B81X()NEYW.AYK*(O'O--^'T[2''"DBR-8Q:2
M'XJ!ZTZ)[*ME),RL8$8)*TK.UX4^OAZ^[BH4F<]&PAPDS$7"/!!,4JC1*-10
M*E2,MBM1#8FB+/CZGD2<;X0\WXDJIQK3_Q)2/7F=N%.B^RH5"3.1,,LXD/UL
M3D=3?3*5Q6\CLSI(F'NX"].),1F/YA-Y%SQ05DF+DT:+DQY:7/L9>?7C#2OE
M&(J!T\\X6;.L$N2QFNI.R>\K2"3,1,*L"C;=.9O:I:;I>VI$IG20,+=3_SU0
M2DF*TT:*4Z44'[(T8"SDY#E+5^6PZ"<!*RK10!)IPO)B8],@2+FXSO\@%\?4
MJ4S95YU(F(F$615LLG-V#6K,9WOJ/&RER2T<9*=<),P#P21ESAIESM0E)0LV
M622*1TX>-EFP]#DCMR\98ZL3Y:02UU=U2)B)A%E(F(V$.4B8BX1Y()BDXWFC
MX_EY;O7G2#TC82829B%A-A+F(&$N$N:!8)*>=:U][*R=[U9*S>XKZYHFW:E3
MJAF:MG>1-:%Y+2C-AM(<*,V%TCP435;NCF&BG_G&2YV@MWSU+C<()C2I!:79
M4)H#I;E0FH>BR=JEK79I9^V2=541^T\Q(YLD%)(5.9^+I9"\^5GF%T]A.P_)
MRL2]-4T/AF2JS2?&=#S=ES4RKP6EV5": Z6Y4)J'HLFR;HTP7>E+_$S6_<4,
M=<AJVJZ81R-]JAT1,]3_@M)L*,V!TEPHS4/19#&W+IBNML&L;RP+(L[$:!P%
MO<H*J!<&I9E0FE739KL5^Z5A[#TT@^9TH#072O-0-%FQK2NFJVTQY5,V,=#6
MP_-C.3S?)B&Y#8+J84:4O) OU>A\5-%0SPQ*,Z$T"TJSH30'2G.A- ]%DY7?
M>G#ZY#S/Y72H^0:EF5":!:794)H#I;E0FH>BR<IN+3W])Y[>=B#O785 C;N:
M-I6N]).IL5\X0STY*,V&TAPHS872/!1-EFSK]>F_8?:),D2,R<2N'F_4-4>_
M8@3J#4)I)I1F06DVE.9 :2Z4YJ%HLOY;CU _DTFH0UU"*,V$TBPHS8;2'"C-
MA=(\%$U^[:(U"ZG:+/SE8D3-[:OLFK9?C.S]JM>$)K6@-!M*<Z T%TKS4#19
MLJU+2-4N85-AB.(C+ N0IA0Y^LA9C>NM5"3-A-(L*,V&TAPHS872/!1-%G1K
M'5)ZGNJ"0IU!*,V$TBPHS8;2'"C-A=(\%$U6=NL>TO_7/:2'?M]<HV.J4[E0
MN%?WJ[>6H>8AE&9#:0Z4YD)I'HHF:[DU#^F9S$/:Q5*[5V?OK5BH*=AI#VQH
M3J=33A>:TZMINR\#S)N$LFQ:!X^J';S;,(R*Z[<?DR!->"3&O?K%_^X",H[\
M#$VG!PJ"FG!0F@6EV5": Z6Y4)J'HLGB;4TXJGX3[BRO'ZES]JY:)P??64,?
M'?R^&)K4@M)L*,V!TEPHS4/19#FWSAM5.V].EG(QV&Y%?4J?1UX<,XQ]1=T?
M::;30]U![3,HS8;2'"C-A=(\%$W676N?4;5])@^C]5T/\9OG5Z>$.#M4F'ZH
M0ZC=!:594)H-I3E0F@NE>2A:I=?ASAQ6*Y:]E!.@<7&1WB1Y-453L[699.VV
MG%IL;[NE7]G55&DMIIJY[8.?O40))S%[%DCM<BKJEJR:#*U:R=-U.5/64YKG
MZ:I<7#)?%,-% _'Y<YKFVY4B03,EW>(_4$L#!!0    ( !!(J5;B 5^8;@,
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M \H%V/VEE.9MXEI:_P=+_P!02P,$%     @ $$BI5HBW*J\5!   6QP  !D
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ME]63K&I'BUWY;.=>:"VR<G,++ %I!YCOUT+HYQW[N*AYGKC\#U!+ P04
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M3D/_I3R(^J?+LR^T;@RB;0RBM^S$VGM?6O>$UM6Z+2?"P5L<M=:70[4=7Y%
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MWG2;'R#'F/SQ!I7.:[TS#FH>4&@FY]IG!+ YI@#J)Z!H H5FLJC]1("<8VK
MJ,VI=#YK=JB$=<G3SN;RO<SNJTWZN;-.CXFJ=VZW9]L? GA7;7]_<O[*N[BN
MM_-KF/K7!6["[#Y*<B>6VP+2/9L7;QY9O6&_/E#IH=K"?I<JE>ZKISL9;F16
M7E"\ODT+@3<'98+V9Q-6_P)02P,$%     @ $$BI5B6.K+4R$0  \N,  !D
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ML8IFXMV9W,T7(G\09]?_^1_F=/#?70D@,8O$;!)S2,PE,8_$?!(+2"R$,"6
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M@]$4#DQ]X^#TI0CC_XR_WHH\B=*NGN<'_3R]TX-V$E#-1C4'U5Q4\U#-1[4
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M4I;Q3*9PF\![D8I\<[AY>'E3K_8.U%93;D3>?3<4"YW81C4'U5Q4\U#-1[4
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MR,_?95GY_)=J@L<L_[;Y=J[_'U!+ P04    "  02*E6#S]\Z3\#  "7"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6R]5EUOTS 4_2M784*;-):O
MMNM&&VD?3$P"4;4,'A /;G+;6#AVL9UVX]=C)VG6=B&PJ>*EC1V?XWO.O;'O
M8"7D#Y4B:KC/&%=#)]5Z<>ZZ*DXQ(^I$+)";-S,A,Z+-4,Y=M9!(D@*4,3?P
MO)Z;$<J=:%#,C60T$+EFE.-(@LJSC,B'2V1B-71\9STQIO-4VPDW&BS('">H
M[Q8C:49NS9+0#+FB@H/$V="Y\,^O?,\"BA5?**[4QC-8*5,A?MC!;3)T/!L1
M,HRUI2#F;XE7R)AE,G'\K$B=>D\+W'Q>L]\4XHV8*5%X)=A7FNATZ/0=2'!&
M<J;'8O4>*T%=RQ<+IHI?6%5K/0?B7&F156 3049Y^4_N*R,V (:G&1!4@& 7
MT/D#(*P 82&TC*R0=4TTB092K$#:U8;-/A3>%&BCAG*;QHF6YBTU.!U]H&1*
M&=4/,$9&-":@!>@4S7")/$>XY1HE*@VC7,:I,0PNYA+19%+#&YB4V0<Q>PIX
MI#Z\1DTH4T<&<3>YAL.#(S@ RN%S*G)%>*(&KC9B;$AN7 5^608>_"'P$#X*
MKE,%[WB"R3;>-2;43@1K)RZ#5L*/1)Y Z!]#X 5A0SQ7_PX/6L()Z\2$!5_X
MU\3<2)'!A#"$3S.XR74NZ^PH^#86C(&IZ!61R?<F&\MM.LW;V%/B7"U(C$/'
M' ,*Y1*=Z/4KO^>];?)@3V1;CG1J1SIM[-%N@2E8D =;AXW54W+U"BY[EBVC
M-Z'O]0;N<E-/PRH_\$_K55N!=NM N\\*M.G3.1S?CBZ.F@)OY7YNOO9$MF5#
MK[:A]W\JN+=/1_9$MN7(:>W(Z3\5!ET7!EM;= Q3G%/.*9^;6XD1'F.3$R5]
M=Z-<@T[8\[H[5=T:Q0LU]FN-_5:-=='CO6DU3,U+C,6<TU^[AW2IJ/]$D>^'
M@;<CJ'7+%PHZJP6=[?'8.7NBI^G8:=WQA7I\[_'*]UY<ALB3O]1@1;YY9@9=
MO^^?[6AL#^*Y(MV-%B=#.2\Z/P6QR+DN[_AZMNXN+XJ>:F?^TG:=1>OT2%.V
MK.8&-Y^@ H8S0^F=G)HLRK(++ =:+(I&:BJT:<N*Q]1TSBCM O-^)H1>#^P&
M=2\>_0902P,$%     @ $$BI5B[[W#Y!"P  J7<  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#(N>&ULM9U;;]LX'L6_"N$=+%J@8^MFQ^DF =KHP@+33C"=
MSCXL]H&Q:%NH+'DH.6X6\^&7NL0R;9JVVC-]:"Q9_/VIYI2WP\O--A=?BR7G
M)?FV2K/B=K LR_7;T:B8+?F*%<-\S3/YS3P7*U;*2[$8%6O!65PG6J4CQ[(F
MHQ5+LL'=37WO0=S=Y)LR33+^($BQ6:V8>'[/TWQ[.[ '+S=^2Q;+LKHQNKM9
MLP7_S,LOZP<AKT8[2IRL>%8D>48$G]\.WMEOJ3>M$M1/_)'P;;'WF52O\ICG
M7ZN+#_'MP*IRQ%,^*RL$DS^>^#U/TXHD\_%G"QWL8E8)]S^_T,/ZY>7+/+*"
MW^?IOY.X7-X.I@,2\SG;I.5O^9;R]H7&%6^6IT7]-]FVSUH#,ML49;YJ$\L<
MK)*L^<F^M?\0>PD<^T0"ITW@'"1PW1,)W#:!>Y# .Y4EKTW@'4:X.I%@W"88
M7QIATB:8'+ZT<R+!59O@ZM*7GK8):KF,FE]'_;OT6<GN;D2^):)Z6M*J#[4@
MZM3R5YADE78_ET)^F\ATY=U]GCUQ42:/*2>?\I(7Y)7/2Y:DQ>N;42D#5(^-
M9BTL:&#."9A-/N99N2Q(D,4\UJ0/S>E=0_J1?+'=VSDO;_?>,0(_Y4]#8KEO
MB&,Y-BF63/!"DZU[,^7763DDCM-2OGSVR:N?7I.?R.@TT;\@7_:D)EH:XFEP
M< '8M0[ ,7LV9S<T4S\R(:EV375[93>Z'.R\@#48:L;X?':,.?G&BI+<W?\3
MMP[AG@SQ6)(/65&*C2RY2_*?7^0#Y$/)5\5_-1E^W] \/:VJD-X6:S;CMP-9
MXQ1<//'!W3__84^L?^GDB83Y2%B A(5(6(2$41!,49ZW4YYGHM\];,1L*6MG
MDL_)C*W7/)8_TI3DZZKR+P@KBGR6L%+>WR;EDLSV2O2L*M%U\C2&["M/),QO
M8),:5C6\GNZ\B57_N1D][4OOT@=#9/8B)(R"8(JLQCM9C<VR$GS-GNNR3 I+
M-H*W3,1$MC=F7V6;=/TBNE*PK&!U.U.G(V.,OCI"POSQD3S&8ZV.F@?'9Q\,
MD=F+D# *@BDZFNQT-#'JZ#Y?K60?I!;.&[)F@CRQ=,/)JR0C<9ZF3!1DS453
M$[\F?YD;(N^-P?H*"@GSD;  "0L;V-6>@JVA9=FJ?"-D2'HNI"*EJYV4KHQ2
M^B);_2)]3K*%K,0Z5=52:A13Z>>T=HSTOMI!PORKHS+&OK[V[.OI05F$#!HB
M81$21D$P1633G<BF1I%];GHL,4\3V4R2C:8R)^625XI;L^SY8K$9H_05&Q+F
M(V$!$A9.C_\;3,9C[Z"BC9 Q*0BF:.UZI[5K<]W8--?OJ^;Z7V2_IM0IRLCJ
MJR@DS$?" B0L1,(B)(R"8(KN;*L;U;.@PQ4M#B0^*,V'T@(H+832(BB-HFBJ
M!/<&EFUCX1=\XV*6R"[D6B2S[^X/F(/T%B:2YK>TJ=)U'-J3@T8=-&@(I450
M&D715,4YG>(<<W6;LJ*H1C.V3 A6#6P((BKO2O9+!5\EFU6EO)DL#]F":\5F
MY/<6&Y+FM[3K_<;3H="0 4,H+8+2*(JF"JWS FSC@*]BFGWF62)UUGAG_H97
M'L2X;NUUSU2UL59O4)< 2O.AM !*"Z&T"$JC*)HJS<XLL#ULPP_J!$!I/I06
M0&DAE!9!:11%4R78&0NVV5FH)9CL)/B&S&4LPE;Y)M.7@E 3 4KSH;3 /C8E
MG*FE-1N@@2,HC:)HJKXZP\$V.PY'^BK*VOU,LI++>"41\E(K-*BY *7Y4%K0
MTO8;B];0\@XUAHP906D415,UUCD1MMF*>!#YC/.X('.1KT@L%?>&9+RV2I.B
MV+!L5HT8%Z6^SPHU(J T'TH+6II2H%W9MK9 @]H14!I%T52Q=8Z$;;8DC@JT
MO2D<+Q?-7%%6)KE6<5 W DKSH;2@I=GVGN1<:^C88_M0<,BX$91&4315<)TM
M89M]B8L%]V-#=U!# TKSH;2@I>W;X:X[M*XGAY*$VA50&D71U'FZG6'A&$>C
MCR4I>,Q7]12W1H5OSHS=F?E]U0:E^5!:T-(,(X$A-& $I5$4315:9TLXYVR)
MV9)E"T[>+03GC=::OFG5N)-2RV;)FJ4O]]J2L>E>Y,J\%*T*H79%2]MO7MG:
MN6D^-&X I8506@2E411-%6/G6#AFQT(GQFV]W$8*CDGAR<*NK81W%2^9IWDN
MOK=2-F>HMT"=8P=L.'$.Q8F,&4!I(90606D415/%V;D<CMGET(FS7,I(RSR-
MJXG!<353+V;/>J%!O8TS61V?RH8/S48 I8506@2E411-U5YG8SC&,6IE5C%Y
MY)70>"O'^.(I>FT,9;Z9=>U-O8-IE_?FS/1N[4%M"R@MA-(B*(VB:*KD.MO"
M.;<@XJ#I5ZVWN60MC9G;NZ2#^A=06@"EA8[&#9EHF[<1-#!%T52A=?Z%<XE_
M<784V4SI+2NH6P&E!5!:V-+V2WWO2BLJJ&&!HJFBZ@P+QVQ8_))GBY]++AJS
M0JLGJ"L!I?E06@"EA<[QX@UG8KE:14%="11-553G2C@7N1*MI\J_K7E6Z$?>
MH.8#E.9#:0&4%CK'RR%<G746M0_N5Y2NKIJDJ/RIBNEL!><"6V'.DG8)H%8K
M4$\ 2O.AM !*"UN:,A+HN(Y6+5!;0!?8&U^K@=4=%;HQ?]<\YO\]TRCEK9<%
M\8+X23&KFNH%>9?%]?H:V:RJ%\57U[_.YUQ4/<>@*;L*\L">F03IA&G.:E]A
M0FD^E!9 :2&4%D%I%$53Y=TY#6XS> S;,@3J'4!I/I060&DAE!9!:11%4R78
M^0NNV5_XDK%5+DO/__&X[A>0N"TQ"9,%Y/D^J!G?6Y+0!1%06M#2]NNYZ;5N
M'A,T; 2E411-5=O>%DGX91%5?2YKZ5Q6UYF^8L;NI(3=2@F[EQ)V,R7L;DK8
M[93^#G/![<P%U\-6S,AA[GLHS8?2 B@MA-(B*(VB:*H$.[/!-9L-X%USS-%Z
M*Q1J04!I04L[L]E-" T:06D415.EU]D/;L_E$\KDS\[@[Z;;54Y8X\0V4U%*
MD2P67&B%"#4MH#0?2@O<XR46]M ]E"%TA0641E$T58:=8>&:#8M+9;@_ST26
M@_*'5G=0<P-*\Z&TP-78$4=]%.A:"RB-HFBJ[#I7PS6[&N_:276MK'ZNML9=
M-QV0T^*"&AQ0F@^E!:[&DC@2%W1=!91&43157)T!XIH-D$^;U:-LM,GJ\G%3
MR.^*XERQ!;5#H#0?2@M:FK+-YJ&PH*LCH#2*HJD[ '=.B6=V2CIAR5JRX+--
MM>'_A56C&=U78U":#Z4%+<VD,6C "$JC*)JJL<ZN\,P+([ZO7Y"R:L$U7^?U
M&HF"I>U\=:T2H08'E.9#:4%+4]=?'^[V&4)C1E :1=%4,7;&A7=F*Z<?&DK^
M?:M=)6N.V5M_4#<#2@N@M!!*BZ TBJ*I.NTL#P][+(0'=3.@-!]*"Z"T$$J+
MH#2*HJD2W#L>PCA4_?>.YYEC]]8KU/J TH*69A[/@X:,H#2*HJDR[!P-K^>N
M3S\TGF<.UEMW4$,#2@N\X_,GCL;SH!$C*(VB:*KL.C?#,[L9WS.>9T;V%A?4
MI(#2 N]X+<31>!XT8@2E411-%5?G47@]/8J^FU*8^;V5!K4EH+2@I9DVI8 &
MC* TBJ*I0NM<":_G#E""_[E)JM,I7M8B;LJB9%E5Q&EU!G4HH#0?2@N\X[40
MMJ,_KPD:.(+2*(K6Z&VT=_[GBHM%?19L0>J9GLUAF;N[N_-FW]6GK![<#^VW
M47-J;(=I#K']R,1""I2D?"Z1UO!*UBFB.1>VN2CS=7W*Z&->EOFJ_KCD+.:B
M>D!^/\_S\N6B"K [G??N_U!+ P04    "  02*E6D&%:F>$"  !2"   &0
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M]X7;<\N%'.&W9=S%YY=Q4,\-A:;+VGAN;-]0_CQ_-@\94)<-BN:#HA$H-%V
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M9:J _'W)>?YVHBK8?WTZ_1=02P,$%     @ $$BI5B"%>C;T!   11D  !D
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M>'YFG]](MLB.O2=,2I9DEW.@(7#=03V?,B8W-WJ \I^3X?]02P,$%     @
M$$BI5LO3("S7!@  _RX  !D   !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL
MO9IK<]HX%(;_BH;M[*0S+6!)-J9+F$G(7OJAVTS3R^Q'!01XZ@LKBR3]]RM?
ML'SCV+CV?DELHW.D1Q?KY46+YT!\#_><2_3BN7YX/=I+>7@WF83K/?=8. X.
MW%>?; /A,:ENQ6X2'@1GFSC(<R=X.K4F'G/\T7(1/[L7RT5PE*[C\WN!PJ/G
M,?'CEKO!\_7(&)T>?')V>QD]F"P7![;C#UQ^.=P+=3?)LFP<C_NA$_A(\.WU
MZ,9XMS+C@+C$5X<_A[EK%*$\!L'WZ.;]YGHTC5K$7;Z640JF_CWQ%7?=*)-J
MQ[]ITE%69Q28OSYE_R.&5S"/+.2KP/WF;.3^>F2/T(9OV=&5GX+GOW@*9$;Y
MUH$;QG_1<UIV.D+K8R@#+PU6+? </_G/7M*.R 5@ZTP 3@-P.< \$T#2 !*#
M)BV+L>Z89,N%")Z1B$JK;-%%W#=QM*)Q_&@8'Z10GSHJ3BX?9+#^CE:!I^9%
MR.*>?8ON;Q\^ANCJCDOFN.%K]>3+PQVZ>O4:O4(3%.Z9X"%R?/3%=V3X1CU4
MUY_WP3%D_B9<3*1J5Y1]LD[;<)NT 9]I T$? E_N0_2[O^&;FO@5'&]@(,%$
M=4C6*_C4*[<8S/B!B3$BQAN$IYC4-0@.O^/K+!P#S2'9()$X'SF3[^^C]\@%
M"K;HXR$:HMH^3E+0^A31V^!=>&!K?CU2RSWDXHF/EK_^8EC3W^KX>DI6H*49
M+86R+S\>92C53'+\'6(2R3U'CWSG^'[T0/7!@0LGV* K->F2J?BZKCN2.LRX
MCNA=]K0D-L4S,EM,GO*D8%LZDIH9J0F2_BF8+WDCBEE!,0R3DNFTA )6UA'%
MRE L$$6]4[?<B6 "@?C+P1'-7%:%ZZV%L6F;)2ZPYHY<LXQK!G+]_L+%V@F;
M8685F/+P@!5UQ+ S#/O2-<7]3;2:HLMV*\JN$%(RH]3$)<YJN?+**R#,,X0Y
MB/"5A]'T4A#1_%(J0-W( #VIQTTMG[=L.=B CB-D3/5./&TSU=BCRYN TDQY
M(FS,Z71*2T1PE5V1<N+" #>N;[&*XINW-T]<*%6(3LL)W0MGK?ZJ7>TAPJR%
M-/K<T?K*5NP)K'L"][6I;0+792*,'B5SH'X*)/79^2DP&\_*[TZX65VQM7 Q
M0*50V.%:<B4)#9Q?K>-(A16YAE HAI8H!JQ1SFYW+2%I%9+8XUGYA02WHBNE
MEB<&K$^*FU]+M*I:*6^$<*U=J;12,6"ITGHO; EL5<?2F(_G=IG::EBP11PM
M4 Q8H33MBRTI9BTIAE QAI8Q!JQCRGMD2SB[TO6$C&EELP3K[LJF]8TQOVRS
M_,0C'R::IBOU]5:PM3PR%WWFPD-7_W"%70_;DXI)^V0(382U)L*P)LJMU3K6
MAF@+_8BZ"6'D)?X 11OVH^[;\ZHA$TTS&=-3JGE-JB*D5DD8U![0"JZ%AK-=
M CV$)L):$V%8$^46<RTG'(U/0V*<0+%UGG0(&82U#,*P@7.SVPF^8Y*C]VHA
M.W[HK-%7YA[KN7MU<OK*5B370@FW-G-J69-H"U +-44,R[3KMTVLM0V&M<VE
MBZY9UL 5=NUI+6LP+&N:5I/5W--#&"U8"QD,"YG8=:YM>D^:(Z4<0L%@K6"P
M_?->+NY)B:3$0^@:K'4-AHV;?OQ<7&/BS.>X8H+"C>D(2[1@(;!0:&GIDJJ!
M4P:!*^H*HD4)@65$%T,W35ET=$UL5M"&T!U$ZP[22G>TX,'-HS2$L""Y'X9@
M?Z4/7S>MHFB/DGEUU&K*%5=@$4)K! )KA)]P=DGU9Y[ZM@]AI! M-D@K(Z6-
MM4NJ0H/:1N4U!U?8%4B+#6(-9^R2GG1&VA-#J!:B50N!54OOQFY:7]ZLL,:S
MLO\)MZHKM58Q!/9A+O=U2?5GH<J<'D*G$*U3"*Q3?M+33;,7'#0U<%89<@A]
M0K4^H:U^9+J(C#:+%;C6KE1:K%!8K/1LZ::UE8>R[,ZGQ<ZNU"*,EB<4EB?]
M&+II)8T,0^@7JO4+A?5+-S\W39KO>'L\+]NY<-5=T7*G6.C_8>?2GI1+VB=#
MZ""J=1"%=5"#&]00;;<R85-0.-4\344R[]!L\G.I%D<4=F(NM)8:LEU$/806
MHEH+T5:'9<Y94 W1)^-Z=N(TR'G0(>0/U?*'PB;.17XN[=7,Z2M;D5R+)-K:
MS*EEG3>ZC#5%#%R_9YI:UIBPK+EPR9G-B@:NL.O!0*UH3%C1-"RE-!KJ9[B"
M2P$FN2/&'A>[^.1UB-;!T9?):>/L:7:Z^R8^TSS1Q9.CX1^84-^/0N3RK0J=
MCF=J&$1RVCJYD<$A/K#\&$@9>/'EGK,-%U$!]?DV".3I)JH@._.^_ ]02P,$
M%     @ $$BI5F]#V1 _ P  & L  !D   !X;"]W;W)K<VAE971S+W-H965T
M-#<N>&ULM99M;],P$(#_BA40VB36Q$Y?TM%&V@L#/@RF5=L^N\VUL9;8Q7;:
M(?'CL9,L#30)ZQ#]4+_>W>/+G7V3K9"/*@;0Z"E-N)HZL=;K4]=5BQA2JGIB
M#=RL+(5,J39#N7+56@*-<J$T<8GG#=V4,NZ$DWSN1H83D>F$<;B12&5I2N6/
M<TC$=NI@YWGBEJUB;2?<<+*F*YB!OEO?2#-R*RT12X$K)CB2L)PZ9_CT'/>M
M0+[CGL%6U?K('F4NQ*,=?(FFCF>)((&%MBJH:39P 4EB-1F.[Z52I[)I!>O]
M9^U7^>'-8>94P85('EBDXZD3."B")<T2?2NVGZ$\T,#J6XA$Y?]H6^[U'+3(
ME!9I*6P(4L:+ECZ5CJ@)^*1%@)0").<N#.64EU33<"+%%DF[VVBSG?RHN;2!
M8]Q^E9F69I49.1W.M%@\H@N1FL^L:.ZH$W0[NU/HZ!(T98DZ+B<FKC;VK)2[
M*'6?%[I)BVX?70NN8X4^\@BBW^5=PUG!DF?8<]*I\)K*'O+Q>T0\XJ.WR$4J
MIA)4V718\"MW^+D%O\7"URR=@T1BV7KD0K[?+&]SZ%2MZ0*FCDD2!7(#3OCN
M#1YZ'SKH^A5=OTM[^"W32E,>,;Y"5",= YK#BG%N)PSS&B03$3IBO/3(,?K9
MZ)OB*(6Q06[,9N\FQ*-A@(/!Q-TT4 XJRD$GY2=)N8:78PSV,8:$]-LPAA7&
ML!/#).T2V"$@PSV0$^SA(,#-(*,*9-0)<@_J$(I1 \4(^V/23!%4%,'+8X='
M*..;@JL,)"B6#H^B8(_7QWCDCT?-O..*=]R9B0_Y?0K1R=D&I'D?T!5E$MW3
M) -T8U)T9H&:>,;_(4&QM[M.O8/<_)<TC4224*GL5.%BZ^O=Q=9XYQ8 0<WA
M02_PZK^6@,6U1P&_.(5?@UB^.:3&V.]AOP6+[+#( 2G]&C"R#S;ND7X+V.[5
MP)W7?CW%7T/E-U*UN6OW6N #GHN&E-]EOHU*V_W'R.SO1>:PY__I7+=6K*0@
M5WE)IM!"9%P7=4LU6Y5]9T6QL]M>U(RF'C!II5 "2R/J]4;F%I)%&58,M%CG
MI<]<:%-(Y=W8E*X@[0:SOA1"/P^L@:H8#G\!4$L#!!0    ( !!(J5;!, R-
M,P,   0+   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;+667V_:,!#
MOXJ535,GK21.($ 'D4J[;GOHAHK:/IOD(%83F]D.=-(^_.PD#9E(,NBT%^)_
M=_>[X\Z^R8Z+)QD#*/2<)DQ.K5BIS85MRS"&E,@>WP#3.RLN4J+T5*QMN1%
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MS<K+'<$Q82I /M]2V;%ZH5[0_#]C_C]02P,$%     @ $$BI5K*=#MO< @
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M-"=+KN];<!QV[:\T8\LR;4?=PD(TH[KV%YA>/VD/JR87$QE=T6S:=%4QL\W
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MVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA])
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M4]9W8Y9__;NXO:>U+IM#/NO^R4\^ 5!+ 0(4 Q0    ( !!(J58'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ $$BI5K'YGA'N    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ $$BI5IE<G",0!@  G"<  !,
M         ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  0
M2*E6R-F:4MP%  #A'@  &               @($-"   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ $$BI5FONKGS'!@  WAP  !@
M         ("!'PX  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0
M   ( !!(J5;8:EU4 P,  !L*   8              " @1P5  !X;"]W;W)K
M<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  02*E6R-C^82T%  !.%@
M&               @(%5&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L!
M A0#%     @ $$BI5G<2>?_K!@  <3,  !@              ("!N!T  'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( !!(J58A!ZPJC 8
M /8;   8              " @=DD  !X;"]W;W)K<VAE971S+W-H965T-BYX
M;6Q02P$"% ,4    "  02*E61,2?CI(/  !<*   &               @(&;
M*P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ $$BI5MRI
MO1%"$P  ?S@  !@              ("!8SL  'AL+W=O<FMS:&5E=',O<VAE
M970X+GAM;%!+ 0(4 Q0    ( !!(J58V,HF%40L  .<C   8
M  " @=M.  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  0
M2*E6::CZ,W4"  !W!0  &0              @(%B6@  >&PO=V]R:W-H965T
M<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( !!(J585C&54)@4  /$-   9
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M970Q-2YX;6Q02P$"% ,4    "  02*E6S$R!D;,"   ;!@  &0
M    @(&OC   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (
M !!(J59W_*$P:@H  #$F   9              " @9F/  !X;"]W;W)K<VAE
M971S+W-H965T,3<N>&UL4$L! A0#%     @ $$BI5K^)>$38 @  6P8  !D
M             ("!.IH  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"
M% ,4    "  02*E6'0H1"DD*  !A'@  &0              @(%)G0  >&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( !!(J584AX0(4 0
M *X*   9              " @<FG  !X;"]W;W)K<VAE971S+W-H965T,C N
M>&UL4$L! A0#%     @ $$BI5A:O; GI @  :0<  !D              ("!
M4*P  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  02*E6
ME0D)O><4   ^0   &0              @(%PKP  >&PO=V]R:W-H965T<R]S
M:&5E=#(R+GAM;%!+ 0(4 Q0    ( !!(J5:*8<FLA (  '8%   9
M      " @8[$  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%
M  @ $$BI5BE<ZWI  P  ^ <  !D              ("!2<<  'AL+W=O<FMS
M:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  02*E6,?LI9BL#  "R!P
M&0              @(' R@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+
M 0(4 Q0    ( !!(J58X,"+OK@(  &L&   9              " @2+.  !X
M;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ $$BI5J<;J&:_
M @  %@8  !D              ("!!]$  'AL+W=O<FMS:&5E=',O<VAE970R
M-RYX;6Q02P$"% ,4    "  02*E6Y3W@+I,$  !(#@  &0
M@(']TP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( !!(
MJ5;A[/S=&@,  & '   9              " @<?8  !X;"]W;W)K<VAE971S
M+W-H965T,CDN>&UL4$L! A0#%     @ $$BI5M9VZP%? P  ) <  !D
M         ("!&-P  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
M    "  02*E6Y2_G/_<"  !9!P  &0              @(&NWP  >&PO=V]R
M:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( !!(J58N$_P>@P<  )Y.
M   9              " @=SB  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
M4$L! A0#%     @ $$BI5N(!7YAN P  B0\  !D              ("!ENH
M 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  02*E6FC)\
M-(H)  #89   &0              @($[[@  >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;%!+ 0(4 Q0    ( !!(J5;G>"61B (  ,T&   9
M  " @?SW  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @
M$$BI5HBW*J\5!   6QP  !D              ("!N_H  'AL+W=O<FMS:&5E
M=',O<VAE970S-BYX;6Q02P$"% ,4    "  02*E6UT,P@Z8$  #>&0  &0
M            @($'_P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4
M Q0    ( !!(J58C:E,\@@,  ,D-   9              " @>0# 0!X;"]W
M;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ $$BI5H*XLWZ7!@
M0D$  !D              ("!G0<! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX
M;6Q02P$"% ,4    "  02*E6)8ZLM3(1  #RXP  &0              @(%K
M#@$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( !!(J58/
M/WSI/P,  )<+   9              " @=0? 0!X;"]W;W)K<VAE971S+W-H
M965T-#$N>&UL4$L! A0#%     @ $$BI5B[[W#Y!"P  J7<  !D
M     ("!2B,! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !!(J59O0]D0/P,  !@+   9              "
M@5M% 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ $$BI
M5L$P#(TS P  ! L  !D              ("!T4@! 'AL+W=O<FMS:&5E=',O
M<VAE970T."YX;6Q02P$"% ,4    "  02*E6HJ#AC2\"  ")!0  &0
M        @($[3 $ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0
M   ( !!(J589ASMN5PX  -_/   9              " @:%. 0!X;"]W;W)K
M<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ $$BI5H[KHS8;!0  &2L
M !D              ("!+UT! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q0
M2P$"% ,4    "  02*E6IXUG2E$$  #;&   &0              @(&!8@$
M>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( !!(J5:RG0[;
MW (  $()   9              " @0EG 0!X;"]W;W)K<VAE971S+W-H965T
M-3,N>&UL4$L! A0#%     @ $$BI5AR."F<Z P  TA,   T
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;72YX;6Q02P4&     #T /0"B$   !W<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>210</ContextCount>
  <ElementCount>304</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CondensedBalanceSheets</Role>
      <ShortName>Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CondensedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Statements of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit</Role>
      <ShortName>Condensed Statements of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CondensedStatementsofCashFlows</Role>
      <ShortName>Condensed Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - The Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/TheCompanyandBasisofPresentation</Role>
      <ShortName>The Company and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Collaborations with Third Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CollaborationswithThirdParties</Role>
      <ShortName>Collaborations with Third Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Inventories, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/Inventoriesnet</Role>
      <ShortName>Inventories, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement</Role>
      <ShortName>Liability Related to the Revenue Interest Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Convertible Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.esperion.com/role/ConvertibleNotes</Role>
      <ShortName>Convertible Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Other Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/OtherAccruedLiabilities</Role>
      <ShortName>Other Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stock Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensation</Role>
      <ShortName>Stock Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Net Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/NetLossPerCommonShare</Role>
      <ShortName>Net Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Statements of Cash Flows and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCash</Role>
      <ShortName>Statements of Cash Flows and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.esperion.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Inventories, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/InventoriesnetTables</Role>
      <ShortName>Inventories, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/Inventoriesnet</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/Investments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/FairValueMeasurements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables</Role>
      <ShortName>Liability Related to the Revenue Interest Purchase Agreement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Other Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/OtherAccruedLiabilitiesTables</Role>
      <ShortName>Other Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/OtherAccruedLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Stock Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationTables</Role>
      <ShortName>Stock Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/StockCompensation</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockholdersDeficitTables</Role>
      <ShortName>Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/StockholdersDeficit</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Net Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/NetLossPerCommonShareTables</Role>
      <ShortName>Net Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/NetLossPerCommonShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Statements of Cash Flows and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables</Role>
      <ShortName>Statements of Cash Flows and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCash</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - The Company and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails</Role>
      <ShortName>The Company and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/TheCompanyandBasisofPresentation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Collaborations with Third Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CollaborationswithThirdPartiesDetails</Role>
      <ShortName>Collaborations with Third Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/CollaborationswithThirdParties</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Inventories, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/InventoriesnetDetails</Role>
      <ShortName>Inventories, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/InventoriesnetTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/CommitmentsandContingencies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Investments - Summary of Cash Equivalents and Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails</Role>
      <ShortName>Investments - Summary of Cash Equivalents and Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails</Role>
      <ShortName>Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails</Role>
      <ShortName>Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.esperion.com/role/ConvertibleNotesDetails</Role>
      <ShortName>Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/ConvertibleNotes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Other Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/OtherAccruedLiabilitiesDetails</Role>
      <ShortName>Other Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/OtherAccruedLiabilitiesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Stock Compensation - Stock Options Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails</Role>
      <ShortName>Stock Compensation - Stock Options Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stock Compensation - Schedule of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails</Role>
      <ShortName>Stock Compensation - Schedule of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Stock Compensation - PBSOs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationPBSOsDetails</Role>
      <ShortName>Stock Compensation - PBSOs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Stock Compensation - RSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationRSUsDetails</Role>
      <ShortName>Stock Compensation - RSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Stock Compensation - PBRSUs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockCompensationPBRSUsDetails</Role>
      <ShortName>Stock Compensation - PBRSUs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/IncomeTaxes</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stockholders' Deficit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockholdersDeficitDetails</Role>
      <ShortName>Stockholders' Deficit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/StockholdersDeficitTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Stockholders' Deficit - Summary of Warrants and Pre-funded Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Deficit - Summary of Warrants and Pre-funded Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/NetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/NetLossPerCommonShareTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="espr-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Statements of Cash Flows and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails</Role>
      <ShortName>Statements of Cash Flows and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockShares in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. espr-20230331.htm 4</Log>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept TreasuryStockMember in us-gaap/2022 used in 4 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. espr-20230331.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: espr:ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount, espr:DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays, espr:PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment -  espr-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="espr-20230331.htm">espr-20230331.htm</File>
    <File>espr-20230331.xsd</File>
    <File>espr-20230331_cal.xml</File>
    <File>espr-20230331_def.xml</File>
    <File>espr-20230331_lab.xml</File>
    <File>espr-20230331_pre.xml</File>
    <File>espr-ex311x03312023.htm</File>
    <File>espr-ex312x03312023.htm</File>
    <File>espr-ex321x03312023.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="527">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "espr-20230331.htm": {
   "axisCustom": 2,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 527,
    "http://xbrl.sec.gov/dei/2022": 29
   },
   "contextCount": 210,
   "dts": {
    "calculationLink": {
     "local": [
      "espr-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "espr-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "espr-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "espr-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "espr-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "espr-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 484,
   "entityCount": 1,
   "hidden": {
    "http://www.esperion.com/20230331": 3,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 8
   },
   "keyCustom": 86,
   "keyStandard": 218,
   "memberCustom": 30,
   "memberStandard": 33,
   "nsprefix": "espr",
   "nsuri": "http://www.esperion.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.esperion.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Inventories, net",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.esperion.com/role/Inventoriesnet",
     "shortName": "Inventories, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.esperion.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Investments",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.esperion.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.esperion.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement",
     "shortName": "Liability Related to the Revenue Interest Purchase Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Convertible Notes",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.esperion.com/role/ConvertibleNotes",
     "shortName": "Convertible Notes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Other Accrued Liabilities",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.esperion.com/role/OtherAccruedLiabilities",
     "shortName": "Other Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Stock Compensation",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.esperion.com/role/StockCompensation",
     "shortName": "Stock Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.esperion.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stockholders' Deficit",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.esperion.com/role/StockholdersDeficit",
     "shortName": "Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.esperion.com/role/CondensedBalanceSheets",
     "shortName": "Condensed Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Net Loss Per Common Share",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.esperion.com/role/NetLossPerCommonShare",
     "shortName": "Net Loss Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Statements of Cash Flows and Restricted Cash",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCash",
     "shortName": "Statements of Cash Flows and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Inventories, net (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.esperion.com/role/InventoriesnetTables",
     "shortName": "Inventories, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Investments (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.esperion.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.esperion.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:ScheduleOfRevenueInterestLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables",
     "shortName": "Liability Related to the Revenue Interest Purchase Agreement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:ScheduleOfRevenueInterestLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Other Accrued Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.esperion.com/role/OtherAccruedLiabilitiesTables",
     "shortName": "Other Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Stock Compensation (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.esperion.com/role/StockCompensationTables",
     "shortName": "Stock Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Stockholders' Deficit (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.esperion.com/role/StockholdersDeficitTables",
     "shortName": "Stockholders' Deficit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical",
     "shortName": "Condensed Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Net Loss Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.esperion.com/role/NetLossPerCommonShareTables",
     "shortName": "Net Loss Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Statements of Cash Flows and Restricted Cash (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables",
     "shortName": "Statements of Cash Flows and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "espr:ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i55f6734ada96468a9b81e77531464725_D20190801-20190831",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "espr:NumberOfStudyPatients",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patient",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - The Company and Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails",
     "shortName": "The Company and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i55f6734ada96468a9b81e77531464725_D20190801-20190831",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "espr:NumberOfStudyPatients",
      "reportCount": 1,
      "unique": true,
      "unitRef": "patient",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "espr:NumberOfSourcesOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "revenue_source",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "espr:NumberOfSourcesOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "revenue_source",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Collaborations with Third Parties (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
     "shortName": "Collaborations with Third Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i437ec51f9da947e4957d1c78257d41ca_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Inventories, net (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.esperion.com/role/InventoriesnetDetails",
     "shortName": "Inventories, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "ia2442189a4e04c14866e4ca5dbe37ae7_D20230327-20230327",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "espr:PotentialProceedsFromPartnerMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.esperion.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "ia2442189a4e04c14866e4ca5dbe37ae7_D20230327-20230327",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "espr:PotentialProceedsFromPartnerMilestonePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Investments - Summary of Cash Equivalents and Short-Term Investments (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails",
     "shortName": "Investments - Summary of Cash Equivalents and Short-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherNonoperatingIncomeExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Investments - Narrative (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.esperion.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "espr:FairValueMeasurementAssetTransfersBetweenLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.esperion.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "espr:FairValueMeasurementAssetTransfersBetweenLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherCostAndExpenseOperating",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCash",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
     "shortName": "Liability Related to the Revenue Interest Purchase Agreement - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "ia380cab0f6c44c18a991dc9247a9f988_D20220101-20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "espr:OneTimePartialCall",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "espr:PaymentsFromRevenueInterestPurchaseAgreement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails",
     "shortName": "Liability Related to the Revenue Interest Purchase Agreement - Summary of Revenue Interest Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "espr:ScheduleOfRevenueInterestLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i60257fb8aa8e4bae83973ec6daf04c7f_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "espr:RevenueInterestLiabilityIncreaseForInterestExpenseRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "icae7497a06dd4ecf932d2ce48689f651_D20201116-20201116",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForDerivativeInstrumentFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Convertible Notes (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.esperion.com/role/ConvertibleNotesDetails",
     "shortName": "Convertible Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "icae7497a06dd4ecf932d2ce48689f651_D20201116-20201116",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForDerivativeInstrumentFinancingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Other Accrued Liabilities (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails",
     "shortName": "Other Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i99ff79bbd6b34af19e4c4f5ffd0dd8bd_I20220531",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Stock Compensation - Stock Options Additional Information (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails",
     "shortName": "Stock Compensation - Stock Options Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i99ff79bbd6b34af19e4c4f5ffd0dd8bd_I20220531",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i914746ebf548485ab38582d5985e0ada_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stock Compensation - Schedule of Stock Options (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails",
     "shortName": "Stock Compensation - Schedule of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i914746ebf548485ab38582d5985e0ada_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Stock Compensation - PBSOs (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.esperion.com/role/StockCompensationPBSOsDetails",
     "shortName": "Stock Compensation - PBSOs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i90499e69e6bd4d118549b0426069e1b5_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i5e9dfbd0c5a54147bd3f860e7e9511c2_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Stock Compensation - RSUs (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.esperion.com/role/StockCompensationRSUsDetails",
     "shortName": "Stock Compensation - RSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i5e9dfbd0c5a54147bd3f860e7e9511c2_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "if882eb7b96d54916b14a19ce79b2ec18_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Stock Compensation - PBRSUs (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
     "shortName": "Stock Compensation - PBRSUs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "if882eb7b96d54916b14a19ce79b2ec18_I20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.esperion.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6e2ffdc00584f51b68b18c17fd34cd7_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Statements of Stockholders' Deficit",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit",
     "shortName": "Condensed Statements of Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6e2ffdc00584f51b68b18c17fd34cd7_I20211231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stockholders' Deficit (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.esperion.com/role/StockholdersDeficitDetails",
     "shortName": "Stockholders' Deficit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i46d8059776cc44b2bb584005f975602b_D20230319-20230319",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "espr:SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Stockholders' Deficit - Summary of Warrants and Pre-funded Warrants Outstanding (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails",
     "shortName": "Stockholders' Deficit - Summary of Warrants and Pre-funded Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Net Loss Per Common Share (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.esperion.com/role/NetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "id6505e18f8b44bb1be4b3c88b659408a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Statements of Cash Flows and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails",
     "shortName": "Statements of Cash Flows and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i99f951895edd442e82a9307c2fd15632_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.esperion.com/role/CondensedStatementsofCashFlows",
     "shortName": "Condensed Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - The Company and Basis of Presentation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.esperion.com/role/TheCompanyandBasisofPresentation",
     "shortName": "The Company and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.esperion.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Collaborations with Third Parties",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.esperion.com/role/CollaborationswithThirdParties",
     "shortName": "Collaborations with Third Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "espr-20230331.htm",
      "contextRef": "i4e6f5efb7b3c4a94a8943a2bac6cc208_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 67,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.esperion.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "espr_AccruedClinicalDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle, if longer).",
        "label": "Accrued Clinical Development Costs, Current",
        "terseLabel": "Accrued clinical development costs"
       }
      }
     },
     "localname": "AccruedClinicalDevelopmentCostsCurrent",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities and Employee-related Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "totalLabel": "Total other accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets",
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AccruedVariableConsiderationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities for co-pay assistance, expected product returns, rebates, and distributor fees",
        "label": "Accrued Variable Consideration, Current",
        "terseLabel": "Accrued variable consideration"
       }
      }
     },
     "localname": "AccruedVariableConsiderationCurrent",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional cash payment to the Company upon grant of marketing authorization dependent on the range of relative risk reduction in the CLEAR outcomes study.",
        "label": "Additional Cash Payment To Be Received Upon Grant Of Marketing Authorization",
        "terseLabel": "Additional cash payment to the Company upon grant of marketing authorization"
       }
      }
     },
     "localname": "AdditionalCashPaymentToBeReceivedUponGrantOfMarketingAuthorization",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of potential future revenue which may be received under the terms of the agreement conditional upon achievement of specified total development and sales milestones.",
        "label": "Aggregate Amount of Potential Future Revenue, Total Development and Sales Milestones",
        "terseLabel": "Potential additional future payments"
       }
      }
     },
     "localname": "AggregateAmountOfPotentialFutureRevenueTotalDevelopmentAndSalesMilestones",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the subsequent installment which is subject to the achievement of the Sales Threshold as defined in the Revenue Interest Purchase Agreement.",
        "label": "Amount of Subsequent Installment, Subject to Achievement of Sales Threshold",
        "terseLabel": "Amount of subsequent installment, subject to achievement of sales threshold"
       }
      }
     },
     "localname": "AmountOfSubsequentInstallmentSubjectToAchievementOfSalesThreshold",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AmountOfSubsequentInstallmentSubjectToRegulatoryApproval": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the subsequent installment which is subject to regulatory approval.",
        "label": "Amount of Subsequent Installment, Subject to Regulatory Approval",
        "terseLabel": "Amount of subsequent installment, subject to regulatory approval"
       }
      }
     },
     "localname": "AmountOfSubsequentInstallmentSubjectToRegulatoryApproval",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the subsequent installment, subject to the terms and conditions of the Revenue Interest Purchase Agreement.",
        "label": "Amount of Subsequent Installment, Subject to Revenue Interest Purchase Agreement Terms and Conditions",
        "terseLabel": "Total amount of subsequent installment, subject to RIPA terms and conditions"
       }
      }
     },
     "localname": "AmountOfSubsequentInstallmentSubjectToRevenueInterestPurchaseAgreementTermsAndConditions",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_AtTheMarketProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At The Market Program",
        "label": "At The Market Program [Member]",
        "terseLabel": "At The Market Program"
       }
      }
     },
     "localname": "AtTheMarketProgramMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold",
        "label": "Blocked Account Deposit Amount If Specified Net Revenue Does Not Meet Threshold",
        "terseLabel": "Company deposit value in blocked account"
       }
      }
     },
     "localname": "BlockedAccountDepositAmountIfSpecifiedNetRevenueDoesNotMeetThreshold",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_CappedCallMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capped Call",
        "label": "Capped Call [Member]",
        "terseLabel": "Capped Call"
       }
      }
     },
     "localname": "CappedCallMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_CardiovascularRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular Risk",
        "label": "Cardiovascular Risk [Member]",
        "terseLabel": "Cardiovascular Risk"
       }
      }
     },
     "localname": "CardiovascularRiskMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular Risk Outcome Greater Than Fifteen But Less Than Twenty Percent",
        "label": "Cardiovascular Risk Outcome Greater Than Fifteen But Less Than Twenty Percent [Member]",
        "terseLabel": "Cardiovascular Risk Outcome Less than Twenty Percent"
       }
      }
     },
     "localname": "CardiovascularRiskOutcomeGreaterThanFifteenButLessThanTwentyPercentMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_CardiovascularRiskOutcomeGreaterThanTwentyPercentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular Risk Outcome Greater Than Twenty Percent",
        "label": "Cardiovascular Risk Outcome Greater Than Twenty Percent [Member]",
        "terseLabel": "Cardiovascular Risk Outcome Greater than Twenty Percent"
       }
      }
     },
     "localname": "CardiovascularRiskOutcomeGreaterThanTwentyPercentMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_CashPaymentToBeReceivedUponCertainCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Payment To Be Received Upon Certain Commercial Milestones",
        "label": "Cash Payment To Be Received Upon Certain Commercial Milestones",
        "terseLabel": "Cash payment to be received upon certain commercial milestones"
       }
      }
     },
     "localname": "CashPaymentToBeReceivedUponCertainCommercialMilestones",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_CashPaymentToBeReceivedUponFirstCommercialSales": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash payment to the Company upon first commercial sales in the DSE Territory.",
        "label": "Cash Payment to be Received upon First Commercial Sales",
        "terseLabel": "Cash payment to the Company upon first commercial sales in the DSE Territory"
       }
      }
     },
     "localname": "CashPaymentToBeReceivedUponFirstCommercialSales",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant Or Right, Additional Consideration Of Warrants Or Rights",
        "label": "Class of Warrant Or Right, Additional Consideration Of Warrants Or Rights",
        "terseLabel": "Additional consideration (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAdditionalConsiderationOfWarrantsOrRights",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Additional Consideration",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights, Additional Consideration",
        "terseLabel": "Additional consideration per amended warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsAdditionalConsideration",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "espr_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage",
        "label": "Class Of Warrant Or Right, Exercise Price Of Warrants Or Rights, Premium Percentage",
        "terseLabel": "Class of warrant or right, premium percentage"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsPremiumPercentage",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercised",
        "label": "Class of Warrant or Right, Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "espr_ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Purchase Price Of Warrants Or Rights",
        "label": "Class of Warrant or Right, Purchase Price Of Warrants Or Rights",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightPurchasePriceOfWarrantsOrRights",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "espr_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_CollaborativeArrangementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Collaborations with Third Parties",
        "terseLabel": "Collaborations with Third Parties"
       }
      }
     },
     "localname": "CollaborativeArrangementAbstract",
     "nsuri": "http://www.esperion.com/20230331",
     "xbrltype": "stringItemType"
    },
    "espr_CommonStockAndAccompanyingWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock And Accompanying Warrant",
        "label": "Common Stock And Accompanying Warrant [Member]",
        "terseLabel": "Common Stock And Accompanying Warrant"
       }
      }
     },
     "localname": "CommonStockAndAccompanyingWarrantMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_CommonStockIssuanceCostsIncurredNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issuance Costs Incurred, Not Yet Paid",
        "label": "Common Stock Issuance Costs Incurred, Not Yet Paid",
        "terseLabel": "Common stock issuance, warrant, and pre-funded warrant issuance costs not yet paid"
       }
      }
     },
     "localname": "CommonStockIssuanceCostsIncurredNotYetPaid",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_CommonStockPurchasableUnderPrefundedWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Purchasable Under Prefunded Warrants",
        "label": "Common Stock Purchasable Under Prefunded Warrants",
        "terseLabel": "Common stock purchasable under prefunded warrants (in shares)"
       }
      }
     },
     "localname": "CommonStockPurchasableUnderPrefundedWarrants",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "espr_CommonStockPurchasableUnderWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Purchasable Under Warrants",
        "label": "Common Stock Purchasable Under Warrants",
        "terseLabel": "Common stock purchasable under warrants (in shares)"
       }
      }
     },
     "localname": "CommonStockPurchasableUnderWarrants",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "espr_ConcentrationRiskNumberOfMajorCustomers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of the Company's major customers.",
        "label": "Concentration Risk, Number of Major Customers",
        "terseLabel": "Number of major customers"
       }
      }
     },
     "localname": "ConcentrationRiskNumberOfMajorCustomers",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "espr_ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consecutive number of months sales must be at or above the milestone amount.",
        "label": "Consecutive Number of Months Sales Must Be At or Above Milestone Amount",
        "terseLabel": "Consecutive number of months sales must be at or above milestone amount"
       }
      }
     },
     "localname": "ConsecutiveNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "espr_ConvertibleSeniorNotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Senior Notes Due 2025",
        "label": "Convertible Senior Notes Due 2025 [Member]",
        "terseLabel": "Convertible Senior Notes Due 2025"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesDue2025Member",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_DaiichiSankyoCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Daiichi Sankyo Co. Ltd",
        "label": "Daiichi Sankyo Co. Ltd [Member]",
        "terseLabel": "Daiichi Sankyo Co. Ltd"
       }
      }
     },
     "localname": "DaiichiSankyoCoLtdMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_DaiichiSankyoEuropeGmbhMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member stands for the Daiichi Sankyo Europe GmbH (\"DSE\").",
        "label": "Daiichi Sankyo Europe Gmbh [Member]",
        "terseLabel": "Daiichi Sankyo Europe GmbH (\"DSE\")"
       }
      }
     },
     "localname": "DaiichiSankyoEuropeGmbhMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price",
        "label": "Debt Instrument, Convertible, Threshold Percentage Of Last Reported Sale Price",
        "terseLabel": "Debt instrument, convertible, threshold percentage of last reported sale price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfLastReportedSalePrice",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_DebtInstrumentCovenantRequiredAmountOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Required Amount Outstanding",
        "label": "Debt Instrument, Covenant, Required Amount Outstanding",
        "terseLabel": "Debt instrument, required amount outstanding"
       }
      }
     },
     "localname": "DebtInstrumentCovenantRequiredAmountOutstanding",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor",
        "label": "Debt Instrument, Exchange Agreement, Conversion, Weighted Average Price Per Share Floor",
        "terseLabel": "Exchange Agreement, weighted average price per share floor (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentExchangeAgreementConversionWeightedAveragePricePerShareFloor",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "espr_DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days",
        "label": "Debt Instrument, Exchange Agreement, Convertible, Threshold Trading Days",
        "terseLabel": "Exchange Agreement, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentExchangeAgreementConvertibleThresholdTradingDays",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "espr_DeferredUpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Up-Front Payment",
        "label": "Deferred Up-Front Payment",
        "terseLabel": "Deferred up-front payment"
       }
      }
     },
     "localname": "DeferredUpFrontPayment",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_EigerIiiSaLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to revenue interest purchase agreement (\"RIPA\") with Oberland.",
        "label": "Eiger Iii Sa Llc [Member]",
        "terseLabel": "Oberland"
       }
      }
     },
     "localname": "EigerIiiSaLlcMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_EmployeeStockPurchasePlanDurationOfOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The duration of offering periods in which employees may purchase stock, , in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Employee Stock Purchase Plan, Duration of Offering Period",
        "terseLabel": "Duration of offering periods"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanDurationOfOfferingPeriod",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to an employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Amount of maximum annual contributions per employee"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to an employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum annual contributions per employee, as a percentage of base salary"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_EmployeeStockPurchasePlanPercentageDiscountOnShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The discount at which shares may be purchased under the employee stock purchase plan, calculated as a stated percentage of the lesser of the closing price of the Company's common stock on the NASDAQ Global Select Market (i) on the first trading day of the offering period or (ii) the last day of any offering period.",
        "label": "Employee Stock Purchase Plan, Percentage Discount on Shares",
        "terseLabel": "Purchase discount"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanPercentageDiscountOnShares",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_ExclusiveDevelopmentalActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to exclusive developmental activities.",
        "label": "Exclusive Developmental Activities [Member]",
        "terseLabel": "Exclusive Developmental Activities"
       }
      }
     },
     "localname": "ExclusiveDevelopmentalActivitiesMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_FairValueMeasurementAssetTransfersBetweenLevels": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the transfer of assets between the levels of fair value hierarchy that have taken place during the period.",
        "label": "Fair Value Measurement Asset Transfers between Levels",
        "terseLabel": "Transfer of assets between levels"
       }
      }
     },
     "localname": "FairValueMeasurementAssetTransfersBetweenLevels",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of potential future payment which becomes due with the achievement of the primary MACE in the CLEAR Outcomes study and the CV risk reduction rate on the U.S. label, depending on the range of relative risk reduction in the CLEAR Outcomes study.",
        "label": "Future Payment Milestone, Achievement of Drug Trial Outcomes Studies",
        "terseLabel": "Milestone payment, achievement of the primary MACE in the CLEAR Outcomes study and CV risk reduction rate on the U.S. label"
       }
      }
     },
     "localname": "FuturePaymentMilestoneAchievementOfDrugTrialOutcomesStudies",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of a potential future payment which becomes due with the first National Health Insurance price listing for NEXLETOL in the Otsuka Territory.",
        "label": "Future Payment Milestone, First National Health Insurance Price Listing, Otsuka Territory",
        "terseLabel": "Milestone payment, first NHI Price Listing for NEXLETOL in the Otsuka Territory"
       }
      }
     },
     "localname": "FuturePaymentMilestoneFirstNationalHealthInsurancePriceListingOtsukaTerritory",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of a potential future payment which becomes due with the submission of a Japanese New Drug Application (JNDA). in the Otsuka Territory.",
        "label": "Future Payment Milestone, First Submission of Japanese New Drug Application, Otsuka Territory",
        "terseLabel": "Milestone payment, first JNDA submissions"
       }
      }
     },
     "localname": "FuturePaymentMilestoneFirstSubmissionOfJapaneseNewDrugApplicationOtsukaTerritory",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_FuturePaymentMilestoneSalesMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of potential future payments related to total net sales achievements for Otsuka in Japan.",
        "label": "Future Payment Milestone, Sales Milestones",
        "terseLabel": "Milestone payments related to total net sales achievements"
       }
      }
     },
     "localname": "FuturePaymentMilestoneSalesMilestones",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_FutureUpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Up-Front Payment",
        "label": "Future Up-Front Payment",
        "terseLabel": "Consideration cash payment"
       }
      }
     },
     "localname": "FutureUpFrontPayment",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_GrossProceedsFromRevenueInterestPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a revenue interest purchase agreement.",
        "label": "Gross Proceeds from Revenue Interest Purchase Agreement",
        "terseLabel": "Gross proceeds from revenue interest liability"
       }
      }
     },
     "localname": "GrossProceedsFromRevenueInterestPurchaseAgreement",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_HypotheticalRepaymentObligationBasedOnSalesGenerated": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hypothetical Repayment Obligation Based On Sales Generated",
        "label": "Hypothetical Repayment Obligation Based On Sales Generated",
        "terseLabel": "Hypothetical repayment obligation"
       }
      }
     },
     "localname": "HypotheticalRepaymentObligationBasedOnSalesGenerated",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_HypotheticalSalesGeneratedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hypothetical Sales Generated Amount",
        "label": "Hypothetical Sales Generated Amount",
        "terseLabel": "Hypothetical sales generated amount"
       }
      }
     },
     "localname": "HypotheticalSalesGeneratedAmount",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_LiabilityFromSaleOfFutureRevenuesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Liability from Sale of Future Revenues [Line Items]",
        "terseLabel": "Liability Related to the Revenue Interest Purchase Agreement"
       }
      }
     },
     "localname": "LiabilityFromSaleOfFutureRevenuesLineItems",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_LiabilityFromSaleOfFutureRevenuesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability From Sale Of Future Revenues",
        "label": "Liability From Sale Of Future Revenues [Roll Forward]",
        "terseLabel": "Liability From Sale Of Future Revenues [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityFromSaleOfFutureRevenuesRollForward",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_LiabilityFromSaleOfFutureRevenuesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about liabilities from the sale of future royalty revenues.",
        "label": "Liability from Sale of Future Revenues [Table]",
        "terseLabel": "Liability from Sale of Future Revenues [Table]"
       }
      }
     },
     "localname": "LiabilityFromSaleOfFutureRevenuesTable",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition.",
        "label": "Liability Related to the Revenue Interest Purchase Agreement",
        "terseLabel": "Liability Related to the Revenue Interest Purchase Agreement"
       }
      }
     },
     "localname": "LiabilityRelatedToRevenueInterestPurchaseAgreementAbstract",
     "nsuri": "http://www.esperion.com/20230331",
     "xbrltype": "stringItemType"
    },
    "espr_LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of liabilities related to the Revenue Interest Purchase Agreement entered into by the Company with Eiger III SA LLC (\"Oberland\").",
        "label": "Liability Related to The Revenue Interest Purchase Agreement [Text Block]",
        "terseLabel": "Liability Related to the Revenue Interest Purchase Agreement"
       }
      }
     },
     "localname": "LiabilityRelatedToRevenueInterestPurchaseAgreementTextBlock",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "espr_MilestoneAmountForWorldwideSalesToReceiveThirdPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone amount for worldwide sales to receive the Third Payment.",
        "label": "Milestone Amount for Worldwide Sales to Receive Third Payment",
        "terseLabel": "Milestone amount for worldwide sales to receive the third payment"
       }
      }
     },
     "localname": "MilestoneAmountForWorldwideSalesToReceiveThirdPayment",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021.",
        "label": "Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate",
        "terseLabel": "Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2021"
       }
      }
     },
     "localname": "MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRate",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold",
        "label": "Minimum Amount of Annual Net Sales To Qualify for Reduced Revenue Interest Rate, Contingent Threshold",
        "terseLabel": "Minimum amount of annual net sales to qualify for reduced revenue interest rate by December 31, 2024, contingent on 100% invested capital received"
       }
      }
     },
     "localname": "MinimumAmountOfAnnualNetSalesToQualifyForReducedRevenueInterestRateContingentThreshold",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_NetSalesThresholdAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Threshold",
        "label": "Net Sales Threshold [Axis]",
        "terseLabel": "Net Sales Threshold [Axis]"
       }
      }
     },
     "localname": "NetSalesThresholdAxis",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_NetSalesThresholdDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Threshold",
        "label": "Net Sales Threshold [Domain]",
        "terseLabel": "Net Sales Threshold [Domain]"
       }
      }
     },
     "localname": "NetSalesThresholdDomain",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_NetSalesThresholdOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Threshold One",
        "label": "Net Sales Threshold One [Member]",
        "terseLabel": "Net Sales Less Than $250 Million"
       }
      }
     },
     "localname": "NetSalesThresholdOneMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Threshold To Include Worldwide Sales In Covered Territory",
        "label": "Net Sales Threshold To Include Worldwide Sales In Covered Territory",
        "terseLabel": "Maximum amount of US net sales to qualify for the Covered Territory expansion to include worldwide sales by December 31, 2021"
       }
      }
     },
     "localname": "NetSalesThresholdToIncludeWorldwideSalesInCoveredTerritory",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_NetSalesThresholdTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Sales Threshold Two",
        "label": "Net Sales Threshold Two [Member]",
        "terseLabel": "Net Sales Greater Than $250 Million But Less Than $350 Million"
       }
      }
     },
     "localname": "NetSalesThresholdTwoMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_NonCashInterestExpenseRelatedToRevenueInterestLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-cash expense included in interest expense associated with the revenue interest liability.",
        "label": "Non Cash Interest Expense Related to Revenue Interest Liability",
        "terseLabel": "Non-cash interest expense related to the revenue interest liability"
       }
      }
     },
     "localname": "NonCashInterestExpenseRelatedToRevenueInterestLiability",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_NonCashRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the difference between the lease asset and the lease liability.",
        "label": "Non Cash Right Of Use Asset",
        "terseLabel": "Non cash right of use asset"
       }
      }
     },
     "localname": "NonCashRightOfUseAsset",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_NumberOfBusinessDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Business Days",
        "label": "Number Of Business Days",
        "terseLabel": "Number of business days"
       }
      }
     },
     "localname": "NumberOfBusinessDays",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "espr_NumberOfConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Consecutive Trading Days",
        "label": "Number Of Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days"
       }
      }
     },
     "localname": "NumberOfConsecutiveTradingDays",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "espr_NumberOfSourcesOfRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Sources Of Revenue",
        "label": "Number Of Sources Of Revenue",
        "terseLabel": "Number of revenue sources"
       }
      }
     },
     "localname": "NumberOfSourcesOfRevenue",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "espr_NumberOfStudyPatients": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Study Patients",
        "label": "Number Of Study Patients",
        "terseLabel": "Study patients enrolled"
       }
      }
     },
     "localname": "NumberOfStudyPatients",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "espr_OneTimePartialCall": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Time Partial Call",
        "label": "One Time Partial Call",
        "terseLabel": "One time partial call"
       }
      }
     },
     "localname": "OneTimePartialCall",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_OtsukaPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Otsuka Pharmaceutical Co, Ltd.",
        "label": "Otsuka Pharmaceutical Co Ltd [Member]",
        "terseLabel": "Otsuka Pharmaceutical Co, Ltd."
       }
      }
     },
     "localname": "OtsukaPharmaceuticalCoLtdMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_PaymentsFromRevenueInterestPurchaseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from a revenue interest purchase agreement.",
        "label": "Payments From Revenue Interest Purchase Agreement",
        "negatedLabel": "Payments on revenue interest liability",
        "negatedTerseLabel": "Revenue Interests payments"
       }
      }
     },
     "localname": "PaymentsFromRevenueInterestPurchaseAgreement",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_PercentageOfCumulativePurchaserPaymentsGuarantee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Cumulative Purchaser Payments, Guarantee",
        "label": "Percentage Of Cumulative Purchaser Payments, Guarantee",
        "terseLabel": "Percentage of cumulative purchaser payments"
       }
      }
     },
     "localname": "PercentageOfCumulativePurchaserPaymentsGuarantee",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of increase in the Royalty Rate upon drawdown of the Third Payment.",
        "label": "Percentage of Increase in Royalty Rate Upon Drawdown of Third Payment",
        "terseLabel": "Percentage of increase in royalty rate upon drawdown of third payment"
       }
      }
     },
     "localname": "PercentageOfIncreaseInRoyaltyRateUponDrawdownOfThirdPayment",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate.",
        "label": "Percentage of Invested Capital Received By December 31, 2024, To Qualify For Second Reduced Revenue Interest Rate",
        "terseLabel": "Percentage of invested capital received by December 31, 2024, to qualify for second reduced revenue interest rate"
       }
      }
     },
     "localname": "PercentageOfInvestedCapitalReceivedByDecember312024ToQualifyForSecondReducedRevenueInterestRate",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage",
        "label": "Percentage Of Revenue Interest Payments Received By December 31, 2024, To Qualify For Third Payment Applicable Percentage",
        "terseLabel": "Percentage of revenue interest payments to qualify for third payment applicable percentage"
       }
      }
     },
     "localname": "PercentageOfRevenueInterestPaymentsReceivedByDecember312024ToQualifyForThirdPaymentApplicablePercentage",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue interests payment on which agreement terminates.",
        "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates",
        "terseLabel": "Percentage of revenue interests payment on which agreement terminates"
       }
      }
     },
     "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminates",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Revenue Interests Payment on Which Agreement Terminates, After Third Anniversary",
        "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates, After Third Anniversary",
        "terseLabel": "Percentage of revenues interests payment on which agreement terminates, after third anniversary"
       }
      }
     },
     "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversary",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised.",
        "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates After the Third Anniversary Of Closing Date If Put Option Is Exercised",
        "terseLabel": "Percentage of revenue interests payment on which agreement terminates, after the third anniversary of the closing date, if put option is exercised"
       }
      }
     },
     "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesAfterThirdAnniversaryOfClosingDateIfPutOptionIsExercised",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised.",
        "label": "Percentage Of Revenue Interests Payment on Which Agreement Terminates Prior to the Third Anniversary Of Closing Date If Put Option Is Exercised",
        "terseLabel": "Percentage of revenue interests payment on which agreement terminates, prior to the third anniversary of the closing date, if put option is exercised"
       }
      }
     },
     "localname": "PercentageOfRevenueInterestsPaymentOnWhichAgreementTerminatesPriorToThirdAnniversaryOfClosingDateIfPutOptionIsExercised",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRiskReduction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Of Risk Reduction",
        "label": "Percentage Of Risk Reduction",
        "terseLabel": "Percentage of risk reduction"
       }
      }
     },
     "localname": "PercentageOfRiskReduction",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PercentageOfRoyaltiesToBeReceivedOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of royalties to be received on net sales.",
        "label": "Percentage of Royalties to be Received on Net Sales",
        "terseLabel": "Percentage of royalties to be received on the net sales"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesToBeReceivedOnNetSales",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_PotentialProceedsFromPartnerMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Proceeds From Partner Milestone Payments",
        "label": "Potential Proceeds From Partner Milestone Payments",
        "terseLabel": "Partner milestone payments"
       }
      }
     },
     "localname": "PotentialProceedsFromPartnerMilestonePayments",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_PreFundedWarrantAndAccompanyingWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Warrant And Accompanying Warrant",
        "label": "Pre Funded Warrant And Accompanying Warrant [Member]",
        "terseLabel": "Pre Funded Warrant And Accompanying Warrant"
       }
      }
     },
     "localname": "PreFundedWarrantAndAccompanyingWarrantMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_PreFundedWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre Funded Warrant",
        "label": "Pre Funded Warrant [Member]",
        "terseLabel": "Pre Funded Warrant"
       }
      }
     },
     "localname": "PreFundedWarrantMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_PrepaidClinicalDevelopmentCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of consideration paid in advance for clinical development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Clinical Development Costs, Current",
        "terseLabel": "Prepaid clinical development costs"
       }
      }
     },
     "localname": "PrepaidClinicalDevelopmentCostsCurrent",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_ProceedsFromRevenueInterestPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Revenue Interest Purchase Agreement",
        "label": "Proceeds from Revenue Interest Purchase Agreement",
        "terseLabel": "Proceeds from Revenue Interest Purchase Agreement"
       }
      }
     },
     "localname": "ProceedsFromRevenueInterestPurchaseAgreement",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchaser Discounts And Commissions And Offering Expenses Payable",
        "label": "Purchaser Discounts And Commissions And Offering Expenses Payable [Member]",
        "terseLabel": "Purchaser Discounts And Commissions And Offering Expenses Payable"
       }
      }
     },
     "localname": "PurchaserDiscountsAndCommissionsAndOfferingExpensesPayableMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_RIPAAmendmentToTheSecurityAgreementAndWaiverMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RIPA Amendment To The Security Agreement And Waiver",
        "label": "RIPA Amendment To The Security Agreement And Waiver [Member]",
        "terseLabel": "RIPA Amendment To The Security Agreement And Waiver"
       }
      }
     },
     "localname": "RIPAAmendmentToTheSecurityAgreementAndWaiverMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_RelativeRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Relative Risk",
        "label": "Relative Risk [Member]",
        "terseLabel": "Relative Risk"
       }
      }
     },
     "localname": "RelativeRiskMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_RevenueInterestLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the current and non-current portion of the Revenue Interest Liability.",
        "label": "Revenue Interest Liability",
        "periodEndLabel": "Revenue interest liability, ending balance",
        "periodStartLabel": "Revenue interest liability, beginning balance",
        "terseLabel": "Revenue interest liability"
       }
      }
     },
     "localname": "RevenueInterestLiability",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to Revenue Interest Purchase Agreement (\"RIPA\"), classified as current.",
        "label": "Revenue Interest Liability, Current",
        "verboseLabel": "Revenue interest liability"
       }
      }
     },
     "localname": "RevenueInterestLiabilityCurrent",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestLiabilityIncreaseForInterestExpenseRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase in the revenue interest liability attributable to interest expense recognized during the period.",
        "label": "Revenue Interest Liability, Increase for Interest Expense Recognized",
        "terseLabel": "Interest expense recognized"
       }
      }
     },
     "localname": "RevenueInterestLiabilityIncreaseForInterestExpenseRecognized",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability related to Revenue Interest Purchase Agreement (\"RIPA\"), classified as noncurrent.",
        "label": "Revenue Interest Liability, NonCurrent",
        "terseLabel": "Revenue interest liability"
       }
      }
     },
     "localname": "RevenueInterestLiabilityNoncurrent",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestPaymentsRedemptionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Payments, Redemption Percentage",
        "label": "Revenue Interest Payments, Redemption Percentage",
        "terseLabel": "Redemption percentage"
       }
      }
     },
     "localname": "RevenueInterestPaymentsRedemptionPercentage",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_RevenueInterestPaymentsRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Payments, Redemption Value",
        "label": "Revenue Interest Payments, Redemption Value",
        "terseLabel": "Redemption amount"
       }
      }
     },
     "localname": "RevenueInterestPaymentsRedemptionValue",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestPaymentsRemainingRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Payments, Remaining Redemption Value",
        "label": "Revenue Interest Payments, Remaining Redemption Value",
        "terseLabel": "Remaining redemption amount"
       }
      }
     },
     "localname": "RevenueInterestPaymentsRemainingRedemptionValue",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestPurchaseAgreementAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest Purchase Agreement Amendment",
        "label": "Revenue Interest Purchase Agreement Amendment [Member]",
        "terseLabel": "RIPA Amendment"
       }
      }
     },
     "localname": "RevenueInterestPurchaseAgreementAmendmentMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of effective annual imputed interest rate under the revenue interest purchase agreement.",
        "label": "Revenue Interest Purchase Agreement, Effective Annual Imputed Interest Rate",
        "terseLabel": "Effective annual imputed interest rate (as a percent)"
       }
      }
     },
     "localname": "RevenueInterestPurchaseAgreementEffectiveAnnualImputedInterestRate",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_RevenueInterestPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to revenue interest purchase agreement (\"RIPA\").",
        "label": "Revenue Interest Purchase Agreement [Member]",
        "terseLabel": "Revenue Interest Purchase Agreement (RIPA)"
       }
      }
     },
     "localname": "RevenueInterestPurchaseAgreementMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_RevenueInterestRateInitialRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The initial revenue interest rate, as a percentage of the Company's net sales in the Covered Territory.",
        "label": "Revenue Interest Rate, Initial Rate",
        "terseLabel": "Initial revenue interest rate"
       }
      }
     },
     "localname": "RevenueInterestRateInitialRate",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_RevenueInterestRateTierThree": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Revenue Interest Rate which will take effect if annual net sales equals or exceeds the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024.",
        "label": "Revenue Interest Rate, Tier Three",
        "terseLabel": "Revenue interest rate if annual net sales equal or exceed the Sales Threshold and if the Purchasers receive 100% of their invested capital by December 31, 2024"
       }
      }
     },
     "localname": "RevenueInterestRateTierThree",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_RevenueInterestRateTierTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Revenue Interest Rate which will take effect if annual net sales equal or exceed $350.0 million by December 31, 2021.",
        "label": "Revenue Interest Rate, Tier Two",
        "terseLabel": "Revenue interest rate which will take effect if annual net sales equals or exceeds the sales threshold by December 31, 2021"
       }
      }
     },
     "localname": "RevenueInterestRateTierTwo",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "espr_RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months",
        "label": "Revenue Interest, Repayment Obligation Amount Expected In Next Twelve Months",
        "terseLabel": "Repayment amount expected to pay in next twelve months"
       }
      }
     },
     "localname": "RevenueInterestRepaymentObligationAmountExpectedInNextTwelveMonths",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RevenueInterestsPaymentOnWhichAgreementTerminates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Interests Payment On Which Agreement Terminates",
        "label": "Revenue Interests Payment On Which Agreement Terminates",
        "terseLabel": "Cumulative purchaser payment adjustment"
       }
      }
     },
     "localname": "RevenueInterestsPaymentOnWhichAgreementTerminates",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_RoyaltyRevenueAndProductSalesBulkTabletsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Revenue And Product Sales Bulk Tablets",
        "label": "Royalty Revenue And Product Sales Bulk Tablets [Member]",
        "terseLabel": "Royalty revenue and product sales bulk tablets"
       }
      }
     },
     "localname": "RoyaltyRevenueAndProductSalesBulkTabletsMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_SaleOfStockAuthorizedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Authorized Amount",
        "label": "Sale Of Stock, Authorized Amount",
        "terseLabel": "Aggregate offering price shares"
       }
      }
     },
     "localname": "SaleOfStockAuthorizedAmount",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of reconciliation of cash and cash equivalents and restricted cash presented on the Condensed Balance Sheets to the same amounts presented on the Condensed Statements of Cash Flows.",
        "label": "Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash and Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "espr_ScheduleOfRevenueInterestLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to the revenue interest liability.",
        "label": "Schedule of Revenue Interest Liability [Table Text Block]",
        "terseLabel": "Summary of Revenue Interest Liability Activity During the Period"
       }
      }
     },
     "localname": "ScheduleOfRevenueInterestLiabilityTableTextBlock",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "espr_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement",
        "label": "Securities Purchase Agreement [Member]",
        "terseLabel": "Securities Purchase Agreement"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_ShareBasedPaymentArrangementOptionPerformanceBasedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Payment Arrangement, Option, Performance Based",
        "label": "Share Based Payment Arrangement, Option, Performance Based [Member]",
        "terseLabel": "PBSOs",
        "verboseLabel": "Common shares under PBSOs"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementOptionPerformanceBasedMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails",
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_SignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_SignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about significant accounting policies.",
        "label": "Significant Accounting Policies [Table]",
        "terseLabel": "Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTable",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Amount of Net Revenue To Qualify For Deposit In Blocked Account",
        "label": "Specified Net Revenue Threshold Triggering Deposit In Blocked Account",
        "terseLabel": "Specified net revenue"
       }
      }
     },
     "localname": "SpecifiedNetRevenueThresholdTriggeringDepositInBlockedAccount",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_StockOptionAndIncentivePlan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Option And Incentive Plan 2022",
        "label": "Stock Option And Incentive Plan 2022 [Member]",
        "terseLabel": "Stock Option And Incentive Plan 2022"
       }
      }
     },
     "localname": "StockOptionAndIncentivePlan2022Member",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary Of Warrants And Pre Funded Warrants Outstanding",
        "label": "Summary Of Warrants And Pre Funded Warrants Outstanding [Table Text Block]",
        "terseLabel": "Summary of Warrants and Pre-funded Warrants Outstanding"
       }
      }
     },
     "localname": "SummaryOfWarrantsAndPreFundedWarrantsOutstandingTableTextBlock",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "espr_TheWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Warrants",
        "label": "The Warrants [Member]",
        "terseLabel": "The Warrants"
       }
      }
     },
     "localname": "TheWarrantsMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The trailing number of months sales must be at or above the milestone amount.",
        "label": "Trailing Number Of Months Sales Must Be At Or Above Milestone Amount",
        "terseLabel": "Trailing number of months sales must be at or above milestone amount"
       }
      }
     },
     "localname": "TrailingNumberOfMonthsSalesMustBeAtOrAboveMilestoneAmount",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "espr_TypeOfRiskAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type Of Risk",
        "label": "Type Of Risk [Axis]",
        "terseLabel": "Type Of Risk[Axis]"
       }
      }
     },
     "localname": "TypeOfRiskAxis",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "espr_TypeOfRiskDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type Of Event [Domain]",
        "label": "Type Of Risk [Domain]",
        "terseLabel": "Type Of Risk [Domain]"
       }
      }
     },
     "localname": "TypeOfRiskDomain",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_UnamortizedTransactionCostsOnRevenueInterestAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction costs on revenue interest agreement.",
        "label": "Unamortized Transaction Costs on Revenue Interest Agreement",
        "terseLabel": "Capitalized issuance costs"
       }
      }
     },
     "localname": "UnamortizedTransactionCostsOnRevenueInterestAgreement",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_UnvestedRestrictedStockAndRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to unvested restricted stock and restricted stock units.",
        "label": "Unvested Restricted Stock And Restricted Stock Units [Member]",
        "terseLabel": "Unvested RSUs"
       }
      }
     },
     "localname": "UnvestedRestrictedStockAndRestrictedStockUnitsMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_UpFrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of up-front payment received (paid) .",
        "label": "Up-Front Payment",
        "terseLabel": "Upfront cash payment received (paid)"
       }
      }
     },
     "localname": "UpFrontPayment",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "espr_WainwrightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wainwright",
        "label": "Wainwright [Member]",
        "terseLabel": "Wainwright"
       }
      }
     },
     "localname": "WainwrightMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "espr_WarrantAmendmentAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Amendment Agreements",
        "label": "Warrant Amendment Agreements [Member]",
        "terseLabel": "Warrant Amendment Agreements"
       }
      }
     },
     "localname": "WarrantAmendmentAgreementsMember",
     "nsuri": "http://www.esperion.com/20230331",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r281",
      "r310",
      "r492",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r338",
      "r458",
      "r470",
      "r483",
      "r484",
      "r508",
      "r513",
      "r518",
      "r556",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r338",
      "r458",
      "r470",
      "r483",
      "r484",
      "r508",
      "r513",
      "r518",
      "r556",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r233",
      "r461",
      "r509",
      "r517",
      "r551",
      "r552",
      "r558",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r233",
      "r461",
      "r509",
      "r517",
      "r551",
      "r552",
      "r558",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r331",
      "r338",
      "r365",
      "r366",
      "r367",
      "r434",
      "r458",
      "r470",
      "r483",
      "r484",
      "r508",
      "r513",
      "r518",
      "r548",
      "r556",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r268",
      "r331",
      "r338",
      "r365",
      "r366",
      "r367",
      "r434",
      "r458",
      "r470",
      "r483",
      "r484",
      "r508",
      "r513",
      "r518",
      "r548",
      "r556",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r181",
      "r182",
      "r281",
      "r310",
      "r493",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r516"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r236",
      "r237"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums and discounts on investments",
        "verboseLabel": "Amortization of premiums and discounts on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows",
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInvestmentIncomeReceivable": {
     "auth_ref": [
      "r118",
      "r140",
      "r528"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest, dividends, rents, ancillary and other revenues earned but not yet received by the entity on its investments.",
        "label": "Accrued Investment Income Receivable",
        "terseLabel": "Accrued interest receivable"
       }
      }
     },
     "localname": "AccruedInvestmentIncomeReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r28",
      "r29",
      "r30",
      "r155",
      "r466",
      "r475",
      "r476"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r27",
      "r30",
      "r106",
      "r426",
      "r471",
      "r472",
      "r531",
      "r532",
      "r533",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r7",
      "r516"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r540",
      "r541",
      "r542",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r100",
      "r101",
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r82",
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs to additional paid in capital"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r78",
      "r82",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Fair value of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r33",
      "r300",
      "r422",
      "r535"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total potential dilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net (Loss) Income Per Common Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails",
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r119",
      "r136",
      "r151",
      "r178",
      "r224",
      "r227",
      "r231",
      "r244",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r396",
      "r398",
      "r413",
      "r516",
      "r554",
      "r555",
      "r590"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r147",
      "r158",
      "r178",
      "r244",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r396",
      "r398",
      "r413",
      "r516",
      "r554",
      "r555",
      "r590"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r239",
      "r251"
     ],
     "calculation": {
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r66",
      "r238",
      "r251",
      "r462"
     ],
     "calculation": {
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "verboseLabel": "Debt Securities, Available-for-Sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails",
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r54",
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "The Company and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/TheCompanyandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r49",
      "r150",
      "r487"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets",
      "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Statements of Cash Flows and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r43",
      "r49",
      "r53"
     ],
     "calculation": {
      "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total cash and cash equivalents and restricted cash shown on the condensed statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows",
      "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r43",
      "r112"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r178",
      "r199",
      "r200",
      "r202",
      "r204",
      "r212",
      "r213",
      "r244",
      "r269",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r308",
      "r309",
      "r312",
      "r316",
      "r323",
      "r413",
      "r485",
      "r526",
      "r537",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r91",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants issued for shares of common stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Total shares of common stock from exercisable warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r392",
      "r393",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborations with Third Parties"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "License and Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborations with Third Parties",
        "verboseLabel": "The Company and Basis of Presentation"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r23",
      "r125",
      "r142"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r73",
      "r262",
      "r263",
      "r482",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r540",
      "r541",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common\u00a0Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical",
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r516"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.001 par value; 240,000,000 shares authorized as of March\u00a031, 2023 and as of December\u00a031, 2022; 89,237,167 shares issued at March\u00a031, 2023 and 76,564,396 shares issued at December\u00a031, 2022"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r31",
      "r161",
      "r163",
      "r168",
      "r463",
      "r467"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r58",
      "r59",
      "r110",
      "r111",
      "r235",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r58",
      "r59",
      "r110",
      "r111",
      "r235",
      "r477",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r58",
      "r59",
      "r110",
      "r111",
      "r235",
      "r481",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r133",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r58",
      "r59",
      "r110",
      "r111",
      "r235",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r326",
      "r327",
      "r330"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue from collaborations"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r77",
      "r278",
      "r279",
      "r290",
      "r291",
      "r292",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Shares issuable upon conversion of convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible notes, net of issuance costs"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r57",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Exchange Agreement, amount of principal amount converted into common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "terseLabel": "Common stock being exchanged (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r176",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r294",
      "r301",
      "r302",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r120",
      "r121",
      "r134",
      "r183",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r423",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r4",
      "r121",
      "r134",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal amount of convertible notes"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r79",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt instrument, convertible, conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r21",
      "r83",
      "r84",
      "r86",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt instrument, convertible, conversion ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Average trading-day period"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Debt instrument, convertible, threshold percentage of stock price trigger"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Trading Days",
        "terseLabel": "Debt instrument, convertible, threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdTradingDays",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r114",
      "r116",
      "r278",
      "r423",
      "r504",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r292",
      "r412",
      "r504",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r20",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt instrument, stated interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r22",
      "r183",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r423",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Period One"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Period Two"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r22",
      "r83",
      "r85",
      "r86",
      "r87",
      "r113",
      "r114",
      "r116",
      "r132",
      "r183",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r284",
      "r290",
      "r291",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r303",
      "r423",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r240",
      "r251",
      "r254",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r115",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Unamortized debt discount and issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r47",
      "r71"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r342",
      "r371",
      "r372",
      "r374",
      "r378",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r169",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r197",
      "r199",
      "r202",
      "r203",
      "r204",
      "r208",
      "r403",
      "r404",
      "r464",
      "r468",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r169",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r199",
      "r202",
      "r203",
      "r204",
      "r208",
      "r403",
      "r404",
      "r464",
      "r468",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Loss Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r370"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "verboseLabel": "Stock-based compensation capitalized into inventory"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period over which remaining unrecognized compensation cost will be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense, RSUs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares issuable related to the ESPP",
        "verboseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options",
        "verboseLabel": "Common shares under option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r82",
      "r145",
      "r164",
      "r165",
      "r166",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r211",
      "r245",
      "r325",
      "r375",
      "r376",
      "r377",
      "r383",
      "r384",
      "r402",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r426",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r405",
      "r406",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r292",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r406",
      "r431",
      "r432",
      "r433",
      "r504",
      "r505",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r408",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r292",
      "r332",
      "r337",
      "r406",
      "r431",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level\u00a01"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r292",
      "r332",
      "r337",
      "r406",
      "r432",
      "r504",
      "r505",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r292",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r406",
      "r433",
      "r504",
      "r505",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r292",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r431",
      "r432",
      "r433",
      "r504",
      "r505",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r409",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring fair value measurement"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r241",
      "r242",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r256",
      "r303",
      "r321",
      "r400",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r502",
      "r544",
      "r545",
      "r546",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt",
        "negatedTerseLabel": "Loss on modification of debt"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r260",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r179",
      "r380",
      "r381",
      "r382",
      "r385",
      "r387",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r180",
      "r195",
      "r196",
      "r223",
      "r379",
      "r386",
      "r388",
      "r469"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r459",
      "r534"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accrued Liabilities",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaids and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r115",
      "r127",
      "r167",
      "r222",
      "r421"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r37",
      "r298",
      "r307",
      "r506",
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "terseLabel": "Debt interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Accrued interest on convertible notes"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.",
        "label": "Interim Period, Costs Not Allocable [Domain]",
        "terseLabel": "Interim Period, Costs Not Allocable [Domain]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/Inventoriesnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r70",
      "r489"
     ],
     "calculation": {
      "http://www.esperion.com/role/InventoriesnetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InventoriesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r157",
      "r488",
      "r516"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.esperion.com/role/InventoriesnetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net",
        "totalLabel": "Total Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets",
      "http://www.esperion.com/role/InventoriesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r156",
      "r210",
      "r257",
      "r258",
      "r259",
      "r460",
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r70",
      "r491"
     ],
     "calculation": {
      "http://www.esperion.com/role/InventoriesnetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InventoriesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r70",
      "r490"
     ],
     "calculation": {
      "http://www.esperion.com/role/InventoriesnetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InventoriesnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r36",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income on investments"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r69",
      "r117",
      "r129",
      "r144",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r178",
      "r244",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r397",
      "r398",
      "r399",
      "r413",
      "r500",
      "r554",
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r122",
      "r139",
      "r516",
      "r539",
      "r547",
      "r589"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r148",
      "r178",
      "r244",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r397",
      "r398",
      "r399",
      "r413",
      "r516",
      "r554",
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r121",
      "r137",
      "r291",
      "r306",
      "r504",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r22",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r74",
      "r75",
      "r264",
      "r265",
      "r266",
      "r549",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfExpenseAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cost or expense.",
        "label": "Nature of Expense [Axis]",
        "terseLabel": "Nature of Expense [Axis]"
       }
      }
     },
     "localname": "NatureOfExpenseAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r43",
      "r45",
      "r48"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r32",
      "r48",
      "r126",
      "r143",
      "r146",
      "r159",
      "r162",
      "r166",
      "r178",
      "r187",
      "r189",
      "r190",
      "r191",
      "r192",
      "r195",
      "r196",
      "r201",
      "r224",
      "r226",
      "r230",
      "r232",
      "r244",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r404",
      "r413",
      "r501",
      "r554"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows",
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently Implemented Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r224",
      "r226",
      "r230",
      "r232",
      "r501"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r425"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r424"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "espr_AccruedLiabilitiesAndEmployeeRelatedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r103",
      "r104",
      "r105"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r160",
      "r163"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other liabilities.",
        "label": "Other Liabilities Disclosure [Text Block]",
        "terseLabel": "Other Accrued Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payments for Commissions",
        "terseLabel": "Estimated offering expenses"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForDerivativeInstrumentFinancingActivities": {
     "auth_ref": [
      "r173",
      "r495"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for derivative instruments during the period, which are classified as financing activities, excluding those designated as hedging instruments.",
        "label": "Payments for Derivative Instrument, Financing Activities",
        "terseLabel": "Purchase of capped call options associated with convertible notes"
       }
      }
     },
     "localname": "PaymentsForDerivativeInstrumentFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "terseLabel": "Prepayment of forward stock repurchase transaction"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfPrivatePlacement": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's raising of capital via private rather than public placement.",
        "label": "Payments for Repurchase of Private Placement",
        "terseLabel": "Placement fees"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedTerseLabel": "Payment of issuance costs",
        "terseLabel": "Payment of issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows",
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PBRSUs",
        "verboseLabel": "Unvested PBRSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails",
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r516"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized and no shares issued or outstanding as of March\u00a031, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Other prepaid and current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r172"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt, net of issuance costs",
        "verboseLabel": "Proceeds from warrant amendment"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails",
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows",
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r65",
      "r170",
      "r171"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "terseLabel": "Proceeds from sales/maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r72",
      "r141",
      "r465",
      "r516"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r527",
      "r536",
      "r598",
      "r600"
     ],
     "calculation": {
      "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/StatementsofCashFlowsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationRSUsDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r88",
      "r138",
      "r474",
      "r476",
      "r516"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r145",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r245",
      "r375",
      "r376",
      "r377",
      "r383",
      "r384",
      "r402",
      "r471",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r219",
      "r220",
      "r225",
      "r228",
      "r229",
      "r233",
      "r234",
      "r235",
      "r328",
      "r329",
      "r461"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total Revenues",
        "verboseLabel": "Collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "verboseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Issued stock (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/OtherAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Shares Excluded From Calculation of Diluted Net (Loss) Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsNarrativeDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of the Company's Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r12",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InventoriesnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-Based Units Activity [Table Text Block]",
        "terseLabel": "Summary of Activity Relating to the Company's PBRSU's"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r339",
      "r341",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r94",
      "r96",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Summary of Activity Relating to the Company's Options and Performance-Based Options to Purchase Common Stock"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Activity Relating to the Company's RSUs"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding and unvested at the ending of period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs",
        "verboseLabel": "Number of PBRSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding and unvested at the at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding and at the beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of commons stock shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "verboseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "periodStartLabel": "Outstanding at the beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r346",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails",
      "http://www.esperion.com/role/StockCompensationPBRSUsDetails",
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationRSUsDetails",
      "http://www.esperion.com/role/StockCompensationStockOptionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r123",
      "r124",
      "r135",
      "r529"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r478",
      "r479",
      "r480",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r54",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r178",
      "r199",
      "r200",
      "r202",
      "r204",
      "r212",
      "r213",
      "r244",
      "r269",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r308",
      "r309",
      "r312",
      "r316",
      "r323",
      "r413",
      "r485",
      "r526",
      "r537",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r26",
      "r82",
      "r145",
      "r164",
      "r165",
      "r166",
      "r184",
      "r185",
      "r186",
      "r188",
      "r194",
      "r196",
      "r211",
      "r245",
      "r325",
      "r375",
      "r376",
      "r377",
      "r383",
      "r384",
      "r402",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r426",
      "r471",
      "r472",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r211",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss",
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r5",
      "r6",
      "r82",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Vesting of ESPP Shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r82",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, warrants, and pre-funded warrants, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r82",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted stock units and performance-based restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r82",
      "r88",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockCompensationPBSOsDetails",
      "http://www.esperion.com/role/StockCompensationScheduleofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r6",
      "r82",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Shares delivered to the company (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r5",
      "r6",
      "r82",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Vesting of ESPP Shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r82",
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock, warrants, and pre-funded warrants, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r64",
      "r516",
      "r539",
      "r547",
      "r589"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets",
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r177",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r322",
      "r325",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Deficit"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r420",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails",
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r420",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails",
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r420",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CommitmentsandContingenciesDetails",
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradeAccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business.",
        "label": "Trade Accounts Receivable [Member]",
        "terseLabel": "Trade Receivables"
       }
      }
     },
     "localname": "TradeAccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r241",
      "r242",
      "r303",
      "r321",
      "r400",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r544",
      "r545",
      "r546",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r25",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofStockholdersDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r25",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r6",
      "r82",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Underlying common stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/ConvertibleNotesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r25",
      "r89",
      "r90"
     ],
     "calculation": {
      "http://www.esperion.com/role/CondensedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedTerseLabel": "Treasury stock, at cost; 1,994,198 shares at March\u00a031, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CollaborationswithThirdPartiesDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementNarrativeDetails",
      "http://www.esperion.com/role/LiabilityRelatedtotheRevenueInterestPurchaseAgreementSummaryofRevenueInterestLiabilityDetails",
      "http://www.esperion.com/role/StockholdersDeficitDetails",
      "http://www.esperion.com/role/StockholdersDeficitSummaryofWarrantsandPrefundedWarrantsOutstandingDetails",
      "http://www.esperion.com/role/TheCompanyandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Notes Securities [Member]",
        "terseLabel": "U.S. treasury notes"
       }
      }
     },
     "localname": "USTreasuryNotesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/FairValueMeasurementsDetails",
      "http://www.esperion.com/role/InvestmentsSummaryofCashEquivalentsandShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Company's Cash Equivalents and Short-Term Investments"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r214",
      "r215",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/NetLossPerCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r198",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r197",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.esperion.com/role/CondensedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3505-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r521": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r522": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r523": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r524": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r525": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e639-108305",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001628280-23-016646-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-016646-xbrl.zip
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MSP<OW^<]/W3@ZNR&_%O+A?63%JB;\?K,Y.KHUC]?W-KC^52=/W@A[ J1$:O
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MU=A("U(HA$/6"N[/*T 16I'G82HQ51]^-'DT<BS:B)AC.E43LI[** (+EG/
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M_F78F07PL6;"&O=ZZ@_*BTX.'AEAL/6N'[<M#K/Y>]C^NI? \5/X[4^?QNG
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M-VU^@S\WM^9=:S![8\WOK^WX=+2=!]=,\Z -USC5U;'"6J&L]EI')R0O?Z7
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M#.A@%!1',>J@@ED %GY^:B<*!VZ#1R90AKPR46,34TDZ8;'%BT6S$H"_Y\=
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MS":A+$@FB%?*&>L<4UB*P-UBT:P$X._9,5#D'BP6F"PK4T$CEHYJ"$@"']G
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MEGF 41S%E%)/E,;<8ES^'()GS4 S22-(9W<:)(63(;" I48RPA]CM8W4<;9
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M.XDP\38*SL C9QI;#5A41P,&$X/+IZX7U*WHMHCXE ?MH_7(<<.+I3\/#H9
M00;-,78+<);='?AT)_0'><L-@B\0ZL=N:]#?V?VX(*#'<4^T9%9Z@9EUQG!!
M@W+41)!$H-?BVL,GI\_\[9ZBT0O/)+*1,:JMB2K _[EV4B,GQ<+9O7G*V!3S
ML 0EX%>P('5*<\ &J\"M0^!E$!YOG-=0T:?,=@SH18*55J<=MAH+BYG!V@%M
M+0EN$1)8[J#A)1!2():?G1Q>'@N&N0M A4@\0YXI:E&D-DH0,(N"67P+]@24
MF;_MD@$1C0TBPDM&([&(6QJ#QH$K0O3B^6SSD:OI62V,(T- B%3:$(0K:LDE
M(82C8(,7@B^^U7IJN9K/ND"4UIJ D1$A58E0T2&ED*48<X,]&I.189Y-/I25
MC+M#VV_YELE/4\'0*]EBA:.]/MAKAKK)OX;!^[QWF)O.[ G*,LSO2=#+31_C
M2$O D$88+XE@7"$#P(-Y[AE@2_#?R-C> 0;)QA]*NV>H= 0%[4DR<E_+1Z9S
MGA1E/!7I8TX0^"B-,MY%8QQ(K45"RP5:=R@=0>>RQF"94DY)YYP2C BKF;/"
M<N9<*E!M['BG)_PI*QU_5'?QLVEUO^<I8W;6FRR!>-/89"EXE-)XC:Q'C&.D
MF42*@<OFK!/!T/$F2X+&6[@KNOQ8IJY1YJ<UDB^:/D9)$A&$DY)HBIF/V@8B
ME5$Z:(85EW'B'F!=5MK]+.D<-./XVA-X"%A/0;!B4( ZE.8.:(*D3WI..Q$C
MUH@://&\@2;9HA/G?1[>#+L^^'&+V>.0RS3ZJ0=^T?0Q2^.I. '"/ H2&3<
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MY 1!#LY5PP1"QKPW#EW-ZV]MT+M_X[)/]*]-P>2M*EZ%\:7#UEO]M"1<BRV
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M$XV1 06G5UXQA9&:#V_>SA\ELOQW!(?'#)8BP\<YJ+W6L6G7PDEPQ6Y0^!E
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M8KUE5&3WQ\L95U>N]T/_E]8$IW4"R]/4.-E-TW6;P5F2LU<>M::.OG IL>#
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MK3?I7 N3>4RT!] HL'(I7P:M4ERFNM/5PE5)@5XES4\IS==17W01>XXS%D(
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M&]>>L:WM;[OT]^H#T2=[__DD$S%!)H&B\P34'P=D DW(Z6"BQ);H7.;OB4X
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MK B226&FO;!&N3&KKKJC&#:SWQFHLHU4114(Y8D[K8B0%*0Q.(EAQ=9:,.D
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M^G'ZP(EM\K(% MF#OX-9U1\C XRKMG@S8(WZ*/.X7C?C0N[7U!9>G]6^/!T
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MRQ#$:H'X/E:M1S4>\2DZ.>D\2_+F:-@':A[_#WCEH6=[Q8CB3IB.4I]+8_;
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M,269S[0K)![.<2OQUDKB72Q(/*HUD;G-0,0YCJAQ#FD'$H]02C07SF$:GKW
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M4_OGQ5=*K6C\Y,S[0343_53'E&D/=@G\)WAV7$IC[1T'BGHS+3/_O?D>C>_
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M.P"VO>Z?X(+'T:S<^?T)0LW=*B VL_?G]OM;,*&.8-!'%],8/\D?V5;?/_I
M#X_V\H.K-]GAB[VOAV^.#:5.E300J@3XY87,B"E82;")9&XC7U" C;\C%O;]
M?Z/LWJ\%WDM2B"\WBUPM\N7!"=B=#O[?<^)M0#*_$(C.L>6+*THN,IMQRL -
M7KK(*_!B"BB56VL!)A 28#6&W8CS;=3ZH_KTJ/ZT1JW?$7&^=%T,7()IVPU@
MFO0G,1A8WP$\#=06PX[_BNH\WB[:D)W&KXC.43?,XVT-K3]53/<._IRU0OS0
M DCJ$W\8]OI?0%:]^R-%/"L3V/WKLK:^6 9V#3\:O(%'[H9+,)O?>8PFO/4
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M]*@H!0\B4SG+,^Z,!&WF5:E91H.T5H5*@8FL4F#PXAJ"DN;)X,&JYVK.@([
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M5TC^]M=@-/*CPWZ,U$[L. :S#@/.W<8<OA&)CG8O]T^./<;'RZ"(S;@B7--
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MWA^#?MP.N+L.!F,_6I3V!Y<FL9Q]^^:9F9U)SC/JE0X,V9"UT89C39;*RR+
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MA\WCO<F)*6"60P:2)OV\>-RO3,/$.A(EMF8T:#>2C)DYTQ/<:37PDW@,.9C
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M[^DBE7NG),M9Y@'C?.:5MD%H!F+BR[+0J=M.7DM&OI&,'RD9AR]VQ?Z;8V9
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MME]Z7*&9I%8;&@K+N<VD5BIS5N6\U"HH*>>R"M)&7[*WS<U[VZR]MQL/NN5
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M-<ATYQW_<_5N_W;*8#'VY(26-E:"*"<9X9)1 EZA)!&726($HQ$HW,W%GCH
M\I, D"V-/=VLAQK^W2XV]1#Z9S$V)2B+LRS-B,GCB'"A!9$@""2V.> 4)J5@
MFXM-;1"/_ P)3!7J]FTA'B*!J6H7L>@0=Y&J+8A4M=:^"TEM5@L>+E>:Q@G7
M44X5YO%;PN-,$:6T)3(70BJ6*XX=[WG6IQMCR]W('NRRG[JCRI\@7M52AEU@
M:G-:<#$PE:I(2R28DE93PO,\(\B/1Y0T/!+6959I]$5SOD6'E%WVTZ,.3*W?
MVET$ZF%V_6($BF6622,UL8GCA*<*/$#)&7&*<B?2)(OB!,/124>SVT&*+8E
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ML(I&3R9Y E Z(H(B0T&6:R)-P@B3*H_R.)/,)D^>\H3VF7@T+% =B5Y'HO?
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MRG$C7'K!._@J-KUY.;^>6^\>8+#CUML"R;W:98 #59J"9\\5851+PBT2; L
M@]89:3-E+ T$V^PKN/7\O-Y(:9:D3VY%0/+@OOD2"X+WS2G;N78C;( *Z.40
MV:N.Y)>]HM2#43D=;P_1SV4EG1__ /G<Y8=_OKN Y\%]WGSZ -)X</62'7Q\
MR0_W3N+W1R=\_^J36)3._3]A)'LG_ -2N[._/Q[\B;]]'N^#O,/SX;?F%'Y_
M=8B1J;W77XZS),D3E\>$QQ1\XUQ9HAQSQ!C#N<E4IM/DR8R;:Q?W="QBH<%O
MIMH:3JW)!05_QL:*:96DL5BD!0ISWH-)M^52T.CQL<*MYOJ[<5*0=ZB".'?
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M4P:.6%17A]#\6E*29WYC>H^X'8_K,.,JG3RK--J_VK]Z?G4<:T1>3A.:445
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MG>+[R14?Y2E/K'*"9SP34L69R)@1>29L)$U ?(RR3O%MF^*CBZ2'$J Y_(?
M2N:$Q[$C@-LU)C3G2J8)31)4?(SWTXVQ7'2*KU-\V_3B=U!\F361 GV71%G$
M;:HDRY,XCB.7Q)3F64!\M%-\VZ?XXD6F>YWG@FM+C.."\"1R1.8Y)3D5UJ:P
MLDY'V.TPZV=?GW6\)<V 'E.0[LU\[L2]0G,_8/']PT7?YE./YG6/*[Y80Z[L
M>-2IG;NHG6(IPI;1R"@79]A6@Q*NTI1DD8Y(8B6E--$TXND34"\9H.??MZAF
MON/,V-+8T77;MH,,7[5W%X-$N8U51%E*&%.P=[,H(3DSG$161U9H%@N#10-1
M/]JJWC@/MW5_\!VZH2!'9U@?8G,N!C)X9)PPEA*6,4>X,S'))5>P0U,1(])/
M!+^G8=WN3?B3VL]->>*=_7RP+;KH<F?@G_ X5D3SA!' /(YD-J'$1E&:<)N!
M<LVVT'[^#"DQ@3/A;M4,Y>GH8EA7)<#>-'986K.V/N&>P9+5M9+15]<L;]T2
MW#?\NHD)^F&LPB93D>Y=J]49D8T9D<NE $H<Z]A9&Q'JD)C9)6!$$D:)89$3
MTJ8V$^R!4I0VL-,>QXE6IW,[G?M]LJ ZG;L-.G<Q\!59K9D0C&01RPG7.B69
MX()$@NDD$2ZF6&+&H@?(CNIT;J=S.YW[H E8G<[=!IV[&,^DL9#:&$WR++.
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ML[] ZYT6JIB@5'S/:7CS/:?!GL#=AKU?/,[ZM0%:/L)6H:T+4)W&8G@BH!K
M?H,I8NH+L%\^)C2V<N)!BS>%"U88O."IML% 8VPE5(/.J?/*FP7S/C.JIR-O
MH"M@*@$@E>&P!K\YA7^#QM_S$7G$*Y/>*;Q4N+_SUF!OI_</8KPBX#K_^ 4P
MB28#']JPX8.U2/PSW!1#8W8(&G-0_;:<3,UE=6P.@^E1CN7)LP'#?7:G)U.
M4W"7/,S?^;@XP]".'9KS43&<U&&$ZEZR#$=K(9@'WRW,G(],(MH$0.!#$&?R
M([ZP"9.Q<A*]+=S???:\]\LB!(%%.@WXQDFL\CV['/E+X*_%T,FQ#D!N=@&
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M%57689BU<.XS]%X[V#GCET7)LO#Y0;)Z8MDH\ZE/.&I$Q6.P3[>=M/;9NY]
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MJ@8W5Q?=CM W9CV.O!A&<_>[PUW^,P5S$"(VD=?48<8##EM8,RS40CL73CM
MPIJ$X7D56LI!L,CG3?I%A=)]S' \\9%P^ T2&V!TQ#,X]&>&SI\X+6-R1",*
MDYYK[1DHW.?\ 'PW$"%?.!:,8I>8T4[,2+O$C.T8RP_)NK-:Z-!V*; 60UOZ
M2%I=;3$ C32JE4L%.XJQ\0<S18/?0L"I\-&0<C)S#&0#*RKON-)=U>['*A \
M?? A/?0O/55+N6QG[AQ4^@XYZ/[%AA83_!2>SH/N=(6W.@UQ#6*QZHV]F?Y7
M0G?27H.A*R03W #0EY/3L@UGYDAKXC"A_Q+)?>_ =E8ECZYM@_*M9K+W=AV"
M:,U>"-(B6O0ER*,R8,0@4RN@,OKYWA3CG,TQ'XQ')V-Y5C:A,.]1@,L !C5D
M#\I6L<IG6SU+@DW4(3FT.4=KA4![_WS7O-PJ=<#'^7!2YC)VYAR@:LP KJJ)
M;:B31CAEUDMO%7I>,:W^M8<GHU H5C--M(@SY@K R]^^+4]$G'PW;>H#*,GO
MWTD*T*A5K(X$>61_B]F.P+E81-0K@6X+??ILH+M,_]Q3T\4%(=V*+*Z(#]T5
MK;2,-7IJMKNVM K[VLG?U0"N\.6Q2LZSJEWZ$ZQVM*KR">LCMI!E4%-:%,,P
M23,_)Z3:CRMB"7N[^L=0YQDJ!+TCY8_<K/TT.\>:]Z;:3UF]'+>'2OU>2* \
M04]U$!A$X$/PE; *%C7HV.?@5'#I'--F)VAA$)C-IF?NJ_'H4@XFER20?:V^
MIO;'\-4+K+WU7;DFEVT/;=R\1D6<$ISRG=ZNP;@]9C>N6BF_CJ.)/VQM4X--
MO3N/I</G 0#Y!*U @H1)>H.JA+1U:BJ+<G:Z*<NJ7 -@%,H)FEE_JEM%5VL.
MDEF69%4',;R6[-!GN\P.+OW>JXBDIB469Y;U$EV&PH6J[G?.LF/.X2 <P.)-
M E28V#D;6P%B[XU7E%(-'/2/;]!PV F(&0U(_>B:?*0M+I6OBFYO+I3?7@W5
M6$)/;N*S*&%41 \DUAH?O>H]*[QD]/ZZ;&IQG_V%2,?7@?D-)"<A>;6L4EY5
ME>WL3WI:=92J&)670V2,*8*<3\])E892AZ_A!CYJ?(XL-CL^1AVJ6E]YMRKV
M&=NH?5# IS6=GB>C@7$,>_%<@5&_57O$YDN/?*YPC6+K2>C/YWO+4$.%.88T
MJS,.FVSCBJ8&KEM(]/6[=UHQ^C0/Q 2=D0E;!LN880V(YZ'R1 !5.O!"K&VQ
MI!R#=<5"&"_H#% (GJ8T\!55/',^6]L[$W6NMJEKP^IDY,9Q:E*G\=##A%QR
MG!JLG\;QM@OB0]HQ9H=7>4EM)=E, ]PH4!@\TEWA(6%S>GI=)KC_5[4#&IJ'
M(!0S(XF"C!.,ZW9FD=:R*$/N;L6>KRY[K>+*]KZ9;9HZK[5 B0[I*.5H?-[.
M>$.9PA-+N]/L&9_-,B?9S?OY43>CA2%(3_2)PXIG(K^B\"!(.:Q[E0<[ND;:
M*K%N@K^=6'\OL7[YU_/]O<.JNF&EQG_VUS=2[=585@I$PX<QXQ<.3!C/?,).
ME3. 4H(+C:Q&F,;36MZZY&$5+43OE]44$CCJ4,<9/OC5TYQAC_&>N2P]:TE@
ME5@MF3Y*,#MU"007M5R.QO7?@D'R6-/?DBS4AQ0A*.A?9F8\9A4X8Q\N#(MQ
M,I*#<G8DZO?%]*RU*\PHL"W6XPA =%!1N*T:\0TC6_OJ"^.=KT1&.^?'A%DK
M>"!9%YTT\],DO%:LH-8\RNWU[NW1\X.]E]7^>M2VHWZ7U?OSV>/<A@^VL<*=
M*X\+R_WKY>U7VVU5F;XM@LNYN$=NNT6JA-2Y KTU;]$2-QQ.T .WW,MR@%SX
MER#%7A>T<?,LHZV)-%POZ^!GVG/I,7!5/%>IG;'_<S2=U+6$CW#[[TUK;7GK
MDXR+UHG0OUC[3*08S@+6=9H0$H8NTWMY1H89;6H=EFXHO2J/Z6>84;8PHS39
MB;['C/Z4A_?9)OKL9*+KL].=^#\8=U!@+F^BI+/&./<)X6U=&-*G-O7QN/@1
MZOKEE^@52XJZ2=[:ZDRUQRA#S]JG.'4<_Q&*T<KW6"%)<Z=6K72=JG@>J^,/
M)^7TD\0H6IM4]MEHI]_[:V)V/(@.UP0DOE!Q#Q?B=56U/<:R5XYL> ? Z!\S
ME^'+O(S.<AY;;]GL%34=?&K@MM?X_I@1Q;F5_#QL#M6:L37IVU6R27O\57UZ
MN=-[Y^]8UZM:L^+F%:T#\;ME=I_ [A_.@F#AI\CX/ZTJ ZJ;_!?+.\)Y8^7M
MXHG2_(H -L/^!;:*+NR^>NG_G'OMII=.JY86G-GE,;7?K0DCMD] 1T$+!29;
M'5*W&R+8L)J%/\\^KRHK +",,9IV6=<:+%0K^D!J\*16#,)7LX]4Q5I2=SFH
MTMGA51??U#^D8A<+]9AA50O;*B%8>48<JCL;&MF0WX;'UT'SUL5)^/O/(&Q>
M"\ZEZO=GA47^5+?-T0 _K/+QVTK>J]=K=H4O7?;'**&2SP^QU4.@$G%D4:K.
MOLN*4KCQ :J(Q9S0/<[#QF?P<CB/)Z,1MDX9#>Z4H+(UZGGQ)5;HYB5)66OQ
MFUQXO7Q?+^U>=%?KHW7Z[#'*QIMV^LQ>2UL]KSS>1R@JA]-KTH(:3]YK(,R\
M;4R@S[J_*2]R2:NOC%S=N<JB;E93E>VLS_OK4LB^/H6LD8%FH0.X6=[H0TR:
M#44:#4E2(UJC\8D<5G8PI.H\>W-8&<!B^!D#XE6WI;*8V*I?4)5^4!/HS]J.
MH15:B!/]WDG! TI!6_M+C=#.I]\NE%3-X.52).^RR:I::A57&Z'Y7U?V!#2.
M9\%KKJII5-K]\R:!$0_DT]9Z9J8_9B6 /MW*+&HDGZ!U%_5S?TGKY&I)NYR=
M#T:7UI(:G,R*86?+"^@$C$YH13:TKICX9,>1_E0E)N+1'?Q(-IEXH'M@B9M[
M=0NVN063@\%(SZV4]]_&=6(L<A9.D-H@5-[!?L:,Q"IMOYR.F\ZF528H[G+4
MWE^5"MXMTW(J?CF90_S^>#NT%:Q*5AIBJC99WV,\O_K'UK*X'LG6=34-BMGI
M'852UO[ZFN*U=[M IC8,&?A*K-8L;Z:&^)D?+&ZKFA]C=7)XOV[MN02&^E5K
MXRH*8F;MFCV/N6?)KP(2E>T\P=:LC: TC8XPOH)IQS V[#TX]9GD/M.M?G1U
M@EU1TE=M:IOA%).*0[:F,)DKD/>\K(4)<S<M,8S@>]O9H?$!!'1.*JJ@._DH
M0VPE.@A>"LBH'0>^BG+2FC+/-G NB\!7U"!0'RV;Q[(6L>R@UT0VZKI$!+#K
MRI:63C$Q8&1&/IV]5J$S('4'\-1O6<-U-K#?J\UJ8S!G34LQL<'/Z)**N%;D
M'>8O5'D7C5#4Y6V/5&OX3/MV^ZU0SG:SJ-5LN,M5;(%BHXX0^_T4Z%0(9EVT
MZCKJH.>Z0W$D^!DM%88T]83S5"SM+L_84>QTA)DS30V"%[ZJ:._FE\,<%:LQ
ME-M$" .!]3R)<.#Q"'T(:PP^1PQ>LQ6M><' 9>Q_^I5\QO[U-%*43WH-'_P<
MS]DDA"?-=#S#B"T]M[KHTE.05DD)HQE#WL+&WE1,(["IU"/LUV/"6\%/0B?7
MI>$]0&PE; IC01B"O?!A:.OK>6;-@F?8?*&O\(I!MN1AE69<53H3(O&KR#.Q
MOQ;&PF?'@OCS+D6DG2*2=_P.VS&6'S+;8[70A5QR[,0X!DLB4;7VD5Y5SFWB
MZ>04X!/L<4]/,)F5 $PKZ!G"?4LJHNI 'CCY:W[\JC,X0O:F>7SU):HP96=G
MD+6QG<>VS6,6#AYART_(\N'=+31_]9B[!K-;I+)M"F)OD>?[82R72<Z1'%7F
MPM:<Z0_]OO>S=(_QZ.=MS=WP9XN[87>>N^$1GP*]O04U10,09X= M<N%CF+E
ME<PQ[NG&D3VWXQ+=I+FP[7K_914!1G6:7;7E_8Q)WQKV374,WM!^V7XKMMR?
M%==6+Q4P]<*KU<X-NIS^^]M,0W7Z5--ZM"*75=#KDLS-0QC7=%B3?,XQ96#Y
MKO4E.+BU;>4@#.P)O@-JM@#^RZHE,?+58M/?!LTBN:6]:#S7>DI:,U1BYIU^
M=!G*43J+\%0G0;?A46DFU]L"6*K@SU2TFA[;5GX,=I69M5Q!;\::VW4XJIOT
M+?K_YR-<KE _WJCKJEMLRQIZ!\@O>5CL(<Q5?<C1<NA0XF'**^+\!1U=-1&$
M-P[W6']\7T]!69^'M+;8J97&R\FC5,TO:UJH2O\^+OF>?X4ZCKF<K?&FRMEI
M+ETF(?:GJF]>OMJM"K*?%R>@REZ^?-E[N]O[ZZ]G(95. 3@%@? M5J5#?[OB
MK:V_Z3VK:1(JQZS-V.=I^EH$N@>CSPV!;O0XLSJ"QG\YQ$W=A\<\QK3>PRJT
M%]YAB*AR,5NQ# &N2GK"I6UV[7&%$Y&\%T,ZLY2U\[$]*Z85B97O"3_UK<;D
M>!ABREY(9'G:]__U_!_@JML9NS4&5SW:+&<,]N&;:],R??IE57%2M=ZJ>%I'
MK?=M[Q0?K*KS!KW&_VQ/"SU8&YIH-3+!E@]VA0:\94E%]F0[_+,U:6TXZPCF
M=V>(X-4(-DB]%&];7L9_JGXSX9OG%6/Q8\2UX0"AU%-O9ZO JAQ<8J5F%8]:
MQ^;2#ENU.&O+V5'*_*]G=,)U>I)GDZFX^FRH["\\;<UH;&8'<16(03?6$]K8
M.=16'68,9D'G^1Y#,+I=P 2P;G5?P%#Y-SO<*>UJSN/*TRPKW]OWNZG)J</"
M?VS$P.,C&4APPKZI<!*H"J\+,"ND+.W$$PZ%0%XM6$N,V+@>@U$Y#8FN(?SN
M2;3#'4*I;NLFQ?J9#H'MNNFSIP%>\P;AY*L.Y_I.0*'I'NJ(^1_"I:< )$=C
MOU^:AHJ@5S\!5L1N?*"BJG>K&@>VV@C-VJ&4+7\#8ZBA_M8'4*L)'3?=RZK#
MPUD"M:VRK+P77XPUJ-])Q>BT$%,-LH9':L$5QU?S6!!6%-]U-@=2X1G$)+1Z
M&_O47M\NH[5\2Y/?#!2#ZUBAB@9%GJ,TXZ&03_Z<IW3"+5=-13U*S#PW!=)!
M-5BZ; M;>-5P124(T[/SYL"PV9>/S7?Q*NC(=PV:Z8+AJ)JQAF4**\U/;'/F
M,1?O:6F"6ENW&AE46RDH%I3BW>$0)_Z-#?1FPX;(_/_.J!?A-W")IT(-MK9N
M6+! W]E%U=O+&/__[5UY=]O(D?\J>,XD\61!FN ETDKF/8UL[SAQQH[ER63_
MR@,)4$0, @P.RYQ/OW7TA8ND9$JB).S;R8Q-H-%=75U75_VJ=XC"RZG3%EZV
MH?C;-?4^:MV@*R\;.A'<O_=%_3&2(-7)*)_(&_@[>P.OZ]HMH))"$;47WFM-
M;MCM28E=^BF+UR\I/^O/#%RHY&("C-JA6HEUZK^4_W&*_>%"=_,RB.A;]-)I
MD=-0$)![#E)="$I:/O\L9,1TVIV,!CC!+(%_//EA(4&Z//?,J_XV[G4G@W[C
MS[VNT_C;MF$=ISL8CFXT[/;?1D]^LKWNV!GN->P+8@9F"& Y9-V_/!L\TWJ)
M$@M?]BR'6%:.IQZ=5A[MK[_BPZ<5K5UF4>;.0TO(R2X!V6.+K%G J -<7NLU
MR++CT6^ENGY4B T4*O LUF,%GB7)]Z"V!,7Z'J3?:\'[$T[JZLI0CXJP_=OA
MZ0>Q_'-RK0H$.)S0>SQ<\CR/W)R:)-OL! 81_QO!HF!<+_W^L$QT_8.\8]NJ
M?27F<]\'7V/+/F#"_-WLPF[+O<>6.]WQO-Q'$NY:[SZ;\&3'V%,&'!?/5*_&
M=Z#2%,T_<U$]ZR$L[;M]5F*N@-JF'M42G!.[-Q#-"_=8#<K":Z[J!O*X98A[
M9(B!/1@-6X9H&4(L86"/3TYNG1\>E_543\GMV%KE4]&_WN)KS\/Q<=.)W9].
MMG+3OEM]0+%S<_ON<6[2R!Y.^NTF'?<F.?;$&=_?)CU(#Z7>JWVOF@#*!/E]
M'-QOC;+>^Z-/0^4V@J4]$2GAV.-1*\N/?)=.;*<_:C?IN#=I:(_ZVQVA5N'N
M1\F/#27^>\CF!\@W \<>3(XMQ/8X2-L?V@-GVI+V5E12;[S=;FC#/OM1<H_2
MU2=FE/:G]K2W72*V]LZ][]*@MU-OM;MT[[OT?#CI57(?6GOT6@&@=W$JBJCC
M:C[R%C;2.2(]!#4TLD0>*"?9X]ZHD9GV7.V]&5F/;COZ]G0R;;?C2+9C9(^=
M\7WMQE.PD\L8 ]]B%#\VYG/ T9V<7%O/WX^0N%43[1'N+#C:[<X^OIT=])MM
MJ?O:U@=IM-?3MX(H\CBCQX[=/QFT$<[;B&_T>RU=;X&NT]'M\^OCLH?KHQ(_
M^YD5QFDE$K&G#A&U8P.@L!?G6,M;4SQV?45[='J@*<7V#NASW.?P^=BQ3YSF
M ,*MT^>.;,^=\]V15=X>I/8@[0C]C.V3@?/H#U)[3MIS\FT1:WLZF3R\8T+&
MY N"+OFA"7_F5JBV%R++_2"&T8C[@^1L*?(\JF5MW8GJ(A0FV9Y]V;$)^W?.
M2;>'('LA=VY9,;!B%L,O@^Y0_7*MH?N$AJM0HA$.#_N-?"5\NG!C?3?HCN7(
MC+.HG@U,/'2/VPAA>^YY$A""G06'\@H1S)MZ*WO<[TFWMOEO[B;86D<"5)MK
M;'IJ&UK;0V+T\ZTU7$>ULAT-N.OZK1O]V%3;['GA2:.I[DW.QDEW4'\T1EV1
M_WR@X_&=TYU<XT#('SW99(C[C0MH:P(ECB1(OVP1;@!@5EN+4P,I&D,<+X12
ME>WL>0 +!DT";M=VI+B1USX<C[,U_8VT@-,]J6?UDZYS4%8O:8)A=UP8?AOW
M&\#4^@2L334HCT!1"J@CH*1$_0G0@Z(R+0[<I&\>B:)HRG%7<,/'N<JM1V/G
MFJYY4FQNL_3=P-%VD5T\+/VAH3&^52? R6O2"=$>?0?Q7.NSXV99$LQRADFD
MWE!-/?JP\1]VH5O)%L1H?L%_*Q!L/$"EUAW<5%/@$Q?:S1">;JE9HRT P6M:
M=YB VX]#RURG%=!Q+OAPG8YN=M[ZT^ZTX;P->M_BHNB^G'C<>B6;3G20-%IW
M7J]1SM;C)X<E.';0-*M8F&M\+@N].4L.#!XOH$P8XK\+XU#_IV+W=AJN^2 ]
M2>1II^WG>!QSN0\0Z>-5%(T)A4>UJ.OU7;JVP"=?9-@=%B1Q2>C#[\[!C*R>
M-MBJ1E907D]1J MOO- XNO1"6>Y3ZZFW'\[8W)(MHAZ'I=.<XG14J[I>XZ<;
MLG!WL(V#>P?T$IQN;ZL#'16:._&::MEX"63PDTI+*]&81S>=2IM>2+#Y2)T_
MO&<OA^&SO5CE[O-;B#/>!?_- P^;[9H]W3[*7K%[8>??#V,["(K^ZS( "72%
M35,NX>NP?6S$9KX*IZJ^C"KB@1LOPB!D8&)3.NJO2^U7%CEQ*3YD='1"XQ9'
MU?P%G!WGETL<:>[[G@C#J(^ Q[?P$SP:9+_:A?YX:!J#9XA.(K?*0^)?N4GB
M4J.@=3X#V02CP @!]KFG#D@K.$5R,/FL]&0[8M9ZC(R/"W4_GM.9PMV:@?,:
M^2G\KAH066MW(V+)N(#&2+/L\R?IJ@[(6K885 ]WL>U@FF-K&G$; <MAQ1%Y
MS5\@Y?'*#8+Y,K NW.CS)J87WF=I_MFE'<(>0SX8VT1%E#'@8V/+HW(?3=Z&
MDC]>LV1Z(MZX(3KP-YPV6?W47 ?>.@,&"9&CG+KEW& -NR?]/K+>^+,$W*F-
MU3><3 QMK["ILL\=M8";(PN8][.*K*M%\%S_ZA/#P0_OWIUSYRIS:2[9J F0
M ?[F-8@-$!KO!8O"^G# L^* Y[ H6-^;(/OM$CU+S_J#NUJ?PCA=<O?D+*@K
M)=V(Q5\"3]M7V$"26J#)0+XUVW"+550[T0:Y.E]S/%??]I4.BQ  V.\:=Q7_
M#6?^#[^;]/N]4S?KP'@=I@K]G7.JSYTM6W531/GLT]^M#TE\F;@K/**:4Z@Q
MV%=PEI$0U$KIHC-0C<RP'R\VI<U3CL\R?19!R.WA*EM'#<>P%Q;W/&.EE%-'
M<V,B:YX(3I#:;(JU2J'$RG$NQ#DO+Q56'1S:U.@^BY(#)RXZO8F.:<!4W.W
MF1H<5>*'"]VGL:[/J$DC[C]V)80$![MIWK2UX/;;U/4.CRL0DC[BP6RPEZ_8
M#=M*EV[BUPC#6OEG2E3B+3E!\]VN];;:F!?IO&-EN(X56S-SD.EN$&D&J/TH
M<RGV4KV$42Y%+]6IW>L/[;[3-Y9FL/<?TR(CB_[#B6\V]])-5F6#+I8^V) -
M9X6=@%/26ZP%OIMV>SULM,W?)#HM78\?7@="O'EBAFK,$\D%/O7WPYA0OI;]
MX\,XQ96+V1L;EL^7/&N*P J**0*1NG6YO:;OU<W5Z8Y&I;G2)*5=23HI0L4=
M+JA7&0;CPC"^DG?EI:F]5U-#$6/(6FI1[OFZ)2(8LTZ?OUV:-YU/X$P_^**O
M5-@"J-X#C1S#)BYU()5TXGA;\3W'\ 5K>D?7D9/FA5ID'F G<-6M6K:V!B&%
MB<Q&O!+^[:>^3T[<(L^PU2+%X J2A]\T592*!9;7(]HF5OM/-V8U%#L_UG1S
M;[P/T&%WY64>UO[L[V5_6K?S\3V-W^I^TRTAV7Q90Z]=V_1Y;-$PG7J9$P/L
M?T5HJ]TSWY?6(5_+;TU="% A+A;8KI!U!,IPR7MT:+7YW<RR6VXJ&WR4'_X\
M2UX<:<;75B_^C#:CUCUGEP9=DXWLL4G-C95W1VI#=F!F>[:N";/[Q0U"I&X'
M*-TAD\MTD5F+9S$8%;#EWSGCOAEG^E4^K#_4W.29/"_TM4'<\31MY5)T9G#H
MD0/TXQVP=L R+'6&OHS!I8K*/:-%;I6??/%E9UPWW#<8-3Z>_?Y$#*_4&;>"
MRU?H?_Y&35?]RIXC4?)4&$FX ?+@8'M:3*40MYZP>S.0I5<OKW$,GMUU,N8=
M-[^;='O3Z8V:WYUTAZ/]>JE=JT7;L-L?-?_\#?WD;MBE;N=D]YO0 5LK5;*9
M%_1_#ZNMTMZ-YMJ6</??$JZ)XYYPK[BV55I-%<:.UFB/JW2VOA(%2V?)!LEE
MZW$%\:Z]MV\!37NDE4H/J=AH-+0'HV9 I@> 3-@RW(-BN,'$GDY;K,5#B69Q
MX^+AQ<IS(:>_%V[W=D'].& R^B,;/M BD-P*J-;$=GJ-H%HM ,E!CNHBB-QH
M?NVC^IC =X=3>SAMNZL<^2X]=^SAX'XLQ0>IN)OAB%02W'.9)O\]W1$V!?:W
MHZ7N5?&_W1M_X&;QX>APW">PW[.=P8YF=0>CQ9VVI&U9^8FQ\O/1Q![UFU%.
M[IV-Z]%,CN**^;KI[RIH=U8U,(]J85OO%'\5V;TB)=8SDA>X;K24\6);*>QJ
ML( =QE0**E\KY;M<,\_%>%MFRC1EM]AFUBKE.'$Z'RP+.4[4I3;7NIJ),C"G
MF;]:^UX<S,%'"#R5F%CZZQ>6_YN?!:M@1DN;!8RU(+ 8VF*[0K%=OTB.MMBN
M+;:[>R[<ZX)%9^N,AC>M*AZ4ZY.G!KC2KI$L6>33M8H3WO=%3J7&$3A-,\T(
M'T/68<!V[I^T9BWRD-Y9I/#.;&-,1R:@U8MV@Z!;I3R^W9BT6%$CAY#,MN5Z
M_\F)*$C1*(XZ[ '*O$K*PL5L>TPB[LP(":1032V>U/E7JL[/U%FU)7XVK&^=
M^*B B$J80K:*P3#Z3?_%?.E&EUS*?14GGRE%E!/3'PG*R%L5+G_0)E)MI+'N
M*H#RH_NC4H7>=0%Z]%FF:BFSB*I0K=60(VA5<P0MSA%L3 PL"R JA:U?GC.Y
M1C&NDG"E-8GD_X.OX@'RUAN0K*E8)%-^1Z:IFY65 .6QSWRJWE0OT]Z@:,("
M&:06;50$B[:R*S_\(K?K<90BOU'!_L<G:.HN,DC0#*?=T0W-%J6_C*K-N"1K
MN,J@N>@(4;; #B@8#:H23U015THBP\"=!6&0;6I$3N-"G1N#OC2L<_]9'GN9
M[_M(%%8Z(UDP?N6+&CH7CON5V$)19)!F0 WV?B-5D&>+['6YV6FI6*E:;*BK
M"_N#Z6V6%R*5C.K"KO5*HWUB59/8>56,I<OFKWQ9 .8,[-YP8)],3QKKY!C(
MBK7-KL*E:4]#-UKDO8*EAP8VOO[=P-".2"5TQZY0/<&/7I#.XUPF_.,,& ,K
M-2(9TC8MU@C6DJ*M;GV"U:UB(O4%J^D2'(P.;C\N((RC2_Y#72$K5T7A]T L
MIG[7ND!G2!;/DDEA3F2&!1:S_XB@($[I2XQ1+!22LH9052=R<9.Q%62R"0PM
MP8DP.-<8;K% 'E&94N\$:^+>EFI1:TJ'HZ+,,([J$@N5X'G"_!ST;6?8MR>C
M28-08X]S/N<3<\WRV]K1R[O*995A&J-='DEIHV:/>L2U!KV.!SP6,Y9S]<M#
M>P)D&/8GA?K^QA6]P.+4G8LJ+Z?\J6UK^E1>@RR^E<*TLA!CXK6SJ?ON.7_S
M0G]33[B@?U0Y+4C W' "58DLP<_T>Q,-YVI7M-+UM1#(M)7+WIKXC@J:@/%$
M_@5/B"\+YF'N2;5L3A]L!]"?T<;6$U>US$)H".KK6ETDA@;Q )8/5BO?"UC[
MBK=I E3'CG)*%CY?Q;+267Y,%FM+A6+O6_PM32*4CU([Y0*'P]AO(5AIF11,
M*DQ<<PZKKR"QEG!V@:F.U.G:*KQN!_? U.K? (#@].U^CS(6KX.%L(<D[/?L
MZ7ADGPQ/&D[O%CP%'G$PL)V3WI81F.4Y?(F>BGQ=\:;O J&XSK_T:E7(_\H3
MP1)B<)O&)P9( '^G8?@/0)TW3!TYA#1DMHX_M)Z#40%'05_]U2Y#0Q7LNP0$
MXHG@S'W7@Y/I?,^S5W8GP<R2(<5,B28_6U&O<3G&-$V103&1R&^:29-L*((M
MW+9LH(7^>A,)..B.RA(P3@*0)XA4)VUJE(F"2C6;?AB"T9:5.:_ZM=VK0QK/
M3&K1)S=LSH,2 \?7A?4+7=+T!?TZ1AGR,&Q$-]$P&"V0R18@D_<MD,DU@4Q*
M%MDZ="7@]B6YA;X"Y0H;["Z*^'7[.O1P$&R4+3.C.0DZ:2B#CPC>ANO[&=Q.
MRQDTQ]R?9/K#H$U_.(ZYW$?ZPSU9YL](&POSX8\@T!$Y)GM&>0_DWZ+O0'D%
M'&"G/"D1!\:K)_3>6+]D2]#_%,ER>IU_J'B<!"2O34' AQ9Y(C!'X4^K8P;S
MWTK(MXAXB>Y-U;&IP?"M8"+B,[;Z'1SE "%'0"SCC;"6VYE46;858OQ.FA?*
M0J-D"/(K['+0#<-YTG&7\3.I^?CS5X;F0F-$*\#O"M,@U6XFTZ$J^>*&A20.
M 0'*AJ9OHC/"?,1GRE\9]8J+9;C0S/@FF)YDPHMUBT8N<%Y3Y.&4C#.-%EG=
MC3/48:2B?HZ[5M\D/Z-BRAVX<HD,!3LX2]P 0?VM-/C:H>LCS+T(O<X5VO&1
MBI$K^BK2+X,$)P!')PSIZ^(:R6BTI*8 .D[T:R)4?T$811;YIHRE4*37&(>W
MV=A7$2-2"Z>P6[[V5) ?7&ZDCQH8["QLX7$)MO=9:AYBL!-PD04,V!V90<1N
M8K,X/F1BQ.+8OT0!3N0"I4H*WKF'X*T8%_()#&E4DQ15E"D7_CH3-S@]6V^[
MYY,)0#E:)EM1/$#\2,YC+J\>=/J-O--BRY-NPB.\W /+D_J4N.F2[E!^CK\(
MFWI@W!V5CC]Q4B*R>.0FF'Q7^CAF]%1Q'5?N9[2&8P3C00=&W*#"7,)0;1V-
MA Y$XJ7J$V*W)-YZ:CVG7A +<K7%)N \J-X%#^2*2*)<<Y/YE&]8HH8BY'/\
M45R4?!!3/(<IBGL2<,5_$9P*VD*1PQ;V)0TAO9Q\E;.QI\)!B?5!WKXVK@%C
MFG+C" #^Y,0^H7\FQ,Y%4UX!.8EQ#1$,'^25HI W999DY_+-K_"<X3!R-IAP
M?[18P+"2>%<= K'3G(51.HFP$#>Z1'E# P^Z@]_C/)S>[V7X68\M:##'; U<
MN>B_MA&$@H^&)4J!'Y\2?A6+5;K=22VT#W7//%QZ*D6O9#(,MX1^)L')L+%>
MXOGJXJJ4<<1B#</YZF)<4F;FAJ2STJ7O2Z2TQ)>L1.N.#=FH19QR,COJUGWE
M9\O8T\DJ.@H=!@N_* [?,*B>HG))!F/<  DO!-QW_;%N*2,I2+DP=(E,1WSE
M@B.5KS@K5)U&]'\&(S/G:>9O8N&3XLM@!M0);5<'/6$C$G3.>H6K2KWM$I?;
M$_8 >-,1WM_IP]L?%44?_G^$/ZI0 \BL. \]<9$MXZ5J$3-0V\KO+3N-IF"%
MSR)K"G>>K$3/&(C@PPN]:I@$;\5?T:;0%:]>GE;L5LKP^B#?Q!CZ=@N9!O;?
MR!2MJC+^O$B:K!,WQCIIG& E @-R+)!78?#9YRP0'DCIQU^Z%UUCVF3NZ/T
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M2DIM]1*9J8(#-(AYCJZSL-^HM:IJG :*HL Q]+?V]/$=(>:E*(M(JI.=JE=
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M27 ^#4 ;BF+)1-ASA9MD)3E(P/T,Z#WH'GA_>;;[3F9Z\NPX*I(;<)\S?R6
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MNPV3N38X;DT)Y4,*MI3Q[/<I@Y=8R)+*9C, PS[="54OP#BH'%KV05L$(*1
MTHLV3M9S9_3[[VER5_#'36=!9KC\L8\_*K![U%_2X<-:\T(4A2O/JP#^.Q8L
M_8/[6?,RP+P"]?>#WK;EJJYP(J:Q8Z6E,,+%WFO<;U%ZFH6.=L7]*^RML:VX
MSCBJ]KHK^OD7PG%6UY*->XDX1B@PY 6&<J<*?2WK/!B6"'33Q9@D<YE6DQG+
MET 2&O(*)8]*RZ[C" .F HDD6WO&D89(\)+\DN^^#9KK]@X;-7MY-4)M[,3F
MJ9SV,EV*Z,1D>Q7!PN,D%79W(RIH@,FE6#-O2R^;+B:0 _#2JXCI(#Y@C"6
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M6ZVR>,H"QL=J#%.4< EHR?0VKU+@H, 7R;!C"R+*W$O*(4&P10%1G..WS>H
MXB P&9G/:6%4","Y[6$."B[;$\YU_^YJ3S*M8M*F51S'7.ZMY^ =LAPUL3U3
M26&>2".C)(A_Y*#&?.R172W@^H>M((RCF(65R'T@P;J74#U%""KNBE%! %^#
M[QX(AT+T@ #A*\84DV4/R5!MOK0!YD$RSU>,-9\R9%*04F8LVO@V6<]:+9$>
MW&5RB1L^J5H8@"J1!?CP)!80Z]1%H2<IYX.RMWW=N:-@\J;"P)!6X'Z68^E"
MTZ6[T6)');PRL?GB!&,A7\ ED*ZYOGA0J;C9DJXG(LR[_95"":!\ U$2)T&V
M3$(V;9*Y-6Q E6S;_?E#&D)X$R-U44EY44,!00?QZ:)F- UE1$B75=0B"7^C
M_#M9B(=;IOO#V^79[\DL,OZS J^,(4JI\G &EALB(D4BS"(_ZILADQB($,GH
M5IF#,M-&X+7IU&DC5+*UKE"FAU<SLUM8IH(JGAX$ELGIWR8LDWP4%CGO .$P
M._8EP\INFNEV[]J],%W_ZS*8!=GIO4_P]E5^W3:='B$BR1CKF&A7'BJRD6"J
M5*2Q4^.,) K2)>:TF^UGMI@Z IV%4(82$RY Y-0+$@FL+%CV5QD?J_Y2P2@2
MZ"?;81R*]+L]BFWWW.Y4&#? GO_KI[<_OI6P9#^_>OVOP]-J\FVD$N<AB]<O
MZ;;PSQ1!U8HP 3'3H0CR.O5?RO\XQ3NFT-V\#"+Z%KU4$@DH^*F#V=P-Q6;0
MOO#/0B=,3[J#\00GF"7PCR<_+#1&E^>>>=7?)MWQ:-KX:Z_KW/"WT:CYF]O>
MW#;78:\[G-YT0G<]V6G7<6XV:CO7;7-U'&#U_D.9;*\[=29[#?N"3BZ?7I /
M*&?^\FSPK)2O\;)G.21?Y'C'\VC?J3S;7W_%IT\KBJ0LT5B8'5J]E&5Z1;OT
M&/1!*V96,;.-0&23NIG_F,4Z^_0:._8@B"!L%HK)_AQW"^L\&.L\"$J\(C#O
M-7H'AZ6", +01(!G+7"$ \^2RWE0)-+F<9P0QUS,P;+.0W\/@NU%A2=%S>L?
MO9:&%8ZDMN)$PE<@QYDY,6^+V?/U>4O5&U"5^@LA)8&\/O-GCO!L=5JP%"R<
MLA-T_X1NQVG'.;IQ;FXY8DIR)1P0KV\<1+]9K'6ZLQ7J_<:"OW%^(A2\S+)U
M^O+%BZNKJRY,LWL9?WEQELR7B-S[PO<NW>2%YV;N"V<X&$[&DQ<P7:<W/!F.
MI\Z@UQM/IN,7;K_OC,9#YS?_:V?P[WYWF8$H'W2=FFCQ;5O:6SFGY8\CXH\S
M ;DB4(4SBAB?X\XMJ&4?AJZUTRJR;#$D_=&_1/P5-\KN@;_JS1?FL(/:+OML
MWK,?)IV_W;,3>V]+'W3[3W7I?\TC7Z05.H.G2H3!8-!Q)I/1=/2-AOKQQQS;
M1W<\VEJ:C]62&/<G_4FO#X)N-)Q,7H@5#1QI8_9;&[/EC!K.*!F29&S*(K+6
M\FPMSV^S/)VGNG0$T.R/N6O%4Z4!R)[.8#2=C%N[\ZD_VMJ=C]ZZZ(_ZPY&V
M+N;:3(@77V!OI"$Z: W1EE7V8962H?E/^,&3W4DU_.HV^Q5-T0/8L%0+Y5E%
ME=Z:M:U9^_26?N&O,V[)ANU_6N.V-6[;1UOC]K%;+/"!R=3!T-G P27&D2?Z
M8(!5D:!1(8W;86O<MJRR#ZM<T$_UUNF/F]"]2AOM4-&N;4KZ]SY21XY,$V--
MWE.U0IZP*:I;%#U9$K0V:/MH:X,^<L-B2XK@\-_B$G?8II"V_+&%/RZP10*8
MFMCH#CNZ7U!'=R,*VEJ1%YTG:T8,GZX1V2:(M@FB[:.M'?D$[ 0P%,:C:7_0
M&XS&@^&+;-4?.#UG,O"<?_M?G5Y'F I.K[4E6Q[9SB,$_8D COX\3QB,^$,.
M0[NI;YW)IAFM2?F$K\A9BCS-M8N^]@+,_*E2H8U-MH^V-N43MQ?ZRJ9LRX]:
M'MG*(]*F_)6:)F=&(F=K4;86I90A3W/MK4796I3MHZU%^<"L!3]=)QU,A'.^
M]@8#!V67R)-TNLZ?6H/P,6^QOEL6)34?DB":!VLWM%Y_]><YM2M_CQVSL:\Z
MMF!WN6;G8Q[ZEC-P.\[PN?L])T;27XT\\5<B+]((/K[^.E^ZT:5OG<T)R-^9
M#H;<N=2+UY@R:7[@PJ<6?=:@UU=#N<G,C?RT\_XK=H83H_1[O5OW6MI'Z^1Z
M29E/6F7^F!]ME?F#DO3]JC+OM\K\46_Q%F7^1O44:Y5Y^^@>RGS<*O/'_&BK
MS!^2I.]7//-^,?OGH+3=W7_LGHG[K1/<1=W_:<VDQWQXKA7S0%MH7S/*F5B_
M="^ZYUUE[SB#46^G433MC5NCZ,@>;2,<3_#10W<&N\=+6*=[<?[3GPYQ!=D_
M^3;U=0_+?TMM.:U__?CQG?7)_8H-Q#<@VC,_2E'>8MNKE6N]BN<YIRNTUY1/
M^]%'=>[/S]ZUY[[VW)^[X3P/V>I[%T2?9Y@'?PTIT(9$'O6CCTH*O#O[L94"
MM5+@G3OSPQN=_];Z?]2//JKS_^'CZ_;\UY[_#XF?PG[=W QHQ<"C?O11B8%7
MK]^T8J!6#+SR%T$4W%@(.$XK!1[SHX]("@R?J@0XCV$FU@?WTK?>XIZX<[K9
M>>5FKH6ML:WGBSA9N1G>R[BI%1@" WN06^YZ'<(Z9O!D)@6(KP1($/';^-]S
MF(L++WOPMY9H#)]:*(#_]'TK3)[\H[3K+S+D)'EYIRYU?Z &[<6;/2.10HS7
MP8/U<CCMCN1Y"R(/!,W+CL/FZ$&/U^[[]3Z>KS_MR#ZXQ8^?%NCB#) &>*0]
M:^DG/I[>;B-)Q3##?O<$J;F.4S(#7G*WBB_^Z57@94LA0\P79W&6Q:N7/?V*
M.TOC,,^:7RG<CZ?Y:N4FFZJRN*?]&_9*%\K&_RX3S8&7?F>6^.[GCKN R;YT
MPRMWDSY[45CH*H@Z)<)>AR:'3@_:CXF..H5E^P1%CL/O@FE_<+*8.:.3:7\R
M[ UGT[$[6<Q/_,5X,?87,_??)\]^^$0Z+%Y8Y_!!X+C4JLDF>$B2YW_^\#MG
MW#NM_N^GI6_-"^D=BSR)@G194,W\+.90D;C(8BM(+0^+ESW,RYCYQEMD"61+
M>. ?N9L _X<;ZZ._CI/,@M&Q&II'0W1K2A:Y"L+0BN(,ARF,^8??3?I]H J*
M*?IOY]0"$P)30D"@^*E ZL%9BR$GUTJ[98AR&TR4N;]6?77(8($_+=VL#%.>
M(MHD$BJ$-06JMPY\)(#9;RS@,*!.-/=;6;I;ECK-LA37$'A_>;;[K#K.Z-DM
M2N#C%;+W/I?;EZ? KI>P18+QG7Z=UWCKS'M2R[P7;__WY[-/OWQ\?=%XT)MF
M+Y3!8'QONN"#D5&' B[Q_YL'"0%1I'O+3WY12<8ER%,O!ZDX=_,4!3C*_X2E
M/@OS%#8-?D _$#XS\Y=NN$"9B0,15XD',E0P>00OT7ANGBWC!%;G-<M406IP
MFU^.V"\D=E.",X'1.T#=T%VG_DOY'Z=>D*Y#=_.2W=@.O71:W#:4"67G'#>1
M?Q;B8CKM3D8#E!@B_"$^+(1)EX2)]( *OPU/NM/AI/'G7M=I_&W;L(.N,QP=
M?-3AJ#ONG>PU[)ZQH$;O<'Q$D9.]4J>?_?#ZXL/KCV_?_VQ]^NGUQ[,/KW_Y
M]/;\PF:SY.W/Y]U]@AJCXPAJ/(C9W2#.>%P,@UT^IM?&/3GZ9?VX>?F8EO,B
M?6%=+/W0PUN/KO6WV(^"R[JS?+<G0^@TU'@]]#,M\ 0"ST)ZG#X8VAXA78^)
M=C3BRR"#3\WWH";>T@=H6I)/?;X,_$6U.*.E\#=0^/F6JI=]+BWZ@U:#MAKT
M*6K0'_WH/S!V9/WD@N_EN9O[ET./0H,>(5V/B7;7E.^L,RL%BRU-#Z,SJY6@
MQ4K1L_D\SJ,,%OH(E:J,-44QA7&WC/YM3[;3.-9I-&0SR/=N<BCWBO96HJ9[
M95'<Y375T=Q(]9MOI%[,8F\#_UIFJ_"'_P=02P,$%     @ $4BI5C C$H;8
M%   7.<  !$   !E<W!R+3(P,C,P,S,Q+GAS9.U=6W/;.+)^GU_!XY>=4[6*
M;=G.9%Q)MF0[SFK+L71D>;/[M 61D(0U16@ T+;FUY\&>!$E7@!2TAJSS#QD
M+(G]X?(!C4:CT?SXE]>%[SQCQ@D-/AV=OCLY<G#@4H\$LT]'C^/;SH>COWS^
MZ:>/_]/I_.-J=.?<4#=<X$ XUPPC@3WGA8BY\]W#_,F9,KIPOE/V1)Y1I_-9
M"5W3Y8J1V5PXW9/NV?:O[/(7-/%.T/E%YQ1-SSOGD\FD@R87W<Z9=W+BX5_.
MIF[7^_/L\N3B[,,OIV?O.^]=[T/G_/S]>6?B74PZ%U-T^N$,HXNN=ZI 7_DE
M=^=X@1QH6, O7_FGH[D0R\OCXY>7EW<O9^\HFQUW3TY.C__Q[>Y!/7H4/^N3
MX&GCZ=<)\Y/GSX[ESQ/$<?(XYDNV\3A\@1GTXSN7+HYE<T_.SDZ3IR46J4 G
M 1<H<%-T3[".6"TQ+Y:!GX_ES[*<D\[)::>[49(G4K%L,1?'T8]'#A*"D4DH
M\"UEBQL\1:$/(F'P6XA\,B78@W'@8\GTQ@.9GP5B,RSNT0*:C5QLT!.??W(<
M21!9+"D33I 3G2(^457E3$BQ[I$3D7E'7234")5/\J15N>>/L2^X_-21G]Z]
M<N_HV+S4D'=F""UKE9R5B4J/OZE3@\S(//WUUU^/7^50*ZY!X=A1SW?DGYU3
MF#JG-8HM&X3F9<.G3B*WCSJLIUF].B1R.]:A<&*5C06=I/K,#:M1/%$-.R$1
MD*V_J%,@Q^Z[&7T^]C Q&?C;C\L_"H8Z"@(JE+S\)OYNN23!E$9?P%>2L,N$
MM1&>)NHKIX8+IH;ZWR5B+J.^9AX=+QD%;20(YED5K@#F#$\_'4E%WDFTU+]\
M-'D'-4D>R16P.?3DS\<@@OV[=4L26<G^IR,.!/@XZAN;&[YDN&[#083#$J&(
M_L.WWT5^W?:#B!OZ_QW-]_"T;O-!A 2D0>NE]!A^=XCWZ>B:@OTY1#.HG?S^
M<=0OMR54L6N!!#7!75?H\XGZ[]3IK$W6CJ,D'2GZ\7A;8 LJY-@;!)_5W]O#
M/!:.'ZD0W!H?QG*;'5LH%G^9]&1E_P8>#D#X"OERD7Z88RRX>6<72FM[O@O=
M_0!=AM.NCW&<&,B)D%I/Q! Q:-(<"P*5W(V532@M16>&%#D_;P#_;QLI2_N)
MT^D V%#UXBCPKND"FCB'A\@SOJ.\_L2J :VE]+R4TG4I#ITZZW(<*,C9*,F1
M1;6=XP=!W:<Y]3W,..Q^B4O$3L06X6G9O#!D,PO^)R>&;SN#UXC/;WWZLMN$
M7*-HV7IOR):$=!1FBR@:S[%4,BA8@;ZY0IQ WPXS+3(E28NCI>D7:1(2[OJ4
MAPS#!X!T8DRE#!6J)"J+VR*J'L+% K$5Z"PR"PCH$A2(GNO2,! DF VI#]H%
M&\\J0S0M;1^V:8N!E?Y;0SMK;"<!;Q%WU]3WT83&:[OTS8_GA'E@OXD:G&E0
MM%S]NLW5)F!T9J @G1BS113U@V>H/&70Z@ ;&Q5;4CH*3D^V*<@ _-D!B!;U
M."CW!1%J_556M=(..*BCQ:H@M%R<YJ=#BA:;WQF\%A$CQR2/^J'./$A$M!W?
M+9H$L72+NOD6$?9WY(?X&T:R(VIU>+&PMNO/MKM>XC@*R,DBM8B&.X(FQ"=B
M-<*^/#H75,SQ"(-:#G$_$!@:)X8A<^>(X]Z,8=5!IC0U ]?2>+Y-8UJ.$Q?D
M".I 44Y<EI,4YB2E.6EQ+>(:-/JS]+U/?'Q/19UU9DM.R]!%?G%)(1R%T:)N
M'\!(9+ #8"'VDI%:8Y4O$]>2\'Z;!(7DQ%!.!JM%9"BOE-Q8XX#7VN/G!;4$
MY#;U"L/)@K2HY_L!]"4>HU?SH9\5T?9V;B\>23M*O$7]O(.3N(D_^#2WKVZ[
MX_<>"WE8,<1,;JEH\#!'S/@8N5A81T(WM[,&''5DX@"2$T$Y"JM%1!2ZS&%K
M.P)+D!$7[$3YK?GD,$+34I7;>)<YXM4N?(VN?FD3>T8^VL-X?HT]P-W<;M[<
M ^S\G/S5IL/K39_A&,&.H):?)2>KI2BWZ]_V.CH_1U!MHR%V.M7G8%-02T!N
MOY[!:&/?%WJOZK%0!:'E([<[+W&#M9&;1BZK>MSM4H26V]RF?Q??6!L'0(F[
MI1[%U2!:$G..@U+/31L9RGEBZG%3)JYE)7_8GW/GM):.3:=! T(* ;24F/D>
MVLA*H1^A'B]5$#IFSLP=$FUDQ\R74'<:U<#4\K>3EZ*-E.IB &^P0,0W9M,4
M3DMDSD%A%%GH_!P7T"8*S7Q#-8FL!ZJE,^?,J.-O:B&GU5&#-;DT ]-RF/.'
M:",16TG=IK>O)E7%PEIJ<JZ1O*^PA4Q4!!K6GD%:)"U'.1='9>1B*PG+.%C3
M]4<:9E]^"\DS\N/N?YA3)L:8+3*/-YAFNQ6DI3OG#,EZCS?6/V5Z9DI6@T&5
MW9&%;[J=VSTJ[A&3J\TS;LYW#D++9$&$1I;)%+"5Y!1Z]&NR4XFAI2?G3"D]
M%F@A/8V<]DUGV7X*TQ%^GO/1['16T/8)W(BT=-'<>C %^T^,'.-*:$=4SFNT
MXXC*+.XY@35T&T?;=DQV;3N\6%S+<,Z=E(OL;B4=)0=^-5G1H&C)R3F'*LX-
M6TA2[N1/?3%8*J]+S_-4.<CO!U/*%DV<MLT+T%*;\QD5'#XF7\8%.NL2G4R1
M/ZA7S+AS[(4^CI-@Q%VV,]^5J%J2<]ZG8I+C0M(D&RGA/Y@%S.'5PV!G(C=
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MB$UXV'&Z&,QS[VIU W_)-IZ==D^ZY]G]5'P'30G$[@UHUAJ\R1YBO^5;L6>
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M^.LQ.V,C&N<RRT8$IKFKY4M\W8_6/"9(1J;6QW^V@#DFT[@K?ZY'$<-JK?W
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M2_48I]:R%G5*EG'4PCCK*13:[+#DE@#&5"5I8.8\FIX:UE2"#G^A@&AUDHR
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M<1U*$BP*'0Q**;5N'?)?1C"&^.WK$V8'K6QH#T^_KS\B]/CS=_\/4$L#!!0
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MY3HJ/,>$R^CE!Y])2&@( X#)0GE(J;8Q=P? _LRWBDH9U9)HQ2#RDF6"MN0
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MSG-98Q\:/"S.IY/2HG%<>EFA$=T+U**AG"4!B)3@N2!1?,Z2!%8&9X1(BN_
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M5[I!>H2D7>G-XY+BEHDH6K7<>T1S=P;=\R74MF(?U9!9Y6I5?_BOMX"(I$+
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M"(8;HM#JL,8GL% [/.TDJXYOI-UV5<<W4<V>JXXG7#H.70R2*:#)$9PF+OM
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M27 RE)ZC9<;H($>IC9#""<ZJ/X.L K)_*Z"&ENYEZ.\JX@X._M_\H,1@O+\
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ME%/%;7*4>,$U,<Y%&1AD5SW,Y4% 3YAE]17605.$6QR?AS(L8$4C=8J(PQO
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M[1Y_OTH+.L^*5<XOB93=F):SA"<)\3T'$A]%$%%?0.RY%&(<89<%G+J.8YA
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M+],2SV<(!SR*70<R[KD046F6$T(2&(9!@F-!F$!:@N[$/%,3=ALRJ_HA,%T
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M+(#$\PG$+O5<QW>(%"W:OF&M*:<F3M:4M?GM!<CKRM7*>5?5#P4+:984B@V
MZ6/*GZOU,DG%UEN,;F$S#,0#BYR:WK5AN*;Q E0T;SZPCZ:!X]DZJB.V8ZJ?
M4%P9RDJN;\IJB1I[T\<:B"P'-V6Q^@.KID[_CI=X8<M=;01TI^=:;Z3QG-A&
MG.WXL\WN--L)&$]G'^334+Y<,B:?O*+:;6[RVSQ[3B53,U_0@"+*(.<(0<24
M=PAA!@D+'3]6?<E#+?E_:J*I2?V:5M 0VW3PD9""EF ]<702WVZ1;A.U@05Y
M?\"T)80N&@?4QH+3GQ^RYU_D$+7&*'_9*(HG!QY%3.BRUPH'[>O[V9?K[)'K
MQ7)5%I^D^)^[;<R6[X2AYQ$8!4R53!,NC),PE'\21_#(1=0S,B\[YIJ:8*AH
M^\=_<$/GGUPS.[(+4#TSTA),0ZMTZ]POU0=-$7H!*E*!>SITT-B.U,#$DAG9
M-=.H5J0&RZ^-2)U;SG3;*O=>\S2'V)7BP(VA% 4N1*Y+(8[]""(O=D,A B]
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MH>_#V!<8>B&F220")R&.29K4UMA&TF"$/*CZ=*-W.L$V:GKO?4\L!G[//VD
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M-TJ\F7S22?;G7_IM-L98_-MWDU_^@56FP9=T^NI2#0'8P@!4((!2HK!1IM9
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MV43!2.6H-KMQBP4HUV!< *S@J SH4F&B#/$6E#80B];0 %:=A$AS>[DJF^T
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MHKRJ#;X;\5IXO7LY/$#U1CB81HY#!70C'TN5A E(0N;#T L%]3SD)8F1YVA
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M-]YD8?:J>;P-%?WVR\^\?(^+Q]L\>TX99^]>ODJ:KA>'^L(0@KS <P.(<9Q
M1$(,"78]&+,$X<0A*/2(23J$_M1&^]0(*1.2<D EZ6#9T*[DUH\K);'2Q4]
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M?/3&R]S74S H;9/P'(R!OJXG811:; 8W7ZTJ0VUQ(VZ:F+TZQ6LF<!RZCI]
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M_Y""&^.4UABAD,;_864SWJQ QI#E,*9?_,)FJ0O[A2WN5:':5?Y2=;EN7J.
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M5/PUE3_*;,&+F2\"$5#/EZM%&41<^4@00I $)/&1@P1UM0*#[)(UM>UIS0?
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M)M(\=AAS.?=0I'7X?V#LJ6T.5>DNU1U3TO>[(M"D],0KV#2D?7\P!A;CVSB
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M.*LQ1>)K/-8H-(\[;FM,,1R,[QIU\1Z.]=?5\S.I7C?#!V\7_+X2^H18\/5
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MZ$_'U#3X;^1'\;QZ!N2Y7#5S87[_"A9B"6I-O\X9^Z\5F1?RU8PW:3H?&8[
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MSE(".1=2>5,Q@5@?)$8IXCG!,1.Q'&4BBAO=4U.!6V2_[= 31_%;VF;3$^K
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M89I*-M/YU/LQDWG&"(Z5IDYD )$02EUKG2VX/N>+4!Z)S-J?[D/!U(RW;1Y
MU3&Q-:3<01?UDHB%;A\:YX$5_@[$:_K!A@'05HXMVA;$:R:&QMYA<QA:!B/M
M& /(PFU+N ;'L_M$KP>/MWE<P_?.CG+5@WK'V,MG/06LC4[]HIXKB^4LBK(@
MT:-7<Q%$$#&*84Y3 =6NDG"L_ ).G7S]$^M,;<NXK\KOA4YM +*LE.%ORI*6
MY$>/"HZCL%K'P*\%:_@@MT9&D;@.:/_44NFQ?NL"#OY"U4=7&3L6?8[5(\'F
MLY?WL#G;8N+ZHZ)MS[3MO(RUDS'C:1S3D!.8!BB&2(=M<A:D$*$X"L,@3O,\
MM\NQ<5Y[@FDU+?6ZFU_EX\S 211YC *B+'](HR2'2#(,"<TXS%@04Q$(&C/D
M,/=V#'F,,=MVWU6N0;N?ND2!G 1A8>U[QW6DV8[="Z[IMCF$& IB!Z-^**A'
M#+F93J/E:BGGY9]-!3DYU"\O'?BDX\;7"4\?!,^:\4X/',]\[\/GCMG>ZP$]
MV^:L:%WP@E2O=Y5N];E\_4TLGTJN:S/KI1#:-[B3)C[PR^OAQ=UEIL_##),X
ME(Q1F'&FS_=C!$F0*QL?I8QS(8G(G$9^^B1N:H[!AEP]EJ<A&#3L@8[P&^-7
MZQ#YUZ; X!4<O:V[ONW,XIAOYO45L/-'WDJP V]K;R)3]Q8[ X#OJ]F.3]+&
M;;LS *@'#7B&6./:;FOO]*0@6NKLD>]BJV]4?;O@7Q1V)WYM&LT29IK7-)I#
M)B$/]=D0"9F *,<9Q$D:02&#C$8HQ%&:.VT>WDF<VA:RP]?.K!Y="[#][Z8N
M8/E$%F#WIGX;AG_A6VX;;RK2@3>/$:1Y13<VWX![[\[FC< WZM;F&^#3W=N\
MK]1O"[FOVC(6LV'=D^JN,K,J^#_(?"7N167RD68B24*2HP@F$=4COWD""18<
M9@+%88"34'*GG@5VRTY-U:^I;O(&;\ +J<!W3;&7<7V6LK#3TOX1'OHT:@UN
MFW2H:-:6>$,U,&3KFI0F&=&?=G4#RI/&M%QT5"WH!L2^9G.\^YJPYGJ8SBVM
MEY52AK,D(B&-@PPF0:RLUB!#$,<)AT&(2)(&),;$R6H]L<[4]%$;KEO3"?[H
M*'4N=CN.JTM<\RJTQHEK.@'5,ZQY$@:O8<W#5=X@K'F2U>-AS=.7O\UHY%_5
MA<OZTZ*IF/NUTOU7<Y(1'&()&=**A- ,$I9*2!$)\EC2B.?IF/..C] X-25D
M2+RFS\H0<K3T9-]6.D.?@WJ<)]QP:AH>M%7!AMOI3 <^(XJ)C/P]1N%?:H[O
M&8A]#^<]MU2_S>*6<S-0B\SO2<$_+=Z1EV))YK\),]LIR%$8\X1"FN$0HHQC
MF,?JCT#& 0URG$3,*61V=K6I*? -L4!3"S\M0$NOFQX_#[&=1O8&W,"Z=1^S
M8HT9^*,AUJ-A:06*)RUW?JU1]945V_N:Q^ZF?CJD'0%K)L#J:6!ZG;81"$Z2
M-.&YA%*&$J(X2_20+@&S,*.,LY3CW*D7R^FEIJ8]=N;B@H[6GDU7SB!LIS_\
MX#:P\N@+F;/BN(R&)ZUQ9J%15<9EAO?UA<4=_2?K?BQJ/3/0&#$?U<^4?QED
M" 4LAR*,=%8G1Q +@963*3%#0@8\%:ZC=0]6F9J*6$^.;2AM70A@:'6?KGL(
MZGG5X VJ@;5"+Y1Z3=@]B<)5(W8/GSKZC-V3C!T;LGOZXCY9]J+2W3O(-QW9
M6SVOYB9NUZ4)5ETJX:\K8DY+Q Q1F69",BB8[F9)40!QS@(H9)0G<4!0R*T,
MAEZK3TU!;.C7&5ELS<$Z"[;JE>7M*I/S>F1PI(>.KVU OI-@0_PZS[OJ3G_T
M>4_'P)!XNZ1]#XC[2*G?GO%W3/KNB=_YQ&_7AXZ8_-V3W]T$\+X/Z>=>_E,4
MWYZ6@M]^%Y5:L^O_]+Z8K]1/F[XP=ZMEO20+KL<=B(BG48@HQ(G.\Y:)#GKF
M*<1IS$),\BA+G'Q.Q_6GMHETY$/2T-\&(W2E14<R@( WW/2/5KA*R<YO'1#[
M@;>5CG+0DK[5IJ_M!;]%]PUH.?+GX_9$SI/CZ[KZJ-YP3VCV7>2^C[DVI[D;
M3-9U7MD;$IQAEF.2Y##A5$"4Q+J-%<9*&\H\XA(3SF6_3.7S"T]-[W5TZR^N
M]VA":]0M ZL#8#ETM/0(C)OV5B--6[9#RWO6[H5EWR@7UPZ,TQFVEO=?Z>T_
ME*]DOE0?W&/YB]##^Y2)R.\67\32-/2884PB&<081K%0CGX8: T5!1#AE#.4
M$1Y*JQ,_UX6GIJ9V??RJ(UZW/Z,"5"W]NM9>-Z)=B"6H-1L]_<]+4G%T]3UB
M/9Z7KV!^V(/Y80MF17S3,&@@B'MZ]QZA'K&F^\7Z[5Z_V=[JN=W!L_;J+SWO
M;1QZ2RY/^O*V]_<S8/4 [G>E&30I%DRM\KE8B$]+\5S/8D(3PF("<8Y2B$C*
M88[47D 1RG).92BD4Q7%Z:6FIOTUI6"'5/"')A88:AVCQ&<0MC-/_> VL";O
M"YFS^7D9#4\&YYF%1C4Q+S.\;U1:W-$S+>V@\(L<K_5JLZ@8H3SB202I#!!$
M/,IA'N9488U8E#"N'&*GN8^.ZT]-K6R3;PHT%0-PBP.PS4+/G!17$=FIH &!
M'U@O^:B0]9[ITA-.7TESCJN/FT;7#YJ#Q+J>C^FG%T]5Q[;?6!8A$24A@2G/
M&419PG401$!,D0CR5(0B=*KW.K_<U+3>YX*M9PUN4:XS^]TZ=5FB;:?1_&'X
M9@K,?^JN'2B>U-"%Q4;5.G:,[RL9R[NNC2S<?B?%7)\&?BPK[?)]%6Q5%<L=
M3R(G+(J2&,.,IS%$L<@@X4$ <1CB/.8(AU'/\(+%ZE/3.$W3&H<$G'Z8NP87
M/",YL-XQ$[0W)-Z -?E0EA4T#:F&\?!Z(>8]RF"S]AN%&AQ@.1UO<'E(/PW6
MC9S]6"QTTK(9\MC4.P:2QLHB$I G^F1)YE)I*ST<.R<849YFA"0NVNKD2E/3
M3.:C*NIZ93+JF:;334.=QM1.&WE!:@S-\ZD#R9#HO8#S(@Z>],GI=4;5'1?9
MW=<3EV_HZRD]/Y<+TW3#=-J8L02C)#)A1BX@XDD*"8THC+#  4>9R$++\5ZG
MEG!YL\<9Z=50V'7E^?^"OP5!N&G.\W<0H> F",S_NK0PLEH^E57Q?YHI2F:H
M:,6>_N/?PS3X>QS> !T8,1Y6\]OW@AD;=.>"Z.\ YS=1G-V$:=8]6"LC_=#E
MR2=FZ4V2HILX3P_O.;Z.JSNW]TK8.G#]Q3RXRV;DVS8&,M3=&(7F,Y/L%/_>
MO+.]QX_LCQUG[M #.W%=GXG1>E#9G?RG.2A:WE4/.H_LPP]1L:(6?)8F-) 1
M8S#FE$$4\1ABEN0P1'%(681CD5N=95NL-36KI26S!J*CT#TAU0;B\Q^^9^"&
MU@&:4*V*6U)U;S!#[ U8D^L/.9<!T-X0'"EAX2HD'><]6V%S?LSS^4>,.-W9
MBI?=H<YVM_3U!NGRTZ)>5N:=^:($WI9*1X%D+,42IHAS90$* 6E())0$Y21B
M>98@IR%/IQ::FE9MW)PUH3= D]HSZG<27%NO\'K(1G$*G='JX1B>A\*;7WAB
MF9'=PO/,'GJ%%ZX?N35:UZ.\HZ@V,=S')[(XVIEGKS3 _/(]68J/I*@:UR-E
M',LPQQ!1D4!$D(0D#E.8\"AF&4U"F4DW;W0RO$W/#=YNQ79M,]K)P#QT+[>W
M?"T&5O$>.L"MYV"LX=E.ZSC3'^Z@+LQ< C140&/5>/$3:" WE/S?NNV<=[[^
M&LWJAA*GMQ9W@Q'8XX1FU_SX\(,]:>K7623ORH5:5<]-W:/BOBK8NJ?SQWE9
M5K,\%"(B*8,RYS%$(960LCQ7GD<F>!SC+$56$2C/=$W-1^EXV:3JW( _.U79
M52Z_:#8V.S>0FI.K=G7?TK8X6'H;&8[M-!V3YX:U(]N@86_3QQX8#M]&B YG
M7&\CS)'.P\86JML1FG_HSQZW>5QNO*,Y_QCM'.,-\/B>?KV.RS1QK_>KJEA\
M:VR$I@;_02@*"[9L1S 88Z/)9* 497F8<8CU,2#2D[U('$4P8'%"4<+R*'+*
M#NE'QM2VXG\H0G53$%VPMZ:YB2&#U:)H*PK43BO+ZEG'["$U'M*)B_OW/^\G
M5$NW>'!1#>W#&H@;#D##PMK';+BX 1L^VG&.K?/JNT?Y55CZ\@?[$3&N\W85
M4 >>UG5/\Q%<:33\LJ!SL5'V1KN',XS2D(<D5RHU#R$*9  )RCGD@HN )DS2
MA/:/MIQ9>6KZM$G%VS*CV(;V[A^:^M:]\7%(:2^E/F$;3]B/[9*\VX9]0WAC
MI X5U[' :I! S[EUWS#R8P''^5"0S0.N+H-8+ O3#ZWXOI6LK,S;^4HI+SWV
M7!]MK1KWZTY^(-5":=^Z,V@W38'"&$D993E,0Y%"E"<4Y@BI/R*&8R*5B2GZ
MUDIX(G%JNG*[VU#;)JUC"FBNP#LR9Z;AH/IP=?IAV[9.-^WX25<C_PS:F5:7
M)^*-]198&J1O*MNAC=4ML6ZSMU7VL9&S-'+>L*AOZIC<.DL8I_.4;V'XKQ[Q
M1>!;E9AX!OA,'8KOE:[=9]:ABMNZ%J9Z^'-!:#$W=/TF2+VJ=/^5!TVKMN]_
M(751[W?[(V&B>V7!%,D$HCA0]C:*$ Q(QBEG.0VPTX0>K]1->7?1W;2TO,GB
M]3]KT%0?%&0.&F[-$<<6OZ!C6.>B;\*TNG$1 6L(@,&@[X;CXW5PW6M&%O*(
MV\Q&2#<79:JDN"?#D787C_![WUA\T/9&>XI'6$]O)SX7Z5OBM/:%M)/4=B60
M''&"TU3M SJS#*O-(,<"0Q3%D4SUO'*W+->CJTQ-LV\1"325KH5!QX"TTZ57
MPS.P3MQ'9I!F#F<@\%8E=&R-D4N%SK!Y6"]T[N(>*2F/ZIX[^5#4_VH3KK,T
MB).8$1@3';SB@JGO/ UA%A'UTS D*;<:R7OTZ5/[OC5]>CR$IM Q<_TX>A:)
M&M=@,O!'[1T.AY2':V 9J_-H"\^'[Z9[C;?4_;/\G\T>.+AIO!R 4_3N1/)/
M7G1%GCV]G 1(3\RY;4N!M+'T:;%4UE-=,&-KA3.>X#B->0BIQ+%2>SIQ/LT"
M*%,<1#*+&9+$>1+Y(*1.38=N4=HCY7T8:5KZJY.0T=#.J\>QY%L,WX URX.D
ME@\J%I^YXL,0.G[R]Z" '\WF'G;%?CO,?=7V#3'I#4VHZ';=NF)&>)Z&49A#
M%I (HB"E34?I*,^B-,G4!B*=9D"=7VYJFGY-;=?Y8ZNI1^]TK N(VVER?S@.
MK(TW$+;--=IHY(98?WK4#A1/NO#"8J/J,SO&]W62Y5T]S]1(_:3_IZM1OI.Y
MKD/9I%+I7]PN^.X/MJZ<R8C0-(XYE#%7:B>6'&*!0B@Y20E2[CD*\>RE2=-:
MDFII>0)W#4TNW]0^90.>2BDB;P!3?P*QH=6<T&^ED9K?$V7UB&_%8M'FI#9$
M.A[P7275!!-! QS"*$;:Y< 2TCP(8)I)E%'*4X:C5JH?%GR2,NWHFHI$A?KQ
MV\B29TE*)(,T0[I1/ ]@3J6$.)19*F.11S&=+<LEF4],CAN:!CPWT6NT,EIP
M.V'63^6?BVX\D=+[7+=@UH8'6;;]Y_7H8GVEG)=_.@9'KY.UY0'^6!(<^J#?
M?(#Z3[!%X$X2>'.)EN+>#[?O\!@7\(&LK_C!5;2,&V?P =M!/,++0WO$+1Y$
M,QY8GRVV@34L YF2 ,%4!FH_U>U9J6 "IGDH29YE:820=>3B\/E3\\8Z"LUI
MO<,A_1'D+*(6U^$QL([:@>)R)-(*$X?0Q778C!2\L'M=W&(6IQD_&[4X<MMX
M<8O3-.]$+LY<=G7A_[ORNUB0Q?)!&T'*X;Q]+E>+Y?84ZXC%-.280<(Q@4@I
M,(BQ<@UR$F<,9T+$B=7DLCZ+3TW/'=2Y5"WE@!C2MR>.]R[LOBP2"QTY(- #
M*] C12T-\=K.:]%NZ-\>+SX@VKUKY;VB_E8%\=>A?TV]NS5\#D7MEY_Y5I7K
MUMR>*4^W?T;/D77\?Z_:62"/Y2WGA7X7R?R>%/S3XAUY*91OW3:\;(HV9TF8
M)5D4$,A2AB%**8,X1A)&<<P%99Q2897!TYN"J>T@)F?W>Y-8+<&?;3-@Q[%T
MSF*P.R88%-R!=XTMVO7DW0WU0).ONY.U#-RL6]_Z;B+>&SY?H^B<UQ]W&%U?
M> [&T?5^4/\Q"T6SWNV"[\P"?5_4;%[J-.A-?0)GF. 0)7IF5 (1548SCG1S
MK"RA."988<?=DI-=EI^:OMNBOAU:MT6_^VP#!SE8'HT.AN[09Z'G@ 4;VL$?
M@Q1X],/-XSP%A\5'G[;@#LRQ60P]GM)S;/FFJ./=JJIT?@M5)B5ARQGB-,_2
M%$&6RUPILR""E.0(JG\)FL@LSK#3T.'32TU.<37D@?F&XO_N.*O\-*QVNLD/
M6 /KH2TBE;/8@O9'1ZC/6>47T? UJ_ST0N/.*K_(\,&L\LMW7#UIJDE&:?T*
M+#&6.44P#@/MWJ42XC2F,%0_#I! 61@X-< YL<[D=,/.S*EV@E/OK+-3X-H;
M,%="-H*ELIG@U#7N&G"$TS$<_$]RVEGEK08Z'6/US%RGHY>_3?V#;L$GN#)N
M/OQX$3H@^UCJ'VT=5NUU5'P0NFI#_5Q;0UJGK<C\453/X2P+PPQ+AF H8UTF
MQG.=O)3!F,1Y0$68XE",62_AC[6I*;Z&,^-OB)8W?=JB)P2/6V_A\>VQ4[/3
M(7A"FMUG/<?6J_5AZ]72/[[9#C4<:<&[A@IL804T6-,I!/$O_XD4CGAD["]5
M:.)?H+X+4P:@L'<3!_.X?Q;+IW<K934_BZIS55Y;1V46R"",&<U@CJF ".%,
MN1)) .-4-_G)2)PBIT9R-HM.;7OM!@6#2GP7BY5H^H0QW2F3EI41O_.9J07T
MMHZ&7T ']SH:<L&?BE[0$7RS[H[SNCZM\-HEPAHB?TTC+B\Y=@\):Q".M)2P
MO[=_]<M6WF>;89>$!,=A%D%$8J5]DC"%)%9_(S)*DIQ)%F16^9IG5YF:NK%.
MBW8 TE*77 O/T,IC#YDA.LJ<@\!C1OCA&J-G>I]D\U@&]^F+^WWOOR\J0>:Z
M;.Y79=SH_JEWBT\+[;$V$>3=YG)1*D/",(%9& 80A0F">90BF(@PB2,A(N86
MO'5:?6KZ8;O7W*:/X,&WH5VVKT]EM83:6 1;[+DI%#=)V2F:P? ?6 %MZ ::
M\*[QKW*MMZ@?M(-?+^0\Z2VWM4?59[U@V==S_1[23_\]"*8G41>R8$W7U]7R
M3MXRMGK6/:8%-R/H]-==B2?E8Q;?1=-=NMW/8Y*'(DE"*$,A(<HYAS02"*9)
M3&46$AI&3A&>Z\B9FH;<YT;G?YL&T!N&VIF9.RRU#;S=U..5@K33E^.)9V %
M>IUD!K#W_"#K2<%>2<RH&M</</LJV--3^^GDYE%?N_KASV5#0]NH+N<B%"@4
M4+",*X<T"F'.4PQ9Q!.9A!+),'!1N6=7FYI&;;^_-;6@(]>Q!Z =U'9*T1N
M ^N\*[!S5F=6F'C25N?7&E496;&]KVOL;KJZ0?+G<O%->V!?RJ6H[\FKMB)U
M"U7ET<H0TB!0]AMF <12I!!SE"88!2)P2^"[L-[4U,EV:^"%IO,&+(0Q!'36
MCI[L!UA9.Q]]70#=^D#=%Y3#GZ6O430D@I;&&_7/!1O@&-T&&/]MEX^N]E8-
MF,^Q?J85\]G;^ND8US;PZ@+U6E0[7>$_%POQ2>F_>D9Y%O"($QC@0)DW419"
M3(,4QCS@(DB4E>,VD=0K=5/37UOE8L\-*ST.UOS*STZYO9E4!E:%O6=NZ*NV
M.>R&<&@F@>'2HW4V"/J>]*U?VD;5SH/ NJ_+AUFD3UN;\I7,EZ\/32Z"6N:^
M*OF*+;^2N:A_6<W_9<XIUY&_,,AE3),8LCPB$*68P#S!&(8!2])8)FDB<ON6
M-TYK3TUKM]2OTSC,,.F& 5!K#@!5+(!EPX-+;Q@WD9Q7U0,#/?0!7XMQ2SE0
MI(.6=F"(!YIZT)+?JQ&/&]@N37H& WVL!CY.X/OJ\-,+M?/=?]P>.6)GH%Z\
M[G8-ZO<(MXV"BV)VJUXXKE^ZCW/R;2:C)$\%03#2<PM03!'$89C!4 J*4\H)
MBZU.+P^>/#4EOR8.:.KL],HA7.=5]%4@#*R +?FW_L9/\GK$[JP%^]NW\OM_
M4_<T)J?ZR\;2/'S2*!_N20:ZS_+T!?W\\B]BJ9,QU'?]O>""__+Z>RWXIS:2
MK"U#MBR^&[-QAFB0,XPB&$?*U481"R ERCB+99CB@ :9T,> ]CUA[9=V^FQ'
M: "KQRB;7JTO+>VZ0.&GE2Y-*!8_J_^U' "R9L'-VW:0BITK/0S6 VL'#;/)
M%+K?AOGW#N8U\>#V,LS.[J\[8IY\6X>%1W5<W0'9]TI[/*&?4MOM:/51O5U-
M%ZM9P *9QWD(,5;F!,(H@%BP$/(PR5D@8H*E4X' J86F9F<<]!R4ZKJVWZ";
M9CH)K9T>\@'8P%KGH'N=IK+M5^=/O5P"PI,R.;G,J*KC$K/[BN+B]3W+C77Y
M<E.X_'ZES[GN35]]<U#VX?EE7KX*8:ZY5^_2$ZG%O7HQ9ID082*B$&:I,+$&
M 6E()>24!U+R.)*YD\[H1<74%,H_VIVWE.##U_O[MB+?L7ZWESCL],S@( ^L
MA QM;7\#T'  &A9NNLA!QT;3% %TC #-B<>:U6N ]%5>VHN&<2M!KX'IH&CS
MJH?U[LZRGZ:FS+4[^4A^S,(@#E,D4RA(3"&2B, \QD*GE46A^B-F.7<:!G)Z
MK:EY>KN)G?.R=N\W=Q)6.TWF":R!]=71!-BFX. &?&FR913%-^!VN:P*NC)A
M"UV;?T]\YWU<A,M?&Y>3*XW=RN42RT?:N5R\I=<0"W-._&FA3!!E('3JZ?9;
M)4S.P0<IA?;QQ.UBL2+S3\\OJZ7V )O+'\A2S+!4?IBD 4QD2'0?%@Y)3!B,
M1!#)D%(N<ZM: 4_T3,WN6E,,B"$9% W-RKEKB :5HAK\1&I ]-@HIKBT;"7E
M2X(V <-1Y3)T$+&-7W7D;2RQ-3_*6%O+K6$)M#QM[M)<C2LHIXD@8PILM DB
M2@?63;?G)]%]+;H9C-JLA-V'MEHHU6AN[^+TZ]^_=*\!Z5#ZF[<Q);ZD<6&L
MR=7+C#D&Q1<F>V-3O#VV9[O\[Z28:V/I8UGIJ*L^&OFJ\W3,.>E6L<FOE3*V
M=HL"?Q&RK(0V-7.,J"X^AB1+\Z8_ >%!IFM"$,=93%(6.K70]T'5U/960RO8
MJYIU;:OO15QVGL'H0ACCX'7#@/(5.@:A(A9J%F]V:N^."NP&4,.;=C<\]N7W
MB;6O7OU>:!JW?[]/& ]Z^GM]> _W9S-'P(2YFFY:C^4OXD$PH?8(_OM+N?A5
MSQ2XD[^1ZE_"!+W:D<R-%18$81[%>0I9J@-4.J<]QSC0_PQ$('D4Q)FU^W,]
M/5-3T5LC.9KX>]L(<%D:&ZQM, %6BB_PS0SH4*;<<\?:>KZ[X<W!V/8@6 NO
M:%QQ#:S,MR35A/!;23V6X!?=;;'A"&B6@.$)W$FPY@K<OIVD'-RB<24VDEOD
M\QL#7+P(/>MXV8T^-HT']1U5-[^QTC,N*Z'3"O4=17/=N\\?;A]TP;T^FZI!
MO5SQ5U_^DS^QG?6?/"PSGO_D#Y,=_\GC8]V32C\LEIN6;\K;+RO]=%U#NZIG
M848P$X1"08U+I*>*94S"4$<T:):E:6JUTUY::&I;:$/K>LK"FEK0D&N?@WH6
MW?/;G4_,!M['^L+EE+)J@T6O#-:S#QXMH=6&O>W\5JOKK^@X_\OE?KB_G.B'
M^^&'J%A1:R_CRZJ9TAV(/,I1"%,A$40)RF&.8@&#0 B"XR3!@L^^BXJ63JWC
M?=+H\CEM4SK@5[4AL?_,"_^RM,PM>4OY#)UWXK$;^Q:?-Z#AU',O]2&$X+,E
MNE?ZQN]L/@2\1QN4#[+0 /'KMDH/922):!A#*G6;\2#'D)*(P20,D,AQ)C-D
M?TACM^;4K$B+H"?XZ>'3_:W/X+-#1:IW4-\^B-RK_-0.48^1X.F6F^Y&>XN%
M+*OG9F][$=6R'?ZQ+&T"N>"G?]/O]K_]/%9$UZ4<U>Y1TXG,GBL_=;NUA\9?
M-X;_J(C608,[^7&U7%6B7;I^*.?SCV6E=YP93A(4LSQ1BC[2!7 !@A1'(<0Y
MPCF)TIP%5EUGG%>>FO9?TPXT\:9:6Q_?-O1W!=TU^$.S %H>7-26DU0LMH.A
ML!YX4Y@4S Y[Q%!PC[13V,'N2?/WP>JL_G=ZX'B[0!\^=_:"7@_P6B?4U+B<
M3,"O9X2'"4U)I+NLQA!Q%,.<TPQB$8L412RG+/50*72)CJGM%L=KA:XX]^DI
M'LO3G>%!'_H,YTSM4#<Y]5SQD,<BZBO!'+9^Z"(54Z@@LH7*LH;(^G%NFK.N
MEK-WND)35"^D6KY^4:_G[8^BGD51FF9,4IBFDD&$,PISW=6+8HYC%M&,"F*C
M$D\M,#5=MTTCT$2"/S29EE;921C/JRX?X RLDYQQL58UEY@_IT/4O5OZ0_UK
MHSM./G84I7")J>YKOWA=#Y?XG>YI?R?_22H3EJ\>]'S'K3A^N:@+]:BFXWUW
M6=U>5\\83BF-&(:$,@)1&"DG.1,"!HG,$468T-2^A=]UM$Q-.6QGUFQ3;DPA
MKB<T5K4^C&K,(I>3TRME9N%"CR>)H3619D3;HBV-X*X"AL@;L)VSMB.?N_75
M]?IREY:+5XK'P?4>3TPC.>/#B\O-7_<#\%D/_LHEQO/I_6"QX^5[>N3;)(=L
M345N$PJ4^Q^0-,E@$,L8(IDSB)6\81YQ(;)<Y)B+V4MCF2_5!CY.@L@!G2[?
M_3ZUPWWZ6V0"LC11&RJ^%8M%>YC04/)V^2.'XD9!R"3#(>14(&7[Y!SF240@
M"Z@0(B4I([@5]X<%_\L(NZ-U5%&+!==";BLS)R9HRZ.DMQ3=T(=,'A.%MOB<
M7J+022%,)%'HD+Z_5*+027A])PJ=7JB?L= N47\L]8BWYZ*N]2HSB4*.T@##
M(*(11'D802HDA1E*4"BS)$TE=HD!'%]F:I[MAWI9/)N:S%)*84Z<Q0\M)->>
M8"=0M=.WUV,UL-+L" 2R-#,C.Q+]:;OS$'A262<6&57OG&=T7WE<N+KO!$:E
M3[[I>4G-E(TO8OEIP>8KK6)^+4O^9S&?S](HD!&G"<Q"R95)F&*(4YQ#'$84
M<YYP$CMU#[19=&K:84,S((9HU_&+%CC;:0C?Z VL+[: :^AM>FG]M*89=$2?
MMHA[3&6TQ\C;<$:+)4>>T6@/PN&H1H=[^U:UZ:9=U4O9G(28L9 F#E"]OBNY
MF$4\#EDB)8RPLCU0$#%(A"3*+\UBRD20Y\BJWX?E>E-3.&W1U@[--\U,4V!V
M7D,YT*2[UKN=Q_V\%AH S8$5D \@>U3"6<%S14'<^>>/7!=GQ>QA>9S=;7V;
M@<[5/\VSOXLM%ZMNYH2Q$[]^5'^KB2GCWIKU%P<H$)B9V=/*(XJS$)(<(2@I
MS:1(HQ1GJ5N!G$_R7#ZV<6KC'K>*[/70KV;&7RG!?9._[M 281!Y)I30!&$*
M11R&$*5$0"IC_3<>I8F@"0F=/-RWDN8XZ2!KXA69X,]B^00>GXI*GX55[F-!
MO,K1SF)^*^D,'07>IGOGS%)_<MO_OEL^F0Y_9 %V;QIFZN80>'MK>.N1M)$[
MY/H'];"E[@!K]-N^S8YQ)V\9TQ:!SOTKYP5[;?Y\%#^6ORAP_C430N0X1@1&
MDN4013R%A*M].B1!FM*(1,*NUY3;LE-3T1ZV5TN\[12N?Q0'5J5K #<DWX"&
M7/!'^U]--S"$>U25;DAY4H*6BXZJWMR V%=<CG?WC)94I:ZR?-5)QDNE$3_\
MUZIXT?KOBUC.<,12H:<RD1!1B!).8"[B &98.0IASI.(,:>8R9G%IJ9^.EJ-
MW2$Z0F_ 0C@.9CJ+L&7\Q!-N0T=16C)O3+5"8[%]V"#WY0QR[O$4"TA\157.
M+35N;,6"Z8,(B\T]_73'3K5"$\UMZ]9IJFR5'&4P$Q3I@JL YGDJ899EH<Q#
M&F>1DP5S<J6I:8VF:J=L(MMN>N(TFIE(B=2C/05/E#V88PPI%@&,A4AI$B0B
MRC*W@QHO>(YSZJ+#@F677]2V=6_P]06OG0[V MG "OAH3L_&I>DR>RXWK'!6
MQQ?1\:2+3Z\SJB*^R.Z^%KY\0S\5_%@)4J^J5_-<,X=JI@NZ:!3'4+),0J0T
M!\0QEC"D-.<X(%&0A+.%^*:S0A[M5?#A2E8O?MZ\^ ?K#7A,VQ(*:DWIC4Y;
M9&6]_#L(;_(<W80Y[I2)^LUO"O&G__CW, W^'H<W0.=\&[/EO6!&/*#]:>2F
M;(Z(Q4[+]$1Y'/6R1O9K@ZRASY\..<V[)^5Q9(%1M<9I!O?5Q9DK?16.M?VY
MQ'U5,'&8L7\BM7^&8AD*K'Q '(6ZE#X.81X'!$99%(8(,4F)E4OHF["I&8(G
M2\IT&9FZ;Z&G9O_9ELX,4V;64\+G%=5;RFWHT,-^15.YKFCJ> .&N:UKZO5%
M]>FZIS<2Y+75:<,+]*U*U087K(?2M>O0=Z]CZ[G>&Q>U78?2Y0JW*Y_?SZC?
MG;+](+AX-AY#TRGB??E,BL4L2WDD(B*@X'D*$<("XI!P'>W/$<51G =.1RPV
MBTYMDSV8"+\A^Z;MK +^:$BW;/3@) ([D]XWL /O@EXP=;;]74#RY U8+3FJ
M?^ "PK['X'3OR%6X^LA9Y\5UU-4F=>/QB2S:$J"/925%8>;S-?3.@HAFA*$,
MLCS2!9L$0<*5BN.$<XY3)!C)ND,,._TV(O4]#D8&5I1K$M^@5K.'].T4Z]0D
M^I>I[VSXWU+R]78RU;KZ<_/2J'>FP6$"U9_]A??6=:$]*/]K5(SV%XFW6M(K
M2.BW&7XN%]\>1?6L]]U9$D84)43"&$>ZF5I(8!ZC!&8TBR,>A3R@V"U M_WX
MZ<7D-'50&?C/@"OZW/:1'>#L%'U?, ;6Q 8%31=X?PX%9]5XC%U/NFOGT:,J
MEV-,[7_]1Z_I]WF:S_]+N="Y#T3G3NFJC&?QH:E]GLE,4H)SKNQ)J9SGA&:0
MH"17_\QHB#G/ KL98W;+3<UM;C;[PI#8(Z'I K9VW[0_Q ;^RANPMBD%#:G@
MIY98CR6>=JAX4@87%AM5/=@QOJ\P+._JFZRMW@,FOCX)L?RL):<M$=WS4Z18
MLC@+8"I"M=LG+-3S9A ,>$;",(T3P6.W].SC"TU-;;1T D,HZ"AUZJ-Z$5L[
MY>$#L8'51C^P>J1:GT?"6W+UB65&3J<^S^QA O6%Z_L68>J,-!.:;[HV=V-1
M!9^1-, !UC5X.=;#2[,$YFE (*,9E3R*\BBWJN^V6&MJZJ%+U&NS;M9T]C]R
M.@>TG:+P!-_0@><&N3:KINW"OZ'49PW;13B\E:2=7FGD"K.++!\6C%V^I4<6
MSN.3Z,*';>)I*B/"<" @DJGNR!SK'NR)@#$.12IE'H9)8)U+<_#XJ>D'73[=
M4>B0$7$(V_E/_WHP!O[:MW'H,SKN$!"'1(^K@!DI7</J17'+L#C)]MD\B<.[
MQLMV.$GQ3L["Z:MZFC9'N_P:IR>D 98X@K'@6#D]@D$L<@FER),\R7 2"N%D
MV)Q::6IJZV3R4"_'YS3 E@:-#]B&-F?Z(N9NSUQ"PY<U<W*=<6V92^P>6#(7
M;^AYNMJ=M[0G+?4LY$1(FB.81K$V960"<1RG4#!".642A8+.EN62S"T/5/=7
M<%(+ZW4&W*3T&F!S)MBOJ^8AD):GI]? ,_2!Z1J3#Y<P<3\?/<6WKR/1@^>/
M>PIZBKV#@\^3%[J/A_J-_"B>5\^M+1D0GI$@#"!*,_4A*V%#G"<,*N<$D4P&
M-$RL]OF#)T]M7V^)LY__M(O3^>_T*NX'_CY;NCP6 9[D]HH13[O/&VVVTU$V
MMH<Z';^@WS9ZRY0_M9KK_"\3R= Y#Y5X4A]T\5TTH8S/9:W;5-[)1_)CIBSO
MC$OU,<81BM0'JL=8)IF $<:2Z6/&4%K-;.NY_M2^X"WR06FB=&R; 3!7M+MM
MQZX"L=NL!X1Y8%6QC7 3!]VA?1T(U>3_W+3 56:_XL'?CM\3/$_V@.OJHUH+
M/:'9MR7Z/N::X(EQ3&[;K30),,K2-(8)TL-9!(D@#J2 >2XQ)7F8T<RQ;^'^
M$E/37-NADCXAD1WX7"(A?4$9)P#2'!S<#M">X#3W7N,=.PN\09CC&(/'HQM'
MK^P1U#C,QMSD:MYU!0BRK)YU(-9<U[ZU*)5)+K(8RIQ)Y6<D 20B22"GE"<T
M2W(B(^O81U\JIJ87[G_Y>N<2&^F-OLB8Q%&<01%QY>H)G,$\BW,HHQ2%0<2B
M("%V":NCX?]VW69&DXI%8&L,I =6]H8%<+%)C2DVZSAI+^\1+>LM#(>@VAA"
M&2GVUE\XGB)UUV)Y-J#7^^'CQ?VNY7\G/'CUPWK:^*1^NEUP_1]=E_&=S$V[
MW>4[4E6OQ>);TQ"'41%PRG4G$8$A4OL.S.,DAP()EH9!P)/<*OO!:=6I[?B:
M6M-PB.F_B W=CFZ!%>*6GH)O'(=V'CH(S5^V2#:MGSJJ?3<K<D+)EY-AM>:X
M?H<+# >NB-/-/;R3^ZID0O#ZHZ+[07P7BY7XM%"?M:B7]^KU>U(:[_9;)8P^
MG.&$Y#+.(IA')(5(9BG,$280XSB.,Y3D*4'6'HG+RE/321WM0(L;M-2#CGS0
MT0_6##B88TX2L;"'A\)Y8)TU&8@=K-RAH![)LO4'N9M!VP>VLT:LTP/',US[
M\+ECK/9Z0-\!D4PWV!/O1?/?3XMWY6)9$;;\9[%\>K>JE^6SJ#X7A!;S8ODZ
MHY&0<8 1)&$20!2':FM(PQ 2+@A"(@JDW6%5S_6GMD&\%U)4E?(0JT9,KE,C
MW<"WLUH'A'3@O:"C'/S4T?ZS;KC0D=_,)NH8N %K%GP.ENR%G;<9DVZKCSQN
MLA<TAY,G^SVF9UZ!F6[Y;J6^4;7%$TEQG&;*N\Y$#E& 0SWX.M2].SF6"<(L
M#5Q2\W:>[J2:1DO+8PUQO8;:[H)G&>'O"\G0\?MV-FU+F<>H_#&&?<7<=YX]
M;D3]&%L'\?*C%_4=%_OUF<SGOZSJ8B'J>J:LC"@/<F5>A)Q"1*,<8JE/QY(H
M1D&<,A99#:4^\?RI&1(-B<#0"#HB70>_[B)X_H/U@,O GZP;)#U&N!YE_(J1
MK;O/&WE$ZU%F#D>R'K_LBBYX]=UJ62_)0D^.GD413H($J1TUR 5$A!!($^4G
MQ&'&&(EIDG(R>S%-A[XN2;6TVV8/UG%Y2?=7&^Y]_45\*Q8+?<!*VXKWZSK,
M[2";2YQ@IO!,PE"I0XECF/-(0A&E.2*Q0&$6M\A^6+CT ;P.UVZM(;4 'PA2
M.X/F*I#&B!\KHV:+.L]MZ8XQ[K-YW,[SQV_Q=HR]HXW8CE[83VM^)$5ECO-_
M,X,-S"'.QTK\UTHLV&O;3C>@@1 XH##(]. 2*CDDF6ZSDB8<!1&)>.K45\5B
MS:D91)KD)E)U [:H!FNR>[8SMH'?3C-X!G5@7=$30V>UX8"*)T5BL^*HJL4!
M@GUEXW)K3Z--9]H^E7-U1]VTBOQ2+L7[HF;S4J^XF06+41;%$24P1(DRYC!G
MD$@D81H3AK'RORBVS(QS7MOENQDG&VZ;]/\$[X4L6.'8+,X>>4O+9 @TA[98
M=F!LN^]JLL&&;O#'(*-XG>'R9>=8KSNN_>,*QX%=Y/R D7NM-X;;I[I>;?73
MSO,L08@AF.!0658L$) HSPIBFO$XD(@EB5.[2Z_43<T&:_LO%8;(-^B7?E2"
M#F[;6\AE#)?ONI[GK50;%B?5T/P<]F_=LOPH;7^-IN3G8/76=OSL(CT2UFX9
MJ]2C_D&J@M"YV!DJU(6D.,)41*%2X:G2Z"A  F(B8A@'/,,HEU'.K<KE;!><
MFGYN20;?6YIWY^LY)$K9@'U>[PX!X= AP1:]CMS=@6:70X4]WUG[-#//<(Z4
M7=:%[@NUQ\A25Z+#%_*J ]"%/D%CXL9TB&&ZDOJE*OF*+4$EEJM*#]JH!"5+
M?:2ILYBYNJ$JZ$KM-D *'\U37&$]FWUF\YSQDLX<N-K)-7.YKY\!WV:PU;>T
M-GD>,T13G$=9 E.,,F6#)RFD<2(5Q#G#*(D"2IURR/87F)J:[NC[[VYF\P%N
M=I;O-6@,K'$[TL ?'7$>_?M3?'LR' \>/ZKM=XJY??/MY'5]"IJ5DBYD(?@7
ML6R?^ZC K+7/_U@5W[XI&V_Q[;UX*>MB^6EA?'W!E3XI5VJ?DPB'/)8")BFF
M$$4HAH2K?R(61A'&RMM.J'U5\S6D3$T=K)G1\R;<$D<]R,7"C!L-[:%]Y370
MNAU+E^>^9@5L> $M,^#3 K3L@):?T03C4F4[EH!&,AF[/ERWSYI W3AG1V E
M^)\K,B_DJY[#UD=4CG6W/M ]7WQ[U0HC5N#Z0&*W#-?+$_O:H=J=T'Z'+K.;
M84:CB+,4)I0E$&4LACC%"0SS0*1$1B)BCE;H]N.GMNELJ#/UM:Z6Z YRMG9H
M7SP&MT+74+P[!T4/"_08Q][LSYV'CVQ]'F/LT/8\>E7/J$_Q;:$4!2.+9?OU
M*[UP7\X+5HAZ$RG5J<"(,0ES$<40X8A#FB8YC#%.<)AS$F7,*9QCM>S4/NZO
MJ^=G4KWJC7.+ ;#A '0L. 9N[(1@&9'Q#NW0YN-Y*(<*4SO!Y"LJ8K?HN.$.
M)R .XAAN=_=34KN3QM^5B^^B6A9TOFW3$)TR^)Z\UK-(<$DC3B$)LA0BE"F/
M6 0!%$@J7SB7G,9.NLII]:FI+$T\*-;4W^C014?_#5BN?;1EPP+@B@<WY>4F
M'#L=-ACD ZLR@_:G+;3?;:.][1$W:+\_A[:S2NN%FB?-YK;VJ JN%RS[>J[?
M0WJ<!AX=H/#AAZA848M[9?>)]2_K]K?U?26>B]7SO;I('R)\$[,(!3@0D8!"
M<*)T(,XA98+#-, HD2)D&;.?\^2%I*DIQO7(D#\W(T,J3?H->&EH!R]KXAT.
MI_S(S^+T<'2I#*P[&X'<;6:XW+4S7&Y QQ4P;&U=4Z\OJF] RQRX?SNQ.9PM
MCBZ^D<X8QQ2CVWFC5\3/GCOZ66F\\T>OR.R<0_I]<H_M]+=BH8^\FQ/O.WF[
M6*S(_(M8?B5SY9^4[8'WQ[)Z$'RE=LB]-C /9*E#]=JI4;2L]_J92$6:AKJE
M <WTT%5$(19A!G.1ADE".":Q_?XZ#(U3VW!;+@%9!Q^(8=1$YVK-*EB6X+_:
M"(3.:*D:=KO0G7)CVLY)E>)8)U^^%\PTCP1Q> /49XB,>]," <H%"(/@_U>W
M?5<WF0/9ET+W:JC4;<7W,_U#1WN-++;YMW\Y!M[WN_=B$Y1J>#2Q*</E=F1*
MOQ<MIX<=M32SQN?J7H$UOV\O:@?3X.U%/E8\\DU%[V8]#"N4L^;$0$N/9U\,
MB]V.P3'P4B.7UC0=D[>+HA_*^5Q1KW\YXS&->!92F"9".?F2)1!S+& >R31$
M4<X1MVH?.BR94[-#OJR,R:"434OV2$4VYV5I&=MY<PD-'0NZONRF976G6P/X
M0[,+6GY]1I$&%<A;U^*<)_*O491C!;2WZAR[U7KXL4?VJ4^+8EF0N?[K+%(&
M Y(R@ FCRA_-!(($I_J\-\PX(8RFJ7TGZ?-K34V?MZ0=]Q(=[/X+"%NX:OYP
M&SPSYZCUW"'YX!4X!\?''X C.3"/3_I]._/^W0!2 [(52=!VQ_))F,V-+%[_
ML]XZ_B@6[:^^"]WJ]E%45:&VG]>_>7)A[. ]ZXI<>,1X+H4=+SNN@>4M;V[B
M*P*K8E$7K!FA$8@HPUDLH*"!4NUA(B -\Q1*G?"?96E*F5OJU5"43FUCL.G6
M-;(L1[?R^TOHKVGHZTVLY=CW^)7!I3(]:W^/SK^JP7\<[@%M_A,+]LD&,<,!
M30N8VX7)SS=F@UJCC9JUH^/R,$WB2$0PQCF#*(JBI@J,!+'D^F])9%^A;[GH
MU/1].TC1T T4X6";\B[4[)(28(F]3:Z&?T2'SL:P ;//=$1;5%U2*?RC.U:R
MQ%6OK&/Z@QM*YQ,<+)\U8@J#&W>[20J.]_J: -,F3-</)AZMNP+,$IP*%B@3
M/R8QAH@*"JE,*,04TT3I]CS,TME"?-.CTQ^OF?YRN+;5YY$WG\<!!<-](AVA
M;=1>4WKM\)<CN-L9YMY@?-,Q+VM$'RXCZF&PRVF(!IOF<F3)-Q[A<AJ$RW-;
MSMSK/@+BJV"KJEB^AA%]+);JS0^#4 8DB& :Z..%-(\@EE1 +D,49#&-DYS8
MSG_8?_C4+$1#E#Z!"Z.?Z,^@(]=^_,,!>N?UQK68#*P?7.%P&OUPBN]><Q\.
M'C;:T(=3;&Q/?#AY3=^CQ+):JJWU^9-)7--F:#W+\EA&0<QAR)5OAU! ($89
MA:%(:12P. NX4Z?R8XM,[7,U-$*UTG.;PV>H=#W+.P*F[3'<=1 -?H*FT='T
M@4\6Z/0X[SK-OK>CJB-+C'S*=)K)PP.B,]?V^]3OR:O>S^O&[:A69+[I0A6'
M,HI32F$<Z)+K$#.U,6<(HICCE.* <^$TK/S,6E/[\#M237>ZCEB;9E;.(-MI
M D_0#:P0>J/FK!HL\/"D(<ZM-*JBL&!Y7U_8W.*C'OISL1"?EN*YGH4QRW6X
M$ H4<H@B?0#,0P1)1+$4083S/.]?^;Q>9VKJ8J_J%ORA*06&5$=5<0I8.S7A
M :Z!540OI*ZL0S[ 89"*X\TJ;UA;?,#J^2KBP\M[#E]5VD688-6SLE"*_V,.
MK>^D'A%@#@Z4 FIKJNIM*SB*@P!1G3,FHU"9%>IO.!:)21PS$^1"0;NS1CM]
MT8^0'@>/0Y\Y;I&O_>.V(+CNNN6VYV?JE[W]DIXR0TJ]!VF:0Q[(#"+.$I@'
M*8)I@,(PPA@%/'*;%3.@S$8='#-=F=EM'L/+8>"]9<T ^&F;A9^U,-9<&&ET
M?-P,X[A>AZ2OD<+]B!AW]O!50!T,*;[N:7V#:NLGZ;U5K=&,R&F/Y(JMKLXQ
M3UE$]63C-(O4'_H$C?(0!E)!)R.)L+0ZZ'9?>FKV\A;E-\"8A/JK;(=$;<CO
M[7 [",4V[C8$U(-'W[RAW",*YPJ8MUB<]<(C1^1< 3F,RSD_P5>>P-WR253M
M_("MJ0^S**#:A ]@*G7]'X]BF#.<P@1G-&?<##=UTVB6*T]-H1DR 6GGC,PW
MA%Z;*7 *>5NU-0">@VNMHSD##<+=))?/%@A[R!RX@-9@Z0.GUGWC'((+<%Q.
M)+CT@#ZS"W325), JS2B6E+IQ^*[N%?OE :ZS>43.8XI90A*)A*(8D1@+E,"
M8R9D$(5<Y$C:SRBP67)J&JK)\&NH-HE^:[J!)EPW+XE<.N!;P7Y>2PT#YM!!
M3PL<^V2EV@'J,CK -[ C9:1>]:(Z]O]W@>A\GW^K)XW8S]^%L]V^_4YW]A_W
M]T[]OF!D_EY\%_/RI>EI62_K;GH:HP'F49Y#A+B *$D2F(>IA$F0*&5-XB@G
MH>O$OPMK3DUE=\8.:\D&?$,W8)IP]XEUEV"WT-C^P1SA7%#CV%$,MD@&AN8K
M1@!> M1]"J!'8,<J(B!59>H%ONMJ(UUPW-884S+7<P!!_23$$G#=-$W]IJ3S
MXILA25<<,\T6UXV@R]6W)_5?TEZI#RM>F@AV,U[PR&?P-_"[KLM;ED!IY[E@
M2[,L:Y "+_H8L#F,US_><LO 3UP1^F>Q?%*N1;D0X%602C=@;7^D+U^4U;-:
MK7PQ,_(4=^R5Z2;*A03S<O%-5#_[*HMV$[S-J,)+CQI]6J$E;\<&%MK>VF,O
M^E(N] 0+T_7Q3JI7Z;:NQ7(6AFD<IH3#2 04HC#"D(@TA"GB),YDPC+&K?>>
MXVM,;:]15)IQ,4T'8OW%K&K])2M2'73B"3PM-I7K41IX$]$ :0J;+K&Z=:PB
M$MSZ <AAD[@>J)$VA0?QHAZG3RN--N6%E$)]KVHWH&+YIQ"-DIV;HQ[SGAF%
MO_E9IZV]-9\XC]Q9K7KBUO&TZ'G:=[3FA4M[:,GNI.;U0<Q-T56YU\CB7KTS
M3TIFM]\J80J5U]$53'(<<)%")%@&44X)5,]/8)PP%(24Y5):C=ZZDHZI:=LU
M)Z!E15LP^M4_Z(O3L036/#EHFRL$9Z&RQQ''P&I]^I)PV!O&D<A(^\>74AGZ
MTO0V*A>^]H#K$3J[3USQ^/'VDNLQV-EO/#RN7YAR*X!PN^#FW$IW2E7JNXF+
MKK^@*,2(Q41 3'"D4];TX3]",!0ARF(:482<ZAAL%Y[JKE.T&?KU%N7_\>\X
M"K._ V$X<(M:6@O"+F@Y!+PC[2(=LFV.Q1")%:[H>(I16B\[:HC2%8S]"*7S
M_0.U9JLO=/;YU8RG^+2X%U51\G\*;=L+?OM=5.2;V!EF,6,T#;)(4LA0A""2
M>AH[S6,H<1(ABC(B<JM(YQO0/C5]:2A7%N%/Q0+P<CXG5:W[*():L_NSYXYN
M'E\!.S4[4<$.';ZUZ/I6V[9]:Q#0V2D-!C>@0P&T,.Q-'!JQ%YQ_Z8W5'<XC
MY=/J%^=?),X=Y 8@H=^6^)$4E>E-9TZG].Z[M1?_)DB]J@2_6SSHW$8]*%Y=
M\*5<5-T_%?U%_=@T+,I(RA%-88:E@(AQ!'$<1I P)A@+9)+E3M:]-\JFMIUI
MQIJ6E#=@3;TQ5[?I!W\8XAT3KOV)TV[S>A,A#;PU>9*/\U;B'4M/&X4_ND;=
M!KS#N:_D_2_0L^CS.RGF^CD?RTH/M]%)Z5NYZ$T-CMZ)ZJ59<R9BFJ,,)U!R
MI:X13QC$A(:0)0*EJ0ACTT>Z7)*YG:9V)<!)(:_)&# OI:/0)*$X5@*Z@F^G
M5X>$=&#U:0I<-K3>@#4O4)85U-S< $O(W2O^>N+FJ];/=?EQJ_QZ@G-0W]?W
M.6_34%]1*46Q5-I8Z^@//UZ*JDEZLG+B0\YI0I,$4A%AJ$=F0T*X+KM.)!5I
M&$41';/I_E7<3,X4;IA1:J"L@-"\C'7,,^@[X^G@9RIOP@2.@FQ/@K8P:0(
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MD'2Z5-WH^Q0M[N1Y06VL>Q6GT?-UR>XB%/T7[<Z_/N)ENXL\[%^XN_SXCPE
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M%RKEMNGONGL3%.LM_*.4T-=__><P#?Z]+1T5Z[</"TI%MC?8C\5HIK"N%,[
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M<E$OYR73_[A=L,^J$&#[(6X,2SS_(G^BO=1Z4_VC$$7&HC"$-$S59: XAGG
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M(V])5[NHNE)2+L!"U>E<:2; D^;"/6'!183].N@'"&9@=768SJ <J$Y*6X9
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M*40Q))1R2%A <Y3A/,ZMJJQ>F&]R9D%++CC>ZRQM@@LX&]H%_M ;VC8X#]P
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MA>=)&$>1R"!.8@01R3',@R2"#,6Y8 P1$B3&KNSAZ%.S%!OZ@"+0PGT[PLS
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M\YC%. _2(BVL0I'&4T]M-^HH5];CG?32*]!R #ZX%DNUD(-AA'(0=(>.5NX
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M5DO FJQ&557Y>5GIY_<"7[BNEW(&Y2/H0!;3O5/!DP[*U(!Q24,SF[J3LZS
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M-5_5FSY=<H>.!<$%9%$A-4<@_U;D*ATZ)"D1F.4TL H1[0\_.4VAJ;-4"_N
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M*"$!(J%14,"=A*FIJ VI &]HM6R.:B\&,^4T++A#G^_S57.^WY&O:@K\I#@
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M<4D/U.F=%-<C!-P/0%Z1G.[KX_7+']LN\+4)./TOUY1P:;42&!0DF^H(;)/
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M2@P\8@"3M ?%16TGECSHK$1A6CEE6R<KWD-&)_G5C3WW \7< 5(N&F%>V,3
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M9%245A5FFP][VI/$3J+Z Q%Q)XU]./5T@+Z[61Y8+S=J\QE'X0&HF#095R.
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MGOJ9[Q?SKU.2W$_?_KZLW9$OVTR^2*OIUTWU\H4$LA0F..>!%4$2*!@AY"A
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M>?-G@!W(&O>X[1&'310X=HARG9_-G77U1?Y._O."'.ER([%\$J,1Q 2"3<6
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M\C]6R_5Z%E"$R+R%*) \)?+2:Y,@!T>>$OKL2&5:#U!ZE)AA(#J)7$!;QG>
MH#I%_\-VBOZ,!>3!H 0C&9F2F!%"0@?)1VF39)D;; R:N]\_#"<GD1PXF+U[
M0X.>RK!L.:'@=O/MYA""<5;J5AZO6:''EM-C&VWMGE%2AAAK T1CC'R#C&%0
M.8G@?BMF=W"9/.P9G:\V97 SDQQ3+J=*?"U_RP$<)RO-^4S/K?/)/IPFT+Q1
M=TO*,-R<<#Q^/Z9W@)UOSK?[Z:^\BO/U5=CCYA_7VW^M11@B%FY% =01R??,
M D(N!:+W==\":NN/,F;T.4*'X>XD O?'$]C4T:I]3OANE<_GE^=W\F 1'=?<
MU8)R1@:AJZ.D21%!UV%8,:;\U=:"Q^91MB!G&!!/(IP_D8PZN"L_K#*N+U=?
M-D6[5[&05_$J9S:SF$*(.H)(49/)H#4] #)!$2YR[55BKO6-^ 0YP^!V$G'[
MULSO $>;(UQ%T7Z\K&.&K@8=71WJWCG?Y_GFQV88L 2G$&J%&RA>+!D4TA H
MI.&8I76Z=;GJ[E0.FV-P$@'Z(XFJ&1C_UW]\Q7-BP+\W_[3YE_I?O<_E?]3_
M__O[-_<^GV[T>JK%_XS+\ZN/?WOQ*:]>Q;BB _TRQS _VW0[_Y@O<'ZVOD_]
M>G[^^2P_]Y0^\XG_<4OIPS-L/_@KJ!Q&=?[K(B\28?;@?NHZ+ZK.#-M\,9ZM
M;Q;'%X92H?+@0]$UJ$D^ 8\9&!<R"\Y\YJT[P9X@Y]!+ZR>2\O)+)A"=U4:K
M._Q]?;FJZCFKHVB3%N3OQ+H"4I,*N%1'QFB9N-/)"=XZ1/$L4=,.B&J%CH>W
M4EM93&WO;S7V/W$UQZLFT?6<Y+*1TO5Y!,>B,GJP.=!YZ+$'#(%8YH7PQ3KN
M<9@U/^#+IAWYU!HSH["X R-J>Z1WJV7)F[F->/9SOE4 ([2Q/F?PA5E0L1XD
M!PY6IJ3I[YEM/MSP:8JF'?(TUDW44 H=8.HZ%KSEUO4IB#U!ZA @AAH\D:Q
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M00%SDH-B3$!@M5'2!AT*8^B,:ZTJ.U-YHL6F(V)_7$'W >;FMB47(09A'/"
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MP(-WH%(D^;HB049BF$9I$L;.%/0(:QA.(8EX"GI[1'"^@$=UZ/Q];53(S!=
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M:-H>P:5H&.$>BN&D$!YKTAL5&,8E2XDACVHOW.R D-%:#(Z"D#T8V8%Y6WV
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MN/V="^Y/W&)4</+S!;LN]%R!F$([Q+B.K-#H0J$Q)6(/7!:,%PM6%<Y4@"/
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M[PLID4RJPXTD<'.V2@(XF8BZ7#E>P8>$+Q$AA(#DU<(W0M_=<0^ZCR%F2H(
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MF];!)Z6F;GU2]KE5G;;N6NX7+?MYF>LXW]Q9U](/G,9&RQH*WJQ2*$E<[GB
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M!^ZSR\_B=EW=\Q_^#U!+ 0(4 Q0    ( !%(J58E9I)%\M@! #,U$@ 1
M          "  0    !E<W!R+3(P,C,P,S,Q+FAT;5!+ 0(4 Q0    ( !%(
MJ58P(Q*&V!0  %SG   1              "  2'9 0!E<W!R+3(P,C,P,S,Q
M+GAS9%!+ 0(4 Q0    ( !%(J58F)#'+J10   ZZ   5              "
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M,RYH=&U02P$"% ,4    "  12*E6HU%&59@%  !"(   %P
M@ $9_P, 97-P<BUE>#,R,7@P,S,Q,C R,RYH=&U02P4&      D "0!9 @
&Y@0$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
